
<html lang="en"     class="pb-page"  data-request-id="81dc0c4b-19cd-4659-bc38-b099d122261b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.6b00935;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2017.60.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets" /></meta><meta name="dc.Creator" content="Yi-Min  Liu" /></meta><meta name="dc.Creator" content="Kunal  Nepali" /></meta><meta name="dc.Creator" content="Jing-Ping  Liou" /></meta><meta name="dc.Description" content="Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in accurate diagnosis, po..." /></meta><meta name="Description" content="Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in accurate diagnosis, po..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 29, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00935" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00935" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00935" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00935" /></link>
        
    
    

<title>Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00935" /></meta><meta property="og:title" content="Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0025.jpeg" /></meta><meta property="og:description" content="Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor. Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF. This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the past 10 years. With a dozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain that some of them will advance to clinical stage investigations. The results of clinical trials for some of the new agents are also awaited to assess their benefits in terms of efficacy and survival benefits." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00935"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00935">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00935&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00935&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00935&amp;href=/doi/10.1021/acs.jmedchem.6b00935" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 527-553</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.6b01036" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Min++Liu">Yi-Min Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kunal++Nepali">Kunal Nepali</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing-Ping++Liou">Jing-Ping Liou</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-3775-6405" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">School of Pharmacy, College of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#cea4bea28ebaa3bbe0abaabbe0bab9"><span class="__cf_email__" data-cfemail="c1abb1ad81b5acb4efa4a5b4efb5b6">[email protected]</span></a>. Phone: +886-2-2736-1661, extension 6130.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00935&amp;href=/doi/10.1021%2Facs.jmedchem.6b00935" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 527–553</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 14, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 June 2016</li><li><span class="item_label"><b>Published</b> online</span>29 November 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 January 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00935" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00935</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D527%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYi-Min%2BLiu%252C%2BKunal%2BNepali%252C%2BJing-Ping%2BLiou%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D2%26contentID%3Dacs.jmedchem.6b00935%26title%3DIdiopathic%2BPulmonary%2BFibrosis%253A%2BCurrent%2BStatus%252C%2BRecent%2BProgress%252C%2Band%2BEmerging%2BTargets%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D553%26publicationDate%3DJanuary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00935"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4533</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">51</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00935" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yi-Min&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Kunal&quot;,&quot;last_name&quot;:&quot;Nepali&quot;},{&quot;first_name&quot;:&quot;Jing-Ping&quot;,&quot;last_name&quot;:&quot;Liou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;527-553&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00935&quot;},&quot;abstract&quot;:&quot;Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor. Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF. This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the past 10 years. With a dozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain that some of them will advance to clinical stage investigations. The results of clinical trials for some of the new a&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00935&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00935" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00935&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00935" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00935&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00935" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00935&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00935&amp;href=/doi/10.1021/acs.jmedchem.6b00935" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00935" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00935" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00935%26sid%3Dliteratum%253Aachs%26pmid%3D28122457%26genre%3Darticle%26aulast%3DLiu%26date%3D2017%26atitle%3DIdiopathic%2BPulmonary%2BFibrosis%253A%2BCurrent%2BStatus%252C%2BRecent%2BProgress%252C%2Band%2BEmerging%2BTargets%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D2%26spage%3D527%26epage%3D553%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292016" title="Therapeutics">Therapeutics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/jmcmar.2017.60.issue-2/20170126/jmcmar.2017.60.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor. Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF. This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the past 10 years. With a dozen antifibrotic agents possessing exciting preclinical potential in the armory, it seems certain that some of them will advance to clinical stage investigations. The results of clinical trials for some of the new agents are also awaited to assess their benefits in terms of efficacy and survival benefits.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13054" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13054" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrosing interstitial pneumonia of unknown cause characterized by worsening of dyspnea and lung function.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> IPF represents one of the major clinical problems of cystic fibrosis and chronic obstructive pulmonary disease.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Despite being a rare disease, IPF is the most common and severe form of the idiopathic interstitial pneumonia (IIP) and is identified histologically as usual interstitial pneumonia (UIP) which is a form of lung disease characterized by progressive fibrosis of both lungs.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a></div><div class="NLM_p">IPF is a fatal lung disease with a median survival time between 3 and 5 years from diagnosis. Usually diagnosed with poor prognosis, the clinical course of IPF is highly variable. The annual incidence of IPF in the U.S. has been estimated as 6.8–8.8 cases per 100 000 population using narrow case definitions and 16.3–17.4 per 100 000 population using broad case definitions. The prevalence of IPF in U.S. was estimated between 14–27.9 cases per 100 000 population using narrow case definitions and between 42.7–63 cases using broad case definitions.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Furthermore, the incidence of IPF is increasing year by year, and recent analysis of IPF-related mortality data from the U.S. indicates that the age-adjusted mortality rate has increased to 28.4% in men and 41.3% in women.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> In the U.K., the status of IPF in terms of both incidence and mortality is close to that of the U.S.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a></div><div class="NLM_p">IPF is more common in men than in women and increases with age, particularly over the age of 50.<a onclick="showRef(event, 'ref5 ref6 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref8">(5, 6, 8)</a> IPF is more frequently encountered in cigarette smokers, and the scenario does not improve even after smoking cessation.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Other potential risk factors that have been described include environmental exposures such as metal and wood dust, microbial agents, and gastroesophageal reflux.<a onclick="showRef(event, 'ref1 ref2 ref11'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref11">(1, 2, 11)</a> Recently, several studies have revealed that gene expression and epigenetic regulation have a significant connection to IPF.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a></div><div class="NLM_p">Diagnosis of IPF is quite difficult. Its symptoms are a dry cough, dyspnoea, and clubbing of the tips of the fingers or toes.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> According to international clinical practice guidelines, the diagnosis of IPF requires consideration of a detailed clinical history of the patient. This requires a comprehensive investigation including environmental exposures and family history, the exclusion of other known causes of interstitial lung disease (ILD) such as connective tissue disease or drug toxicity and radiographic concordance. In some cases, a confirmatory diagnosis of IPF requires surgical lung biopsy. Overall, an accurate diagnosis of IPF needs to be accomplished by multidisciplinary discussion with experienced clinical experts in the field of ILD.<a onclick="showRef(event, 'ref1 ref15'); return false;" href="javascript:void(0);" class="ref ref1 ref15">(1, 15)</a></div><div class="NLM_p">In October 2014, the U.S. Food and Drug Administration (FDA) approved two drugs for treatment of IPF: pirfenidone (<b>1</b>, Esbriet) and nintedanib (<b>2</b>, Ofev). Both drugs reduced the progression of IPF and offered other survival benefits. However, no treatment is strongly recommended for patients with IPF.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Problems in accurate diagnosis along with poor prognosis limited clinical therapy, and high mortality rate clearly demonstrate the need to develop efficient therapeutic strategies for IPF in the near future.</div><div class="NLM_p last">This review article is basically focused on various aspects of IPF such as pathogenesis, therapeutic interventions, and treatment approaches. Only two drugs have been approved for IPF, but medicinal chemists have made several attempts to design and evaluate new chemical architectures along with structural modifications of the existing approved agents. The present compilation also covers some selected interesting strategies employed for the design of antifibrotic agents and in the later sections the patent literature for the past 10 years. The data presented can serve as a guide to a better understanding of the rare disease with an overview of the potent antifibrotics possessing significant to moderate antifibrotic activity. With a reasonable number of antifibrotic agents possessing exciting preclinical potential in the pipeline, it seems certain that some of them will advance to clinical stage investigations.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Pathogenesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In recent years, there has been a transition in the concept of pathogenesis for IPF from an inflammatory-driven to an epithelial-driven disease. The former concept categorizes it as a chronic inflammatory disease associated with the interactions of mononuclear cells, fibroblasts, and cytokines. However, more recently, new thoughts have been brought up and elucidated.<a onclick="showRef(event, 'ref4 ref17'); return false;" href="javascript:void(0);" class="ref ref4 ref17">(4, 17)</a> IPF represents a form of abnormal wound healing involving the interstitial and alveolar spaces of the lung related to the excessive proliferation of myofibroblasts resulting in fibrosis (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). The inflammation is not the prime cause of the IPF, but it plays a significant role in the onset and progression of the disease.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pathogenesis and therapeutic targets of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">At first, the lung is repeatedly attacked by microinjuries such as cigarette smoking and viral infections on alveolar epithelial cells (AECs). These injuries lead to the death of epithelial cells and promote the wound healing process. Under normal conditions, the apoptosis of epithelial cells initiates the wound healing process which enhances the vascular permeability to proteins (fibrinogen and fibronectin) and forms the wound clot. The damaged/dead cells are removed by the action of inflammation followed by the growth of fibroblasts forming a new extracellular matrix (ECM). After re-epithelialization, cells such as differentiated myofibroblasts which are involved in the wound healing process undergo apoptosis. In IPF, however, the abnormal wound healing responses lead to formation of fibroblast hyperplasia and exaggerated ECM deposition. This ultimately affects the balance between fibrotic mediators and antifibrotic mediators. The levels of active transforming growth factor β (TGF-β) are increased in patients with IPF. When this aberrant process is sustained, the repetitive lung remodeling eventually leads to the formation of honeycomb cysts and demolition of lung architecture ultimately causing progressive lung fibrosis along with loss of function.<a onclick="showRef(event, 'ref2 ref13 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref2 ref13 ref17 ref18 ref19 ref20">(2, 13, 17-20)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">3 Therapeutic Targets</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On the basis of the pathogenesis of IPF, several therapeutic targets have been recognized and have led to the development of anti-IPF agents. Some of these anti-IPF agents have already entered into clinical trials and are being marketed (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Therapeutic Intervention of IPF</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0023.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0024.gif" alt="" id="GRAPHIC-d46e265-autogenerated" /></img><div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1 Epithelial Cell Injury</h3><div class="NLM_p">Apoptosis of epithelial cells can be attributed to repetitive microinjuries. The sources of injuries have not yet been confirmed and vary among patients, including, for instance, environmental exposures or gastroesophageal reflux disease (GERD). Antioxidants and antireflux agents such as proton pump inhibitors (PPIs) or histamine-2 blocker receptor antagonists are probably suitable therapeutics. Antacid medication as mentioned in the latest guideline is a conditional recommendation for use but with very low estimated confidence in its effects.<a onclick="showRef(event, 'ref16 ref21'); return false;" href="javascript:void(0);" class="ref ref16 ref21">(16, 21)</a> Though the relationship remains unclear, up to 90% of patients with IPF have symptoms of gastroesophageal reflux. Retrospective studies have indicated the beneficial effects of PPIs together with good prognosis and extended survival. However, patients with long-term intake of PPIs should be aware of drug–drug interactions.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21-23)</a></div><div class="NLM_p">There is ample evidence that the use of antioxidants improves the problem of high lung oxidant burden in IPF patients. However, the antioxidant <b>3</b>, a precursor of the endogenous antioxidant glutathione, is not recommended for use of IPF.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> According to the Idiopathic Pulmonary Fibrosis International Group Exploring <i>N</i>-Acetylcysteine I Annual (IFIGENIA) study, the addition of <b>3</b> to therapy with prednisone and azathioprine preserved vital capacity and better carbon monoxide diffusing capacity (DL<sub>CO</sub>) in patients with IPF, but the results of the study had some potential limitations such as the lack of a true placebo arm due to the very high dropout rate. Moreover, there were no significant effects on survival. The study was therefore assumed either to underestimate or to overestimate the effects of <b>3</b>.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Another study revealed the increased risks of death and hospitalization in patients with IPF who were treated with a combination of prednisone, azathioprine, and <b>3</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compared to placebos, <b>3</b> offered no significant benefits with respect to the preservation of forced vital capacity (FVC).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> These investigations provide sufficient evidence against the use of this combination in IPF patients.<a onclick="showRef(event, 'ref24 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref26 ref27">(24, 26, 27)</a> Recently, a phase II study has also suggested that addition of <b>3</b> to a pirfenidone administration does not substantially alter the tolerability profile of pirfenidone and is unlikely to be beneficial in IPF.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Overall, the use of antioxidants as therapeutic strategy still needs exploration to ascertain conclusive benefits.</div><div class="NLM_p last">Recently, accumulation of repeated microinjuries due to the cellular senescence associated with aging or telomere shortening has been reported. Aging is related to alteration of DNA methylation and histone modification which in turn is connected to epigenetic modifications.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Several preclinical studies have already indicated that IPF is related to epigenetic modifications such as upregulation of histone deacetylase (HDAC) or enhancement of bromodomain proteins.<a onclick="showRef(event, 'ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32">(29-32)</a> According to Tang et al., <b>4</b>, a Brd4 inhibitor, is capable of inhibiting the profibrotic effects of IPF lung fibroblasts and attenuates bleomycin-induced lung fibrosis in mice.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> The results of the preclinical investigation conducted by Sanders et al. indicate that SAHA (<b>5</b>, vorinostat, Zolinza), an approved HDAC inhibitor, promotes fibroblast apoptosis and ameliorates pulmonary fibrosis.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Primary mutations of <i>TERT</i> (telomerase reverse transcriptase) and <i>TERC</i> (telomerase RNA component) lead to short telomere lengths, and telomere shortening of circulating leukocytes has been proposed as a marker of an increased predisposition toward the development of this age-associated disease.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> A common polymorphism in the promoter of <i>MUC5B</i> gene, which is upregulated two-digit times higher in the patients with IPF, has also been identified as a risk with strong associations with development of this chronic progressive parenchymal lung disease.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> Though the studies evaluating the effects of gene expression alteration and epigenetic modification are still at the preclinical stages, they hold enough promise and optimism as a new strategy for the treatment of IPF.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.2 Early Phase of Wound Healing</h3><div class="NLM_p last">Normally, wound healing can be divided into four phases, blood clotting (hemostasis), inflammation, tissue proliferation, and tissue remodeling. At the beginning of the blood clotting phase, vascular permeability increases and extravascular coagulation is induced by clotting factors. The balance between thrombus formation and fibrinolysis determines the vessel occlusion or bleeding.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> The prothrombotic state is 4 times higher in patients with IPF, and the existence of a prothrombotic state has an adverse impact on survival due to a combination of inherited and acquired defects in the clotting cascade.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The use of the traditional anticoagulant, warfarin (<b>6</b>), has been terminated due to increased deaths in the warfarin arm at interim analysis in the Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF) trial.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Other studies also suggested that anticoagulants may contribute to an underlying deterioration of respiratory status in patients with IPF.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Despite these unfavorable reports, two new groups of oral anticoagulants have been found to possess not only anticoagulant effects but also antifibrotic effects. One group is direct thrombin inhibitors, such as dabigatran (<b>7</b>), and the other is direct factor Xa inhibitors such as apixaban (<b>8</b>) and rivaroxaban (<b>9</b>). Thus, it is still hoped that these groups may provide a whole new anticoagulant therapeutic strategy in the near future.<a onclick="showRef(event, 'ref37 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref37 ref41 ref42 ref43">(37, 41-43)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.3 Immune Activation</h3><div class="NLM_p">The second phase of wound healing is inflammation, characterized by the sequential infiltration of neutrophils, macrophages, and lymphocytes. Macrophages can release cytokines to promote the inflammatory response and remove the apoptotic or damaged cells. The macrophages then secrete large amounts of growth factors such as TGF-β, platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) to promote fibrosis.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> In addition, connective tissue growth factor (CTGF) is an important downstream mediator of TGF-β and inhibition of CTGF in the lungs has the potential to reverse tissue remodeling and the process of fibrosis.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> Interleukin-13 (IL-13) released by T helper 2 (T<sub>H</sub>2) cells can also promote proliferation of fibroblasts.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> IL-13 monoclonal antibodies such as CAT354 can attenuate lung fibrosis and epithelial damage in a humanized mouse model of IPF.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Two phase II trials of the anti-IL-13 antibodies, CAT354 and QAX576, have been terminated for reasons that have not been disclosed, and lebrikizumab is currently recruiting participants for a phase II, randomized, double-blind, placebo-controlled trial.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> All these factors have been found to be expressed in high levels in patients with IPF, and consequently, inhibition of these factors presents a logical therapeutic approach for IPF.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Historically, due to their anti-inflammatory effects, corticosteroids, especially prednisone, have been used for treatment of IPF. However, the results of IFIGENIA and PANTHER-IPF studies investigating effects of the combination of prednisone, azathioprine, and <b>3</b> have produced discouraging outcomes.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> Moreover the anticipated beneficial effects of corticosteroids have not been demonstrated by other studies, and current recommendations are against the use of immunosuppressants in IPF.<a onclick="showRef(event, 'ref16 ref50'); return false;" href="javascript:void(0);" class="ref ref16 ref50">(16, 50)</a></div><div class="NLM_p last">The αvβ6 integrin which is required for the activation of latent TGF-β is elevated in fibrotic diseases, and partial inhibition of αvβ6 integrin can inhibit pulmonary fibrosis without exacerbating inflammation.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a> BG00011 (STX-100), a humanized monoclonal antibody against αvβ6, has recently entered into a phase II clinical trial for the treatment of IPF.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> FG-3019, an anti-CTGF monoclonal antibody, has been reported to be safe and well-tolerated for 45 weeks in IPF patients participating in the open-label phase II trial. The clinical study demonstrated favorable outcomes in the context of changes in pulmonary function and extent of pulmonary fibrosis.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.4 Tissue Proliferation</h3><div class="NLM_p">After the inflammation, the wound healing process enters the proliferative phase where proliferation of fibroblasts and angiogenesis is initiated. In IPF, the myofibroblasts which differ from fibroblasts accumulate predominantly into the injuries, producing collagen and ECM components. In this period, some profibrotic mediators also provide a mechanistic link to prolongation of fibrosis. Thus, despite an accomplished repair process, the condition of abnormal fibrosis remains.</div><div class="NLM_p">PAR1 (proteinase-activated receptors) possess a potent fibrogenic effect which includes promotion of PDGF-mediated fibroblast proliferation and increased collagen synthesis.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> An animal study also indicated that absence of PAR1 signaling can lead to protection from bleomycin-induced lung fibrosis.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> PAI-1 (plasminogen activator inhibitor 1) is a potent downstream effector of TGF-β in fibrotic processes and plays an important role in the regulation of ECM degradation.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57, 58)</a> Inhibition of PAI-1 has been reported to limit the development of bleomycin-induced lung fibrosis in mice.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Both targets could emerge in future as effective therapeutic interventions for the treatment of IPF.</div><div class="NLM_p last">Fibroblasts, the most targeted cells, are considered to be an evaluation standard for potential treatments of IPF. To date, two drugs, pirfenidone (<b>1</b>) and nintedanib (<b>2</b>) approved for the treatment of IPF, also target fibroblasts and are discussed in detail in the next section. Apart from this, lysophosphatidic acid (LPA) and its specific G-protein-coupled receptor (LPA<sub>1</sub>) can mediate fibroblast recruitment and apoptosis through LPA–LPA<sub>1</sub> signaling.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60, 61)</a> Compound <b>10</b>, a novel, orally active potent LPA<sub>1</sub> antagonist, inhibits lung fibrosis in the mouse bleomycin model and another structurally related compound, BMS-986020 (structure not disclosed), has recently entered into phase II clinical trial for the treatment of IPF.<a onclick="showRef(event, 'ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64">(62-64)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">4 Treatment Approaches</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The treatment of IPF can involve either of two different approaches, pharmacological therapy and nonpharmacologic therapy. The treatment of concomitant conditions of IPF is also another important subject that must be addressed. Currently, only two drugs, pirfenidone and nintedanib, have been approved by U.S. Food and Drug Administration (FDA) for treatment of IPF.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.1 Pirfenidone</h3><div class="NLM_p">Pirfenidone (<b>1</b>) is an orally available pyridone derivative (5-methyl-1-phenyl-1<i>H</i>-pyridin-2-one) that has been licensed in numerous countries including Japan, India, China, Europe, Canada, and the United States for the treatment of IPF. The approved dose is nine 267 mg capsules, for a total of 2403 mg, per day. The treatment should be used in a titration manner with the recommended daily dose over 2 weeks and taken with food to reduce the adverse gastrointestinal effects. Pirfenidone is predominantly metabolized by cytochrome P450 (CYP450) 1A2 enzyme and excreted renally. The elimination half-life of pirfenidone is about 3 h, and its most frequent adverse effects include skin rashes, diarrhea, and fatigue.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66, 67)</a></div><div class="NLM_p">Although the mode of action of pirfenidone has not yet been established, it possesses antifibrotic, anti-inflammatory, and antioxidant potential.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68, 69)</a> The antifibrotic properties of pirfenidone are attributed to its ability to reduce expression of cytokines such as TGF-β, resulting ultimately in inhibition of fibrosis.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70, 71)</a> Pirfenidone exerts anti-inflammatory effects via inhibition of proinflammatory cytokines, for instance, the IL-6, IL-8, and tumor necrosis factor (TNF)-α, as well as enhancement of the anti-inflammatory cytokine IL-10.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72, 73)</a> Pirfenidone is ineffective as a scavenger of superoxide radicals but is a scavenger of hydroxyl radicals and superoxide anions, indicating its antioxidant properties.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p last">Four phase III clinical studies of pirfenidone in IPF have been completed and reported.<a onclick="showRef(event, 'ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77">(75-77)</a> A study conducted in Japan demonstrated that pirfenidone preserves vital capacity and improves progression-free survival time without serious adverse events and is better than a placebo in IPF patients with mild functional impairment.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The CAPACITY (clinical studies assessing pirfenidone in idiopathic pulmonary fibrosis: research of efficacy and safety outcome) studies included two randomized trials (studies 004 and 006) that demonstrated clinical benefits along with a favorable safety profile of pirfenidone. Overall, the study presented a suitable treatment option for patients with IPF.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Another phase III trial, ASCEND (assessment of pirfenidone to confirm efficacy and safety in idiopathic pulmonary fibrosis) study, also confirmed that pirfenidone reduces disease progression in patients with IPF and that the treatment is safe compared with placebo with an acceptable side effect profile.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.2 Nintedanib</h3><div class="NLM_p">Nintedanib (<b>2</b>), formerly known as BIBF1120, is an indolinone derivative that was identified in a lead optimization program designed for angiogenesis inhibitors with anticancer effects. Nintedanib is a potent and orally available triple tyrosine kinase inhibitor that targets the PDGF receptors α/β, FGF receptors 1–3, and all three vascular endothelial growth factor (VEGF) receptor subtypes.<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78, 79)</a> The approved dose of nintedanib is 300 mg/day, and each capsule contains 150 mg. The appropriate dosage regimen recommends 150 mg of nintedanib to be taken orally (with food) twice daily approximately 12 h apart. Nintedanib is predominantly metabolized by the CYP450 enzymes via ester cleavage and oxidative N-demethylation. It is mainly excreted in the bile. The elimination half-life of nintedanib is about 9.5 h, and the common adverse effects of nintedanib are diarrhea, nausea, and abdominal pain.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80, 81)</a></div><div class="NLM_p">PDGFs are expressed in many types of cells including fibroblasts, vascular endothelial cells, macrophages, and platelets. PDGFs can induce fibroblast chemotaxis and are the strongest stimulus of fibroblast proliferation. They therefore play an important role in the expansion of myofibroblasts and act as a stimulator of collagen synthesis.<a onclick="showRef(event, 'ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref84">(82-84)</a> PDGF inhibitors such as imatinib have been reported to alter fibrogenic response, thereby reducing pulmonary fibrosis in animal studies.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85, 86)</a> The FGF pathway is an essential signaling pathway controlling angiogenesis, morphogenesis, and remodeling in the airway. Specifically, FGFR-1 and -2 are expressed in myofibroblast-like cells.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Although VEGF signaling is prominent in vascular remodeling, the relationship between VEGF and IPF has not yet been established.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> However, there are reports that with bleomycin-induced fibrosis in mice, a VEGFR-2 antagonist could attenuate histopathologic fibroplasias and collagen deposition by regulating angiogenesis and inflammation in the lung.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Thus, the signaling of PDGF, FGF, and VEGF has emerged as an logical therapeutic target of IPF. Methyl (<i>Z</i>)-3-(((4-(2-(dimethylamino)-<i>N</i>-methylacetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate (BIBF1000), a small molecule inhibitor targeting PDGF, FGF, and VEGF, has attenuated fibrosis by reducing collagen deposition and inhibiting profibrotic gene expression in rats.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Nintedanib has demonstrated significant antifibrotic effects by inhibition of proliferation in primary human lung fibroblasts derived from patients with IPF.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><div class="NLM_p last">Nintedanib has been investigated in phase II and phase III clinical trials.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92, 93)</a> The randomized, double-blind, placebo-controlled phase II trial, also known as the TOMORROW trial, suggested that treatment with 150 mg of nintedanib twice per day resulted in reduced decline in FVC with fewer acute exacerbations and preserved quality of life compared with a placebo.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In the two replicate phase III trials, the INPULSIS-1 and INPULSIS-2, the primary outcome was achieved, with an approximately 50% reduction in the annual rate of FVC decline in the nintedanib group compared to placebo. This was found to be consistent with a slowing of the disease progression. The most frequently encountered adverse event was diarrhea reported in 62% of patients. However, less than 5% of nintedanib-treated patients discontinued the trial.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The INPULSIS-ON trial, an open-label extension of the INPULSIS trials, has confirmed the long-term efficacy and safety of nintedanib in an interim analysis.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">5 Rational Approaches, Design Strategies, and Structure–Activity Relationship of Antifibrotic Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This section presents the rational approaches and design strategies employed by researchers to synthesize antifibrotic agents for IPF. The structure–activity relationships and the key interactions revealed from the molecular modeling studies and the key findings of the pharmacological evaluation are also discussed.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">5.1 Pyrazolo-pyrido-diazepine, -pyrazine, and -oxazinedione Derivatives as Novel Dual Nox4/Nox1 Inhibitors</h3><div class="NLM_p">There is much evidence that NADPH oxidase isoform 4 (Nox4) is the key source of reactive oxygen species (ROS) in the pathogenesis of idiopathic pulmonary fibrosis. Nox4 has also been found to be upregulated in mouse models of IPF and in lung fibroblasts of human IPF patients. Abrogation of fibrogenesis in bleomycin-induced/FITC-induced models of lung injury via genetic or pharmacologic silencing has also been reported.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Keeping in view the role of Nox4 in tissue fibrogenesis and therapeutic benefits of targeting Nox4 in fibrotic disorders, a group of researchers led by Patrick Page identified pyrazolopyridine diones as first in class, potent, and orally bioavailable Nox4 inhibitors. The most potent molecule displayed significant efficacy in in vitro assays on human fibroblasts differentiation, epithelial cells apoptosis, and epithelial–mesenchymal transition. It also exhibited remarkable benefits in preventive and curative murine models of bleomycin-induced pulmonary fibrosis. In extension of this work, pyrazolo-pyrido-diazepine dione derivatives were designed and synthesized by the same group.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Among the compounds synthesized, <b>12</b> (<i>K</i><sub>i</sub>(Nox1) = 101 ± 10 nM, <i>K</i><sub>i</sub>(Nox4) = 72 ± 3 nM) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) exhibited high potency in the in vitro assays of human lung fibroblast differentiation as well as in curative murine models of bleomycin-induced pulmonary fibrosis. Compound <b>12</b> was found to be endowed with efficiency superior to that of pirfenidone. It exhibited a good compromise between microsomal metabolism, free fraction, permeability, and physical properties associated with high Nox4/Nox1 potency and the highest Nox4/Nox2 selectivity ratio (18.6). The pharmacokinetic profiling of <b>12</b> was also very exciting with high exposure owing to its good physicochemical properties and higher permeability. A counterscreening assay for potential ROS scavenging was performed to evaluate the Nox specificity of <b>12</b>. The results indicated no potential problem regarding CYP450 inhibition and also revealed that <b>12</b> was not mutagenic or genotoxic. Lung fibrosis was strongly abrogated by <b>12</b> following once daily oral administration from day 10 to day 25 after bleomycin intratracheal administration in a curative model of bleomycin-induced pulmonary fibrosis. Compound <b>12</b> (10 mg/kg po) inhibited the collagen deposition by 64% at this dose as compared to only 12% inhibition by pirfenidone (100 mg/kg po). The study concluded that <b>12</b> possesses an excellent pharmacological and safety profile with <i>K</i><sub>i</sub> in the two-digit nanomolar range on Nox4 and deserves to be investigated clinically for the treatment of idiopathic pulmonary fibrosis.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pyrazolo-pyrido-diazepine, -pyrazine, and -oxazinedione derivatives as novel dual Nox4/Nox1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">5.2 Novel Pirfenidone Analogues for the Treatment of Pulmonary Fibrosis</h3><div class="NLM_p">Motivated by the ability of pirfenidone, administered at 0.5% (w/w) of the diet to decrease the biochemical evidence of lung fibrosis in a variety of animal models,<a onclick="showRef(event, 'ref99 ref100 ref101 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101 ref102 ref103">(99-103)</a> a series of polysubstituted 1-aryl-2-oxo-1,2-dihydropyridine-3-carbonitriles, pyrazolo[3,4-<i>b</i>]pyridine-5-carbonitriles, and pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitriles (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) were synthesized and their antifibrotic activity was evaluated.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Among the compounds synthesized, <b>13</b> and <b>14</b> displayed promising antifibrotic potential. For the biological evaluation, the lung content of hydroxyproline (HP) was determined as a biochemical index of fibrosis. Compound <b>13</b> (HP = 48.55 μmol/lung) with a 4-ethoxyphenyl group (at the 1 position) was the most potent compound when compared to pirfenidone (HP = 158.39 μmol/lung). The biochemical evidence was well supported by a histopathological study. The positive influence of the electron releasing group on the activity was further confirmed by the drastic decline in the antifibrotic potential of another analogue possessing the 4-fluorophenyl group. The decline in antifibrotic potential was attributed to the electron withdrawing property of fluorine which was assumed to increase the hypoxanthine level. A similar trend was observed with <b>14</b> which was also endowed with impressive antifibrotic activity. Significant activity of <b>14</b> (HP = 119.55 μmol/lung) compared to that of the pirfenidone group was attributed to the electron releasing effect of the substituents conferring a higher antifibrotic activity. Compounds <b>13</b> and <b>14</b> showed remarkable decreases in the lactate dehydrogenase (LDH) activity levels. Compound <b>14</b> normalized the protein content, whereas <b>13</b> led to no noticeable change in the protein concentration.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Novel pirfenidone analogues for the treatment of pulmonary fibrosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.3 Pirfenidone Derivatives as Antifibrotic Agents</h3><div class="NLM_p">The reduced bioactivity owing to the fast metabolism of pirfenidone in the human body has motivated researchers to modify pirfenidone structurally with the aim of increasing its half-time and antifibrotic activity.<a onclick="showRef(event, 'ref105 ref106 ref107 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref105 ref106 ref107 ref108 ref109">(105-109)</a> With this background, a group of researchers led by Zhengrong Shen designed and synthesized pirfenidone derivatives and evaluated the influence of different side chains on their antifibrotic potency. The design strategy involved introduction of a side chain with a 4-alkoxylphenyl group, including a terminal amine to the 1-position of a pyridone scaffold, and variation of the length of the linker between the scaffold and the amine and selection of different amines to determine the influence of hydrophobicity on the biological activity. Twenty-four pirfenidone derivatives were synthesized and evaluated for their inhibitory activity against the human lung fibroblast cell line MRC-5. All the synthesized compounds exhibited significant inhibitory potential against MRC-5 compared to pirfenidone which possessed an IC<sub>50</sub> value of 14.4 mM. Compound <b>15</b> exhibited the most potent inhibitory potential against MRC-5 cell line (10-fold more potent than pirfenidone) with an IC<sub>50</sub> value of 1.36 mM. The association of fibrogenesis with inflammation is well evidenced with TNF-α and TGF-β being the two major molecules for tissue fibrosis. TNF-α and TGF-β play vital roles in the induction of fibrosis. p38, a member of the stress activated protein kinase family, also has a key role in the mediation of inflammatory response and tissue remodeling. Thus, molecular docking studies of <b>16</b> were performed with p38, TNF-α, and TGF-β using the Discovery Studio 2.1/Flexible Docking protocol on a model structure (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HP2">3HP2</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QSC">1QSC</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FAA">3FAA</a>). The results of the docking study revealed that <b>16</b> was well stabilized within the active site of p38 by hydrogen bonding interactions. Such interactions were not observed with the amino acid residues of TNF-α and TGF-β, and thus <b>16</b> appeared more likely to be the ligand of p38. Rationalization of the computational study was carried out, and the synthesized compounds were evaluated for their binding activity with p38 in vitro. In the assay, it (IC<sub>50</sub> = 4.07 μM) was found to be 40-fold more potent than pirfenidone (IC<sub>50</sub> = 165.40 μM). Overall the study concluded that three or four methylenes between scaffold and amine, and heterocyclic amines might be beneficial for inhibitory activity against p38. The results indicated strongly the induction of antifibrotic effects by the synthesized compounds via the p38 MAPK pathway. Thus, p38 could be the possible target for the design of new antifibrotics (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pirfenidone derivatives as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">5.4 Pyridin-2(1<i>H</i>)-one Derivatives as Regulators of Translation Initiation Factor 3A</h3><div class="NLM_p">Several reports indicated that pulmonary fibrosis possesses a similar pathological basis as lung cancer mediated by growth factors.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> It is well-known that pulmonary fibrosis is associated with an increased risk of lung cancer.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112, 113)</a> With this background, pyridin-2(1<i>H</i>)-ones with different substituents at the N-1 position and C-5 position of pyridin-2(1<i>H</i>)-one scaffold were designed. The design included a study of structure–selectivity relationships (SSRs) and structure–activity relationships together with mechanistic studies. A series of synthetic 1,5-disubstituted-pyridin-2(1<i>H</i>)-one derivatives were tested for anticancer and antifibrosis effects. For the evaluation, A549 (human lung adenocarcinoma cell with high expression of eIF3a) and NIH3T3 (a mouse embryonic fibroblast cell line with low expression of eIF3a) cell viability assays were employed. Among the synthesized compounds, exciting results were observed with <b>17</b> which exhibited both potency and selectivity (IC<sub>50</sub> = 0.13 mM) for the A549 cell line via inhibition of translation initiation (eIF3a suppression-biomarker for lung cancer). The study proposed <b>17</b> as a lead compound with which to construct novel scaffolds as eIF3a regulators and antilung cancer agents. Compounds <b>18</b> (IC<sub>50</sub> = 0.016 mM) and <b>19</b> (IC<sub>50</sub> = 0.014 mM) exhibited significant antifibrotic potential against NIH3T3 cell proliferation (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pyridin-2(1<i>H</i>)-one derivatives as regulators of translation initiation factor 3A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">5.5 Carbohydrate-Modified 1-(Substituted aryl)-5-trifluoromethyl-2(1<i>H</i>)-pyridones as Antifibrotic Agents</h3><div class="NLM_p">With the objective of preparing antifibrotics with greater water solubility and improved pharmacokinetics, carbohydrate modified 1-(substituted aryl)-5-trifluoromethyl-2(1<i>H</i>) pyridones were designed and synthesized by Lou et al.<a onclick="showRef(event, 'ref108 ref115'); return false;" href="javascript:void(0);" class="ref ref108 ref115">(108, 115)</a> Fluorofenidone, [1-(3-fluorophenyl)-5-methyl-2-(1<i>H</i>)-pyridone], a small molecule compound structurally related to perfinedone with anti-inflammatory and antifibrotic properties was employed as a standard. Promising results were observed with most of the compounds whose inhibitory activity was comparable to or better than that of fluorofenidone. Compound <b>20</b> (IC<sub>50</sub> = 0.17 mM), for example, exhibited remarkable inhibitory potential against NIH3T3 cells and was the most potent of the synthesized compounds. The results of the biological evaluation highlighted the key structural features essential for potent inhibition of NIH3T3 cells. Glucose appeared to be the preferred carbohydrate among those tested. The positioning of the amine on the chemical architecture of the designed compounds was crucial for activity with the amine functionality preferred at the ortho position. A methylene group linkage between the substituted phenyl ring and 5-trifluoromethyl-2(1<i>H</i>)-pyridone resulted in potent compounds, and this was attributed to the increased flexibility between two substituted aryl rings (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Overall the study indicated that modifications of pirfenidone analogues with carbohydrates potentiate the inhibitory activity against NIH3T3 cell proliferation.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1<i>H</i>) pyridones as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">5.6 5-Substituted 2(1<i>H</i>)-Pyridone Derivatives as Antifibrotic Agents</h3><div class="NLM_p">Pirfenidone and fluorofenidone are multitarget antifibrotic agents that act on TNF-α, TGF-β, PDGF, and NF-κB. Despite their remarkable efficacy for the treatment of lung fibrosis, both drugs possess some limitations, including short half-life, low efficacy, and requirement of high doses.<a onclick="showRef(event, 'ref115 ref116 ref117 ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref117 ref118 ref119">(115-119)</a> With the objective of overcoming these shortcomings while retaining the multitargeting potential, two series of novel 5-substituted-2(1<i>H</i>)-pyridone compounds were synthesized by Chen et al. A total of 31 novel pyridine derivatives were synthesized and tested against NIH3T3 cell proliferation using an MTT assay. Pirfenidone and fluorofenidone were employed as positive controls. The synthesized compounds were found to have good inhibitory effects against NIH3T3 cells with <b>21</b> being the most potent with IC<sub>50</sub> = 0.08 mM, 34 times that of fluorofenidone (IC<sub>50</sub> = 2.75 mM). Some details of the structure–activity relationships emerged from the results of the biological evaluation (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. 5-Substituted-2(1<i>H</i>)-pyridone derivatives as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">5.7 N1-Substituted Phenylhydroquinolinone Derivatives with Antifibrosis Activity</h3><div class="NLM_p">In view of the requirement of high doses of pirfenidone for antifibrosis activity,<a onclick="showRef(event, 'ref115 ref116 ref117 ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref117 ref118 ref119">(115-119)</a> N1-substituted phenylhydroquinolinone derivatives retaining the 1-phenyl-2(1<i>H</i>)-pyridone scaffold were designed and synthesized in the hope of maintaining the multitargeting potential. The design strategy involved (a) cyclization through C-5 and C-6 to form the phenylhydroquinolinone scaffold to prevent the rapid metabolism of the 5-CH<sub>3</sub>, (b) placement of hydrogen bond donors or acceptors at C-5 of hydroquinolinones, (c) introduction of different substituents on the N-1 phenyl group. The designed compounds were synthesized and evaluated against NIH3T3 cell lines using an MTT assay. Significant inhibition of NIH3T3 cell proliferation was exhibited by the compounds (IC<sub>50</sub> = 0.09–26 mM). Compound <b>22</b> with IC<sub>50</sub> = 0.3 mM exhibited 14 times higher potency than that of fluorofenidone (IC<sub>50</sub> = 4.2 mM). Compound <b>23</b> (IC<sub>50</sub> = 0.09 mM) exhibited potency 46 times higher than that of fluorofenidone. Structure–activity relationship studies revealed that the presence of a hydrogen bond donor on C-5 of the hydroquinolinones and aromatization of tetrahydroquinolin-2(1<i>H</i>)-one to dihydroquinolin-2(1<i>H</i>)-one proved beneficial to the antifibrotic activity. The study proposed N1-substituted phenylhydroquinolinone as a promising scaffold for the development of novel antifibrotic agents (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. N1-substituted phenylhydroquinolinone derivatives with antifibrosis activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">5.8 1,5-Disubstituted Pyridone Derivatives as Antifibrotic and Anti-Lung-Cancer Agents</h3><div class="NLM_p">In the search of potent anti-lung-cancer agents possessing antifibrotic potential, a series of 1,5-disubstituted pyridone derivatives were designed and synthesized. The design strategy involved introduction of benzyl groups in place of phenyl group at N-1 of the pyridine moiety and placing of various substituents on the two aromatic rings. Compounds <b>24</b> and <b>25</b>, which were earlier reported to possess potency and selectivity against A549 and NIH3T3 cell lines, were employed as leads.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The designed molecules were synthesized and evaluated for their inhibitory effects against A549 and NIH3T3 cell lines. Among the synthesized compounds, <b>26</b> was found to be the most potent and selective toward A549 cell lines with IC<sub>50</sub> = 20 μM in comparison to cisplatin (IC<sub>50</sub> = 10 μM). The inhibitory activity of <b>26</b> was found to be superior to that of the lead compound (<b>25</b>). NIH3T3 cells were also found to be sensitive to exposure to <b>26</b> (IC<sub>50</sub> = 55 μM). Compound <b>27</b> exhibited remarkable antifibrotic potential with IC<sub>50</sub> = 3 μM, almost 151-fold higher than that of pirfenidone (IC<sub>50</sub> = 454 μM). 3D-QSAR models based on the activity data indicated the need for further studies on promising anti-lung-cancer agents with antifibrotic effects (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. 1,5-Disubstituted pyridone derivatives as antifibrotic and anti-lung-cancer agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">5.9 5-Ene Amino/Iminothiazolidinones as Antifibrotic Agents</h3><div class="NLM_p">Evidence exists that superoxide anion radicals play an important role in fibrotic disorders. They activate fibroblasts to produce collagen and the profibrotic cytokine TGF-β.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122, 123)</a> With this background and anticipation of the advantages of the superoxide scavenging properties of anticancer and antifibrotic agents, a series of 5-ene amino/iminothiazolidinones was synthesized. A one pot multicomponent strategy involving [2 + 3] cyclocondensation and Knoevenagel condensation was employed for the synthesis of desired compounds. The formation of potentially reactive and electrophilic compounds by allowing Michael addition of nucleophilic protein residues to the exocyclic double bond as a result of the conjugation of the 5-ene fragment to the C4 carbonyl group of the thiazolidinones and the need for new drugs for the treatment of idiopathic pulmonary fibrosis basically led the authors to explore the pharmacological attributes of 5-ene amino/iminothiazolidinones. Michael acceptors are considered to be the most effective activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) which offers much scope for the treatment of inflammation and cancer.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> The results of a fibroblast viability assay (SRB assay) were promising because the compounds significantly reduced the viability of fibroblasts. However, anticancer activity was not demonstrated by the compounds that possess significant antifibrotic activity. Compounds <b>28</b>–<b>31</b> (IC<sub>50</sub> = 0.03–0.57 μM) were potent antifibrotics with activity profiles similar to that of pirfenidone (IC<sub>50</sub> = 0.71 μM) (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). However, these compounds failed to exhibit superoxide scavenging activity. The results of the study revealed thiazolidinone derivatives to be interesting candidates for the design of new chemical architectures as potent antifibrotics.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. 5-Ene amino/iminothiazolidinones as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">5.10 Lysophosphatidic Acid Receptor 1 Antagonists with Potent Activity on Human Lung Fibroblasts</h3><div class="NLM_p">LPA, a class of biologically active phospholipids produced from lysophosphatidylcholine (LPC) catalyzed by the enzyme autotaxin (ATX), exerts a wide range of cellular responses such as calcium mobilization, cell proliferation, cell transformation, and chemotaxis through a family of membrane bound GPCRs.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Recently an increase in the LPA levels in bronchoalveolar lavage fluid (BALF) following lung injury was seen in an in vivo model of murine bleomycin-induced pulmonary fibrosis. The results of this study indicated that blocking LPA<sub>1</sub> signaling could be the basis of a logical strategy for the treatment of idiopathic pulmonary fibrosis.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> In view of this, pyrazole- and triazole-derived carbamates were designed as LPA<sub>1</sub> selective and LPA1/3 dual antagonists in the anticipation that aminopyrazole or aminotriazole could function as bioisosteres of the aminoisoxazole in 3-((4-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)isoxazol-5-yl)benzyl)thio)propanoic acid (Ki16425) and 2-(4′-(4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1′-biphenyl]-4-yl)acetic acid (AM095), previously reported LPA<sub>1</sub> antagonists, respectively.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The results of the study were exciting with <b>32</b> (LPA<sub>1</sub>, IC<sub>50</sub> = 25.2 nM) as the most selective LPA<sub>1</sub> antagonist (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). Inhibition of proliferation and contraction of normal human lung fibroblasts (NHLF) following LPA stimulation was induced by <b>32</b>. A dose dependent reduction of plasma histamine levels in a murine LPA challenge model was observed with <b>32</b> orally administered to mice. Mediation of the profibrotic responses by LPA1/2/3 was investigated, and LPA<sub>1</sub> was found to be the major receptor subtype mediating LPA-induced proliferation and contraction of NHLF. Structure–activity relationship studies indicated that (a) <i>N</i>-aryltriazoles were more selective for LPA<sub>1</sub> than compounds from the corresponding pyrazoles, (b) substitution on the phenyl ring of the carbamate or replacement of the phenyl group with alkyl groups led to reduced antiproliferative potency, (c) for the heterocyclic triazole core, deletion of the methyl group or substitution with an ethyl group on the triazole moiety was well tolerated, and (d) <i>N</i>-aryl[1,2,3]triazoles were more active than the <i>N</i>-aryl[1,2,4]triazoles. This was attributed to conformational differences between the two heterocyclic systems due to unfavorable electronic repulsion in <i>N</i>-aryl[1,2,4]triazoles.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Lysophosphatidic acid receptor 1 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">5.11 5-Amino-4-cyanopyrazole Derivatives as Potent and Highly Selective LPA<sub>1</sub>R Antagonists</h3><div class="NLM_p">Strong evidence of elevated LPA levels in BALF in patients with IPF and the identification of the LPA<sub>1</sub>R as the predominant LPA receptor in lung fibroblasts of IPF patients responsible for enhanced fibroblast cell migration together motivated researchers to design LPA<sub>1</sub>R antagonists as a potential therapeutic approach to treat IPF.<a onclick="showRef(event, 'ref127 ref128 ref130'); return false;" href="javascript:void(0);" class="ref ref127 ref128 ref130">(127, 128, 130)</a> The chemical library of LPA1R antagonists was subjected to high throughput screening (HTS) which led to the identification of <b>33</b> as a potent antagonist of the LPA<sub>1</sub> receptor (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). Detailed investigation of this compound revealed that a degradation product of <b>33</b> was responsible for the LPA<sub>1</sub>R antagonist activity. Sidduri et al. isolated and characterized the degradation products, and this was followed by evaluation of their LPA1R antagonist activity. Several analogues were synthesized using the one-pot Groebke–Blackburn–Bienaymé reaction, and bicyclic heterocycles were constructed. Compounds <b>33</b>–<b>35</b> were the most potent among those tested (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). The results of the investigation demonstrated the inhibition of LPA-induced proliferation and contraction of NHLF by non-carboxylic acid LPA<sub>1</sub>R antagonists.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. 5-Amino-4-cyanopyrazole derivatives as potent and highly selective LPA<sub>1</sub>R antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">5.12 Protein Kinase Inhibitors in the Treatment of Pulmonary Fibrosis</h3><div class="NLM_p">The emergence of apoptosis resistant myofibroblasts following activation of the protein kinase pathways and the ability of protein kinase inhibitors to target prosurvival signaling for the treatment of pulmonary fibrosis highlighted their potential as interesting antifibrotic agents.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The structures of selected protein kinase inhibitors with antifibrotic properties are shown in <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>. Imatinib mesylate, an inhibitor of the Abl protein tyrosine kinase was found to be effective in the murine model of bleomycin-induced pulmonary fibrosis. However, the results were not very consistent, and this could be due to the difference in dosage regimen or the genetic background of the mice.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Rapamycin, a natural product of the soil bacterium, <i>Streptomyces hygroscopicus</i>, inhibits mTOR, a mammalian homolog of target of rapamycin and also the proliferation of mesenchymal cells. In the murine model of bleomycin induced pulmonary fibrosis, it exhibited the potential to protect against fibrogenesis.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Compounds <b>36</b> (GW6604) and <b>37</b> (SB-525334) represent the kinase inhibitors targeting the TGF-β receptor I with antifibrotic activity in IPF.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Compound <b>38</b> (AG1879), a SRC kinase-specific inhibitor, inhibits activation of FAK and AKT. It also reduces the accumulation of myofibroblasts in association with abrogated fibrotic responses to lung injury.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Compound <b>39</b> (EW-7197), a novel ALK-5 kinase inhibitor, has also exhibited strong potential as an antifibrotic therapeutic agent for pulmonary fibrosis by inhibition of TGF-β/Smad2/3 and ROS signaling (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>).<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Protein kinase inhibitors with antifibrotic effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A clear understanding of structural requirements for c-Jun N-terminal kinase (JNK) potency along with kinase selectivity<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> enabled the group of researchers to perform optimization of a diaminopurine series as a new class of JNK inhibitors. In an attempt to improve the physicochemical properties and increase the potency and selectivity, <b>40</b> (CC-930) was identified as an orally active antifibrotic JNK inhibitor. This compound has favorable physicochemical properties and was found to be kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (<i>K</i><sub>i</sub>(JNK1) = 44 ± 3 nM, IC<sub>50</sub>(JNK1) = 61 nM, <i>K</i><sub>i</sub>(JNK2) = 6.2 ± 0.6 nM, IC<sub>50</sub>(JNK2) = 5 nM, IC<sub>50</sub>(JNK3) = 5 nM). It also displayed selectivity against MAP kinases ERK1 and p38a with IC<sub>50</sub> values of 0.48 and 3.4 μM, respectively (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> A preliminary investigation in healthy male volunteers demonstrated that <b>40</b> is well-tolerated, and the exposure is dose-proportional.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> A phase II clinical trial of <b>40</b> in patients with IPF began in January 2010 but terminated in 2013 due to the benefit and risk profile.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> However, <b>40</b> is currently being clinically evaluated for lung fibrosis.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <b>40</b>, an orally active antifibrotic JNK inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A lead optimization study on <b>41</b> led to the development of <b>42</b> (AX13587) as a JNK inhibitor.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Docking studies were performed to identify key molecular interactions with JNK1. The results of kinase profiling indicated promising results, as <b>42</b> was found to significantly inhibit JNK, MAST3, and MAST4. The methylene homolog of <b>42</b>, <b>43</b> (AX14373) (native JNK1 IC<sub>50</sub>= 47 nM) was reported to be a highly specific JNK inhibitor (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> With these promising results, it can be anticipated that <b>43</b> may possess significant potential for the treatment of IPF as the other JNK inhibitor.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. <b>42</b> as a JNK inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The involvement of TGF-β1, a fibrogenic cytokine, in the pathogenesis of pulmonary fibrosis by regulation of extracellular matrix deposition in the response to lung tissue injury has been well reported. TNF-α is an important proinflammatory cytokine that is involved in regulation of the inflammation in response to lung tissue injury.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Motivated by the clinical promise of ivacaftor in pulmonary fibrosis, along with the well-evidenced role of cytokines in the pathogenesis of this chronic progressive parenchymal lung disease, several 4-oxoquinoline-3-carboxamide derivatives were synthesized by Zhu et al. employing ivacaftor as the lead. Among the synthetic derivatives, <b>44</b>–<b>46</b> displayed potent inhibitory potential of both TGF-β1-induced total collagen accumulation and lipopolysaccharides (LPS)-stimulated TNF-α production. Compound <b>45</b> at 20 mg kg<sup>–1</sup> day<sup>–1</sup>, administered orally for 4 weeks, remarkably attenuated lung inflammation and injury. It was also found to decrease the lung collagen accumulation in a bleomycin-induced pulmonary fibrosis model. The results of the investigation demonstrated the promise of <b>45</b> as a potential orally active antifibrotic agent for pulmonary fibrosis (<a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. 4-Oxoquinoline-3-carboxamides derivatives as potent antifibrosis agents for pulmonary fibrosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">6 Patent Literature</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This section presents the structures of the compounds patented since 2006 for the treatment of IPF. In 2016, Schwiebert et al. filed a patent on various coumarin derivatives for the treatment of IPF. Of all the synthesized coumarin derivatives, seven coumarin compounds were tested with varied dosages from 0.001 to 100 μM, and subsequent inhibition of fibrosis growth was determined. Among all the tested compounds, <b>47</b> exhibited significant growth inhibitory effect with GI<sub>50</sub> = 0.19 μM (<a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Patented compounds (<b>47</b>–<b>55</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2016, Gilbert et al. published a patent on dihydropyrimidinoisoquionolinones for the treatment of an inflammatory condition, i.e., IPF. The preparation and evaluation of the compounds were reported. The compounds were found to antagonize the GPR84, a G-protein-coupled receptor that is indirectly involved in this inflammatory disease. All the compounds were evaluated by in vitro as well as in vivo methods. Compounds <b>48</b>–<b>55</b> were found to be most potent, exhibiting IC<sub>50</sub> values ranging from 0.01 to 100 μM. The solubility and the pharmacokinetic profile of the compounds were also determined, and the results indicated that the compounds could be administered through different routes depending on their formulation (<a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">Josef et al. filed a patent in 2015 for the synthesis and evaluation of various derivatives of methylpyrrolopyrimidinecarboxamides for the treatment of IPF. All the compounds significantly inhibited the enzyme phosphodiesterase 4 and 5 (PDE-4, -5), an enzyme that leads to drastic inflammatory conditions, specifically IPF. Most of the compounds exhibited a −log IC<sub>50</sub> value ranging from 8 to 9 mol<sup>–1</sup> against PDE-5 and from 6 to 7 mol<sup>–1</sup> against PDE-4. Pharmacological evaluation of the compounds in animals was carried out against both enzymes using Sprague Dawley rats. All the compounds tested were administered orally. In this model changes to the arterial vascular response and the PDE-5 activity were assessed. The percentage change vs control was found to be approximately between −11% and −40% for compounds <b>56</b>–<b>60</b>. Similarly, pharmacological testing was done for PDE-4. On the other hand, the compounds were tested for inhibition of LPS-induced TNF-α production in male Sprague Dawley rats. The inhibition of LPS in this model achieved by the compounds <b>61</b>–<b>65</b> was between 7% and 99%. These active molecules thus could be used to treat the inflammatory condition, IPF (<a class="ref internalNav" href="#fig18" aria-label="Figure 18">Figure 18</a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Patented compounds (<b>56</b>–<b>65</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">John et al. filed a patent in 2015 on various analogues of 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridines for the treatment of IPF. The Wnt/β-catenin pathway is implicated in the etiology of this disease, and it was postulated that the β-catenin is overexpressed in epithelial cells, increasing the presence of proliferating fibroblasts which leads to excess collagen deposition in the lungs, a pathological hallmark of IPF. The synthesized compounds were screened in a β-catenin based receptor assay in a transformed epithelial cell line (NL-20) using (6<i>S</i>,9a<i>S</i>)-6-(4-hydroxybenzyl)-<i>N</i>-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxohexahydro-2<i>H</i>-pyrazino[1,2-<i>a</i>]pyrimidine-1(6<i>H</i>)-carboxamide (ICG-001), a small catenin inhibitor, as a control. Among all the synthetic derivatives, nine compounds (<b>66</b>–<b>74</b>) were found to inhibit Wnt activity with promising IC<sub>50</sub> values ranging between 0.067 and 2.03 μM. Compound <b>68</b> was the most potent molecule and could be used to treat IPF (<a class="ref internalNav" href="#fig19" aria-label="Figure 19">Figure 19</a>).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Patented compounds (<b>66</b>–<b>75</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2014, Gregory et al. filed a patent on compounds with apoptosis signal-regulating kinase (ASK) inhibitory potential that could be used to treat an ASK-mediated disease such as IPF. ASK phosphorylation can lead to many serious conditions, including IPF. In this aspect, ASK inhibitors define a key role in the treatment of this fatal lung disease. All the synthesized derivatives were evaluated against ASK1 kinase using a TR-FRET ASK1 kinase assay which determines the amount of phosphate transferred from ATP to a peptide substrate. Fluorescence was measured at 665 nm, and IC<sub>50</sub> values were calculated. All the derivatives inhibited the kinase ASK1 significantly, and <b>75</b> was found to be the most potent inhibitor with IC<sub>50</sub> = 0.7 nM (<a class="ref internalNav" href="#fig19" aria-label="Figure 19">Figure 19</a>).<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><div class="NLM_p">In 2012, Marcello Allegretti et al. published a patent on 2-phenylpropionic acid and its derivatives which are useful for inhibition of chemotactic activation of neutrophils and can be further utilized for prevention and treatment of pathological conditions such as IPF. The compounds were evaluated in vitro as inhibitors of chemotaxis of polymorphonuclear leukocytes (PMN leukocytes) induced by fractions of interleukins (IL-8), GRO-α, and C5a. Compounds <b>76</b> and <b>77</b> were found to be most potent, inducing significant inhibition of PMN migration (<a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>).<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Patented compounds (<b>76</b>–<b>83</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2011, Alessio Moriconi et al. patented 2-arylacetic acid derivatives for the treatment of IPF by their inhibition of the chemotactic activation of neutrophils. Compounds were tested in vitro for their ability to inhibit chemotaxis of PMN leukocytes induced by IL-8 and GRO-α. Compounds <b>78</b> and <b>79</b> showed the highest percentage inhibition of IL-8 induced PMN chemotaxis and GRO induced PMN chemotaxis (<a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div><div class="NLM_p">In 2009, Leslie Holsinger et al. patented compounds with potential to inhibit cathepsin B, a lysosome cysteine protease, increased levels of which lead to pulmonary fibrosis and hence can be used to cure IPF. The compounds were evaluated for cathepsin inhibition employing a biochemical assay, and IC<sub>50</sub> values were determined. Compound <b>80</b> was found to possess interesting inhibitory potential (<a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><div class="NLM_p">In 2009, Kossen et al. published a patent on compounds used to treat fibrotic disorders by inhibition of p38 MAPK. The activation of p38 MAPK kinase leads to the response of various cytokines associated with inflammation. The enhanced activity of this kinase enzyme can cause pulmonary conditions similar to IPF. The synthesized compounds were screened for p38 MAP kinase inhibition in vitro. Most of the compounds exhibited good inhibitory activity with IC<sub>50</sub> = 0.05–10 μM. Compounds <b>81</b> and <b>82</b> were the most potent inhibitors (<a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><div class="NLM_p">In 2008, Thomas G. Gant et al. published a patent on <i>N</i>-arylpyridinones as fibrotic inhibitors based on <b>83</b> which can be used in the management of IPF. A dystrophic mouse muscle fibrosis assay was carried out for these compounds, and all the compounds displayed good activity in fibrotic disorders (<a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><div class="NLM_p">In 2006, Barry Hart et al. published a patent on fused bicyclic pyrimidine compounds useful in the treatment of related disorders like IPF, with enhanced TGF-β activity. The compounds were assessed for their ability to inhibit TGF-β, and it was found that <b>84</b> and <b>85</b> exhibited the highest potency with low IC<sub>50</sub> values (<a class="ref internalNav" href="#fig21" aria-label="Figure 21">Figure 21</a>).<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Patented compounds (<b>84</b>–<b>87</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2006, Levin et al. patented β-sulfonamide hydroxamic acids as inhibitors of TNF-α converting enzyme (TACE) or matrix metalloproteinase (MMP) which helps in prevention and treatment of IPF. Compounds were assessed for inhibition of the cleavage of the pro-TNF peptide by TACE using TACE FRET assay, and the IC<sub>50</sub> values were determined. Compounds <b>86</b> and <b>87</b> were found to be the most potent (<a class="ref internalNav" href="#fig21" aria-label="Figure 21">Figure 21</a>).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><div class="NLM_p last">In addition to presenting potent scaffolds with antifibrotic potential, the patent literature has further expanded the library of the enzymes, targets, and factors with a key role in fibrosis. This patent literature, coupled with a clear understanding of the pathogenesis of the disease, will certainly be beneficial when exploiting the mediators involved.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">7 Conclusions and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">IPF, a chronic dysregulated response to microinjuries with fibroblast hyperplasia and exaggerated ECM deposition resulting in abnormal lung remodeling, is a progressive and fatal lung disease. It is well evident that fibrosis is a complicated condition, and the probability of a single drug or pathway intervention to be curative is very less. In view of the complex etiology of fibrosis and the broad spectrum pharmacological profile of the perfinedone and nintedanib, it can be ascertained that drugs possessing polypharmacology may prove to be advantageous and efficacious antifibrotic agents as compared to the agents acting on a single target. However, this is a huge challenge for the experts working in this field, as the design and discovery of agents possessing polypharmacology often rely on serendipity. Pirfenidone and nintedanib are the two approved drugs for IPF with positive and favorable recommendations. Both drugs exhibit polypharmacology.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The mechanism of pirfenidone has been extensively studied, and it is categorized as a multiple-target drug against inflammatory, antioxidative stress, and antiproliferative processes. It acts on TNF-α, TGF-β, PDGF, and NF-κβ. As an antifibrotic, pirfinedone displays broad spectrum efficacy to treat pulmonary, liver, renal, and cardiac muscle fibrosis. Similar to pirfinedone, nintedanib acts on multiple targets and is a potent oral angiokinase inhibitor that targets the proangiogenic pathways mediated by VEGFR1–3, fibroblast growth factor receptor (FGFR) 1–3, and PDGFR α and β.<a onclick="showRef(event, 'ref115 ref159'); return false;" href="javascript:void(0);" class="ref ref115 ref159">(115, 159)</a></div><div class="NLM_p">Both pirfenidone and nintedanib can slow down functional decline of the lung and disease progression but cannot cure the disease. This indicates the collaborative efforts required of medicinal chemists and biologists to design and evaluate new chemical architectures with antifibrotic potential for treatment of IPF. Recently, several new compounds have entered into clinical trials, and a significant clinical outcome is awaited. It is quite possible that some of these compounds will emerge as future novel therapeutics for IPF. Various biomarkers and pathways involved in this fatal lung disease have been identified. A potential role for protein kinase inhibitors (PKIs) that target prosurvival signaling in the treatment of pulmonary fibrosis has also been established. This has enabled chemists to rationally synthesize and preclinically evaluate new antifibrotic agents for IPF. Apart from targeting the mediators of inflammation and various kinases, blocking of LPA<sub>1</sub> signaling also appears to be a logical therapeutic strategy for IPF. The role of HDACs in the progression of tissue fibrosis has also been reported. Recently, SAHA, an HDAC inhibitor, has been reported in a preclinical study to promote fibroblast apoptosis and ameliorate pulmonary fibrosis.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This is an exciting advance in the medicinal attributes of HDAC inhibitors, and if this preclinical promise of SAHA to attenuate pulmonary fibrosis can be replicated clinically, a variety of similar inhibitors will be available for initial screening as anti-IPF agents. LBH589/panobinostat (pan-HDAC inhibitor), a proven antitumor agent, significantly downregulates collagen biosynthesis and antiapoptotic genes in IPF fibroblast populations, and thus pan-HDAC inhibition also presents a therapeutic strategy for patients with IPF.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> With such positive results, it is really astonishing that an extensive screening program to evaluate such inhibitors for the treatment of IPF by various laboratories working extensively on the development of HDAC inhibitors has not been initiated yet. Numerous inhibitors have been synthesized employing SAHA and LBH589 as the leads, and the library of such agents must be evaluated for their potential as antifibrotic agents for IPF. Ultimately, such a program may lead to the discovery of novel HDAC inhibitor as a useful therapeutic agent for IPF or at a minimum, another target for the fatal lung disease will be fully identified.</div><div class="NLM_p">The role of Brd on the profibrotic responses of lung fibroblasts patients with rapidly progressing IPF and mouse bleomycin model of lung fibrosis has been identified in a recent study. It was observed that Brd4 inhibition remarkably attenuates the enhanced migration, proliferation, and IL-6 release observed in lung fibroblasts in patients with IPF. Enhanced histone H4 lysine5 acetylation and association of Brd4 with genes involved in the profibrotic responses in IPF were also observed. Compound <b>4</b>, a Brd 4 inhibitor at a dose of 200 mg/kg administered orally, significantly attenuated the bleomycin induced lung fibrosis in C57BL/6 mice. Overall the study concluded that <b>4</b> possesses the potential to inhibit the profibrotic effects of IPF and indicates the promise of Brd4 inhibitors as a novel and efficacious therapy for rapidly progressing IPF. Keeping this in view, the chemist must emphasize on these interesting findings and should work on the design of novel Brd4 inhibitors for this fatal lung disease. Moreover, the existing Brd4 inhibitors shall also be evaluated for their antifibrotic effects in IPF.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">In view of the favorable outcomes with polypharmacological interventions, it can be anticipated that dual inhibitors of Brd4-HDAC, HDAC-LPA1, Brd4-4-LPA1 along with agents targeting various kinases may be a logical drug design strategy in future. These multitargeting agents can be synthesized via a molecular hybridization technique that comprises the incorporation of two drug pharmacophores in a single chemical architecture. Moreover such hybrid drugs can also counterbalance the known side effects associated with the other hybrid part.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> It is really a high time for the experts to rationally design such scaffolds for the treatment of IPF.</div><div class="NLM_p">The link between thrombotic vascular events and IPF is supported by compelling evidence. Despite of the conflicting outcomes of the clinical trials of anticoagulation in IPF, it can still be concluded that the manipulation of the coagulation system plays a role in IPF pathogenesis and future investigations should be directed toward the exploration of the mechanisms underlying the prothrombotic state in IPF. The effects of new classes of anticoagulants in IPF also need to be assesed.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">This compilation presents the pathogenesis, therapeutic interventions and the treatment approaches for IPF. Based on the new concept of pathogenesis of IPF, several targets are in the development pipeline. Activator protein 1 (AP-1) related to regulation of cytokines and chemokines and NADPH oxidase isoform 4 (Nox4) inhibitors capable of attenuating pulmonary fibrosis represent such targets.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The new drugs or therapeutic inventions and the novel pathways for IPF await full discovery, understanding, and establishment. IPF is now viewed more as a neoproliferative disorder of the lungs. Categorizing IPF as a cancer-like disease provides a better and clearer understanding of the pathogenesis of the disease. The pathogenic pathways common to both cancer and IPF offer much scope for new clinical trials with existing anticancer agents and drug combinations.</div><div class="NLM_p">The present review article also encompasses the design strategies employed for the synthesis of agents with promising activity for the treatment of IPF. Over the past few years, the researchers have identified some promising scaffolds, at the preclinical level, which display remarkable antifibrotic potential in pulmonary fibrosis. In addition to design strategies, the article also highlights the structure–activity relationships and the mechanistic insights revealed during the biological evaluation of these agents. The research literature indicates that chemists have extensively attempted to evaluate pirfenidone derivatives, and their efforts have been aimed mainly at overcoming the drawbacks of pirfenidone such as its short half-life, low efficacy, and requirement of high doses. The expertise of formulation chemists to improve the pharmacokinetic properties of pirfenidone can lead to new dimensions in pharmacological profile of the compound. However, the need of the hour is the search of novel agents with antifibrotic potential in IPF. The medicinal chemist should draw its attention toward the design of such novel scaffold relying on the biologist and the formulation experts to evaluate already existing agents and modify the pharmacokinetic parameters.</div><div class="NLM_p">Thirteen patents have been published during the past 10 years detailing the synthesis and evaluation of antifibrotic agents for IPF. This review article emphasizes the patent literature with an overview of the chemical structures and the IC<sub>50</sub>/GI<sub>50</sub> values indicating the inhibitory effects. The patent literature presents activity profiles of coumarins, isoquinolinones, pyrrolopyrimidinecarboxamides, pyrazolo-pyridines, 2-aryl acetic or propanoic acid derivatives and sulfonamide hydroxamic acids for the treatment of IPF. The biological evaluation of most of the patented compounds has been limited to in vitro studies, and in vivo pharmacological evaluation with detailed mechanistic studies is necessary. Some of the patented molecules have displayed promising inhibitory effects with IC<sub>50</sub> values in the low micromolar range and even at the nanomolar level. With a dozen of antifibrotic agents possessing exciting preclinical potential in the armory, it can be anticipated that some of them will advance to clinical investigation.</div><div class="NLM_p">At present, the difficult diagnosis and high mortality rate in IPF pose the main challenges for the researchers working in this field. A reliable and fast diagnosis technique and effective treatment are highly desirable. A timely diagnosis of IPF requires high resolution computed tomography (HRCT) and/or surgical lung biopsy. Currently, there are no other simple, quick, and effective means of diagnosis for physicians, and the identification of diagnostic biomarkers will be of great help for the physician especially when the HRCT or biopsy cannot be obtained. Biomarkers can provide valuable information such as pathogenesis, prognosis, and therapeutic outcomes. Several molecular biomarkers for IPF such as surfactant proteins A and D (SPA and SPD), MMP1 and MMP7, and periostin have already been outlined.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> All these biomarkers are highly expressed in the patients with IPF, and a detailed investigation could lead to their emergence as effective clinical tools for accurate diagnosis of IPF.</div><div class="NLM_p last">Last but not the least, nonpharmacological approaches also hold enough promise and have been recognized as effective measures for IPF. Among these approaches, lung transplantation (LTx) is an accepted therapy for patients with chronic, end-stage lung disease for whom no effective medical therapy exists. LTx confers quality of life and survival benefits and is reported to be the best available therapy for selected IPF patients. On the basis of the recommendations in the guidelines, IPF patients should be referred for transplantation in the presence of a DL<sub>CO</sub> below 39%, a greater than 10% FVC decline over 6 months or desaturation under 88% in pulse oximetry during a 6 min walking test.<a onclick="showRef(event, 'ref163 ref164 ref165 ref166 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref163 ref164 ref165 ref166 ref167 ref168">(163-168)</a> Pulmonary rehabilitation (PR) has also proved its effectiveness in alleviating symptoms and improving exercise tolerance, functional capacity, dyspnea scores, leg strength, and quality of life in patients with IPF. However, the limitation and the long-term effects of PR should be observed in a detailed manner, and further investigations are required.<a onclick="showRef(event, 'ref169 ref170 ref171 ref172 ref173 ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref169 ref170 ref171 ref172 ref173 ref174 ref175">(169-175)</a> In addition, beneficial effects can also be observed for patients with IPF if the comorbidities such as GERD, pulmonary hypertension, and obstructive sleep apnea which are frequently associated with IPF can be taken care of.<a onclick="showRef(event, 'ref176 ref177 ref178 ref179 ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref176 ref177 ref178 ref179 ref180 ref181">(176-181)</a></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00935" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing-Ping Liou</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, College
of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3775-6405" title="Orcid link">http://orcid.org/0000-0002-3775-6405</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0268726e42766f772c6766772c7675"><span class="__cf_email__" data-cfemail="b3d9c3dff3c7dec69dd6d7c69dc7c4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Min Liu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, College
of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kunal Nepali</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, College
of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Yi-Min Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=BIO-d46e1850-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yi-Min Liu</b> received her Ph.D. degree in Pharmacy from College of Pharmacy, Taipei Medical University, Taipei, Taiwan, under the supervision of Professor Jing-Ping Liou. Her research work is focused on the rational drug design of small molecule inhibitors of relevant drug targets and optimization of synthetic procedures for the preparation of compounds along with structure–activity relationship studies. She is currently a Postdoctoral Fellow in the Department of Medicinal Chemistry at the same institution.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Kunal Nepali</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=BIO-d46e1855-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kunal Nepali</b> obtained his Ph.D. degree in Pharmaceutical Chemistry in 2012 from ISF College of Pharmacy, Moga, Punjab, India. He is currently a Posdoctoral Fellow in the Department of Medicinal Chemistry, Taipei Medical University, Taiwan, working under the direction and supervision of Prof. Jing-Ping Liou. His research area is focused on the design and synthesis of new chemical architectures with bioactive potential. Prior to his appointment a Postdoctoral Fellow, he was an Assistant Professor in Department of Pharmaceutical Sciences, Guru Nanak Dev University, Punjab, India.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Jing-Ping Liou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=BIO-d46e1860-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jing-Ping Liou</b> is a Professor of Medicinal Chemistry and Associate Dean of the College of Pharmacy, Taipei Medical University, Taiwan. He received his Ph.D. degree in 2000 from the College of Medicine, National Taiwan University, Taiwan. His scientific interests are centered on the design and synthesis of novel molecular entities as future therapeutics to address the pharmacological problems that lie at the interface of chemistry and biology. He also collaborates with the industrial sector for the optimization of synthetic protocols for rationally designed inhibitors with the potential of modulating the functions of biological targets.</p></figure></div><div class="ack" id="ACK-d46e1865-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research were supported by the Ministry of Science and Technology of the Republic of China (Grant MOST 103-2113-M-038-001-MY3).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i31" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i31"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i32" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i32"> Abbreviations Used</h2><tr><td class="NLM_term">AEC</td><td class="NLM_def"><p class="first last">alveolar epithelial cell</p></td></tr><tr><td class="NLM_term">AP-1</td><td class="NLM_def"><p class="first last">activator protein 1</p></td></tr><tr><td class="NLM_term">ASK</td><td class="NLM_def"><p class="first last">apoptosis signal-regulating kinase</p></td></tr><tr><td class="NLM_term">ATX</td><td class="NLM_def"><p class="first last">autotaxin</p></td></tr><tr><td class="NLM_term">BALF</td><td class="NLM_def"><p class="first last">bronchoalveolar lavage fluid</p></td></tr><tr><td class="NLM_term">BLTx</td><td class="NLM_def"><p class="first last">bilateral lung transplantation</p></td></tr><tr><td class="NLM_term">CPAP</td><td class="NLM_def"><p class="first last">continuous positive airway pressure</p></td></tr><tr><td class="NLM_term">CTGF</td><td class="NLM_def"><p class="first last">connective tissue growth factor</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome p450</p></td></tr><tr><td class="NLM_term">DL<sub>CO</sub></td><td class="NLM_def"><p class="first last">carbon monoxide diffusing capacity</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">FGF</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">FVC</td><td class="NLM_def"><p class="first last">forced vital capacity</p></td></tr><tr><td class="NLM_term">GERD</td><td class="NLM_def"><p class="first last">gastroesophageal reflux disease</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HP</td><td class="NLM_def"><p class="first last">hydroxyproline</p></td></tr><tr><td class="NLM_term">HRCT</td><td class="NLM_def"><p class="first last">high resolution computed tomography</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">IIP</td><td class="NLM_def"><p class="first last">idiopathic interstitial pneumonia</p></td></tr><tr><td class="NLM_term">IL-13</td><td class="NLM_def"><p class="first last">interleukin 13</p></td></tr><tr><td class="NLM_term">ILD</td><td class="NLM_def"><p class="first last">interstitial lung disease</p></td></tr><tr><td class="NLM_term">IPF</td><td class="NLM_def"><p class="first last">idiopathic pulmonary fibrosis</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">LDH</td><td class="NLM_def"><p class="first last">lactate dehydrogenase</p></td></tr><tr><td class="NLM_term">LPA</td><td class="NLM_def"><p class="first last">lysophosphatidic acid</p></td></tr><tr><td class="NLM_term">LPA<sub>1</sub></td><td class="NLM_def"><p class="first last">lysophosphatidic acid receptor 1</p></td></tr><tr><td class="NLM_term">LPC</td><td class="NLM_def"><p class="first last">lysophosphatidylcholine</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">LTx</td><td class="NLM_def"><p class="first last">lung transplantation</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian homolog of target of rapamycin</p></td></tr><tr><td class="NLM_term">NAC</td><td class="NLM_def"><p class="first last"><i>N</i>-acetylcysteine</p></td></tr><tr><td class="NLM_term">NHLF</td><td class="NLM_def"><p class="first last">normal human lung fibroblast</p></td></tr><tr><td class="NLM_term">Nox 4</td><td class="NLM_def"><p class="first last">NADPH oxidase isoform 4</p></td></tr><tr><td class="NLM_term">Nrf2</td><td class="NLM_def"><p class="first last">nuclear factor (erythroid-derived 2)-like 2</p></td></tr><tr><td class="NLM_term">OSA</td><td class="NLM_def"><p class="first last">obstructive sleep apnea</p></td></tr><tr><td class="NLM_term">PAI-1</td><td class="NLM_def"><p class="first last">plasminogen activator inhibitor 1</p></td></tr><tr><td class="NLM_term">PAR1</td><td class="NLM_def"><p class="first last">proteinase activated receptor</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">PKI</td><td class="NLM_def"><p class="first last">protein kinase inhibitor</p></td></tr><tr><td class="NLM_term">PMN</td><td class="NLM_def"><p class="first last">polymorphonuclear</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">proton pump inhibitor</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">pulmonary rehabilitation</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SLTx</td><td class="NLM_def"><p class="first last">single lung transplantation</p></td></tr><tr><td class="NLM_term">SPA and SPD</td><td class="NLM_def"><p class="first last">surfactant proteins A and D</p></td></tr><tr><td class="NLM_term">TACE</td><td class="NLM_def"><p class="first last">TNF-α converting enzyme</p></td></tr><tr><td class="NLM_term"><i>TERC</i></td><td class="NLM_def"><p class="first last">Telomerase RNA component</p></td></tr><tr><td class="NLM_term"><i>TERT</i></td><td class="NLM_def"><p class="first last">telomerase reverse transcriptase</p></td></tr><tr><td class="NLM_term">TGF-β</td><td class="NLM_def"><p class="first last">transforming growth factor β</p></td></tr><tr><td class="NLM_term">T<sub>H</sub>2</td><td class="NLM_def"><p class="first last">T helper 2</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">UIP</td><td class="NLM_def"><p class="first last">usual interstitial pneumonia</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 181 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordier, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancochea, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johkoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudden, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griss, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzko, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schünemann, H. J.</span><span> </span><span class="NLM_article-title">An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1164/rccm.2009-040GL</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.2009-040GL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21471066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=788-824&author=G.+Raghuauthor=H.+R.+Collardauthor=J.+J.+Eganauthor=F.+J.+Martinezauthor=J.+Behrauthor=K.+K.+Brownauthor=T.+V.+Colbyauthor=J.-F.+Cordierauthor=K.+R.+Flahertyauthor=J.+A.+Laskyauthor=D.+A.+Lynchauthor=J.+H.+Ryuauthor=J.+J.+Swigrisauthor=A.+U.+Wellsauthor=J.+Ancocheaauthor=D.+Bourosauthor=C.+Carvalhoauthor=U.+Costabelauthor=M.+Ebinaauthor=D.+M.+Hansellauthor=T.+Johkohauthor=D.+S.+Kimauthor=T.+E.+Kingauthor=Y.+Kondohauthor=J.+Myersauthor=N.+L.+M%C3%BCllerauthor=A.+G.+Nicholsonauthor=L.+Richeldiauthor=M.+Selmanauthor=R.+F.+Duddenauthor=B.+S.+Grissauthor=S.+L.+Protzkoauthor=H.+J.+Sch%C3%BCnemann&title=An+official+ATS%2FERS%2FJRS%2FALAT+statement%3A+idiopathic+pulmonary+fibrosis%3A+evidence-based+guidelines+for+diagnosis+and+management&doi=10.1164%2Frccm.2009-040GL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span></div><div class="casAuthors">Raghu Ganesh; Collard Harold R; Egan Jim J; Martinez Fernando J; Behr Juergen; Brown Kevin K; Colby Thomas V; Cordier Jean-Francois; Flaherty Kevin R; Lasky Joseph A; Lynch David A; Ryu Jay H; Swigris Jeffrey J; Wells Athol U; Ancochea Julio; Bouros Demosthenes; Carvalho Carlos; Costabel Ulrich; Ebina Masahito; Hansell David M; Johkoh Takeshi; Kim Dong Soon; King Talmadge E Jr; Kondoh Yasuhiro; Myers Jeffrey; Muller Nestor L; Nicholson Andrew G; Richeldi Luca; Selman Moises; Dudden Rosalind F; Griss Barbara S; Protzko Shandra L; Schunemann Holger J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association.  It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course.  For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format.  For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak).  Recommendations were based on majority vote.  It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd3NNagTHJTiXXDYhVZBdlfW6udTcc2eYw0VTwOeBgvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D&md5=f47abe4551c8684d3af81f66598e9b2c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1164%2Frccm.2009-040GL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.2009-040GL%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DColby%26aufirst%3DT.%2BV.%26aulast%3DCordier%26aufirst%3DJ.-F.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DLynch%26aufirst%3DD.%2BA.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DAncochea%26aufirst%3DJ.%26aulast%3DBouros%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DC.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DEbina%26aufirst%3DM.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DJohkoh%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DN.%2BL.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DDudden%26aufirst%3DR.%2BF.%26aulast%3DGriss%26aufirst%3DB.%2BS.%26aulast%3DProtzko%26aufirst%3DS.%2BL.%26aulast%3DSch%25C3%25BCnemann%26aufirst%3DH.%2BJ.%26atitle%3DAn%2520official%2520ATS%252FERS%252FJRS%252FALAT%2520statement%253A%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520evidence-based%2520guidelines%2520for%2520diagnosis%2520and%2520management%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D788%26epage%3D824%26doi%3D10.1164%2Frccm.2009-040GL" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Spagnolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sverzellati, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzouvelekis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vancheri, C.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: an update</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.3109/07853890.2014.982165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3109%2F07853890.2014.982165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25613170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1ant70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=15-27&author=P.+Spagnoloauthor=N.+Sverzellatiauthor=G.+Rossiauthor=A.+Cavazzaauthor=A.+Tzouvelekisauthor=B.+Crestaniauthor=C.+Vancheri&title=Idiopathic+pulmonary+fibrosis%3A+an+update&doi=10.3109%2F07853890.2014.982165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: An update</span></div><div class="casAuthors">Spagnolo, Paolo; Sverzellati, Nicola; Rossi, Giulio; Cavazza, Alberto; Tzouvelekis, Argyris; Crestani, Bruno; Vancheri, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic interstitial pneumonia.  The disease, which occurs primarily in middle-aged and older adults, is thought to arise following an aberrant reparative response to alveolar epithelial cell injury characterized by secretion of excessive amts. of extracellular matrix components, resulting in scarring of the lung, architectural distortion, and irreversible loss of function.  A complex interplay between environmental and host factors is thought to contribute to the development of the disease, although the cause of IPF remains elusive and its pathogenesis incompletely understood.  Over the last decade, disease definition and diagnostic criteria have evolved significantly, and this has facilitated the design of a no. of high-quality clin. trials evaluating novel therapeutic agents for IPF.  This massive effort of the medical and industry community has led to the identification of two compds. (pirfenidone and nintedanib) able to reduce functional decline and disease progression.  These promising results notwithstanding, IPF remains a major cause of morbidity and mortality and a largely unmet medical need.  A real cure for this devastating disease has yet to emerge and will likely consist of a combination of drugs targeting the plethora of pathways potentially involved in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKq0R58Wx0w7Vg90H21EOLACvtfcHk0li9qqco5jwPgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1ant70%253D&md5=04f982abb607ec3d577b084f668c7f5b</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.3109%2F07853890.2014.982165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07853890.2014.982165%26sid%3Dliteratum%253Aachs%26aulast%3DSpagnolo%26aufirst%3DP.%26aulast%3DSverzellati%26aufirst%3DN.%26aulast%3DRossi%26aufirst%3DG.%26aulast%3DCavazza%26aufirst%3DA.%26aulast%3DTzouvelekis%26aufirst%3DA.%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DVancheri%26aufirst%3DC.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520an%2520update%26jtitle%3DAnn.%2520Med.%26date%3D2015%26volume%3D47%26spage%3D15%26epage%3D27%26doi%3D10.3109%2F07853890.2014.982165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. P.,  3rd</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.2165/00003495-200464040-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2165%2F00003495-200464040-00005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=405-430&author=M.+Selmanauthor=V.+J.+Thannickalauthor=A.+Pardoauthor=D.+A.+Zismanauthor=F.+J.+Martinezauthor=J.+P.+Lynch&title=Idiopathic+pulmonary+fibrosis%3A+pathogenesis+and+therapeutic+approaches&doi=10.2165%2F00003495-200464040-00005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464040-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464040-00005%26sid%3Dliteratum%253Aachs%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DZisman%26aufirst%3DD.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520pathogenesis%2520and%2520therapeutic%2520approaches%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D405%26epage%3D430%26doi%3D10.2165%2F00003495-200464040-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ziobro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentsch, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbins, E.</span><span> </span><span class="NLM_article-title">Ceramide mediates lung fibrosis in cystic fibrosis</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">709</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bbrc.2013.03.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2013&pages=705-709&author=R.+Ziobroauthor=B.+Henryauthor=M.+J.+Edwardsauthor=A.+B.+Lentschauthor=E.+Gulbins&title=Ceramide+mediates+lung+fibrosis+in+cystic+fibrosis&doi=10.1016%2Fj.bbrc.2013.03.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DZiobro%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DB.%26aulast%3DEdwards%26aufirst%3DM.%2BJ.%26aulast%3DLentsch%26aufirst%3DA.%2BB.%26aulast%3DGulbins%26aufirst%3DE.%26atitle%3DCeramide%2520mediates%2520lung%2520fibrosis%2520in%2520cystic%2520fibrosis%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D434%26spage%3D705%26epage%3D709%26doi%3D10.1016%2Fj.bbrc.2013.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Wilson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Pulmonary fibrosis: pathogenesis, etiology and regulation</span> <span class="citation_source-journal">Mucosal Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/mi.2008.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fmi.2008.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19129758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=103-121&author=M.+S.+Wilsonauthor=T.+A.+Wynn&title=Pulmonary+fibrosis%3A+pathogenesis%2C+etiology+and+regulation&doi=10.1038%2Fmi.2008.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary fibrosis: pathogenesis, etiology and regulation</span></div><div class="casAuthors">Wilson, M. S.; Wynn, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mucosal Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-121</span>CODEN:
                <span class="NLM_cas:coden">MIUMAK</span>;
        ISSN:<span class="NLM_cas:issn">1933-0219</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences.  The etiol. of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chems., radiation and environmental particles.  However, the cause of one of the most common pulmonary fibrotic conditions, idiopathic pulmonary fibrosis (IPF), is still unclear.  This review examines common mechanisms of pulmonary wound-healing responses following lung injury, and highlights the pathogenesis of some of the most widespread pulmonary fibrotic diseases.  A 3 phase model of wound repair is reviewed that includes; (1) injury; (2) inflammation; and (3) repair.  In most pulmonary fibrotic conditions dysregulation at one or more of these phases was reported.  Chronic inflammation can lead to an imbalance in the prodn. of chemokines, cytokines, growth factors, and disrupt cellular recruitment.  These changes coupled with excessive pro-fibrotic IL-13 and/or TGFβ1 prodn. can turn a well-controlled healing response into a pathogenic fibrotic response.  Endogenous regulatory mechanisms are discussed including novel areas of therapeutic intervention.  Restoring homeostasis to these dysregulated healing responses, or simply neutralizing the key pro-fibrotic mediators may prevent or slow the progression of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPykZAQ68KP7Vg90H21EOLACvtfcHk0lgugrHl7xl8Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D&md5=1e7d72291a39f09cfe113b5028188f28</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1038%2Fmi.2008.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmi.2008.85%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DM.%2BS.%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DPulmonary%2520fibrosis%253A%2520pathogenesis%252C%2520etiology%2520and%2520regulation%26jtitle%3DMucosal%2520Immunol.%26date%3D2009%26volume%3D2%26spage%3D103%26epage%3D121%26doi%3D10.1038%2Fmi.2008.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2013.11.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=220-223&author=Z.+Maauthor=Y.+Panauthor=W.+Huangauthor=Y.+Yangauthor=Z.+Wangauthor=Q.+Liauthor=Y.+Zhaoauthor=X.+Zhangauthor=Z.+Shen&title=Synthesis+and+biological+evaluation+of+the+pirfenidone+derivatives+as+antifibrotic+agents&doi=10.1016%2Fj.bmcl.2013.11.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%2520pirfenidone%2520derivatives%2520as%2520antifibrotic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D220%26epage%3D223%26doi%3D10.1016%2Fj.bmcl.2013.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomic, R.</span><span> </span><span class="NLM_article-title">Natural history of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1016/j.rmed.2015.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.rmed.2015.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25727856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2MrpvVehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2015&pages=661-670&author=H.+J.+Kimauthor=D.+Perlmanauthor=R.+Tomic&title=Natural+history+of+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.rmed.2015.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Natural history of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Kim Hyun Joo; Perlman David; Tomic Rade</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">661-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a parenchymal lung disease characterized by progressive interstitial fibrosis.  IPF has a poor prognosis, with a median survival time of 2-3 years from diagnosis, but varying from a few months to a decade.  The natural history of IPF is highly variable and the course of disease in an individual patient is difficult to predict.  Some patients with IPF experience rapid decline, others progress much more slowly, and some patients show periods of relative stability interspersed with acute deteriorations in respiratory function.  Many clinical, radiographic, serologic, and histopathologic variables have been shown to predict mortality in IPF.  However, the accuracy of these predictors varies due to the retrospective nature of some of the studies and variations in study design.  The ability to identify clinical characteristics that predict disease progression and survival would be useful for counseling patients, treatment decision-making, and prompt consideration for lung transplantation.  A number of indices for predicting mortality in patients with IPF are available, but they require further validation.  As high-resolution computed tomography scans become more widely available and patients with IPF are diagnosed earlier, survival times following diagnosis will improve.  Early referral to interstitial lung disease specialty centers is important for accurate diagnosis and may be associated with improved outcomes.  The goal of this review is to examine the natural history of IPF, discuss predictors of mortality, and highlight the importance of prompt diagnosis and referral for patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmk1qjjc9BVbHHuJhbyicZfW6udTcc2ebKrDGBo10Hxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrpvVehtg%253D%253D&md5=260adda76e9ac35c945dc04f6e981fd3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2015.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DPerlman%26aufirst%3DD.%26aulast%3DTomic%26aufirst%3DR.%26atitle%3DNatural%2520history%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Med.%26date%3D2015%26volume%3D109%26spage%3D661%26epage%3D670%26doi%3D10.1016%2Fj.rmed.2015.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Chakraborty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambi, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dastidar, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span> </span><span class="NLM_article-title">Emerging therapeutic interventions for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span><span class="refDoi"> DOI: 10.1517/13543784.2014.913569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F13543784.2014.913569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24766571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=893-910&author=S.+Chakrabortyauthor=P.+Chopraauthor=S.+V.+Ambiauthor=S.+G.+Dastidarauthor=A.+Ray&title=Emerging+therapeutic+interventions+for+idiopathic+pulmonary+fibrosis&doi=10.1517%2F13543784.2014.913569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapeutic interventions for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Chakraborty, Sushmita; Chopra, Puneet; Ambi, Senthil V.; Dastidar, Sunanda G.; Ray, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">893-910</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Idiopathic pulmonary fibrosis (IPF) is a devastating and relentlessly progressive lung disorder.  Previously, it was thought to be a chronic inflammatory disease; however, it is now considered to be an epithelial-fibroblastic disease.  In accordance with this paradigm change, efforts toward the development of novel therapeutic targets for IPF have acquired a new direction.  Currently available therapies are largely ineffective in reversing the lung damage, and lung transplantation is the only effective treatment for end-stage disease.  Limitations in advancement of IPF therapeutics are due to a poor understanding of its pathogenesis, unavailability of reliable animal models and slow disease progression.  Recent research on IPF has resulted in the identification of a plethora of novel targets that are in various stages of development and offers hope that in the near future that there will be better therapeutic options available for the treatment of IPF.  Areas covered: This review discusses existing therapies and highlights some of the recent, novel therapeutics being explored in the current clin. landscape for the treatment of this chronic, disabling disorder.  The review also discusses the pathogenic rationale behind current therapies.  Expert opinion: Targeting one fibrotic signaling pathway at a time may not have any significant effect on the control of IPF.  It is therefore recommended that future IPF management focuses on targeting multiple pro-fibrotic pathways assocd. with its complex pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNRbowI1OJrVg90H21EOLACvtfcHk0ljBA70ZZwsiJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WitLk%253D&md5=13687207ba9129eeac40f47c0e341e7f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.913569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.913569%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DChopra%26aufirst%3DP.%26aulast%3DAmbi%26aufirst%3DS.%2BV.%26aulast%3DDastidar%26aufirst%3DS.%2BG.%26aulast%3DRay%26aufirst%3DA.%26atitle%3DEmerging%2520therapeutic%2520interventions%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D893%26epage%3D910%26doi%3D10.1517%2F13543784.2014.913569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weycker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelsberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oster, G.</span><span> </span><span class="NLM_article-title">Incidence and prevalence of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1164/rccm.200602-163OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200602-163OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16809633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD28rmtFGisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2006&pages=810-816&author=G.+Raghuauthor=D.+Weyckerauthor=J.+Edelsbergauthor=W.+Z.+Bradfordauthor=G.+Oster&title=Incidence+and+prevalence+of+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.200602-163OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prevalence of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Raghu Ganesh; Weycker Derek; Edelsberg John; Bradford Williamson Z; Oster Gerry</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">810-6</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  Idiopathic pulmonary fibrosis is a chronic interstitial lung disease of unknown etiology; its epidemiology in the United States has not been well characterized.  OBJECTIVE:  To estimate the annual incidence and prevalence of idiopathic pulmonary fibrosis in the United States.  METHODS:  Retrospective cohort design utilizing a large health care claims database spanning the period January 1996 through December 2000.  MEASUREMENTS AND MAIN RESULTS:  Persons with idiopathic pulmonary fibrosis were identified based on diagnosis and procedure codes.  Using broad case-finding criteria, prevalence was estimated to range from 4.0 per 100,000 persons aged 18 to 34 yr to 227.2 per 100,000 among those 75 yr or older; annual incidence was estimated to range from 1.2 to 76.4 per 100,000.  Using narrow case-finding criteria, prevalence ranged from 0.8 to 64.7 per 100,000 persons; comparable figures for incidence were 0.4 to 27.1 per 100,000 persons.  Extrapolating these rates to the overall United States' population, prevalence was estimated to be 42.7 per 100,000 (incidence, 16.3 per 100,000) using broad criteria; with narrow criteria, prevalence was estimated to be 14.0 per 100,000 (incidence, 6.8 per 100,000).  CONCLUSIONS:  Our results suggest that idiopathic pulmonary fibrosis is probably more common in the United States than previously reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSTT_ssflIzuxsqfvU0ziafW6udTcc2ebKrDGBo10Hxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rmtFGisw%253D%253D&md5=d99a682e24bdca385029acb81b80c594</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1164%2Frccm.200602-163OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200602-163OC%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DWeycker%26aufirst%3DD.%26aulast%3DEdelsberg%26aufirst%3DJ.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DOster%26aufirst%3DG.%26atitle%3DIncidence%2520and%2520prevalence%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D174%26spage%3D810%26epage%3D816%26doi%3D10.1164%2Frccm.200602-163OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Nalysnyk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid-Ruzafa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser, D.</span><span> </span><span class="NLM_article-title">Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature</span> <span class="citation_source-journal">Eur. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1183/09059180.00002512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09059180.00002512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23204124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3s7osVSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=355-361&author=L.+Nalysnykauthor=J.+Cid-Ruzafaauthor=P.+Rotellaauthor=D.+Esser&title=Incidence+and+prevalence+of+idiopathic+pulmonary+fibrosis%3A+review+of+the+literature&doi=10.1183%2F09059180.00002512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature</span></div><div class="casAuthors">Nalysnyk Luba; Cid-Ruzafa Javier; Rotella Philip; Esser Dirk</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">126</span>),
    <span class="NLM_cas:pages">355-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown aetiology.  It is a rare disease, and its incidence and prevalence are not clear.  Therefore, we sought to review the published evidence on the global epidemiology of IPF.  A comprehensive review of English language literature was performed by searching Medline and EMBASE for studies on IPF epidemiology published between January 1990 and August 2011.  Studies providing quantitative data on IPF incidence and/or prevalence were identified and key data collected. 15 studies reporting on the incidence and/or prevalence of IPF were identified and summarised.  IPF prevalence estimates in the USA varied between 14 and 27.9 cases per 100,000 population using narrow case definitions, and 42.7 and 63 per 100,000 population using broad case definitions.  In Europe, IPF prevalence ranged from 1.25 to 23.4 cases per 100,000 population.  The annual incidence of IPF in the USA was estimated at 6.8-8.8 per 100,000 population using narrow case definitions and 16.3-17.4 per 100,000 population using broad case definitions.  In Europe, the annual incidence ranged between 0.22 and 7.4 per 100,000 population.  IPF prevalence and incidence increase with age, are higher among males and appear to be on the increase in recent years.  IPF is an orphan disease that affects a potentially increasing number of people in Europe and the USA.  The observed variability in IPF incidence and prevalence may be explained by the differences in diagnostic criteria used, case definition, study population and study design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEz6Y0MyQh7GPgL4LrC-0VfW6udTcc2eY30kOzK2AO2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7osVSmsw%253D%253D&md5=38b5db109bdda71b170d96860afdd6cc</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1183%2F09059180.00002512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09059180.00002512%26sid%3Dliteratum%253Aachs%26aulast%3DNalysnyk%26aufirst%3DL.%26aulast%3DCid-Ruzafa%26aufirst%3DJ.%26aulast%3DRotella%26aufirst%3DP.%26aulast%3DEsser%26aufirst%3DD.%26atitle%3DIncidence%2520and%2520prevalence%2520of%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520review%2520of%2520the%2520literature%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2012%26volume%3D21%26spage%3D355%26epage%3D361%26doi%3D10.1183%2F09059180.00002512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Olson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lezotte, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span> </span><span class="NLM_article-title">Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1164/rccm.200701-044OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200701-044OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17478620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2svitFCgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2007&pages=277-284&author=A.+L.+Olsonauthor=J.+J.+Swigrisauthor=D.+C.+Lezotteauthor=J.+M.+Norrisauthor=C.+G.+Wilsonauthor=K.+K.+Brown&title=Mortality+from+pulmonary+fibrosis+increased+in+the+United+States+from+1992+to+2003&doi=10.1164%2Frccm.200701-044OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003</span></div><div class="casAuthors">Olson Amy L; Swigris Jeffrey J; Lezotte Dennis C; Norris Jill M; Wilson Carla G; Brown Kevin K</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-84</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  From the late 1970s to the early 1990s, studies found that mortality rates for pulmonary fibrosis were increasing.  Recent data for mortality from pulmonary fibrosis are unavailable.  OBJECTIVES:  We sought to determine mortality rates for pulmonary fibrosis in the United States from 1992 through 2003.  METHODS:  Using data from the National Center for Health Statistics, we calculated age-adjusted mortality rates from the deaths of persons with pulmonary fibrosis and stratified the data to determine differences in mortality rates by age, sex, race/ethnicity, and geography of the decedent.  We developed a multivariable model to predict future mortality rates, and we determined the underlying cause of death in patients with pulmonary fibrosis.  MEASUREMENTS AND MAIN RESULTS:  From 1992 to 2003, there were 28,176,224 deaths in the United States and 175,088 decedents with pulmonary fibrosis.  The average age- and sex-adjusted mortality rate was 50.8 per 1,000,000 people.  The age-adjusted mortality rate increased 28.4% in men (from 40.2 deaths per 1,000,000 in 1992 to 61.9 deaths per 1,000,000 in 2003) and 41.3% in women (from 39.0 deaths per 1,000,000 in 1992 to 55.1 deaths per 1,000,000 in 2003).  While increases were significant in both men and women (p < 0.0001), the rate of increase was higher in women (p < 0.0001).  The most common cause of death in patients with pulmonary fibrosis was the disease itself.  CONCLUSIONS:  From 1992 to 2003, mortality rates for pulmonary fibrosis significantly increased.  Further investigation is needed to determine the etiology of these trends, which are predicted to continue to increase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgwRyAmhODdCXXDYhVZBdlfW6udTcc2eY30kOzK2AO2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svitFCgsQ%253D%253D&md5=cf9d57b242028eb940ed2b424eb57d31</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1164%2Frccm.200701-044OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200701-044OC%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DA.%2BL.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DLezotte%26aufirst%3DD.%2BC.%26aulast%3DNorris%26aufirst%3DJ.%2BM.%26aulast%3DWilson%26aufirst%3DC.%2BG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26atitle%3DMortality%2520from%2520pulmonary%2520fibrosis%2520increased%2520in%2520the%2520United%2520States%2520from%25201992%2520to%25202003%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D176%26spage%3D277%26epage%3D284%26doi%3D10.1164%2Frccm.200701-044OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hutchinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever, T.</span><span> </span><span class="NLM_article-title">Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">806</span><span class="refDoi"> DOI: 10.1183/09031936.00185114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00185114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25976683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2MfktV2itw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=795-806&author=J.+Hutchinsonauthor=A.+Fogartyauthor=R.+Hubbardauthor=T.+McKeever&title=Global+incidence+and+mortality+of+idiopathic+pulmonary+fibrosis%3A+a+systematic+review&doi=10.1183%2F09031936.00185114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review</span></div><div class="casAuthors">Hutchinson John; Fogarty Andrew; Hubbard Richard; McKeever Tricia</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">795-806</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally.  This study aims to systematically assess all available studies to investigate the global burden of disease.Medline and Embase databases were searched systematically for all population-based studies of incidence or mortality of idiopathic pulmonary fibrosis.  Clinical case series and prevalence studies were excluded.  The search was supplemented using the Google search engine, hand-searching of references and conference abstracts.  Data were extracted independently by two authors using a pre-specified proforma, with assessment of methodological quality.34 studies were identified, providing data from 21 countries from 1968-2012. 28 studies reported incidence data and eight reported mortality data.  In studies from the year 2000 onwards, we estimated a conservative incidence range of 3-9 cases per 100 000 per year for Europe and North America.  Incidence was lower in East Asia and South America.  The majority of studies showed an increase in incidence over time.The incidence of idiopathic pulmonary fibrosis is increasing worldwide and rates are coming together across countries.  Current data suggest incidence is similar to that of conditions such as stomach, liver, testicular and cervical cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXhjIAwp-wmoFEOhA_Im3cfW6udTcc2eY30kOzK2AO2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfktV2itw%253D%253D&md5=df2df5567392e37bf340ef3ee81d0b83</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1183%2F09031936.00185114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00185114%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DJ.%26aulast%3DFogarty%26aufirst%3DA.%26aulast%3DHubbard%26aufirst%3DR.%26aulast%3DMcKeever%26aufirst%3DT.%26atitle%3DGlobal%2520incidence%2520and%2520mortality%2520of%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520systematic%2520review%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D795%26epage%3D806%26doi%3D10.1183%2F09031936.00185114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gribbin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Jeune, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, L. J.</span><span> </span><span class="NLM_article-title">Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">980</span><span class="NLM_x">–</span> <span class="NLM_lpage">985</span><span class="refDoi"> DOI: 10.1136/thx.2006.062836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthx.2006.062836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16844727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD28njs1enuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2006&pages=980-985&author=J.+Gribbinauthor=R.+B.+Hubbardauthor=I.+Le+Jeuneauthor=C.+J.+P.+Smithauthor=J.+Westauthor=L.+J.+Tata&title=Incidence+and+mortality+of+idiopathic+pulmonary+fibrosis+and+sarcoidosis+in+the+UK&doi=10.1136%2Fthx.2006.062836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK</span></div><div class="casAuthors">Gribbin J; Hubbard R B; Le Jeune I; Smith C J P; West J; Tata L J</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">980-5</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in patients attending chest clinics, but little is known about the epidemiology of these diseases.  We used data from a general practice database to provide information on the current incidence of IPF and sarcoidosis in the UK.  METHODS:  Data were extracted for all patients with a diagnosis of IPF or sarcoidosis between 1991 and 2003.  The whole population of the database was used to calculate disease incidence stratified by age, sex, region, and time period.  Poisson regression was used to compare the incidence between populations and Cox regression was used to compare survival between populations.  RESULTS:  920 cases of IPF (mean age 71 years, 62% male) and 1019 cases of sarcoidosis (mean age 47 years, 47% male) were identified.  The overall incidence rate per 100 000 person-years was 4.6 for IPF and 5.0 for sarcoidosis.  The incidence of IPF increased progressively between 1991 and 2003 (p<0.00001), and was highest in Northern England and Scotland (p<0.0001).  The survival of patients with IPF was stable over time.  In contrast, the incidence of sarcoidosis was highest in London, West Midlands and Northern Ireland and remained stable over time.  CONCLUSIONS:  The incidence of IPF has more than doubled between 1990 and 2003; this is not due to the ageing of the UK population or an increased ascertainment of milder cases.  The incidence of sarcoidosis has not changed during this time period.  Our findings suggest that more than 4000 new cases of IPF and 3000 new cases of sarcoidosis are currently diagnosed each year in the UK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLGAqzGm7Sha91pGlMMoT5fW6udTcc2eZMDvW4luVfFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28njs1enuw%253D%253D&md5=945d0b9613174e307c98d5c32b01e567</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.062836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.062836%26sid%3Dliteratum%253Aachs%26aulast%3DGribbin%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DR.%2BB.%26aulast%3DLe%2BJeune%26aufirst%3DI.%26aulast%3DSmith%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DTata%26aufirst%3DL.%2BJ.%26atitle%3DIncidence%2520and%2520mortality%2520of%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520sarcoidosis%2520in%2520the%2520UK%26jtitle%3DThorax%26date%3D2006%26volume%3D61%26spage%3D980%26epage%3D985%26doi%3D10.1136%2Fthx.2006.062836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Navaratnam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. B.</span><span> </span><span class="NLM_article-title">The rising incidence of idiopathic pulmonary fibrosis in the UK</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1136/thx.2010.148031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthx.2010.148031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21525528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3MrksVajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2011&pages=462-467&author=V.+Navaratnamauthor=K.+M.+Flemingauthor=J.+Westauthor=C.+J.+Smithauthor=R.+G.+Jenkinsauthor=A.+Fogartyauthor=R.+B.+Hubbard&title=The+rising+incidence+of+idiopathic+pulmonary+fibrosis+in+the+UK&doi=10.1136%2Fthx.2010.148031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The rising incidence of idiopathic pulmonary fibrosis in the U.K</span></div><div class="casAuthors">Navaratnam V; Fleming K M; West J; Smith C J P; Jenkins R G; Fogarty A; Hubbard R B</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">462-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Previous studies have shown that the incidence of idiopathic pulmonary fibrosis (IPF) is rising in the U.K. and U.S.A.  Death registrations and primary care data were used to determine the current trends in IPF incidence in the U.K.  Because routine clinical data sets were used, the term IPF clinical syndrome (IPF-CS) is used to describe individuals in this study.  METHODS:  Age- and stratum-specific death registration rates between 1968 and 2008 were calculated and these were applied to the 2008 population to generate annual standardised expected number of deaths.  Annual mortality rate ratios were calculated using Poisson regression.  Computerised primary care records were used to determine incidence rates of IPF-CS between 2000 and 2008 stratified by age, sex and geographical region, and survival rates between calendar periods were compared.  RESULTS:  Annual death certificate recording of IPF-CS rose sixfold across the study period from 0.92 per 100,000 in the 1968-1972 calendar periods to 5.10 per 100,000 in the 2006-2008 calendar period, and were higher in men and the older age groups.  The incidence of IPF-CS in primary care increased by 35% from 2000 to 2008, with an overall incidence rate of 7.44 per 100,000 person-years (95% CI 7.12 to 7.77).  Incidence was higher in men, the older population and in Northwest England.  CONCLUSIONS:  The incidence of IPF-CS in primary care and registered deaths from this cause in the U.K. continues to rise in the 21st century.  The current findings suggest that there are >5000 new cases diagnosed each year in the U.K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlwd8eUEX3NLt7lRqEFUJVfW6udTcc2eZMDvW4luVfFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrksVajsQ%253D%253D&md5=9c28a75a8117323c90169470fe65630f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fthx.2010.148031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2010.148031%26sid%3Dliteratum%253Aachs%26aulast%3DNavaratnam%26aufirst%3DV.%26aulast%3DFleming%26aufirst%3DK.%2BM.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DC.%2BJ.%26aulast%3DJenkins%26aufirst%3DR.%2BG.%26aulast%3DFogarty%26aufirst%3DA.%26aulast%3DHubbard%26aufirst%3DR.%2BB.%26atitle%3DThe%2520rising%2520incidence%2520of%2520idiopathic%2520pulmonary%2520fibrosis%2520in%2520the%2520UK%26jtitle%3DThorax%26date%3D2011%26volume%3D66%26spage%3D462%26epage%3D467%26doi%3D10.1136%2Fthx.2010.148031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Macneal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. A.</span><span> </span><span class="NLM_article-title">The genetic and environmental causes of pulmonary fibrosis</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1513/pats.201112-055AW</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1513%2Fpats.201112-055AW" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22802285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKju7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=120-125&author=K.+Macnealauthor=D.+A.+Schwartz&title=The+genetic+and+environmental+causes+of+pulmonary+fibrosis&doi=10.1513%2Fpats.201112-055AW"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The genetic and environmental causes of pulmonary fibrosis</span></div><div class="casAuthors">MacNeal, Ken; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">120-125</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Although substantial progress has been made in understanding the clin., radiol., and pathol. manifestations of fibrosing interstitial lung diseases (ILD), it remains difficult for the clinician to predict the clin. course or the response to therapy for the subtypes of ILD, even from individual to individual with the same diagnosis.  This article reviews the genetic and environmental causes of pulmonary fibrosis, specifically focusing on genetic and epigenetic variants of MUC5B and several types of ILD, to discuss why only some individuals with the MUC5B promoter polymorphism develop pulmonary fibrosis.  Once we discover how these genetic and epigenetic risks lead to the development of ILD, we and others can apply these discoveries to: (1) identify individuals at risk of developing ILD, (2) diagnose the condition at an earlier stage, (3) Identify novel mechanisms that cause ILD, and (4) eventually develop personalized therapeutic strategies for intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdXK3H2s_FtLVg90H21EOLACvtfcHk0lgoB6tVgdv-BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKju7zP&md5=cbe10a294dacd985aae7ade5f18cb8af</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1513%2Fpats.201112-055AW&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.201112-055AW%26sid%3Dliteratum%253Aachs%26aulast%3DMacneal%26aufirst%3DK.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26atitle%3DThe%2520genetic%2520and%2520environmental%2520causes%2520of%2520pulmonary%2520fibrosis%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2012%26volume%3D9%26spage%3D120%26epage%3D125%26doi%3D10.1513%2Fpats.201112-055AW" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Yang, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. A.</span><span> </span><span class="NLM_article-title">Epigenetics of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Transl. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1016/j.trsl.2014.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.trsl.2014.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24746870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1eht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2015&pages=48-60&author=I.+V.+Yangauthor=D.+A.+Schwartz&title=Epigenetics+of+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.trsl.2014.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Yang, Ivana V.; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-60</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a complex lung disease of unknown etiol.  Development of IPF is influenced by both genetic and environmental factors.  Recent work by our and other groups has identified strong genetic predisposition factors for the development of pulmonary fibrosis, and cigarette smoke remains the most strongly assocd. environmental exposure risk factor.  Gene expression profiling studies of IPF lung have taught us quite a bit about the biol. of this fatal disease, and those of peripheral blood have provided important biomarkers.  However, epigenetic marks may be the missing link that connects the environmental exposure in genetically predisposed individuals to transcriptional changes assocd. with disease development.  Moreover, epigenetic marks represent a promising therapeutic target for IPF.  In this review, the disease is introduced, genetic and gene expression studies in IPF are summarized, exposures relevant to IPF and known epigenetic changes assocd. with cigarette smoke exposure are discussed, and epigenetic studies conducted so far in IPF are summarized.  Limitations, challenges, and future opportunities in this field are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrucclb9qMiKbVg90H21EOLACvtfcHk0lgMVoVQkuwqlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1eht74%253D&md5=f239cc89ca03fb73326c6a285711750d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2014.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2014.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DI.%2BV.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26atitle%3DEpigenetics%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DTransl.%2520Res.%26date%3D2015%26volume%3D165%26spage%3D48%26epage%3D60%26doi%3D10.1016%2Fj.trsl.2014.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wolters, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. D.</span><span> </span><span class="NLM_article-title">Pathogenesis of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1146/annurev-pathol-012513-104706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1146%2Fannurev-pathol-012513-104706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24050627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1emsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=157-179&author=P.+J.+Woltersauthor=H.+R.+Collardauthor=K.+D.+Jones&title=Pathogenesis+of+idiopathic+pulmonary+fibrosis&doi=10.1146%2Fannurev-pathol-012513-104706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Wolters, Paul J.; Collard, Harold R.; Jones, Kirk D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157-179</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease assocd. with aging that is characterized by the histopathol. pattern of usual interstitial pneumonia.  Although an understanding of the pathogenesis of IPF is incomplete, recent advances delineating specific clin. and pathol. features of IPF have led to better definition of the mol. pathways that are pathol. activated in the disease.  In this review we highlight several of these advances, with a focus on genetic predisposition to IPF and how genetic changes, which occur primarily in epithelial cells, lead to activation of profibrotic pathways in epithelial cells.  We then discuss the pathol. changes within IPF fibroblasts and the extracellular matrix, and we conclude with a summary of how these profibrotic pathways may be interrelated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8HgCa8pK4XrVg90H21EOLACvtfcHk0lgMVoVQkuwqlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1emsbg%253D&md5=8ab726d67353aa8659d842ade0af9d1c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pathol-012513-104706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pathol-012513-104706%26sid%3Dliteratum%253Aachs%26aulast%3DWolters%26aufirst%3DP.%2BJ.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DJones%26aufirst%3DK.%2BD.%26atitle%3DPathogenesis%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2014%26volume%3D9%26spage%3D157%26epage%3D179%26doi%3D10.1146%2Fannurev-pathol-012513-104706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span>National Institutes of Health. <a href="https://www.nhlbi.nih.gov/" class="extLink">https://www.nhlbi.nih.gov/</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Institutes+of+Health.+https%3A%2F%2Fwww.nhlbi.nih.gov%2F+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Rafii, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. L.</span><span> </span><span class="NLM_article-title">A review of current and novel therapies for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">J. Thorac. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.3978/j.issn.2072-1439.2012.12.07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3978%2Fj.issn.2072-1439.2012.12.07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23372951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3szks1ymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=48-73&author=R.+Rafiiauthor=M.+M.+Juarezauthor=T.+E.+Albertsonauthor=A.+L.+Chan&title=A+review+of+current+and+novel+therapies+for+idiopathic+pulmonary+fibrosis&doi=10.3978%2Fj.issn.2072-1439.2012.12.07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A review of current and novel therapies for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Rafii Rokhsara; Juarez Maya M; Albertson Timothy E; Chan Andrew L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-73</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that is associated with a median survival of 2-3 years from initial diagnosis.  To date, there is no treatment approved for IPF in the United States, and only one pharmacological agent has been approved outside of the United States.  Nevertheless, research over the past 10 years has provided us with a wealth of information on its histopathology, diagnostic work-up, and a greater understanding of its pathophysiology.  Specifically, IPF is no longer thought to be a predominantly pro-inflammatory disorder.  Rather, the fibrosis in IPF is increasingly understood to be the result of a fibroproliferative and aberrant wound healing cascade.  The development of therapeutic targets has shifted in accord with this paradigm change.  This review highlights the current understanding of IPF, and the recent as well as novel therapeutics being explored in clinical trials for the treatment of this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQf4PiIM4UfkEwlCcfExbvbfW6udTcc2eaOCmnIccIhBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szks1ymtg%253D%253D&md5=595c026cb5e8897fb2a750f6a32f7c02</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2072-1439.2012.12.07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2072-1439.2012.12.07%26sid%3Dliteratum%253Aachs%26aulast%3DRafii%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DM.%2BM.%26aulast%3DAlbertson%26aufirst%3DT.%2BE.%26aulast%3DChan%26aufirst%3DA.%2BL.%26atitle%3DA%2520review%2520of%2520current%2520and%2520novel%2520therapies%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2013%26volume%3D5%26spage%3D48%26epage%3D73%26doi%3D10.3978%2Fj.issn.2072-1439.2012.12.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochwerg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuello Garcia, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brozek, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johkoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzko, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rind, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogsteden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schünemann, H. J.</span><span> </span><span class="NLM_article-title">An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3</span><span class="NLM_x">–</span> <span class="NLM_lpage">e19</span><span class="refDoi"> DOI: 10.1164/rccm.201506-1063ST</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201506-1063ST" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=e3-e19&author=G.+Raghuauthor=B.+Rochwergauthor=Y.+Zhangauthor=C.+A.+Cuello+Garciaauthor=A.+Azumaauthor=J.+Behrauthor=J.+L.+Brozekauthor=H.+R.+Collardauthor=W.+Cunninghamauthor=S.+Hommaauthor=T.+Johkohauthor=F.+J.+Martinezauthor=J.+Myersauthor=S.+L.+Protzkoauthor=L.+Richeldiauthor=D.+Rindauthor=M.+Selmanauthor=A.+Theodoreauthor=A.+U.+Wellsauthor=H.+Hoogstedenauthor=H.+J.+Sch%C3%BCnemann&title=An+official+ATS%2FERS%2FJRS%2FALAT+clinical+practice+guideline%3A+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.201506-1063ST"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1164%2Frccm.201506-1063ST&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201506-1063ST%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DRochwerg%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCuello%2BGarcia%26aufirst%3DC.%2BA.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBrozek%26aufirst%3DJ.%2BL.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DCunningham%26aufirst%3DW.%26aulast%3DHomma%26aufirst%3DS.%26aulast%3DJohkoh%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DProtzko%26aufirst%3DS.%2BL.%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DRind%26aufirst%3DD.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTheodore%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DHoogsteden%26aufirst%3DH.%26aulast%3DSch%25C3%25BCnemann%26aufirst%3DH.%2BJ.%26atitle%3DAn%2520official%2520ATS%252FERS%252FJRS%252FALAT%2520clinical%2520practice%2520guideline%253A%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D192%26spage%3De3%26epage%3De19%26doi%3D10.1164%2Frccm.201506-1063ST" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">136</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.7326/0003-4819-134-2-200101160-00015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.7326%2F0003-4819-134-2-200101160-00015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=11177318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD3M7ktVSgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2001&pages=136-151&author=M.+Selmanauthor=T.+E.+Kingauthor=A.+Pardo&title=Idiopathic+pulmonary+fibrosis%3A+prevailing+and+evolving+hypotheses+about+its+pathogenesis+and+implications+for+therapy&doi=10.7326%2F0003-4819-134-2-200101160-00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy</span></div><div class="casAuthors">Selman M; King T E; Pardo A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-51</span>
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and usually fatal lung disease characterized by fibroblast proliferation and extracellular matrix remodeling, which result in irreversible distortion of the lung's architecture.  Although the pathogenetic mechanisms remain to be determined, the prevailing hypothesis holds that fibrosis is preceded and provoked by a chronic inflammatory process that injures the lung and modulates lung fibrogenesis, leading to the end-stage fibrotic scar.  However, there is little evidence that inflammation is prominent in early disease, and it is unclear whether inflammation is relevant to the development of the fibrotic process.  Evidence suggests that inflammation does not play a pivotal role.  Inflammation is not a prominent histopathologic finding, and epithelial injury in the absence of ongoing inflammation is sufficient to stimulate the development of fibrosis.  In addition, the inflammatory response to a lung fibrogenic insult is not necessarily related to the fibrotic response.  Clinical measurements of inflammation fail to correlate with stage or outcome, and potent anti-inflammatory therapy does not improve outcome.  This review presents a growing body of evidence suggesting that idiopathic pulmonary fibrosis involves abnormal wound healing in response to multiple, microscopic sites of ongoing alveolar epithelial injury and activation associated with the formation of patchy fibroblast-myofibroblast foci, which evolve to fibrosis.  Progress in understanding the fibrogenic mechanisms in the lung is likely to yield more effective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSToVCX1QgwKeb6AVA-44PTfW6udTcc2eaw9Bv41SAvu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7ktVSgtA%253D%253D&md5=c47919b4b378653b30209ac0273a4642</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-134-2-200101160-00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-134-2-200101160-00015%26sid%3Dliteratum%253Aachs%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DPardo%26aufirst%3DA.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520prevailing%2520and%2520evolving%2520hypotheses%2520about%2520its%2520pathogenesis%2520and%2520implications%2520for%2520therapy%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2001%26volume%3D134%26spage%3D136%26epage%3D151%26doi%3D10.7326%2F0003-4819-134-2-200101160-00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">King, T. E.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">1949</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span><span class="refDoi"> DOI: 10.1016/S0140-6736(11)60052-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0140-6736%2811%2960052-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21719092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FksVeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=1949-1961&author=T.+E.+Kingauthor=A.+Pardoauthor=M.+Selman&title=Idiopathic+pulmonary+fibrosis&doi=10.1016%2FS0140-6736%2811%2960052-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis</span></div><div class="casAuthors">King Talmadge E Jr; Pardo Annie; Selman Moises</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9807</span>),
    <span class="NLM_cas:pages">1949-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a devastating, age-related lung disease of unknown cause that has few treatment options.  This disease was once thought to be a chronic inflammatory process, but current evidence indicates that the fibrotic response is driven by abnormally activated alveolar epithelial cells (AECs).  These cells produce mediators that induce the formation of fibroblast and myofibroblast foci through the proliferation of resident mesenchymal cells, attraction of circulating fibrocytes, and stimulation of the epithelial to mesenchymal transition.  The fibroblast and myofibroblast foci secrete excessive amounts of extracellular matrix, mainly collagens, resulting in scarring and destruction of the lung architecture.  The mechanisms that link idiopathic pulmonary fibrosis with ageing and aberrant epithelial activation are unknown; evidence suggests that the abnormal recapitulation of developmental pathways and epigenetic changes have a role.  In this Seminar, we review recent data on the clinical course, therapeutic options, and underlying mechanisms thought to be involved in the pathogenesis of idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9GcvvCbsuQA20zIbnCCI3fW6udTcc2eaw9Bv41SAvu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FksVeisg%253D%253D&md5=a3cae8b12a792e2d079ad6293c4023eb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960052-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960052-4%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DSelman%26aufirst%3DM.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D1949%26epage%3D1961%26doi%3D10.1016%2FS0140-6736%2811%2960052-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ahluwalia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span> </span><span class="NLM_article-title">New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">867</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1164/rccm.201403-0509PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201403-0509PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25090037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyiur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2014&pages=867-878&author=N.+Ahluwaliaauthor=B.+S.+Sheaauthor=A.+M.+Tager&title=New+therapeutic+targets+in+idiopathic+pulmonary+fibrosis.+Aiming+to+rein+in+runaway+wound-healing+responses&doi=10.1164%2Frccm.201403-0509PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">New therapeutic targets in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Ahluwalia, Neil; Shea, Barry S.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">867-878</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival as short as 3 years from the time ofdiagnosis and no pharmacol. therapies yet approved by the U.S.  Food and Drug Administration.  To address the great unmet need for effective IPF therapy, a no. of new drugs have recently been, or are now being, evaluated in clin. trials.  The rationales for most of these therapeutic candidates are based on the current paradigm of IPF pathogenesis, in which recurrent injury to the alveolar epithelium is believed to drive aberrant wound healing responses, resulting in fibrosis rather than repair.  Here we discuss drugs in recently completed or currently ongoing phase II and Ill IPF clin. trials in the context of their putative mechanisms of action and the aberrant repair processes they are believed to target: innate immune activation and polarization, fibroblast accumulation and myofibroblast differentiation, or adracellular matrix deposition and stiffening.  Placed in this context, the pos. results of recently completed trials of pirfenidone and nintedanib, and results that will come from ongoing trials of other agents, should provide valuable insights into the still-enigmatic pathogenesis of this disease, in addn. to providing benefits to patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzLozevTD5CbVg90H21EOLACvtfcHk0ljlAbhnPY5RVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyiur%252FK&md5=5a7939da26f2c40f9b01b3699bff0c2b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1164%2Frccm.201403-0509PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201403-0509PP%26sid%3Dliteratum%253Aachs%26aulast%3DAhluwalia%26aufirst%3DN.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DNew%2520therapeutic%2520targets%2520in%2520idiopathic%2520pulmonary%2520fibrosis.%2520Aiming%2520to%2520rein%2520in%2520runaway%2520wound-healing%2520responses%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2014%26volume%3D190%26spage%3D867%26epage%3D878%26doi%3D10.1164%2Frccm.201403-0509PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Chambers, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, P. F.</span><span> </span><span class="NLM_article-title">Mechanisms of alveolar epithelial injury, repair, and fibrosis</span> <span class="citation_source-journal">Ann. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">S16</span><span class="NLM_x">–</span> <span class="NLM_lpage">S20</span><span class="refDoi"> DOI: 10.1513/AnnalsATS.201410-448MG</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1513%2FAnnalsATS.201410-448MG" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=S16-S20&author=R.+C.+Chambersauthor=P.+F.+Mercer&title=Mechanisms+of+alveolar+epithelial+injury%2C+repair%2C+and+fibrosis&doi=10.1513%2FAnnalsATS.201410-448MG"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201410-448MG&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201410-448MG%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DR.%2BC.%26aulast%3DMercer%26aufirst%3DP.%2BF.%26atitle%3DMechanisms%2520of%2520alveolar%2520epithelial%2520injury%252C%2520repair%252C%2520and%2520fibrosis%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2015%26volume%3D12%26spage%3DS16%26epage%3DS20%26doi%3D10.1513%2FAnnalsATS.201410-448MG" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Fulton, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryerson, C. J.</span><span> </span><span class="NLM_article-title">Managing comorbidities in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Int. J. Gen. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">318</span><span class="refDoi"> DOI: 10.2147/IJGM.S74880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2147%2FIJGM.S74880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26451121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28zgsValtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=309-318&author=B.+G.+Fultonauthor=C.+J.+Ryerson&title=Managing+comorbidities+in+idiopathic+pulmonary+fibrosis&doi=10.2147%2FIJGM.S74880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Managing comorbidities in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Fulton Blair G; Ryerson Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of general medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">309-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pulmonary and extra-pulmonary diseases.  IPF can be associated with additional comorbidities through other mechanisms as either a cause or a consequence of these diseases.  We review the literature regarding the management of common pulmonary and extra-pulmonary comorbidities, including chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, venous thromboembolism, sleep-disordered breathing, gastroesophageal reflux disease, coronary artery disease, depression and anxiety, and deconditioning.  Recent studies have provided some guidance on the management of these diseases in IPF; however, most treatment recommendations are extrapolated from studies of non-IPF patients.  Additional studies are required to more accurately determine the clinical features of these comorbidities in patients with IPF and to evaluate conventional treatments and management strategies that are beneficial in non-IPF populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnrNHbQN3_Si-bLEOO4dYpfW6udTcc2eZ0izURwJVqlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zgsValtA%253D%253D&md5=ee1ab3cc8be65592fc29a5e9745f7827</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2147%2FIJGM.S74880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJGM.S74880%26sid%3Dliteratum%253Aachs%26aulast%3DFulton%26aufirst%3DB.%2BG.%26aulast%3DRyerson%26aufirst%3DC.%2BJ.%26atitle%3DManaging%2520comorbidities%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DInt.%2520J.%2520Gen.%2520Med.%26date%3D2015%26volume%3D8%26spage%3D309%26epage%3D318%26doi%3D10.2147%2FIJGM.S74880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlers-Tenenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruhwyler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltmanns, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heussel, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herth, F. J. F.</span><span> </span><span class="NLM_article-title">Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0151425</span><span class="refDoi"> DOI: 10.1371/journal.pone.0151425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1371%2Fjournal.pone.0151425" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0151425&author=M.+Kreuterauthor=S.+Ehlers-Tenenbaumauthor=K.+Palmowskiauthor=J.+Bruhwylerauthor=U.+Oltmannsauthor=T.+Muleyauthor=C.+P.+Heusselauthor=A.+Warthauthor=M.+Kolbauthor=F.+J.+F.+Herth&title=Impact+of+comorbidities+on+mortality+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1371%2Fjournal.pone.0151425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0151425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0151425%26sid%3Dliteratum%253Aachs%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DEhlers-Tenenbaum%26aufirst%3DS.%26aulast%3DPalmowski%26aufirst%3DK.%26aulast%3DBruhwyler%26aufirst%3DJ.%26aulast%3DOltmanns%26aufirst%3DU.%26aulast%3DMuley%26aufirst%3DT.%26aulast%3DHeussel%26aufirst%3DC.%2BP.%26aulast%3DWarth%26aufirst%3DA.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DHerth%26aufirst%3DF.%2BJ.%2BF.%26atitle%3DImpact%2520of%2520comorbidities%2520on%2520mortality%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0151425%26doi%3D10.1371%2Fjournal.pone.0151425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lee, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span> </span><span class="NLM_article-title">Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">J. Neurogastroenterol. Motil.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span><span class="refDoi"> DOI: 10.5056/jnm15192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.5056%2Fjnm15192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26932897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28jmsVGquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=444-451&author=C.+M.+Leeauthor=D.+H.+Leeauthor=B.+K.+Ahnauthor=J.+J.+Hwangauthor=H.+Yoonauthor=C.+M.+Shinauthor=Y.+S.+Parkauthor=N.+Kim&title=Protective+effect+of+proton+pump+inhibitor+for+survival+in+patients+with+gastroesophageal+reflux+disease+and+idiopathic+pulmonary+fibrosis&doi=10.5056%2Fjnm15192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Protective Effect of Proton Pump Inhibitor for Survival in Patients with Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Lee Chang Min; Lee Dong Ho; Ahn Byung Kyu; Hwang Jae Jin; Yoon Hyuk; Shin Cheol Min; Park Young Soo; Kim Nayoung; Lee Dong Ho; Shin Cheol Min; Park Young Soo; Kim Nayoung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurogastroenterology and motility</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-51</span>
        ISSN:<span class="NLM_cas:issn">2093-0879</span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  The prevalence of gastroesophageal reflux disease (GERD) is high in patients with idiopathic pulmonary fibrosis (IPF).  GERD may cause chronic microaspiration that leads to repeated subclinical lung injury, which leads to pulmonary fibrosis.  Although some studies have suggested that proton pump inhibitors (PPI) were associated with a good prognosis in IPF, their effects remain unclear.  METHODS:  We retrospectively reviewed 786 consecutive adult patients with IPF at Seoul National University Bundang Hospital between April 2003 and March 2015.  RESULTS:  Mean duration of follow-up was 2.6 ± 2.8 years.  Of the 786 patients with IPF, 107 (13.6%) were given diagnoses of GERD, and 103 (13.1%) died due to IPF-related pneumonia or respiratory failure.  The prevalence of GERD and the cumulative incidence of de novo GERD increased depending on the period of follow-up in patients with IPF.  Patients administered PPI for more than four months had a lower IPF-related mortality rate than patients on PPI less than 4 months (Log-rank P -value = 0.024 in Kaplan-Meier curve).  In a univariate and multivariate Cox regression hazard model, younger age (hazard ratio [HR], 1.06; 95% CI, 1.03-1.10; P = 0.001), higher initial forced vital capacity (HR, 0.98; 95% CI, 0.96-0.99; P = 0.004), and longer duration of PPI use (HR, 0.97; 95% CI, 0.95-1.00; P = 0.022), but not a diagnosis of GERD, were significantly associated with lower IPF-related mortality.  CONCLUSIONS:  In Korean patients with IPF, the prevalence of GERD was lower than in other countries.  PPI use for at least 4 months may have a protective effect against IPF-related mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBc9R17lEcF9y3lHz94U-GfW6udTcc2ebzSWSypZXNI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmsVGquw%253D%253D&md5=09e359c5e39e90ef7b607e4729ecae25</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.5056%2Fjnm15192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5056%252Fjnm15192%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DAhn%26aufirst%3DB.%2BK.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DC.%2BM.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DN.%26atitle%3DProtective%2520effect%2520of%2520proton%2520pump%2520inhibitor%2520for%2520survival%2520in%2520patients%2520with%2520gastroesophageal%2520reflux%2520disease%2520and%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Neurogastroenterol.%2520Motil.%26date%3D2016%26volume%3D22%26spage%3D444%26epage%3D451%26doi%3D10.5056%2Fjnm15192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Luppi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span> </span><span class="NLM_article-title">The big clinical trials in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Opin. Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1097/MCP.0b013e3283567ff9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1097%2FMCP.0b013e3283567ff9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22759771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=428-432&author=F.+Luppiauthor=P.+Spagnoloauthor=S.+Cerriauthor=L.+Richeldi&title=The+big+clinical+trials+in+idiopathic+pulmonary+fibrosis&doi=10.1097%2FMCP.0b013e3283567ff9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The big clinical trials in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Luppi, Fabrizio; Spagnolo, Paolo; Cerri, Stefania; Richeldi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">428-432</span>CODEN:
                <span class="NLM_cas:coden">COPMFY</span>;
        ISSN:<span class="NLM_cas:issn">1070-5287</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Since the late 1990 s, when a more uniform definition of idiopathic pulmonary fibrosis (IPF) was proposed, more than 3000 patients have been enrolled in clin. studies exploring novel therapies.  Some of the most relevant trials have been published only recently.  Recent findings: This review describes and comments on the randomized clin. trials in IPF published within the past 18 mo, with emphasis on the studies evaluating pirfenidone, which at present is the only drug approved for IPF (at least in Europe and Japan), and bosentan.  This latter represents the largest single trial performed in IPF so far.  Summary: Despite multiple clin. trials, there is no strong, definitive evidence in favor of any agent to treat IPF.  On the other hand, the placebo arms of these large trials have provided us with important crit. information on the natural history of this disease.  Clin. heterogeneity represents a crit. issue to be taken into account in designing future clin. trials.  The limited effectiveness of current treatment regimes has fuelled the search for a variety of new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1lqOC8P3lZrVg90H21EOLACvtfcHk0lhmGfLUZQJjLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7M&md5=c0153c0bfb93c6898a16976ce2868028</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e3283567ff9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e3283567ff9%26sid%3Dliteratum%253Aachs%26aulast%3DLuppi%26aufirst%3DF.%26aulast%3DSpagnolo%26aufirst%3DP.%26aulast%3DCerri%26aufirst%3DS.%26aulast%3DRicheldi%26aufirst%3DL.%26atitle%3DThe%2520big%2520clinical%2520trials%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D428%26epage%3D432%26doi%3D10.1097%2FMCP.0b013e3283567ff9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Demedts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekhuijzen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNee, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomeer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallaert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbeken, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verschakelen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, C. D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capron, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petruzzelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vuyst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Bosch, J. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Becerra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvasce, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lankhorst, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sardina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, M.</span><span> </span><span class="NLM_article-title">IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">2229</span><span class="NLM_x">–</span> <span class="NLM_lpage">2242</span><span class="refDoi"> DOI: 10.1056/NEJMoa042976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa042976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16306520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GrsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2229-2242&author=M.+Demedtsauthor=J.+Behrauthor=R.+Buhlauthor=U.+Costabelauthor=R.+Dekhuijzenauthor=H.+K.+Jansenauthor=W.+MacNeeauthor=M.+Thomeerauthor=B.+Wallaertauthor=F.+Laurentauthor=A.+G.+Nicholsonauthor=E.+K.+Verbekenauthor=J.+Verschakelenauthor=C.+D.+R.+Flowerauthor=F.+Capronauthor=S.+Petruzzelliauthor=P.+De+Vuystauthor=J.+M.+M.+van+den+Boschauthor=E.+Rodriguez-Becerraauthor=G.+Corvasceauthor=I.+Lankhorstauthor=M.+Sardinaauthor=M.+Montanari&title=IFIGENIA+Study+Group.+High-dose+acetylcysteine+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa042976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High dose acetylcysteine in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Demedts, Maurits; Behr, Juergen; Buhl, Roland; Costabel, Ulrich; Dekhuijzen, Richard; Jansen, Henk M.; MacNee, William; Thomeer, Michiel; Wallaert, Benoit; Laurent, Francois; Nicholson, Andrew G.; Verbeken, Eric K.; Verschakelen, Johny; Flower, Christopher D. R.; Capron, Frederique; Petruzzelli, Stefano; De Vuyst, Paul; van den Bosch, Jules M. M.; Rodriguez-Becerra, Eulogio; Corvasce, Giuseppina; Lankhorst, Ida; Sardina, Marco; Montanari, Mauro; Demedts, M.; Behr, J.; Buhl, R.; Costabel, U.; Dekhuijzen, P. N. R.; Jansen, H. M.; MacNee, W.; Wallaert, B.; Thomeer, M.; Flower, C. D. R.; Verschakelen, J.; Nicholson, A. G.; Verbeken, E. K.; Capron, F.; Behr, J.; van den Bosch, J. M. M.; De Vuyst, P.; Rodriguez-Becerra, E.; Petruzzelli, S.; Wallaert, B.; Corvasce, G.; Peviani, A.; Lankhorst, I.; Makin, E.; Licciardello, L.; Bellinvia, S.; Di Padova, C.; Sardina, M.; Kormoss, N.; Boulanger, P.; Esteras, A.; Sirtori, F.; Moroni, G.; Ardia, A.; Montanari, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2229-2242</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis.  METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to std. therapy with prednisone plus azathioprine.  The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DLCO).  RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo).  Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resoln. computed tomog. and histol. findings reviewed by expert committees, and did not withdraw consent before the start of treatment.  Fifty-seven of the 80 patients taking acetylcysteine (71 %) and 51 of the 75 patients taking placebo (68 %) completed one year of treatment.  Acetylcysteine slowed the deterioration of vital capacity and DLCO: at 12 mo, the abs. differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 L (95 % confidence interval, 0.03 to 0.32), ora relative difference of 9 %, for vital capacity (P = 0.02), and 0.75 mmol per min per kilopascal (95 % confidence interval, 0.27 to 1.23), or 24 %, for DLCO (P = 0.003).  Mortality during the study was 9 % among patients taking acetylcysteine and 11 % among those taking placebo (P = 0.69).  There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P = 0.03).  CONCLUSIONS Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DLCO in patients with idiopathic pulmonary fibrosis better than does std. therapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPUO4Xw_rvcLVg90H21EOLACvtfcHk0lhAFKt1zyfB0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GrsbjP&md5=8f342bf2b15b6be1dc6eda6ce123ea0e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa042976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa042976%26sid%3Dliteratum%253Aachs%26aulast%3DDemedts%26aufirst%3DM.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DDekhuijzen%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DH.%2BK.%26aulast%3DMacNee%26aufirst%3DW.%26aulast%3DThomeer%26aufirst%3DM.%26aulast%3DWallaert%26aufirst%3DB.%26aulast%3DLaurent%26aufirst%3DF.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DVerbeken%26aufirst%3DE.%2BK.%26aulast%3DVerschakelen%26aufirst%3DJ.%26aulast%3DFlower%26aufirst%3DC.%2BD.%2BR.%26aulast%3DCapron%26aufirst%3DF.%26aulast%3DPetruzzelli%26aufirst%3DS.%26aulast%3DDe%2BVuyst%26aufirst%3DP.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DJ.%2BM.%2BM.%26aulast%3DRodriguez-Becerra%26aufirst%3DE.%26aulast%3DCorvasce%26aufirst%3DG.%26aulast%3DLankhorst%26aufirst%3DI.%26aulast%3DSardina%26aufirst%3DM.%26aulast%3DMontanari%26aufirst%3DM.%26atitle%3DIFIGENIA%2520Study%2520Group.%2520High-dose%2520acetylcysteine%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2229%26epage%3D2242%26doi%3D10.1056%2FNEJMoa042976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">The Idiopathic Pulmonary Fibrosis Clinical Research Network</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anstrom, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J. A.</span><span> </span><span class="NLM_article-title">Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">1968</span><span class="NLM_x">–</span> <span class="NLM_lpage">1977</span><span class="refDoi"> DOI: 10.1056/NEJMoa1113354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1113354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22607134" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1968-1977&author=The+Idiopathic+Pulmonary+Fibrosis+Clinical+Research+Networkauthor=G.+Raghuauthor=K.+J.+Anstromauthor=T.+E.+Kingauthor=J.+A.+Laskyauthor=F.+J.+A.+Martinez&title=Prednisone%2C+azathioprine%2C+and+N-acetylcysteine+for+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1113354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113354%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%2BA.%26atitle%3DPrednisone%252C%2520azathioprine%252C%2520and%2520N-acetylcysteine%2520for%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1968%26epage%3D1977%26doi%3D10.1056%2FNEJMoa1113354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">The Idiopathic Pulmonary Fibrosis Clinical Research Network</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Andrade, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anstrom, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span> </span><span class="NLM_article-title">Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2093</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1056/NEJMoa1401739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1401739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24836309" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2093-2101&author=The+Idiopathic+Pulmonary+Fibrosis+Clinical+Research+Networkauthor=F.+J.+Martinezauthor=J.+A.+de+Andradeauthor=K.+J.+Anstromauthor=T.+E.+Kingauthor=G.+Raghu&title=Randomized+trial+of+acetylcysteine+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1401739"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401739%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BAndrade%26aufirst%3DJ.%2BA.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DRaghu%26aufirst%3DG.%26atitle%3DRandomized%2520trial%2520of%2520acetylcysteine%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2093%26epage%3D2101%26doi%3D10.1056%2FNEJMoa1401739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendstrup, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olschewski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sköld, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuyts, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koschel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallaert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albera, C.</span><span> </span><span class="NLM_article-title">Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, Phase 2 trial</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span><span class="refDoi"> DOI: 10.1016/S2213-2600(16)30044-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS2213-2600%2816%2930044-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=27161257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVChsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=445-453&author=J.+Behrauthor=E.+Bendstrupauthor=B.+Crestaniauthor=A.+G%C3%BCntherauthor=H.+Olschewskiauthor=C.+M.+Sk%C3%B6ldauthor=A.+Wellsauthor=W.+Wuytsauthor=D.+Koschelauthor=M.+Kreuterauthor=B.+Wallaertauthor=C.+Y.+Linauthor=J.+Beckauthor=C.+Albera&title=Safety+and+tolerability+of+acetylcysteine+and+pirfenidone+combination+therapy+in+idiopathic+pulmonary+fibrosis%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+Phase+2+trial&doi=10.1016%2FS2213-2600%2816%2930044-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial</span></div><div class="casAuthors">Behr, Juergen; Bendstrup, Elisabeth; Crestani, Bruno; Guenther, Andreas; Olschewski, Horst; Skoeld, C. Magnus; Wells, Athol; Wuyts, Wim; Koschel, Dirk; Kreuter, Michael; Wallaert, Benoit; Lin, Chin-Yu; Beck, Juergen; Albera, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">445-453</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Oral acetylcysteine (also known as N-acetylcysteine) is used with pirfenidone to treat idiopathic pulmonary fibrosis (IPF) in Europe.  However, no randomised studies have investigated the safety and tolerability of this combination.  The PANORAMA study assessed the safety and tolerability of acetylcysteine combined with pirfenidone in patients with IPF.  Exploratory efficacy endpoints were also assessed.  We did a double-blind randomised trial at 48 sites in eight countries.  Patients with IPF aged 40-80 years and established on pirfenidone (at least 1602 mg/day for 8 wk or longer) were randomly assigned in a 1:1 ratio by interactive voice response system to receive concomitant oral acetylcysteine (600 mg, three times daily) or placebo for 24 wk.  A stratified blocked randomisation scheme was used with a block size of 4.  Randomisation was stratified by dose of pirfenidone (2403 mg/day [the max. dose] or <2403 mg/day).  Patients, physicians, study staff and the sponsor were masked to treatment group allocation.  The primary endpoint was assessment of adverse events, which were collected at each visit and for 28 days after the last dose of study drug.  Exploratory efficacy measurements included forced vital capacity (FVC), carbon monoxide diffusing capacity, and 6 min walk distance.  Analyses were done in the modified intention-to-treat population, which included all patients who were randomised and received at least one dose of study medication.  This study is registered with the European Clin. Trials Database (EudraCT no. 2012-000564-14) and has been completed.123 patients participated in the study between June 28, 2013, and Feb 24, 2015. 61 were assigned to the acetylcysteine group (60 received study medication and included in anal.) and 62 were assigned to the placebo group (all included in anal.).  The occurrence of at least one adverse event (46 [77%] patients receiving acetylcysteine vs 50 [81%] receiving placebo), adverse events related to study treatment (17 [28%] vs 16 [26%]), and the no. of patients experiencing severe adverse events (three [5%] vs two [3%]), life-threatening adverse events (one [2%] vs one [2%]), or death (one [2%] vs three [5%]) was similar between treatment groups.  One case of diarrhoea in the acetylcysteine group was considered severe and related to study treatment.  Nine serious adverse events were reported by seven patients: dyspnoea, headache, hypertension, intervertebral disk protrusion, and malignant lung neoplasm in the acetylcysteine group, and aortic aneurysm, contusion, forearm fracture, and worsening IPF in the placebo group.  The most common adverse events were cough, nasopharyngitis, and diarrhoea.  Photosensitivity occurred more frequently with acetylcysteine (eight [13%] patients) than placebo (one [2%] patient; difference 11·7%; 95% CI 2·6-20·9; p=0·016]), and was not attributable to differences in location, season, or concomitant medication.  Four (7%) patients receiving acetylcysteine and three (5%) receiving placebo discontinued study treatment due to adverse events.  In the exploratory anal., change in FVC indicated that clin. benefit from addn. of acetylcysteine to pirfenidone is unlikely, with the possibility of a harmful effect in patients with IPF (adjusted rate of decline 125·6 mL/6 mo for acetylcysteine vs 34·3 mL/6 mo for placebo; difference -91·3 mL; 95% CI -174·4 to -8·3; p=0·031).  Findings from the PANORAMA study suggest that addn. of acetylcysteine to pirfenidone does not substantially alter the tolerability profile of pirfenidone, and is unlikely to be beneficial in IPF.  InterMune International AG (Roche).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfqE-KT1ZYU7Vg90H21EOLACvtfcHk0lhAFKt1zyfB0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVChsLc%253D&md5=7d910d8c1411570b986868d4bf7d1dce</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930044-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930044-3%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBendstrup%26aufirst%3DE.%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DG%25C3%25BCnther%26aufirst%3DA.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%2BM.%26aulast%3DWells%26aufirst%3DA.%26aulast%3DWuyts%26aufirst%3DW.%26aulast%3DKoschel%26aufirst%3DD.%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DWallaert%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DAlbera%26aufirst%3DC.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520acetylcysteine%2520and%2520pirfenidone%2520combination%2520therapy%2520in%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520Phase%25202%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D445%26epage%3D453%26doi%3D10.1016%2FS2213-2600%2816%2930044-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Comer, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerthoffer, W. T.</span><span> </span><span class="NLM_article-title">Epigenetic targets for novel therapies of lung diseases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.pharmthera.2014.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25448041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=91-110&author=B.+S.+Comerauthor=M.+Baauthor=C.+A.+Singerauthor=W.+T.+Gerthoffer&title=Epigenetic+targets+for+novel+therapies+of+lung+diseases&doi=10.1016%2Fj.pharmthera.2014.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic targets for novel therapies of lung diseases</span></div><div class="casAuthors">Comer, Brian S.; Ba, Mariam; Singer, Cherie A.; Gerthoffer, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-110</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  In spite of substantial advances in defining the immunobiol. and function of structural cells in lung diseases there is still insufficient knowledge to develop fundamentally new classes of drugs to treat many lung diseases.  For example, there is a compelling need for new therapeutic approaches to address severe persistent asthma that is insensitive to inhaled corticosteroids.  Although the prevalence of steroid-resistant asthma is 5-10%, severe asthmatics require a disproportionate level of health care spending and constitute a majority of fatal asthma episodes.  None of the established drug therapies including long-acting beta agonists or inhaled corticosteroids reverse established airway remodeling.  Obstructive airways remodeling in patients with chronic obstructive pulmonary disease (COPD), restrictive remodeling in idiopathic pulmonary fibrosis (IPF) and occlusive vascular remodeling in pulmonary hypertension are similarly unresponsive to current drug therapy.  Therefore, drugs are needed to achieve long-acting suppression and reversal of pathol. airway and vascular remodeling.  Novel drug classes are emerging from advances in epigenetics.  Novel mechanisms are emerging by which cells adapt to environmental cues, which include changes in DNA methylation, histone modifications and regulation of transcription and translation by noncoding RNAs.  In this review we will summarize current epigenetic approaches being applied to preclin. drug development addressing important therapeutic challenges in lung diseases.  These challenges are being addressed by advances in lung delivery of oligonucleotides and small mols. that modify the histone code, DNA methylation patterns and miRNA function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorspcOaxa6BrVg90H21EOLACvtfcHk0ljqmn_HyHs28w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrtLvL&md5=cde9d2ce965b31bc6700235f7fcf48d1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DComer%26aufirst%3DB.%2BS.%26aulast%3DBa%26aufirst%3DM.%26aulast%3DSinger%26aufirst%3DC.%2BA.%26aulast%3DGerthoffer%26aufirst%3DW.%2BT.%26atitle%3DEpigenetic%2520targets%2520for%2520novel%2520therapies%2520of%2520lung%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D147%26spage%3D91%26epage%3D110%26doi%3D10.1016%2Fj.pharmthera.2014.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deguzman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apparsundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C.M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denton, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span> </span><span class="NLM_article-title">Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and <i>in vivo</i> models of lung fibrosis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1016/j.ajpath.2013.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ajpath.2013.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23759512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2013&pages=470-479&author=X.+Tangauthor=R.+Pengauthor=J.+E.+Phillipsauthor=J.+Deguzmanauthor=Y.+Renauthor=S.+Apparsundaramauthor=Q.+Luoauthor=C.+M.+Bauerauthor=M.+E.+Fuentesauthor=J.+A.+DeMartinoauthor=G.+Tyagiauthor=R.+Garridoauthor=C.M.+Hogaboamauthor=C.+P.+Dentonauthor=A.+M.+Holmesauthor=C.+Kitsonauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Assessment+of+Brd4+inhibition+in+idiopathic+pulmonary+fibrosis+lung+fibroblasts+and+in+vivo+models+of+lung+fibrosis&doi=10.1016%2Fj.ajpath.2013.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis</span></div><div class="casAuthors">Tang, Xiaoyan; Peng, Ruoqi; Phillips, Jonathan E.; Deguzman, Jeremy; Ren, Yonglin; Apparsundaram, Subramanium; Luo, Qi; Bauer, Carla M.; Fuentes, Maria E.; DeMartino, Julie A.; Tyagi, Gaurav; Garrido, Rosario; Hogaboam, Cory M.; Denton, Christopher P.; Holmes, Alan M.; Kitson, Christopher; Stevenson, Christopher S.; Budd, David C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">470-479</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of high unmet medical need.  Although bromodomain (Brd) and extra terminal domain isoforms have recently been implicated in mediating inflammatory and oncol. indications, their roles in lung fibrosis have not been comprehensively assessed.  We investigated the role of Brd on the profibrotic responses of lung fibroblasts (LFs) in patients with rapidly progressing IPF and a mouse bleomycin model of lung fibrosis.  The enhanced migration, proliferation, and IL-6 release obsd. in LFs from patients with rapidly progressing IPF are attenuated by pharmacol. inhibition of Brd4.  These changes are accompanied by enhanced histone H4 lysine5 acetylation and assocn. of Brd4 with genes involved in the profibrotic responses in IPF LFs as demonstrated using chromatin immunopptn. and quant. PCR.  Oral administration of 200 mg/kg per day Brd4 inhibitor JQ1 in a therapeutic dosing regimen substantially attenuated lung fibrosis induced by bleomycin in C57BL/6 mice.  In conclusion, this study shows that the Brd4 inhibitor JQ1, administered in a therapeutic dosage, is capable of inhibiting the profibrotic effects of IPF LFs and attenuates bleomycin-induced lung fibrosis in mice.  These results suggest that Brd4 inhibitors may represent a novel therapy for the treatment of rapidly progressing IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeyA6Tfi6PObVg90H21EOLACvtfcHk0ljqmn_HyHs28w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I&md5=8a7b094630ce44df6cd1b2b9de6cc6ec</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2013.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2013.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DDeguzman%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DApparsundaram%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DBauer%26aufirst%3DC.%2BM.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DTyagi%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DR.%26aulast%3DHogaboam%26aufirst%3DC.M.%26aulast%3DDenton%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BM.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DAssessment%2520of%2520Brd4%2520inhibition%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520lung%2520fibroblasts%2520and%2520in%2520vivo%2520models%2520of%2520lung%2520fibrosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2013%26volume%3D183%26spage%3D470%26epage%3D479%26doi%3D10.1016%2Fj.ajpath.2013.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Tang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apparsundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deguzman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span> </span><span class="NLM_article-title">BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in belomycin-induced pulmonary fibrosis</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span><span class="refDoi"> DOI: 10.1124/mol.112.081661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1124%2Fmol.112.081661" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=283-293&author=X.+Tangauthor=R.+Pengauthor=Y.+Renauthor=S.+Apparsundaramauthor=J.+Deguzmanauthor=C.+M.+Bauerauthor=A.+F.+Hoffmanauthor=S.+Hamiltonauthor=Z.+Liangauthor=H.+Zengauthor=M.+E.+Fuentesauthor=J.+A.+DeMartinoauthor=C.+Kitsonauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=BET+bromodomain+proteins+mediate+downstream+signaling+events+following+growth+factor+stimulation+in+human+lung+fibroblasts+and+are+involved+in+belomycin-induced+pulmonary+fibrosis&doi=10.1124%2Fmol.112.081661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.081661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.081661%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DApparsundaram%26aufirst%3DS.%26aulast%3DDeguzman%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DC.%2BM.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DHamilton%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DBET%2520bromodomain%2520proteins%2520mediate%2520downstream%2520signaling%2520events%2520following%2520growth%2520factor%2520stimulation%2520in%2520human%2520lung%2520fibroblasts%2520and%2520are%2520involved%2520in%2520belomycin-induced%2520pulmonary%2520fibrosis%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D283%26epage%3D293%26doi%3D10.1124%2Fmol.112.081661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sanders, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagood, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambalavanan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1448</span><span class="NLM_x">–</span> <span class="NLM_lpage">1458</span><span class="refDoi"> DOI: 10.1183/09031936.00095113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00095113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24603818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1448-1458&author=Y.+Y.+Sandersauthor=J.+S.+Hagoodauthor=H.+Liuauthor=W.+Zhangauthor=N.+Ambalavananauthor=V.+J.+Thannickal&title=Histone+deacetylase+inhibition+promotes+fibroblast+apoptosis+and+ameliorates+pulmonary+fibrosis+in+mice&doi=10.1183%2F09031936.00095113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice</span></div><div class="casAuthors">Sanders, Yan Y.; Hagood, James S.; Liu, Hui; Zhang, Wei; Ambalavanan, Namasivayam; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1448-1458</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a fatal disease, and therapeutic agents have shown only modest efficacy.  Epigenetic alterations contribute to the pathogenesis of IPF.  The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), has been approved for clin. use in cancer; however, its potential efficacy in modulating fibroblast survival and lung fibrosis has not been extensively investigated.  We investigated the effects of SAHA on apoptosis of primary IPF myofibroblasts and on injury-induced lung fibrosis in a murine model.  SAHA-induced apoptosis of IPF myofibroblasts, an effect that was mediated, at least in part, by upregulation of the pro-apoptotic gene Bak and downregulation of the anti-apoptotic gene Bcl-xL.  Alterations in the expression of these apoptosis-related genes were assocd. with histone modifications and changes in DNA methylation.  In addn. to the expected higher levels of histone acetylation in treated cells, we also detected changes in other histone modifications, such as histone methylation.  In a murine model of bleomycin-induced pulmonary fibrosis, SAHA-treated mice displayed decreased lung fibrosis and improved lung function compared to the bleomycin only group.  These results suggest that histone deacetylase inhibitors may offer a new therapeutic strategy in IPF by modulating myofibroblast susceptibility to apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruyks7TCWdMbVg90H21EOLACvtfcHk0lhgkdTTClQxDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73J&md5=86f2617a181392acfc8040c9449d8102</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1183%2F09031936.00095113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00095113%26sid%3Dliteratum%253Aachs%26aulast%3DSanders%26aufirst%3DY.%2BY.%26aulast%3DHagood%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DAmbalavanan%26aufirst%3DN.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520promotes%2520fibroblast%2520apoptosis%2520and%2520ameliorates%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1448%26epage%3D1458%26doi%3D10.1183%2F09031936.00095113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Cronkhite, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, C. K.</span><span> </span><span class="NLM_article-title">Telomere shortening in familial and sporadic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">737</span><span class="refDoi"> DOI: 10.1164/rccm.200804-550OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200804-550OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18635888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GqsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2008&pages=729-737&author=J.+T.+Cronkhiteauthor=C.+Xingauthor=G.+Raghuauthor=K.+M.+Chinauthor=F.+Torresauthor=R.+L.+Rosenblattauthor=C.+K.+Garcia&title=Telomere+shortening+in+familial+and+sporadic+pulmonary+fibrosis&doi=10.1164%2Frccm.200804-550OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Telomere shortening in familial and sporadic pulmonary fibrosis</span></div><div class="casAuthors">Cronkhite, Jennifer T.; Xing, Chao; Raghu, Ganesh; Chin, Kelly M.; Torres, Fernando; Rosenblatt, Randall L.; Garcia, Christine Kim</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">729-737</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Heterozygous mutations in the coding regions of the telomerase genes, TERT and TERC, have been found in familial and sporadic cases of idiopathic interstitial pneumonia.  All affected patients with mutations have short telomeres.  To test whether telomere shortening is a frequent mechanism underlying pulmonary fibrosis, we have characterized telomere lengths in subjects with familial or sporadic disease who do not have coding mutations in TERT or TERC.  Using a modified Southern blot assay, the telomerase restriction fragment length method, and a quant. polymerase chain reaction assay we have measured telomere lengths of genomic DNA isolated from circulating leukocytes from normal control subjects and subjects with pulmonary fibrosis.  All affected patients with telomerase mutations, including case subjects heterozygous for newly reported mutations in TERT, have short telomere lengths.  A significantly higher proportion of probands with familial pulmonary fibrosis (24%) and sporadic case subjects (23%) in which no coding mutation in TERT or TERC was found had telomere lengths less than the 10th percentile when compared with control subjects (P = 2.6 × 10-8).  Pulmonary fibrosis affectation status was significantly assocd. with telomerase restriction fragment lengths, even after controlling for age, sex, and ethnicity (P = 6.1 × 10-11).  Overall, 25% of sporadic cases and 37% of familial cases of pulmonary fibrosis had telomere lengths less than the 10th percentile.  A significant fraction of individuals with pulmonary fibrosis have short telomere lengths that cannot be explained by coding mutations in telomerase.  Telomere shortening of circulating leukocytes may be a marker for an increased predisposition toward the development of this age-assocd. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5OLrx3eOI7Vg90H21EOLACvtfcHk0lhgkdTTClQxDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GqsLzI&md5=49b8d3a32dea7e1368dcd8e403e02cb3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1164%2Frccm.200804-550OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200804-550OC%26sid%3Dliteratum%253Aachs%26aulast%3DCronkhite%26aufirst%3DJ.%2BT.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DChin%26aufirst%3DK.%2BM.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DRosenblatt%26aufirst%3DR.%2BL.%26aulast%3DGarcia%26aufirst%3DC.%2BK.%26atitle%3DTelomere%2520shortening%2520in%2520familial%2520and%2520sporadic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D178%26spage%3D729%26epage%3D737%26doi%3D10.1164%2Frccm.200804-550OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Seibold, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyd, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingerlin, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudmundsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groshong, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garantziotis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kervitsky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbert, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slifer, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auerbach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennessy, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. A.</span><span> </span><span class="NLM_article-title">A common <i>MUC5B</i> promoter polymorphism and pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1503</span><span class="NLM_x">–</span> <span class="NLM_lpage">1512</span><span class="refDoi"> DOI: 10.1056/NEJMoa1013660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1013660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21506741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlCjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1503-1512&author=M.+A.+Seiboldauthor=A.+L.+Wiseauthor=M.+C.+Speerauthor=M.+P.+Steeleauthor=K.+K.+Brownauthor=J.+E.+Loydauthor=T.+E.+Fingerlinauthor=W.+Zhangauthor=G.+Gudmundssonauthor=S.+D.+Groshongauthor=C.+M.+Evansauthor=S.+Garantziotisauthor=K.+B.+Adlerauthor=B.+F.+Dickeyauthor=R.+M.+du+Boisauthor=I.+V.+Yangauthor=A.+Herronauthor=D.+Kervitskyauthor=J.+L.+Talbertauthor=C.+Markinauthor=J.+Parkauthor=A.+L.+Crewsauthor=S.+H.+Sliferauthor=S.+Auerbachauthor=M.+G.+Royauthor=J.+Linauthor=C.+E.+Hennessyauthor=M.+I.+Schwarzauthor=D.+A.+Schwartz&title=A+common+MUC5B+promoter+polymorphism+and+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1013660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A common MUC5B promoter polymorphism and pulmonary fibrosis</span></div><div class="casAuthors">Seibold, Max A.; Wise, Anastasia L.; Speer, Marcy C.; Steele, Mark P.; Brown, Kevin K.; Loyd, James E.; Fingerlin, Tasha E.; Zhang, Weiming; Gudmundsson, Gunnar; Groshong, Steve D.; Evans, Christopher M.; Garantziotis, Stavros; Adler, Kenneth B.; Dickey, Burton F.; Du Bois, Roland M.; Yang, Ivana V.; Herron, Aretha; Kervitsky, Dolly; Talbert, Janet L.; Markin, Cheryl; Park, Joungjoa; Crews, Anne L.; Slifer, Susan H.; Auerbach, Scott; Roy, Michelle G.; Lin, Jia; Hennessy, Corinne E.; Schwarz, Marvin I.; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1503-1512</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The mutations that have been implicated in pulmonary fibrosis account for only a small proportion of the population risk.  METHODS Using a genomewide linkage scan, we detected linkage between idiopathic interstitial pneumonia and a 3.4-Mb region of chromosome 11p15 in 82 families.  We then evaluated genetic variation in this region in gel-forming mucin genes expressed in the lung among 83 subjects with familial interstitial pneumonia, 492 subjects with idiopathic pulmonary fibrosis, and 322 controls.  MUC5B expression was assessed in lung tissue.  RESULTS Linkage and fine mapping were used to identify a region of interest on the p-terminus of chromosome 11 that included gel-forming mucin genes.  The minor-allele of the single-nucleotide polymorphism (SNP) rs35705950, located 3 kb upstream of the MUCSB transcription start site, was present at a frequency of 34% among subjects with familial interstitial pneumonia, 38% among subjects with idiopathic pulmonary fibrosis, and 9% among controls (allelic assocn. with familial interstitial pneumonia, P = 1.2 x 10-15; allelic assocn. with idiopathic pulmonary fibrosis, P = 2.5 x 10-37).  The odds ratios for disease among subjects who were heterozygous and those who were homozygous for the minor allele of this SNP were 6.8 (95% confidence interval [CI], 3.9 to 12.0) and 20.8 (95% CI, 3.8 to 113.7), resp., for familial interstitial pneumonia and 9.0 (95% CI, 6.2 to 13.1) and 21.8 (95% CI, 5.1 to 93.5), resp., for idiopathic pulmonary fibrosis.  MUC5B expression in the lung was 14.1 times as high in subjects who had idiopathic pulmonary fibrosis as in those who did not (P < 0.001).  The variant allele of rs35705950 was assocd. with up-regulation in MUCSB expression in the lung in unaffected subjects (expression was 37.4 times as high as in unaffected subjects homozygous for the wild-type allele, P < 0.001).  MUC5B protein was expressed in lesions of idiopathic pulmonary fibrosis.  CONCLUSIONS A common polymorphism in the promoter of MUCSB is assocd. with familial interstitial pneumonia and idiopathic pulmonary fibrosis.  Our findings suggest that dys-regulated MUCSB expression in the lung may be involved in the pathogenesis of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqgU61mlv8D7Vg90H21EOLACvtfcHk0lgRZPZkGD8rBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlCjt74%253D&md5=035e9ac9ba09c6f8a1764228a112ef20</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013660%26sid%3Dliteratum%253Aachs%26aulast%3DSeibold%26aufirst%3DM.%2BA.%26aulast%3DWise%26aufirst%3DA.%2BL.%26aulast%3DSpeer%26aufirst%3DM.%2BC.%26aulast%3DSteele%26aufirst%3DM.%2BP.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DFingerlin%26aufirst%3DT.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGudmundsson%26aufirst%3DG.%26aulast%3DGroshong%26aufirst%3DS.%2BD.%26aulast%3DEvans%26aufirst%3DC.%2BM.%26aulast%3DGarantziotis%26aufirst%3DS.%26aulast%3DAdler%26aufirst%3DK.%2BB.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DI.%2BV.%26aulast%3DHerron%26aufirst%3DA.%26aulast%3DKervitsky%26aufirst%3DD.%26aulast%3DTalbert%26aufirst%3DJ.%2BL.%26aulast%3DMarkin%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DA.%2BL.%26aulast%3DSlifer%26aufirst%3DS.%2BH.%26aulast%3DAuerbach%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DM.%2BG.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHennessy%26aufirst%3DC.%2BE.%26aulast%3DSchwarz%26aufirst%3DM.%2BI.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26atitle%3DA%2520common%2520MUC5B%2520promoter%2520polymorphism%2520and%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1503%26epage%3D1512%26doi%3D10.1056%2FNEJMoa1013660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Hunninghake, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatabu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latourelle, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zazueta, O. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurugol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San José Estépar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyd, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingerlin, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosas, I. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washko, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D.</span><span> </span><span class="NLM_article-title">A. <i>MUC5B</i> promoter polymorphism and interstitial lung abnormalities</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2192</span><span class="NLM_x">–</span> <span class="NLM_lpage">2200</span><span class="refDoi"> DOI: 10.1056/NEJMoa1216076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1216076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23692170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2192-2200&author=G.+M.+Hunninghakeauthor=H.+Hatabuauthor=Y.+Okajimaauthor=W.+Gaoauthor=J.+Dupuisauthor=J.+C.+Latourelleauthor=M.+Nishinoauthor=T.+Arakiauthor=O.+E.+Zazuetaauthor=S.+Kurugolauthor=J.+C.+Rossauthor=R.+San+Jos%C3%A9+Est%C3%A9parauthor=E.+Murphyauthor=M.+P.+Steeleauthor=J.+E.+Loydauthor=M.+I.+Schwarzauthor=T.+E.+Fingerlinauthor=I.+O.+Rosasauthor=G.+R.+Washkoauthor=G.+T.+O%E2%80%99Connorauthor=D.+Schwartz&title=A.+MUC5B+promoter+polymorphism+and+interstitial+lung+abnormalities&doi=10.1056%2FNEJMoa1216076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">MUC5B promoter polymorphism and interstitial lung abnormalities</span></div><div class="casAuthors">Hunninghake, Gary M.; Hatabu, Hiroto; Okajima, Yuka; Gao, Wei; Dupuis, Josee; Latourelle, Jeanne C.; Nishino, Mizuki; Araki, Tetsuro; Zazueta, Oscar E.; Kurugol, Sila; Ross, James C.; Estepar, Raul San Jose; Murphy, Elissa; Steele, Mark P.; Loyd, James E.; Schwarz, Marvin I.; Fingerlin, Tasha E.; Rosas, Ivan O.; Washko, George R.; O'Connor, George T.; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2192-2200</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: A common promoter polymorphism (rs35705950) in MUC5B, the gene encoding mucin 5B, is assocd. with idiopathic pulmonary fibrosis.  It is not known whether this polymorphism is assocd. with interstitial lung disease in the general population.  Methods: We performed a blinded assessment of interstitial lung abnormalities detected in 2633 participants in the Framingham Heart Study by means of volumetric chest computed tomog. (CT).  We evaluated the relationship between the abnormalities and the genotype at the rs35705950 locus.  Results: Of the 2633 chest CT scans that were evaluated, interstitial lung abnormalities were present in 177 (7%).  Participants with such abnormalities were more likely to have shortness of breath and chronic cough and reduced measures of total lung and diffusion capacity, as compared with participants without such abnormalities.  After adjustment for covariates, for each copy of the minor rs35705950 allele, the odds of interstitial lung abnormalities were 2.8 times greater (95% confidence interval [CI], 2.0 to 3.9; P<0.001), and the odds of definite CT evidence of pulmonary fibrosis were 6.3 times greater (95% CI, 3.1 to 12.7; P<0.001).  Although the evidence of an assocn. between the MUC5B genotype and interstitial lung abnormalities was greater among participants who were older than 50 years of age, a history of cigarette smoking did not appear to influence the assocn.  Conclusions: The MUC5B promoter polymorphism was found to be assocd. with interstitial lung disease in the general population.  Although this assocn. was more apparent in older persons, it did not appear to be influenced by cigarette smoking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6MPYpJhlNvbVg90H21EOLACvtfcHk0lgRZPZkGD8rBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1Oqu7c%253D&md5=3893c4b4eebefee6aa436588f00f2d53</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1216076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1216076%26sid%3Dliteratum%253Aachs%26aulast%3DHunninghake%26aufirst%3DG.%2BM.%26aulast%3DHatabu%26aufirst%3DH.%26aulast%3DOkajima%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DLatourelle%26aufirst%3DJ.%2BC.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DZazueta%26aufirst%3DO.%2BE.%26aulast%3DKurugol%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BJos%25C3%25A9%2BEst%25C3%25A9par%26aufirst%3DR.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DSteele%26aufirst%3DM.%2BP.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DSchwarz%26aufirst%3DM.%2BI.%26aulast%3DFingerlin%26aufirst%3DT.%2BE.%26aulast%3DRosas%26aufirst%3DI.%2BO.%26aulast%3DWashko%26aufirst%3DG.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DG.%2BT.%26aulast%3DSchwartz%26aufirst%3DD.%26atitle%3DA.%2520MUC5B%2520promoter%2520polymorphism%2520and%2520interstitial%2520lung%2520abnormalities%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2192%26epage%3D2200%26doi%3D10.1056%2FNEJMoa1216076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Guo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L. A.</span><span> </span><span class="NLM_article-title">Factors affecting would healing</span> <span class="citation_source-journal">J. Dent. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1177/0022034509359125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1177%2F0022034509359125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20139336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2010&pages=219-229&author=S.+Guoauthor=L.+A.+DiPietro&title=Factors+affecting+would+healing&doi=10.1177%2F0022034509359125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Factors affecting wound healing</span></div><div class="casAuthors">Guo, S.; Di Pietro, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dental Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-229</span>CODEN:
                <span class="NLM_cas:coden">JDREAF</span>;
        ISSN:<span class="NLM_cas:issn">0022-0345</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Wound healing, as a normal biol. process in the human body, is achieved through four precisely and highly programmed phases: hemostasis, inflammation, proliferation, and remodeling.  For a wound to heal successfully, all four phases must occur in the proper sequence and time frame.  Many factors can interfere with one or more phases of this process, thus causing improper or impaired wound healing.  This article reviews the recent literature on the most significant factors that affect cutaneous wound healing and the potential cellular and/or mol. mechanisms involved.  The factors discussed include oxygenation, infection, age and sex hormones, stress, diabetes, obesity, medications, alcoholism, smoking, and nutrition.  A better understanding of the influence of these factors on repair may lead to therapeutics that improve wound healing and resolve impaired wounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXmA0AOrfXT7Vg90H21EOLACvtfcHk0lgRZPZkGD8rBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOnsLc%253D&md5=a42f3a6d9a5a275ced98dd32f6f7870f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1177%2F0022034509359125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0022034509359125%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DDiPietro%26aufirst%3DL.%2BA.%26atitle%3DFactors%2520affecting%2520would%2520healing%26jtitle%3DJ.%2520Dent.%2520Res.%26date%3D2010%26volume%3D89%26spage%3D219%26epage%3D229%26doi%3D10.1177%2F0022034509359125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Crooks, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S. P.</span><span> </span><span class="NLM_article-title">Coagulation and anticoagulation in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span><span class="refDoi"> DOI: 10.1183/16000617.00008414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F16000617.00008414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26324800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC287nvVyisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=392-399&author=M.+G.+Crooksauthor=S.+P.+Hart&title=Coagulation+and+anticoagulation+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F16000617.00008414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Coagulation and anticoagulation in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Crooks Michael G; Hart Simon P</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">137</span>),
    <span class="NLM_cas:pages">392-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers.  Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.  Coagulation and fibrinolytic systems play central roles in wound healing and repair, processes hypothesised to be abnormal within the IPF lung.  Animal models of pulmonary fibrosis have demonstrated an imbalance between thrombosis and fibrinolysis within the alveolar compartment, a finding that is also observed in IPF patients.  A systemic prothrombotic state also occurs in IPF and is associated with increased mortality, but trials of anticoagulation in IPF have provided conflicting results.  Differences in methodology, intervention and study populations may contribute to the inconsistent trial outcomes.  The new oral anticoagulants have properties that may prove advantageous in targeting both thrombotic risk and progression of lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9BMw_xouW2nO4gDb7JggCfW6udTcc2ebcGzUA-Otlerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nvVyisw%253D%253D&md5=a1a305119d546bdd570344669869ef8d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1183%2F16000617.00008414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.00008414%26sid%3Dliteratum%253Aachs%26aulast%3DCrooks%26aufirst%3DM.%2BG.%26aulast%3DHart%26aufirst%3DS.%2BP.%26atitle%3DCoagulation%2520and%2520anticoagulation%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2015%26volume%3D24%26spage%3D392%26epage%3D399%26doi%3D10.1183%2F16000617.00008414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Navaratnam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumaran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pointon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. B.</span><span> </span><span class="NLM_article-title">Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1136/thoraxjnl-2013-203740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthoraxjnl-2013-203740" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=207-215&author=V.+Navaratnamauthor=A.+W.+Fogartyauthor=T.+McKeeverauthor=N.+Thompsonauthor=G.+Jenkinsauthor=S.+R.+Johnsonauthor=G.+Dolanauthor=M.+Kumaranauthor=K.+Pointonauthor=R.+B.+Hubbard&title=Presence+of+a+prothrombotic+state+in+people+with+idiopathic+pulmonary+fibrosis%3A+a+population-based+case-control+study&doi=10.1136%2Fthoraxjnl-2013-203740"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2013-203740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2013-203740%26sid%3Dliteratum%253Aachs%26aulast%3DNavaratnam%26aufirst%3DV.%26aulast%3DFogarty%26aufirst%3DA.%2BW.%26aulast%3DMcKeever%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DN.%26aulast%3DJenkins%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DDolan%26aufirst%3DG.%26aulast%3DKumaran%26aufirst%3DM.%26aulast%3DPointon%26aufirst%3DK.%26aulast%3DHubbard%26aufirst%3DR.%2BB.%26atitle%3DPresence%2520of%2520a%2520prothrombotic%2520state%2520in%2520people%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520population-based%2520case-control%2520study%26jtitle%3DThorax%26date%3D2014%26volume%3D69%26spage%3D207%26epage%3D215%26doi%3D10.1136%2Fthoraxjnl-2013-203740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Noth, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anstrom, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Andrade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olman, M. A.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis clinical network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1164/rccm.201202-0314OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201202-0314OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22561965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Sht7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2012&pages=88-95&author=I.+Nothauthor=K.+J.+Anstromauthor=S.+B.+Calvertauthor=J.+de+Andradeauthor=K.+R.+Flahertyauthor=C.+Glazerauthor=R.+J.+Kanerauthor=M.+A.+Olman&title=Idiopathic+pulmonary+fibrosis+clinical+network+%28IPFnet%29.+A+placebo-controlled+randomized+trial+of+warfarin+in+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.201202-0314OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Noth, Imre; Anstrom, Kevin J.; Calvert, Sara Bristol; de Andrade, Joao; Flaherty, Kevin R.; Glazer, Craig; Kaner, Robert J.; Olman, Mitchell A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis.  Objectives: In a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC.  Methods: This was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients with IPF.  Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 wk.  International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy.  Measurements and Main Results: The primary outcome measure was the composite outcome of time to death, hospitalization (nonbleeding, nonelective), or a 10% or greater abs. decline in FVC.  Due to a low probability of benefit and an increase in mortality obsd. in the subjects randomized to warfarin (14 warfarin vs. 3 placebo deaths; P = 0.005) an independent Data and Safety Monitoring Board recommended stopping the study after 145 of the planned 256 subjects were enrolled (72 warfarin, 73 placebo).  The mean follow-up was 28 wk.  Conclusions: This study did not show a benefit for warfarin in the treatment of patients with progressive IPF.  Treatment with warfarin was assocd. with an increased risk of mortality in an IPF population who lacked other indications for anticoagulation.  Clin. trial registered with www.clinicaltrials.gov (NCT00957242).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotkK3yFmGEFbVg90H21EOLACvtfcHk0lgHSUvEgdQG2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Sht7nI&md5=904caeacc1f8a5350cf7f13f59101d55</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1164%2Frccm.201202-0314OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201202-0314OC%26sid%3Dliteratum%253Aachs%26aulast%3DNoth%26aufirst%3DI.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DCalvert%26aufirst%3DS.%2BB.%26aulast%3Dde%2BAndrade%26aufirst%3DJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DGlazer%26aufirst%3DC.%26aulast%3DKaner%26aufirst%3DR.%2BJ.%26aulast%3DOlman%26aufirst%3DM.%2BA.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%2520clinical%2520network%2520%2528IPFnet%2529.%2520A%2520placebo-controlled%2520randomized%2520trial%2520of%2520warfarin%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D186%26spage%3D88%26epage%3D95%26doi%3D10.1164%2Frccm.201202-0314OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijsenbeek, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasakova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weycker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchgaessler, K.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, T. M.</span><span> </span><span class="NLM_article-title">Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1776</span><span class="NLM_x">–</span> <span class="NLM_lpage">1784</span><span class="refDoi"> DOI: 10.1183/13993003.02087-2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.02087-2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=27103382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28bit1Khtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2016&pages=1776-1784&author=M.+Kreuterauthor=M.+S.+Wijsenbeekauthor=M.+Vasakovaauthor=P.+Spagnoloauthor=M.+Kolbauthor=U.+Costabelauthor=D.+Weyckerauthor=K.-U.+Kirchgaesslerauthor=T.+M.+Maher&title=Unfavourable+effects+of+medically+indicated+oral+anticoagulants+on+survival+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F13993003.02087-2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Kreuter Michael; Wijsenbeek Marlies S; Vasakova Martina; Spagnolo Paolo; Kolb Martin; Costabel Ulrich; Weycker Derek; Kirchgaessler Klaus-Uwe; Maher Toby M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1776-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Procoagulant and antifibrinolytic activity has been associated with idiopathic pulmonary fibrosis (IPF); however, investigation of anticoagulant therapy in IPF has suggested deleterious effects.  This post hoc analysis evaluated the effect of medically indicated anticoagulation on mortality and other clinical outcomes in IPF.Patients randomised to placebo (n=624) from three controlled trials in IPF were analysed by oral anticoagulant use.  End-points included all-cause and IPF-related mortality, disease progression, hospitalisation, and adverse events, over 1 year.At baseline, 32 (5.1%) patients randomised to placebo were prescribed anticoagulants for non-IPF indications, 29 (90.6%) of whom received warfarin.  Unadjusted analyses demonstrated significantly higher all-cause and IPF-related mortality at 1 year in baseline anticoagulant users versus nonusers (15.6% versus 6.3%, p=0.039 and 15.6% versus 3.9%, p=0.002, respectively).  In multivariate analyses, baseline use of anticoagulants was an independent predictor of IPF-related mortality (hazard ratio 4.7, p=0.034), but not other end-points.  Rates of bleeding and cardiac events did not differ significantly between groups.  In an exploratory analysis, anticoagulant use at any time during the study was an independent predictor of all end-points.This post hoc analysis suggests that anticoagulants used for non-IPF indications may have unfavourable effects in IPF patients.  Future studies are needed to explore this relationship further.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-HQ8dhmJilT0O18WR3iAofW6udTcc2eZlESYTpstbQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bit1Khtg%253D%253D&md5=c8f3bc8a4e1fec3272aedcc46c5ce14d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1183%2F13993003.02087-2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02087-2015%26sid%3Dliteratum%253Aachs%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DWijsenbeek%26aufirst%3DM.%2BS.%26aulast%3DVasakova%26aufirst%3DM.%26aulast%3DSpagnolo%26aufirst%3DP.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DWeycker%26aufirst%3DD.%26aulast%3DKirchgaessler%26aufirst%3DK.-U.%26aulast%3DMaher%26aufirst%3DT.%2BM.%26atitle%3DUnfavourable%2520effects%2520of%2520medically%2520indicated%2520oral%2520anticoagulants%2520on%2520survival%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2016%26volume%3D47%26spage%3D1776%26epage%3D1784%26doi%3D10.1183%2F13993003.02087-2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Bogatkevich, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwicka-bradley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. M.</span><span> </span><span class="NLM_article-title">Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3455</span><span class="NLM_x">–</span> <span class="NLM_lpage">3464</span><span class="refDoi"> DOI: 10.1002/art.24935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fart.24935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19877031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFentLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=3455-3464&author=G.+S.+Bogatkevichauthor=A.+Ludwicka-bradleyauthor=R.+M.+Silver&title=Dabigatran%2C+a+direct+thrombin+inhibitor%2C+demonstrates+antifibrotic+effects+on+lung+fibroblasts&doi=10.1002%2Fart.24935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts</span></div><div class="casAuthors">Bogatkevich, Galina S.; Ludwicka-Bradley, Anna; Silver, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3455-3464</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. Myofibroblasts are the principal mesenchymal cells responsible for tissue remodeling, collagen deposition, and the restrictive nature of lung parenchyma assocd. with pulmonary fibrosis.  We previously reported that thrombin activates protease-activated receptor 1 (PAR-1) and induces a myofibroblast phenotype in normal lung fibroblasts resembling the phenotype of scleroderma lung myofibroblasts.  We undertook this study to investigate whether a selective direct thrombin inhibitor, dabigatran, interferes with signal transduction in human lung fibroblasts induced by thrombin and mediated via PAR-1.  Methods. Lung fibroblast proliferation was analyzed using the Quick Cell Proliferation Assay.  Expression and organization of α-smooth muscle actin (α-SMA) was studied by immunofluorescence staining and immunoblotting.  Contractile activity of lung fibroblasts was measured by a collagen gel contraction assay.  Connective tissue growth factor (CTGF) and type I collagen expression was analyzed on Western blots.  Results. Dabigatran, at concns. of 50-1,000 ng/mL, inhibited thrombin-induced cell proliferation, α-SMA expression and organization, and the prodn. of collagen and CTGF in normal lung fibroblasts.  Moreover, when treated with dabigatran (1 μg/mL), scleroderma lung myofibroblasts produced 6-fold less α-SMA, 3-fold less CTGF, and 2-fold less type I collagen compared with untreated cells.  Conclusion. Dabigatran restrains important profibrotic events in lung fibroblasts and warrants study as a potential antifibrotic drug for the treatment of fibrosing lung diseases such as scleroderma lung disease and idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ8f5odQC10LVg90H21EOLACvtfcHk0liWlzvUgiFblg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFentLzE&md5=e97b12aac12c7e25c28c2ab0f1dfb961</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fart.24935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24935%26sid%3Dliteratum%253Aachs%26aulast%3DBogatkevich%26aufirst%3DG.%2BS.%26aulast%3DLudwicka-bradley%26aufirst%3DA.%26aulast%3DSilver%26aufirst%3DR.%2BM.%26atitle%3DDabigatran%252C%2520a%2520direct%2520thrombin%2520inhibitor%252C%2520demonstrates%2520antifibrotic%2520effects%2520on%2520lung%2520fibroblasts%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D3455%26epage%3D3464%26doi%3D10.1002%2Fart.24935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Bogatkevich, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwicka-bradley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nietert, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Ryn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. M.</span><span> </span><span class="NLM_article-title">Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1416</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span><span class="refDoi"> DOI: 10.1002/art.30255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fart.30255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21312187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=1416-1425&author=G.+S.+Bogatkevichauthor=A.+Ludwicka-bradleyauthor=P.+J.+Nietertauthor=T.+Akterauthor=J.+van+Rynauthor=R.+M.+Silver&title=Antiinflammatory+and+antifibrotic+effects+of+the+oral+direct+thrombin+inhibitor+dabigatran+etexilate+in+a+murine+model+of+interstitial+lung+disease&doi=10.1002%2Fart.30255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease</span></div><div class="casAuthors">Bogatkevich, Galina S.; Ludwicka-Bradley, Anna; Nietert, Paul J.; Akter, Tanjina; van Ryn, Joanne; Silver, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1416-1425</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Activation of the coagulation cascade leading to generation of thrombin has been documented extensively in various forms of lung injury, including that assocd. with systemic sclerosis.  We previously demonstrated that the direct thrombin inhibitor dabigatran inhibits thrombin-induced profibrotic signaling in lung fibroblasts.  This study was undertaken to test whether dabigatran etexilate attenuates lung injury in a murine model of interstitial lung disease.  Lung injury was induced in female C57BL/6 mice by a single intratracheal instillation of bleomycin.  Dabigatran etexilate was given as supplemented chow beginning on day 1 of bleomycin instillation (early treatment, study of antiinflammatory effect) or on day 8 following bleomycin instillation (late treatment, study of antifibrotic effect).  Mice were killed 2 wk or 3 wk after bleomycin instillation, and lung tissue, bronchoalveolar lavage (BAL) fluid, and plasma were investigated.  Both early treatment and late treatment with dabigatran etexilate attenuated the development of bleomycin-induced pulmonary fibrosis.  Dabigatran etexilate significantly reduced thrombin activity and levels of transforming growth factor β1 in BAL fluid, while simultaneously reducing the no. of inflammatory cells and protein concns.  Histol. evident lung inflammation and fibrosis were significantly decreased in dabigatran etexilate-treated mice.  Addnl., dabigatran etexilate reduced collagen, connective tissue growth factor, and α-smooth muscle actin expression in mice with bleomycin-induced lung fibrosis, whereas it had no effect on basal levels of these proteins.  Inhibition of thrombin using the oral direct thrombin inhibitor dabigatran etexilate has marked antiinflammatory and antifibrotic effects in a bleomycin model of pulmonary fibrosis.  Our data provide preclin. information about the feasibility and efficacy of dabigatran etexilate as a new therapeutic approach for the treatment of interstitial lung disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6d_EuqwQ5grVg90H21EOLACvtfcHk0liWlzvUgiFblg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGht74%253D&md5=40fbb918854846010a3045f597458d49</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fart.30255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.30255%26sid%3Dliteratum%253Aachs%26aulast%3DBogatkevich%26aufirst%3DG.%2BS.%26aulast%3DLudwicka-bradley%26aufirst%3DA.%26aulast%3DNietert%26aufirst%3DP.%2BJ.%26aulast%3DAkter%26aufirst%3DT.%26aulast%3Dvan%2BRyn%26aufirst%3DJ.%26aulast%3DSilver%26aufirst%3DR.%2BM.%26atitle%3DAntiinflammatory%2520and%2520antifibrotic%2520effects%2520of%2520the%2520oral%2520direct%2520thrombin%2520inhibitor%2520dabigatran%2520etexilate%2520in%2520a%2520murine%2520model%2520of%2520interstitial%2520lung%2520disease%26jtitle%3DArthritis%2520Rheum.%26date%3D2011%26volume%3D63%26spage%3D1416%26epage%3D1425%26doi%3D10.1002%2Fart.30255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Scotton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupiczojc, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Königshoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffatt, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derian, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickelberg, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">2550</span><span class="NLM_x">–</span> <span class="NLM_lpage">2563</span><span class="refDoi"> DOI: 10.1172/JCI33288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1172%2FJCI33288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=2550-2563&author=C.+J.+Scottonauthor=M.+A.+Krupiczojcauthor=M.+K%C3%B6nigshoffauthor=P.+F.+Mercerauthor=Y.+C.+Leeauthor=N.+Kaminskiauthor=J.+Morserauthor=J.+M.+Postauthor=T.+M.+Maherauthor=A.+G.+Nicholsonauthor=J.+D.+Moffattauthor=G.+J.+Laurentauthor=C.+K.+Derianauthor=O.+Eickelbergauthor=R.+C.+Chambers&title=Increased+local+expression+of+coagulation+factor+X+contributes+to+the+fibrotic+response+in+human+and+murine+lung+injury&doi=10.1172%2FJCI33288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1172%2FJCI33288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI33288%26sid%3Dliteratum%253Aachs%26aulast%3DScotton%26aufirst%3DC.%2BJ.%26aulast%3DKrupiczojc%26aufirst%3DM.%2BA.%26aulast%3DK%25C3%25B6nigshoff%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DP.%2BF.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DMaher%26aufirst%3DT.%2BM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DMoffatt%26aufirst%3DJ.%2BD.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DDerian%26aufirst%3DC.%2BK.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DIncreased%2520local%2520expression%2520of%2520coagulation%2520factor%2520X%2520contributes%2520to%2520the%2520fibrotic%2520response%2520in%2520human%2520and%2520murine%2520lung%2520injury%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D2550%26epage%3D2563%26doi%3D10.1172%2FJCI33288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spong, S.</span><span> </span><span class="NLM_article-title">CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">S24</span><span class="refDoi"> DOI: 10.1186/1755-1536-5-S1-S24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2F1755-1536-5-S1-S24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=S24&author=K.+E.+Lipsonauthor=C.+Wongauthor=Y.+Tengauthor=S.+Spong&title=CTGF+is+a+central+mediator+of+tissue+remodeling+and+fibrosis+and+its+inhibition+can+reverse+the+process+of+fibrosis&doi=10.1186%2F1755-1536-5-S1-S24"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-5-S1-S24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-5-S1-S24%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DTeng%26aufirst%3DY.%26aulast%3DSpong%26aufirst%3DS.%26atitle%3DCTGF%2520is%2520a%2520central%2520mediator%2520of%2520tissue%2520remodeling%2520and%2520fibrosis%2520and%2520its%2520inhibition%2520can%2520reverse%2520the%2520process%2520of%2520fibrosis%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2012%26volume%3D5%26spage%3DS24%26doi%3D10.1186%2F1755-1536-5-S1-S24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Kono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukamachi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, P.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chida, K.</span><span> </span><span class="NLM_article-title">Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)</span> <span class="citation_source-journal">Clin. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2215</span><span class="refDoi"> DOI: 10.1016/j.cca.2011.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.cca.2011.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21864521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2011&pages=2211-2215&author=M.+Konoauthor=Y.+Nakamuraauthor=T.+Sudaauthor=M.+Katoauthor=Y.+Kaidaauthor=D.+Hashimotoauthor=N.+Inuiauthor=E.+Hamadaauthor=O.+Miyazakiauthor=S.+Kurashitaauthor=I.+Fukamachiauthor=K.+Endoauthor=P.-S.+Ngauthor=K.+Takeharaauthor=H.+Nakamuraauthor=M.+Maekawaauthor=K.+Chida&title=Plasma+CCN2+%28connective+tissue+growth+factor%3B+CTGF%29+is+a+potential+biomarker+in+idiopathic+pulmonary+fibrosis+%28IPF%29&doi=10.1016%2Fj.cca.2011.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)</span></div><div class="casAuthors">Kono, Masato; Nakamura, Yutaro; Suda, Takafumi; Kato, Masato; Kaida, Yusuke; Hashimoto, Dai; Inui, Naoki; Hamada, Etsuko; Miyazaki, Osamu; Kurashita, Syunsuke; Fukamachi, Isamu; Endo, Koki; Ng, Poh-Sing; Takehara, Kazuhiko; Nakamura, Hirotoshi; Maekawa, Masato; Chida, Kingo</div><div class="citationInfo"><span class="NLM_cas:title">Clinica Chimica Acta</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">412</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">2211-2215</span>CODEN:
                <span class="NLM_cas:coden">CCATAR</span>;
        ISSN:<span class="NLM_cas:issn">0009-8981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal pulmonary fibrotic disease and useful biomarkers are required to diagnose and predict disease activity.  CCN2 (connective tissue growth factor; CTGF) has been reported as one of the key profibrotic factors assocd. with transforming growth factor-β (TGF-β), and its assay has potential as a non-invasive measure in various fibrotic diseases.  Recently, we developed a new subtraction method for detn. of plasma CCN2 levels.  We examd. the utility of plasma CCN2 levels as a surrogate marker in IPF.  Plasma CCN2 levels were calcd. in 33 patients with IPF, 14 patients with non-IPF idiopathic interstitial pneumonias (IIPs) and 101 healthy volunteers by sandwich ELISA using specific monoclonal antibodies for two distinct epitopes of human CCN2.  We evaluated the utility of plasma CCN2 levels by comparison with clin. parameters.  Plasma CCN2 levels were significantly higher in patients with IPF than in those with non-IPF IIPs and healthy volunteers.  Importantly, plasma CCN2 levels showed significantly neg. correlation with 6-mo change of forced vital capacity (FVC) in patients with IPF.  Plasma CCN2 is a potential biomarker for IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9kmyL2fV0ObVg90H21EOLACvtfcHk0lioVc5bAAp_WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktLvJ&md5=d7512848b4254b3a14cc1d0672600011</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cca.2011.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cca.2011.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DSuda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKaida%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DD.%26aulast%3DInui%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DE.%26aulast%3DMiyazaki%26aufirst%3DO.%26aulast%3DKurashita%26aufirst%3DS.%26aulast%3DFukamachi%26aufirst%3DI.%26aulast%3DEndo%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DP.-S.%26aulast%3DTakehara%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DMaekawa%26aufirst%3DM.%26aulast%3DChida%26aufirst%3DK.%26atitle%3DPlasma%2520CCN2%2520%2528connective%2520tissue%2520growth%2520factor%253B%2520CTGF%2529%2520is%2520a%2520potential%2520biomarker%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528IPF%2529%26jtitle%3DClin.%2520Chim.%2520Acta%26date%3D2011%26volume%3D412%26spage%3D2211%26epage%3D2215%26doi%3D10.1016%2Fj.cca.2011.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Type 2 cytokines: mechanisms and therapeutic strategies</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1038/nri3831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnri3831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25882242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=271-282&author=T.+A.+Wynn&title=Type+2+cytokines%3A+mechanisms+and+therapeutic+strategies&doi=10.1038%2Fnri3831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 cytokines: mechanisms and therapeutic strategies</span></div><div class="casAuthors">Wynn, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">271-282</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Type 2 immune responses are defined by the cytokines interleukin-4 (IL-4), IL-5, IL-9 and IL-13, which can either be host protective or have pathogenic activity.  Type 2 immunity promotes antihelminth immunity, suppresses type 1-driven autoimmune disease, neutralizes toxins, maintains metabolic homeostasis, and regulates wound repair and tissue regeneration pathways following infection or injury.  Nevertheless, when type 2 responses are dysregulated, they can become important drivers of disease.  Type 2 immunity induces a complex inflammatory response characterized by eosinophils, mast cells, basophils, type 2 innate lymphoid cells, IL-4-and/or IL-13-conditioned macrophages and T helper 2 (TH2) cells, which are crucial to the pathogenesis of many allergic and fibrotic disorders.  As chronic type 2 immune responses promote disease, the mechanisms that regulate their maintenance are thought to function as crucial disease modifiers.  This Review discusses the many endogenous neg. regulatory mechanisms that antagonize type 2 immunity and highlights how therapies that target some of these pathways are being developed to treat type 2-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU2G_VQvzQ2LVg90H21EOLACvtfcHk0lioVc5bAAp_WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wru7zP&md5=d9e3a4a8e7d9752eff45f2746f2024f5</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnri3831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3831%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DType%25202%2520cytokines%253A%2520mechanisms%2520and%2520therapeutic%2520strategies%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2015%26volume%3D15%26spage%3D271%26epage%3D282%26doi%3D10.1038%2Fnri3831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Murray, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oak, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleeman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzog, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C. M.</span><span> </span><span class="NLM_article-title">Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">994</span><span class="refDoi"> DOI: 10.1165/rcmb.2013-0342OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2013-0342OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24325475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=985-994&author=L.+A.+Murrayauthor=H.+Zhangauthor=S.+R.+Oakauthor=A.+L.+Coelhoauthor=A.+Herathauthor=K.+R.+Flahertyauthor=J.+Leeauthor=M.+Bellauthor=D.+A.+Knightauthor=F.+J.+Martinezauthor=M.+A.+Sleemanauthor=E.+L.+Herzogauthor=C.+M.+Hogaboam&title=Targeting+interleukin-13+with+tralokinumab+attenuates+lung+fibrosis+and+epithelial+damage+in+a+humanized+SCID+idiopathic+pulmonary+fibrosis+model&doi=10.1165%2Frcmb.2013-0342OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model</span></div><div class="casAuthors">Murray, Lynne A.; Zhang, Huilan; Oak, Sameer R.; Coelho, Ana Lucia; Herath, Athula; Flaherty, Kevin R.; Lee, Joyce; Bell, Matt; Knight, Darryl A.; Martinez, Fernando J.; Sleeman, Matthew A.; Herzog, Erica L.; Hogaboam, Cory M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">985-994, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The aberrant fibrotic and repair responses in the lung are major hallmarks of idiopathic pulmonary fibrosis (IPF).  Numerous antifibrotic strategies have been used in the clinic with limited success, raising the possibility that an effective therapeutic strategy in this disease must inhibit fibrosis and promote appropriate lung repair mechanisms.  IL-13 represents an attractive target in IPF, but its disease assocn. and mechanism of action remains unknown.  In the present study, an overexpression of IL-13 and IL-13 pathway markers was assocd. with IPF, particularly a rapidly progressive form of this disease.  Targeting IL-13 in a humanized exptl. model of pulmonary fibrosis using tralokinumab (CAT354) was found to therapeutically block aberrant lung remodeling in this model.  However, targeting IL-13 was also found to promote lung repair and to restore epithelial integrity.  Thus, targeting IL-13 inhibits fibrotic processes and enhances repair processes in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ5PV-S-_ZNbVg90H21EOLACvtfcHk0lj_LMyPHE23GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLvL&md5=2b557ab3778dccc984e59ba622e1eb77</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0342OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0342OC%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DL.%2BA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DOak%26aufirst%3DS.%2BR.%26aulast%3DCoelho%26aufirst%3DA.%2BL.%26aulast%3DHerath%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBell%26aufirst%3DM.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DSleeman%26aufirst%3DM.%2BA.%26aulast%3DHerzog%26aufirst%3DE.%2BL.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26atitle%3DTargeting%2520interleukin-13%2520with%2520tralokinumab%2520attenuates%2520lung%2520fibrosis%2520and%2520epithelial%2520damage%2520in%2520a%2520humanized%2520SCID%2520idiopathic%2520pulmonary%2520fibrosis%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D50%26spage%3D985%26epage%3D994%26doi%3D10.1165%2Frcmb.2013-0342OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span>ClinicalTrials.gov. A study of lebrikizumab in patients with idiopathic pulmonary fibrosis. <a href="https://clinicaltrials.gov/ct2/show/NCT01872689" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01872689</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+study+of+lebrikizumab+in+patients+with+idiopathic+pulmonary+fibrosis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01872689+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Wilson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Pulmonary fibrosis: pathogenesis, etiology and regulation</span> <span class="citation_source-journal">Mucosal Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/mi.2008.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fmi.2008.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19129758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=103-121&author=M.+S.+Wilsonauthor=T.+A.+Wynn&title=Pulmonary+fibrosis%3A+pathogenesis%2C+etiology+and+regulation&doi=10.1038%2Fmi.2008.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary fibrosis: pathogenesis, etiology and regulation</span></div><div class="casAuthors">Wilson, M. S.; Wynn, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mucosal Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-121</span>CODEN:
                <span class="NLM_cas:coden">MIUMAK</span>;
        ISSN:<span class="NLM_cas:issn">1933-0219</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences.  The etiol. of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chems., radiation and environmental particles.  However, the cause of one of the most common pulmonary fibrotic conditions, idiopathic pulmonary fibrosis (IPF), is still unclear.  This review examines common mechanisms of pulmonary wound-healing responses following lung injury, and highlights the pathogenesis of some of the most widespread pulmonary fibrotic diseases.  A 3 phase model of wound repair is reviewed that includes; (1) injury; (2) inflammation; and (3) repair.  In most pulmonary fibrotic conditions dysregulation at one or more of these phases was reported.  Chronic inflammation can lead to an imbalance in the prodn. of chemokines, cytokines, growth factors, and disrupt cellular recruitment.  These changes coupled with excessive pro-fibrotic IL-13 and/or TGFβ1 prodn. can turn a well-controlled healing response into a pathogenic fibrotic response.  Endogenous regulatory mechanisms are discussed including novel areas of therapeutic intervention.  Restoring homeostasis to these dysregulated healing responses, or simply neutralizing the key pro-fibrotic mediators may prevent or slow the progression of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPykZAQ68KP7Vg90H21EOLACvtfcHk0lj_LMyPHE23GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D&md5=1e7d72291a39f09cfe113b5028188f28</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fmi.2008.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmi.2008.85%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DM.%2BS.%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DPulmonary%2520fibrosis%253A%2520pathogenesis%252C%2520etiology%2520and%2520regulation%26jtitle%3DMucosal%2520Immunol.%26date%3D2009%26volume%3D2%26spage%3D103%26epage%3D121%26doi%3D10.1038%2Fmi.2008.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Staitieh, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzoni, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veeraraghavan, S.</span><span> </span><span class="NLM_article-title">Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.3109/07853890.2014.991751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3109%2F07853890.2014.991751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25613169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=100-105&author=B.+S.+Staitiehauthor=E.+A.+Renzoniauthor=S.+Veeraraghavan&title=Pharmacologic+therapies+for+idiopathic+pulmonary+fibrosis%2C+past+and+future&doi=10.3109%2F07853890.2014.991751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future</span></div><div class="casAuthors">Staitieh, Bashar S.; Renzoni, Elisabetta A.; Veeraraghavan, Srihari</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-105</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic disease of the lung of unknown etiol. that affects approx. 150,000 patients in the United States.  It carries a median survival of two to three years, but clin. course can vary markedly from patient to patient.  There has been no established treatment for IPF, but recent advances in coordinated clin. trials through groups such as IPFnet and academia-industry partnerships have allowed this relatively rare disease to be studied in much greater depth.  Historically, the default therapy for IPF was a combination of prednisone, N-acetylcysteine, and azathioprine, but recent trials have shown that this regimen actually increases mortality.  An enormous body of work in recent years, spanning the bench to the bedside, has radically altered our understanding of the mol. mechanisms underlying IPF.  Newer modalities, particularly those involving monoclonal antibodies targeted at specific pathways known to contribute to the fibrotic process, have generated a great deal of excitement in the field, and recent clin. trials on therapies such as pirfenidone and nintedanib herald a new era in targeted IPF therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHl-kNPBMJOLVg90H21EOLACvtfcHk0lj_LMyPHE23GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gsb8%253D&md5=d9e113052b26d7160b3f315d20e6ef1a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3109%2F07853890.2014.991751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07853890.2014.991751%26sid%3Dliteratum%253Aachs%26aulast%3DStaitieh%26aufirst%3DB.%2BS.%26aulast%3DRenzoni%26aufirst%3DE.%2BA.%26aulast%3DVeeraraghavan%26aufirst%3DS.%26atitle%3DPharmacologic%2520therapies%2520for%2520idiopathic%2520pulmonary%2520fibrosis%252C%2520past%2520and%2520future%26jtitle%3DAnn.%2520Med.%26date%3D2015%26volume%3D47%26spage%3D100%26epage%3D105%26doi%3D10.3109%2F07853890.2014.991751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Horan, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukashev, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinreb, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahm, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allaire, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinaldi, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feghali-Bostwick, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matteson, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafyatis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violette, S. M.</span><span> </span><span class="NLM_article-title">Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1164/rccm.200706-805OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200706-805OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17916809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12mt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2008&pages=56-65&author=G.+S.+Horanauthor=S.+Woodauthor=V.+Onaauthor=D.+J.+Liauthor=M.+E.+Lukashevauthor=P.+H.+Weinrebauthor=K.+J.+Simonauthor=K.+Hahmauthor=N.+E.+Allaireauthor=N.+J.+Rinaldiauthor=J.+Goyalauthor=C.+A.+Feghali-Bostwickauthor=E.+L.+Mattesonauthor=C.+O%E2%80%99Haraauthor=R.+Lafyatisauthor=G.+S.+Davisauthor=X.+Huangauthor=D.+Sheppardauthor=S.+M.+Violette&title=Partial+inhibition+of+integrin+%CE%B1v%CE%B26+prevents+pulmonary+fibrosis+without+exacerbating+inflammation&doi=10.1164%2Frccm.200706-805OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation</span></div><div class="casAuthors">Horan, Gerald S.; Wood, Susan; Ona, Victor; Li, Dan Jun; Lukashev, Matvey E.; Weinreb, Paul H.; Simon, Kenneth J.; Hahm, Kyungmin; Allaire, Norman E.; Rinaldi, Nicola J.; Goyal, Jaya; Feghali-Bostwick, Carol A.; Matteson, Eric L.; O'Hara, Carl; Lafyatis, Robert; Davis, Gerald S.; Huang, Xiaozhu; Sheppard, Dean; Violette, Shelia M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-65</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Transforming growth factor (TGF)-β has a central role in driving many of the pathol. processes that characterize pulmonary fibrosis.  Inhibition of the integrin αvβ6, a key activator of TCF-β in lung, is an attractive therapeutic strategy, as it may be possible to inhibit TGF-β at sites of αvβ6 up-regulation without affecting other homeostatic roles of TGF-β.  Objectives: To analyze the expression of αvβ6 in human pulmonary fibrosis, and to functionally test the efficacy of therapeutic inhibition of αvβ6-mediated TGF-β activation in murine bleomycin-induced pulmonary fibrosis.  Methods: Lung biopsies from patients with a diagnosis of systemic sclerosis or idiopathic pulmonary fibrosis were stained for αvβ6 expression.  A range of concns. of a monoclonal antibody that blocks αvβ6-mediated TGF-β activation was evaluated in murine bleomycin-induced lung fibrosis.  Measurements and Main Results: αvβ6 is overexpressed in human lung fibrosis within pneumocytes lining the alveolar ducts and alveoli.  In the bleomycin model, αvβ6 antibody was effective in blocking pulmonary fibrosis.  At high doses, there was increased expression of markers of inflammation and macrophage activation, consistent with the effects of TGF-β inhibition in the lung.  Low doses of antibody attenuated collagen expression without increasing alveolar inflammatory cell populations or macrophage activation markers.  Conclusions: Partial inhibition of TGF-β using αvβ6 integrin antibodies is effective in blocking murine pulmonary fibrosis without exacerbating inflammation.  In addn., the elevated expression of αvβ6, an activator of the fibrogenic cytokine, TGF-β, in human pulmonary fibrosis suggests that αvβ6 monoclonal antibodies could represent a promising new therapeutic strategy for treating pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQeX6SpcmK-7Vg90H21EOLACvtfcHk0lhJINSG9vXzcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12mt70%253D&md5=54ef649e15766e07b4716672c4634d08</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1164%2Frccm.200706-805OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200706-805OC%26sid%3Dliteratum%253Aachs%26aulast%3DHoran%26aufirst%3DG.%2BS.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DOna%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DD.%2BJ.%26aulast%3DLukashev%26aufirst%3DM.%2BE.%26aulast%3DWeinreb%26aufirst%3DP.%2BH.%26aulast%3DSimon%26aufirst%3DK.%2BJ.%26aulast%3DHahm%26aufirst%3DK.%26aulast%3DAllaire%26aufirst%3DN.%2BE.%26aulast%3DRinaldi%26aufirst%3DN.%2BJ.%26aulast%3DGoyal%26aufirst%3DJ.%26aulast%3DFeghali-Bostwick%26aufirst%3DC.%2BA.%26aulast%3DMatteson%26aufirst%3DE.%2BL.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DC.%26aulast%3DLafyatis%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DG.%2BS.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DViolette%26aufirst%3DS.%2BM.%26atitle%3DPartial%2520inhibition%2520of%2520integrin%2520%25CE%25B1v%25CE%25B26%2520prevents%2520pulmonary%2520fibrosis%2520without%2520exacerbating%2520inflammation%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D177%26spage%3D56%26epage%3D65%26doi%3D10.1164%2Frccm.200706-805OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Porte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, G.</span><span> </span><span class="NLM_article-title">Assessment of the effect of potential antifibrotic compounds on total and αvβ6 integrin-mediated TGF-β activation</span> <span class="citation_source-journal">Pharmacol. Res. Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e00030</span><span class="refDoi"> DOI: 10.1002/prp2.30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fprp2.30" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=e00030&author=J.+Porteauthor=G.+Jenkins&title=Assessment+of+the+effect+of+potential+antifibrotic+compounds+on+total+and+%CE%B1v%CE%B26+integrin-mediated+TGF-%CE%B2+activation&doi=10.1002%2Fprp2.30"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fprp2.30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.30%26sid%3Dliteratum%253Aachs%26aulast%3DPorte%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DG.%26atitle%3DAssessment%2520of%2520the%2520effect%2520of%2520potential%2520antifibrotic%2520compounds%2520on%2520total%2520and%2520%25CE%25B1v%25CE%25B26%2520integrin-mediated%2520TGF-%25CE%25B2%2520activation%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2014%26volume%3D2%26spage%3De00030%26doi%3D10.1002%2Fprp2.30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span>ClinicalTrials.gov. STX-100 in patients with idiopathic pulmonary fibrosis (IPF). <a href="http://clinicaltrials.gov/ct2/show/NCT01371305" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01371305</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+STX-100+in+patients+with+idiopathic+pulmonary+fibrosis+%28IPF%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01371305+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholand, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Andrade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mageto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wencel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neff, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, S.</span><span> </span><span class="NLM_article-title">FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1481</span><span class="NLM_x">–</span> <span class="NLM_lpage">1491</span><span class="refDoi"> DOI: 10.1183/13993003.01030-2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.01030-2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26965296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28jptVyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2016&pages=1481-1491&author=G.+Raghuauthor=M.+B.+Scholandauthor=J.+de+Andradeauthor=L.+Lancasterauthor=Y.+Magetoauthor=J.+Goldinauthor=K.+K.+Brownauthor=K.+R.+Flahertyauthor=M.+Wencelauthor=J.+Wangerauthor=T.+Neffauthor=F.+Valoneauthor=J.+Staufferauthor=S.+Porter&title=FG-3019+anti-connective+tissue+growth+factor+monoclonal+antibody%3A+results+of+an+open-label+clinical+trial+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F13993003.01030-2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Raghu Ganesh; Scholand Mary Beth; de Andrade Joao; Lancaster Lisa; Mageto Yolanda; Goldin Jonathan; Brown Kevin K; Flaherty Kevin R; Wencel Mark; Wanger Jack; Neff Thomas; Valone Frank; Stauffer John; Porter Seth</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1481-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FG-3019 is a fully human monoclonal antibody that interferes with the action of connective tissue growth factor, a central mediator in the pathogenesis of fibrosis.This open-label phase 2 trial evaluated the safety and efficacy of two doses of FG-3019 administered by intravenous infusion every 3 weeks for 45 weeks in patients with idiopathic pulmonary fibrosis (IPF).  Subjects had a diagnosis of IPF within the prior 5 years defined by either usual interstitial pneumonia (UIP) pattern on a recent high-resolution computed tomography (HRCT) scan, or a possible UIP pattern on HRCT scan and a recent surgical lung biopsy showing UIP pattern.  Pulmonary function tests were performed every 12 weeks, and changes in the extent of pulmonary fibrosis were measured by quantitative HRCT scans performed at baseline and every 24 weeks.FG-3019 was safe and well-tolerated in IPF patients participating in the study.  Changes in fibrosis were correlated with changes in pulmonary function.Further investigation of FG-3019 in IPF with a placebo-controlled clinical trial is warranted and is underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiPI6xnbyBKcK3uFsUIZtkfW6udTcc2eZFTUzj6XqrDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jptVyqsw%253D%253D&md5=08922be8777c18f497dc4640cd5846da</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1183%2F13993003.01030-2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01030-2015%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DScholand%26aufirst%3DM.%2BB.%26aulast%3Dde%2BAndrade%26aufirst%3DJ.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DMageto%26aufirst%3DY.%26aulast%3DGoldin%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DWencel%26aufirst%3DM.%26aulast%3DWanger%26aufirst%3DJ.%26aulast%3DNeff%26aufirst%3DT.%26aulast%3DValone%26aufirst%3DF.%26aulast%3DStauffer%26aufirst%3DJ.%26aulast%3DPorter%26aufirst%3DS.%26atitle%3DFG-3019%2520anti-connective%2520tissue%2520growth%2520factor%2520monoclonal%2520antibody%253A%2520results%2520of%2520an%2520open-label%2520clinical%2520trial%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2016%26volume%3D47%26spage%3D1481%26epage%3D1491%26doi%3D10.1183%2F13993003.01030-2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">José, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Proteinase-activated receptors in fibroproliferative lung disease</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">190</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1136/thoraxjnl-2013-204367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthoraxjnl-2013-204367" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=190-192&author=R.+J.+Jos%C3%A9author=A.+E.+Williamsauthor=R.+C.+Chambers&title=Proteinase-activated+receptors+in+fibroproliferative+lung+disease&doi=10.1136%2Fthoraxjnl-2013-204367"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2013-204367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2013-204367%26sid%3Dliteratum%253Aachs%26aulast%3DJos%25C3%25A9%26aufirst%3DR.%2BJ.%26aulast%3DWilliams%26aufirst%3DA.%2BE.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DProteinase-activated%2520receptors%2520in%2520fibroproliferative%2520lung%2520disease%26jtitle%3DThorax%26date%3D2014%26volume%3D69%26spage%3D190%26epage%3D192%26doi%3D10.1136%2Fthoraxjnl-2013-204367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Howell, D. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johns, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scotton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">1353</span><span class="NLM_x">–</span> <span class="NLM_lpage">1365</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)62354-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0002-9440%2810%2962354-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15855637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFGmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2005&pages=1353-1365&author=D.+C.+J.+Howellauthor=R.+H.+Johnsauthor=J.+A.+Laskyauthor=B.+Shanauthor=C.+J.+Scottonauthor=G.+J.+Laurentauthor=R.+C.+Chambers&title=Absence+of+proteinase-activated+receptor-1+signaling+affords+protection+from+bleomycin-induced+lung+inflammation+and+fibrosis&doi=10.1016%2FS0002-9440%2810%2962354-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis</span></div><div class="casAuthors">Howell, David C. J.; Johns, Robin H.; Lasky, Joseph A.; Shan, Bin; Scotton, Chris J.; Laurent, Geoffrey J.; Chambers, Rachel C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1353-1365</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Activation of the coagulation cascade is commonly obsd. in the lungs of patients with both acute and chronic inflammatory and fibrotic lung disorders, as well as in animal models of these disorders.  The aim of this study was to examine the contribution of the major thrombin receptor, proteinase-activated receptor-1 (PAR-1), during the acute inflammatory and chronic fibrotic phases of lung injury induced by intratracheal instillation of bleomycin in mice.  Inflammatory cell recruitment and increases in bronchoalveolar lavage fluid (BALF) protein were attenuated by 56 ± 10% (P < 0.05) and 53 ± 12% (P < 0.05), resp., in PAR-1-deficient (PAR-1-/-) mice compared with wild-type (WT) mice.  PAR-1-/- mice were also protected from bleomycin-induced pulmonary fibrosis with total lung collagen accumulation reduced by 59 ± 5% (P < 0.05).  The protection afforded by PAR-1 deficiency was accompanied by significant redns. in pulmonary levels of the potent PAR-1-inducible proinflammatory and profibrotic mediators, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor-β-1 (TGF-β1), and connective tissue growth factor/fibroblast-inducible secreted protein-12 (CTGF/FISP12).  In addn., PAR-1 was highly expressed in inflammatory and fibroproliferative lesions in lung sections obtained from patients with fibrotic lung disease.  These data show for the first time that PAR-1 signaling plays a key role in exptl. induced lung injury, and they further identify PAR-1 as one of the crit. receptors involved in orchestrating the interplay between coagulation, inflammation, and remodeling in response to tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRfQvRih-qwrVg90H21EOLACvtfcHk0lgwmAzLl1W1kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFGmtLo%253D&md5=869016992c6de14641ccaec373da99de</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2962354-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252962354-1%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DD.%2BC.%2BJ.%26aulast%3DJohns%26aufirst%3DR.%2BH.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DScotton%26aufirst%3DC.%2BJ.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DAbsence%2520of%2520proteinase-activated%2520receptor-1%2520signaling%2520affords%2520protection%2520from%2520bleomycin-induced%2520lung%2520inflammation%2520and%2520fibrosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D166%26spage%3D1353%26epage%3D1365%26doi%3D10.1016%2FS0002-9440%2810%2962354-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Liu, R.-M.</span><span> </span><span class="NLM_article-title">Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis</span> <span class="citation_source-journal">Antioxid. Redox Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span><span class="refDoi"> DOI: 10.1089/ars.2007.1903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1089%2Fars.2007.1903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17979497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Siug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=303-319&author=R.-M.+Liu&title=Oxidative+stress%2C+plasminogen+activator+inhibitor+1%2C+and+lung+fibrosis&doi=10.1089%2Fars.2007.1903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Stress, Plasminogen Activator Inhibitor 1, and Lung Fibrosis</span></div><div class="casAuthors">Liu, Rui-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-320</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Fibrosis is characterized by excessive accumulation of extracellular matrix (ECM) in basement membranes and interstitial tissues, resulting from increased synthesis or decreased degrdn. of ECM or both.  The plasminogen activator/plasmin system plays an important role in ECM degrdn., whereas the plasminogen activator inhibitor 1 (PAI-1) is a physiol. inhibitor of plasminogen activators.  PAI-1 expression is increased in the lung fibrotic diseases and in exptl. fibrosis models.  The deletion of the PAI-1 gene reduces, whereas the overexpression of PAI-1 enhances, the susceptibility of animals to lung fibrosis induced by different stimuli, indicating an important role of PAI-1 in the development of lung fibrosis.  Many growth factors, including transforming growth factor beta (TGF-β) and tumor necrosis factor alpha (TNF-α), as well as other chems./agents, induce PAI-1 expression in cultured cells and in vivo.  Reactive oxygen and nitrogen species (ROS/RNS) have been shown to mediate the induction of PAI-1 by many of these stimuli.  This review summarizes some recent findings that help us to understand the role of PAI-1 in the development of lung fibrosis and ROS/RNS in the regulation of PAI-1 expression during fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo040YfNXbqg7Vg90H21EOLACvtfcHk0lgwmAzLl1W1kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Siug%253D%253D&md5=2630491829edc69e7689d894e5dd610c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1089%2Fars.2007.1903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2007.1903%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.-M.%26atitle%3DOxidative%2520stress%252C%2520plasminogen%2520activator%2520inhibitor%25201%252C%2520and%2520lung%2520fibrosis%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2008%26volume%3D10%26spage%3D303%26epage%3D319%26doi%3D10.1089%2Fars.2007.1903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Osterholzer, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lama, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subbotina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdock, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morey, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olszewski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sisson, T. H.</span><span> </span><span class="NLM_article-title">PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">170</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1002/path.3992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fpath.3992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22262246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWqtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2012&pages=170-180&author=J.+J.+Osterholzerauthor=P.+J.+Christensenauthor=V.+Lamaauthor=J.+C.+Horowitzauthor=N.+Hattoriauthor=N.+Subbotinaauthor=A.+Cunninghamauthor=Y.+Linauthor=B.+J.+Murdockauthor=R.+E.+Moreyauthor=M.+A.+Olszewskiauthor=D.+A.+Lawrenceauthor=R.+H.+Simonauthor=T.+H.+Sisson&title=PAI-1+promotes+the+accumulation+of+exudate+macrophages+and+worsens+pulmonary+fibrosis+following+type+II+alveolar+epithelial+cell+injury&doi=10.1002%2Fpath.3992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury</span></div><div class="casAuthors">Osterholzer, John J.; Christensen, Paul J.; Lama, Vibha; Horowitz, Jeffrey C.; Hattori, Noboru; Subbotina, Natalya; Cunningham, Andrew; Lin, Yujing; Murdock, Benjamin J.; Morey, Roger E.; Olszewski, Michal A.; Lawrence, Daniel A.; Simon, Richard H.; Sisson, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-180</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Fibrotic disorders of the lung are assocd. with perturbations in the plasminogen activation system.  Specifically, plasminogen activator inhibitor-1 (PAI-1) expression is increased relative to the plasminogen activators.  A direct role for this imbalance in modulating the severity of lung scarring following injury has been substantiated in the bleomycin model of pulmonary fibrosis.  However, it remains unclear whether derangements in the plasminogen activation system contribute more generally to the pathogenesis of lung fibrosis beyond bleomycin injury.  To answer this question, we employed an alternative model of lung scarring, in which type II alveolar epithelial cells (AECs) are specifically injured by administering diphtheria toxin (DT) to mice genetically engineered to express the human DT receptor (DTR) off the surfactant protein C promoter.  This targeted AEC injury results in the diffuse accumulation of interstitial collagen.  In the present study, we found that this targeted type II cell insult also increases PAI-1 expression in the alveolar compartment.  We identified AECs and lung macrophages to be sources of PAI-1 prodn.  To det. whether this elevated PAI-1 concn. was directly related to the severity of fibrosis, DTR+ mice were crossed into a PAI-1-deficient background (DTR+: PAI-1-/-).  DT administration to DTR+: PAI-1-/- animals caused significantly less fibrosis than was measured in DTR+ mice with intact PAI-1 prodn.  PAI-1 deficiency also abrogated the accumulation of CD11b+ exudate macrophages that were found to express PAI-1 and type-1 collagen.  These observations substantiate the crit. function of PAI-1 in pulmonary fibrosis pathogenesis and provide new insight into a potential mechanism by which this pro-fibrotic mol. influences collagen accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdORCT8myTPLVg90H21EOLACvtfcHk0ljzAXX2WzFp6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWqtr3N&md5=fdec8c935840db1f9f6edec85b64dde2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fpath.3992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3992%26sid%3Dliteratum%253Aachs%26aulast%3DOsterholzer%26aufirst%3DJ.%2BJ.%26aulast%3DChristensen%26aufirst%3DP.%2BJ.%26aulast%3DLama%26aufirst%3DV.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DHattori%26aufirst%3DN.%26aulast%3DSubbotina%26aufirst%3DN.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DMurdock%26aufirst%3DB.%2BJ.%26aulast%3DMorey%26aufirst%3DR.%2BE.%26aulast%3DOlszewski%26aufirst%3DM.%2BA.%26aulast%3DLawrence%26aufirst%3DD.%2BA.%26aulast%3DSimon%26aufirst%3DR.%2BH.%26aulast%3DSisson%26aufirst%3DT.%2BH.%26atitle%3DPAI-1%2520promotes%2520the%2520accumulation%2520of%2520exudate%2520macrophages%2520and%2520worsens%2520pulmonary%2520fibrosis%2520following%2520type%2520II%2520alveolar%2520epithelial%2520cell%2520injury%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D228%26spage%3D170%26epage%3D180%26doi%3D10.1002%2Fpath.3992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Omori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senoo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujitaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, N.</span><span> </span><span class="NLM_article-title">Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0148969</span><span class="refDoi"> DOI: 10.1371/journal.pone.0148969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1371%2Fjournal.pone.0148969" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0148969&author=K.+Omoriauthor=N.+Hattoriauthor=T.+Senooauthor=Y.+Takayamaauthor=T.+Masudaauthor=T.+Nakashimaauthor=H.+Iwamotoauthor=K.+Fujitakaauthor=H.+Hamadaauthor=N.+Kohno&title=Inhibition+of+plasminogen+activator+inhibitor-1+attenuates+transforming+growth+factor-%CE%B2-dependent+epithelial+mesenchymal+transition+and+differentiation+of+fibroblasts+to+myofibroblasts&doi=10.1371%2Fjournal.pone.0148969"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0148969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0148969%26sid%3Dliteratum%253Aachs%26aulast%3DOmori%26aufirst%3DK.%26aulast%3DHattori%26aufirst%3DN.%26aulast%3DSenoo%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DY.%26aulast%3DMasuda%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DFujitaka%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DH.%26aulast%3DKohno%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520plasminogen%2520activator%2520inhibitor-1%2520attenuates%2520transforming%2520growth%2520factor-%25CE%25B2-dependent%2520epithelial%2520mesenchymal%2520transition%2520and%2520differentiation%2520of%2520fibroblasts%2520to%2520myofibroblasts%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0148969%26doi%3D10.1371%2Fjournal.pone.0148969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Tager, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCamera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campanella, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polosukhin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karimi-Shah, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA<sub>1</sub> links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1038/nm1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18066075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=45-54&author=A.+M.+Tagerauthor=P.+LaCameraauthor=B.+S.+Sheaauthor=G.+S.+Campanellaauthor=M.+Selmanauthor=Z.+Zhaoauthor=V.+Polosukhinauthor=J.+Wainauthor=B.+A.+Karimi-Shahauthor=N.+D.+Kimauthor=W.+K.+Hartauthor=A.+Pardoauthor=T.+S.+Blackwellauthor=Y.+Xuauthor=J.+Chunauthor=A.+D.+Luster&title=The+lysophosphatidic+acid+receptor+LPA1+links+pulmonary+fibrosis+to+lung+injury+by+mediating+fibroblast+recruitment+and+vascular+leak&doi=10.1038%2Fnm1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span></div><div class="casAuthors">Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Selman, Moises; Zhao, Zhenwen; Polosukhin, Vasiliy; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Pardo, Annie; Blackwell, Timothy S.; Xu, Yan; Chun, Jerold; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathol. responses have yet to be fully identified.  We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model.  The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury.  In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid.  LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pk5JY4qBbLVg90H21EOLACvtfcHk0lgZIZXsjJL3rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D&md5=1a7e86264154df8960699d18a7ef2407</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnm1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1685%26sid%3Dliteratum%253Aachs%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DLaCamera%26aufirst%3DP.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DCampanella%26aufirst%3DG.%2BS.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolosukhin%26aufirst%3DV.%26aulast%3DWain%26aufirst%3DJ.%26aulast%3DKarimi-Shah%26aufirst%3DB.%2BA.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DHart%26aufirst%3DW.%2BK.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DBlackwell%26aufirst%3DT.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520links%2520pulmonary%2520fibrosis%2520to%2520lung%2520injury%2520by%2520mediating%2520fibroblast%2520recruitment%2520and%2520vascular%2520leak%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnm1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Funke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA<sub>1</sub> promotes epithelial cell apoptosis after lung injury</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1165/rcmb.2010-0155OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2010-0155OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22021336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1ertbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=355-364&author=M.+Funkeauthor=Z.+Zhaoauthor=Y.+Xuauthor=J.+Chunauthor=A.+M.+Tager&title=The+lysophosphatidic+acid+receptor+LPA1+promotes+epithelial+cell+apoptosis+after+lung+injury&doi=10.1165%2Frcmb.2010-0155OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury</span></div><div class="casAuthors">Funke, Manuela; Zhao, Zhenwen; Xu, Yan; Chun, Jerold; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Increased epithelial cell apoptosis in response to lung injury has been implicated in the development of idiopathic pulmonary fibrosis (IPF), but the mol. pathways promoting epithelial cell apoptosis in this disease have yet to be fully identified.  Lysophosphatidic acid (LPA), which we have previously demonstrated to mediate bleomycin lung injury-induced fibroblast recruitment and vascular leak in mice and fibroblast recruitment in patients with IPF, is an important regulator of survival and apoptosis in many cell types.  We now show that LPA signaling through its receptor LPA1 promotes epithelial cell apoptosis induced by bleomycin injury.  The no. of apoptotic cells present in the alveolar and bronchial epithelia of LPA1-deficient mice was significantly reduced compared with wild-type mice at Day 3 after bleomycin challenge, as was lung caspase-3 activity.  Consistent with these in vivo results, we found that LPA signaling through LPA1 induced apoptosis in normal human bronchial epithelial cells in culture.  LPA-LPA1 signaling appeared to specifically mediate anoikis, the apoptosis of anchorage-dependent cells induced by their detachment.  Similarly, LPA neg. regulated attachment of R3/1 rat alveolar epithelial cell line cells.  In contrast, LPA signaling through LPA1 promoted the resistance of lung fibroblasts to apoptosis, which has also been implicated in IPF.  The ability of LPA-LPA1 signaling to promote epithelial cell apoptosis and fibroblast resistance to apoptosis may therefore contribute to the capacity of this signaling pathway to regulate the development of pulmonary fibrosis after lung injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_okuklehf2bVg90H21EOLACvtfcHk0lgZIZXsjJL3rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1ertbw%253D&md5=ae97ec6b86cb2006ed7c3ce6b7d35c0b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2010-0155OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2010-0155OC%26sid%3Dliteratum%253Aachs%26aulast%3DFunke%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520promotes%2520epithelial%2520cell%2520apoptosis%2520after%2520lung%2520injury%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2012%26volume%3D46%26spage%3D355%26epage%3D364%26doi%3D10.1165%2Frcmb.2010-0155OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stebbins, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodanovich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span> </span><span class="NLM_article-title">A novel, orally active LPA<sub>1</sub> receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1699</span><span class="NLM_x">–</span> <span class="NLM_lpage">1713</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00828.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1111%2Fj.1476-5381.2010.00828.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20649573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1699-1713&author=J.+S.+Swaneyauthor=C.+Chapmanauthor=L.+D.+Correaauthor=K.+J.+Stebbinsauthor=R.+A.+Bundeyauthor=P.+C.+Prodanovichauthor=P.+Faganauthor=C.+S.+Bacceiauthor=A.+M.+Santiniauthor=J.+H.+Hutchinsonauthor=T.+J.+Seidersauthor=T.+A.+Parrauthor=P.+Prasitauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=A+novel%2C+orally+active+LPA1+receptor+antagonist+inhibits+lung+fibrosis+in+the+mouse+bleomycin+model&doi=10.1111%2Fj.1476-5381.2010.00828.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span></div><div class="casAuthors">Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Bundey, R. A.; Prodanovich, P. C.; Fagan, P.; Baccei, C. S.; Santini, A. M.; Hutchinson, J. H.; Seiders, T. J.; Parr, T. A.; Prasit, P.; Evans, J. F.; Lorrain, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699-1713</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to assess the potential of an antagonist selective for the lysophosphatidic acid receptor, LPA1, in treating lung fibrosis.  We evaluated the in vitro and in vivo pharmacol. properties of the high affinity, selective, oral LPA1-antagonist (4'-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (AM966).  The potency and selectivity of AM966 for LPA1 receptors was detd. in vitro by calcium flux and cell chemotaxis assays using recombinant and native cell cultures.  The in vivo efficacy of AM966 to reduce tissue injury, vascular leakage, inflammation and fibrosis was assessed at several time points in the mouse bleomycin model.  AM966 was a potent antagonist of LPA1 receptors, with selectivity for this receptor over the other LPA receptors.  In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC50 = 17 nM) from Chinese hamster ovary cells stably expressing human LPA1 receptors and inhibited LPA-induced chemotaxis (IC50 = 181 nM) of human IMR-90 lung fibroblasts expressing LPA1 receptors.  AM966 demonstrated a good pharmacokinetic profile following oral dosing in mice.  In the mouse, AM966 reduced lung injury, vascular leakage, inflammation and fibrosis at multiple time points following intratracheal bleomycin instillation.  AM966 also decreased lactate dehydrogenase activity and tissue inhibitor of metalloproteinase-1, transforming growth factor β1, hyaluronan and matrix metalloproteinase-7, in bronchoalveolar lavage fluid.  These findings demonstrate that AM966 is a potent, selective, orally bioavailable LPA1 receptor antagonist that may be beneficial in treating lung injury and fibrosis, as well as other diseases that are characterized by pathol. inflammation, edema and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0rImMbkAWbVg90H21EOLACvtfcHk0lgZIZXsjJL3rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ&md5=73f26734408141d8b0350d7488b54a6c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00828.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00828.x%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBundey%26aufirst%3DR.%2BA.%26aulast%3DProdanovich%26aufirst%3DP.%2BC.%26aulast%3DFagan%26aufirst%3DP.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DSeiders%26aufirst%3DT.%2BJ.%26aulast%3DParr%26aufirst%3DT.%2BA.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DA%2520novel%252C%2520orally%2520active%2520LPA1%2520receptor%2520antagonist%2520inhibits%2520lung%2520fibrosis%2520in%2520the%2520mouse%2520bleomycin%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1699%26epage%3D1713%26doi%3D10.1111%2Fj.1476-5381.2010.00828.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">González-Gil, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vázquez-Villa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega-Gutiérrez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Rodríguez, M. L.</span><span> </span><span class="NLM_article-title">The status of the lysophosphatidic acid receptor type 1 (LPA<sub>1</sub>R)</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1039/C4MD00333K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1039%2FC4MD00333K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=13-23&author=I.+Gonz%C3%A1lez-Gilauthor=D.+Zianauthor=H.+V%C3%A1zquez-Villaauthor=S.+Ortega-Guti%C3%A9rrezauthor=M.+L.+L%C3%B3pez-Rodr%C3%ADguez&title=The+status+of+the+lysophosphatidic+acid+receptor+type+1+%28LPA1R%29&doi=10.1039%2FC4MD00333K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2FC4MD00333K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00333K%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Gil%26aufirst%3DI.%26aulast%3DZian%26aufirst%3DD.%26aulast%3DV%25C3%25A1zquez-Villa%26aufirst%3DH.%26aulast%3DOrtega-Guti%25C3%25A9rrez%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez-Rodr%25C3%25ADguez%26aufirst%3DM.%2BL.%26atitle%3DThe%2520status%2520of%2520the%2520lysophosphatidic%2520acid%2520receptor%2520type%25201%2520%2528LPA1R%2529%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D13%26epage%3D23%26doi%3D10.1039%2FC4MD00333K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span>ClinicalTrials.gov. Safety and efficacy of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis. <a href="https://clinicaltrials.gov/ct2/show/NCT01766817" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01766817</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+efficacy+of+a+lysophosphatidic+acid+receptor+antagonist+in+idiopathic+pulmonary+fibrosis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01766817+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span><span class="NLM_x">. Novel drug approvalsfor 2014. </span><a href="http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm429247.htm" class="extLink">http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm429247.htm</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+and+Drug+Administration.+Novel+drug+approvalsfor+2014.+http%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdevelopmentapprovalprocess%2Fdruginnovation%2Fucm429247.htm+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span>Data were generated using Micromedex. <a href="http://www.micromedexsolutions.com/micromedex2/librarian" class="extLink">http://www.micromedexsolutions.com/micromedex2/librarian</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Data+were+generated+using+Micromedex.+http%3A%2F%2Fwww.micromedexsolutions.com%2Fmicromedex2%2Flibrarian+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Pirfenidone: a review of its use in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.1007/s40265-015-0350-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs40265-015-0350-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25604027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVagtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=219-230&author=E.+S.+Kimauthor=G.+M.+Keating&title=Pirfenidone%3A+a+review+of+its+use+in+idiopathic+pulmonary+fibrosis&doi=10.1007%2Fs40265-015-0350-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Kim, Esther S.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-230</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Pirfenidone (Esbriet) is an orally administered, synthetic, pyridone compd. that is approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU, and for the treatment of IPF in the USA.  This article summarizes pharmacol., efficacy and tolerability data relevant to the use of pirfenidone in these indications.  In the randomized, double-blind, placebo-controlled, multinational CAPACITY trials in patients with mild to moderate IPF, a significant redn. in the rate of decline in forced vital capacity (FVC) was seen with pirfenidone vs. placebo in study 004 but not in study 006.  Pirfenidone also reduced the rate of decline in FVC to a significantly greater extent than placebo in the randomized, double-blind, multinational ASCEND trial in this patient population.  In addn., pirfenidone showed a significant treatment effect on the 6-min walking test distance and progression-free survival in the ASCEND trial and in a pooled anal. of the CAPACITY trials.  Pirfenidone had a manageable tolerability profile in all three studies.  Gastrointestinal and skin-related events (e.g. nausea, rash, photosensitivity reaction), which were the most commonly occurring treatment-emergent adverse events, were generally mild to moderate in severity.  In addn., a prespecified mortality anal. across all three studies demonstrated a significant redn. in IPF-related and all-cause mortality with pirfenidone.  In conclusion, oral pirfenidone is a valuable agent for use in patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTFreSdm1Nx7Vg90H21EOLACvtfcHk0lgv5Y-Ud7t4eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVagtb4%253D&md5=e025359ae98f4366a18062a4e7d58e96</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0350-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0350-9%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DPirfenidone%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D219%26epage%3D230%26doi%3D10.1007%2Fs40265-015-0350-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Xaubet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Mollar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancochea, J.</span><span> </span><span class="NLM_article-title">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span><span class="refDoi"> DOI: 10.1517/14656566.2014.867328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F14656566.2014.867328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24308635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=275-281&author=A.+Xaubetauthor=A.+Serrano-Mollarauthor=J.+Ancochea&title=Pirfenidone+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1517%2F14656566.2014.867328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Xaubet, Antoni; Serrano-Mollar, Anna; Ancochea, Julio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-281</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal fibrosing interstitial pneumonia.  The median survival from the onset of the symptoms is 2.8 - 4.2 years and the 5-yr survival rate is 20%.  Its poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies.  During the past decade there has been a huge rise in clin. trials with anti-fibrotic drugs, although only (Esbriet) has shown a beneficial effect.  Areas covered: This article reviews the medical literature on the effectiveness and safety of pirfenidone in IPF, by means of a PubMed search from 1995 to present, completed with some data on file from the manufacturer.  Expert opinion: Pirfenidone is the only anti-fibrotic drug approved for the treatment of IPF.  Pirfenidone provides a meaningful clin. effect on redns. in the decrease in forced vital capacity (FVC), six-minute walk test (6MWT) distance and mortality, and it improves the progression-free survival in IPF patients with mild-to-moderate disease.  Pirfenidone is well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity.  Pirfenidone has a favorable benefit-risk profile and represents a suitable treatment option for patients with mild-to-moderate IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Ejf0R_dDv7Vg90H21EOLACvtfcHk0lgv5Y-Ud7t4eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptFartg%253D%253D&md5=52c09f1582966cfb0897289c36f983d5</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1517%2F14656566.2014.867328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2014.867328%26sid%3Dliteratum%253Aachs%26aulast%3DXaubet%26aufirst%3DA.%26aulast%3DSerrano-Mollar%26aufirst%3DA.%26aulast%3DAncochea%26aufirst%3DJ.%26atitle%3DPirfenidone%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2014%26volume%3D15%26spage%3D275%26epage%3D281%26doi%3D10.1517%2F14656566.2014.867328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Poletti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravaglia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassetti, S.</span><span> </span><span class="NLM_article-title">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Expert Rev. Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1586/17476348.2014.915750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1586%2F17476348.2014.915750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25113033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=539-545&author=V.+Polettiauthor=C.+Ravagliaauthor=S.+Tomassetti&title=Pirfenidone+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1586%2F17476348.2014.915750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Poletti, Venerino; Ravaglia, Claudia; Tomassetti, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">539-545</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Pirfenidone is an orally administered drug with anti-fibrotic, anti-inflammatory and anti-oxidant properties.  The efficacy of pirfenidone is supported by a no. of Phase III trials as well as a Cochrane meta-anal. and tolerability data are also provided by clin. trials and a long-term extension phase of these studies.  These trials led to the approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan in 2008 and in Europe in 2011 and it is now indicated for treatment of patients with mild-to-moderate IPF.  The primary endpoint of these studies has usually been the change in percentage predicted forced vital capacity from baseline; there has been no improvement in respiratory symptoms and/or quality of life measurements and/or decrease in mortality.  Clin. and basic research studies are needed to expand our knowledge, understanding the final role of pirfenidone in the treatment of IPF and also identifing genetic factors that influence the effectiveness of this treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8jIYgIAB-m7Vg90H21EOLACvtfcHk0lgubmlnF7hksQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7rE&md5=60e8cab50dc8d5203f9a1d2599c55dcf</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1586%2F17476348.2014.915750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17476348.2014.915750%26sid%3Dliteratum%253Aachs%26aulast%3DPoletti%26aufirst%3DV.%26aulast%3DRavaglia%26aufirst%3DC.%26aulast%3DTomassetti%26aufirst%3DS.%26atitle%3DPirfenidone%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2014%26volume%3D8%26spage%3D539%26epage%3D545%26doi%3D10.1586%2F17476348.2014.915750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Hisatomi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukae, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishimatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakugawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamichi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubota, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, S.</span><span> </span><span class="NLM_article-title">Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells</span> <span class="citation_source-journal">BMC Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="refDoi"> DOI: 10.1186/1471-2466-12-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2F1471-2466-12-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22694981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=24&author=K.+Hisatomiauthor=H.+Mukaeauthor=N.+Sakamotoauthor=Y.+Ishimatsuauthor=T.+Kakugawaauthor=S.+Haraauthor=H.+Fujitaauthor=S.+Nakamichiauthor=H.+Okuauthor=Y.+Urataauthor=H.+Kubotaauthor=K.+Nagataauthor=S.+Kohno&title=Pirfenidone+inhibits+TGF-%CE%B21-induced+over-expression+of+collagen+type+I+and+heat+shock+protein+47+in+A549+cells&doi=10.1186%2F1471-2466-12-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells</span></div><div class="casAuthors">Hisatomi, Keiko; Mukae, Hiroshi; Sakamoto, Noriho; Ishimatsu, Yuji; Kakugawa, Tomoyuki; Hara, Shintaro; Fujita, Hanako; Nakamichi, Seiko; Oku, Hisashi; Urata, Yoshishige; Kubota, Hiroshi; Nagata, Kazuhiro; Kohno, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>CODEN:
                <span class="NLM_cas:coden">BPMMBB</span>;
        ISSN:<span class="NLM_cas:issn">1471-2466</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Pirfenidone is a novel anti-fibrotic and anti-inflammatory agent that inhibits the progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis (IPF).  We previously showed that pirfenidone inhibits the over-expression of collagen type I and of heat shock protein (HSP) 47, a collagen-specific mol. chaperone, in human lung fibroblasts stimulated with transforming growth factor (TGF)-β1 in vitro.  The increased nos. of HSP47-pos. type II pneumocytes as well as fibroblasts were also diminished by pirfenidone in an animal model of pulmonary fibrosis induced by bleomycin.  The present study evaluates the effects of pirfenidone on collagen type I and HSP47 expression in the human alveolar epithelial cell line, A549 cells in vitro.  Methods: The expression of collagen type I, HSP47 and E-cadherin mRNAs in A549 cells stimulated with TGF-β1 was evaluated by Northern blotting or real-time PCR.  The expression of collagen type I, HSP47 and fibronectin proteins was assessed by immunocytochem. staining.  Results: TGF-β1 stimulated collagen type I and HSP47 mRNA and protein expression in A549 cells, and pirfenidone significantly inhibited this process.  Pirfenidone also inhibited over-expression of the fibroblast phenotypic marker fibronectin in A549 cells induced by TGF-β1.  Conclusion: We concluded that the anti-fibrotic effects of pirfenidone might be mediated not only through the direct inhibition of collagen type I expression but also through the inhibition of HSP47 expression in alveolar epithelial cells, which results in reduced collagen synthesis in lung fibrosis.  Furthermore, pirfenidone might partially inhibit the epithelial-mesenchymal transition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCyJFZ5P_kJLVg90H21EOLACvtfcHk0lgubmlnF7hksQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7fN&md5=fd4d8fc33321044a60fb4d2f809b88ad</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2F1471-2466-12-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2466-12-24%26sid%3Dliteratum%253Aachs%26aulast%3DHisatomi%26aufirst%3DK.%26aulast%3DMukae%26aufirst%3DH.%26aulast%3DSakamoto%26aufirst%3DN.%26aulast%3DIshimatsu%26aufirst%3DY.%26aulast%3DKakugawa%26aufirst%3DT.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DNakamichi%26aufirst%3DS.%26aulast%3DOku%26aufirst%3DH.%26aulast%3DUrata%26aufirst%3DY.%26aulast%3DKubota%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DS.%26atitle%3DPirfenidone%2520inhibits%2520TGF-%25CE%25B21-induced%2520over-expression%2520of%2520collagen%2520type%2520I%2520and%2520heat%2520shock%2520protein%252047%2520in%2520A549%2520cells%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2012%26volume%3D12%26spage%3D24%26doi%3D10.1186%2F1471-2466-12-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Akhurst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, A.</span><span> </span><span class="NLM_article-title">Targeting the TGFβ signaling pathway in disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1038/nrd3810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd3810" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=790-811&author=R.+J.+Akhurstauthor=A.+Hata&title=Targeting+the+TGF%CE%B2+signaling+pathway+in+disease&doi=10.1038%2Fnrd3810"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrd3810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3810%26sid%3Dliteratum%253Aachs%26aulast%3DAkhurst%26aufirst%3DR.%2BJ.%26aulast%3DHata%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520TGF%25CE%25B2%2520signaling%2520pathway%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D790%26epage%3D811%26doi%3D10.1038%2Fnrd3810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Nakazato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span> </span><span class="NLM_article-title">A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/S0014-2999(02)01758-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0014-2999%2802%2901758-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12098600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFGqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2002&pages=177-185&author=H.+Nakazatoauthor=H.+Okuauthor=S.+Yamaneauthor=Y.+Tsurutaauthor=R.+Suzuki&title=A+novel+anti-fibrotic+agent+pirfenidone+suppresses+tumor+necrosis+factor-%CE%B1+at+the+translational+level&doi=10.1016%2FS0014-2999%2802%2901758-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level</span></div><div class="casAuthors">Nakazato, Hitoshi; Oku, Hisashi; Yamane, Shoji; Tsuruta, Yuji; Suzuki, Ryuji</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">177-185</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A new exptl. drug pirfenidone (5-methyl-1-phenyl-2-1H-pyridine-2-one) has been reported to have beneficial effects for the treatment of certain fibrotic diseases.  Here, we studied the anti-inflammatory activities of pirfenidone by investigating the mechanism of its inhibitory effect on cytokine prodn.  In RAW264.7 cells, a murine macrophage-like cell line, pirfenidone suppressed the proinflammatory cytokine tumor necrosis factor-α (TNF-α) by a translational mechanism, which was independent of activation of the mitogen-activated protein kinase (MAPK) 2, p38 MAP kinase, and c-Jun N-terminal kinase (JNK).  In the murine endotoxin shock model, pirfenidone potently inhibited the prodn. of the proinflammatory cytokines, TNF-α, interferon-γ, and interleukin-6, but enhanced the prodn. of the anti-inflammatory cytokine, interleukin-10.  The in vivo model also showed that pirfenidone suppressed the cytokine prodn. by a translational mechanism, though interleukin-10 transcription was activated by pirfenidone.  These findings show that pirfenidone inhibits the prodn. of the proinflammatory cytokine selectively at the translational level.  Therefore, cytokine inhibitory activities play an important role in the anti-inflammatory activities of pirfenidone.  Coupled with the fact that this inhibitory effect is selective, translational, and not for total protein synthesis, this drug may have a clin. effect on inflammation and fibrosis with very low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeMS2f7xnkhLVg90H21EOLACvtfcHk0lgubmlnF7hksQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFGqsro%253D&md5=763cf51977561bd6158283e9cdd26704</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901758-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901758-2%26sid%3Dliteratum%253Aachs%26aulast%3DNakazato%26aufirst%3DH.%26aulast%3DOku%26aufirst%3DH.%26aulast%3DYamane%26aufirst%3DS.%26aulast%3DTsuruta%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26atitle%3DA%2520novel%2520anti-fibrotic%2520agent%2520pirfenidone%2520suppresses%2520tumor%2520necrosis%2520factor-%25CE%25B1%2520at%2520the%2520translational%2520level%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D446%26spage%3D177%26epage%3D185%26doi%3D10.1016%2FS0014-2999%2802%2901758-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Oku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span> </span><span class="NLM_article-title">Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span><span class="refDoi"> DOI: 10.1016/S0014-2999(02)01757-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0014-2999%2802%2901757-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12098599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFGqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2002&pages=167-176&author=H.+Okuauthor=H.+Nakazatoauthor=T.+Horikawaauthor=Y.+Tsurutaauthor=R.+Suzuki&title=Pirfenidone+suppresses+tumor+necrosis+factor-%CE%B1%2C+enhances+interleukin-10+and+protects+mice+from+endotoxic+shock&doi=10.1016%2FS0014-2999%2802%2901757-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock</span></div><div class="casAuthors">Oku, Hisashi; Nakazato, Hitoshi; Horikawa, Tatsuya; Tsuruta, Yuji; Suzuki, Ryuji</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A new exptl. drug, pirfenidone (5-methyl-1-phenyl-1H-pyridine-one; S-7701), has been reported to have beneficial effects for the treatment of certain fibrotic diseases.  We investigated the anti-inflammatory properties in murine endotoxic shock to det. the pharmacol. characteristics.  The present study describes the prophylactic effect, cytokine regulatory profiles and therapeutic effect of pirfenidone in murine endotoxic shock, which was induced in mice using an i.p. injection of lipopolysaccharide and d-galactosamine.  First, we examd. the prophylactic effect and cytokine regulatory profiles.  A single oral administration of pirfenidone prior to lipopolysaccharide/d-galactosamine challenge inhibited the prodn. of circulating tumor necrosis factor-α (TNF-α), interleukin-12 and interferon-γ, markedly enhanced that of interleukin-10, and offered protection from subsequent lethal symptoms in a dose-dependent manner.  Second, we examd. the therapeutic effect.  A single oral administration of pirfenidone 1, 2, 3, 4 and 5 h post lipopolysaccharide/d-galactosamine challenge provided protection against lethal shock in a time-dependent manner.  At the histopathol. level, apoptotic pos. cells were suppressed in the liver.  The transforming growth factor (TGF)-β1 level was markedly elevated in the liver of lipopolysaccharide/d-galactosamine-challenged mice, suppressed in pirfenidone-treated mice.  These findings may offer an alternative for both protective and therapeutical treatment of several human acute or chronic inflammatory diseases by pirfenidone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1KVDArelcFbVg90H21EOLACvtfcHk0lh8Aio5iinkbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFGqsr0%253D&md5=7cf35223ba991350fa09f9f59c4e7282</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901757-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901757-0%26sid%3Dliteratum%253Aachs%26aulast%3DOku%26aufirst%3DH.%26aulast%3DNakazato%26aufirst%3DH.%26aulast%3DHorikawa%26aufirst%3DT.%26aulast%3DTsuruta%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26atitle%3DPirfenidone%2520suppresses%2520tumor%2520necrosis%2520factor-%25CE%25B1%252C%2520enhances%2520interleukin-10%2520and%2520protects%2520mice%2520from%2520endotoxic%2520shock%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D446%26spage%3D167%26epage%3D176%26doi%3D10.1016%2FS0014-2999%2802%2901757-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Misra, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabideau, C.</span><span> </span><span class="NLM_article-title">Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1023/A:1007023532508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1023%2FA%3A1007023532508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2000&pages=119-126&author=H.+P.+Misraauthor=C.+Rabideau&title=Pirfenidone+inhibits+NADPH-dependent+microsomal+lipid+peroxidation+and+scavenges+hydroxyl+radicals&doi=10.1023%2FA%3A1007023532508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1023%2FA%3A1007023532508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1007023532508%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DH.%2BP.%26aulast%3DRabideau%26aufirst%3DC.%26atitle%3DPirfenidone%2520inhibits%2520NADPH-dependent%2520microsomal%2520lipid%2520peroxidation%2520and%2520scavenges%2520hydroxyl%2520radicals%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2000%26volume%3D204%26spage%3D119%26epage%3D126%26doi%3D10.1023%2FA%3A1007023532508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">The Pirfenidone Clinical Study Group in Japan.</span><span> </span><span class="NLM_article-title">Pirfenidone in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">821</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span><span class="refDoi"> DOI: 10.1183/09031936.00005209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00005209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19996196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVWjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=821-829&author=H.+Taniguchiauthor=M.+Ebinaauthor=Y.+Kondohauthor=T.+Oguraauthor=A.+Azumaauthor=M.+Sugaauthor=Y.+Taguchiauthor=H.+Takahashiauthor=K.+Nakataauthor=A.+Satoauthor=M.+Takeuchiauthor=G.+Raghuauthor=S.+Kudohauthor=T.+Nukiwaauthor=The+Pirfenidone+Clinical+Study+Group+in+Japan.&title=Pirfenidone+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F09031936.00005209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Taniguchi, H.; Ebina, M.; Kondoh, Y.; Ogura, T.; Azuma, A.; Suga, M.; Taguchi, Y.; Takahashi, H.; Nakata, K.; Sato, A.; Takeuchi, M.; Raghu, G.; Kudoh, S.; Nukiwa, T.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">821-829</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy.  A multicenter, double-blind, placebo-controlled, randomized phase III clin. trial was conducted in Japanese patients with well-defined IPF to det. the efficacy and safety of pirfenidone, a novel antifibrotic oral agent, over 52 wk.  Of 275 patients randomized (high-dose, 1800 mg/day-1; low-dose, 1200 mg/day-1; or placebo groups in the ratio 2:1:2), 267 patients were evaluated for the efficacy of pirfenidone.  Prior to unblinding, the primary end-point was revised; the change in vital capacity (VC) was assessed at week 52.  Secondary end-points included the progression-free survival (PFS) time.  Significant differences were obsd. in VC decline (primary end-point) between the placebo group (-0.16 L) and the high-dose group (-0.09 L) (p = 0.0416); differences between the two groups (p = 0.0280) were also obsd. in the PFS (the secondary end-point).  Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients.  Pirfenidone was relatively well tolerated in patients with IPF.  Treatment with pirfenidone may decrease the rate of decline in VC and may increase the PFS time over 52 wk.  Addnl. studies are needed to confirm these findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEG3o2Gv6tFrVg90H21EOLACvtfcHk0ljJ3XACTRPguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVWjtrc%253D&md5=5a6a211535e0fc5f2bc494b903c93292</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1183%2F09031936.00005209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00005209%26sid%3Dliteratum%253Aachs%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DEbina%26aufirst%3DM.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DSuga%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DNakata%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DA.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26aulast%3D%26atitle%3DPirfenidone%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D821%26epage%3D829%26doi%3D10.1183%2F09031936.00005209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glassberg, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardatzke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szwarcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valeyre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span> </span><span class="NLM_article-title">CAPACITY Study group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1760</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Bois&title=CAPACITY+Study+group.+Pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis+%28CAPACITY%29%3A+two+randomized+trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DCAPACITY%2520Study%2520group.%2520Pirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528CAPACITY%2529%253A%2520two%2520randomized%2520trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Bernardini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspole, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glassberg, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardatzke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span> </span><span class="NLM_article-title">ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2092</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1402582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24836312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2083-2092&author=T.+E.+Kingauthor=W.+Z.+Bradfordauthor=S.+Castro-Bernardiniauthor=E.+A.+Faganauthor=I.+Glaspoleauthor=M.+K.+Glassbergauthor=E.+Gorinaauthor=P.+M.+Hopkinsauthor=D.+Kardatzkeauthor=L.+Lancasterauthor=D.+J.+Ledererauthor=S.+D.+Nathanauthor=C.+A.+Pereiraauthor=S.+A.+Sahnauthor=R.+Sussmanauthor=J.+J.+Swigrisauthor=P.+W.+Noble&title=ASCEND+Study+Group.+A+phase+3+trial+of+pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1402582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">King, Talmadge E.; Bradford, Williamson Z.; Castro-Bernardini, Socorro; Fagan, Elizabeth A.; Glaspole, Ian; Glassberg, Marilyn K.; Gorina, Eduard; Hopkins, Peter M.; Kardatzke, David; Lancaster, Lisa; Lederer, David J.; Nathan, Steven D.; Pereira, Carlos A.; Sahn, Steven A.; Sussman, Robert; Swigris, Jeffrey J.; Noble, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2083-2092, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved.  We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients.  Methods: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 wk.  The primary end point was the change in FVC or death at week 52.  Secondary end points were the 6-min walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis.  Results: In the pirfenidone group, as compared with the placebo group, there was a relative redn. of 47.9% in the proportion of patients who had an abs. decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P < 0.001).  Pirfenidone reduced the decline in the 6-min walk distance (P = 0.04) and improved progression-free survival (P < 0.001).  There was no significant between-group difference in dyspnea scores (P = 0.16) or in rates of death from any cause (P = 0.10) or from idiopathic pulmonary fibrosis (P = 0.23).  However, in a prespecified pooled anal. incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P = 0.01) and from idiopathic pulmonary fibrosis (P = 0.006).  Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation.  Conclusions: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.  Treatment was assocd. with an acceptable sideeffect profile and fewer deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBkQ8hqTWxxLVg90H21EOLACvtfcHk0ljJ3XACTRPguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ&md5=17bfe4782c11521d3b7890ae387bbaf6</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402582%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCastro-Bernardini%26aufirst%3DS.%26aulast%3DFagan%26aufirst%3DE.%2BA.%26aulast%3DGlaspole%26aufirst%3DI.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DGorina%26aufirst%3DE.%26aulast%3DHopkins%26aufirst%3DP.%2BM.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DNathan%26aufirst%3DS.%2BD.%26aulast%3DPereira%26aufirst%3DC.%2BA.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSussman%26aufirst%3DR.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26atitle%3DASCEND%2520Study%2520Group.%2520A%2520phase%25203%2520trial%2520of%2520pirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2083%26epage%3D2092%26doi%3D10.1056%2FNEJMoa1402582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">–</span> <span class="NLM_lpage">4480</span><span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF1120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Dimitroulis, I. A.</span><span> </span><span class="NLM_article-title">Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Care.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1450</span><span class="NLM_x">–</span> <span class="NLM_lpage">1455</span><span class="refDoi"> DOI: 10.4187/respcare.03023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4187%2Frespcare.03023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24782550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2cnosV2htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1450-1455&author=I.+A.+Dimitroulis&title=Nintedanib%3A+a+novel+therapeutic+approach+for+idiopathic+pulmonary+fibrosis&doi=10.4187%2Frespcare.03023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Dimitroulis Ioannis A</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory care</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1450-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and few therapeutic options.  Growth factors that act as mediators in the development of this disease might be important therapeutic targets.  Nintedanib is a triple-tyrosine kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, and it is currently evaluated in clinical trials as a potential IPF therapy.  Treatment with nintedanib may slow decline in lung function, decrease the frequency of exacerbations, and improve quality of life in subjects with IPF.  This observation, together with extensive safety and pharmacokinetic data from studies of nintedanib in malignancy, led the way for the clinical development of this drug in IPF.  Observations from clinical trials, together with the preclinical data, suggest that nintedanib may become an important therapeutic option for individuals with IPF.  High-dose nintedanib improved the quality of life, slowed the progression of lung fibrosis and the decline of lung function, and reduced the rate of exacerbations in individuals with mild and moderate IPF.  This is a short review based on the available data (September 2013) on nintedanib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-hhlDQr-lqP_I8Jvzw4xCfW6udTcc2eYVQBRNob48Sbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnosV2htA%253D%253D&md5=dbcd4d2ca9e17ba7a3ea6948ac2fd5d0</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.4187%2Frespcare.03023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4187%252Frespcare.03023%26sid%3Dliteratum%253Aachs%26aulast%3DDimitroulis%26aufirst%3DI.%2BA.%26atitle%3DNintedanib%253A%2520a%2520novel%2520therapeutic%2520approach%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Care.%26date%3D2014%26volume%3D59%26spage%3D1450%26epage%3D1455%26doi%3D10.4187%2Frespcare.03023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollin, S.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span> </span><span class="NLM_article-title">Nintedanib: from discovery to the clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span><span class="refDoi"> DOI: 10.1021/jm501562a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501562a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1053-1063&author=G.+J.+Rothauthor=R.+Binderauthor=F.+Colbatzkyauthor=C.+Dallingerauthor=R.+Schlenker-Hercegauthor=F.+Hilbergauthor=S.-L.+Wollinauthor=R.+Kaiser&title=Nintedanib%3A+from+discovery+to+the+clinic&doi=10.1021%2Fjm501562a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Nintedanib: From Discovery to the Clinic</span></div><div class="casAuthors">Roth, Gerald J.; Binder, Rudolf; Colbatzky, Florian; Dallinger, Claudia; Schlenker-Herceg, Rozsa; Hilberg, Frank; Wollin, Stefan-Lutz; Kaiser, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1053-1063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nintedanib (BIBF1120) is a potent, oral, small-mol. tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis.  Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the VEGFR family, the fibroblast growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family, as well as Src and Flt-3 kinases.  The compd. was identified during a lead optimization program for small-mol. inhibitors of angiogenesis and has since undergone extensive clin. investigation for the treatment of various solid tumors, and in patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF).  Recent clin. evidence from phase III studies has shown that nintedanib has significant efficacy in the treatment of NSCLC, ovarian cancer, and IPF.  This review article provides a comprehensive summary of the preclin. and clin. research and development of nintedanib from the initial drug discovery process to the latest available clin. trial data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogcUBGOgC1bbVg90H21EOLACvtfcHk0lh_QyobXB7W6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegurnO&md5=dd1bc3c81b83b21cfb9b0d3da7f7b55d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm501562a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501562a%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DBinder%26aufirst%3DR.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DDallinger%26aufirst%3DC.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DWollin%26aufirst%3DS.-L.%26aulast%3DKaiser%26aufirst%3DR.%26atitle%3DNintedanib%253A%2520from%2520discovery%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1053%26epage%3D1063%26doi%3D10.1021%2Fjm501562a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span>Data were generated using Micromedex. <a href="http://www.micromedexsolutions.com/micromedex2/librarian" class="extLink">http://www.micromedexsolutions.com/micromedex2/librarian</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Data+were+generated+using+Micromedex.+http%3A%2F%2Fwww.micromedexsolutions.com%2Fmicromedex2%2Flibrarian+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Noskovičová, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petřek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickelberg, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinzelmann, K.</span><span> </span><span class="NLM_article-title">Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1165/rcmb.2014-0294TR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2014-0294TR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25303647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1ansLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2015&pages=263-284&author=N.+Noskovi%C4%8Dov%C3%A1author=M.+Pet%C5%99ekauthor=O.+Eickelbergauthor=K.+Heinzelmann&title=Platelet-derived+growth+factor+signaling+in+the+lung.+From+lung+development+and+disease+to+clinical+studies&doi=10.1165%2Frcmb.2014-0294TR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet-derived growth factor signaling in the lung from lung development and disease to clinical studies</span></div><div class="casAuthors">Noskovicova, Nina; Petrek, Martin; Eickelberg, Oliver; Heinzelmann, Katharina</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">263-284</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) represent one of the most intensively studied families of growth factors in the last four decades.  PDGF signaling plays an essential role in cell proliferation, differentiation, migration, and survival.  In vivo studies have documented an important role of PDGF signaling in the normal development of several organs, such as the kidney, eye, or lung.  PDGF signaling is essential for the formation of intact mesenchymal cells during embryogenesis.  Recently, this knowledge has been extended to a role of PDGF signaling in diseases in general, such as cancer and atherosclerosis, and more importantly in lung diseases, including pulmonary arterial hypertension, lung cancer, and lung fibrosis.  In this review, we provide an up-to-date overview of PDGF signaling, including tissue- and cell-type-specific expression patterns and effects.  We highlight current therapeutic approaches modifying PDGF signaling in lung diseases and summarize clin. trials in which PDGF signaling has been inhibited.  In conclusion, although PDGF inhibition has been used in multiple clin. trials, we suggest that more elaborate and specific approaches for spatiotemporal control of PDGF signaling are required for developing personalized approaches involving PDGF signaling in lung disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6hnrAtTuUrVg90H21EOLACvtfcHk0lh_QyobXB7W6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1ansLs%253D&md5=d050eff86a550d5455faf649069e7133</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2014-0294TR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2014-0294TR%26sid%3Dliteratum%253Aachs%26aulast%3DNoskovi%25C4%258Dov%25C3%25A1%26aufirst%3DN.%26aulast%3DPet%25C5%2599ek%26aufirst%3DM.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DHeinzelmann%26aufirst%3DK.%26atitle%3DPlatelet-derived%2520growth%2520factor%2520signaling%2520in%2520the%2520lung.%2520From%2520lung%2520development%2520and%2520disease%2520to%2520clinical%2520studies%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2015%26volume%3D52%26spage%3D263%26epage%3D284%26doi%3D10.1165%2Frcmb.2014-0294TR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Andrae, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betsholtz, C.</span><span> </span><span class="NLM_article-title">Role of platelet-derived growth factors in physiology and medicine</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">–</span> <span class="NLM_lpage">1312</span><span class="refDoi"> DOI: 10.1101/gad.1653708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1101%2Fgad.1653708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18483217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVWmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1276-1312&author=J.+Andraeauthor=R.+Galliniauthor=C.+Betsholtz&title=Role+of+platelet-derived+growth+factors+in+physiology+and+medicine&doi=10.1101%2Fgad.1653708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Role of platelet-derived growth factors in physiology and medicine</span></div><div class="casAuthors">Andrae, Johanna; Gallini, Radiosa; Betsholtz, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1276-1312</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have served as prototypes for growth factor and receptor tyrosine kinase function for more than 25 years.  Studies of PDGFs and PDGFRs in animal development have revealed roles for PDGFR-α signaling in gastrulation and in the development of the cranial and cardiac neural crest, gonads, lung, intestine, skin, CNS, and skeleton.  Similarly, roles for PDGFR-β signaling have been established in blood vessel formation and early hematopoiesis.  PDGF signaling is implicated in a range of diseases.  Autocrine activation of PDGF signaling pathways is involved in certain gliomas, sarcomas, and leukemias.  Paracrine PDGF signaling is commonly obsd. in epithelial cancers, where it triggers stromal recruitment and may be involved in epithelial-mesenchymal transition, thereby affecting tumor growth, angiogenesis, invasion, and metastasis.  PDGFs drive pathol. mesenchymal responses in vascular disorders such as atherosclerosis, restenosis, pulmonary hypertension, and retinal diseases, as well as in fibrotic diseases, including pulmonary fibrosis, liver cirrhosis, scleroderma, glomerulosclerosis, and cardiac fibrosis.  The authors review basic aspects of the PDGF ligands and receptors, their developmental and pathol. functions, principles of their pharmacol. inhibition, and results using PDGF pathway-inhibitory or stimulatory drugs in preclin. and clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEyOanAaNQd7Vg90H21EOLACvtfcHk0lh_QyobXB7W6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVWmsbs%253D&md5=f043191bea91ed97baf40963fe01fa1f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1101%2Fgad.1653708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1653708%26sid%3Dliteratum%253Aachs%26aulast%3DAndrae%26aufirst%3DJ.%26aulast%3DGallini%26aufirst%3DR.%26aulast%3DBetsholtz%26aufirst%3DC.%26atitle%3DRole%2520of%2520platelet-derived%2520growth%2520factors%2520in%2520physiology%2520and%2520medicine%26jtitle%3DGenes%2520Dev.%26date%3D2008%26volume%3D22%26spage%3D1276%26epage%3D1312%26doi%3D10.1101%2Fgad.1653708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aono, Y.</span><span> </span><span class="NLM_article-title">Targeting platelet-derived growth factors as a therapeutic approach in pulmonary fibrosis</span> <span class="citation_source-journal">J. Med. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.2152/jmi.60.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2152%2Fjmi.60.175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=175-183&author=Y.+Nishiokaauthor=M.+Azumaauthor=M.+Kishiauthor=Y.+Aono&title=Targeting+platelet-derived+growth+factors+as+a+therapeutic+approach+in+pulmonary+fibrosis&doi=10.2152%2Fjmi.60.175"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2152%2Fjmi.60.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2152%252Fjmi.60.175%26sid%3Dliteratum%253Aachs%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DKishi%26aufirst%3DM.%26aulast%3DAono%26aufirst%3DY.%26atitle%3DTargeting%2520platelet-derived%2520growth%2520factors%2520as%2520a%2520therapeutic%2520approach%2520in%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Invest.%26date%3D2013%26volume%3D60%26spage%3D175%26epage%3D183%26doi%3D10.2152%2Fjmi.60.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Abdollahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ping, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plathow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domhan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gröne, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, P. E.</span><span> </span><span class="NLM_article-title">Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">201</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1084/jem.20041393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1084%2Fjem.20041393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=925-935&author=A.+Abdollahiauthor=M.+Liauthor=G.+Pingauthor=C.+Plathowauthor=S.+Domhanauthor=F.+Kiesslingauthor=L.+B.+Leeauthor=G.+McMahonauthor=H.-J.+Gr%C3%B6neauthor=K.+E.+Lipsonauthor=P.+E.+Huber&title=Inhibition+of+platelet-derived+growth+factor+signaling+attenuates+pulmonary+fibrosis&doi=10.1084%2Fjem.20041393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041393%26sid%3Dliteratum%253Aachs%26aulast%3DAbdollahi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DPing%26aufirst%3DG.%26aulast%3DPlathow%26aufirst%3DC.%26aulast%3DDomhan%26aufirst%3DS.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DGr%25C3%25B6ne%26aufirst%3DH.-J.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DHuber%26aufirst%3DP.%2BE.%26atitle%3DInhibition%2520of%2520platelet-derived%2520growth%2520factor%2520signaling%2520attenuates%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D925%26epage%3D935%26doi%3D10.1084%2Fjem.20041393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Bonner, J. C.</span><span> </span><span class="NLM_article-title">Regulation of PDGF and its receptors in fibrotic diseases</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2004.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.cytogfr.2004.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15207816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVKhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=255-273&author=J.+C.+Bonner&title=Regulation+of+PDGF+and+its+receptors+in+fibrotic+diseases&doi=10.1016%2Fj.cytogfr.2004.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of PDGF and its receptors in fibrotic diseases</span></div><div class="casAuthors">Bonner, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-273</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  Platelet-derived growth factor (PDGF) isoforms play a major role in stimulating the replication, survival, and migration of myofibroblasts during the pathogenesis of fibrotic diseases.  During fibrogenesis, PDGF is secreted by a variety of cell types as a response to injury, and many pro-inflammatory cytokines mediate their mitogenic effects via the autocrine release of PDGF.  PDGF action is detd. by the relative expression of PDGF α-receptors (PDGFRα) and β-receptors (PDGFRβ) on the surface of myofibroblasts.  These receptors are induced during fibrogenesis, thereby amplifying biol. responses to PDGF isoforms.  PDGF action is also modulated by extracellular binding proteins and matrix mols.  This review summarizes the literature on the role of PDGF and its receptors in the development of fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbPFb3UPOMdrVg90H21EOLACvtfcHk0liC8Tqb-kRx8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVKhtL8%253D&md5=bae162438898b6cf16c769f825d2bd9c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2004.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2004.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DBonner%26aufirst%3DJ.%2BC.%26atitle%3DRegulation%2520of%2520PDGF%2520and%2520its%2520receptors%2520in%2520fibrotic%2520diseases%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2004%26volume%3D15%26spage%3D255%26epage%3D273%26doi%3D10.1016%2Fj.cytogfr.2004.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Dosanjh, A.</span><span> </span><span class="NLM_article-title">The fibroblast growth factor pathway and its role in the pathogenesis of lung disease</span> <span class="citation_source-journal">J. Interferon Cytokine Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1089/jir.2011.0079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1089%2Fjir.2011.0079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22280103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFKlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=111-114&author=A.+Dosanjh&title=The+fibroblast+growth+factor+pathway+and+its+role+in+the+pathogenesis+of+lung+disease&doi=10.1089%2Fjir.2011.0079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The Fibroblast Growth Factor Pathway and Its Role in the Pathogenesis of Lung Disease</span></div><div class="casAuthors">Dosanjh, Amrita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Interferon & Cytokine Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">111-114</span>CODEN:
                <span class="NLM_cas:coden">JICRFJ</span>;
        ISSN:<span class="NLM_cas:issn">1079-9907</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor (FGF) signaling pathway is integral to the pathogenesis of many airway diseases and in the growth and development of the normal lung.  The FGF pathway has a role in key regulatory pathways of fibrosis, and provides a no. of potential therapeutic targets for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0X7WljOq6HrVg90H21EOLACvtfcHk0lh-xdI83r8Zfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFKlu7s%253D&md5=b046be487ed5dd60f2585b582ce2ba8f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1089%2Fjir.2011.0079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjir.2011.0079%26sid%3Dliteratum%253Aachs%26aulast%3DDosanjh%26aufirst%3DA.%26atitle%3DThe%2520fibroblast%2520growth%2520factor%2520pathway%2520and%2520its%2520role%2520in%2520the%2520pathogenesis%2520of%2520lung%2520disease%26jtitle%3DJ.%2520Interferon%2520Cytokine%2520Res.%26date%3D2012%26volume%3D32%26spage%3D111%26epage%3D114%26doi%3D10.1089%2Fjir.2011.0079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Yan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ping, Z.</span><span> </span><span class="NLM_article-title">Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Autoimmun. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1020</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span><span class="refDoi"> DOI: 10.1016/j.autrev.2014.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.autrev.2014.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25182202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1020-1025&author=Z.+Yanauthor=Z.+Kuiauthor=Z.+Ping&title=Reviews+and+prospectives+of+signaling+pathway+analysis+in+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.autrev.2014.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Yan, Zheng; Zhang, kui; Ping, Zhu</div><div class="citationInfo"><span class="NLM_cas:title">Autoimmunity Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1020-1025</span>CODEN:
                <span class="NLM_cas:coden">ARUEBU</span>;
        ISSN:<span class="NLM_cas:issn">1568-9972</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing disease with disappointing survival rate, and uneffective therapeutic progress has been made in the last few years, forcing the urgent need to improve research to this disease.  The commonly accepted pathogenic hypothesis of IPF is the trigger from continuous alveolar epithelium microinjuries and in the following series events, many signaling pathways were reported to lead to abnormal tissue repair and lung structure derangement in IPF, such as TGF-β, wnt, VEGF and PI3K-Akt signaling pathways.  Traditional research of IPF related signaling pathway always focus on the independent function of pathway and disease signals, but the crosstalks and interactions among them were rarely valued.  In this review, we summarize the signaling pathways which were reported to play important roles in the pathol. changes of IPF and the synergistic effect among those pathways.  Next we discuss the application of genomics research and bioinformatics tools on IPF related pathway anal., and give a systems biol. perspective by integrating multi-level disease related data.  The novel prospective of pathway anal. could tease out the complex pathway interaction profiles of IPF, and is powerful to detect IPF related biomarkers for early diagnose and potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSHUGveibP8LVg90H21EOLACvtfcHk0lh-xdI83r8Zfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtr7I&md5=ca1f4c1ca4cd3d9848e049baea2b0cac</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.autrev.2014.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.autrev.2014.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DKui%26aufirst%3DZ.%26aulast%3DPing%26aufirst%3DZ.%26atitle%3DReviews%2520and%2520prospectives%2520of%2520signaling%2520pathway%2520analysis%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAutoimmun.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D1020%26epage%3D1025%26doi%3D10.1016%2Fj.autrev.2014.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Ou, X.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, F.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.intimp.2008.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.intimp.2008.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18976720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Wrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=70-79&author=X.-M.+Ouauthor=W.-C.+Liauthor=D.-S.+Liuauthor=Y.-P.+Liauthor=F.-Q.+Wenauthor=Y.-L.+Fengauthor=S.-F.+Zhangauthor=X.-Y.+Huangauthor=T.+Wangauthor=K.+Wangauthor=X.+Wangauthor=L.+Chen&title=VEGFR-2+antagonist+SU5416+attenuates+bleomycin-induced+pulmonary+fibrosis+in+mice&doi=10.1016%2Fj.intimp.2008.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Ou, Xue-Mei; Li, Wan-Cheng; Liu, Dai-Shun; Li, Yan-Ping; Wen, Fu-Qiang; Feng, Yu-Lin; Zhang, Shang-Fu; Huang, Xiang-Yang; Wang, Tao; Wang, Ke; Wang, Xun; Chen, Lei</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Abnormal angiogenesis is a central hallmark for the development and progression of idiopathic pulmonary fibrosis.  It has been shown that vascular endothelial growth factor (VEGF) is one of the crit. angiogenic factors in angiogenesis.  The aim of the present study was to assess whether disruption of VEGF pathway would attenuate bleomycin-induced pulmonary fibrosis.  Methods: Bleomycin-induced pulmonary fibrosis mice were treated i.p. with VEGF receptor tyrosine kinase inhibitor SU5416 at different phases after bleomycin infusion.  We measured angiogenesis and inflammatory response in both bleomycin-treated and control mice, and correlated these levels with pulmonary fibrosis.  Results: The increased expressions of VEGF/VEGFR (Flk-1) were correlated to a larger no. of microvessels and a higher score of pulmonary fibrosis.  Early administration of SU5416 inhibited pulmonary collagen deposition, histopathol. fibroplasias and the activation of TGF-β1/Smad3 signaling pathway in bleomycin-stimulated lung.  These were also paralleled by a redn. of VEGF/VEGFR-2 (Flk-1) expression and microvessel nos. in lung.  Furthermore, SU5416 inhibited inflammatory cell nos. and LDH activity in BALF and IL-13 expression in lung tissue at early inflammatory phase of bleomycin-induced pulmonary fibrosis.  These results suggest that the VEGFR-2 inhibitor, SU5416, attenuates histopathol. fibroplasias and collagen deposition by regulating angiogenesis and inflammation in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG6t_l12OTo7Vg90H21EOLACvtfcHk0lh-xdI83r8Zfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Wrug%253D%253D&md5=03dbeb3ca2eb7eed6501617614b465ea</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2008.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2008.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DX.-M.%26aulast%3DLi%26aufirst%3DW.-C.%26aulast%3DLiu%26aufirst%3DD.-S.%26aulast%3DLi%26aufirst%3DY.-P.%26aulast%3DWen%26aufirst%3DF.-Q.%26aulast%3DFeng%26aufirst%3DY.-L.%26aulast%3DZhang%26aufirst%3DS.-F.%26aulast%3DHuang%26aufirst%3DX.-Y.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DVEGFR-2%2520antagonist%2520SU5416%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2009%26volume%3D9%26spage%3D70%26epage%3D79%26doi%3D10.1016%2Fj.intimp.2008.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Chaudhary, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Quernheim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zissel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. E.</span><span> </span><span class="NLM_article-title">Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">976</span><span class="NLM_x">–</span> <span class="NLM_lpage">985</span><span class="refDoi"> DOI: 10.1183/09031936.00152106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00152106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17301095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFOhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=976-985&author=N.+I.+Chaudharyauthor=G.+J.+Rothauthor=F.+Hilbergauthor=J.+M%C3%BCller-Quernheimauthor=A.+Prasseauthor=G.+Zisselauthor=A.+Schnappauthor=J.+E.+Park&title=Inhibition+of+PDGF%2C+VEGF+and+FGF+signalling+attenuates+fibrosis&doi=10.1183%2F09031936.00152106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis</span></div><div class="casAuthors">Chaudhary, N. I.; Roth, G. J.; Hilberg, F.; Mueller-Quernheim, J.; Prasse, A.; Zissel, G.; Schnapp, A.; Park, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">976-985</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">BIBF 1000 is a small mol. inhibitor targeting the receptor kinases of platelet-derived growth factor (PDGF), basic fibroblast growth factor and vascular endothelial growth factor, which have known roles in the pathogenesis of pulmonary fibrosis.  The anti-fibrotic potential of BIBF 1000 was detd. in a rat model of bleomycin-induced lung fibrosis and in an ex vivo fibroblast differentiation assay.  Rats exposed to a single intra-tracheal injection of bleomycin were treated with BIBF 1000 starting 10 days after bleomycin administration.  To gauge for anti-fibrotic activity, collagen deposition and pro-fibrotic growth factor gene expression was analyzed in isolated lungs.  Furthermore, the activity of BIBF 1000 was compared with imatinib mesylate (combined PDGF receptor, c-kit and c-abl kinase inhibitor) and SB-431542 (transforming growth factor (TGF)-β receptor I kinase inhibitor) in an ex vivo TGF-β-driven fibroblast to myofibroblast differentiation assay, performed in primary human bronchial fibroblasts.  Treatment of rats with BIBF 1000 resulted in the attenuation of fibrosis as assessed by the redn. of collagen deposition and the inhibition of pro-fibrotic gene expression.  In the cellular assay both SB-431542 and BIBF 1000 showed dose-dependent inhibition of TGF-β-induced differentiation, whereas imatinib mesylate was inactive.  BIBF 1000, or related small mols. with a similar kinase inhibition profile, may represent a novel therapeutic approach for the treatment of idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKuwMAPritBrVg90H21EOLACvtfcHk0ljrxinf2Cki3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFOhurw%253D&md5=fdaef254b5e6a2d950ffb47cdf2d3bbb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1183%2F09031936.00152106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00152106%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DN.%2BI.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Quernheim%26aufirst%3DJ.%26aulast%3DPrasse%26aufirst%3DA.%26aulast%3DZissel%26aufirst%3DG.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26atitle%3DInhibition%2520of%2520PDGF%252C%2520VEGF%2520and%2520FGF%2520signalling%2520attenuates%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2007%26volume%3D29%26spage%3D976%26epage%3D985%26doi%3D10.1183%2F09031936.00152106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Hostettler, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papakonstantinou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakiulakis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lardinois, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, M.</span><span> </span><span class="NLM_article-title">Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="refDoi"> DOI: 10.1186/s12931-014-0157-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2Fs12931-014-0157-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25496490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFOjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=157&author=K.+E.+Hostettlerauthor=J.+Zhongauthor=E.+Papakonstantinouauthor=G.+Karakiulakisauthor=M.+Tammauthor=P.+Seidelauthor=Q.+Sunauthor=J.+Mandalauthor=D.+Lardinoisauthor=C.+Lambersauthor=M.+Roth&title=Anti-fibrotic+effects+of+nintedanib+in+lung+fibroblasts+derived+from+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1186%2Fs12931-014-0157-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Hostettler, Katrin E.; Zhong, Jun; Papakonstantinou, Eleni; Karakiulakis, George; Tamm, Michael; Seidel, Petra; Sun, Qingzhu; Mandal, Jyotshna; Lardinois, Didier; Lambers, Christopher; Roth, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157/1-157/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis.  The kinase inhibitor nintedanib specific for vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) significantly reduced the rate of decline of forced vital capacity vs. placebo.  Aim: To det. the in vitro effect of nintedanib on primary human lung fibroblasts.  Methods: Fibroblasts were isolated from lungs of IPF patients and from non-fibrotic controls.  We assessed the effect of VEGF, PDGF-BB and basic FGF (bFGF) ± nintedanib on: (i) expression/activation of VEGFR, PDGFR, and FGFR, (ii) cell proliferation, secretion of (iii) matrix metalloproteinases (MMP), (iv) tissue inhibitor of metalloproteinase (TIMP), and (v) collagen.  Results: IPF fibroblasts expressed higher levels of PDGFR and FGFR than controls.  PDGF-BB, bFGF, and VEGF caused a pro-proliferative effect which was prevented by nintedanib.  Nintedanib enhanced the expression of pro-MMP-2, and inhibited the expression of TIMP-2.  Transforming growth factor-beta-induced secretion of collagens was inhibited by nintedanib.  Conclusion: Our data demonstrate a significant anti-fibrotic effect of nintedanib in IPF fibroblasts.  This effect consists of the drug's anti-proliferative capacity, and on its effect on the extracellular matrix, the degrdn. of which seems to be enhanced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRsCwj6A3mwrVg90H21EOLACvtfcHk0ljrxinf2Cki3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFOjt78%253D&md5=9e01a92fcdfcf165a4d99c62c6c9a46b</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fs12931-014-0157-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-014-0157-3%26sid%3Dliteratum%253Aachs%26aulast%3DHostettler%26aufirst%3DK.%2BE.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DPapakonstantinou%26aufirst%3DE.%26aulast%3DKarakiulakis%26aufirst%3DG.%26aulast%3DTamm%26aufirst%3DM.%26aulast%3DSeidel%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DMandal%26aufirst%3DJ.%26aulast%3DLardinois%26aufirst%3DD.%26aulast%3DLambers%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DM.%26atitle%3DAnti-fibrotic%2520effects%2520of%2520nintedanib%2520in%2520lung%2520fibroblasts%2520derived%2520from%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Res.%26date%3D2014%26volume%3D15%26spage%3D157%26doi%3D10.1186%2Fs12931-014-0157-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Inomata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span> </span><span class="NLM_article-title">Ninedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Core Evidence</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.2147/CE.S82905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2147%2FCE.S82905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=89-98&author=M.+Inomataauthor=Y.+Nishiokaauthor=A.+Azuma&title=Ninedanib%3A+evidence+for+its+therapeutic+potential+in+idiopathic+pulmonary+fibrosis&doi=10.2147%2FCE.S82905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.2147%2FCE.S82905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCE.S82905%26sid%3Dliteratum%253Aachs%26aulast%3DInomata%26aufirst%3DM.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DAzuma%26aufirst%3DA.%26atitle%3DNinedanib%253A%2520evidence%2520for%2520its%2520therapeutic%2520potential%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DCore%2520Evidence%26date%3D2015%26volume%3D10%26spage%3D89%26epage%3D98%26doi%3D10.2147%2FCE.S82905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Bonella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollin, L.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6407</span><span class="NLM_x">–</span> <span class="NLM_lpage">6419</span><span class="refDoi"> DOI: 10.2147/DDDT.S76648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2147%2FDDDT.S76648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26715838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6407-6419&author=F.+Bonellaauthor=S.+Stowasserauthor=L.+Wollin&title=Idiopathic+pulmonary+fibrosis%3A+current+treatment+options+and+critical+appraisal+of+nintedanib&doi=10.2147%2FDDDT.S76648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: Current treatment options and critical appraisal of nintedanib</span></div><div class="casAuthors">Bonella, Francesco; Stowasser, Susanne; Wollin, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6407-6419</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is characterized by a poor prognosis, with an estd. 5-yr survival of approx. 20%.  Progressive and irreversible lung functional impairment leads to chronic respiratory insufficiency with a severely impaired quality of life.  In the last 2 decades, novel treatments for IPF have been developed as a consequence of an increasing understanding of disease pathogenesis and pathobiol.  In IPF, injured dysfunctional alveolar epithelial cells promote fibroblast recruitment and proliferation, resulting in scarring of the lung tissue.  Recently, pirfenidone and nintedanib have been approved for the treatment of IPF, having shown efficacy to slow functional decline and disease progression.  This article focuses on the pharmacol. characteristics and clin. evidence supporting the use of nintedanib, a potent small-mol. tyrosine kinase inhibitor, as therapy for IPF.  After introducing the mechanism of action and pharmacokinetics, an overview of the safety and efficacy results from the most recent clin. trials of nintedanib in IPF is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfjUsaFPn0erVg90H21EOLACvtfcHk0ljrxinf2Cki3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D&md5=ad6fa39dba483ae329daf63d5e38cc5a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S76648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S76648%26sid%3Dliteratum%253Aachs%26aulast%3DBonella%26aufirst%3DF.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DWollin%26aufirst%3DL.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520treatment%2520options%2520and%2520critical%2520appraisal%2520of%2520nintedanib%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6407%26epage%3D6419%26doi%3D10.2147%2FDDDT.S76648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juhel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüglich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span> </span><span class="NLM_article-title">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span><span class="refDoi"> DOI: 10.1056/NEJMoa1103690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1103690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21992121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1079-1087&author=L.+Richeldiauthor=U.+Costabelauthor=M.+Selmanauthor=D.+S.+Kimauthor=D.+M.+Hansellauthor=A.+G.+Nicholsonauthor=K.+K.+Brownauthor=K.+R.+Flahertyauthor=P.+W.+Nobleauthor=G.+Raghuauthor=M.+Brunauthor=A.+Guptaauthor=N.+Juhelauthor=M.+Kl%C3%BCglichauthor=R.+M.+du+Bois&title=Efficacy+of+a+tyrosine+kinase+inhibitor+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1103690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; Costabel, Ulrich; Selman, Moises; Kim, Dong Soon; Hansell, David M.; Nicholson, Andrew G.; Brown, Kevin K.; Flaherty, Kevin R.; Noble, Paul W.; Raghu, Ganesh; Brun, Michele; Gupta, Abhya; Juhel, Nolwenn; Kluglich, Matthias; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1079-1087</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate.  Because the signaling pathways activated by several tyrosine kinase receptors were shown to be involved in lung fibrosis, it was suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis.  In a 12-mo, phase 2 trial, we assessed the efficacy and safety of 4 different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity.  A total of 432 patients underwent randomization to receive one of 4 doses of B1BF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo.  In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 L per yr, as compared with 0.19 L per yr in the placebo group, a 68.4% redn. in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure).  This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007).  Gastrointestinal symptoms (which led to more discontinuations in the. group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group.  In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was assocd. with a trend toward a redn. in the decline in lung function, with fewer acute exacerbations and preserved quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4JXOIjFKCRbVg90H21EOLACvtfcHk0liBdyWmgV5CEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN&md5=6c076ac8d837944b4638ee7c444bb775</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103690%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DJuhel%26aufirst%3DN.%26aulast%3DKl%25C3%25BCglich%26aufirst%3DM.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DEfficacy%2520of%2520a%2520tyrosine%2520kinase%2520inhibitor%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1079%26epage%3D1087%26doi%3D10.1056%2FNEJMoa1103690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Maulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">INPULSIS trial investigators</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2082</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1402584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24836310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2071-2082&author=L.+Richeldiauthor=R.+M.+du+Boisauthor=G.+Raghuauthor=A.+Azumaauthor=K.+K.+Brownauthor=U.+Costabelauthor=V.+Cottinauthor=K.+R.+Flahertyauthor=D.+M.+Hansellauthor=Y.+Inoueauthor=D.+S.+Kimauthor=M.+Kolbauthor=A.+G.+Nicholsonauthor=P.+W.+Nobleauthor=M.+Selmanauthor=H.+Taniguchiauthor=M.+Brunauthor=F.+Le+Maulfauthor=M.+Girardauthor=S.+Stowasserauthor=R.+Schlenker-Hercegauthor=B.+Disseauthor=H.+R.+Collard&title=INPULSIS+trial+investigators&doi=10.1056%2FNEJMoa1402584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; du Bois, Roland M.; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, David M.; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moises; Taniguchi, Hiroyuki; Brun, Michele; Le Maulf, Florence; Girard, Mannaig; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Disse, Bernd; Collard, Harold R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2071-2082, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases.  A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.  Methods: We conducted two replicate 52-wk, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St.  George's Respiratory Questionnaire, both assessed over a 52-wk period.  Results: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo.  The adjusted annual rate of change in FVC was -114.7 mL with nintedanib vs. -239.9 mL with placebo (difference, 125.3 mL; 95% confidence interval [CI], 77.7 to 172.8; P < 0.001) in INPULSIS-1 and -113.6 mL with nintedanib vs. -207.3 mL with placebo (difference, 93.7 mL; 95% CI, 44.8 to 142.7; P < 0.001) in INPULSIS-2.  In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P = 0.67); in INPULSIS-2, there was a significant benefit with nintedanib vs. placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).  The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, resp., in INPULSIS-1 and 63.2% and 18.3% in the two groups, resp., in INPULSIS-2.  Conclusions: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently assocd. with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuOhVKeZaSrVg90H21EOLACvtfcHk0liBdyWmgV5CEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK&md5=be977cd3b402c7c401f4a3dfaa0f484f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402584%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DLe%2BMaulf%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DINPULSIS%2520trial%2520investigators%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2071%26epage%3D2082%26doi%3D10.1056%2FNEJMoa1402584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelling, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaresma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, M.</span><span> </span><span class="NLM_article-title">Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">OA4495</span><span class="refDoi"> DOI: 10.1183/13993003.congress-2015.OA4495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.congress-2015.OA4495" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=OA4495&author=B.+Crestaniauthor=T.+Oguraauthor=K.+Pellingauthor=C.+Coeckauthor=M.+Quaresmaauthor=M.+Kreuterauthor=M.+Kaye&title=Interim+analysis+of+nintedanib+in+an+open-label+extension+of+the+INPULSIS%C2%AE+trials+%28INPULSIS%C2%AE-ON%29&doi=10.1183%2F13993003.congress-2015.OA4495"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.OA4495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.OA4495%26sid%3Dliteratum%253Aachs%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DPelling%26aufirst%3DK.%26aulast%3DCoeck%26aufirst%3DC.%26aulast%3DQuaresma%26aufirst%3DM.%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DKaye%26aufirst%3DM.%26atitle%3DInterim%2520analysis%2520of%2520nintedanib%2520in%2520an%2520open-label%2520extension%2520of%2520the%2520INPULSIS%25C2%25AE%2520trials%2520%2528INPULSIS%25C2%25AE-ON%2529%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3DOA4495%26doi%3D10.1183%2F13993003.congress-2015.OA4495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Hecker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagirdar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luckhardt, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennathur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V.</span><span> </span><span class="NLM_article-title">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span><span class="refDoi"> DOI: 10.1038/nm.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19701206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1077-1081&author=L.+Heckerauthor=R.+Vittalauthor=T.+Jonesauthor=R.+Jagirdarauthor=T.+R.+Luckhardtauthor=J.+C.+Horowitzauthor=S.+Pennathurauthor=F.+J.+Martinezauthor=V.+Thannickal&title=NADPH+oxidase-4+mediates+myofibroblast+activation+and+fibrogenic+responses+to+lung+injury&doi=10.1038%2Fnm.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span></div><div class="casAuthors">Hecker, Louise; Vittal, Ragini; Jones, Tamara; Jagirdar, Rajesh; Luckhardt, Tracy R.; Horowitz, Jeffrey C.; Pennathur, Subramaniam; Martinez, Fernando J.; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1081</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Members of the NADPH oxidase (NOX) family of enzymes, which catalyze the redn. of O2 to reactive oxygen species, have increased in no. during eukaryotic evolution.  Seven isoforms of the NOX gene family have been identified in mammals; however, specific roles of NOX enzymes in mammalian physiol. and pathophysiol. have not been fully elucidated.  The best established physiol. role of NOX enzymes is in host defense against pathogen invasion in diverse species, including plants.  The prototypical member of this family, NOX-2 (gp91phox), is expressed in phagocytic cells and mediates microbicidal activities.  Here we report a role for the NOX4 isoform in tissue repair functions of myofibroblasts and fibrogenesis.  Transforming growth factor-β1 (TGF-β1) induces NOX-4 expression in lung mesenchymal cells via SMAD-3, a receptor-regulated protein that modulates gene transcription.  NOX-4-dependent generation of hydrogen peroxide (H2O2) is required for TGF-β1-induced myofibroblast differentiation, extracellular matrix (ECM) prodn. and contractility.  NOX-4 is upregulated in lungs of mice subjected to noninfectious injury and in cases of human idiopathic pulmonary fibrosis (IPF).  Genetic or pharmacol. targeting of NOX-4 abrogates fibrogenesis in two murine models of lung injury.  These studies support a function for NOX4 in tissue fibrogenesis and provide proof of concept for therapeutic targeting of NOX-4 in recalcitrant fibrotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmporyhulB_bVg90H21EOLACvtfcHk0lhAABVKYxhf7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM&md5=7b7eaee1597ce9e91807879f5d0f7f1d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnm.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2005%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DL.%26aulast%3DVittal%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DJagirdar%26aufirst%3DR.%26aulast%3DLuckhardt%26aufirst%3DT.%2BR.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DPennathur%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DThannickal%26aufirst%3DV.%26atitle%3DNADPH%2520oxidase-4%2520mediates%2520myofibroblast%2520activation%2520and%2520fibrogenic%2520responses%2520to%2520lung%2520injury%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D1077%26epage%3D1081%26doi%3D10.1038%2Fnm.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Laleu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaggini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orchard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioraso-Cartier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagnon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houngninou-Molango, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duboux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szyndralewiez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, P.</span><span> </span><span class="NLM_article-title">First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7715</span><span class="NLM_x">–</span> <span class="NLM_lpage">7730</span><span class="refDoi"> DOI: 10.1021/jm100773e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100773e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7715-7730&author=B.+Laleuauthor=F.+Gagginiauthor=M.+Orchardauthor=L.+Fioraso-Cartierauthor=L.+Cagnonauthor=S.+Houngninou-Molangoauthor=A.+Gradiaauthor=G.+Dubouxauthor=C.+Merlotauthor=F.+Heitzauthor=C.+Szyndralewiezauthor=P.+Page&title=First+in+class%2C+potent%2C+and+orally+bioavailable+NADPH+oxidase+isoform+4+%28Nox4%29+inhibitors+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1021%2Fjm100773e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98aR"><div class="casContent"><span class="casTitleNuber">98a</span><div class="casTitle"><span class="NLM_cas:atitle">First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Laleu, Benoit; Gaggini, Francesca; Orchard, Mike; Fioraso-Cartier, Laetitia; Cagnon, Laurene; Houngninou-Molango, Sophie; Gradia, Angelo; Duboux, Guillaume; Merlot, Cedric; Heitz, Freddy; Szyndralewiez, Cedric; Page, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7715-7730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and optimization of first-in-class series of inhibitors I (R1 = H, MeCO, 4-FC6H4CH2, etc.; R2 = Ph, 2-ClC6H4, 2-benzothiazolyl, etc.; R3 = Me, 2-FC6H4, 1-pyrrolidinylmethyl, PhCH2NMeCH2, etc.; R4 = MeOCH2CH2, 3-pyridylmethyl, 4-morpholinyl, etc.) of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease, is described.  Initially, several moderately potent pyrazolopyridine dione derivs. were found during a high-throughput screening campaign.  SAR investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) prodn., showing high potency on Nox4 and Nox1.  The compds. have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms.  The specificity of these compds. was confirmed in an extensive in vitro pharmacol. profile, as well as in a counterscreening assay for potential ROS scavenging.  Concomitant benefits are good oral bioavailability and high plasma concns. in vivo, allowing further clin. trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSPjijoh4dLVg90H21EOLACvtfcHk0lhAABVKYxhf7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI&md5=39f3be6bed0d02fce6693e626788f125</span></div><a href="/servlet/linkout?suffix=cit98a&amp;dbid=16384&amp;doi=10.1021%2Fjm100773e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100773e%26sid%3Dliteratum%253Aachs%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DGaggini%26aufirst%3DF.%26aulast%3DOrchard%26aufirst%3DM.%26aulast%3DFioraso-Cartier%26aufirst%3DL.%26aulast%3DCagnon%26aufirst%3DL.%26aulast%3DHoungninou-Molango%26aufirst%3DS.%26aulast%3DGradia%26aufirst%3DA.%26aulast%3DDuboux%26aufirst%3DG.%26aulast%3DMerlot%26aufirst%3DC.%26aulast%3DHeitz%26aufirst%3DF.%26aulast%3DSzyndralewiez%26aufirst%3DC.%26aulast%3DPage%26aufirst%3DP.%26atitle%3DFirst%2520in%2520class%252C%2520potent%252C%2520and%2520orally%2520bioavailable%2520NADPH%2520oxidase%2520isoform%25204%2520%2528Nox4%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7715%26epage%3D7730%26doi%3D10.1021%2Fjm100773e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit98b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gaggini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laleu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orchard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioraso-Cartier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagnon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houngninou-Molango, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duboux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szyndralewiez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, P.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6989</span><span class="NLM_x">–</span> <span class="NLM_lpage">6999</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmc.2011.10.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=6989-6999&author=F.+Gagginiauthor=B.+Laleuauthor=M.+Orchardauthor=L.+Fioraso-Cartierauthor=L.+Cagnonauthor=S.+Houngninou-Molangoauthor=A.+Gradiaauthor=G.+Dubouxauthor=C.+Merlotauthor=F.+Heitzauthor=C.+Szyndralewiezauthor=P.+Page&title=Design%2C+synthesis+and+biological+activity+of+original+pyrazolo-pyrido-diazepine%2C+-pyrazine+and+-oxazine+dione+derivatives+as+novel+dual+Nox4%2FNox1+inhibitors&doi=10.1016%2Fj.bmc.2011.10.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DGaggini%26aufirst%3DF.%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DOrchard%26aufirst%3DM.%26aulast%3DFioraso-Cartier%26aufirst%3DL.%26aulast%3DCagnon%26aufirst%3DL.%26aulast%3DHoungninou-Molango%26aufirst%3DS.%26aulast%3DGradia%26aufirst%3DA.%26aulast%3DDuboux%26aufirst%3DG.%26aulast%3DMerlot%26aufirst%3DC.%26aulast%3DHeitz%26aufirst%3DF.%26aulast%3DSzyndralewiez%26aufirst%3DC.%26aulast%3DPage%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520activity%2520of%2520original%2520pyrazolo-pyrido-diazepine%252C%2520-pyrazine%2520and%2520-oxazine%2520dione%2520derivatives%2520as%2520novel%2520dual%2520Nox4%252FNox1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D6989%26epage%3D6999%26doi%3D10.1016%2Fj.bmc.2011.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Kehrer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span> </span><span class="NLM_article-title">Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1016/S0378-4274(96)03845-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0378-4274%2896%2903845-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=9067480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADyaK2sXhtFSgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1997&pages=125-132&author=J.+P.+Kehrerauthor=S.+B.+Margolin&title=Pirfenidone+diminishes+cyclophosphamide-induced+lung+fibrosis+in+mice&doi=10.1016%2FS0378-4274%2896%2903845-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice</span></div><div class="casAuthors">Kehrer, James P.; Margolin, Solomon B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The deposition of excess or abnormal collagen characteristic of pulmonary fibrosis can disrupt gas exchange resulting in severe respiratory impairment.  There currently are no effective pharmacol. agents available that inhibit the fibrotic process.  Pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) is an investigational drug that, when administered at 0.5% (wt./wt.) of the diet, decreases both histol. and biochem. evidence of lung fibrosis in hamsters treated intratracheally with bleomycin.  The effectiveness of pirfenidone against lung fibrosis initiated by a systemically administered agent was investigated in mice treated i.p. with 200 mg/kg cyclophosphamide (CP).  Control and treated animals were fed a diet contg. 0.277% (wt./wt.) pirfenidone beginning 1 day after CP.  Despite anorexia in the CP-treated mice the first day after treatment, they ingested a greater av. pirfenidone dose over 20 days than saline-treated control mice (717 vs. 564 mg/kg per day, resp.).  Total lung hydroxyproline content, an index of fibrosis, was significantly lower 21 days after treatment with CP plus pirfenidone as compared to mice treated with CP alone.  Although microscopic lung fibrosis scores were not significantly decreased by pirfenidone in CP-treated mice, the overall incidence of fibrosis was significantly decreased.  Histol., mice treated with CP showed fibrosis while mice treated with CP plus pirfenidone exhibited fewer abnormalities.  The rate of hydroxyproline synthesis by lung tissue 9 days after treatment with CP was significantly elevated.  This rate was not affected by pirfenidone treatment.  Overall, these data support an antifibrotic effect of pirfenidone against CP-induced lung fibrosis in mice.  The mechanism of its effect is not known, but appears to be unrelated to an inhibition of collagen synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeSnHwnNvRIrVg90H21EOLACvtfcHk0lh0TW31T5uZHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtFSgur4%253D&md5=016c5be3f31afffcf7dd2e2dbd4c2224</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2FS0378-4274%2896%2903845-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-4274%252896%252903845-3%26sid%3Dliteratum%253Aachs%26aulast%3DKehrer%26aufirst%3DJ.%2BP.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26atitle%3DPirfenidone%2520diminishes%2520cyclophosphamide-induced%2520lung%2520fibrosis%2520in%2520mice%26jtitle%3DToxicol.%2520Lett.%26date%3D1997%26volume%3D90%26spage%3D125%26epage%3D132%26doi%3D10.1016%2FS0378-4274%2896%2903845-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Yehualaeshet, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begleiter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy-Ullrich, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalil, N.</span><span> </span><span class="NLM_article-title">A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1165/ajrcmb.23.2.4089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Fajrcmb.23.2.4089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10919987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1Ogurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=204-212&author=T.+Yehualaeshetauthor=R.+O%E2%80%99Connorauthor=A.+Begleiterauthor=J.+E.+Murphy-Ullrichauthor=R.+Silversteinauthor=N.+Khalil&title=A+CD36+synthetic+peptide+inhibits+bleomycin-induced+pulmonary+inflammation+and+connective+tissue+synthesis+in+the+rat&doi=10.1165%2Fajrcmb.23.2.4089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat</span></div><div class="casAuthors">Yehualaeshet, Teshome; O'Connor, Robert; Begleiter, Asher; Murphy-Ullrich, Joanne E.; Silverstein, Roy; Khalil, Nasreen</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-212</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Transforming growth factor (TGF)-β1 is an important regulator of inflammation and fibrosis.  TGF-β1 is usually secreted as a biol. latent protein called latent TGF-β1 (L-TGF-β1).  L-TGF-β1 has no biol. effect unless L-TGF-β1 is converted to its active form.  Using a well-recognized model of lung injury induced by the antineoplastic antibiotic bleomycin (Blm), the authors demonstrated that 7 d after intratracheal Blm administration, total lung TGF-β was maximally increased.  This induction was due to TGF-β1 prodn. by alveolar macrophages that, when explanted, generated increased quantities of L-TGF-β1 complexed with the glycoprotein thrombospondin (TSP)-1.  The TSP-1/L-TGF-β1 complex was assocd. with CD36, a receptor for TSP-1.  The assocn. of TSP-1/L-TGF-β1 to CD36 was crit. for plasmin-mediated release of mature TGF-β1.  In this paper the authors show that, compared with administration of Blm by itself, when a synthetic peptide of CD36 between amino acids 93 and 110 is given concomitantly with Blm to rats, alveolar macrophages generate markedly less active TGF-β1, the rats gain wt. more rapidly, and there is less inflammation, collagen I and III, and fibronectin synthesis.  These findings demonstrate a novel in vivo mechanism of activation of L-TGF-β1 in lung injury and the importance of alveolar macrophage-derived active TGF-β1 in the pathogenesis of pulmonary inflammation and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSLhDKfWOyKbVg90H21EOLACvtfcHk0lh0TW31T5uZHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1Ogurw%253D&md5=acce0ceab84802df9a5d5b62a94e570c</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1165%2Fajrcmb.23.2.4089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Fajrcmb.23.2.4089%26sid%3Dliteratum%253Aachs%26aulast%3DYehualaeshet%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DBegleiter%26aufirst%3DA.%26aulast%3DMurphy-Ullrich%26aufirst%3DJ.%2BE.%26aulast%3DSilverstein%26aufirst%3DR.%26aulast%3DKhalil%26aufirst%3DN.%26atitle%3DA%2520CD36%2520synthetic%2520peptide%2520inhibits%2520bleomycin-induced%2520pulmonary%2520inflammation%2520and%2520connective%2520tissue%2520synthesis%2520in%2520the%2520rat%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2000%26volume%3D23%26spage%3D204%26epage%3D212%26doi%3D10.1165%2Fajrcmb.23.2.4089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Iyer, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurujeyalakshmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S. N.</span><span> </span><span class="NLM_article-title">Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10490926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlaktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=367-373&author=S.+N.+Iyerauthor=G.+Gurujeyalakshmiauthor=S.+N.+Giri&title=Effects+of+pirfenidone+on+transforming+growth+factor-beta+gene+expression+at+the+transcriptional+level+in+bleomycin+hamster+model+of+lung+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis</span></div><div class="casAuthors">Iyer, S. N.; Gurujeyalakshmi, G.; Giri, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">367-373</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was undertaken to investigate whether treatment with the antifibrotic drug pirfenidone (PD) down-regulates the bleomycin (BL)-induced overexpression of transforming growth factor (TGF)-β gene in the lungs.  Hamsters were intratracheally instilled with SA or BL (6.5 U/kg/4 mL) under anesthesia.  They were fed a diet contg. 0.5% PD or the same control diet (CD) without the drug 2 days before and throughout the study.  After the animals were sacrificed, their lungs were appropriately processed.  The BL treatment elevated the total influx of inflammatory cells, including macrophages, by severalfold at different days in bronchoalveolar lavage fluid (BALF) from hamsters in BL + CD groups, relative to the corresponding SA + CD control groups.  Treatment with PD significantly (P ≤.05) suppressed the influx of inflammatory cells and macrophages at day 7 in the BL + PD groups, relative to the corresponding BL + CD groups.  In addn., the levels of TGF-β in BALF from hamsters in BL + CD groups were elevated by 2.6- to 4.5-fold at different days, relative to the corresponding SA + CD groups.  Treatment with PD significantly (P ≤.05) reduced the TGF-β protein in BALF from BL + PD groups at 14 and 21 days, when compared with the corresponding BL + CD groups.  The intratracheal instillation of BL significantly (P ≤.05) elevated the TGF-β mRNA at 7, 14, and 21 days in BL + CD groups, relative to the corresponding SA + CD groups, and treatment with PD significantly (P ≤.05) suppressed the TGF-β gene expression in BL + PD groups at these times, when compared with the corresponding BL + CD groups.  Nuclear runoff studies revealed that PD suppressed the BL-induced increase in TGF-β gene transcription by 33%.  It was concluded that one of the mechanisms for antifibrotic effect of PD is its ability to suppress the BL-induced overexpression of TGF-β gene at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4drE2AFRazLVg90H21EOLACvtfcHk0lh0TW31T5uZHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlaktrw%253D&md5=bf01d4da527b591684e703edff65dde3</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%2BN.%26aulast%3DGurujeyalakshmi%26aufirst%3DG.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26atitle%3DEffects%2520of%2520pirfenidone%2520on%2520transforming%2520growth%2520factor-beta%2520gene%2520expression%2520at%2520the%2520transcriptional%2520level%2520in%2520bleomycin%2520hamster%2520model%2520of%2520lung%2520fibrosis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D367%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Iyer, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiedt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S. N.</span><span> </span><span class="NLM_article-title">Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters</span> <span class="citation_source-journal">J. Lab. Clin. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">785</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=1995&pages=779-785&author=S.+N.+Iyerauthor=J.+S.+Wildauthor=M.+J.+Schiedtauthor=D.+M.+Hydeauthor=S.+B.+Margolinauthor=S.+N.+Giri&title=Dietary+intake+of+pirfenidone+ameliorates+bleomycin-induced+lung+fibrosis+in+hamsters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%2BN.%26aulast%3DWild%26aufirst%3DJ.%2BS.%26aulast%3DSchiedt%26aufirst%3DM.%2BJ.%26aulast%3DHyde%26aufirst%3DD.%2BM.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26atitle%3DDietary%2520intake%2520of%2520pirfenidone%2520ameliorates%2520bleomycin-induced%2520lung%2520fibrosis%2520in%2520hamsters%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1995%26volume%3D125%26spage%3D779%26epage%3D785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Shetlar, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetlar, C. L.</span><span> </span><span class="NLM_article-title">Effect of antifibrosis drug on the survival of keloid transplants in athymic mice</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">A967</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=A967&author=M.+R.+Shetlarauthor=C.+L.+Shetlar&title=Effect+of+antifibrosis+drug+on+the+survival+of+keloid+transplants+in+athymic+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShetlar%26aufirst%3DM.%2BR.%26aulast%3DShetlar%26aufirst%3DC.%2BL.%26atitle%3DEffect%2520of%2520antifibrosis%2520drug%2520on%2520the%2520survival%2520of%2520keloid%2520transplants%2520in%2520athymic%2520mice%26jtitle%3DFASEB%2520J.%26date%3D1995%26volume%3D9%26spage%3DA967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Ammar, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail, M. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sehrawi, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noaman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayomi, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawer, T. Z.</span><span> </span><span class="NLM_article-title">Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span><span class="refDoi"> DOI: 10.1002/ardp.200600017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fardp.200600017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2006&pages=429-436&author=Y.+A.+Ammarauthor=M.+M.+F.+Ismailauthor=H.+M.+El-Sehrawiauthor=E.+Noamanauthor=A.+H.+Bayomiauthor=T.+Z.+Shawer&title=Novel+pirfenidone+analogues%3A+synthesis+of+pyridin-2-ones+for+the+treatment+of+pulmonary+fibrosis&doi=10.1002%2Fardp.200600017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis</span></div><div class="casAuthors">Ammar, Yousry A.; Ismail, Magda M. F.; El-Sehrawi, Hend M.; Noaman, Eman; Bayomi, Ashraf H.; Shawer, Taghreed Z.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">429-436</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of polysubstituted 1-aryl-2-oxo-1,2-dihydropyridine-3-carbonitriles and pyrazolo[3,4-b]pyridine-5-carbonitriles and pyrido[2,3-d]pyrimidine-6-carbonitriles have been synthesized and tested for their antifibrotic activity.  Among the tested compds., two compds. exhibited higher antifibrotic activity than the std. pirfenidone PD.  However, bicyclic pyridone displayed a high mortality rate.  Detailed syntheses, spectroscopic and biol. data are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRbqTVxHLNw7Vg90H21EOLACvtfcHk0ljgdwocBMxrQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWgs74%253D&md5=838f7948a2b0a2c6ebaf59a6a89dc793</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fardp.200600017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200600017%26sid%3Dliteratum%253Aachs%26aulast%3DAmmar%26aufirst%3DY.%2BA.%26aulast%3DIsmail%26aufirst%3DM.%2BM.%2BF.%26aulast%3DEl-Sehrawi%26aufirst%3DH.%2BM.%26aulast%3DNoaman%26aufirst%3DE.%26aulast%3DBayomi%26aufirst%3DA.%2BH.%26aulast%3DShawer%26aufirst%3DT.%2BZ.%26atitle%3DNovel%2520pirfenidone%2520analogues%253A%2520synthesis%2520of%2520pyridin-2-ones%2520for%2520the%2520treatment%2520of%2520pulmonary%2520fibrosis%26jtitle%3DArch.%2520Pharm.%26date%3D2006%26volume%3D339%26spage%3D429%26epage%3D436%26doi%3D10.1002%2Fardp.200600017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Giri, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lango, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckpitt, A. R.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration</span> <span class="citation_source-journal">Biopharm. Drug Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1002/bdd.311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fbdd.311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12116052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvV2nsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=203-211&author=S.+N.+Giriauthor=Q.+Wangauthor=Y.+Xieauthor=J.+Langoauthor=D.+Morinauthor=S.+B.+Margolinauthor=A.+R.+Buckpitt&title=Pharmacokinetics+and+metabolism+of+a+novel+antifibrotic+drug+pirfenidone%2C+in+mice+following+intravenous+administration&doi=10.1002%2Fbdd.311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration</span></div><div class="casAuthors">Giri, Shri N.; Wang, Qingjian; Xie, Yan; Lango, Jozsef; Morin, Dexter; Margolin, Solomon B.; Buckpitt, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The present study describes the pharmacokinetics and metab. of pirfenidone (PD), a compd. which has been shown to have significant antifibrotic effects in rodent models of pulmonary and cardiac fibrosis.  Despite the fact that this compd. is currently in phase II clin. trials, little data are available on the metab. and disposition of this agent in rodents or humans.  Radioactive PD [benzene ring 14C(U)] was administered i.v. to mice at 40 mg PD/kg body wt., and animals were killed at varying times for detn. of parent compd. and metabolites in various tissues.  The disappearance of parent compd. from the plasma followed apparent 2-compartment elimination kinetics with a terminal elimination half-life of 8.6 min.  Cl (0.10 mL/min/g) and Vd(ss) (0.67 mL/g) indicated that PD was rapidly distributed in body water.  This is consistent with the finding that peak tissue radioactivity occurred within 5 min following the i.v. administration of [14C]-PD and that well-perfused tissues, kidney > liver > lung have much higher levels of parent compd. and metabolites than did fat.  Two peaks isolated from plasma samples by HPLC yielded mass spectra that were consistent with initial oxidn. to the alc. followed by further metab. to the carboxylic acid.  The radioactivity recovered in the 24 h urine samples averaged 97% of the administered dose and none of that was assocd. with the parent compd.  The short plasma half-life of parent compd. in mice supports the need for addnl. studies in humans where the compd. has been shown to have clin. benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ifBkB7uIJbVg90H21EOLACvtfcHk0ljgdwocBMxrQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvV2nsr0%253D&md5=4dcedca61461a161f06068c3eaa90e69</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1002%2Fbdd.311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.311%26sid%3Dliteratum%253Aachs%26aulast%3DGiri%26aufirst%3DS.%2BN.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DLango%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DD.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DBuckpitt%26aufirst%3DA.%2BR.%26atitle%3DPharmacokinetics%2520and%2520metabolism%2520of%2520a%2520novel%2520antifibrotic%2520drug%2520pirfenidone%252C%2520in%2520mice%2520following%2520intravenous%2520administration%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2002%26volume%3D23%26spage%3D203%26epage%3D211%26doi%3D10.1002%2Fbdd.311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G. Y.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2302</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2012.01.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2300-2302&author=J.+Chenauthor=M.+M.+Luauthor=B.+Liuauthor=Z.+Chenauthor=Q.+B.+Liauthor=L.+J.+Taoauthor=G.+Y.+Hu&title=Synthesis+and+structure%E2%80%93activity+relationship+of+5-substituent-2%281H%29-pyridone+derivatives+as+anti-fibrosis+agents&doi=10.1016%2Fj.bmcl.2012.01.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%2BB.%26aulast%3DTao%26aufirst%3DL.%2BJ.%26aulast%3DHu%26aufirst%3DG.%2BY.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%25205-substituent-2%25281H%2529-pyridone%2520derivatives%2520as%2520anti-fibrosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2300%26epage%3D2302%26doi%3D10.1016%2Fj.bmcl.2012.01.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span> </span><span class="NLM_article-title">Design, synthesis and anti-fibrosis activity study of N<sub>1</sub>-substituted phenylhydroquinolinone derivatives</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1387</span><span class="refDoi"> DOI: 10.3390/molecules17021373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3390%2Fmolecules17021373" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1373-1387&author=L.+Wuauthor=B.+Liuauthor=Q.+Liauthor=J.+Chenauthor=L.+Taoauthor=G.+Hu&title=Design%2C+synthesis+and+anti-fibrosis+activity+study+of+N1-substituted+phenylhydroquinolinone+derivatives&doi=10.3390%2Fmolecules17021373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3390%2Fmolecules17021373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules17021373%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anti-fibrosis%2520activity%2520study%2520of%2520N1-substituted%2520phenylhydroquinolinone%2520derivatives%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D1373%26epage%3D1387%26doi%3D10.3390%2Fmolecules17021373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Lou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span> </span><span class="NLM_article-title">Design, synthesis and antifibrotic activities of carbohydrate- modified 1-(substituted aryl)-5-trifluoromethyl-2(1<i>H</i>) pyridones</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">884</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span><span class="refDoi"> DOI: 10.3390/molecules17010884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3390%2Fmolecules17010884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=884-896&author=Q.+Louauthor=X.+Mengauthor=Z.+Laoauthor=L.+Xuanauthor=J.+Baiauthor=Q.+Houauthor=G.+Huauthor=R.+Luoauthor=L.+Taoauthor=Z.+Li&title=Design%2C+synthesis+and+antifibrotic+activities+of+carbohydrate-+modified+1-%28substituted+aryl%29-5-trifluoromethyl-2%281H%29+pyridones&doi=10.3390%2Fmolecules17010884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.3390%2Fmolecules17010884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules17010884%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DQ.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DLao%26aufirst%3DZ.%26aulast%3DXuan%26aufirst%3DL.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antifibrotic%2520activities%2520of%2520carbohydrate-%2520modified%25201-%2528substituted%2520aryl%2529-5-trifluoromethyl-2%25281H%2529%2520pyridones%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D884%26epage%3D896%26doi%3D10.3390%2Fmolecules17010884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Kossen, K.; Seiwert, S. D.; Serebryany, V.; Ruhrmund, D.; Beigelman, L.; Raveglia, L. F.; Vallese, S.; Bianchi, I.; Hu, T.</span><span> </span><span class="NLM_article-title">Compounds and methods for treating inflammatory and fibrotic disorders</span>. U.S. Patent 20090318455 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Kossen&author=S.+D.+Seiwert&author=V.+Serebryany&author=D.+Ruhrmund&author=L.+Beigelman&author=L.+F.+Raveglia&author=S.+Vallese&author=I.+Bianchi&author=T.+Hu&title=Compounds+and+methods+for+treating+inflammatory+and+fibrotic+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKossen%26aufirst%3DK.%26atitle%3DCompounds%2520and%2520methods%2520for%2520treating%2520inflammatory%2520and%2520fibrotic%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2013.11.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=220-223&author=Z.+Maauthor=Y.+Panauthor=W.+Huangauthor=Y.+Yangauthor=Z.+Wangauthor=Q.+Liauthor=Y.+Zhaoauthor=X.+Zhangauthor=Z.+Shen&title=Synthesis+and+biological+evaluation+of+the+pirfenidone+derivatives+as+antifibrotic+agents&doi=10.1016%2Fj.bmcl.2013.11.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%2520pirfenidone%2520derivatives%2520as%2520antifibrotic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D220%26epage%3D223%26doi%3D10.1016%2Fj.bmcl.2013.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Ueki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amuro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashino, K.</span><span> </span><span class="NLM_article-title">Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">1137</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1137&publication_year=1992&pages=189-196&author=N.+Uekiauthor=M.+Nakazatoauthor=T.+Ohkawaauthor=T.+Ikedaauthor=Y.+Amuroauthor=T.+Hadaauthor=K.+Higashino&title=Excessive+production+of+transforming+growth-factor+beta+1+can+play+an+important+role+in+the+development+of+tumorigenesis+by+its+action+for+angiogenesis%3A+validity+of+neutralizing+antibodies+to+block+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUeki%26aufirst%3DN.%26aulast%3DNakazato%26aufirst%3DM.%26aulast%3DOhkawa%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DAmuro%26aufirst%3DY.%26aulast%3DHada%26aufirst%3DT.%26aulast%3DHigashino%26aufirst%3DK.%26atitle%3DExcessive%2520production%2520of%2520transforming%2520growth-factor%2520beta%25201%2520can%2520play%2520an%2520important%2520role%2520in%2520the%2520development%2520of%2520tumorigenesis%2520by%2520its%2520action%2520for%2520angiogenesis%253A%2520validity%2520of%2520neutralizing%2520antibodies%2520to%2520block%2520tumor%2520growth%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1992%26volume%3D1137%26spage%3D189%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K. S.</span><span> </span><span class="NLM_article-title">Lung cancer in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1216</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1183/09031936.01.99055301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.01.99055301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=11491167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD3MvksFWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2001&pages=1216-1219&author=J.+Parkauthor=D.+S.+Kimauthor=T.+S.+Shimauthor=C.+M.+Limauthor=Y.+Kohauthor=S.+D.+Leeauthor=W.+S.+Kimauthor=W.+D.+Kimauthor=J.+S.+Leeauthor=K.+S.+Song&title=Lung+cancer+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1183%2F09031936.01.99055301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Lung cancer in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Park J; Kim D S; Shim T S; Lim C M; Koh Y; Lee S D; Kim W S; Kim W D; Lee J S; Song K S</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1216-9</span>
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) was reported to be associated with increased risk of lung cancer as a result of the occurrence of atypical or dysplastic epithelial changes in fibrosis which progressed to invasive malignancy.  In that situation, the cancer will develop in the area of major fibrosis.  To investigate the direct relationship between fibrosis and cancer development, the real concordance rate of the two lesions in the chest computed tomography (CT) was analysed and compared to the histological types of lung cancer.  The subjects included 63 patients with combined lung cancer and IPF (IPF-CA), 218 patients with lone IPF, and 2,660 patients with primary lung cancer.  All patients were diagnosed at Asan Medical Center during the same period.  The age, percentage of smokers, and the male sex were significantly higher in IPF-CA compared with lone IPF.  The odds ratio of smoking was 2.71 compared to nonsmoking IPF controls.  In IPF-CA, 56% of the cancer was located in the periphery of the lung and 52% in the upper lobe.  The majority of the cancers (64%) were found in the nonfibrotic area at chest CT.  The most frequent cell type was squamous cell carcinoma (35%), and there was no significant difference in the cancer cell type between IPF-CA and total lung cancer population.  These findings suggest that in combined lung cancer and idiopathic pulmonary fibrosis patients, the features of the lung cancer are similar to the total lung cancer population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcWbvkNiVQre_Q9URG6Dx8fW6udTcc2eZJ9TJZny6hqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvksFWltA%253D%253D&md5=d188ff9c1ae1adeac619ebf862a3f3cf</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1183%2F09031936.01.99055301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.01.99055301%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DShim%26aufirst%3DT.%2BS.%26aulast%3DLim%26aufirst%3DC.%2BM.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DSong%26aufirst%3DK.%2BS.%26atitle%3DLung%2520cancer%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2001%26volume%3D17%26spage%3D1216%26epage%3D1219%26doi%3D10.1183%2F09031936.01.99055301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Aubry, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazelaar, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washington Stephens, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschamps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pankratz, V. S.</span><span> </span><span class="NLM_article-title">Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Mayo Clin. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.4065/77.8.763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4065%2F77.8.763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12173712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD38vhvFCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2002&pages=763-770&author=M.+C.+Aubryauthor=J.+L.+Myersauthor=W.+W.+Douglasauthor=H.+D.+Tazelaarauthor=T.+L.+Washington+Stephensauthor=T.+E.+Hartmanauthor=C.+Deschampsauthor=V.+S.+Pankratz&title=Primary+pulmonary+carcinoma+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.4065%2F77.8.763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Aubry Marie-Christine; Myers Jeffrey L; Douglas William W; Tazelaar Henry D; Washington Stephens Tanya L; Hartman Thomas E; Deschamps Claude; Pankratz V Shane</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">763-70</span>
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    </div><div class="casAbstract">OBJECTIVE:  To identify distinguishing characteristics between patients with idiopathic pulmonary fibrosis (IPF) and primary lung carcinoma and patients with either IPF or carcinoma alone.  PATIENTS AND METHODS:  The study group consisted of 24 patients with histologically proven usual interstitial pneumonia and lung carcinoma identified through a search of the Rochester Mayo Clinic database for 1990 to 1998.  Medical records, radiographs, and histological slides were reviewed.  Several variables including survival were compared in 2 control groups, IPF only and carcinoma only, by using various statistical methods.  RESULTS:  Our study group included 21 men and 3 women (mean age, 72.3 years).  Twenty-two were past or current smokers.  Approximately half of the lung carcinomas were incidental findings.  Of the 14 patients with preoperative computed tomographic scans, 12 had peripheral tumors situated in areas of fibrosis.  Squamous cell carcinoma was the most common histological type, accounting for 16 cases.  Almost all patients underwent surgical treatment; nearly 40% developed postoperative complications, and 3 died within 30 days of surgery.  The ratio of men to women in patients with IPF and carcinoma was 7:1 compared with 1:1 in patients with IPF only (P=.003).  Patients with IPF and carcinoma were also older, with a mean age of 72.3 years compared with 64.4 years (P=.001), and were more often smokers (P=.002).  Carcinomas involved the lower lobes in 42% of patients with IPF and carcinoma compared with 29% of patients with carcinoma only (P=.004) and were mainly composed of squamous cell carcinoma (P=.004).  Mean survival in patients with IPF and lung carcinoma was 2.3 years after the diagnosis of IPF and 1.6 years after that of carcinoma.  This finding did not differ significantly from survival of patients with either IPF or carcinoma alone.  However, statistical power was limited.  CONCLUSION:  Carcinoma in patients with IPF arises in older male smokers and usually presents as peripheral squamous cell carcinoma.  The prognosis is poor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7PQKpEBgkRMzK395ZObgVfW6udTcc2ebhiBH7FliZj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vhvFCqsg%253D%253D&md5=cbe0368942849a52db53f3a5998fa6c4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.4065%2F77.8.763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4065%252F77.8.763%26sid%3Dliteratum%253Aachs%26aulast%3DAubry%26aufirst%3DM.%2BC.%26aulast%3DMyers%26aufirst%3DJ.%2BL.%26aulast%3DDouglas%26aufirst%3DW.%2BW.%26aulast%3DTazelaar%26aufirst%3DH.%2BD.%26aulast%3DWashington%2BStephens%26aufirst%3DT.%2BL.%26aulast%3DHartman%26aufirst%3DT.%2BE.%26aulast%3DDeschamps%26aufirst%3DC.%26aulast%3DPankratz%26aufirst%3DV.%2BS.%26atitle%3DPrimary%2520pulmonary%2520carcinoma%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2002%26volume%3D77%26spage%3D763%26epage%3D770%26doi%3D10.4065%2F77.8.763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span> </span><span class="NLM_article-title">Synthesis, pharmacophores, and mechanism study of pyridin-2(1<i>H</i>)-one derivatives as regulators of translation initiation factor 3A</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">666</span><span class="refDoi"> DOI: 10.1002/ardp.201300138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fardp.201300138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yks7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=654-666&author=W.+Zhuauthor=J.+Shenauthor=Q.+Liauthor=Q.+Peiauthor=J.+Chenauthor=Z.+Chenauthor=Z.+Liuauthor=G.+Hu&title=Synthesis%2C+pharmacophores%2C+and+mechanism+study+of+pyridin-2%281H%29-one+derivatives+as+regulators+of+translation+initiation+factor+3A&doi=10.1002%2Fardp.201300138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, pharmacophores, and mechanism study of pyridin-2(1H)-one derivatives as regulators of translation initiation factor 3a</span></div><div class="casAuthors">Zhu, Weixing; Shen, Jie; Li, Qianbin; Pei, Qi; Chen, Jun; Chen, Zhuo; Liu, Zhaoqian; Hu, Gaoyun</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">654-666</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Twenty-seven 1,5-disubstituted-pyridin-2(1H)-one derivs. were synthesized and evaluated for their anticancer and antifibrosis activity by A549 and NIH3T3 cell viability assays, resp.  To study the selectivity between the cancer and fibrosis cell lines, pharmacophore models (F1-F4) were built in advance for compds. with pyridin-2(1H)-one scaffold, which revealed the relationship between the occupation of the arom. sub-site F4 and potent anti-cancer activity.  The relationship between structure and anti-cancer activity for all target compds. is also reported herein: 1-Phenyl-5-((m-tolylamino)methyl)pyridine-2(1H)-one (22) displayed both potency and selectivity (IC50 = 0.13 mM) toward the A549 cell line through the inhibition of translation initiation, esp. by eIF3a suppression, and can be treated as a lead for the design of novel eIF3a regulators and anti-lung cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHSDWP5U8VebVg90H21EOLACvtfcHk0lgcLUfBux2EhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yks7%252FP&md5=b644c20f431f198399fa919bdeb427c6</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fardp.201300138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201300138%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DPei%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520pharmacophores%252C%2520and%2520mechanism%2520study%2520of%2520pyridin-2%25281H%2529-one%2520derivatives%2520as%2520regulators%2520of%2520translation%2520initiation%2520factor%25203A%26jtitle%3DArch.%2520Pharm.%26date%3D2013%26volume%3D346%26spage%3D654%26epage%3D666%26doi%3D10.1002%2Fardp.201300138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Lasky, J.</span><span> </span><span class="NLM_article-title">Pirfenidone</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15057662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntF2ksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=166-172&author=J.+Lasky&title=Pirfenidone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone(InterMune/Shionogi/Marnac)</span></div><div class="casAuthors">Lasky, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-172</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_3VFnr6wLWrVg90H21EOLACvtfcHk0lgcLUfBux2EhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntF2ksr0%253D&md5=79bbb53c4305e82fab25a0a249b47f96</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLasky%26aufirst%3DJ.%26atitle%3DPirfenidone%26jtitle%3DIDrugs%26date%3D2004%26volume%3D7%26spage%3D166%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Tao, L. J.; Hu, G. Y.; Tan, G. S.</span><span> </span><span class="NLM_article-title">Antifibrosis pyridinone medicine and its preparing process</span>. CN 1386737A,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=L.+J.+Tao&author=G.+Y.+Hu&author=G.+S.+Tan&title=Antifibrosis+pyridinone+medicine+and+its+preparing+process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%2BJ.%26atitle%3DAntifibrosis%2520pyridinone%2520medicine%2520and%2520its%2520preparing%2520process%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Tao, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G. Y.</span><span> </span><span class="NLM_article-title">Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H)-pyridone on renal fibroblast in rats</span> <span class="citation_source-journal">Zhong Nan Da Xue Xue Bao Yi Xue Ban</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16145895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2MvnslWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=139-141&author=L.+J.+Taoauthor=J.+Zhangauthor=G.+Y.+Hu&title=Effects+of+1-%283-fluorophenyl%29-5-methyl-2-%281H%29-pyridone+on+renal+fibroblast+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H)-pyridone on renal fibroblast in rats</span></div><div class="casAuthors">Tao Li-Jian; Zhang Jun; Hu Gao-Yun</div><div class="citationInfo"><span class="NLM_cas:title">Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-41</span>
        ISSN:<span class="NLM_cas:issn">1672-7347</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore the curative effects of 1-(3-fluorophenyl)-5-methyl-2- (1H)-pyridone (FMP) on renal fibrosis in rats.  METHODS:  The effects of FMP on the cell proliferation and Fn secretion were measured by methyl thiazolyl tetrazolium and enzyme-linked immunoabsorbent assay, respectively.  RESULTS:  FMP obviously inhibited the proliferation and Fn secretion in rat renal fibroblast 48 hours after the treatment.  FMP (1 000 microg/ml) obviously inhibited the proliferation of rat renal fibroblast 24 hours after the treatment.  CONCLUSION:  1-(3-Fluorophenyl) -5-methyl-2-(1H)-pyridone can obviously inhibit the proliferation of rat renal fibroblast, which may be effective for renal interstitial fibrosis prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkJliHwPw3BpPlX7E30qdzfW6udTcc2eYUYsx_fkMUc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvnslWnsQ%253D%253D&md5=72a018ad9bbb35f8f5ff8bb2816bf602</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DG.%2BY.%26atitle%3DEffects%2520of%25201-%25283-fluorophenyl%2529-5-methyl-2-%25281H%2529-pyridone%2520on%2520renal%2520fibroblast%2520in%2520rats%26jtitle%3DZhong%2520Nan%2520Da%2520Xue%2520Xue%2520Bao%2520Yi%2520Xue%2520Ban%26date%3D2004%26volume%3D29%26spage%3D139%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Mirkovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenning, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strachan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L.</span><span> </span><span class="NLM_article-title">Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0704539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fsj.bjp.0704539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=11861324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1Cntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=961-968&author=S.+Mirkovicauthor=A.+M.+Seymourauthor=A.+Fenningauthor=A.+Strachanauthor=S.+B.+Margolinauthor=S.+M.+Taylorauthor=L.+Brown&title=Attenuation+of+cardiac+fibrosis+by+pirfenidone+and+amiloride+in+DOCA-salt+hypertensive+rats&doi=10.1038%2Fsj.bjp.0704539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats</span></div><div class="casAuthors">Mirkovic, Stevo; Seymour, Anne-Marie L.; Fenning, Andrew; Strachan, Anna; Margolin, Solomon B.; Taylor, Stephen M.; Brown, Lindsay</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">961-968</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study has administered pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) or amiloride to attenuate the remodelling and assocd. functional changes, esp. an increased cardiac stiffness, in DOCA-salt hypertensive rats.  In control rats, the elimination half-life of pirfenidone following a single i.v. dose of 200 mg kg-1 was 37 min while oral bioavailability at this dose was 25.7%.  Plasma pirfenidone concns. in control rats averaged 1.9±0.1 μg ml-1 over 24 h after 14 days' administration as a 0.4% mixt. in food.  Pirfenidone (approx. 250-300 mg kg-1 day-1 as 0.4% in food) and amiloride (1 mg kg-1 day-1 s.c.) were administered for 2 wk starting 2 wk post-surgery.  Pirfenidone but not amiloride attenuated ventricular hypertrophy (2.69±0.09, UNX 2.01±0.05. DOCA-salt 3.11±0.09 mg kg-1 body wt.) without lowering systolic blood pressure.  Collagen deposition was significantly increased in the interstitium after 2 wk and further increased with scarring of the left ventricle after 4 wk; pirfenidone and amiloride reversed the increases and prevented further increases.  This accumulation of collagen was accompanied by an increase in diastolic stiffness const.; both amiloride and pirfenidone reversed this increase.  Noradrenaline potency (pos. chronotropy) was decreased in right atria (neg. log EC50: control 6.92±0.06; DOCA-salt 6.64±0.08); pirfenidone but not amiloride reversed this change.  Noradrenaline was a more potent vasoconstrictor in thoracic aortic rings (neg. log EC50: control 6.91±0.10; DOCA-salt 7.90±0.07); pirfenidone treatment did not change noradrenaline potency.  Thus, pirfenidone and amiloride reverse and prevent cardiac remodelling and the increased cardiac stiffness without reversing the increased vascular responses to noradrenaline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaFFgkYGNrArVg90H21EOLACvtfcHk0liiFW5AgeJDow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1Cntbo%253D&md5=e3966b0ae08814933f0784cc40987502</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704539%26sid%3Dliteratum%253Aachs%26aulast%3DMirkovic%26aufirst%3DS.%26aulast%3DSeymour%26aufirst%3DA.%2BM.%26aulast%3DFenning%26aufirst%3DA.%26aulast%3DStrachan%26aufirst%3DA.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DTaylor%26aufirst%3DS.%2BM.%26aulast%3DBrown%26aufirst%3DL.%26atitle%3DAttenuation%2520of%2520cardiac%2520fibrosis%2520by%2520pirfenidone%2520and%2520amiloride%2520in%2520DOCA-salt%2520hypertensive%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D961%26epage%3D968%26doi%3D10.1038%2Fsj.bjp.0704539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Iyer, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S. N.</span><span> </span><span class="NLM_article-title">Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model</span> <span class="citation_source-journal">Exp. Lung Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.3109/01902149809046058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3109%2F01902149809046058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=9457473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADyaK1cXit1Kis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1998&pages=119-132&author=S.+N.+Iyerauthor=S.+B.+Margolinauthor=D.+M.+Hydeauthor=S.+N.+Giri&title=Lung+fibrosis+is+ameliorated+by+pirfenidone+fed+in+diet+after+the+second+dose+in+a+three-dose+bleomycin-hamster+model&doi=10.3109%2F01902149809046058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model</span></div><div class="casAuthors">Iyer, Swarnalatha N.; Margolin, S. B.; Hyde, D. M.; Giri, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Lung Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-132</span>CODEN:
                <span class="NLM_cas:coden">EXLRDA</span>;
        ISSN:<span class="NLM_cas:issn">0190-2148</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis</span>)
        </div><div class="casAbstract">Interstitial lung fibrosis (ILF) is a life-threatening disease which has no known drug for prevention and cure.  In the present study, we evaluated the antifibrotic potential of pirfenidone (PD) (5-methyl-1-phenyl-2-(1H)-pyridone) in a three-dose bleomycin (BL)-hamster model of lung fibrosis.  Hamsters were intratracheally (IT) instilled with three consecutive doses of bleomycin sulfate (2.5 U/kg/5mL, 2.0 U/kg/5mL, 1.5 U/kg/3.75mL) or an equiv. vol. of saline at weekly intervals.  Hamsters were fed a diet after the second dose of BL contg. 0.5% PD and hamsters in the control groups were fed the same diet without the drug.  The four groups were saline-instilled fed control diet (SCD); saline-instilled fed the same diet contg. PD (SPD); BL-instilled fed control diet (BCD); and BL-instilled fed the diet contg. PD (BPD).  Hamsters were sacrificed at 28 days after IT instillation of last dose of saline or BL and their lungs processed for various assays.  Lung hydroxyproline, an index of fibrosis, in SCD, SPD, BCD and BPD were 830, 804, 1609, 1235 μg/lung, resp.  Lung prolyl hydroxylase activities in the SPD, BCD and BPD groups were 103%, 313%, 157% of the control SCD group (5.99 × 104 dpm/lung/30 min) resp.  Malondialdehyde equiv. levels and superoxide dismutase activity in the corresponding groups were 99, 79, 240 and 145 nmoles/lung and 412, 433, 538 and 410 units/lung resp.  Lung myeloperoxidase activities in the corresponding groups were 56%, 179%, and 116% of the control group (0.44 units/lung).  It is concluded that PD is a novel antifibrotic drug that has therapeutic potential in arresting the progression of an ongoing fibrotic process in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYluNu74sAH7Vg90H21EOLACvtfcHk0liiFW5AgeJDow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1Kis78%253D&md5=af6f0f9cc056c47a3360bb73259c098e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3109%2F01902149809046058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F01902149809046058%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%2BN.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DHyde%26aufirst%3DD.%2BM.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26atitle%3DLung%2520fibrosis%2520is%2520ameliorated%2520by%2520pirfenidone%2520fed%2520in%2520diet%2520after%2520the%2520second%2520dose%2520in%2520a%2520three-dose%2520bleomycin-hamster%2520model%26jtitle%3DExp.%2520Lung%2520Res.%26date%3D1998%26volume%3D24%26spage%3D119%26epage%3D132%26doi%3D10.3109%2F01902149809046058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G. Y.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationship of 5-substituent-2(1<i>H</i>)-pyridone derivatives as anti-fibrosis agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2302</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2012.01.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2300-2302&author=J.+Chenauthor=M.+M.+Luauthor=B.+Liuauthor=Z.+Chenauthor=Q.+B.+Liauthor=L.+J.+Taoauthor=G.+Y.+Hu&title=Synthesis+and+structure%E2%80%93activity+relationship+of+5-substituent-2%281H%29-pyridone+derivatives+as+anti-fibrosis+agents&doi=10.1016%2Fj.bmcl.2012.01.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%2BB.%26aulast%3DTao%26aufirst%3DL.%2BJ.%26aulast%3DHu%26aufirst%3DG.%2BY.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%25205-substituent-2%25281H%2529-pyridone%2520derivatives%2520as%2520anti-fibrosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2300%26epage%3D2302%26doi%3D10.1016%2Fj.bmcl.2012.01.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span> </span><span class="NLM_article-title">Synthesis, preliminary biological evaluation and 3D-QSAR study of novel 1,5-disubstituted-2(1<i>H</i>)-pyridone derivatives as potential anti-lung cancer agents</span> <span class="citation_source-journal">Arabian J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1016/j.arabjc.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.arabjc.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWht7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=721-735&author=Q.+Xuauthor=X.+Jiangauthor=W.+Zhuauthor=C.+Chenauthor=G.+Huauthor=Q.+Li&title=Synthesis%2C+preliminary+biological+evaluation+and+3D-QSAR+study+of+novel+1%2C5-disubstituted-2%281H%29-pyridone+derivatives+as+potential+anti-lung+cancer+agents&doi=10.1016%2Fj.arabjc.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, preliminary biological evaluation and 3D-QSAR study of novel 1,5-disubstituted-2(1H)-pyridone derivatives as potential anti-lung cancer agents</span></div><div class="casAuthors">Xu, Qifei; Jiang, Xiaoding; Zhu, Weixing; Chen, Chuo; Hu, Gaoyun; Li, Qianbin</div><div class="citationInfo"><span class="NLM_cas:title">Arabian Journal of Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-735</span>CODEN:
                <span class="NLM_cas:coden">AJCRDR</span>;
        ISSN:<span class="NLM_cas:issn">1878-5352</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Twenty-eight novel 1,5-disubstituted-2(1H)-pyridone derivs. I (R1 = 2-F, 4-Me, 2-MeO, etc.; R2 = H, 2-F, 4-F, 4-OMe), II were designed and synthesized for discovering more potent anti-lung cancer agents combined with anti-fibrotic profiles.  The in vitro antiproliferative activities of the derivs. against A549 and NIH3T3 cell lines were tested by MTT assays.  The majority of the tested analogs exhibited equiv. or an improved anti-lung cancer activity.  Prominently, compd. II (R1 = 4-F; R2 = 4-OMe) displayed the best potency and selectivity toward A549 with an IC50 value of 20 μM, nearly comparable to the pos. control cisplatin (IC50 = 10 μM) and even superior to the lead compd. III (IC50 = 130 μM).  Simultaneously, compd. II (R1 = 4-F; R2 = 4-OMe) showed significant inhibitory activity against NIH3T3 (IC50 = 55 μM), which may contribute to hindering the proliferation of lung cancer cells fundamentally.  The 3D-QSAR models established on the activity data provided new insights into the design of novel 2(1H)-pyridone derivs. and lay a theor. foundation for further studies of promising anti-lung cancer activity with the maintenance of anti-fibrotic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDnfEPmL404rVg90H21EOLACvtfcHk0lh_qzBki7bq5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWht7%252FJ&md5=73e83d3f303ead0e8638de3f071d4f7b</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.arabjc.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.arabjc.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DSynthesis%252C%2520preliminary%2520biological%2520evaluation%2520and%25203D-QSAR%2520study%2520of%2520novel%25201%252C5-disubstituted-2%25281H%2529-pyridone%2520derivatives%2520as%2520potential%2520anti-lung%2520cancer%2520agents%26jtitle%3DArabian%2520J.%2520Chem.%26date%3D2016%26volume%3D9%26spage%3D721%26epage%3D735%26doi%3D10.1016%2Fj.arabjc.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Semen, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminskyy, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirota, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maij, N. G. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelisyeyeva, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span> </span><span class="NLM_article-title">Redox modulation by amaranth oil in human lung fibroblasts</span> <span class="citation_source-journal">Nat. Prod. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1000122</span><span class="refDoi"> DOI: 10.4172/2329-6836.1000122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4172%2F2329-6836.1000122" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=1000122&author=K.+O.+Semenauthor=G.+J.+den+Hartogauthor=D.+V.+Kaminskyyauthor=T.+V.+Sirotaauthor=N.+G.+A.+A.+Maijauthor=O.+P.+Yelisyeyevaauthor=A.+Bast&title=Redox+modulation+by+amaranth+oil+in+human+lung+fibroblasts&doi=10.4172%2F2329-6836.1000122"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.4172%2F2329-6836.1000122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2329-6836.1000122%26sid%3Dliteratum%253Aachs%26aulast%3DSemen%26aufirst%3DK.%2BO.%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DKaminskyy%26aufirst%3DD.%2BV.%26aulast%3DSirota%26aufirst%3DT.%2BV.%26aulast%3DMaij%26aufirst%3DN.%2BG.%2BA.%2BA.%26aulast%3DYelisyeyeva%26aufirst%3DO.%2BP.%26aulast%3DBast%26aufirst%3DA.%26atitle%3DRedox%2520modulation%2520by%2520amaranth%2520oil%2520in%2520human%2520lung%2520fibroblasts%26jtitle%3DNat.%2520Prod.%2520Chem.%2520Res.%26date%3D2013%26volume%3D2%26spage%3D1000122%26doi%3D10.4172%2F2329-6836.1000122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Tilburg, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koek, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span> </span><span class="NLM_article-title">Superoxide anion radicals activate hepatic stellate cells after entry through chloride channels: a new target in liver fibrosis</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">724</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2013.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ejphar.2013.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24378345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=724&publication_year=2014&pages=140-144&author=G.+J.+den+Hartogauthor=S.+Qiauthor=J.+H.+van+Tilburgauthor=G.+H.+Koekauthor=A.+Bast&title=Superoxide+anion+radicals+activate+hepatic+stellate+cells+after+entry+through+chloride+channels%3A+a+new+target+in+liver+fibrosis&doi=10.1016%2Fj.ejphar.2013.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123aR"><div class="casContent"><span class="casTitleNuber">123a</span><div class="casTitle"><span class="NLM_cas:atitle">Superoxide anion radicals activate hepatic stellate cells after entry through chloride channels: A new target in liver fibrosis</span></div><div class="casAuthors">den Hartog, Gertjan J. M.; Qi, Shufan; van Tilburg, Jonathan H. O.; Koek, Ger H.; Bast, Aalt</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">724</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">140-144</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is generally accepted that reactive oxygen species (ROS) play an important role in the pathogenesis of liver fibrosis.  ROS, however, constitute a group of species with varying properties making it likely that their contribution to the pathol. mechanism varies.  LX-2 hepatic stellate cells (HSCs) were exposed to superoxide anion radicals (O2-) generated by xanthine and xanthine oxidase.  To rule out that the activation of HSCs is due to hydrogen peroxide derived from O2-, control incubations with copper, zinc-superoxide dismutase and tempol were studied as well.  Influx of O2- activated HSCs, evidenced by the expression of α-smooth muscle actin and the secretion of transforming growth factor β1 and collagen.  We further found that blockade of chloride channels with 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), 5-nitro-2-(3-phenylpropyl-amino) benzoic acid (NPPB) or indanyloxyacetic acid (IAA-94) prevented the increase of intracellular O2- levels as well as the activation of HSCs.  These findings suggest that O2- is involved in the development of liver fibrosis and that entry of O2-, through chloride channels, in stellate cells is crit. for their activation.  This study provides new insight into the mechanism by which ROS induce liver fibrosis.  Furthermore, our data suggest that chloride channels constitute a potential target for new anti-fibrotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritMGazRQYlLVg90H21EOLACvtfcHk0lh_qzBki7bq5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGmtbg%253D&md5=5dbd1070a25c30903aa41393ff6623e8</span></div><a href="/servlet/linkout?suffix=cit123a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.12.033%26sid%3Dliteratum%253Aachs%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DQi%26aufirst%3DS.%26aulast%3Dvan%2BTilburg%26aufirst%3DJ.%2BH.%26aulast%3DKoek%26aufirst%3DG.%2BH.%26aulast%3DBast%26aufirst%3DA.%26atitle%3DSuperoxide%2520anion%2520radicals%2520activate%2520hepatic%2520stellate%2520cells%2520after%2520entry%2520through%2520chloride%2520channels%253A%2520a%2520new%2520target%2520in%2520liver%2520fibrosis%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D724%26spage%3D140%26epage%3D144%26doi%3D10.1016%2Fj.ejphar.2013.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit123b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span> </span><span class="NLM_article-title">Superoxide radicals increase transforming growth factor-beta1 and collagen release from human lung fibroblasts via cellular influx through chloride channels</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1016/j.taap.2009.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.taap.2009.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19268487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Grtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2009&pages=111-118&author=S.+Qiauthor=G.+J.+den+Hartogauthor=A.+Bast&title=Superoxide+radicals+increase+transforming+growth+factor-beta1+and+collagen+release+from+human+lung+fibroblasts+via+cellular+influx+through+chloride+channels&doi=10.1016%2Fj.taap.2009.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123bR"><div class="casContent"><span class="casTitleNuber">123b</span><div class="casTitle"><span class="NLM_cas:atitle">Superoxide radicals increase transforming growth factor-β1 and collagen release from human lung fibroblasts via cellular influx through chloride channels</span></div><div class="casAuthors">Qi, Shufan; den Hartog, Gertjan J. M.; Bast, Aalt</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Reactive oxygen species (ROS) have been implicated in the pathogenesis of fibrosis.  However, it remains unclear which ROS is the major cause.  We hypothesize that superoxide elicits specific toxicity to human lung fibroblasts and plays an important role in the development of pulmonary fibrosis.  In this study, superoxide generated from xanthine and xanthine oxidase activated lung fibroblasts by increasing the release of TGF-β1 and collagen.  This was assocd. with increased levels of intracellular superoxide.  SOD and tempol, by scavenging resp. extracellular and intracellular superoxide, prevented the activation of fibroblasts induced by exposure to exogenous superoxide, whereas catalase did not.  Moreover, hydrogen peroxide did not activate fibroblasts.  Apparently, superoxide rather than hydrogen peroxide is involved in the regulation of TGF-β1 and collagen release in lung fibroblasts.  The chloride channel blocker, DIDS, inhibited the increase of intracellular superoxide levels induced by exogenous superoxide and consequently prevented the activation of fibroblasts.  This suggests that the cellular influx of superoxide through chloride channels is essential for superoxide-induced activation of fibroblasts.  ERK1/2 and p38 MAPKs are involved in the intracellular pathway leading to superoxide-induced fibroblasts activation.  Superoxide possesses until now undiscovered specific pro-fibrotic properties in human lung fibroblasts.  This takes place via the cellular influx of superoxide through chloride channels rather than via the formation of hydrogen peroxide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHtiBrV1pMLVg90H21EOLACvtfcHk0ljziIV_zNHqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Grtbk%253D&md5=d4d32ee5e40169e385f2397fa19078c5</span></div><a href="/servlet/linkout?suffix=cit123b&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2009.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2009.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DS.%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DBast%26aufirst%3DA.%26atitle%3DSuperoxide%2520radicals%2520increase%2520transforming%2520growth%2520factor-beta1%2520and%2520collagen%2520release%2520from%2520human%2520lung%2520fibroblasts%2520via%2520cellular%2520influx%2520through%2520chloride%2520channels%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2009%26volume%3D237%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.taap.2009.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kaminskyy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subtel’na, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimenkovsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gzella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesyk, R.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2(5<i>H</i>)-one derivatives</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">530</span><span class="refDoi"> DOI: 10.2174/1573406411666150211112049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F1573406411666150211112049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25669320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OmsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=517-530&author=D.+Kaminskyyauthor=I.+Subtel%E2%80%99naauthor=B.+Zimenkovskyauthor=O.+Karpenkoauthor=A.+Gzellaauthor=R.+Lesyk&title=Synthesis+and+evaluation+of+anticancer+activity+of+5-ylidene-4-aminothiazol-2%285H%29-one+derivatives&doi=10.2174%2F1573406411666150211112049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124aR"><div class="casContent"><span class="casTitleNuber">124a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Anticancer Activity of 5-Ylidene-4- Aminothiazol-2(5H)-one Derivatives</span></div><div class="casAuthors">Kaminskyy, Danylo; Subtel'na, Ivanna; Zimenkovsky, Borys; Karpenko, Olexandr; Gzella, Andrzej; Lesyk, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">517-530</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The synthesis and antitumor activity screening of 4-aminothiazol-2(5H)-one derivs. were performed.  The absence of possible 4-amino-imino tautomerism of thiazolidinones-2 has been confirmed based on the study of the mol. structures.  The existence of the alone amino-form was confirmed.  An anticancer activity screening was performed within the Developmental Therapeutics Program (National Cancer Institute/NIH, USA).  Tested compds. possess low to moderate anticancer activity (av. values - 60 cancer cell lines assay) with significant selective action on certain cancer cell lines (CCRF-CEM and RPMI-8226/leukemia, U251/CNS cancer, RFX 393/renal cancer, OVCAR/ovarian cancer etc.).  The advantage of 5-ylidene-4-R-amino derivs. in comparison with compds. with free amino group was shown.  Some structure-activity findings, the comparison of target compds. with isomeric 5-ylidene-2-imino(amino)thiazol-4(5H)-ones, as well as COMPARE anal. were described.  Among the tested compds. (Z)-5-(furan-2-ylmethylidene)-4-(4-chlorophenylamino)thiazol-2(5H)-one (IIIk) and (Z)-5-(4-diethylaminophenylmethylidene)-4-(4-hydroxy-5-isopropyl-2-methylphenylamino)thiazol-2(5H)-one (IIIp) possessed the highest levels of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolfT0YO0xtcrVg90H21EOLACvtfcHk0ljziIV_zNHqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OmsLvJ&md5=413ccbe723aa8cb74cb3e5aa9f385e37</span></div><a href="/servlet/linkout?suffix=cit124a&amp;dbid=16384&amp;doi=10.2174%2F1573406411666150211112049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406411666150211112049%26sid%3Dliteratum%253Aachs%26aulast%3DKaminskyy%26aufirst%3DD.%26aulast%3DSubtel%25E2%2580%2599na%26aufirst%3DI.%26aulast%3DZimenkovsky%26aufirst%3DB.%26aulast%3DKarpenko%26aufirst%3DO.%26aulast%3DGzella%26aufirst%3DA.%26aulast%3DLesyk%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520anticancer%2520activity%2520of%25205-ylidene-4-aminothiazol-2%25285H%2529-one%2520derivatives%26jtitle%3DMed.%2520Chem.%26date%3D2015%26volume%3D11%26spage%3D517%26epage%3D530%26doi%3D10.2174%2F1573406411666150211112049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit124b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124bR"><div class="casContent"><span class="casTitleNuber">124b</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0li4i-g0GsuoIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit124b&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit124c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mendgen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C. D.</span><span> </span><span class="NLM_article-title">Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">743</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1021/jm201243p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201243p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=743-753&author=T.+Mendgenauthor=C.+Steuerauthor=C.+D.+Klein&title=Privileged+scaffolds+or+promiscuous+binders%3A+a+comparative+study+on+rhodanines+and+related+heterocycles+in+medicinal+chemistry&doi=10.1021%2Fjm201243p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124cR"><div class="casContent"><span class="casTitleNuber">124c</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry</span></div><div class="casAuthors">Mendgen, Thomas; Steuer, Christian; Klein, Christian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">743-753</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rhodanines and related five-membered heterocycles with multiple heteroatoms have recently gained a reputation of being unselective compds. that appear as "frequent hitters" in screening campaigns and therefore have little value in drug discovery.  However, this judgment appears to be based mostly on anecdotal evidence.  Having identified various rhodanines and related compds. in screening campaigns, we decided to perform a systematic study on their promiscuity.  An amt. of 163 rhodanines, hydantoins, thiohydantoins, and thiazolidinediones were synthesized and tested against several targets.  The compds. were also characterized with respect to aggregation and electrophilic reactivity, and the binding modes of rhodanines and related compds. in published x-ray cocrystal structures were analyzed.  The results indicate that the exocyclic, double bonded sulfur atom in rhodanines and thiohydantoins, in addn. to other structural features, offers a particularly high d. of interaction sites for polar interactions and hydrogen bonds.  This causes a promiscuous behavior at concns. in the "screening range" but should not be regarded as a general knockout criterion that excludes such screening hits from further development.  It is suggested that special criteria for target affinity and selectivity are applied to these classes of compds. and that their exceptional and potentially valuable biomol. binding properties are consequently exploited in a useful way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzna8Pcz1iLVg90H21EOLACvtfcHk0li4i-g0GsuoIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN&md5=6a94d097f44bdbaaec9a56fd6b371521</span></div><a href="/servlet/linkout?suffix=cit124c&amp;dbid=16384&amp;doi=10.1021%2Fjm201243p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201243p%26sid%3Dliteratum%253Aachs%26aulast%3DMendgen%26aufirst%3DT.%26aulast%3DSteuer%26aufirst%3DC.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26atitle%3DPrivileged%2520scaffolds%2520or%2520promiscuous%2520binders%253A%2520a%2520comparative%2520study%2520on%2520rhodanines%2520and%2520related%2520heterocycles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D743%26epage%3D753%26doi%3D10.1021%2Fjm201243p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit124d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span> </span><span class="NLM_article-title">A decade of fragment-based drug design: strategic advances and lessons learned</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1038/nrd2220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd2220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17290284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit12rtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=211-219&author=P.+J.+Hajdukauthor=J.+Greer&title=A+decade+of+fragment-based+drug+design%3A+strategic+advances+and+lessons+learned&doi=10.1038%2Fnrd2220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124dR"><div class="casContent"><span class="casTitleNuber">124d</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of fragment-based drug design: strategic advances and lessons learned</span></div><div class="casAuthors">Hajduk, Philip J.; Greer, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the early 1990s, several technol. and scientific advances - such as combinatorial chem., high-throughput screening and the sequencing of the human genome - have been heralded as remedies to the problems facing the pharmaceutical industry.  The use of these technologies in some form is now well established at most pharmaceutical companies; however, the return on investment in terms of marketed products has not met expectations.  Fragment-based drug design is another tool for drug discovery that has emerged in the past decade.  Here, we describe the development and evolution of fragment-based drug design, analyze the role that this approach can have in combination with other discovery technologies and highlight the impact that fragment-based methods have made in progressing new medicines into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB8K3AESqTbVg90H21EOLACvtfcHk0li4i-g0GsuoIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit12rtr4%253D&md5=bae574da3671475d8488615c3bfa9849</span></div><a href="/servlet/linkout?suffix=cit124d&amp;dbid=16384&amp;doi=10.1038%2Fnrd2220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2220%26sid%3Dliteratum%253Aachs%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%26atitle%3DA%2520decade%2520of%2520fragment-based%2520drug%2520design%253A%2520strategic%2520advances%2520and%2520lessons%2520learned%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D211%26epage%3D219%26doi%3D10.1038%2Fnrd2220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit124e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Forman, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursini, F.</span><span> </span><span class="NLM_article-title">How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo</span> <span class="citation_source-journal">Free Radical Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2013.05.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.freeradbiomed.2013.05.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23747930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCgtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=24-35&author=H.+J.+Formanauthor=K.+J.+Daviesauthor=F.+Ursini&title=How+do+nutritional+antioxidants+really+work%3A+nucleophilic+tone+and+para-hormesis+versus+free+radical+scavenging+in+vivo&doi=10.1016%2Fj.freeradbiomed.2013.05.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124eR"><div class="casContent"><span class="casTitleNuber">124e</span><div class="casTitle"><span class="NLM_cas:atitle">How do nutritional antioxidants really work: Nucleophilic tone and para-hormesis versus free radical scavenging in vivo</span></div><div class="casAuthors">Forman, Henry J.; Davies, Kelvin J. A.; Ursini, Fulvio</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-35</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  We present arguments for an evolution in our understanding of how antioxidants in fruits and vegetables exert their health-protective effects.  There is much epidemiol. evidence for disease prevention by dietary antioxidants and chem. evidence that such compds. react in one-electron reactions with free radicals in vitro.  Nonetheless, kinetic constraints indicate that in vivo scavenging of radicals is ineffective in antioxidant defense.  Instead, enzymic removal of nonradical electrophiles, such as hydroperoxides, in two-electron redox reactions is the major antioxidant mechanism.  Furthermore, we propose that a major mechanism of action for nutritional antioxidants is the paradoxical oxidative activation of the Nrf2 (NF-E2-related factor 2) signaling pathway, which maintains protective oxidoreductases and their nucleophilic substrates.  This maintenance of "nucleophilic tone," by a mechanism that can be called "para-hormesis," provides a means for regulating physiol. nontoxic concns. of the nonradical oxidant electrophiles that boost antioxidant enzymes, and damage removal and repair systems (for proteins, lipids, and DNA), at the optimal levels consistent with good health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvuNaIhdw4WrVg90H21EOLACvtfcHk0ljAkT4IhtF5WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCgtrfN&md5=3731cb7e45d0f9d6744b6c4a26ab7792</span></div><a href="/servlet/linkout?suffix=cit124e&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2013.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2013.05.045%26sid%3Dliteratum%253Aachs%26aulast%3DForman%26aufirst%3DH.%2BJ.%26aulast%3DDavies%26aufirst%3DK.%2BJ.%26aulast%3DUrsini%26aufirst%3DF.%26atitle%3DHow%2520do%2520nutritional%2520antioxidants%2520really%2520work%253A%2520nucleophilic%2520tone%2520and%2520para-hormesis%2520versus%2520free%2520radical%2520scavenging%2520in%2520vivo%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2014%26volume%3D66%26spage%3D24%26epage%3D35%26doi%3D10.1016%2Fj.freeradbiomed.2013.05.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Kaminskyy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojtyra, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelyukh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gzella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesyk, R.</span><span> </span><span class="NLM_article-title">Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ejmech.2016.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26896707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislyqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2016&pages=180-195&author=D.+Kaminskyyauthor=G.+J.+den+Hartogauthor=M.+Wojtyraauthor=M.+Lelyukhauthor=A.+Gzellaauthor=A.+Bastauthor=R.+Lesyk&title=Antifibrotic+and+anticancer+action+of+5-ene+amino%2Fiminothiazolidinones&doi=10.1016%2Fj.ejmech.2016.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones</span></div><div class="casAuthors">Kaminskyy, Danylo; den Hartog, Gertjan J. M.; Wojtyra, Magdalena; Lelyukh, Maryan; Gzella, Andrzej; Bast, Aalt; Lesyk, Roman</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180-195</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Here we describe the synthesis and the antifibrotic and anticancer activity detn. of amino(imino)thiazolidinone derivs.  An efficient one-pot three-component reaction which involved [2 + 3]-cyclocondensation and Knoevenagel condensation was used for the synthesis of 5-ene-2-amino(imino)-4-thiazolidinones.  Following amino-imino tautomerism, the compd. structures were confirmed by X-ray anal.  Comparison of SRB assays on fibroblasts and cancer cells revealed that compds. which significantly reduced the viability of fibroblasts did not possess an anticancer effect.  A series of thiazolidinone derivs. as interesting candidates for further testing has been identified.  Among the tested compds. 2-{3-furan-2-ylmethyl-2-[(2-methyl-3-phenylallylidene)hydrazono]-thiazolidin-4-one-5-yl}-N-(3-trifluoromethylphenyl)-acetamide, N-(2-methoxyphenyl)-2-[5-(4-oxothiazolidin-2-ylideneamino)-[1,3,4]thiadiazol-2-ylsulfanyl]-acetamide, 3-[3-allyl-4-oxo-2-(thiazol-2-ylimino)thiazolidin-5-ylidene]-1,3-dihydroindol-2-one, and 5(Z)-(thiophen-2-ylmethylene)-4-(4-chlorophenylamino)thiazol-2(5H)-one possessed high antifibrotic activity levels, had a similar effect as Pirfenidone, and did not scavenge superoxide radicals.  Their antifibrotic potential was confirmed using the xCelligence system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn9EH9so_baLVg90H21EOLACvtfcHk0ljAkT4IhtF5WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislyqsbo%253D&md5=ec9388a3e08c29a5ae23375b7aca275c</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DKaminskyy%26aufirst%3DD.%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DWojtyra%26aufirst%3DM.%26aulast%3DLelyukh%26aufirst%3DM.%26aulast%3DGzella%26aufirst%3DA.%26aulast%3DBast%26aufirst%3DA.%26aulast%3DLesyk%26aufirst%3DR.%26atitle%3DAntifibrotic%2520and%2520anticancer%2520action%2520of%25205-ene%2520amino%252Fiminothiazolidinones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D112%26spage%3D180%26epage%3D195%26doi%3D10.1016%2Fj.ejmech.2016.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parrill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span> </span><span class="NLM_article-title">Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1625</span><span class="refDoi"> DOI: 10.1517/13543776.2010.533658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F13543776.2010.533658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21047298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1619-1625&author=A.+L.+Parrillauthor=D.+L.+Baker&title=Autotaxin+inhibitors%3A+a+perspective+on+initial+medicinal+chemistry+efforts&doi=10.1517%2F13543776.2010.533658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126aR"><div class="casContent"><span class="casTitleNuber">126a</span><div class="casTitle"><span class="NLM_cas:atitle">Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts</span></div><div class="casAuthors">Parrill, Abby L.; Baker, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1619-1625</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The lysophospholipase D enzyme, autotaxin (ATX), has been linked to numerous human diseases including cancer, neurophatic pain, obesity and Alzheimer's disease.  Although the ATX protein was initially purified and characterized in 1992, a link to bioactive lipid metab. was not made until 2002.  In the past decade, metal chelators, lysophospholipid product analogs, and more recently, small non-lipid inhibitors of the enzyme were successfully identified.  The majority of these inhibitors have been characterized using recombinant purified ATX in vitro, with very few examples studied in more complex systems.  Translation of ATX inhibitors from the hands of medicinal chemists to clin. use will require substantially expanded characterization of ATX inhibitors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWuFyKHNmQC7Vg90H21EOLACvtfcHk0ljxAoTNoECBhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7fN&md5=5aed6b92b1ccd459bfe0546e282c2d9d</span></div><a href="/servlet/linkout?suffix=cit126a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.533658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.533658%26sid%3Dliteratum%253Aachs%26aulast%3DParrill%26aufirst%3DA.%2BL.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26atitle%3DAutotaxin%2520inhibitors%253A%2520a%2520perspective%2520on%2520initial%2520medicinal%2520chemistry%2520efforts%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D1619%26epage%3D1625%26doi%3D10.1517%2F13543776.2010.533658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span> </span><span class="NLM_article-title">Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance</span> <span class="citation_source-journal">Prostaglandins Other Lipid Mediators</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1016/j.prostaglandins.2009.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.prostaglandins.2009.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20331961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslSiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2010&pages=130-138&author=M.+E.+Linauthor=D.+R.+Herrauthor=J.+Chun&title=Lysophosphatidic+acid+%28LPA%29+receptors%3A+signaling+properties+and+disease+relevance&doi=10.1016%2Fj.prostaglandins.2009.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126bR"><div class="casContent"><span class="casTitleNuber">126b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance</span></div><div class="casAuthors">Lin, Mu-En; Herr, Deron R.; Chun, Jerold</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins & Other Lipid Mediators</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">POLMFL</span>;
        ISSN:<span class="NLM_cas:issn">1098-8823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Lysophosphatidic acid (LPA), a water-sol. phospholipid, has gained significant attention in recent years since the discovery that it acts as a potent signaling mol. with wide-ranging effects on many different target tissues.  There are currently five identified G protein-coupled receptors for LPA and more are undergoing validation.  The complexity of the expression pattern and signaling properties of LPA receptors results in multiple influences on developmental, physiol., and pathol. processes.  This review provides a summary of LPA receptor signaling and current views on the potential involvement of this pathway in human diseases that include cardiovascular, cancer, neuropathic pain, neuropsychiatric disorders, reproductive disorders, and fibrosis.  The involvement of LPA signaling in these processes implicates multiple, potential drug targets including LPA receptor subtypes and LPA metabolizing enzymes.  Modulation of LPA signaling may thus provide therapeutic inroads for the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqIqNSV9ngb7Vg90H21EOLACvtfcHk0ljxAoTNoECBhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslSiu7k%253D&md5=097555859468db9673c1ccf9ea8c2a60</span></div><a href="/servlet/linkout?suffix=cit126b&amp;dbid=16384&amp;doi=10.1016%2Fj.prostaglandins.2009.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prostaglandins.2009.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DM.%2BE.%26aulast%3DHerr%26aufirst%3DD.%2BR.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DLysophosphatidic%2520acid%2520%2528LPA%2529%2520receptors%253A%2520signaling%2520properties%2520and%2520disease%2520relevance%26jtitle%3DProstaglandins%2520Other%2520Lipid%2520Mediators%26date%3D2010%26volume%3D91%26spage%3D130%26epage%3D138%26doi%3D10.1016%2Fj.prostaglandins.2009.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Tager, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCamera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campanella, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polosukhin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karimi-Shah, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1038/nm1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18066075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=45-54&author=A.+M.+Tagerauthor=P.+LaCameraauthor=B.+S.+Sheaauthor=G.+S.+Campanellaauthor=M.+Selmanauthor=Z.+Zhaoauthor=V.+Polosukhinauthor=J.+Wainauthor=B.+A.+Karimi-Shahauthor=N.+D.+Kimauthor=W.+K.+Hartauthor=A.+Pardoauthor=T.+S.+Blackwellauthor=Y.+Xuauthor=J.+Chunauthor=A.+D.+Luster&title=The+lysophosphatidic+acid+receptor+LPA1+links+pulmonary+fibrosis+to+lung+injury+by+mediating+fibroblast+recruitment+and+vascular+leak&doi=10.1038%2Fnm1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span></div><div class="casAuthors">Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Selman, Moises; Zhao, Zhenwen; Polosukhin, Vasiliy; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Pardo, Annie; Blackwell, Timothy S.; Xu, Yan; Chun, Jerold; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathol. responses have yet to be fully identified.  We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model.  The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury.  In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid.  LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pk5JY4qBbLVg90H21EOLACvtfcHk0lgB8Ngk5z3JTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D&md5=1a7e86264154df8960699d18a7ef2407</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fnm1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1685%26sid%3Dliteratum%253Aachs%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DLaCamera%26aufirst%3DP.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DCampanella%26aufirst%3DG.%2BS.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolosukhin%26aufirst%3DV.%26aulast%3DWain%26aufirst%3DJ.%26aulast%3DKarimi-Shah%26aufirst%3DB.%2BA.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DHart%26aufirst%3DW.%2BK.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DBlackwell%26aufirst%3DT.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520links%2520pulmonary%2520fibrosis%2520to%2520lung%2520injury%2520by%2520mediating%2520fibroblast%2520recruitment%2520and%2520vascular%2520leak%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnm1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ohta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damirin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malchinkhuu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishitoba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nochi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okajima, F.</span><span> </span><span class="NLM_article-title">Ki16425, a subtypeselective antagonist for EDG-family lysophosphatidic acid receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">994</span><span class="NLM_x">–</span> <span class="NLM_lpage">1005</span><span class="refDoi"> DOI: 10.1124/mol.64.4.994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1124%2Fmol.64.4.994" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=994-1005&author=H.+Ohtaauthor=K.+Satoauthor=N.+Murataauthor=A.+Damirinauthor=E.+Malchinkhuuauthor=J.+Konauthor=T.+Kimuraauthor=M.+Toboauthor=Y.+Yamazakiauthor=T.+Watanabeauthor=M.+Yagiauthor=M.+Satoauthor=R.+Suzukiauthor=H.+Murookaauthor=T.+Sakaiauthor=T.+Nishitobaauthor=D.+S.+Imauthor=H.+Nochiauthor=K.+Tamotoauthor=H.+Tomuraauthor=F.+Okajima&title=Ki16425%2C+a+subtypeselective+antagonist+for+EDG-family+lysophosphatidic+acid+receptors&doi=10.1124%2Fmol.64.4.994"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1124%2Fmol.64.4.994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.64.4.994%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DN.%26aulast%3DDamirin%26aufirst%3DA.%26aulast%3DMalchinkhuu%26aufirst%3DE.%26aulast%3DKon%26aufirst%3DJ.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DTobo%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DYagi%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DNishitoba%26aufirst%3DT.%26aulast%3DIm%26aufirst%3DD.%2BS.%26aulast%3DNochi%26aufirst%3DH.%26aulast%3DTamoto%26aufirst%3DK.%26aulast%3DTomura%26aufirst%3DH.%26aulast%3DOkajima%26aufirst%3DF.%26atitle%3DKi16425%252C%2520a%2520subtypeselective%2520antagonist%2520for%2520EDG-family%2520lysophosphatidic%2520acid%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D64%26spage%3D994%26epage%3D1005%26doi%3D10.1124%2Fmol.64.4.994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stebbins, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodanovich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span> </span><span class="NLM_article-title">A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1699</span><span class="NLM_x">–</span> <span class="NLM_lpage">1713</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00828.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1111%2Fj.1476-5381.2010.00828.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20649573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1699-1713&author=J.+S.+Swaneyauthor=C.+Chapmanauthor=L.+D.+Correaauthor=K.+J.+Stebbinsauthor=R.+A.+Bundeyauthor=P.+C.+Prodanovichauthor=P.+Faganauthor=C.+S.+Bacceiauthor=A.+M.+Santiniauthor=J.+H.+Hutchinsonauthor=T.+J.+Seidersauthor=T.+A.+Parrauthor=P.+Prasitauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=A+novel%2C+orally+active+LPA%281%29+receptor+antagonist+inhibits+lung+fibrosis+in+the+mouse+bleomycin+model&doi=10.1111%2Fj.1476-5381.2010.00828.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128bR"><div class="casContent"><span class="casTitleNuber">128b</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span></div><div class="casAuthors">Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Bundey, R. A.; Prodanovich, P. C.; Fagan, P.; Baccei, C. S.; Santini, A. M.; Hutchinson, J. H.; Seiders, T. J.; Parr, T. A.; Prasit, P.; Evans, J. F.; Lorrain, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699-1713</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to assess the potential of an antagonist selective for the lysophosphatidic acid receptor, LPA1, in treating lung fibrosis.  We evaluated the in vitro and in vivo pharmacol. properties of the high affinity, selective, oral LPA1-antagonist (4'-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (AM966).  The potency and selectivity of AM966 for LPA1 receptors was detd. in vitro by calcium flux and cell chemotaxis assays using recombinant and native cell cultures.  The in vivo efficacy of AM966 to reduce tissue injury, vascular leakage, inflammation and fibrosis was assessed at several time points in the mouse bleomycin model.  AM966 was a potent antagonist of LPA1 receptors, with selectivity for this receptor over the other LPA receptors.  In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC50 = 17 nM) from Chinese hamster ovary cells stably expressing human LPA1 receptors and inhibited LPA-induced chemotaxis (IC50 = 181 nM) of human IMR-90 lung fibroblasts expressing LPA1 receptors.  AM966 demonstrated a good pharmacokinetic profile following oral dosing in mice.  In the mouse, AM966 reduced lung injury, vascular leakage, inflammation and fibrosis at multiple time points following intratracheal bleomycin instillation.  AM966 also decreased lactate dehydrogenase activity and tissue inhibitor of metalloproteinase-1, transforming growth factor β1, hyaluronan and matrix metalloproteinase-7, in bronchoalveolar lavage fluid.  These findings demonstrate that AM966 is a potent, selective, orally bioavailable LPA1 receptor antagonist that may be beneficial in treating lung injury and fibrosis, as well as other diseases that are characterized by pathol. inflammation, edema and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0rImMbkAWbVg90H21EOLACvtfcHk0lgB8Ngk5z3JTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ&md5=73f26734408141d8b0350d7488b54a6c</span></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00828.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00828.x%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBundey%26aufirst%3DR.%2BA.%26aulast%3DProdanovich%26aufirst%3DP.%2BC.%26aulast%3DFagan%26aufirst%3DP.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DSeiders%26aufirst%3DT.%2BJ.%26aulast%3DParr%26aufirst%3DT.%2BA.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DA%2520novel%252C%2520orally%2520active%2520LPA%25281%2529%2520receptor%2520antagonist%2520inhibits%2520lung%2520fibrosis%2520in%2520the%2520mouse%2520bleomycin%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1699%26epage%3D1713%26doi%3D10.1111%2Fj.1476-5381.2010.00828.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit128c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stebbins, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadhead, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darlington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roppe, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1124/jpet.110.175901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1124%2Fjpet.110.175901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21159750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVKqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=693-700&author=J.+S.+Swaneyauthor=C.+Chapmanauthor=L.+D.+Correaauthor=K.+J.+Stebbinsauthor=A.+R.+Broadheadauthor=G.+Bainauthor=A.+M.+Santiniauthor=J.+Darlingtonauthor=C.+D.+Kingauthor=C.+S.+Bacceiauthor=C.+Leeauthor=T.+A.+Parrauthor=J.+R.+Roppeauthor=T.+J.+Seidersauthor=J.+Ziffauthor=P.+Prasitauthor=J.+H.+Hutchinsonauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=Pharmacokinetic+and+pharmacodynamic+characterization+of+an+oral+lysophosphatidic+acid+type+1+receptor-selective+antagonist&doi=10.1124%2Fjpet.110.175901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128cR"><div class="casContent"><span class="casTitleNuber">128c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist</span></div><div class="casAuthors">Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Broadhead, A. R.; Bain, G.; Santini, A. M.; Darlington, J.; King, C. D.; Baccei, C. S.; Lee, C.; Parr, T. A.; Roppe, J. R.; Seiders, T. J.; Ziff, J.; Prasit, P.; Hutchinson, J. H.; Evans, J. F.; Lorrain, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-700</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lysophosphatidic acid (LPA) is a bioactive phospholipid that signals through a family of at least six G protein-coupled receptors designated LPA1-6.  LPA type 1 receptor (LPA1) exhibits wide-spread tissue distribution and regulates a variety of physiol. and pathol. cellular functions.  Here, we evaluated the in vitro pharmacol., pharmacokinetic, and pharmacodynamic properties of the LPA1-selective antagonist AM095 (sodium, {4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetate) and assessed the effects of AM095 in rodent models of lung and kidney fibrosis and dermal wound healing.  In vitro, AM095 was a potent LPA1 receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 μM, resp., and exhibited no LPA1 agonism.  In functional assays, AM095 inhibited LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 (IC50 = 778 nM) and human A2058 melanoma cells (IC50 = 233 nM).  In vivo, we demonstrated that AM095: (1) had high oral bioavailability and a moderate half-life and was well tolerated at the doses tested in rats and dogs after oral and i.v. dosing, (2) dose-dependently reduced LPA-stimulated histamine release, (3) attenuated bleomycin-induced increases in collagen, protein, and inflammatory cell infiltration in bronchalveolar lavage fluid, and (4) decreased kidney fibrosis in a mouse unilateral ureteral obstruction model.  Despite its antifibrotic activity, AM095 had no effect on normal wound healing after incisional and excisional wounding in rats.  These data demonstrate that AM095 is an LPA1 receptor antagonist with good oral exposure and antifibrotic activity in rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYo8MBYXos7Vg90H21EOLACvtfcHk0lhvwI96JP1IYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVKqtr4%253D&md5=72388f534912ad0e440a6fff949d7710</span></div><a href="/servlet/linkout?suffix=cit128c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.175901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.175901%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBroadhead%26aufirst%3DA.%2BR.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DParr%26aufirst%3DT.%2BA.%26aulast%3DRoppe%26aufirst%3DJ.%2BR.%26aulast%3DSeiders%26aufirst%3DT.%2BJ.%26aulast%3DZiff%26aufirst%3DJ.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520characterization%2520of%2520an%2520oral%2520lysophosphatidic%2520acid%2520type%25201%2520receptor-selective%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D693%26epage%3D700%26doi%3D10.1124%2Fjpet.110.175901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit128d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Castelino, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span> </span><span class="NLM_article-title">Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1002/art.30262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fart.30262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21305523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=1405-1415&author=F.+V.+Castelinoauthor=J.+Seidersauthor=G.+Bainauthor=S.+F.+Brooksauthor=C.+D.+Kingauthor=J.+S.+Swaneyauthor=D.+S.+Lorrainauthor=J.+Chunauthor=A.+D.+Lusterauthor=A.+M.+Tager&title=Amelioration+of+dermal+fibrosis+by+genetic+deletion+or+pharmacologic+antagonism+of+lysophosphatidic+acid+receptor+1+in+a+mouse+model+of+scleroderma&doi=10.1002%2Fart.30262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128dR"><div class="casContent"><span class="casTitleNuber">128d</span><div class="casTitle"><span class="NLM_cas:atitle">Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma</span></div><div class="casAuthors">Castelino, Flavia V.; Seiders, Jon; Bain, Gretchen; Brooks, Sarah F.; King, Christopher D.; Swaney, James S.; Lorrain, Daniel S.; Chun, Jerold; Luster, Andrew D.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1405-1415</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Scleroderma (systemic sclerosis [SSc]), is characterized by progressive multiorgan fibrosis.  We recently implicated lysophosphatidic acid (LPA) in the pathogenesis of pulmonary fibrosis.  The purpose of the present study was to investigate the roles of LPA and two of its receptors, LPA1 and LPA2, in dermal fibrosis in a mouse model of SSc.  Methods : Wild type (WT), and LPA1-knockout (KO) and LPA2-KO mice were injected s.c. with bleomycin or phosphate buffered saline (PBS) once daily for 28 days.  Dermal thickness, collagen content, and nos. of cells pos. for α-smooth muscle actin (α-SMA) or phospho-Smad2 were detd. in bleomycin-injected and PBS-injected skin.  In sep. expts., a novel selective LPA1 antagonist AM095 or vehicle alone was administered by oral gavage to C57BL/6 mice that were challenged with 28 daily injections of bleomycin or PBS.  AM095 or vehicle treatments were initiated concurrently with, or 7 or 14 days after, the initiation of bleomycin and PBS injections and continued to the end of the expts.  Dermal thickness and collagen content were detd. in injected skin.  Results : The LPA1-KO mice were markedly resistant to bleomycin-induced increases in dermal thickness and collagen content, whereas the LPA2-KO mice were as susceptible as the WT mice.  Bleomycin-induced increases in dermal α-SMA+ and phospho-Smad2+ cells were abrogated in LPA1-KO mice.  Pharmacol. antagonism of LPA1 with AM095 significantly attenuated bleomycin-induced dermal fibrosis when administered according to either a preventive regimen or two therapeutic regimens.  Conclusion : These results suggest that LPA/LPA1 pathway inhibition has the potential to be an effective new therapeutic strategy for SSc, and that LPA1 is an attractive pharmacol. target in dermal fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR6SISG5m67LVg90H21EOLACvtfcHk0lhvwI96JP1IYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGhtrY%253D&md5=a13b1f9f7826b3075728ed13e533102c</span></div><a href="/servlet/linkout?suffix=cit128d&amp;dbid=16384&amp;doi=10.1002%2Fart.30262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.30262%26sid%3Dliteratum%253Aachs%26aulast%3DCastelino%26aufirst%3DF.%2BV.%26aulast%3DSeiders%26aufirst%3DJ.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DBrooks%26aufirst%3DS.%2BF.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DAmelioration%2520of%2520dermal%2520fibrosis%2520by%2520genetic%2520deletion%2520or%2520pharmacologic%2520antagonism%2520of%2520lysophosphatidic%2520acid%2520receptor%25201%2520in%2520a%2520mouse%2520model%2520of%2520scleroderma%26jtitle%3DArthritis%2520Rheum.%26date%3D2011%26volume%3D63%26spage%3D1405%26epage%3D1415%26doi%3D10.1002%2Fart.30262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidduri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span> </span><span class="NLM_article-title">Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7920</span><span class="NLM_x">–</span> <span class="NLM_lpage">7939</span><span class="refDoi"> DOI: 10.1021/jm301022v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301022v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7920-7939&author=Y.+Qianauthor=M.+Hamiltonauthor=A.+Sidduriauthor=S.+Gabrielauthor=Y.+Renauthor=R.+Pengauthor=R.+Kondruauthor=A.+Narayananauthor=T.+Truittauthor=R.+Hamidauthor=Y.+Chenauthor=L.+Zhangauthor=A.+J.+Fretlandauthor=R.+A.+Sanchezauthor=K.+C.+Changauthor=M.+Lucasauthor=R.+C.+Schoenfeldauthor=D.+Laineauthor=M.+E.+Fuentesauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Discovery+of+highly+selective+and+orally+active+lysophosphatidic+acid+receptor-1+antagonists+with+potent+activity+on+human+lung+fibroblasts&doi=10.1021%2Fjm301022v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm301022v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301022v%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DHamid%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFretland%26aufirst%3DA.%2BJ.%26aulast%3DSanchez%26aufirst%3DR.%2BA.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DLaine%26aufirst%3DD.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DDiscovery%2520of%2520highly%2520selective%2520and%2520orally%2520active%2520lysophosphatidic%2520acid%2520receptor-1%2520antagonists%2520with%2520potent%2520activity%2520on%2520human%2520lung%2520fibroblasts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7920%26epage%3D7939%26doi%3D10.1021%2Fjm301022v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rancoule, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradere, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bascands, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schanstra, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier-Blache, J. S.</span><span> </span><span class="NLM_article-title">Lysophosphatidic acid-1-receptor targeting agents for fibrosis</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1517/13543784.2011.566864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F13543784.2011.566864" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=657-667&author=C.+Rancouleauthor=J.+P.+Pradereauthor=J.+Gonzalezauthor=J.+Kleinauthor=P.+Valetauthor=J.+L.+Bascandsauthor=J.+P.+Schanstraauthor=J.+S.+Saulnier-Blache&title=Lysophosphatidic+acid-1-receptor+targeting+agents+for+fibrosis&doi=10.1517%2F13543784.2011.566864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.566864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.566864%26sid%3Dliteratum%253Aachs%26aulast%3DRancoule%26aufirst%3DC.%26aulast%3DPradere%26aufirst%3DJ.%2BP.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DKlein%26aufirst%3DJ.%26aulast%3DValet%26aufirst%3DP.%26aulast%3DBascands%26aufirst%3DJ.%2BL.%26aulast%3DSchanstra%26aufirst%3DJ.%2BP.%26aulast%3DSaulnier-Blache%26aufirst%3DJ.%2BS.%26atitle%3DLysophosphatidic%2520acid-1-receptor%2520targeting%2520agents%2520for%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D657%26epage%3D667%26doi%3D10.1517%2F13543784.2011.566864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit130b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Budd, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span> </span><span class="NLM_article-title">Development of lysophosphatidic acid pathway modulators as therapies for fibrosis</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1935</span><span class="NLM_x">–</span> <span class="NLM_lpage">1952</span><span class="refDoi"> DOI: 10.4155/fmc.13.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4155%2Ffmc.13.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24175745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislynsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1935-1952&author=D.+C.+Buddauthor=Y.+Qian&title=Development+of+lysophosphatidic+acid+pathway+modulators+as+therapies+for+fibrosis&doi=10.4155%2Ffmc.13.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130bR"><div class="casContent"><span class="casTitleNuber">130b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of lysophosphatidic acid pathway modulators as therapies for fibrosis</span></div><div class="casAuthors">Budd, David C.; Qian, Yimin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1935-1952</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Lysophosphatidic acid (LPA) is a class of bioactive phospholipid that displays a wide range of cellular effects via LPA receptors, of which six have been identified (LPAR1-6).  In serum and plasma, LPA prodn. occurs mainly by the hydrolysis of lysophosphatidylcholine by the phospholipase D activity of autotaxin (ATX).  The involvement of the LPA pathway in driving chronic wound-healing conditions, such as idiopathic pulmonary fibrosis, has suggested targets in this pathway could provide potential therapeutic approaches.  Mice with LPAR1 knockout or tissue-specific ATX deletion have demonstrated reduced lung fibrosis following bleomycin challenge.  Therefore, strategies aimed at antagonizing LPA receptors or inhibiting ATX have gained considerable attention.  This Review will summarize the current status of identifying small-mol. modulators of the LPA pathway.  The therapeutic utility of LPA modulators for the treatment of fibrotic diseases will soon be revealed as clin. trials are already in progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Jpew1zYC8rVg90H21EOLACvtfcHk0limgukdpKKySg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislynsg%253D%253D&md5=ee2db60359f2a0217de52a3bf115dd22</span></div><a href="/servlet/linkout?suffix=cit130b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.154%26sid%3Dliteratum%253Aachs%26aulast%3DBudd%26aufirst%3DD.%2BC.%26aulast%3DQian%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520lysophosphatidic%2520acid%2520pathway%2520modulators%2520as%2520therapies%2520for%2520fibrosis%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D1935%26epage%3D1952%26doi%3D10.4155%2Ffmc.13.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Sidduri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span> </span><span class="NLM_article-title">Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4450</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2014.08.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4450-4454&author=A.+Sidduriauthor=D.+C.+Buddauthor=M.+E.+Fuentesauthor=T.+Lambrosauthor=Y.+Renauthor=V.+Roongtaauthor=R.+C.+Schoenfeldauthor=P.+Gillespieauthor=C.+S.+Stevensonauthor=T.+Truittauthor=Y.+Qian&title=Discovery+of+novel+non-carboxylic+acid+5-amino-4-cyanopyrazole+derivatives+as+potent+and+highly+selective+LPA1R+antagonists&doi=10.1016%2Fj.bmcl.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DLambros%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DRoongta%26aufirst%3DV.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DGillespie%26aufirst%3DP.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DQian%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520non-carboxylic%2520acid%25205-amino-4-cyanopyrazole%2520derivatives%2520as%2520potent%2520and%2520highly%2520selective%2520LPA1R%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4450%26epage%3D4454%26doi%3D10.1016%2Fj.bmcl.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Garneau-Tsodikova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2632</span><span class="NLM_x">–</span> <span class="NLM_lpage">2640</span><span class="refDoi"> DOI: 10.2174/092986708785908969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F092986708785908969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18855683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2632-2640&author=S.+Garneau-Tsodikovaauthor=V.+J.+Thannickal&title=Protein+kinase+inhibitors+in+the+treatment+of+pulmonary+fibrosis&doi=10.2174%2F092986708785908969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span></div><div class="casAuthors">Garneau-Tsodikova, Sylvie; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2632-2640</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis of the lung and other organ systems is an increasing cause of morbidity and mortality worldwide.  Effective anti-fibrotic agents for such disorders are currently lacking.  Injury to epithelium-lined tissues in mammals is typically assocd. with a mesenchymal response, including the activation of myofibroblasts.  Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease that results from effacement of the normal alveolar architecture of the lung.  Loss of lung capacity for gas-exchange and increased work of breathing eventually leads to respiratory failure and death.  In cutaneous wound models, apoptosis of myofibroblasts are essential to scar-less wound healing.  Recent studies indicate that acquisition of an apoptosis-resistant myofibroblast phenotype in the injured lung is assocd. with non-resolving and persistent fibrosis.  The acquired resistance to apoptosis in myofibroblasts is mediated, at least in part, by the sustained activation of two crit. pro-survival protein kinases, focal adhesion kinase (FAK) and protein kinase B (PKB/AKT).  Therapeutic interventions that modulate the activity of these protein kinases with resultant alterations in the phenotype of myofibroblasts may prove to be effective anti-fibrotic therapeutic strategies.  We discuss the potential roles for protein kinase inhibitors as novel drugs for fibrotic disorders.  Progress in pre-clin. and clin. development of small mol. inhibitors targeting pro-survival protein kinases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriAW2A7_uv37Vg90H21EOLACvtfcHk0ljDkPjNNUb-Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN&md5=030118de5dbd67f6ba3cedb95b872d52</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2174%2F092986708785908969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785908969%26sid%3Dliteratum%253Aachs%26aulast%3DGarneau-Tsodikova%26aufirst%3DS.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2632%26epage%3D2640%26doi%3D10.2174%2F092986708785908969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Daniels, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkes, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottom, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limper, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leof, E. B.</span><span> </span><span class="NLM_article-title">Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1308</span><span class="NLM_x">–</span> <span class="NLM_lpage">1316</span><span class="refDoi"> DOI: 10.1172/JCI200419603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1172%2FJCI200419603" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=1308-1316&author=C.+E.+Danielsauthor=M.+C.+Wilkesauthor=M.+Edensauthor=T.+J.+Kottomauthor=S.+J.+Murphyauthor=A.+H.+Limperauthor=E.+B.+Leof&title=Imatinib+mesylate+inhibits+the+profibrogenic+activity+of+TGF-beta+and+prevents+bleomycin-mediated+lung+fibrosis&doi=10.1172%2FJCI200419603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133a&amp;dbid=16384&amp;doi=10.1172%2FJCI200419603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200419603%26sid%3Dliteratum%253Aachs%26aulast%3DDaniels%26aufirst%3DC.%2BE.%26aulast%3DWilkes%26aufirst%3DM.%2BC.%26aulast%3DEdens%26aufirst%3DM.%26aulast%3DKottom%26aufirst%3DT.%2BJ.%26aulast%3DMurphy%26aufirst%3DS.%2BJ.%26aulast%3DLimper%26aufirst%3DA.%2BH.%26aulast%3DLeof%26aufirst%3DE.%2BB.%26atitle%3DImatinib%2520mesylate%2520inhibits%2520the%2520profibrogenic%2520activity%2520of%2520TGF-beta%2520and%2520prevents%2520bleomycin-mediated%2520lung%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D1308%26epage%3D1316%26doi%3D10.1172%2FJCI200419603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit133b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aono, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, S.</span><span> </span><span class="NLM_article-title">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">1279</span><span class="NLM_x">–</span> <span class="NLM_lpage">1285</span><span class="refDoi"> DOI: 10.1164/rccm.200404-531OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200404-531OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15735062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2005&pages=1279-1285&author=Y.+Aonoauthor=Y.+Nishiokaauthor=M.+Inayamaauthor=M.+Ugaiauthor=J.+Kishiauthor=H.+Ueharaauthor=K.+Izumiauthor=S.+Sone&title=Imatinib+as+a+novel+antifibrotic+agent+in+bleomycin-induced+pulmonary+fibrosis+in+mice&doi=10.1164%2Frccm.200404-531OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133bR"><div class="casContent"><span class="casTitleNuber">133b</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Aono Yoshinori; Nishioka Yasuhiko; Inayama Mami; Ugai Momoyo; Kishi Jun; Uehara Hisanori; Izumi Keisuke; Sone Saburo</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1279-85</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Imatinib mesylate is a potent and specific tyrosine kinase inhibitor against c-ABL, BCR-ABL, and c-KIT, and has been demonstrated to be highly active in chronic myeloid leukemia and gastrointestinal stromal tumors.  We examined the antifibrotic effects of imatinib using a bleomycin-induced lung fibrosis model in mice because imatinib also inhibits tyrosine kinase of platelet-derived growth factor receptors (PDGFRs).  Imatinib inhibited the growth of primary murine lung fibroblasts and the autophosphorylation of PDGFR-beta induced by PDGF.  Administration of imatinib significantly prevented bleomycin-induced pulmonary fibrosis in mice, partly by reducing the number of mesenchymal cells incorporating bromodeoxyuridine.  Analysis of bronchoalveolar lavage cells demonstrated that imatinib did not suppress early inflammation on Days 7 and 14 caused by bleomycin.  These results suggest that imatinib has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that imatinib might be useful for the treatment of pulmonary fibrosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6Hl7Y7MSGmVZoq0fPSOTvfW6udTcc2eYwTQCfSJOlzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D&md5=998232993f5ca1d46769358d0ac73cb1</span></div><a href="/servlet/linkout?suffix=cit133b&amp;dbid=16384&amp;doi=10.1164%2Frccm.200404-531OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200404-531OC%26sid%3Dliteratum%253Aachs%26aulast%3DAono%26aufirst%3DY.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DInayama%26aufirst%3DM.%26aulast%3DUgai%26aufirst%3DM.%26aulast%3DKishi%26aufirst%3DJ.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DIzumi%26aufirst%3DK.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DImatinib%2520as%2520a%2520novel%2520antifibrotic%2520agent%2520in%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D171%26spage%3D1279%26epage%3D1285%26doi%3D10.1164%2Frccm.200404-531OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit133c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chaudhary, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. E.</span><span> </span><span class="NLM_article-title">Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">776</span><span class="refDoi"> DOI: 10.1164/rccm.200505-717OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200505-717OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16415276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Cgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2006&pages=769-776&author=N.+I.+Chaudharyauthor=A.+Schnappauthor=J.+E.+Park&title=Pharmacologic+differentiation+of+inflammation+and+fibrosis+in+the+rat+bleomycin+model&doi=10.1164%2Frccm.200505-717OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133cR"><div class="casContent"><span class="casTitleNuber">133c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model</span></div><div class="casAuthors">Chaudhary, Nveed I.; Schnapp, Andreas; Park, John E.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-776</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The model most often used to study the pathogenesis of pulmonary fibroses is the bleomycin (BLM)-induced lung fibrosis model.  Several treatments have been efficacious in this model, but not in the clinic.  To describe the time course of inflammation and fibrosis in the BLM model and to study the effect of timing of antiinflammatory and antifibrotic treatments on efficacy.  Rats were given single intratracheal injections of BLM on Day 0.  At specified time points, 10 rats were killed and their lungs studied for proinflammatory cytokines and for profibrotic growth factor mRNA.  After a single intratracheal injection of BLM on Day 0, rats were treated from Day 1 or 10 daily with oral prednisolone (10 mg/kg) or oral imatinib mesylate (50 mg/kg) for 21 d.  After BLM administration, the expression of inflammatory cytokines was elevated and returned to background levels at later time points.  Profibrotic gene expression peaked between Days 9 and 14 and remained elevated till the end of the expt., suggesting a "switch" between inflammation and fibrosis in this interval.  Antiinflammatory treatment (oral prednisolone) was beneficial when commenced at Day 1, but had no effect if administered from Day 10 onward.  However, imatinib mesylate was effective independently of the dosing regime.  The response of the BLM model to antifibrotic or antiinflammatory interventions is critically dependent on timing after the initial injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCR_9p19ggt7Vg90H21EOLACvtfcHk0li_1H62HVrBjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Cgsbc%253D&md5=02b62c6b17e03e86b6515d966da516f6</span></div><a href="/servlet/linkout?suffix=cit133c&amp;dbid=16384&amp;doi=10.1164%2Frccm.200505-717OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200505-717OC%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DN.%2BI.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26atitle%3DPharmacologic%2520differentiation%2520of%2520inflammation%2520and%2520fibrosis%2520in%2520the%2520rat%2520bleomycin%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D173%26spage%3D769%26epage%3D776%26doi%3D10.1164%2Frccm.200505-717OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Easton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">mTOR and cancer therapy</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6436</span><span class="NLM_x">–</span> <span class="NLM_lpage">6446</span><span class="refDoi"> DOI: 10.1038/sj.onc.1209886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fsj.onc.1209886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17041628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6436-6446&author=J.+B.+Eastonauthor=P.+J.+Houghton&title=mTOR+and+cancer+therapy&doi=10.1038%2Fsj.onc.1209886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134aR"><div class="casContent"><span class="casTitleNuber">134a</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR and cancer therapy</span></div><div class="casAuthors">Easton, J. B.; Houghton, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">6436-6446</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of the targets of the mTOR kinase, are overexpressed or mutated in cancer.  Rapamycin, the naturally occurring inhibitor of mTOR, along with a no. of recently developed rapamycin analogs (rapalogs) consisting of synthetically derived compds. contg. minor chem. modifications to the parent structure, inhibit the growth of cell lines derived from multiple tumor types in vitro, and tumor models in vivo.  Results from clin. trials indicate that the rapalogs may be useful for the treatment of subsets of certain types of cancer.  The sporadic responses from the initial clin. trials, based on the hypothesis of general translation inhibition of cancer cells are now beginning to be understood owing to a more complete understanding of the dynamics of mTOR regulation and the function of mTOR in the tumor microenvironment.  This review will summarize the preclin. and clin. data and recent discoveries of the function of mTOR in cancer and growth regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDA4eeQiQCbVg90H21EOLACvtfcHk0lgs-hDeFxacJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrN&md5=7a676e4128d249409e320924b26356eb</span></div><a href="/servlet/linkout?suffix=cit134a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209886%26sid%3Dliteratum%253Aachs%26aulast%3DEaston%26aufirst%3DJ.%2BB.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DmTOR%2520and%2520cancer%2520therapy%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6436%26epage%3D6446%26doi%3D10.1038%2Fsj.onc.1209886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mota, A.</span><span> </span><span class="NLM_article-title">Sirolimus: a new option in transplantation</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span><span class="refDoi"> DOI: 10.1517/14656566.6.3.479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F14656566.6.3.479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15794738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVyrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=479-487&author=A.+Mota&title=Sirolimus%3A+a+new+option+in+transplantation&doi=10.1517%2F14656566.6.3.479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134bR"><div class="casContent"><span class="casTitleNuber">134b</span><div class="casTitle"><span class="NLM_cas:atitle">Sirolimus: A new option in transplantation</span></div><div class="casAuthors">Mota, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">This review of immunosuppression in renal transplantation has allowed us to highlight the deleterious effect of calcineurin inhibitor nephrotoxicity and to emphasize the importance of sirolimus.  Now, a whole new set of possibilities has opened up in immunosuppression: sirolimus-based immunosuppression without calcineurin inhibitors; sirolimus in combination with calcineurin inhibitors in reduced doses; early calcineurin inhibitor withdrawal from a regimen that combines sirolimus, calcineurin inhibitors and steroids; and calcineurin inhibitor conversion to sirolimus when the first signs of graft nephrotoxicity appear.  These new strategies in immunosuppression in renal transplantation are assocd. with good results in graft and patient survival in year 1, and with better renal function.  Therefore, we can hope for better long-term results in transplantation, with a significant increase in the graft half-life and in the patient survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKyY1zznLvrVg90H21EOLACvtfcHk0lgs-hDeFxacJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVyrtrg%253D&md5=e57687bee134605a1852492bd2d97339</span></div><a href="/servlet/linkout?suffix=cit134b&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.3.479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.3.479%26sid%3Dliteratum%253Aachs%26aulast%3DMota%26aufirst%3DA.%26atitle%3DSirolimus%253A%2520a%2520new%2520option%2520in%2520transplantation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D479%26epage%3D487%26doi%3D10.1517%2F14656566.6.3.479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Simler, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsack, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasleton, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span> </span><span class="NLM_article-title">The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1183/09031936.02.00281602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.02.00281602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12108867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVWktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1124-1127&author=N.+R.+Simlerauthor=D.+C.+Howellauthor=R.+P.+Marshallauthor=N.+R.+Goldsackauthor=P.+S.+Hasletonauthor=G.+J.+Laurentauthor=R.+C.+Chambersauthor=J.+J.+Egan&title=The+rapamycin+analogue+SDZ+RAD+attenuates+bleomycin-induced+pulmonary+fibrosis+in+rats&doi=10.1183%2F09031936.02.00281602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134cR"><div class="casContent"><span class="casTitleNuber">134c</span><div class="casTitle"><span class="NLM_cas:atitle">The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats</span></div><div class="casAuthors">Simler, N. R.; Howell, D. C. J.; Marshall, R. P.; Goldsack, N. R.; Hasleton, P. S.; Laurent, G. J.; Chambers, R. C.; Egan, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1124-1127</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix proteins within the pulmonary interstitium.  The new macrolide immunosuppressant SDZ RAD, a rapamycin analog, inhibits growth-factor dependent proliferation of mesenchymal cells and might therefore be of therapeutic interest for the treatment of fibrotic lung disease.  In this study the effect of SDZ RAD on lung-collagen accumulation in the bleomycin model of pulmonary fibrosis in rats was investigated.  SDZ RAD (2.5 mg·kg-1.day-1) or drug vehicle were administered orally by daily gavage.  Successful dosing was confirmed by measuring splenic wt.  Total lung-collagen content was measured by high-performance liq. chromatog. quantitation of hydroxyproline.  In animals given bleomycin and drug vehicle, total lung collagen was increased by 182±11% (mean±SEM) compared with saline controls at 14 days (p<0.001).  The increase in lung-collagen accumulation was reduced by 75±12% (p<0.01) in animals given SDZ RAD and was accompanied by a concomitant 56±6%, (p<0.001) redn. in lung wt.  SDZ RAD is currently in clin. trials for the prevention of solid organ graft rejection, another condition characterized by excessive extracellular matrix prodn.  The authors propose that SDZ RAD warrants evaluation as a novel therapeutic agent for fibrotic lung disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp116TYl5H2vrVg90H21EOLACvtfcHk0ljZaj6cJauPvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVWktbc%253D&md5=847a4c29fbbeac6d0a8d02a0ef684543</span></div><a href="/servlet/linkout?suffix=cit134c&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00281602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00281602%26sid%3Dliteratum%253Aachs%26aulast%3DSimler%26aufirst%3DN.%2BR.%26aulast%3DHowell%26aufirst%3DD.%2BC.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DGoldsack%26aufirst%3DN.%2BR.%26aulast%3DHasleton%26aufirst%3DP.%2BS.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520rapamycin%2520analogue%2520SDZ%2520RAD%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520rats%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D19%26spage%3D1124%26epage%3D1127%26doi%3D10.1183%2F09031936.02.00281602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Laping, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huet, S.</span><span> </span><span class="NLM_article-title">TGF-β receptor kinase inhibitors for treatment of fibrosis</span> <span class="citation_source-journal">Smad Signal Transduction</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span><span class="refDoi"> DOI: 10.1007/1-4020-4709-6_22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2F1-4020-4709-6_22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=443-459&author=N.+J.+Lapingauthor=S.+Huet&title=TGF-%CE%B2+receptor+kinase+inhibitors+for+treatment+of+fibrosis&doi=10.1007%2F1-4020-4709-6_22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2F1-4020-4709-6_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F1-4020-4709-6_22%26sid%3Dliteratum%253Aachs%26aulast%3DLaping%26aufirst%3DN.%2BJ.%26aulast%3DHuet%26aufirst%3DS.%26atitle%3DTGF-%25CE%25B2%2520receptor%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520fibrosis%26jtitle%3DSmad%2520Signal%2520Transduction%26date%3D2006%26volume%3D5%26spage%3D443%26epage%3D459%26doi%3D10.1007%2F1-4020-4709-6_22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hanke, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weringer, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connelly, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span><span class="refDoi"> DOI: 10.1074/jbc.271.2.695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1074%2Fjbc.271.2.695" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=695-701&author=J.+H.+Hankeauthor=J.+P.+Gardnerauthor=R.+L.+Dowauthor=P.+S.+Changelianauthor=W.+H.+Brissetteauthor=E.+J.+Weringerauthor=B.+A.+Pollokauthor=P.+A.+Connelly&title=Discovery+of+a+novel%2C+potent%2C+and+Src+family-selective+tyrosine+kinase+inhibitor.+Study+of+Lck-+and+FynT-dependent+T+cell+activation&doi=10.1074%2Fjbc.271.2.695"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.2.695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.2.695%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DJ.%2BH.%26aulast%3DGardner%26aufirst%3DJ.%2BP.%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DWeringer%26aufirst%3DE.%2BJ.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26aulast%3DConnelly%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%252C%2520potent%252C%2520and%2520Src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor.%2520Study%2520of%2520Lck-%2520and%2520FynT-dependent%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D695%26epage%3D701%26doi%3D10.1074%2Fjbc.271.2.695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit136b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vittal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toews, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standiford, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span> </span><span class="NLM_article-title">Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">375</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)62260-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0002-9440%2810%2962260-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15681821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2005&pages=367-375&author=R.+Vittalauthor=J.+C.+Horowitzauthor=B.+B.+Mooreauthor=H.+Zhangauthor=F.+J.+Martinezauthor=G.+B.+Toewsauthor=T.+J.+Standifordauthor=V.+J.+Thannickal&title=Modulation+of+prosurvival+signaling+in+fibroblasts+by+a+protein+kinase+inhibitor+protects+against+fibrotic+tissue+injury&doi=10.1016%2FS0002-9440%2810%2962260-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136bR"><div class="casContent"><span class="casTitleNuber">136b</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury</span></div><div class="casAuthors">Vittal, Ragini; Horowitz, Jeffrey C.; Moore, Bethany B.; Zhang, Hengmin; Martinez, Fernando J.; Toews, Galen B.; Standiford, Theodore J.; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">367-375</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Progressive fibrotic diseases involving diverse organ systems are assocd. with the persistence of fibroblasts/myofibroblasts in injured tissues.  Activation of focal adhesion kinase (FAK) and protein kinase B (PKB/Akt) by transforming growth factor-β1 mediate stable induction of myofibroblast differentiation and survival.  In this report, we demonstrate that transforming growth factor-β1-induced activation of both PKB/Akt and FAK are dose dependently inhibited by the protein kinase inhibitor, AG1879, in cultured human lung fibroblasts.  In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily i.p. injections of AG1879 (bleomycin-AG1879) vs. a chem. inactive analog (bleomycin-control).  PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice.  Accumulation of α-smooth muscle actin-expressing myofibroblasts is markedly reduced in lungs of bleomycin-AG1879 mice.  The nos. of recruited inflammatory cells were not significantly different between these groups.  Bleomycin-AG1879 mice are protected from lung fibrosis as evidenced by histopathol., trichrome staining, and biochem. anal. for collagen.  Thus, targeting of prosurvival signaling pathways in fibroblasts/myofibroblasts may provide a novel and effective strategy for anti-fibrotic therapy of treatment-unresponsive fibrotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLhlwNwRkt7Vg90H21EOLACvtfcHk0liCfCLIIHUkVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGntbc%253D&md5=443cc2237e453023d72f83d58785fa20</span></div><a href="/servlet/linkout?suffix=cit136b&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2962260-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252962260-2%26sid%3Dliteratum%253Aachs%26aulast%3DVittal%26aufirst%3DR.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DMoore%26aufirst%3DB.%2BB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DToews%26aufirst%3DG.%2BB.%26aulast%3DStandiford%26aufirst%3DT.%2BJ.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DModulation%2520of%2520prosurvival%2520signaling%2520in%2520fibroblasts%2520by%2520a%2520protein%2520kinase%2520inhibitor%2520protects%2520against%2520fibrotic%2520tissue%2520injury%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D166%26spage%3D367%26epage%3D375%26doi%3D10.1016%2FS0002-9440%2810%2962260-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Son, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheen, Y. Y.</span><span> </span><span class="NLM_article-title">EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1704</span><span class="NLM_x">–</span> <span class="NLM_lpage">1716</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1158%2F1535-7163.MCT-13-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24817629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1704-1716&author=J.+Y.+Sonauthor=S.+Y.+Parkauthor=S.+J.+Kimauthor=S.+J.+Leeauthor=S.+A.+Parkauthor=M.+J.+Kimauthor=S.+W.+Kimauthor=D.+K.+Kimauthor=J.+S.+Namauthor=Y.+Y.+Sheen&title=EW-7197%2C+a+novel+ALK-5+kinase+inhibitor%2C+potently+inhibits+breast+to+lung+metastasis&doi=10.1158%2F1535-7163.MCT-13-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis</span></div><div class="casAuthors">Son, Ji Yeon; Park, So-Yeon; Kim, Sol-Ji; Lee, Seon Joo; Park, Sang-A.; Kim, Min-Jin; Kim, Seung Won; Kim, Dae-Kee; Nam, Jeong-Seok; Sheen, Yhun Yhong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1704-1716</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Advanced tumors produce an excessive amt. of transforming growth factor β (TGFβ), which promotes tumor progression at late stages of malignancy.  The purpose of this study was to develop anti-TGFβ therapeutics for cancer.  We synthesized a novel small-mol. TGFβ receptor I kinase (activin receptor-like kinase 5) inhibitor termed N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]methyl]-2-fluoroaniline (EW-7197), and we investigated its potential antimetastatic efficacy in mouse mammary tumor virus (MMTV)/c-Neu mice and 4T1 orthotopic-grafted mice.  EW-7197 inhibited Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice and 4T1 orthotopic-grafted mice.  EW-7197 also inhibited the epithelial-to-mesenchymal transition (EMT) in both TGFβ-treated breast cancer cells and 4T1 orthotopic-grafted mice.  Furthermore, EW-7197 enhanced cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice.  In summary, EW-7197 showed potent in vivo antimetastatic activity, indicating its potential for use as an anticancer therapy.  Mol Cancer Ther; 13(7); 1704-16. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAUbXlCEkKMrVg90H21EOLACvtfcHk0liCfCLIIHUkVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfP&md5=4507cbbaf0f2c41bb0ae751a0368fce9</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0903%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DJ.%2BY.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DNam%26aufirst%3DJ.%2BS.%26aulast%3DSheen%26aufirst%3DY.%2BY.%26atitle%3DEW-7197%252C%2520a%2520novel%2520ALK-5%2520kinase%2520inhibitor%252C%2520potently%2520inhibits%2520breast%2520to%2520lung%2520metastasis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1704%26epage%3D1716%26doi%3D10.1158%2F1535-7163.MCT-13-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Siddiqui, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P. A.</span><span> </span><span class="NLM_article-title">Small molecule JNK (c-Jun N-terminal kinase) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3005</span><span class="NLM_x">–</span> <span class="NLM_lpage">3012</span><span class="refDoi"> DOI: 10.1021/jm9003279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9003279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3005-3012&author=M.+A.+Siddiquiauthor=P.+A.+Reddy&title=Small+molecule+JNK+%28c-Jun+N-terminal+kinase%29+inhibitors&doi=10.1021%2Fjm9003279"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm9003279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9003279%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26aulast%3DReddy%26aufirst%3DP.%2BA.%26atitle%3DSmall%2520molecule%2520JNK%2520%2528c-Jun%2520N-terminal%2520kinase%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3005%26epage%3D3012%26doi%3D10.1021%2Fjm9003279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Plantevin Krenitsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadolny, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clareen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgraf, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Sidocky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapienza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahmanyar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delker, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giegel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celeridad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowitzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khatsenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirley, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benish, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodine, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blease, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathers, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span> </span><span class="NLM_article-title">Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.12.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2011.12.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22244937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1433-1438&author=V.+Plantevin+Krenitskyauthor=L.+Nadolnyauthor=M.+Delgadoauthor=L.+Ayalaauthor=S.+S.+Clareenauthor=R.+Hilgrafauthor=R.+Albersauthor=S.+Hegdeauthor=N.+D%E2%80%99Sidockyauthor=J.+Sapienzaauthor=J.+Wrightauthor=M.+McCarrickauthor=S.+Bahmanyarauthor=P.+Chamberlainauthor=S.+L.+Delkerauthor=J.+Muirauthor=D.+Giegelauthor=L.+Xuauthor=M.+Celeridadauthor=J.+Lachowitzerauthor=B.+Bennettauthor=M.+Moghaddamauthor=O.+Khatsenkoauthor=J.+Katzauthor=R.+Fanauthor=A.+Baiauthor=Y.+Tangauthor=M.+A.+Shirleyauthor=B.+Benishauthor=T.+Bodineauthor=K.+Bleaseauthor=H.+Raymonauthor=B.+E.+Cathersauthor=Y.+Satoh&title=Discovery+of+CC-930%2C+an+orally+active+anti-fibrotic+JNK+inhibitor&doi=10.1016%2Fj.bmcl.2011.12.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor</span></div><div class="casAuthors">Plantevin Krenitsky, Veronique; Nadolny, Lisa; Delgado, Mercedes; Ayala, Leticia; Clareen, Steven S.; Hilgraf, Robert; Albers, Ronald; Hegde, Sayee; D'Sidocky, Neil; Sapienza, John; Wright, Jonathan; McCarrick, Meg; Bahmanyar, Sogole; Chamberlain, Philip; Delker, Silvia L.; Muir, Jeff; Giegel, David; Xu, Li; Celeridad, Maria; Lachowitzer, Jeff; Bennett, Brydon; Moghaddam, Mehran; Khatsenko, Oleg; Katz, Jason; Fan, Rachel; Bai, April; Tang, Yang; Shirley, Michael A.; Benish, Brent; Bodine, Tracey; Blease, Kate; Raymon, Heather; Cathers, Brian E.; Satoh, Yoshitaka</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1433-1438</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors.  Improving the physico-chem. properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors.  Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 1 (CC-930, I) as a development candidate, which is currently in Phase II clin. trial for IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKdVqRxZzsLVg90H21EOLACvtfcHk0lhRpnPHnL7CiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCls7c%253D&md5=fc99284fc784d1649286c95888a94e5e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.12.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.12.027%26sid%3Dliteratum%253Aachs%26aulast%3DPlantevin%2BKrenitsky%26aufirst%3DV.%26aulast%3DNadolny%26aufirst%3DL.%26aulast%3DDelgado%26aufirst%3DM.%26aulast%3DAyala%26aufirst%3DL.%26aulast%3DClareen%26aufirst%3DS.%2BS.%26aulast%3DHilgraf%26aufirst%3DR.%26aulast%3DAlbers%26aufirst%3DR.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Sidocky%26aufirst%3DN.%26aulast%3DSapienza%26aufirst%3DJ.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DMcCarrick%26aufirst%3DM.%26aulast%3DBahmanyar%26aufirst%3DS.%26aulast%3DChamberlain%26aufirst%3DP.%26aulast%3DDelker%26aufirst%3DS.%2BL.%26aulast%3DMuir%26aufirst%3DJ.%26aulast%3DGiegel%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCeleridad%26aufirst%3DM.%26aulast%3DLachowitzer%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DB.%26aulast%3DMoghaddam%26aufirst%3DM.%26aulast%3DKhatsenko%26aufirst%3DO.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DR.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShirley%26aufirst%3DM.%2BA.%26aulast%3DBenish%26aufirst%3DB.%26aulast%3DBodine%26aufirst%3DT.%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DRaymon%26aufirst%3DH.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DSatoh%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520CC-930%252C%2520an%2520orally%2520active%2520anti-fibrotic%2520JNK%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1433%26epage%3D1438%26doi%3D10.1016%2Fj.bmcl.2011.12.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Cook, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romashkan, S.</span><span> </span><span class="NLM_article-title">Why do we need a trial on the effects of testosterone therapy in older men?</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1038/clpt.2010.217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fclpt.2010.217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21170069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=29-31&author=N.+L.+Cookauthor=S.+Romashkan&title=Why+do+we+need+a+trial+on+the+effects+of+testosterone+therapy+in+older+men%3F&doi=10.1038%2Fclpt.2010.217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Why Do We Need a Trial on the Effects of Testosterone Therapy in Older Men?</span></div><div class="casAuthors">Cook, N. L.; Romashkan, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-31</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Decreases in levels of sex hormones occur with aging.  Observational studies have found assocns. of low testosterone concns. in older men with adverse symptoms; however, these assocns. do not prove causality.  Therefore, the question arises whether to treat older men whose serum testosterone is low.  In 2009, the Testosterone Trial (T Trial) was funded to examine the efficacy of therapy in 800 elderly men with low testosterone levels; potentially assocd. symptoms; and abnormalities in phys., sexual, or cognitive function or vitality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXHB8555yibVg90H21EOLACvtfcHk0lguCiK6MLzRJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zO&md5=38da4d2f09437a48e96387bc0a727818</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.217%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DN.%2BL.%26aulast%3DRomashkan%26aufirst%3DS.%26atitle%3DWhy%2520do%2520we%2520need%2520a%2520trial%2520on%2520the%2520effects%2520of%2520testosterone%2520therapy%2520in%2520older%2520men%253F%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D29%26epage%3D31%26doi%3D10.1038%2Fclpt.2010.217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span>ClinicalTrials.gov. A study to characterize the safety, PK and biological activity of CC-930 in idiopathic pulmonary fibrosis (IPF). <a href="http://clinicaltrials.gov/ct2/show/NCT01203943" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01203943</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+study+to+characterize+the+safety%2C+PK+and+biological+activity+of+CC-930+in+idiopathic+pulmonary+fibrosis+%28IPF%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01203943+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Deleuze-Masquefa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moarbess, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gayraud-Paniagua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bressolle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinguet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, P. A.</span><span> </span><span class="NLM_article-title">New imidazo[1,2-<i>a</i>]quinoxaline derivatives: Synthesis and <i>in vitro</i> activity against human melanoma</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3406</span><span class="NLM_x">–</span> <span class="NLM_lpage">3411</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2009.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ejmech.2009.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=3406-3411&author=C.+Deleuze-Masquefaauthor=G.+Moarbessauthor=S.+Khierauthor=N.+Davidauthor=S.+Gayraud-Paniaguaauthor=F.+Bressolleauthor=F.+Pinguetauthor=P.+A.+Bonnet&title=New+imidazo%5B1%2C2-a%5Dquinoxaline+derivatives%3A+Synthesis+and+in+vitro+activity+against+human+melanoma&doi=10.1016%2Fj.ejmech.2009.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DDeleuze-Masquefa%26aufirst%3DC.%26aulast%3DMoarbess%26aufirst%3DG.%26aulast%3DKhier%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DN.%26aulast%3DGayraud-Paniagua%26aufirst%3DS.%26aulast%3DBressolle%26aufirst%3DF.%26aulast%3DPinguet%26aufirst%3DF.%26aulast%3DBonnet%26aufirst%3DP.%2BA.%26atitle%3DNew%2520imidazo%255B1%252C2-a%255Dquinoxaline%2520derivatives%253A%2520Synthesis%2520and%2520in%2520vitro%2520activity%2520against%2520human%2520melanoma%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D3406%26epage%3D3411%26doi%3D10.1016%2Fj.ejmech.2009.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cociorva, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liyanage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajica, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreder, K. R.</span><span> </span><span class="NLM_article-title">Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5217</span><span class="NLM_x">–</span> <span class="NLM_lpage">5222</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2013.06.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5217-5222&author=B.+Liauthor=O.+M.+Cociorvaauthor=T.+Nomanbhoyauthor=H.+Weissigauthor=Q.+Liauthor=K.+Nakamuraauthor=M.+Liyanageauthor=M.+C.+Zhangauthor=A.+Y.+Shihauthor=A.+Abanauthor=Y.+Huauthor=J.+Cajicaauthor=L.+Phamauthor=J.+W.+Kozarichauthor=K.+R.+Shreder&title=Hit-to-lead+optimization+and+kinase+selectivity+of+imidazo%5B1%2C2-a%5Dquinoxalin-4-amine+derived+JNK1+inhibitors&doi=10.1016%2Fj.bmcl.2013.06.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.087%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCociorva%26aufirst%3DO.%2BM.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DLiyanage%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DM.%2BC.%26aulast%3DShih%26aufirst%3DA.%2BY.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCajica%26aufirst%3DJ.%26aulast%3DPham%26aufirst%3DL.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26atitle%3DHit-to-lead%2520optimization%2520and%2520kinase%2520selectivity%2520of%2520imidazo%255B1%252C2-a%255Dquinoxalin-4-amine%2520derived%2520JNK1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5217%26epage%3D5222%26doi%3D10.1016%2Fj.bmcl.2013.06.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wynn, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, T. R.</span><span> </span><span class="NLM_article-title">Mechanisms of fibrosis: therapeutic translation for fibrotic disease</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1040</span><span class="refDoi"> DOI: 10.1038/nm.2807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm.2807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22772564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1028-1040&author=T.+A.+Wynnauthor=T.+R.+Ramalingam&title=Mechanisms+of+fibrosis%3A+therapeutic+translation+for+fibrotic+disease&doi=10.1038%2Fnm.2807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144aR"><div class="casContent"><span class="casTitleNuber">144a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fibrosis: therapeutic translation for fibrotic disease</span></div><div class="casAuthors">Wynn, Thomas A.; Ramalingam, Thirumalai R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1028-1040</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis is a pathol. feature of most chronic inflammatory diseases.  Fibrosis, or scarring, is defined by the accumulation of excess extracellular matrix components.  If highly progressive, the fibrotic process eventually leads to organ malfunction and death.  Fibrosis affects nearly every tissue in the body.  Here we discuss how key components of the innate and adaptive immune response contribute to the pathogenesis of fibrosis.  We also describe how cell-intrinsic changes in important structural cells can perpetuate the fibrotic response by regulating the differentiation, recruitment, proliferation and activation of extracellular matrix-producing myofibroblasts.  Finally, we highlight some of the key mechanisms and pathways of fibrosis that are being targeted as potential therapies for a variety of important human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnrbAxW_Afa7Vg90H21EOLACvtfcHk0lgGdZ0QJ9UzlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGgtLc%253D&md5=1ddde8289d7c57ae16e4d14348ef3b7f</span></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=10.1038%2Fnm.2807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2807%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26aulast%3DRamalingam%26aufirst%3DT.%2BR.%26atitle%3DMechanisms%2520of%2520fibrosis%253A%2520therapeutic%2520translation%2520for%2520fibrotic%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D1028%26epage%3D1040%26doi%3D10.1038%2Fnm.2807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartram, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speer, C. P.</span><span> </span><span class="NLM_article-title">The role of transforming growth factor beta in lung development and disease</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">754</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span><span class="refDoi"> DOI: 10.1378/chest.125.2.754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1378%2Fchest.125.2.754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=14769761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Fmsl2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2004&pages=754-765&author=U.+Bartramauthor=C.+P.+Speer&title=The+role+of+transforming+growth+factor+beta+in+lung+development+and+disease&doi=10.1378%2Fchest.125.2.754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144bR"><div class="casContent"><span class="casTitleNuber">144b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of transforming growth factor beta in lung development and disease</span></div><div class="casAuthors">Bartram Ulrike; Speer Christian P</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">754-65</span>
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">Transforming growth factor (TGF) beta plays an important role in normal pulmonary morphogenesis and function and in the pathogenesis of lung disease.  The effect of TGFbeta is regulated via a selective pathway of TGFbeta synthesis and signaling that involves activation of latent TGFbeta, specific TGFbeta receptors, and intracellular signaling via Smad molecules.  All three isoforms of TGFbeta are expressed at high levels during normal lung development, being particularly important for branching morphogenesis and epithelial cell differentiation with maturation of surfactant synthesis.  Small amounts of TGFbeta are still present in the adult lung, and TGFbeta is involved in normal tissue repair following lung injury.  However, in a variety of forms of pulmonary pathology, the expression of TGFbeta is increased.  These include chronic lung disease of prematurity as well as several forms of acute and chronic adult lung disease.  While TGFbeta1 appears to be the predominant isoform involved, elevated levels of all three isoforms have been demonstrated.  The increase in TGFbeta precedes abnormalities in lung function and detectable lung pathology, but correlates with the severity of the disease.  TGFbeta plays a key role in mediating fibrotic tissue remodeling by increasing the production and decreasing the degradation of connective tissue via several mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRidiEnxLJRVU2yPDyEFiigfW6udTcc2eZprsc9rQv_Mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Fmsl2ksw%253D%253D&md5=a1e1522ae1ab55078fa7f2ca085ba5a4</span></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=10.1378%2Fchest.125.2.754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.125.2.754%26sid%3Dliteratum%253Aachs%26aulast%3DBartram%26aufirst%3DU.%26aulast%3DSpeer%26aufirst%3DC.%2BP.%26atitle%3DThe%2520role%2520of%2520transforming%2520growth%2520factor%2520beta%2520in%2520lung%2520development%2520and%2520disease%26jtitle%3DChest%26date%3D2004%26volume%3D125%26spage%3D754%26epage%3D765%26doi%3D10.1378%2Fchest.125.2.754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Strieter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrad, B.</span><span> </span><span class="NLM_article-title">New mechanisms of pulmonary fibrosis</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">1364</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span><span class="refDoi"> DOI: 10.1378/chest.09-0510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1378%2Fchest.09-0510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19892675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjkt1agtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=1364-1370&author=R.+M.+Strieterauthor=B.+Mehrad&title=New+mechanisms+of+pulmonary+fibrosis&doi=10.1378%2Fchest.09-0510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144cR"><div class="casContent"><span class="casTitleNuber">144c</span><div class="casTitle"><span class="NLM_cas:atitle">New mechanisms of pulmonary fibrosis</span></div><div class="casAuthors">Strieter Robert M; Mehrad Borna</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1364-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The understanding of the pathogenesis of pulmonary fibrosis continues to evolve.  The initial hypothetical model suggested chronic inflammation as the cause of pulmonary fibrosis, whereas a subsequent hypothesis posited epithelial injury and impaired wound repair as the etiology of fibrosis without preceding inflammation.  Over the past decade, several concepts have led to refinement of these hypotheses.  These include the following: (1) the importance of the integrity of the alveolar-capillary barrier basement membrane (BM) to conserving the architecture of the injured lung; (2) conversely, that the failure of reepithelialization and reendothelialization of this BM results in pathologic fibrosis; (3) transforming growth factor-beta is necessary but not sufficient to the pathologic fibrosis of the lungs; (4) the role of persistent antigens in the pathogenesis of usual interstitial pneumonia; and (5) the contribution of epithelial-to-mesenchymal transformation and bone marrow-derived progenitor cells in the pathogenesis of lung fibrosis.  In this review, we will discuss these evolving conceptual mechanisms for the pathogenesis of pulmonary fibrosis relevant to idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr0URydcEFMukdrW1FkXG-fW6udTcc2eZprsc9rQv_Mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjkt1agtA%253D%253D&md5=91f35d9b6466b7393deca1a9cd02a7ce</span></div><a href="/servlet/linkout?suffix=cit144c&amp;dbid=16384&amp;doi=10.1378%2Fchest.09-0510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.09-0510%26sid%3Dliteratum%253Aachs%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DMehrad%26aufirst%3DB.%26atitle%3DNew%2520mechanisms%2520of%2520pulmonary%2520fibrosis%26jtitle%3DChest%26date%3D2009%26volume%3D136%26spage%3D1364%26epage%3D1370%26doi%3D10.1378%2Fchest.09-0510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Arribillaga, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basagoiti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riezu-Boj, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrás-Cuesta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasarte, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarobe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornet, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feijoó, E.</span><span> </span><span class="NLM_article-title">Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis</span> <span class="citation_source-journal">Cytokine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1016/j.cyto.2010.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.cyto.2010.11.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2011&pages=327-333&author=L.+Arribillagaauthor=J.+Dotorauthor=M.+Basagoitiauthor=J.+I.+Riezu-Bojauthor=F.+Borr%C3%A1s-Cuestaauthor=J.+J.+Lasarteauthor=P.+Sarobeauthor=M.+E.+Cornetauthor=E.+Feijo%C3%B3&title=Therapeutic+effect+of+a+peptide+inhibitor+of+TGF-%CE%B2+on+pulmonary+fibrosis&doi=10.1016%2Fj.cyto.2010.11.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144d&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2010.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2010.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DArribillaga%26aufirst%3DL.%26aulast%3DDotor%26aufirst%3DJ.%26aulast%3DBasagoiti%26aufirst%3DM.%26aulast%3DRiezu-Boj%26aufirst%3DJ.%2BI.%26aulast%3DBorr%25C3%25A1s-Cuesta%26aufirst%3DF.%26aulast%3DLasarte%26aufirst%3DJ.%2BJ.%26aulast%3DSarobe%26aufirst%3DP.%26aulast%3DCornet%26aufirst%3DM.%2BE.%26aulast%3DFeijo%25C3%25B3%26aufirst%3DE.%26atitle%3DTherapeutic%2520effect%2520of%2520a%2520peptide%2520inhibitor%2520of%2520TGF-%25CE%25B2%2520on%2520pulmonary%2520fibrosis%26jtitle%3DCytokine%26date%3D2011%26volume%3D53%26spage%3D327%26epage%3D333%26doi%3D10.1016%2Fj.cyto.2010.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Khasnis, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, L. H.</span><span> </span><span class="NLM_article-title">Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span><span class="refDoi"> DOI: 10.1016/j.semarthrit.2009.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.semarthrit.2009.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19914686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Wht7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=147-163&author=A.+A.+Khasnisauthor=L.+H.+Calabrese&title=Tumor+necrosis+factor+inhibitors+and+lung+disease%3A+a+paradox+of+efficacy+and+risk&doi=10.1016%2Fj.semarthrit.2009.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144eR"><div class="casContent"><span class="casTitleNuber">144e</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Necrosis Factor Inhibitors and Lung Disease: A Paradox of Efficacy and Risk</span></div><div class="casAuthors">Khasnis, Atul A.; Calabrese, Leonard H.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Arthritis and Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-163</span>CODEN:
                <span class="NLM_cas:coden">SAHRBF</span>;
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Objective: Tumor necrosis factor inhibitors (TNFi) are being increasingly used for a wide range of indications.  There are increasing reports of pulmonary toxicity related to the use of TNFi.  In this review, we have attempted to synthesize the available literature regarding noninfectious complications related to TNFi use.  Methods: We reviewed case reports, case series, and clin. trials accessed from the PubMed database (www.pubmed.gov), European League Against Rheumatism web archive (http://www.abstrs.2view.com/eular/index.php), and the British Society of Rheumatol. Biologics Register Newsletter website (http://www.rheumatol.org.uk/publications) using 23 search terms.  Results: There are increasing data available about use of TNFi in treatment of systemic inflammatory rheumatol. disorders and their attempted use for various pulmonary indications.  Currently reported noninfectious pulmonary complications related to TNFi use include most commonly granulomatous disease and pulmonary fibrosis/interstitial lung disease and rarely alveolar hemorrhage and antisynthetase syndrome.  De novo granulomatous disease seems to be mostly reversible, whereas pulmonary fibrosis carries the worst prognosis esp. in the setting of prior lung fibrosis.  Conclusions: Serious and potentially fatal pulmonary toxicity has been reported during the use of TNFi, specifically from pulmonary fibrosis.  Increased awareness during trial design and increased postmarketing surveillance is needed to provide more information about the epidemiol. of these complications.  Early recognition of these complications may help avert therapeutic misadventures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-bdekO323bVg90H21EOLACvtfcHk0ljtcICwcrEMCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Wht7rF&md5=a5568339efdc982a6cb5dbfc054c9376</span></div><a href="/servlet/linkout?suffix=cit144e&amp;dbid=16384&amp;doi=10.1016%2Fj.semarthrit.2009.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semarthrit.2009.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKhasnis%26aufirst%3DA.%2BA.%26aulast%3DCalabrese%26aufirst%3DL.%2BH.%26atitle%3DTumor%2520necrosis%2520factor%2520inhibitors%2520and%2520lung%2520disease%253A%2520a%2520paradox%2520of%2520efficacy%2520and%2520risk%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D2010%26volume%3D40%26spage%3D147%26epage%3D163%26doi%3D10.1016%2Fj.semarthrit.2009.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 4-oxoquinoline-3-carboxamides derivatives as potent anti-fibrosis agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">5666</span><span class="NLM_x">–</span> <span class="NLM_lpage">5670</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2014.10.071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5666-5670&author=J.+Zhuauthor=L.+Heauthor=L.+Maauthor=Z.+Weiauthor=J.+Heauthor=Z.+Yangauthor=Y.+Puauthor=D.+Caoauthor=Y.+Wuauthor=M.+Xiangauthor=A.+Pengauthor=Y.+Weiauthor=L.+Chen&title=Synthesis+and+biological+evaluation+of+4-oxoquinoline-3-carboxamides+derivatives+as+potent+anti-fibrosis+agents&doi=10.1016%2Fj.bmcl.2014.10.071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPu%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DA.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25204-oxoquinoline-3-carboxamides%2520derivatives%2520as%2520potent%2520anti-fibrosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5666%26epage%3D5670%26doi%3D10.1016%2Fj.bmcl.2014.10.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Schwiebert, E.; Streiff, J.; Dixon, J.; Gao, H.; Ritchie, J. P.; Seales, E. C.; Mai, D.</span><span> </span><span class="NLM_article-title">Coumarin derivatives and methods of use in treating hyperproliferative diseases</span>. U.S. Patent 20160038475 A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Schwiebert&author=J.+Streiff&author=J.+Dixon&author=H.+Gao&author=J.+P.+Ritchie&author=E.+C.+Seales&author=D.+Mai&title=Coumarin+derivatives+and+methods+of+use+in+treating+hyperproliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchwiebert%26aufirst%3DE.%26atitle%3DCoumarin%2520derivatives%2520and%2520methods%2520of%2520use%2520in%2520treating%2520hyperproliferative%2520diseases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gilbert, F.; Robert, G. J.; Jonathan, L.; Maurice, L. R.; Fletcher, S. R.</span><span> </span><span class="NLM_article-title">Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)</span>. U.S. Patent 20160039807 A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Gilbert&author=G.+J.+Robert&author=L.+Jonathan&author=L.+R.+Maurice&author=S.+R.+Fletcher&title=Novel+dihydropyrimidinoisoquinolinones+and+pharmaceutical+compositions+thereof+for+the+treatment+of+inflammatory+disorders+%28gpr84+antagonists%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DF.%26atitle%3DNovel%2520dihydropyrimidinoisoquinolinones%2520and%2520pharmaceutical%2520compositions%2520thereof%2520for%2520the%2520treatment%2520of%2520inflammatory%2520disorders%2520%2528gpr84%2520antagonists%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit147b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gilbert, F.; Robert, G. J.; Jonathan, L.; Maurice, L. R.; Fletcher, S. R.</span><span> </span><span class="NLM_article-title">Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders</span>. U.S. Patent 20140121204 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=F.+Gilbert&author=G.+J.+Robert&author=L.+Jonathan&author=L.+R.+Maurice&author=S.+R.+Fletcher&title=Novel+dihydropyrimidinoisoquinolinones+and+pharmaceutical+compositions+thereof+for+the+treatment+of+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DF.%26atitle%3DNovel%2520dihydropyrimidinoisoquinolinones%2520and%2520pharmaceutical%2520compositions%2520thereof%2520for%2520the%2520treatment%2520of%2520inflammatory%2520disorders%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Stadlwieser, J.; Schmidt, B.; Bernsmann, H.; Dunkern, T.; Benediktus, E.; Pahl, A.; Hussong, R.; Nimz, O.; Mueller, M.; Viertelhaus, M.</span><span> </span><span class="NLM_article-title">Methylpyrrolopyrimidinecarboxamides</span>. U.S. Patent 20150073001,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Stadlwieser&author=B.+Schmidt&author=H.+Bernsmann&author=T.+Dunkern&author=E.+Benediktus&author=A.+Pahl&author=R.+Hussong&author=O.+Nimz&author=M.+Mueller&author=M.+Viertelhaus&title=Methylpyrrolopyrimidinecarboxamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStadlwieser%26aufirst%3DJ.%26atitle%3DMethylpyrrolopyrimidinecarboxamides%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hood, J.; Kumar, S. K. C.; Wallace, D. M.</span><span> </span><span class="NLM_article-title">1H-Pyrazolo[3,4-b]pyridines and therapeutic uses thereof</span>. U.S. Patent 20150150862,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Hood&author=S.+K.+C.+Kumar&author=D.+M.+Wallace&title=1H-Pyrazolo%5B3%2C4-b%5Dpyridines+and+therapeutic+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHood%26aufirst%3DJ.%26atitle%3D1H-Pyrazolo%255B3%252C4-b%255Dpyridines%2520and%2520therapeutic%2520uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit149b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hood, J.; Kumar, S. K. C.; Wallace, D. M.</span><span> </span><span class="NLM_article-title">1H-Pyrazolo[3,4-b]pyridines and therapeutic uses thereof</span>. U.S. Patent 20130296302,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Hood&author=S.+K.+C.+Kumar&author=D.+M.+Wallace&title=1H-Pyrazolo%5B3%2C4-b%5Dpyridines+and+therapeutic+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHood%26aufirst%3DJ.%26atitle%3D1H-Pyrazolo%255B3%252C4-b%255Dpyridines%2520and%2520therapeutic%2520uses%2520thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Notte, G.</span><span> </span><span class="NLM_article-title">Apoptosis signal-regulating kinase inhibitors</span>. U.S. Patent 20140179663 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+Notte&title=Apoptosis+signal-regulating+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNotte%26aufirst%3DG.%26atitle%3DApoptosis%2520signal-regulating%2520kinase%2520inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Allegretti, M.; Cesta, M. C.; Bertini, R.; Mosca, M.; Colotta, F.</span><span> </span><span class="NLM_article-title">2-Phenylpropionic acid derivatives and pharmaceutical compositions containing them</span>. U.S. Patent 20120004264 A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Allegretti&author=M.+C.+Cesta&author=R.+Bertini&author=M.+Mosca&author=F.+Colotta&title=2-Phenylpropionic+acid+derivatives+and+pharmaceutical+compositions+containing+them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DM.%26atitle%3D2-Phenylpropionic%2520acid%2520derivatives%2520and%2520pharmaceutical%2520compositions%2520containing%2520them%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Moriconi, A.; Allegretti, M.; Cesta, M. C.; Bertini, R.; Bizzarri, C.; Colotta, F.</span><span> </span><span class="NLM_article-title">2-Aryl-acetic acids, their derivatives and pharmaceutical compositions containing them</span>. U.S. Patent 20110195967 A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Moriconi&author=M.+Allegretti&author=M.+C.+Cesta&author=R.+Bertini&author=C.+Bizzarri&author=F.+Colotta&title=2-Aryl-acetic+acids%2C+their+derivatives+and+pharmaceutical+compositions+containing+them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoriconi%26aufirst%3DA.%26atitle%3D2-Aryl-acetic%2520acids%252C%2520their%2520derivatives%2520and%2520pharmaceutical%2520compositions%2520containing%2520them%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Holsinger, L.</span><span> </span><span class="NLM_article-title">Inhibitors of cathepsinb</span>. U.S. Patent 20090203629 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=L.+Holsinger&title=Inhibitors+of+cathepsinb"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHolsinger%26aufirst%3DL.%26atitle%3DInhibitors%2520of%2520cathepsinb%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Kossen, K.; Seiwert, S. D.; Serebryany, V.; Ruhrmund, D.; Beigelman, L.; Raveglia, L. F.; Vallese, S.; Bianchi, I.; Hu, T.</span><span> </span><span class="NLM_article-title">Compounds and methods for treating inflammatory and fibrotic disorders</span>. U.S. Patent 20090318455 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Kossen&author=S.+D.+Seiwert&author=V.+Serebryany&author=D.+Ruhrmund&author=L.+Beigelman&author=L.+F.+Raveglia&author=S.+Vallese&author=I.+Bianchi&author=T.+Hu&title=Compounds+and+methods+for+treating+inflammatory+and+fibrotic+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKossen%26aufirst%3DK.%26atitle%3DCompounds%2520and%2520methods%2520for%2520treating%2520inflammatory%2520and%2520fibrotic%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Gant, T. G.; Sarshar, S.</span><span> </span><span class="NLM_article-title">Substituted n-aryl pyridinones</span>. U.S. Patent 20080319026 A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+G.+Gant&author=S.+Sarshar&title=Substituted+n-aryl+pyridinones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DSubstituted%2520n-aryl%2520pyridinones%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Hart, B.; Axon, J. R.; Chakravarty, S.; Murphy, A.; Mcenroe, G.</span><span> </span><span class="NLM_article-title">Heterocyclic inhibitors of TGF-β</span>. WO 2006105063 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+Hart&author=J.+R.+Axon&author=S.+Chakravarty&author=A.+Murphy&author=G.+Mcenroe&title=Heterocyclic+inhibitors+of+TGF-%CE%B2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DB.%26atitle%3DHeterocyclic%2520inhibitors%2520of%2520TGF-%25CE%25B2%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Levin, J.; Li, Z.; Diamantidis, G.; Lovering, F.; Wang, W.; Condon, J.; Lin, Y.- I.; Skotnicki, J.; Park, K.</span><span> </span><span class="NLM_article-title">Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase</span>. U.S. Patent 20060211730 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+Levin&author=Z.+Li&author=G.+Diamantidis&author=F.+Lovering&author=W.+Wang&author=J.+Condon&author=Y.-+I.+Lin&author=J.+Skotnicki&author=K.+Park&title=Beta-sulfonamide+hydroxamic+acid+inhibitors+of+tace%2Fmatrix+metalloproteinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DJ.%26atitle%3DBeta-sulfonamide%2520hydroxamic%2520acid%2520inhibitors%2520of%2520tace%252Fmatrix%2520metalloproteinase%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nanthakumar, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatley, R. J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauldie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span><span class="refDoi"> DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26338155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&author=C.+B.+Nanthakumarauthor=R.+J.+D.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+F.+Macdonald&title=Dissecting+fibrosis%3A+therapeutic+insights+from+the+small-molecule+toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158aR"><div class="casContent"><span class="casTitleNuber">158a</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span></div><div class="casAuthors">Nanthakumar, Carmel B.; Hatley, Richard J. D.; Lemma, Seble; Gauldie, Jack; Marshall, Richard P.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-720</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estd. to contribute to ∼45% of deaths in the developed world, and so new therapeutics to modulate fibrosis are urgently needed.  Major advances in our understanding of the mechanisms underlying pathol. fibrosis are supporting the search for such therapeutics, and the recent approval of two anti-fibrotic drugs for idiopathic pulmonary fibrosis has demonstrated the tractability of this area for drug discovery.  This Review examines the pharmacol. and structural information for small mols. being evaluated for lung, liver, kidney and skin fibrosis.  In particular, we discuss the insights gained from the use of these pharmacol. tools, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk6pfSk3gsCrVg90H21EOLACvtfcHk0lg8TPMKkoMgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ&md5=b05a37db6ede2acc0f5c65826aa344f3</span></div><a href="/servlet/linkout?suffix=cit158a&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%2BD.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DDissecting%2520fibrosis%253A%2520therapeutic%2520insights%2520from%2520the%2520small-molecule%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit158b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span><span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158bR"><div class="casContent"><span class="casTitleNuber">158b</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lieqQOHIU9uHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit158b&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159a"><span><span class="NLM_label">(a) </span><span> </span><span class="NLM_article-title">Regulatory watch: First drug for idiopathic pulmonary fibrosis approved in Japan</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">966</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span>, DOI: <span class="refDoi"> DOI: 10.1038/nrd2767</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd2767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Regulatory+watch%3A+First+drug+for+idiopathic+pulmonary+fibrosis+approved+in+Japan.+Nat.+Rev.+Drug+Discovery+2008%2C+7%2C+966%E2%80%93967%2C+DOI%3A+10.1038%2Fnrd2767."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2767%26sid%3Dliteratum%253Aachs%26atitle%3DRegulatory%2520watch%253A%2520First%2520drug%2520for%2520idiopathic%2520pulmonary%2520fibrosis%2520approved%2520in%2520Japan%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D966%26epage%3D967%26doi%3D10.1038%2Fnrd2767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit159b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Macías-Barragán, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandoval-Rodríguez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro-Partida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armendáriz-Borunda, J.</span><span> </span><span class="NLM_article-title">The multifaceted role of pirfenidone and its novel targets</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="refDoi"> DOI: 10.1186/1755-1536-3-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2F1755-1536-3-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20809935" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=16&author=J.+Mac%C3%ADas-Barrag%C3%A1nauthor=A.+Sandoval-Rodr%C3%ADguezauthor=J.+Navarro-Partidaauthor=J.+Armend%C3%A1riz-Borunda&title=The+multifaceted+role+of+pirfenidone+and+its+novel+targets&doi=10.1186%2F1755-1536-3-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159b&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-3-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-3-16%26sid%3Dliteratum%253Aachs%26aulast%3DMac%25C3%25ADas-Barrag%25C3%25A1n%26aufirst%3DJ.%26aulast%3DSandoval-Rodr%25C3%25ADguez%26aufirst%3DA.%26aulast%3DNavarro-Partida%26aufirst%3DJ.%26aulast%3DArmend%25C3%25A1riz-Borunda%26aufirst%3DJ.%26atitle%3DThe%2520multifaceted%2520role%2520of%2520pirfenidone%2520and%2520its%2520novel%2520targets%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2010%26volume%3D3%26spage%3D16%26doi%3D10.1186%2F1755-1536-3-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit159c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Han, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwangbo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span> </span><span class="NLM_article-title">A phase II study of nintedanib in patients with relapsed small cell lung cancer</span> <span class="citation_source-journal">Lung Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2016.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.lungcan.2016.04.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=108-112&author=Y.+J.+Hanauthor=H.+Y.+Kimauthor=K.+Y.+Limauthor=B.+Hwangboauthor=J.+S.+Lee&title=A+phase+II+study+of+nintedanib+in+patients+with+relapsed+small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2016.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159c&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DLim%26aufirst%3DK.%2BY.%26aulast%3DHwangbo%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520nintedanib%2520in%2520patients%2520with%2520relapsed%2520small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2016%26volume%3D96%26spage%3D108%26epage%3D112%26doi%3D10.1016%2Fj.lungcan.2016.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Korfei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skwarna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henneke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klymenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von der Beck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahavadi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellusci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullamsetti, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krämer, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guenther, A.</span><span> </span><span class="NLM_article-title">Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1032</span><span class="refDoi"> DOI: 10.1136/thoraxjnl-2014-206411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthoraxjnl-2014-206411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26359372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC283htFemsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=1022-1032&author=M.+Korfeiauthor=S.+Skwarnaauthor=I.+Hennekeauthor=B.+MacKenzieauthor=O.+Klymenkoauthor=S.+Saitoauthor=C.+Ruppertauthor=D.+von+der+Beckauthor=P.+Mahavadiauthor=W.+Klepetkoauthor=S.+Bellusciauthor=B.+Crestaniauthor=S.+S.+Pullamsettiauthor=L.+Finkauthor=W.+Seegerauthor=O.+H.+Kr%C3%A4merauthor=A.+Guenther&title=Aberrant+expression+and+activity+of+histone+deacetylases+in+sporadic+idiopathic+pulmonary+fibrosis&doi=10.1136%2Fthoraxjnl-2014-206411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Korfei Martina; Skwarna Sylwia; Henneke Ingrid; MacKenzie BreAnne; Klymenko Oleksiy; von der Beck Daniel; Mahavadi Poornima; Saito Shigeki; Ruppert Clemens; Bellusci Saverio; Seeger Werner; Klepetko Walter; Crestani Bruno; Pullamsetti Soni Savai; Fink Ludger; Kramer Oliver Holger; Guenther Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1022-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Activation and differentiation of fibroblasts into contractile protein-expressing myofibroblasts and their acquired apoptosis-resistant phenotype are critical factors towards the development of idiopathic pulmonary fibrosis (IPF), a fatal disease characterised by distorted pulmonary structure and excessive extracellular matrix (ECM) deposition.  The molecular mechanisms underlying these processes in IPF remain incompletely understood.  We investigated the possible implication of aberrant overexpression and activity of histone deacetylases (HDACs) in IPF.  METHODS:  We analysed lung tissues from patients with sporadic IPF (n=26) and non-diseased control lungs (n=16) for expression of class I and II HDACs.  Primary IPF fibroblasts were treated with HDAC inhibitors (HDACi) LBH589 or valproic acid (VPA).  RESULTS:  Compared to control lungs, protein levels of class I (HDAC1, HDAC2, HDAC3, HDAC8) and class II HDACs (HDAC4, HDAC 5, HDAC 7, HDAC 9) were significantly elevated in IPF lungs.  Using immunohistochemistry, strong induction of nearly all HDAC enzymes was observed in myofibroblasts of fibroblast foci and in abnormal bronchiolar basal cells at sites of aberrant re-epithelialisation in IPF lungs, but not in controls.  Treatment of primary IPF fibroblasts with the pan-HDACi LBH589 resulted in significantly reduced expression of genes associated with ECM synthesis, proliferation and cell survival, as well as in suppression of HDAC7, and was paralleled by induction of endoplasmic reticulum stress and apoptosis.  The profibrotic and apoptosis-resistant phenotype of IPF fibroblasts was also partly attenuated by the class I HDACi VPA.  CONCLUSIONS:  Aberrant overexpression of HDACs in basal cells of IPF lungs may contribute to the bronchiolisation process in this disease.  Similarly, generation and apoptosis resistance of IPF fibroblasts are mediated by enhanced activity of HDAC enzymes.  Therefore, pan-HDAC inhibition by LBH589 may present a novel therapeutic option for patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAcwMJAE2LJNhSDZx9hyjKfW6udTcc2eb8WRrw6u3Q9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htFemsQ%253D%253D&md5=621f4bd5c66ff41ed4c4cbf894644a4a</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2014-206411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2014-206411%26sid%3Dliteratum%253Aachs%26aulast%3DKorfei%26aufirst%3DM.%26aulast%3DSkwarna%26aufirst%3DS.%26aulast%3DHenneke%26aufirst%3DI.%26aulast%3DMacKenzie%26aufirst%3DB.%26aulast%3DKlymenko%26aufirst%3DO.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DRuppert%26aufirst%3DC.%26aulast%3Dvon%2Bder%2BBeck%26aufirst%3DD.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DBellusci%26aufirst%3DS.%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DFink%26aufirst%3DL.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%2BH.%26aulast%3DGuenther%26aufirst%3DA.%26atitle%3DAberrant%2520expression%2520and%2520activity%2520of%2520histone%2520deacetylases%2520in%2520sporadic%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DThorax%26date%3D2015%26volume%3D70%26spage%3D1022%26epage%3D1032%26doi%3D10.1136%2Fthoraxjnl-2014-206411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, E.</span><span> </span><span class="NLM_article-title">The medicinal chemistry of hybrid-based drugs targeting multiple sites of action</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2714</span><span class="NLM_x">–</span> <span class="NLM_lpage">2715</span><span class="refDoi"> DOI: 10.2174/156802611798184382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F156802611798184382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22039874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2714-2715&author=J.+Marco-Contellesauthor=E.+Soriano&title=The+medicinal+chemistry+of+hybrid-based+drugs+targeting+multiple+sites+of+action&doi=10.2174%2F156802611798184382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161aR"><div class="casContent"><span class="casTitleNuber">161a</span><div class="casTitle"><span class="NLM_cas:atitle">The medicinal chemistry of hybrid-based drugs targeting multiple sites of action</span></div><div class="casAuthors">Marco-Contelles, Jose; Soriano, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2714-2715</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz2NIERHgjDrVg90H21EOLACvtfcHk0ljLJUoZk3S9hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtLc%253D&md5=3764c335948f5ab792c5d9b764e8892c</span></div><a href="/servlet/linkout?suffix=cit161a&amp;dbid=16384&amp;doi=10.2174%2F156802611798184382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184382%26sid%3Dliteratum%253Aachs%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSoriano%26aufirst%3DE.%26atitle%3DThe%2520medicinal%2520chemistry%2520of%2520hybrid-based%2520drugs%2520targeting%2520multiple%2520sites%2520of%2520action%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2714%26epage%3D2715%26doi%3D10.2174%2F156802611798184382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit161b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Viegas-Junior, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danuello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Silva Bolzani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barreiro, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraga, C. A.</span><span> </span><span class="NLM_article-title">Molecular hybridization: a useful tool in the design of new drug prototypes</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1829</span><span class="NLM_x">–</span> <span class="NLM_lpage">1852</span><span class="refDoi"> DOI: 10.2174/092986707781058805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F092986707781058805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17627520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFanuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1829-1852&author=C.+Viegas-Juniorauthor=A.+Danuelloauthor=V.+da+Silva+Bolzaniauthor=E.+J.+Barreiroauthor=C.+A.+Fraga&title=Molecular+hybridization%3A+a+useful+tool+in+the+design+of+new+drug+prototypes&doi=10.2174%2F092986707781058805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161bR"><div class="casContent"><span class="casTitleNuber">161b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular hybridization: a useful tool in the design of new drug prototypes</span></div><div class="casAuthors">Viegas-Junior, Claudio; Danuello, Amanda; da Silva Bolzani, Vanderlan; Barreiro, Eliezer J.; Fraga, Carlos Alberto Manssour</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1829-1852</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mol. hybridization is a new concept in drug design and development based on the combination of pharmacophoric moieties of different bioactive substances to produce a new hybrid compd. with improved affinity and efficacy, when compared to the parent drugs.  Addnl., this strategy can result in compds. presenting modified selectivity profile, different and/or dual modes of action and reduced undesired side effects.  So, in this paper, we described several examples of different strategies for drug design, discovery and pharmacomodulation focused on new innovative hybrid compds. presenting analgesic, anti-inflammatory, platelet anti-aggregating, anti-infectious, anticancer, cardio- and neuroactive properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvbzA71FPqLVg90H21EOLACvtfcHk0lgVY9w-ERoZ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFanuro%253D&md5=7d3a16e3deeacb735bc0357fc6a99c37</span></div><a href="/servlet/linkout?suffix=cit161b&amp;dbid=16384&amp;doi=10.2174%2F092986707781058805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707781058805%26sid%3Dliteratum%253Aachs%26aulast%3DViegas-Junior%26aufirst%3DC.%26aulast%3DDanuello%26aufirst%3DA.%26aulast%3Dda%2BSilva%2BBolzani%26aufirst%3DV.%26aulast%3DBarreiro%26aufirst%3DE.%2BJ.%26aulast%3DFraga%26aufirst%3DC.%2BA.%26atitle%3DMolecular%2520hybridization%253A%2520a%2520useful%2520tool%2520in%2520the%2520design%2520of%2520new%2520drug%2520prototypes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D1829%26epage%3D1852%26doi%3D10.2174%2F092986707781058805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit161c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Biot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chibale, K.</span><span> </span><span class="NLM_article-title">Novel approaches to antimalarial drug discovery</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.2174/187152606784112155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F187152606784112155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16789878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFersL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=173-204&author=C.+Biotauthor=K.+Chibale&title=Novel+approaches+to+antimalarial+drug+discovery&doi=10.2174%2F187152606784112155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161cR"><div class="casContent"><span class="casTitleNuber">161c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches to antimalarial drug discovery</span></div><div class="casAuthors">Biot, Christophe; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-204</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Major advances in the understanding of malaria parasite biol. have been made.  Coupled with the completion of the malaria genome, this has presented exciting opportunities for target-based antimalarial drug discovery.  However, the unraveling of more validated biol. targets will not necessarily translate into the identification of new chem. entities that are effective against drug-resistant parasites in the long term.  As history has already shown, development of antiplasmodial agents aimed at a single parasite target or specialized process has failed to stem the tide of drug resistance.  This review highlights recent starting points and(or) approaches to antimalarial drug discovery with particular emphasis on innovative efforts, which are not necessarily based on the identification of new drug targets and attendant inhibitor design.  Approaches covered include utilization of validated chem. scaffolds, bioprecursor and carrier prodrugs, double drug development and(or) multi-therapeutic strategies, use of metallocenic scaffolds, the medicinal chem. of antimalarial natural products, and in silico drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKDqBssJ35LVg90H21EOLACvtfcHk0lgVY9w-ERoZ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFersL0%253D&md5=f0e513e08db67f0f0186d279142cf99a</span></div><a href="/servlet/linkout?suffix=cit161c&amp;dbid=16384&amp;doi=10.2174%2F187152606784112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606784112155%26sid%3Dliteratum%253Aachs%26aulast%3DBiot%26aufirst%3DC.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DNovel%2520approaches%2520to%2520antimalarial%2520drug%2520discovery%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D173%26epage%3D204%26doi%3D10.2174%2F187152606784112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit161d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tietze, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekhar, S.</span><span> </span><span class="NLM_article-title">Natural product hybrids as new leads for drug discovery</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3996</span><span class="NLM_x">–</span> <span class="NLM_lpage">4028</span><span class="refDoi"> DOI: 10.1002/anie.200200553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fanie.200200553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslSlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=3996-4028&author=L.+F.+Tietzeauthor=H.+P.+Bellauthor=S.+Chandrasekhar&title=Natural+product+hybrids+as+new+leads+for+drug+discovery&doi=10.1002%2Fanie.200200553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161dR"><div class="casContent"><span class="casTitleNuber">161d</span><div class="casTitle"><span class="NLM_cas:atitle">Natural product hybrids as new leads for drug discovery</span></div><div class="casAuthors">Tietze, Lutz F.; Bell, Hubertus P.; Chandrasekhar, Srivari</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3996-4028</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Natural products play an important role in the development of drugs, esp. for the treatment of infections and cancer, as well as immunosuppressive compds.  However, the no. of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepd.  This new approach seems to be very promising in the development of leads for both medicinal and agrochem. applications, as the biol. activity of several new hybrids exceeds that of the parent compds.  The advantage of this concept over a combinatorial chem. approach is the high diversity and the inherent biol. activity of the hybrids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGTkEzD4p1YbVg90H21EOLACvtfcHk0lg1kdbRD98M5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslSlsrk%253D&md5=b0582d7a40ce53ce5b957b287b74d750</span></div><a href="/servlet/linkout?suffix=cit161d&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200553%26sid%3Dliteratum%253Aachs%26aulast%3DTietze%26aufirst%3DL.%2BF.%26aulast%3DBell%26aufirst%3DH.%2BP.%26aulast%3DChandrasekhar%26aufirst%3DS.%26atitle%3DNatural%2520product%2520hybrids%2520as%2520new%2520leads%2520for%2520drug%2520discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D3996%26epage%3D4028%26doi%3D10.1002%2Fanie.200200553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">Molecular biomarkers in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Physiol. Lung Cell Mol. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">L681</span><span class="NLM_x">–</span> <span class="NLM_lpage">L691</span><span class="refDoi"> DOI: 10.1152/ajplung.00014.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1152%2Fajplung.00014.2014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2014&pages=L681-L691&author=B.+Leyauthor=K.+K.+Brownauthor=H.+R.+Collard&title=Molecular+biomarkers+in+idiopathic+pulmonary+fibrosis&doi=10.1152%2Fajplung.00014.2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00014.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00014.2014%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DB.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DMolecular%2520biomarkers%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2014%26volume%3D307%26spage%3DL681%26epage%3DL691%26doi%3D10.1152%2Fajplung.00014.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit162b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Small molecular inhibitors targeting activator protein 1 (AP-1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6930</span><span class="NLM_x">–</span> <span class="NLM_lpage">6948</span><span class="refDoi"> DOI: 10.1021/jm5004733</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004733" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6930-6948&author=N.+Yeauthor=Y.+Dingauthor=C.+Wildauthor=Q.+Shenauthor=J.+Zhou&title=Small+molecular+inhibitors+targeting+activator+protein+1+%28AP-1%29&doi=10.1021%2Fjm5004733"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=10.1021%2Fjm5004733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004733%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DSmall%2520molecular%2520inhibitors%2520targeting%2520activator%2520protein%25201%2520%2528AP-1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6930%26epage%3D6948%26doi%3D10.1021%2Fjm5004733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit162c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jarman, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khambata, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cope, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellenie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarai, G.</span><span> </span><span class="NLM_article-title">An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1165/rcmb.2013-0174OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2013-0174OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23977848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtV2mtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=158-169&author=E.+R.+Jarmanauthor=V.+S.+Khambataauthor=C.+Copeauthor=P.+Jonesauthor=J.+Rogerauthor=L.+Y.+Yeauthor=N.+Dugganauthor=D.+Headauthor=A.+Pearceauthor=N.+J.+Pressauthor=B.+Bellenieauthor=B.+Sohalauthor=G.+Jarai&title=An+inhibitor+of+NADPH+oxidase-4+attenuates+established+pulmonary+fibrosis+in+a+rodent+disease+model&doi=10.1165%2Frcmb.2013-0174OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162cR"><div class="casContent"><span class="casTitleNuber">162c</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model</span></div><div class="casAuthors">Jarman, Elizabeth R.; Khambata, Valerie S.; Cope, Claire; Jones, Peter; Roger, Jan; Ye, Li Yun; Duggan, Nicholas; Head, Denise; Pearce, Andrew; Press, Neil J.; Bellenie, Ben; Sohal, Bindi; Jarai, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-169, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a chronic progressive disease of increasing prevalence for which there is no effective therapy.  Increased oxidative stress assocd. with an oxidant-antioxidant imbalance is thought to contribute to disease progression.  NADPH oxidases (Nox) are a primary source of reactive oxygen species within the lung and cardiovascular system.  We demonstrate that the Nox4 isoform is up-regulated in the lungs of patients with IPF and in a rodent model of bleomycin-induced pulmonary fibrosis and vascular remodeling.  Nox4 is constitutively active, and therefore increased expression levels are likely to contribute to disease pathol.  Using a small mol. Nox4/Nox1 inhibitor, we demonstrate that targeting Nox4 results in attenuation of an established fibrotic response, with redns. in gene transcripts for the extracellular matrix components collagen 1α1, collagen 3α1, and fibronectin and in principle pathway components assocd. with pulmonary fibrosis and hypoxia-mediated vascular remodeling: transforming growth factor (TGF)-β1, plasminogen activator inhibitor-1, hypoxia-inducible factor, and Nox4.  TGF-β1 is a principle fibrotic mediator responsible for inducing up-regulation of profibrotic pathways assocd. with disease pathol.  Using normal human lung-derived primary fibroblasts, we demonstrate that inhibition of Nox4 activity using a small mol. antagonist attenuates TGF-β1-mediated up-regulation in expression of profibrotic genes and inhibits the differentiation of fibroblast to myofibroblasts, that is assocd. with up-regulation in smooth muscle actin and acquisition of a contractile phenotype.  These studies support the view that targeting Nox4 may provide a therapeutic approach for attenuating pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWfXYamqYDi7Vg90H21EOLACvtfcHk0lhGONi3fQZNhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtV2mtr4%253D&md5=da9e2288b3be2c59a9991f8e69f83902</span></div><a href="/servlet/linkout?suffix=cit162c&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0174OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0174OC%26sid%3Dliteratum%253Aachs%26aulast%3DJarman%26aufirst%3DE.%2BR.%26aulast%3DKhambata%26aufirst%3DV.%2BS.%26aulast%3DCope%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DRoger%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DL.%2BY.%26aulast%3DDuggan%26aufirst%3DN.%26aulast%3DHead%26aufirst%3DD.%26aulast%3DPearce%26aufirst%3DA.%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DBellenie%26aufirst%3DB.%26aulast%3DSohal%26aufirst%3DB.%26aulast%3DJarai%26aufirst%3DG.%26atitle%3DAn%2520inhibitor%2520of%2520NADPH%2520oxidase-4%2520attenuates%2520established%2520pulmonary%2520fibrosis%2520in%2520a%2520rodent%2520disease%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D50%26spage%3D158%26epage%3D169%26doi%3D10.1165%2Frcmb.2013-0174OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit162d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Vij, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noth, I.</span><span> </span><span class="NLM_article-title">Peripheral blood biomarkers in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Transl. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.trsl.2012.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.trsl.2012.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22424426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVGntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2012&pages=218-227&author=R.+Vijauthor=I.+Noth&title=Peripheral+blood+biomarkers+in+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.trsl.2012.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162dR"><div class="casContent"><span class="casTitleNuber">162d</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral blood biomarkers in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Vij, Rekha; Noth, Imre</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">218-227</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">In this article, we review the evidence for peripheral blood biomarkers in idiopathic pulmonary fibrosis (IPF), a life-threatening fibrotic lung disease of unknown etiol.  We focus on selected biomarkers present in peripheral blood, as they are easy to obtain, can be measured longitudinally, and have the greatest likelihood of achieving clin. utility.  This article concs. on biomarkers with mechanistic plausibility that may be directly involved in the development of IPF, including KL-6, surfactant proteins A and D, matrix metalloproteases (MMP) 1 and 7, CCL18, VEGF, YKL-40, osteopontin, circulating fibrocytes, and T cells.  After reviewing the evidence base for each, we designate the biomarkers that may have utility as: (1) diagnostic biomarkers to distinguish IPF from other interstitial lung diseases, (2) prognostic biomarkers that are correlated with disease progression or mortality, or (3) biomarkers that can be used as tools for serial monitoring of disease severity.  Although there are no validated biomarkers that are currently available, the need for surrogates of diagnosis, prognosis, and monitoring of disease course with emerging therapies is great.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEIy7th6E_17Vg90H21EOLACvtfcHk0lhGONi3fQZNhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVGntLs%253D&md5=4636c31e0d430ca5596a87af5c6f6123</span></div><a href="/servlet/linkout?suffix=cit162d&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2012.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2012.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DVij%26aufirst%3DR.%26aulast%3DNoth%26aufirst%3DI.%26atitle%3DPeripheral%2520blood%2520biomarkers%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DTransl.%2520Res.%26date%3D2012%26volume%3D159%26spage%3D218%26epage%3D227%26doi%3D10.1016%2Fj.trsl.2012.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Orens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estenne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcasoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshavjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotloff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vachiery, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanville, A. R.</span><span> </span><span class="NLM_article-title">International guidelines for the selection of lung transplant candidates: 2006 updates-a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation</span> <span class="citation_source-journal">J. Heart. Lung. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1016/j.healun.2006.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.healun.2006.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16818116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD28zpvFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=J.+B.+Orensauthor=M.+Estenneauthor=S.+Arcasoyauthor=J.+V.+Conteauthor=P.+Corrisauthor=J.+J.+Eganauthor=T.+Eganauthor=S.+Keshavjeeauthor=C.+Knoopauthor=R.+Kotloffauthor=F.+J.+Martinezauthor=S.+Nathanauthor=S.+Palmerauthor=A.+Pattersonauthor=L.+Singerauthor=G.+Snellauthor=S.+Studerauthor=J.+L.+Vachieryauthor=A.+R.+Glanville&title=International+guidelines+for+the+selection+of+lung+transplant+candidates%3A+2006+updates-a+consensus+report+from+the+pulmonary+scientific+council+of+the+international+society+for+heart+and+lung+transplantation&doi=10.1016%2Fj.healun.2006.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation</span></div><div class="casAuthors">Orens Jonathan B; Estenne Marc; Arcasoy Selim; Conte John V; Corris Paul; Egan Jim J; Egan Thomas; Keshavjee Shaf; Knoop Christiane; Kotloff Robert; Martinez Fernando J; Nathan Steven; Palmer Scott; Patterson Alec; Singer Lianne; Snell Gregory; Studer Sean; Vachiery J L; Glanville Allan R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">745-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlo1JPaJWqwJVVjGoY74BafW6udTcc2eZxgXgmecQCa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zpvFOrsg%253D%253D&md5=8aaba362d6b0fcec46366a6b06b6212c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2006.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2006.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DOrens%26aufirst%3DJ.%2BB.%26aulast%3DEstenne%26aufirst%3DM.%26aulast%3DArcasoy%26aufirst%3DS.%26aulast%3DConte%26aufirst%3DJ.%2BV.%26aulast%3DCorris%26aufirst%3DP.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26aulast%3DEgan%26aufirst%3DT.%26aulast%3DKeshavjee%26aufirst%3DS.%26aulast%3DKnoop%26aufirst%3DC.%26aulast%3DKotloff%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNathan%26aufirst%3DS.%26aulast%3DPalmer%26aufirst%3DS.%26aulast%3DPatterson%26aufirst%3DA.%26aulast%3DSinger%26aufirst%3DL.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DStuder%26aufirst%3DS.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGlanville%26aufirst%3DA.%2BR.%26atitle%3DInternational%2520guidelines%2520for%2520the%2520selection%2520of%2520lung%2520transplant%2520candidates%253A%25202006%2520updates-a%2520consensus%2520report%2520from%2520the%2520pulmonary%2520scientific%2520council%2520of%2520the%2520international%2520society%2520for%2520heart%2520and%2520lung%2520transplantation%26jtitle%3DJ.%2520Heart.%2520Lung.%2520Transplant.%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755%26doi%3D10.1016%2Fj.healun.2006.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Weill, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dark, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshavjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleden, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamora, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanville, A. R.</span><span> </span><span class="NLM_article-title">A consensus document for the selection of lung transplant candidates: 2014-an updates from the pulmonary transplantation council of the international society for heart and lung transplantation</span> <span class="citation_source-journal">J. Heart. Lung. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.healun.2014.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.healun.2014.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25085497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2cbotFehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1-15&author=D.+Weillauthor=C.+Bendenauthor=P.+A.+Corrisauthor=J.+H.+Darkauthor=R.+D.+Davisauthor=S.+Keshavjeeauthor=D.+J.+Ledererauthor=M.+J.+Mulliganauthor=G.+A.+Pattersonauthor=L.+G.+Singerauthor=G.+I.+Snellauthor=G.+M.+Verledenauthor=M.+R.+Zamoraauthor=A.+R.+Glanville&title=A+consensus+document+for+the+selection+of+lung+transplant+candidates%3A+2014-an+updates+from+the+pulmonary+transplantation+council+of+the+international+society+for+heart+and+lung+transplantation&doi=10.1016%2Fj.healun.2014.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation</span></div><div class="casAuthors">Weill David; Benden Christian; Corris Paul A; Dark John H; Davis R Duane; Keshavjee Shaf; Singer Lianne G; Lederer David J; Mulligan Michael J; Patterson G Alexander; Snell Greg I; Verleden Geert M; Zamora Martin R; Glanville Allan R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The appropriate selection of lung transplant recipients is an important determinant of outcomes.  This consensus document is an update of the recipient selection guidelines published in 2006.  The Pulmonary Council of the International Society for Heart and Lung Transplantation (ISHLT) organized a Writing Committee of international experts to provide consensus opinion regarding the appropriate timing of referral and listing of candidates for lung transplantation.  A comprehensive search of the medical literature was conducted with the assistance of a medical librarian.  Writing Committee members were assigned specific topics to research and discuss.  The Chairs of the Writing Committee were responsible for evaluating the completeness of the literature search, providing editorial support for the manuscript, and organizing group discussions regarding its content.  The consensus document makes specific recommendations regarding the timing of referral and of listing for lung transplantation.  These recommendations include discussions not present in previous ISHLT guidelines, including lung allocation scores, bridging to transplant with mechanical circulatory and ventilator support, and expanded indications for lung transplantation.  In the absence of high-grade evidence to support decision making, these consensus guidelines remain part of a continuum of expert opinion based on available studies and personal experience.  Some positions are immutable.  Although transplant is rightly a treatment of last resort for end-stage lung disease, early referral allows proper evaluation and thorough patient education.  Subsequent waiting list activation implies a tacit agreement that transplant offers a significant individual survival advantage.  It is both the challenge and the responsibility of the transplant community globally to ensure organ allocation maximizes the potential benefits of a scarce resource, thereby achieving that advantage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPdE4kgM2ochOk4JA3soTqfW6udTcc2eZwj0y0gjhywLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbotFehuw%253D%253D&md5=cccd0b6dc28554515625ebbbb0e99878</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2014.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2014.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DWeill%26aufirst%3DD.%26aulast%3DBenden%26aufirst%3DC.%26aulast%3DCorris%26aufirst%3DP.%2BA.%26aulast%3DDark%26aufirst%3DJ.%2BH.%26aulast%3DDavis%26aufirst%3DR.%2BD.%26aulast%3DKeshavjee%26aufirst%3DS.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DMulligan%26aufirst%3DM.%2BJ.%26aulast%3DPatterson%26aufirst%3DG.%2BA.%26aulast%3DSinger%26aufirst%3DL.%2BG.%26aulast%3DSnell%26aufirst%3DG.%2BI.%26aulast%3DVerleden%26aufirst%3DG.%2BM.%26aulast%3DZamora%26aufirst%3DM.%2BR.%26aulast%3DGlanville%26aufirst%3DA.%2BR.%26atitle%3DA%2520consensus%2520document%2520for%2520the%2520selection%2520of%2520lung%2520transplant%2520candidates%253A%25202014-an%2520updates%2520from%2520the%2520pulmonary%2520transplantation%2520council%2520of%2520the%2520international%2520society%2520for%2520heart%2520and%2520lung%2520transplantation%26jtitle%3DJ.%2520Heart.%2520Lung.%2520Transplant.%26date%3D2015%26volume%3D34%26spage%3D1%26epage%3D15%26doi%3D10.1016%2Fj.healun.2014.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Thabut, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauriat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jebrak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesèche, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mal, H.</span><span> </span><span class="NLM_article-title">Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.7326/0003-4819-151-11-200912010-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.7326%2F0003-4819-151-11-200912010-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19949142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjpt1Cnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2009&pages=767-774&author=G.+Thabutauthor=J.+D.+Christieauthor=P.+Ravaudauthor=Y.+Castierauthor=G.+Dauriatauthor=G.+Jebrakauthor=M.+Fournierauthor=G.+Les%C3%A8cheauthor=R.+Porcherauthor=H.+Mal&title=Survival+after+bilateral+versus+single-lung+transplantation+for+idiopathic+pulmonary+fibrosis&doi=10.7326%2F0003-4819-151-11-200912010-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Thabut Gabriel; Christie Jason D; Ravaud Philippe; Castier Yves; Dauriat Gaelle; Jebrak Gilles; Fournier Michel; Leseche Guy; Porcher Raphael; Mal Herve</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">767-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Patients with end-stage idiopathic pulmonary fibrosis (IPF) are increasingly having bilateral rather than single-lung transplantation.  OBJECTIVE:  To compare survival after single and bilateral lung transplantation in patients with IPF.  DESIGN:  Analysis of data from the United Network of Organ Sharing registry.  SETTING:  Transplantation centers in the United States.  PATIENTS:  3327 patients with IPF who had single (2146 patients [64.5%]) or bilateral (1181 patients [35.5%]) lung transplantation between 1987 and 2009.  MEASUREMENTS:  Survival times and causes of death after lung transplantation.  Selection bias was accounted for by multivariate risk adjustment, propensity score risk adjustment, and propensity-based matching.  RESULTS:  Median survival time was longer after bilateral lung transplantation than single-lung transplantation (5.2 years [CI, 4.3 to 6.7 years] vs. 3.8 years [CI, 3.6 to 4.1 years]; P < 0.001).  However, survival times for the 2 procedures did not differ after adjustment for baseline differences, with adjusted hazard ratios (HRs) for mortality with bilateral transplantation ranging from 0.89 (95% CI, 0.79 to 1.02) to 0.96 (CI, 0.77 to 1.20) in different analyses.  Bilateral lung transplantation seemed to result in harm within the first year (HR, 1.18 [CI, 0.98 to 1.42]) but survival benefit thereafter (HR, 0.72 [CI, 0.59 to 0.87]).  Primary graft failure was a more common cause of death among patients who had bilateral rather than single-lung transplantation (3.7% vs. 1.9%; P = 0.002).  Cancer was a more common cause of death among patients who had single rather than bilateral lung transplantation (unadjusted HR for death among single vs. bilateral transplant recipients, 3.60 [CI, 2.16 to 6.05]; P <0.001).  LIMITATION:  Causes of death were ascertained without an adjudication committee and must be interpreted cautiously.  CONCLUSION:  Survival did not differ between patients who had single and bilateral lung transplantation.  Single-lung transplantation confers short-term survival benefit but long-term harm, whereas bilateral transplantation confers short-term harm but long-term survival benefit.  PRIMARY FUNDING SOURCE:  None.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSijjivBBaVk5dYoSR9eyvsfW6udTcc2ebeuwNsxAb-Lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjpt1Cnuw%253D%253D&md5=b89c199bbd9edb3f44e73b76fd75af64</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-151-11-200912010-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-151-11-200912010-00004%26sid%3Dliteratum%253Aachs%26aulast%3DThabut%26aufirst%3DG.%26aulast%3DChristie%26aufirst%3DJ.%2BD.%26aulast%3DRavaud%26aufirst%3DP.%26aulast%3DCastier%26aufirst%3DY.%26aulast%3DDauriat%26aufirst%3DG.%26aulast%3DJebrak%26aufirst%3DG.%26aulast%3DFournier%26aufirst%3DM.%26aulast%3DLes%25C3%25A8che%26aufirst%3DG.%26aulast%3DPorcher%26aufirst%3DR.%26aulast%3DMal%26aufirst%3DH.%26atitle%3DSurvival%2520after%2520bilateral%2520versus%2520single-lung%2520transplantation%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2009%26volume%3D151%26spage%3D767%26epage%3D774%26doi%3D10.7326%2F0003-4819-151-11-200912010-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanam, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozzay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seethamraju, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shariati, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, M. J.</span><span> </span><span class="NLM_article-title">Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation</span> <span class="citation_source-journal">J. Heart. Lung. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span><span class="refDoi"> DOI: 10.1016/j.healun.2015.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.healun.2015.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26856664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28nosleqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=657-660&author=D.+Chauhanauthor=A.+B.+Karanamauthor=A.+Merloauthor=T.+Bozzayauthor=M.+J.+Zuckerauthor=H.+Seethamrajuauthor=N.+Shariatiauthor=M.+J.+Russo&title=Post-transplant+survival+in+idiopathic+pulmonary+fibrosis+patients+concurrently+listed+for+single+and+double+lung+transplantation&doi=10.1016%2Fj.healun.2015.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation</span></div><div class="casAuthors">Chauhan Dhaval; Karanam Ashwin B; Merlo Aurelie; Tom Bozzay P A; Zucker Mark J; Seethamraju Harish; Shariati Nazly; Russo Mark J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung transplantation is a widely accepted treatment for patients with end-stage lung disease related to idiopathic pulmonary fibrosis (IPF).  However, there are conflicting data on whether double lung transplant (DLT) or single lung transplant (SLT) is the superior therapy in these patients.  The purpose of this study was to determine whether actuarial post-transplant graft survival among IPF patients concurrently listed for DLT and SLT is greater for recipients undergoing the former or the latter.  METHODS:  The United Network for Organ Sharing provided de-identified patient-level data.  Analysis included lung transplant candidates with IPF listed between January 1, 2001 and December 31, 2009 (n = 3,411).  The study population included 1,001 (29.3%) lung transplant recipients concurrently listed for DLT and SLT, all ≥18 years of age.  The primary outcome measure was actuarial post-transplant graft survival, expressed in years.  RESULTS:  Among the study population, 433 (43.26%) recipients underwent SLT and 568 (56.74%) recipients underwent DLT.  The analysis included 2,722.5 years at risk, with median graft survival of 5.31 years.  On univariate (p = 0.317) and multivariate (p = 0.415) regression analyses, there was no difference in graft survival between DLT and SLT.  CONCLUSIONS:  Among IPF recipients concurrently listed for DLT and SLT, there is no statistical difference in actuarial graft survival between recipients undergoing DLT vs SLT.  This analysis suggests that increased use of SLT for IPF patients may increase the availability of organs to other candidates, and thus increase the net benefit of these organs, without measurably compromising outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ74ukb0R4Fylm8bhe6roZYfW6udTcc2ebeuwNsxAb-Lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nosleqsA%253D%253D&md5=04b20065ddae1833e55d29ed7e043df8</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2015.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2015.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DKaranam%26aufirst%3DA.%2BB.%26aulast%3DMerlo%26aufirst%3DA.%26aulast%3DBozzay%26aufirst%3DT.%26aulast%3DZucker%26aufirst%3DM.%2BJ.%26aulast%3DSeethamraju%26aufirst%3DH.%26aulast%3DShariati%26aufirst%3DN.%26aulast%3DRusso%26aufirst%3DM.%2BJ.%26atitle%3DPost-transplant%2520survival%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520patients%2520concurrently%2520listed%2520for%2520single%2520and%2520double%2520lung%2520transplantation%26jtitle%3DJ.%2520Heart.%2520Lung.%2520Transplant.%26date%3D2016%26volume%3D35%26spage%3D657%26epage%3D660%26doi%3D10.1016%2Fj.healun.2015.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Bennett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargagli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Refini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieroni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiribelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paladini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voltolini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottoli, P.</span><span> </span><span class="NLM_article-title">Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">681</span><span class="refDoi"> DOI: 10.1007/s00408-015-9767-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs00408-015-9767-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2015&pages=677-681&author=D.+Bennettauthor=A.+Fossiauthor=E.+Bargagliauthor=R.+M.+Refiniauthor=M.+Pieroniauthor=L.+Luzziauthor=C.+Ghiribelliauthor=P.+Paladiniauthor=L.+Voltoliniauthor=P.+Rottoli&title=Mortality+on+the+waiting+list+for+lung+transplantation+in+patients+with+idiopathic+pulmonary+fibrosis%3A+a+single-centre+experience&doi=10.1007%2Fs00408-015-9767-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1007%2Fs00408-015-9767-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-015-9767-x%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DD.%26aulast%3DFossi%26aufirst%3DA.%26aulast%3DBargagli%26aufirst%3DE.%26aulast%3DRefini%26aufirst%3DR.%2BM.%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DLuzzi%26aufirst%3DL.%26aulast%3DGhiribelli%26aufirst%3DC.%26aulast%3DPaladini%26aufirst%3DP.%26aulast%3DVoltolini%26aufirst%3DL.%26aulast%3DRottoli%26aufirst%3DP.%26atitle%3DMortality%2520on%2520the%2520waiting%2520list%2520for%2520lung%2520transplantation%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520single-centre%2520experience%26jtitle%3DLung%26date%3D2015%26volume%3D193%26spage%3D677%26epage%3D681%26doi%3D10.1007%2Fs00408-015-9767-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">He, W.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.-N.</span><span> </span><span class="NLM_article-title">Outcomes of Chinese patients with end-stage pulmonary disease while awaiting lung transplantation: a single-center study</span> <span class="citation_source-journal">Chin. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.4103/0366-6999.172547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4103%2F0366-6999.172547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26712425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28bhs1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2016&pages=3-7&author=W.-X.+Heauthor=Y.-L.+Yangauthor=Y.+Xiaauthor=N.+Songauthor=M.+Liuauthor=P.+Zhangauthor=J.+Fanauthor=G.-N.+Jiang&title=Outcomes+of+Chinese+patients+with+end-stage+pulmonary+disease+while+awaiting+lung+transplantation%3A+a+single-center+study&doi=10.4103%2F0366-6999.172547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Outcomes of Chinese Patients with End-stage Pulmonary Disease while Awaiting Lung Transplantation: A Single-center Study</span></div><div class="casAuthors">He Wen-Xin; Yang Yu-Ling; Xia Yan; Song Nan; Liu Ming; Zhang Peng; Fan Jiang; Jiang Ge-Ning</div><div class="citationInfo"><span class="NLM_cas:title">Chinese medical journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-7</span>
        ISSN:<span class="NLM_cas:issn">0366-6999</span>.
    </div><div class="casAbstract">BACKGROUND:  The factors affecting the outcome of patients referred for lung transplantation (LTx) still have not been investigated extensively.  The aim of this study was to characterize the patient outcomes and identify the prognostic factors for death while awaiting the LTx.  METHODS:  From January 2003 to November 2013, the clinical data of 103 patients with end-stage lung disease that had been referred for LTx to Department of Thoracic Surgery, Shanghai Pulmonary Hospital were analyzed retrospectively.  The relationship between predictors and survival was evaluated using the Kaplan-Meier method and the Cox proportional hazards model.  RESULTS:  Twenty-five patients (24.3%) died while awaiting the LTx.  Fifty patients (48.5%) underwent LTx, and 28 patients (27.2%) were still on the waitlist.  Compared to the candidates with chronic obstructive pulmonary disease (COPD), patients with idiopathic pulmonary fibrosis (IPF) had a higher mortality while awaiting the LTx (40.0% vs. 12.3%, P = 0.003).  Patients requiring mechanical ventilation (MV) had a higher mortality while waiting than others (50.0% vs. 20.2%, P = 0.038).  Two variables, using MV and IPF but not COPD as primary disease, emerged as significant independent risk factors for death on the waitlist (hazard ratio [HR] = 56.048, 95% confidence interval [CI]: 3.935-798.263, P = 0.003 and HR = 14.859, 95% CI: 2.695-81.932, P = 0.002, respectively).  CONCLUSION:  The type of end-stage lung disease, pulmonary hypertension, and MV may be distinctive prognostic factors for death while awaiting the LTx.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyUx63XGow6ZSWdIdmEou5fW6udTcc2ebqJMjBYXY2O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhs1Wguw%253D%253D&md5=8c373484c0e1881d1adab3e062a7ed49</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.4103%2F0366-6999.172547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0366-6999.172547%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.-X.%26aulast%3DYang%26aufirst%3DY.-L.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DG.-N.%26atitle%3DOutcomes%2520of%2520Chinese%2520patients%2520with%2520end-stage%2520pulmonary%2520disease%2520while%2520awaiting%2520lung%2520transplantation%253A%2520a%2520single-center%2520study%26jtitle%3DChin.%2520Med.%2520J.%26date%3D2016%26volume%3D129%26spage%3D3%26epage%3D7%26doi%3D10.4103%2F0366-6999.172547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Kenn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloeckl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span> </span><span class="NLM_article-title">Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis-a review</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1159/000354112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1159%2F000354112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=89-99&author=K.+Kennauthor=R.+Gloecklauthor=J.+Behr&title=Pulmonary+rehabilitation+in+patients+with+idiopathic+pulmonary+fibrosis-a+review&doi=10.1159%2F000354112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1159%2F000354112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000354112%26sid%3Dliteratum%253Aachs%26aulast%3DKenn%26aufirst%3DK.%26aulast%3DGloeckl%26aufirst%3DR.%26aulast%3DBehr%26aufirst%3DJ.%26atitle%3DPulmonary%2520rehabilitation%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis-a%2520review%26jtitle%3DRespiration%26date%3D2013%26volume%3D86%26spage%3D89%26epage%3D99%26doi%3D10.1159%2F000354112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Nishiyama, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arizono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span> </span><span class="NLM_article-title">Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respirology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span><span class="refDoi"> DOI: 10.1111/j.1440-1843.2007.01205.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1111%2Fj.1440-1843.2007.01205.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=394-399&author=O.+Nishiyamaauthor=Y.+Kondohauthor=T.+Kimuraauthor=K.+Katoauthor=K.+Kataokaauthor=T.+Ogawaauthor=F.+Watanabeauthor=S.+Arizonoauthor=K.+Nishimuraauthor=H.+Taniguchi&title=Effects+of+pulmonary+rehabilitation+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1111%2Fj.1440-1843.2007.01205.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2007.01205.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2007.01205.x%26sid%3Dliteratum%253Aachs%26aulast%3DNishiyama%26aufirst%3DO.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DK.%26aulast%3DKataoka%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DF.%26aulast%3DArizono%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DK.%26aulast%3DTaniguchi%26aufirst%3DH.%26atitle%3DEffects%2520of%2520pulmonary%2520rehabilitation%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespirology%26date%3D2008%26volume%3D13%26spage%3D394%26epage%3D399%26doi%3D10.1111%2Fj.1440-1843.2007.01205.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Vainshelboim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soreck, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruchter, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. R.</span><span> </span><span class="NLM_article-title">Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1007/s00408-015-9703-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs00408-015-9703-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2015&pages=345-354&author=B.+Vainshelboimauthor=J.+Oliveiraauthor=B.+D.+Foxauthor=Y.+Soreckauthor=O.+Fruchterauthor=M.+R.+Kramer&title=Long-term+effects+of+a+12-week+exercise+training+program+on+clinical+outcomes+in+idiopathic+pulmonary+fibrosis&doi=10.1007%2Fs00408-015-9703-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1007%2Fs00408-015-9703-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-015-9703-0%26sid%3Dliteratum%253Aachs%26aulast%3DVainshelboim%26aufirst%3DB.%26aulast%3DOliveira%26aufirst%3DJ.%26aulast%3DFox%26aufirst%3DB.%2BD.%26aulast%3DSoreck%26aufirst%3DY.%26aulast%3DFruchter%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DM.%2BR.%26atitle%3DLong-term%2520effects%2520of%2520a%252012-week%2520exercise%2520training%2520program%2520on%2520clinical%2520outcomes%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DLung%26date%3D2015%26volume%3D193%26spage%3D345%26epage%3D354%26doi%3D10.1007%2Fs00408-015-9703-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairclough, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Make, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozora, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wamboldt, F. S.</span><span> </span><span class="NLM_article-title">Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Care.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">789</span><span class="refDoi"> DOI: 10.4187/respcare.00939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4187%2Frespcare.00939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21333082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3MnhtFWisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2011&pages=783-789&author=J.+J.+Swigrisauthor=D.+L.+Faircloughauthor=M.+Morrisonauthor=B.+Makeauthor=E.+Kozoraauthor=K.+K.+Brownauthor=F.+S.+Wamboldt&title=Benefits+of+pulmonary+rehabilitation+in+idiopathic+pulmonary+fibrosis&doi=10.4187%2Frespcare.00939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Swigris Jeffrey J; Fairclough Diane L; Morrison Marianne; Make Barry; Kozora Elizabeth; Brown Kevin K; Wamboldt Frederick S</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory care</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">783-9</span>
        ISSN:<span class="NLM_cas:issn">0020-1324</span>.
    </div><div class="casAbstract">BACKGROUND:  Information on the benefits of pulmonary rehabilitation (PR) in patients with idiopathic pulmonary fibrosis (IPF) is growing, but PR's effects on certain important outcomes is lacking.  METHODS:  We conducted a pilot study of PR in IPF and analyzed changes in functional capacity, fatigue, anxiety, depression, sleep, and health status from baseline to after completion of a standard, 6-week PR program.  RESULTS:  Six-min walk distance improved a mean ± standard error 202 ± 135 feet (P = .01) from baseline.  Fatigue Severity Scale score also improved significantly, declining an average 1.5 ± 0.5 points from baseline.  There were trends toward improvement in anxiety, depression, and health status.  CONCLUSIONS:  PR improves functional capacity and fatigue in patients with IPF. (Clinical Trials.gov registration NCT00692796.)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ20JQt49kmKUewzGPswiWOfW6udTcc2eawUXvC9lGIRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnhtFWisA%253D%253D&md5=1681c09003b057942d2967dba0252aef</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.4187%2Frespcare.00939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4187%252Frespcare.00939%26sid%3Dliteratum%253Aachs%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DFairclough%26aufirst%3DD.%2BL.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DMake%26aufirst%3DB.%26aulast%3DKozora%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DWamboldt%26aufirst%3DF.%2BS.%26atitle%3DBenefits%2520of%2520pulmonary%2520rehabilitation%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Care.%26date%3D2011%26volume%3D56%26spage%3D783%26epage%3D789%26doi%3D10.4187%2Frespcare.00939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Gaunaurd, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Marín, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalin, L.P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenas, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. M.</span><span> </span><span class="NLM_article-title">Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program</span> <span class="citation_source-journal">Respir. Care.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.4187/respcare.03180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4187%2Frespcare.03180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25185149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsFyqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1872-1879&author=I.+A.+Gaunaurdauthor=O.+W.+G%C3%B3mez-Mar%C3%ADnauthor=C.+F.+Ramosauthor=C.+M.+Solauthor=M.+I.+Cohenauthor=L.P.+Cahalinauthor=D.+D.+Cardenasauthor=R.+M.+Jackson&title=Physical+activity+and+quality+of+life+improvements+of+patients+with+idiopathic+pulmonary+fibrosis+completing+a+pulmonary+rehabilitation+program&doi=10.4187%2Frespcare.03180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program</span></div><div class="casAuthors">Gaunaurd Ignacio A; Ramos Carol F; Sol Constanza M; Jackson Robert M; Gomez-Marin Orlando W; Cohen Meryl I; Cahalin Lawrence P; Cardenas Diana D</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory care</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1872-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Pulmonary rehabilitation is effective for patients with COPD, but its benefit is less clearly established in idiopathic pulmonary fibrosis (IPF), especially in regard to levels of physical activity and health-related quality of life.  The objectives were to determine whether pulmonary rehabilitation increased physical activity as assessed by the International Physical Activity Questionnaire (IPAQ), and improved quality of life and symptoms as assessed by the St George respiratory questionnaire for IPF (SGRQ-I) and the Borg dyspnea index (BDI).  METHODS:  Subjects who met current criteria for IPF were randomized to a 3-month pulmonary rehabilitation program (n = 11) or to a control group (n = 10).  The rehabilitation group participated in twice-weekly, 90-min exercise sessions (24 total sessions).  The control group maintained its preceding, normal physical activity.  All subjects underwent 6-min walk tests to assess the postexertion BDI.  The SGRQ-I and a 5-point self-assessment of health were completed at baseline, after 3 months of intervention or observation, and after 3-month follow-up.  All subjects completed the IPAQ weekly.  RESULTS:  Subjects in the rehabilitation group maintained significantly higher levels of physical activity throughout the 3-month rehabilitation program (rehabilitation: 51,364 ± 57,713 [mean ± SD] metabolic equivalent of task-minutes; control: 20,832 ± 37,155, P = .027 by 2-tailed Mann-Whitney test).  SGRQ-I symptom domain scores improved considerably by -9 ± 22 in the rehabilitation group, whereas in the control group they worsened (16 ± 12 rehabilitation compared with control, P = .013 by 2-tailed Mann-Whitney test).  During the 3-month follow-up, self-reported physical activity levels in the rehabilitation group were 14,428 ± 8,884 metabolic equivalent of task-minutes and in the control group 16,923 ± 32,620 (P = .17 by 2-tailed Mann-Whitney test), demonstrating substantial reversal of activity in the rehabilitation group.  BDI scores after 6-min walk tests did not change significantly.  CONCLUSIONS:  A 3-month rehabilitation program significantly improved symptoms (SGRQ-I) and physical activity levels (IPAQ) in subjects with IPF while they participated actively in the program. (ClinicalTrials.gov registration NCT01118221.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLF3vyupOcNa__Jf7-eMvJfW6udTcc2eawUXvC9lGIRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsFyqsg%253D%253D&md5=962e922c199aeca7aa4d90dd6d4791ae</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.4187%2Frespcare.03180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4187%252Frespcare.03180%26sid%3Dliteratum%253Aachs%26aulast%3DGaunaurd%26aufirst%3DI.%2BA.%26aulast%3DG%25C3%25B3mez-Mar%25C3%25ADn%26aufirst%3DO.%2BW.%26aulast%3DRamos%26aufirst%3DC.%2BF.%26aulast%3DSol%26aufirst%3DC.%2BM.%26aulast%3DCohen%26aufirst%3DM.%2BI.%26aulast%3DCahalin%26aufirst%3DL.P.%26aulast%3DCardenas%26aufirst%3DD.%2BD.%26aulast%3DJackson%26aufirst%3DR.%2BM.%26atitle%3DPhysical%2520activity%2520and%2520quality%2520of%2520life%2520improvements%2520of%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520completing%2520a%2520pulmonary%2520rehabilitation%2520program%26jtitle%3DRespir.%2520Care.%26date%3D2014%26volume%3D59%26spage%3D1872%26epage%3D1879%26doi%3D10.4187%2Frespcare.03180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Vainshelboim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yehoshua, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruchter, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. R.</span><span> </span><span class="NLM_article-title">Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span><span class="refDoi"> DOI: 10.1159/000367899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1159%2F000367899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=378-388&author=B.+Vainshelboimauthor=J.+Oliveiraauthor=L.+Yehoshuaauthor=I.+Weissauthor=B.+D.+Foxauthor=O.+Fruchterauthor=M.+R.+Kramer&title=Exercise+training-based+pulmonary+rehabilitation+program+is+clinically+beneficial+for+idiopathic+pulmonary+fibrosis&doi=10.1159%2F000367899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1159%2F000367899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000367899%26sid%3Dliteratum%253Aachs%26aulast%3DVainshelboim%26aufirst%3DB.%26aulast%3DOliveira%26aufirst%3DJ.%26aulast%3DYehoshua%26aufirst%3DL.%26aulast%3DWeiss%26aufirst%3DI.%26aulast%3DFox%26aufirst%3DB.%2BD.%26aulast%3DFruchter%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DM.%2BR.%26atitle%3DExercise%2520training-based%2520pulmonary%2520rehabilitation%2520program%2520is%2520clinically%2520beneficial%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespiration%26date%3D2014%26volume%3D88%26spage%3D378%26epage%3D388%26doi%3D10.1159%2F000367899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Jackson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Marín, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaunaurd, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalin, L.P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenas, D. D.</span><span> </span><span class="NLM_article-title">Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span><span class="refDoi"> DOI: 10.1007/s00408-014-9566-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs00408-014-9566-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=367-376&author=R.+M.+Jacksonauthor=O.+W.+G%C3%B3mez-Mar%C3%ADnauthor=C.+F.+Ramosauthor=C.+M.+Solauthor=M.+I.+Cohenauthor=I.+A.+Gaunaurdauthor=L.P.+Cahalinauthor=D.+D.+Cardenas&title=Exercise+limitation+in+IPF+patients%3A+a+randomized+trial+of+pulmonary+rehabilitation&doi=10.1007%2Fs00408-014-9566-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs00408-014-9566-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-014-9566-9%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DR.%2BM.%26aulast%3DG%25C3%25B3mez-Mar%25C3%25ADn%26aufirst%3DO.%2BW.%26aulast%3DRamos%26aufirst%3DC.%2BF.%26aulast%3DSol%26aufirst%3DC.%2BM.%26aulast%3DCohen%26aufirst%3DM.%2BI.%26aulast%3DGaunaurd%26aufirst%3DI.%2BA.%26aulast%3DCahalin%26aufirst%3DL.P.%26aulast%3DCardenas%26aufirst%3DD.%2BD.%26atitle%3DExercise%2520limitation%2520in%2520IPF%2520patients%253A%2520a%2520randomized%2520trial%2520of%2520pulmonary%2520rehabilitation%26jtitle%3DLung%26date%3D2014%26volume%3D192%26spage%3D367%26epage%3D376%26doi%3D10.1007%2Fs00408-014-9566-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elicker, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydell, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolters, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">1390</span><span class="NLM_x">–</span> <span class="NLM_lpage">1394</span><span class="refDoi"> DOI: 10.1164/rccm.201101-0138OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201101-0138OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21700909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Flsl2msQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2011&pages=1390-1394&author=J.+S.+Leeauthor=J.+H.+Ryuauthor=B.+M.+Elickerauthor=C.+P.+Lydellauthor=K.+D.+Jonesauthor=P.+J.+Woltersauthor=T.+E.+Kingauthor=H.+R.+Collard&title=Gastroesophageal+reflux+therapy+is+associated+with+longer+survival+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.201101-0138OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Lee Joyce S; Ryu Jay H; Elicker Brett M; Lydell Carmen P; Jones Kirk D; Wolters Paul J; King Talmadge E Jr; Collard Harold R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1390-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Gastroesophageal reflux (GER) is highly prevalent in patients with idiopathic pulmonary fibrosis (IPF).  Chronic microaspiration secondary to GER may play a role in the pathogenesis and natural history of IPF.  OBJECTIVES:  To investigate the relationship between GER-related variables and survival time in patients with IPF.  METHODS:  Regression analysis was used to investigate the relationship between GER-related variables and survival time in a retrospectively identified cohort of patients with well-characterized IPF from two academic medical centers.  MEASUREMENTS AND MAIN RESULTS:  Two hundred four patients were identified for inclusion.  GER-related variables were common in this cohort: reported symptoms of GER (34%), a history of GER disease (45%), reported use of GER medications (47%), and Nissen fundoplication (5%).  These GER-related variables were significantly associated with longer survival time on unadjusted analysis.  After adjustment, the use of GER medications was an independent predictor of longer survival time.  In addition, the use of gastroesophageal reflux medications was associated with a lower radiologic fibrosis score.  These findings were present regardless of center.  CONCLUSIONS:  The reported use of GER medications is associated with decreased radiologic fibrosis and is an independent predictor of longer survival time in patients with IPF.  These findings further support the hypothesis that GER and chronic microaspiration may play important roles in the pathobiology of IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdrLw-Ift0GacY7HFp97qMfW6udTcc2ebuO2IdOf69grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Flsl2msQ%253D%253D&md5=75fcba1dfad357fc957aefccb1e8f647</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1164%2Frccm.201101-0138OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201101-0138OC%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DElicker%26aufirst%3DB.%2BM.%26aulast%3DLydell%26aufirst%3DC.%2BP.%26aulast%3DJones%26aufirst%3DK.%2BD.%26aulast%3DWolters%26aufirst%3DP.%2BJ.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DGastroesophageal%2520reflux%2520therapy%2520is%2520associated%2520with%2520longer%2520survival%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D184%26spage%3D1390%26epage%3D1394%26doi%3D10.1164%2Frccm.201101-0138OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatto, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span> </span><span class="NLM_article-title">Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1113</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1183/13993003.02316-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.02316-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26424523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVChsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=1113-1130&author=G.+Raghuauthor=V.+C.+Amattoauthor=J.+Behrauthor=S.+Stowasser&title=Comorbidities+in+idiopathic+pulmonary+fibrosis+patients%3A+a+systematic+literature+review&doi=10.1183%2F13993003.02316-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review</span></div><div class="casAuthors">Raghu, Ganesh; Amatto, Valeria C.; Behr, Jurgen; Stowasser, Susanne</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1113-1130</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is assocd. with a fatal prognosis and manifests in patients over 60 years old who may have comorbidities.  The prevalence and impact of comorbidities on the clin. course of IPF is unclear.  This systematic literature review examd. the prevalence of comorbidities and mortality assocd. with comorbidities in IPF patients.  Relevant observational studies published in English from Jan. 1990 to Jan. 2015 identified via MEDLINE and EMBASE were included; bibliogs. of articles were also searched.  Among the 126 studies included, prevalence of pulmonary hypertension (PH) was 3-86%, 6-91% for obstructive sleep apnoea, 3-48% for lung cancer and 6-67% for chronic obstructive pulmonary disease (COPD).  Nonrespiratory comorbidities included ischemic heart disease (IHD) (3-68%) and gastro-oesophageal reflux (GER) (0-94%).  Mortality was highest among patients with IPF and lung cancer.  Most studies assessed relatively small samples of patients with IPF.  PH, COPD, lung cancer, GER and IHD are significant comorbidities; differences in IPF severity, case definitions and patient characteristics limited the comparability of findings.  The identification and prompt treatment of comorbidities may have a clin. significant impact on overall outcome that is meaningful for patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJU8q6LwCJLVg90H21EOLACvtfcHk0lhz_NGpsSQYrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVChsr4%253D&md5=694f040b69595ffe1b260309d6b521eb</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1183%2F13993003.02316-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02316-2014%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAmatto%26aufirst%3DV.%2BC.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DStowasser%26aufirst%3DS.%26atitle%3DComorbidities%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520patients%253A%2520a%2520systematic%2520literature%2520review%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D1113%26epage%3D1130%26doi%3D10.1183%2F13993003.02316-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">King, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S. D.</span><span> </span><span class="NLM_article-title">Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases</span> <span class="citation_source-journal">Curr. Opin. Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1097/MCP.0b013e328363f460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1097%2FMCP.0b013e328363f460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23912191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3sfms1Chsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=466-473&author=C.+Kingauthor=S.+D.+Nathan&title=Identification+and+treatment+of+comorbidities+in+idiopathic+pulmonary+fibrosis+and+other+fibrotic+lung+diseases&doi=10.1097%2FMCP.0b013e328363f460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases</span></div><div class="casAuthors">King Christopher; Nathan Steven D</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pulmonary medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The interstitial lung diseases (ILDs) frequently result in considerable disability and reduced survival in affected patients.  Unfortunately, they are often poorly responsive to available therapies.  Comorbidities, both pulmonary and nonpulmonary, frequently accompany ILDs and contribute to adverse outcomes.  RECENT FINDINGS:  Multiple comorbidities, including gastroesophageal reflux disease, venous thromboembolism, coronary artery disease, sleep-disordered breathing, depression, emphysema, pulmonary hypertension, and lung cancer contribute to the morbidity and mortality of fibrotic lung disease.  SUMMARY:  The identification and treatment of comorbidities may improve morbidity and potentially impact mortality in patients with ILD.  A high index of suspicion and an awareness of the spectrum of comorbidities are important in optimizing outcomes in this group of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxX3oP0Et5cBdUSIfHIn4FfW6udTcc2ebuO2IdOf69grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfms1Chsg%253D%253D&md5=40242bafcd55ba2d5495092bfee08a20</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e328363f460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e328363f460%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DC.%26aulast%3DNathan%26aufirst%3DS.%2BD.%26atitle%3DIdentification%2520and%2520treatment%2520of%2520comorbidities%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520other%2520fibrotic%2520lung%2520diseases%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D466%26epage%3D473%26doi%3D10.1097%2FMCP.0b013e328363f460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Schiza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermigkis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margaritopoulos, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniil, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poletti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzoni, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torre, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouloukaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sourvinos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoniou, K. M.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night</span> <span class="citation_source-journal">Eur. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1183/16000617.00009114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F16000617.00009114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26028644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2MblslSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=327-339&author=S.+Schizaauthor=C.+Mermigkisauthor=G.+A.+Margaritopoulosauthor=Z.+Daniilauthor=S.+Harariauthor=V.+Polettiauthor=E.+A.+Renzoniauthor=O.+Torreauthor=D.+Viscaauthor=I.+Bouloukakiauthor=G.+Sourvinosauthor=K.+M.+Antoniou&title=Idiopathic+pulmonary+fibrosis+and+sleep+disorders%3A+no+longer+strangers+in+the+night&doi=10.1183%2F16000617.00009114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night</span></div><div class="casAuthors">Schiza Sophia; Mermigkis Charalampos; Margaritopoulos George A; Daniil Zoi; Harari Sergio; Torre Olga; Poletti Venerino; Renzoni Elizabetta A; Visca Dina; Bouloukaki Isolde; Sourvinos George; Antoniou Katerina M</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">136</span>),
    <span class="NLM_cas:pages">327-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prevalence of obstructive sleep apnoea (OSA) is continuously increasing in patients with idiopathic pulmonary fibrosis (IPF) and, for the first time, the recent IPF guidelines recognise OSA as an important associated comorbidity that can affect patient's survival.  Thus, it becomes conceivable that clinicians should refer patients with newly diagnosed IPF to sleep centres for the diagnosis and treatment of OSA as well as for addressing issues regarding the reduced compliance of patients with continuous positive airway pressure therapy.  The discovery of biomarkers common to both disorders may help early diagnosis, institution of the most appropriate treatment and follow-up of patients.  Better understanding of epigenetic changes may provide useful information about pathogenesis and, possibly, development of new drugs for a dismal disease like IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQImIQDUdvi8g20zIbnCCI3fW6udTcc2eY4XJzWjmIug7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblslSitg%253D%253D&md5=0c76f651ce845b7fbe08b35acd6a1314</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1183%2F16000617.00009114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.00009114%26sid%3Dliteratum%253Aachs%26aulast%3DSchiza%26aufirst%3DS.%26aulast%3DMermigkis%26aufirst%3DC.%26aulast%3DMargaritopoulos%26aufirst%3DG.%2BA.%26aulast%3DDaniil%26aufirst%3DZ.%26aulast%3DHarari%26aufirst%3DS.%26aulast%3DPoletti%26aufirst%3DV.%26aulast%3DRenzoni%26aufirst%3DE.%2BA.%26aulast%3DTorre%26aufirst%3DO.%26aulast%3DVisca%26aufirst%3DD.%26aulast%3DBouloukaki%26aufirst%3DI.%26aulast%3DSourvinos%26aufirst%3DG.%26aulast%3DAntoniou%26aufirst%3DK.%2BM.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%2520and%2520sleep%2520disorders%253A%2520no%2520longer%2520strangers%2520in%2520the%2520night%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2015%26volume%3D24%26spage%3D327%26epage%3D339%26doi%3D10.1183%2F16000617.00009114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Pihtili, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingol, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuhadaroglu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issever, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbaran, Z.</span><span> </span><span class="NLM_article-title">Obstructive sleep apnea is common in patients with interstitial lung disease</span> <span class="citation_source-journal">Sleep. Breath.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1007/s11325-013-0834-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs11325-013-0834-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23563999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3srivFOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1281-1288&author=A.+Pihtiliauthor=Z.+Bingolauthor=E.+Kiyanauthor=C.+Cuhadarogluauthor=H.+Isseverauthor=Z.+Gulbaran&title=Obstructive+sleep+apnea+is+common+in+patients+with+interstitial+lung+disease&doi=10.1007%2Fs11325-013-0834-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Obstructive sleep apnea is common in patients with interstitial lung disease</span></div><div class="casAuthors">Pihtili Aylin; Bingol Zuleyha; Kiyan Esen; Cuhadaroglu Caglar; Issever Halim; Gulbaran Ziya</div><div class="citationInfo"><span class="NLM_cas:title">Sleep & breathing = Schlaf & Atmung</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1281-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The incidence of obstructive sleep apnea (OSA) in interstitial lung disease (ILD) has been reported at different frequencies in several studies.  The aims of our study were to evaluate the frequency of OSA in ILD and to analyze the relationship between polysomnography (PSG) findings and pulmonary function, disease severity, parenchymal involvement, and Epworth Sleepiness Scale (ESS) scores.  METHODS:  ILD patients with parenchymal involvement were evaluated.  The disease severity was assessed using an index consisting of body mass index (BMI), carbon monoxide diffusion capacity, the Modified Medical Research Council dyspnea scale, and the 6-min walking distance.  All of the patients had lung function, chest X-ray, PSG, ESS scoring, and an upper airway examination.  Patients with a BMI ≥ 30 or significant upper airway pathologies were excluded.  RESULTS:  Of 62 patients, 50 patients comprised the study group (14 male, 36 female; mean age 54 ± 12.35 years, mean BMI 25.9 ± 3.44 kg/m(2)) with diagnoses of idiopathic pulmonary fibrosis (IPF; n = 17), stage II-III sarcoidosis (n = 15), or scleroderma (n = 18).  The frequency of OSA was 68 %.  The mean apnea-hypopnea index (AHI) was 11.4 ± 12.5.  OSA was more common in IPF patients (p = 0.009).  The frequency of rapid eye movement-related sleep apnea was 52.9 %.  The frequency of OSA was higher in patients with a disease severity index ≥3 (p = 0.04).  The oxygen desaturation index and the AHI were higher in patients with diffuse radiological involvement (p = 0.007 and p = 0.043, respectively).  CONCLUSIONS:  OSA is common in ILD.  PSG or at minimum nocturnal oximetry should be performed, particularly in patients with functionally and radiologically severe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQl8YUkrTWr9ts4TFFB11gfW6udTcc2eY4XJzWjmIug7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srivFOgsg%253D%253D&md5=b24f98f5a342674eefa653e195e88052</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1007%2Fs11325-013-0834-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11325-013-0834-3%26sid%3Dliteratum%253Aachs%26aulast%3DPihtili%26aufirst%3DA.%26aulast%3DBingol%26aufirst%3DZ.%26aulast%3DKiyan%26aufirst%3DE.%26aulast%3DCuhadaroglu%26aufirst%3DC.%26aulast%3DIssever%26aufirst%3DH.%26aulast%3DGulbaran%26aufirst%3DZ.%26atitle%3DObstructive%2520sleep%2520apnea%2520is%2520common%2520in%2520patients%2520with%2520interstitial%2520lung%2520disease%26jtitle%3DSleep.%2520Breath.%26date%3D2013%26volume%3D17%26spage%3D1281%26epage%3D1288%26doi%3D10.1007%2Fs11325-013-0834-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Mermigkis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouloukaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoniou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadogiannis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannarakis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varouchakis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siafakas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiza, E. S.</span><span> </span><span class="NLM_article-title">Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Sleep. Breath.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1007/s11325-014-1033-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs11325-014-1033-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25028171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2cbis1ehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=385-391&author=C.+Mermigkisauthor=I.+Bouloukakiauthor=K.+Antoniouauthor=G.+Papadogiannisauthor=I.+Giannarakisauthor=G.+Varouchakisauthor=N.+Siafakasauthor=E.+S.+Schiza&title=Obstructive+sleep+apnea+should+be+treated+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1007%2Fs11325-014-1033-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Mermigkis Charalampos; Bouloukaki Izolde; Antoniou Katerina; Papadogiannis Georgios; Giannarakis Ioannis; Varouchakis Georgios; Siafakas Nikolaos; Schiza Sophia E</div><div class="citationInfo"><span class="NLM_cas:title">Sleep & breathing = Schlaf & Atmung</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">385-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVES:  The most recent idiopathic pulmonary fibrosis (IPF) guidelines include obstructive sleep apnea (OSA) among the IPF-associated comorbidities.  Furthermore, they recognize the paucity of studies related to continuous positive airway pressure(CPAP) treatment in this patient group and call for intensive research in this field.  Our aim was to assess the effect of CPAP treatment on sleep and overall life quality parameters, morbidity, and mortality in IPF patients with OSA.  METHODS:  Ninety-two treatment-naive, newly diagnosed, consecutive IPF patients underwent overnight-attended polysomnography (PSG).  In those patients with an apnea-hypopnea index (AHI) of ≥15, therapy with CPAP was initiated.  Patients were divided into poor and good CPAP compliance groups.  All subjects completed multiple quality-of-life and sleep instruments before CPAP initiation and at 1 year after the start of CPAP treatment.  RESULTS:  The good CPAP compliance group (37 patients) showed statistically significant improvement in all quality-of-life and sleep instruments after 1 year's CPAP treatment.  The poor CPAP compliance group (18 patients) showed significant changes of smaller strength only in a minority of the used instruments.  During the 24-month follow-up period after CPAP initiation, three patients from the CPAP poor compliance group died, whereas all patients from the good CPAP compliance group remained alive.  CONCLUSION:  Early OSA recognition and treatment is crucial in a fatal disease such as IPF.  Effective CPAP treatment in IPF patients with OSA results in a significant improvement in daily living activities and quality of sleep and life.  Good CPAP compliance appears to improve mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC-JJtYEFupLHHuJhbyicZfW6udTcc2ebbpFfzuqn2t7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbis1ehtg%253D%253D&md5=935828b75d0920f1c8dbaff21b2b5374</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1007%2Fs11325-014-1033-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11325-014-1033-6%26sid%3Dliteratum%253Aachs%26aulast%3DMermigkis%26aufirst%3DC.%26aulast%3DBouloukaki%26aufirst%3DI.%26aulast%3DAntoniou%26aufirst%3DK.%26aulast%3DPapadogiannis%26aufirst%3DG.%26aulast%3DGiannarakis%26aufirst%3DI.%26aulast%3DVarouchakis%26aufirst%3DG.%26aulast%3DSiafakas%26aufirst%3DN.%26aulast%3DSchiza%26aufirst%3DE.%2BS.%26atitle%3DObstructive%2520sleep%2520apnea%2520should%2520be%2520treated%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DSleep.%2520Breath.%26date%3D2015%26volume%3D19%26spage%3D385%26epage%3D391%26doi%3D10.1007%2Fs11325-014-1033-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98a','cit98b'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123a','cit123b'],'ref124':['cit124a','cit124b','cit124c','cit124d','cit124e'],'ref125':['cit125'],'ref126':['cit126a','cit126b'],'ref127':['cit127'],'ref128':['cit128a','cit128b','cit128c','cit128d'],'ref129':['cit129'],'ref130':['cit130a','cit130b'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133a','cit133b','cit133c'],'ref134':['cit134a','cit134b','cit134c'],'ref135':['cit135'],'ref136':['cit136a','cit136b'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144a','cit144b','cit144c','cit144d','cit144e'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147a','cit147b'],'ref148':['cit148'],'ref149':['cit149a','cit149b'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158a','cit158b'],'ref159':['cit159a','cit159b','cit159c'],'ref160':['cit160'],'ref161':['cit161a','cit161b','cit161c','cit161d'],'ref162':['cit162a','cit162b','cit162c','cit162d'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 51 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hartmut Beck, Tobias Thaler, Daniel Meibom, Mark Meininghaus, Hannah Jörißen, Lisa Dietz, Carsten Terjung, Michaela Bairlein, Clemens-Jeremias von Bühler, Sonja Anlauf, Chantal Fürstner, Timo Stellfeld, Dirk Schneider, Kersten M. Gericke, Thomas Buyck, Kai Lovis, Uwe Münster, Johanna Anlahr, Elisabeth Kersten, Guillaume Levilain, Virginia Marossek, <span class="NLM_string-name hlFld-ContribAuthor">Raimund Kast</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11639-11662. <a href="https://doi.org/10.1021/acs.jmedchem.0c00834" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00834</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00834%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252BSelective%252BHuman%252BProstaglandin%252BF%252B%252528FP%252529%252BReceptor%252BAntagonist%252B%252528BAY-6672%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%252B%252528IPF%252529%26aulast%3DBeck%26aufirst%3DHartmut%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16052020%26date%3D08102020%26date%3D24092020%26volume%3D63%26issue%3D20%26spage%3D11639%26epage%3D11662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shenzhi Zhou, Wei Li, Min Tian, Na Zhang, Xiaojing Yang, Weiwei Li, Ying Peng, <span class="NLM_string-name hlFld-ContribAuthor">Jiang Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic Activation of Pirfenidone Mediated by Cytochrome P450s and Sulfotransferases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8059-8068. <a href="https://doi.org/10.1021/acs.jmedchem.9b02073" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02073%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMetabolic%252BActivation%252Bof%252BPirfenidone%252BMediated%252Bby%252BCytochrome%252BP450s%252Band%252BSulfotransferases%26aulast%3DZhou%26aufirst%3DShenzhi%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D13122019%26date%3D18072020%26date%3D09072020%26volume%3D63%26issue%3D15%26spage%3D8059%26epage%3D8068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Inés González-Gil, Debora Zian, Henar Vázquez-Villa, Gloria Hernández-Torres, R. Fernando Martínez, Nora Khiar-Fernández, Richard Rivera, Yasuyuki Kihara, Isabel Devesa, Sakthikumar Mathivanan, Cristina Rosell del Valle, Emma Zambrana-Infantes, María Puigdomenech, Giovanni Cincilla, Melchor Sanchez-Martinez, Fernando Rodríguez de Fonseca, Antonio V. Ferrer-Montiel, Jerold Chun, Rubén López-Vales, María L. López-Rodríguez, <span class="NLM_string-name hlFld-ContribAuthor">Silvia Ortega-Gutiérrez</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 2372-2390. <a href="https://doi.org/10.1021/acs.jmedchem.9b01287" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01287</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01287%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BNovel%252BAgonist%252Bof%252Bthe%252BType%252B1%252BLysophosphatidic%252BAcid%252BReceptor%252B%252528LPA1%252529%25252C%252BUCM-05194%25252C%252BShows%252BEfficacy%252Bin%252BNeuropathic%252BPain%252BAmelioration%26aulast%3DGonz%25C3%25A1lez-Gil%26aufirst%3DIn%25C3%25A9s%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D07082019%26date%3D16122019%26date%3D02122019%26volume%3D63%26issue%3D5%26spage%3D2372%26epage%3D2390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Songwen Lin, Jing Jin, Ying Liu, Hua Tian, Yan Zhang, Rong Fu, Jingbo Zhang, Mingjin Wang, Tingting Du, Ming Ji, Deyu Wu, Kehui Zhang, Li Sheng, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (19)
                                     , 8873-8879. <a href="https://doi.org/10.1021/acs.jmedchem.9b00969" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00969</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00969%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Methylquinazoline%252BBased%252BPI3K%252BInhibitors%252Bfor%252Bthe%252BPotential%252BTreatment%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%26aulast%3DLin%26aufirst%3DSongwen%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18062019%26date%3D06082019%26date%3D23072019%26volume%3D62%26issue%3D19%26spage%3D8873%26epage%3D8879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lucienne Juillerat-Jeanneret, John-David Aubert, Josip Mikulic, <span class="NLM_string-name hlFld-ContribAuthor">Dela Golshayan</span>. </span><span class="cited-content_cbyCitation_article-title">Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 9811-9840. <a href="https://doi.org/10.1021/acs.jmedchem.8b00294" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00294</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00294%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFibrogenic%252BDisorders%252Bin%252BHuman%252BDiseases%25253A%252BFrom%252BInflammation%252Bto%252BOrgan%252BDysfunction%26aulast%3DJuillerat-Jeanneret%26aufirst%3DLucienne%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D21022018%26date%3D17072018%26date%3D03072018%26volume%3D61%26issue%3D22%26spage%3D9811%26epage%3D9840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aikaterini Nikolaou, Ioanna Ninou, Maroula G. Kokotou, Eleanna Kaffe, Antreas Afantitis, Vassilis Aidinis, <span class="NLM_string-name hlFld-ContribAuthor">George Kokotos</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (8)
                                     , 3697-3711. <a href="https://doi.org/10.1021/acs.jmedchem.8b00232" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00232%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHydroxamic%252BAcids%252BConstitute%252Ba%252BNovel%252BClass%252Bof%252BAutotaxin%252BInhibitors%252Bthat%252BExhibit%252Bin%252BVivo%252BEfficacy%252Bin%252Ba%252BPulmonary%252BFibrosis%252BModel%26aulast%3DNikolaou%26aufirst%3DAikaterini%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12022018%26date%3D18042018%26date%3D05042018%26volume%3D61%26issue%3D8%26spage%3D3697%26epage%3D3711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Yue</span>, <span class="hlFld-ContribAuthor ">Yaojie  Shi</span>, <span class="hlFld-ContribAuthor ">Xingping  Su</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Tinghong  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113714. <a href="https://doi.org/10.1016/j.ejmech.2021.113714" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113714%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMatrix%252Bmetalloproteinases%252Binhibitors%252Bin%252Bidiopathic%252Bpulmonary%252Bfibrosis%25253A%252BMedicinal%252Bchemistry%252Bperspectives%26aulast%3DYue%26aufirst%3DLin%26date%3D2021%26volume%3D224%26spage%3D113714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weibin  Qian</span>, <span class="hlFld-ContribAuthor ">Xinrui  Cai</span>, <span class="hlFld-ContribAuthor ">Qiuhai  Qian</span>, <span class="hlFld-ContribAuthor ">Xinying  Zhang</span>, . </span><span class="cited-content_cbyCitation_article-title">Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis. </span><span class="cited-content_cbyCitation_journal-name">BioMed Research International</span><span> <strong>2021,</strong> <em>2021 </em>, 1-15. <a href="https://doi.org/10.1155/2021/5545312" title="DOI URL">https://doi.org/10.1155/2021/5545312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2021/5545312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2021%2F5545312%26sid%3Dliteratum%253Aachs%26jtitle%3DBioMed%2520Research%2520International%26atitle%3DIdentification%252Band%252BValidation%252Bof%252BPotential%252BBiomarkers%252Band%252BPathways%252Bfor%252BIdiopathic%252BPulmonary%252BFibrosis%252Bby%252BComprehensive%252BBioinformatics%252BAnalysis%26aulast%3DQian%26aufirst%3DWeibin%26date%3D2021%26volume%3D2021%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jincheng  Wang</span>, <span class="hlFld-ContribAuthor ">Kaili  Hu</span>, <span class="hlFld-ContribAuthor ">Xuanyan  Cai</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Qiaojun  He</span>, <span class="hlFld-ContribAuthor ">Jiajia  Wang</span>, <span class="hlFld-ContribAuthor ">Qinjie  Weng</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>3 </em><a href="https://doi.org/10.1016/j.apsb.2021.07.023" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DTargeting%252BPI3K%25252FAKT%252Bsignaling%252Bfor%252Btreatment%252Bof%252Bidiopathic%252Bpulmonary%252Bfibrosis%26aulast%3DWang%26aufirst%3DJincheng%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Micaely Cristina dos Santos  Tenório</span>, <span class="hlFld-ContribAuthor ">Nayara Gomes  Graciliano</span>, <span class="hlFld-ContribAuthor ">Fabiana Andréa  Moura</span>, <span class="hlFld-ContribAuthor ">Alane Cabral Menezes de  Oliveira</span>, <span class="hlFld-ContribAuthor ">Marília Oliveira Fonseca  Goulart</span>. </span><span class="cited-content_cbyCitation_article-title">N-Acetylcysteine (NAC): Impacts on Human Health. </span><span class="cited-content_cbyCitation_journal-name">Antioxidants</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 967. <a href="https://doi.org/10.3390/antiox10060967" title="DOI URL">https://doi.org/10.3390/antiox10060967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antiox10060967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantiox10060967%26sid%3Dliteratum%253Aachs%26jtitle%3DAntioxidants%26atitle%3DN-Acetylcysteine%252B%252528NAC%252529%25253A%252BImpacts%252Bon%252BHuman%252BHealth%26aulast%3DTen%25C3%25B3rio%26aufirst%3DMicaely%2BCristina%2Bdos%2BSantos%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giovanni  Forte</span>, <span class="hlFld-ContribAuthor ">Beatrice  Bocca</span>, <span class="hlFld-ContribAuthor ">Andrea  Pisano</span>, <span class="hlFld-ContribAuthor ">Claudia  Collu</span>, <span class="hlFld-ContribAuthor ">Cristiano  Farace</span>, <span class="hlFld-ContribAuthor ">Angela  Sabalic</span>, <span class="hlFld-ContribAuthor ">Marta  Senofonte</span>, <span class="hlFld-ContribAuthor ">Alessandro Giuseppe  Fois</span>, <span class="hlFld-ContribAuthor ">Vittorio Lorenzo  Mazzarello</span>, <span class="hlFld-ContribAuthor ">Pietro  Pirina</span>, <span class="hlFld-ContribAuthor ">Roberto  Madeddu</span>. </span><span class="cited-content_cbyCitation_article-title">The levels of trace elements in sputum as biomarkers for idiopathic pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Chemosphere</span><span> <strong>2021,</strong> <em>271 </em>, 129514. <a href="https://doi.org/10.1016/j.chemosphere.2020.129514" title="DOI URL">https://doi.org/10.1016/j.chemosphere.2020.129514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chemosphere.2020.129514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chemosphere.2020.129514%26sid%3Dliteratum%253Aachs%26jtitle%3DChemosphere%26atitle%3DThe%252Blevels%252Bof%252Btrace%252Belements%252Bin%252Bsputum%252Bas%252Bbiomarkers%252Bfor%252Bidiopathic%252Bpulmonary%252Bfibrosis%26aulast%3DForte%26aufirst%3DGiovanni%26date%3D2021%26volume%3D271%26spage%3D129514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatmah  Al‐Habeeb</span>, <span class="hlFld-ContribAuthor ">Noof  Aloufi</span>, <span class="hlFld-ContribAuthor ">Hussein  Traboulsi</span>, <span class="hlFld-ContribAuthor ">Xingxing  Liu</span>, <span class="hlFld-ContribAuthor ">Parameswaran  Nair</span>, <span class="hlFld-ContribAuthor ">Christina  Haston</span>, <span class="hlFld-ContribAuthor ">Ilan  Azuelos</span>, <span class="hlFld-ContribAuthor ">Steven K.  Huang</span>, <span class="hlFld-ContribAuthor ">Eric S.  White</span>, <span class="hlFld-ContribAuthor ">Imed E.  Gallouzi</span>, <span class="hlFld-ContribAuthor ">Sergio  Di Marco</span>, <span class="hlFld-ContribAuthor ">David H.  Eidelman</span>, <span class="hlFld-ContribAuthor ">Carolyn J.  Baglole</span>. </span><span class="cited-content_cbyCitation_article-title">Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2021,</strong> <em>111 </em><a href="https://doi.org/10.1002/jcp.30380" title="DOI URL">https://doi.org/10.1002/jcp.30380</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.30380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.30380%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DHuman%252Bantigen%252BR%252Bpromotes%252Blung%252Bfibroblast%252Bdifferentiation%252Bto%252Bmyofibroblasts%252Band%252Bincreases%252Bextracellular%252Bmatrix%252Bproduction%26aulast%3DAl%25E2%2580%2590Habeeb%26aufirst%3DFatmah%26date%3D2021%26date%3D2021%26volume%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Su</span>, <span class="hlFld-ContribAuthor ">Kun  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Xie</span>, <span class="hlFld-ContribAuthor ">Mengdi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao  Wu</span>, <span class="hlFld-ContribAuthor ">Yijie  Zhang</span>, <span class="hlFld-ContribAuthor ">Junpeng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Mushroom Inonotus sanghuang alleviates experimental pulmonary fibrosis: Implications for therapy of pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2021,</strong> <em>133 </em>, 110919. <a href="https://doi.org/10.1016/j.biopha.2020.110919" title="DOI URL">https://doi.org/10.1016/j.biopha.2020.110919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2020.110919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2020.110919%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DMushroom%252BInonotus%252Bsanghuang%252Balleviates%252Bexperimental%252Bpulmonary%252Bfibrosis%25253A%252BImplications%252Bfor%252Btherapy%252Bof%252Bpulmonary%252Bfibrosis%26aulast%3DSu%26aufirst%3DXing%26date%3D2021%26volume%3D133%26spage%3D110919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ebuka-Olisaemeka  Nwafor</span>, <span class="hlFld-ContribAuthor ">Peng  Lu</span>, <span class="hlFld-ContribAuthor ">Yiting  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Peng</span>, <span class="hlFld-ContribAuthor ">Huan  Qin</span>, <span class="hlFld-ContribAuthor ">Kuibin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhe  Ma</span>, <span class="hlFld-ContribAuthor ">Bin  Xing</span>, <span class="hlFld-ContribAuthor ">Yukun  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiawei  Li</span>, <span class="hlFld-ContribAuthor ">Zhidong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Active Components from Traditional Herbal Medicine for the Potential Therapeutics of Idiopathic Pulmonary Fibrosis: A Systemic Review. </span><span class="cited-content_cbyCitation_journal-name">The American Journal of Chinese Medicine</span><span> <strong>2021,</strong> <em>49 </em>
                                    (05)
                                     , 1093-1114. <a href="https://doi.org/10.1142/S0192415X2150052X" title="DOI URL">https://doi.org/10.1142/S0192415X2150052X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1142/S0192415X2150052X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1142%2FS0192415X2150052X%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520American%2520Journal%2520of%2520Chinese%2520Medicine%26atitle%3DActive%252BComponents%252Bfrom%252BTraditional%252BHerbal%252BMedicine%252Bfor%252Bthe%252BPotential%252BTherapeutics%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%25253A%252BA%252BSystemic%252BReview%26aulast%3DNwafor%26aufirst%3DEbuka-Olisaemeka%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D05%26spage%3D1093%26epage%3D1114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martina  Bonifazi</span>, <span class="hlFld-ContribAuthor ">Mariangela  Di Vincenzo</span>, <span class="hlFld-ContribAuthor ">Miriam  Caffarini</span>, <span class="hlFld-ContribAuthor ">Federico  Mei</span>, <span class="hlFld-ContribAuthor ">Michele  Salati</span>, <span class="hlFld-ContribAuthor ">Lina  Zuccatosta</span>, <span class="hlFld-ContribAuthor ">Majed  Refai</span>, <span class="hlFld-ContribAuthor ">Monica  Mattioli-Belmonte</span>, <span class="hlFld-ContribAuthor ">Stefano  Gasparini</span>, <span class="hlFld-ContribAuthor ">Monia  Orciani</span>. </span><span class="cited-content_cbyCitation_article-title">How the Pathological Microenvironment Affects the Behavior of Mesenchymal Stem Cells in the Idiopathic Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (21)
                                     , 8140. <a href="https://doi.org/10.3390/ijms21218140" title="DOI URL">https://doi.org/10.3390/ijms21218140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21218140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21218140%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DHow%252Bthe%252BPathological%252BMicroenvironment%252BAffects%252Bthe%252BBehavior%252Bof%252BMesenchymal%252BStem%252BCells%252Bin%252Bthe%252BIdiopathic%252BPulmonary%252BFibrosis%26aulast%3DBonifazi%26aufirst%3DMartina%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D21%26spage%3D8140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suraj U.  Hettiarachchi</span>, <span class="hlFld-ContribAuthor ">Yen-Hsing  Li</span>, <span class="hlFld-ContribAuthor ">Jyoti  Roy</span>, <span class="hlFld-ContribAuthor ">Fenghua  Zhang</span>, <span class="hlFld-ContribAuthor ">Estela  Puchulu-Campanella</span>, <span class="hlFld-ContribAuthor ">Spencer D.  Lindeman</span>, <span class="hlFld-ContribAuthor ">Madduri  Srinivasarao</span>, <span class="hlFld-ContribAuthor ">Konstantin  Tsoyi</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Liang</span>, <span class="hlFld-ContribAuthor ">Ehab A.  Ayaub</span>, <span class="hlFld-ContribAuthor ">Cheryl  Nickerson-Nutter</span>, <span class="hlFld-ContribAuthor ">Ivan O.  Rosas</span>, <span class="hlFld-ContribAuthor ">Philip S.  Low</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models. </span><span class="cited-content_cbyCitation_journal-name">Science Translational Medicine</span><span> <strong>2020,</strong> <em>12 </em>
                                    (567)
                                     , eaay3724. <a href="https://doi.org/10.1126/scitranslmed.aay3724" title="DOI URL">https://doi.org/10.1126/scitranslmed.aay3724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scitranslmed.aay3724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscitranslmed.aay3724%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Translational%2520Medicine%26atitle%3DTargeted%252Binhibition%252Bof%252BPI3%252Bkinase%25252FmTOR%252Bspecifically%252Bin%252Bfibrotic%252Blung%252Bfibroblasts%252Bsuppresses%252Bpulmonary%252Bfibrosis%252Bin%252Bexperimental%252Bmodels%26aulast%3DHettiarachchi%26aufirst%3DSuraj%2BU.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D567%26spage%3Deaay3724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  Liang</span>, <span class="hlFld-ContribAuthor ">Wuyang  Cai</span>, <span class="hlFld-ContribAuthor ">Yaxue  Zhao</span>, <span class="hlFld-ContribAuthor ">Huanbai  Xu</span>, <span class="hlFld-ContribAuthor ">Huirong  Tang</span>, <span class="hlFld-ContribAuthor ">Daijie  Chen</span>, <span class="hlFld-ContribAuthor ">Feng  Qian</span>, <span class="hlFld-ContribAuthor ">Lei  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>158 </em>, 104884. <a href="https://doi.org/10.1016/j.phrs.2020.104884" title="DOI URL">https://doi.org/10.1016/j.phrs.2020.104884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2020.104884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2020.104884%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DLycorine%252Bameliorates%252Bbleomycin-induced%252Bpulmonary%252Bfibrosis%252Bvia%252Binhibiting%252BNLRP3%252Binflammasome%252Bactivation%252Band%252Bpyroptosis%26aulast%3DLiang%26aufirst%3DQing%26date%3D2020%26volume%3D158%26spage%3D104884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuang  Lin</span>, <span class="hlFld-ContribAuthor ">Rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Rui  Ma</span>, <span class="hlFld-ContribAuthor ">Liming  Xu</span>, <span class="hlFld-ContribAuthor ">Linghua  Zhu</span>, <span class="hlFld-ContribAuthor ">Jian  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaoxia  An</span>. </span><span class="cited-content_cbyCitation_article-title">LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2020,</strong> <em>11 </em>
                                    (8)
                                     <a href="https://doi.org/10.1038/s41419-020-02889-w" title="DOI URL">https://doi.org/10.1038/s41419-020-02889-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-020-02889-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-020-02889-w%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DLncRNA%252BHoxaas3%252Bpromotes%252Blung%252Bfibroblast%252Bactivation%252Band%252Bfibrosis%252Bby%252Btargeting%252BmiR-450b-5p%252Bto%252Bregulate%252BRunx1%26aulast%3DLin%26aufirst%3DShuang%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elke  Boxhammer</span>, <span class="hlFld-ContribAuthor ">Karla  Lehle</span>, <span class="hlFld-ContribAuthor ">Christof  Schmid</span>, <span class="hlFld-ContribAuthor ">Marietta  von Suesskind-Schwendi</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-oxidative effect of the tyrosine kinase inhibitor nintedanib: a potential therapy for chronic lung allograft dysfunction?. </span><span class="cited-content_cbyCitation_journal-name">Experimental Lung Research</span><span> <strong>2020,</strong> <em>46 </em>
                                    (5)
                                     , 128-145. <a href="https://doi.org/10.1080/01902148.2020.1738594" title="DOI URL">https://doi.org/10.1080/01902148.2020.1738594</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/01902148.2020.1738594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F01902148.2020.1738594%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Lung%2520Research%26atitle%3DAnti-oxidative%252Beffect%252Bof%252Bthe%252Btyrosine%252Bkinase%252Binhibitor%252Bnintedanib%25253A%252Ba%252Bpotential%252Btherapy%252Bfor%252Bchronic%252Blung%252Ballograft%252Bdysfunction%25253F%26aulast%3DBoxhammer%26aufirst%3DElke%26date%3D2020%26date%3D2020%26volume%3D46%26issue%3D5%26spage%3D128%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hairui  Wu</span>, <span class="hlFld-ContribAuthor ">Xi  Gu</span>, <span class="hlFld-ContribAuthor ">Jinling  Li</span>, <span class="hlFld-ContribAuthor ">Mingxing  Wang</span>, <span class="hlFld-ContribAuthor ">Yanchun  Li</span>, <span class="hlFld-ContribAuthor ">Lei  Yuan</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Enlong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of potential platelet-derived growth factor receptor α inhibitors by computational screening and binding simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>96 </em>, 107527. <a href="https://doi.org/10.1016/j.jmgm.2019.107527" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.107527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.107527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.107527%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DIdentification%252Bof%252Bpotential%252Bplatelet-derived%252Bgrowth%252Bfactor%252Breceptor%252B%2525CE%2525B1%252Binhibitors%252Bby%252Bcomputational%252Bscreening%252Band%252Bbinding%252Bsimulations%26aulast%3DWu%26aufirst%3DHairui%26date%3D2020%26volume%3D96%26spage%3D107527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Liming  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaoxia  An</span>, <span class="hlFld-ContribAuthor ">Xinbing  Sui</span>, <span class="hlFld-ContribAuthor ">Shuang  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Astragalus polysaccharides attenuate pulmonary�fibrosis by inhibiting the epithelial-mesenchymal�transition and NF-κB pathway activation. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Medicine</span><span> <strong>2020,</strong> <em> </em><a href="https://doi.org/10.3892/ijmm.2020.4574" title="DOI URL">https://doi.org/10.3892/ijmm.2020.4574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ijmm.2020.4574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fijmm.2020.4574%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Medicine%26atitle%3DAstragalus%252Bpolysaccharides%252Battenuate%252Bpulmonary%2525EF%2525BF%2525BDfibrosis%252Bby%252Binhibiting%252Bthe%252Bepithelial-mesenchymal%2525EF%2525BF%2525BDtransition%252Band%252BNF-%2525CE%2525BAB%252Bpathway%252Bactivation%26aulast%3DZhang%26aufirst%3DRui%26date%3D2020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daoyong  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Jiao</span>, <span class="hlFld-ContribAuthor ">Yonggui Robin  Chi</span>, <span class="hlFld-ContribAuthor ">Théo P.  Gonçalves</span>, <span class="hlFld-ContribAuthor ">Kuo‐Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Jianrong Steve  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Three‐Component Heck Arylation/Amination of Nonconjugated Cyclodienes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (13)
                                     , 5379-5383. <a href="https://doi.org/10.1002/ange.201915864" title="DOI URL">https://doi.org/10.1002/ange.201915864</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201915864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201915864%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAsymmetric%252BThree%2525E2%252580%252590Component%252BHeck%252BArylation%25252FAmination%252Bof%252BNonconjugated%252BCyclodienes%26aulast%3DZhu%26aufirst%3DDaoyong%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D13%26spage%3D5379%26epage%3D5383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daoyong  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Jiao</span>, <span class="hlFld-ContribAuthor ">Yonggui Robin  Chi</span>, <span class="hlFld-ContribAuthor ">Théo P.  Gonçalves</span>, <span class="hlFld-ContribAuthor ">Kuo‐Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Jianrong Steve  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Three‐Component Heck Arylation/Amination of Nonconjugated Cyclodienes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (13)
                                     , 5341-5345. <a href="https://doi.org/10.1002/anie.201915864" title="DOI URL">https://doi.org/10.1002/anie.201915864</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201915864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201915864%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DAsymmetric%252BThree%2525E2%252580%252590Component%252BHeck%252BArylation%25252FAmination%252Bof%252BNonconjugated%252BCyclodienes%26aulast%3DZhu%26aufirst%3DDaoyong%26date%3D2020%26volume%3D59%26issue%3D13%26spage%3D5341%26epage%3D5345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Liu</span>, <span class="hlFld-ContribAuthor ">Xu  Zheng</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (2)
                                     , 182-187. <a href="https://doi.org/10.1002/cmdc.201900606" title="DOI URL">https://doi.org/10.1002/cmdc.201900606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900606%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNovel%252BPyrimidines%252Bas%252BMultitarget%252BProtein%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%252B%252528IPF%252529%26aulast%3DSun%26aufirst%3DBo%26date%3D2020%26date%3D2019%26volume%3D15%26issue%3D2%26spage%3D182%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dexin  Deng</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Linlin  Xue</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Shoujun  Zheng</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111790. <a href="https://doi.org/10.1016/j.ejmech.2019.111790" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111790%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bdiscovery%252Bof%252Bnew%252Bcompounds%252Bbearing%252Bcoumarin%252Bscaffold%252Bfor%252Bthe%252Btreatment%252Bof%252Bpulmonary%252Bfibrosis%26aulast%3DDeng%26aufirst%3DDexin%26date%3D2020%26volume%3D185%26spage%3D111790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-hui  Ma</span>, <span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Hai-feng  Ma</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Li  Liu</span>, <span class="hlFld-ContribAuthor ">Yan  Yin</span>, <span class="hlFld-ContribAuthor ">Xiao-ming  Zhou</span>, <span class="hlFld-ContribAuthor ">Gang  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>241 </em>, 117139. <a href="https://doi.org/10.1016/j.lfs.2019.117139" title="DOI URL">https://doi.org/10.1016/j.lfs.2019.117139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2019.117139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2019.117139%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DProtective%252Beffects%252Bof%252BGHK-Cu%252Bin%252Bbleomycin-induced%252Bpulmonary%252Bfibrosis%252Bvia%252Banti-oxidative%252Bstress%252Band%252Banti-inflammation%252Bpathways%26aulast%3DMa%26aufirst%3DWen-hui%26date%3D2020%26volume%3D241%26spage%3D117139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Chen</span>, <span class="hlFld-ContribAuthor ">Guangbao  Su</span>, <span class="hlFld-ContribAuthor ">Ping  Song</span>, <span class="hlFld-ContribAuthor ">Miao  Jiang</span>, <span class="hlFld-ContribAuthor ">Jiening  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">An animal research and a chemical composition analysis of a Chinese prescription for pulmonary fibrosis: Yangfei Huoxue Decoction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Ethnopharmacology</span><span> <strong>2019,</strong> <em>245 </em>, 112126. <a href="https://doi.org/10.1016/j.jep.2019.112126" title="DOI URL">https://doi.org/10.1016/j.jep.2019.112126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jep.2019.112126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jep.2019.112126%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Ethnopharmacology%26atitle%3DAn%252Banimal%252Bresearch%252Band%252Ba%252Bchemical%252Bcomposition%252Banalysis%252Bof%252Ba%252BChinese%252Bprescription%252Bfor%252Bpulmonary%252Bfibrosis%25253A%252BYangfei%252BHuoxue%252BDecoction%26aulast%3DLiu%26aufirst%3DXiao%26date%3D2019%26volume%3D245%26spage%3D112126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Qiuhong  Li</span>, <span class="hlFld-ContribAuthor ">Lei  Wei</span>, <span class="hlFld-ContribAuthor ">Zhongfu  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Ma</span>, <span class="hlFld-ContribAuthor ">Fangying  Liu</span>, <span class="hlFld-ContribAuthor ">Yanhua  Shen</span>, <span class="hlFld-ContribAuthor ">Shanfang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiulian  Zhang</span>, <span class="hlFld-ContribAuthor ">Huiping  Li</span>, <span class="hlFld-ContribAuthor ">Yechang  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Dexamethasone combined with berberine is an effective therapy for bleomycin‑induced pulmonary fibrosis in rats. </span><span class="cited-content_cbyCitation_journal-name">Experimental and Therapeutic Medicine</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.3892/etm.2019.7861" title="DOI URL">https://doi.org/10.3892/etm.2019.7861</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/etm.2019.7861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fetm.2019.7861%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520and%2520Therapeutic%2520Medicine%26atitle%3DDexamethasone%252Bcombined%252Bwith%252Bberberine%252Bis%252Ban%252Beffective%252Btherapy%252Bfor%252Bbleomycin%2525E2%252580%252591induced%252Bpulmonary%252Bfibrosis%252Bin%252Brats%26aulast%3DLi%26aufirst%3DLi%26date%3D2019%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lijuan  Fang</span>, <span class="hlFld-ContribAuthor ">Qingmei  Cheng</span>, <span class="hlFld-ContribAuthor ">Feiyan  Zhao</span>, <span class="hlFld-ContribAuthor ">Haipeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Yongyu  Luo</span>, <span class="hlFld-ContribAuthor ">Xingwen  Bao</span>, <span class="hlFld-ContribAuthor ">Yanghang  Li</span>, <span class="hlFld-ContribAuthor ">Xinyue  Liang</span>, <span class="hlFld-ContribAuthor ">Yanhong  Huang</span>, <span class="hlFld-ContribAuthor ">Jianping  Xu</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Han</span>, <span class="hlFld-ContribAuthor ">Yiting  Tang</span>, <span class="hlFld-ContribAuthor ">Siyuan  Tang</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Ziqiang  Luo</span>, <span class="hlFld-ContribAuthor ">DanDan  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Cigarette smoke exposure combined with lipopolysaccharides induced pulmonary fibrosis in mice. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Physiology & Neurobiology</span><span> <strong>2019,</strong> <em>266 </em>, 9-17. <a href="https://doi.org/10.1016/j.resp.2019.04.010" title="DOI URL">https://doi.org/10.1016/j.resp.2019.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.resp.2019.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.resp.2019.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Physiology%2520%2526%2520Neurobiology%26atitle%3DCigarette%252Bsmoke%252Bexposure%252Bcombined%252Bwith%252Blipopolysaccharides%252Binduced%252Bpulmonary%252Bfibrosis%252Bin%252Bmice%26aulast%3DFang%26aufirst%3DLijuan%26date%3D2019%26volume%3D266%26spage%3D9%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hirotomo  Shimizu</span>, <span class="hlFld-ContribAuthor ">Akitoshi  Ito</span>, <span class="hlFld-ContribAuthor ">Katsuhiko  Sakurada</span>, <span class="hlFld-ContribAuthor ">Junji  Nakamura</span>, <span class="hlFld-ContribAuthor ">Kosuke  Tanaka</span>, <span class="hlFld-ContribAuthor ">Masakazu  Komatsu</span>, <span class="hlFld-ContribAuthor ">Mineko  Takeda</span>, <span class="hlFld-ContribAuthor ">Kenichi  Saito</span>, <span class="hlFld-ContribAuthor ">Yukiko  Endo</span>, <span class="hlFld-ContribAuthor ">Tomohito  Kozaki</span>, <span class="hlFld-ContribAuthor ">Motoshi  Shoda</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Kuriyama</span>. </span><span class="cited-content_cbyCitation_article-title">AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A
              2
              : In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>369 </em>
                                    (3)
                                     , 511-522. <a href="https://doi.org/10.1124/jpet.118.255034" title="DOI URL">https://doi.org/10.1124/jpet.118.255034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.118.255034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.118.255034%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DAK106-001616%25252C%252Ba%252BPotent%252Band%252BSelective%252BInhibitor%252Bof%252BCytosolic%252BPhospholipase%252BA%252B2%252B%25253A%252BIn%252BVivo%252BEfficacy%252Bfor%252BInflammation%25252C%252BNeuropathic%252BPain%25252C%252Band%252BPulmonary%252BFibrosis%26aulast%3DShimizu%26aufirst%3DHirotomo%26date%3D2019%26date%3D2019%26volume%3D369%26issue%3D3%26spage%3D511%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fanchao  Fen</span>, <span class="hlFld-ContribAuthor ">Jiarui  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhichao  Wang</span>, <span class="hlFld-ContribAuthor ">Qi  Wu</span>, <span class="hlFld-ContribAuthor ">Xianmei  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and safety of N‑acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta‑analysis. </span><span class="cited-content_cbyCitation_journal-name">Experimental and Therapeutic Medicine</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.3892/etm.2019.7579" title="DOI URL">https://doi.org/10.3892/etm.2019.7579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/etm.2019.7579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fetm.2019.7579%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520and%2520Therapeutic%2520Medicine%26atitle%3DEfficacy%252Band%252Bsafety%252Bof%252BN%2525E2%252580%252591acetylcysteine%252Btherapy%252Bfor%252Bidiopathic%252Bpulmonary%252Bfibrosis%25253A%252BAn%252Bupdated%252Bsystematic%252Breview%252Band%252Bmeta%2525E2%252580%252591analysis%26aulast%3DFen%26aufirst%3DFanchao%26date%3D2019%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangping  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Li</span>, <span class="hlFld-ContribAuthor ">Chen  Li</span>, <span class="hlFld-ContribAuthor ">Shaojie  Yue</span>, <span class="hlFld-ContribAuthor ">Yanhong  Huang</span>, <span class="hlFld-ContribAuthor ">Pu  Huang</span>, <span class="hlFld-ContribAuthor ">Haipeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Yan  Zhou</span>, <span class="hlFld-ContribAuthor ">Yiting  Tang</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Dandan  Feng</span>, <span class="hlFld-ContribAuthor ">Ziqiang  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">NMDA receptor activation inhibits the protective effect of BM‑MSCs on bleomycin‑induced lung epithelial cell damage by inhibiting ERK signaling and the paracrine factor HGF. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Medicine</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.3892/ijmm.2019.4195" title="DOI URL">https://doi.org/10.3892/ijmm.2019.4195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ijmm.2019.4195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fijmm.2019.4195%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Medicine%26atitle%3DNMDA%252Breceptor%252Bactivation%252Binhibits%252Bthe%252Bprotective%252Beffect%252Bof%252BBM%2525E2%252580%252591MSCs%252Bon%252Bbleomycin%2525E2%252580%252591induced%252Blung%252Bepithelial%252Bcell%252Bdamage%252Bby%252Binhibiting%252BERK%252Bsignaling%252Band%252Bthe%252Bparacrine%252Bfactor%252BHGF%26aulast%3DPeng%26aufirst%3DXiangping%26date%3D2019%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Neumann</span>, <span class="hlFld-ContribAuthor ">Nina  Lepper</span>, <span class="hlFld-ContribAuthor ">Massimiliano  Vasile</span>, <span class="hlFld-ContribAuthor ">Valeria  Riccieri</span>, <span class="hlFld-ContribAuthor ">Marvin  Peters</span>, <span class="hlFld-ContribAuthor ">Florian  Meier</span>, <span class="hlFld-ContribAuthor ">Marie-Lisa  Hülser</span>, <span class="hlFld-ContribAuthor ">Oliver  Distler</span>, <span class="hlFld-ContribAuthor ">Steffen  Gay</span>, <span class="hlFld-ContribAuthor ">Poornima  Mahavadi</span>, <span class="hlFld-ContribAuthor ">Andreas  Günther</span>, <span class="hlFld-ContribAuthor ">Elke  Roeb</span>, <span class="hlFld-ContribAuthor ">Klaus W.  Frommer</span>, <span class="hlFld-ContribAuthor ">Magnus  Diller</span>, <span class="hlFld-ContribAuthor ">Ulf  Müller-Ladner</span>. </span><span class="cited-content_cbyCitation_article-title">Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. </span><span class="cited-content_cbyCitation_journal-name">Cytokine</span><span> <strong>2019,</strong> <em>117 </em>, 41-49. <a href="https://doi.org/10.1016/j.cyto.2018.11.013" title="DOI URL">https://doi.org/10.1016/j.cyto.2018.11.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cyto.2018.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cyto.2018.11.013%26sid%3Dliteratum%253Aachs%26jtitle%3DCytokine%26atitle%3DAdipokine%252Bexpression%252Bin%252Bsystemic%252Bsclerosis%252Blung%252Band%252Bgastrointestinal%252Borgan%252Binvolvement%26aulast%3DNeumann%26aufirst%3DElena%26date%3D2019%26volume%3D117%26spage%3D41%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomonari  Kinoshita</span>, <span class="hlFld-ContribAuthor ">Taichiro  Goto</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (6)
                                     , 1461. <a href="https://doi.org/10.3390/ijms20061461" title="DOI URL">https://doi.org/10.3390/ijms20061461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20061461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20061461%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BMechanisms%252Bof%252BPulmonary%252BFibrogenesis%252Band%252BIts%252BProgression%252Bto%252BLung%252BCancer%25253A%252BA%252BReview%26aulast%3DKinoshita%26aufirst%3DTomonari%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D1461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Song</span>, <span class="hlFld-ContribAuthor ">Pan  Xu</span>, <span class="hlFld-ContribAuthor ">Chao  Meng</span>, <span class="hlFld-ContribAuthor ">Chenguang  Song</span>, <span class="hlFld-ContribAuthor ">Timothy S.  Blackwell</span>, <span class="hlFld-ContribAuthor ">Rongrong  Li</span>, <span class="hlFld-ContribAuthor ">Hongbo  Li</span>, <span class="hlFld-ContribAuthor ">Jinjin  Zhang</span>, <span class="hlFld-ContribAuthor ">Changjun  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">lncITPF Promotes Pulmonary Fibrosis by Targeting hnRNP-L Depending on Its Host Gene ITGBL1. </span><span class="cited-content_cbyCitation_journal-name">Molecular Therapy</span><span> <strong>2019,</strong> <em>27 </em>
                                    (2)
                                     , 380-393. <a href="https://doi.org/10.1016/j.ymthe.2018.08.026" title="DOI URL">https://doi.org/10.1016/j.ymthe.2018.08.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ymthe.2018.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ymthe.2018.08.026%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Therapy%26atitle%3DlncITPF%252BPromotes%252BPulmonary%252BFibrosis%252Bby%252BTargeting%252BhnRNP-L%252BDepending%252Bon%252BIts%252BHost%252BGene%252BITGBL1%26aulast%3DSong%26aufirst%3DXiaodong%26date%3D2019%26volume%3D27%26issue%3D2%26spage%3D380%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yulia. B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The literature of heterocyclic chemistry, part XVII, 2017. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 337-418. <a href="https://doi.org/10.1016/bs.aihch.2019.01.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2019.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2019.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2019.01.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252Bliterature%252Bof%252Bheterocyclic%252Bchemistry%25252C%252Bpart%252BXVII%25252C%252B2017%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DLeonid%2BI.%26date%3D2019%26spage%3D337%26epage%3D418%26pub%3DElsevier%26date%3D2019%26volume%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sang Hoon  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Sun  Park</span>, <span class="hlFld-ContribAuthor ">Song Yee  Kim</span>, <span class="hlFld-ContribAuthor ">Dong Soon  Kim</span>, <span class="hlFld-ContribAuthor ">Young Whan  Kim</span>, <span class="hlFld-ContribAuthor ">Man Pyo  Chung</span>, <span class="hlFld-ContribAuthor ">Soo Taek  Uh</span>, <span class="hlFld-ContribAuthor ">Choon Sik  Park</span>, <span class="hlFld-ContribAuthor ">Sung Woo  Park</span>, <span class="hlFld-ContribAuthor ">Sung Hwan  Jeong</span>, <span class="hlFld-ContribAuthor ">Yong Bum  Park</span>, <span class="hlFld-ContribAuthor ">Hong Lyeol  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Wook  Shin</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Lee</span>, <span class="hlFld-ContribAuthor ">Jin Hwa  Lee</span>, <span class="hlFld-ContribAuthor ">Yangin  Jegal</span>, <span class="hlFld-ContribAuthor ">Hyun Kyung  Lee</span>, <span class="hlFld-ContribAuthor ">Yong Hyun  Kim</span>, <span class="hlFld-ContribAuthor ">Jin Woo  Song</span>, <span class="hlFld-ContribAuthor ">Moo Suk  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-23073-3" title="DOI URL">https://doi.org/10.1038/s41598-018-23073-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-23073-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-23073-3%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DComparison%252Bof%252BCPI%252Band%252BGAP%252Bmodels%252Bin%252Bpatients%252Bwith%252Bidiopathic%252Bpulmonary%252Bfibrosis%25253A%252Ba%252Bnationwide%252Bcohort%252Bstudy%26aulast%3DLee%26aufirst%3DSang%2BHoon%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giacomo  Sgalla</span>, <span class="hlFld-ContribAuthor ">Bruno  Iovene</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Calvello</span>, <span class="hlFld-ContribAuthor ">Margherita  Ori</span>, <span class="hlFld-ContribAuthor ">Francesco  Varone</span>, <span class="hlFld-ContribAuthor ">Luca  Richeldi</span>. </span><span class="cited-content_cbyCitation_article-title">Idiopathic pulmonary fibrosis: pathogenesis and management. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2018,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-018-0730-2" title="DOI URL">https://doi.org/10.1186/s12931-018-0730-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-018-0730-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-018-0730-2%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DIdiopathic%252Bpulmonary%252Bfibrosis%25253A%252Bpathogenesis%252Band%252Bmanagement%26aulast%3DSgalla%26aufirst%3DGiacomo%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro G.  Fois</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Paliogiannis</span>, <span class="hlFld-ContribAuthor ">Salvatore  Sotgia</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Zinellu</span>, <span class="hlFld-ContribAuthor ">Pietro  Pirina</span>, <span class="hlFld-ContribAuthor ">Ciriaco  Carru</span>, <span class="hlFld-ContribAuthor ">Angelo  Zinellu</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2018,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-018-0754-7" title="DOI URL">https://doi.org/10.1186/s12931-018-0754-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-018-0754-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-018-0754-7%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DEvaluation%252Bof%252Boxidative%252Bstress%252Bbiomarkers%252Bin%252Bidiopathic%252Bpulmonary%252Bfibrosis%252Band%252Btherapeutic%252Bapplications%25253A%252Ba%252Bsystematic%252Breview%26aulast%3DFois%26aufirst%3DAlessandro%2BG.%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Panagiotis  Paliogiannis</span>, <span class="hlFld-ContribAuthor ">Alessandro G  Fois</span>, <span class="hlFld-ContribAuthor ">Claudia  Collu</span>, <span class="hlFld-ContribAuthor ">Antonietta  Bandinu</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Zinellu</span>, <span class="hlFld-ContribAuthor ">Ciriaco  Carru</span>, <span class="hlFld-ContribAuthor ">Pietro  Pirina</span>, <span class="hlFld-ContribAuthor ">Arduino A  Mangoni</span>, <span class="hlFld-ContribAuthor ">Angelo  Zinellu</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative stress-linked biomarkers in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. </span><span class="cited-content_cbyCitation_journal-name">Biomarkers in Medicine</span><span> <strong>2018,</strong> <em>12 </em>
                                    (10)
                                     , 1175-1184. <a href="https://doi.org/10.2217/bmm-2018-0108" title="DOI URL">https://doi.org/10.2217/bmm-2018-0108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/bmm-2018-0108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fbmm-2018-0108%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomarkers%2520in%2520Medicine%26atitle%3DOxidative%252Bstress-linked%252Bbiomarkers%252Bin%252Bidiopathic%252Bpulmonary%252Bfibrosis%25253A%252Ba%252Bsystematic%252Breview%252Band%252Bmeta-analysis%26aulast%3DPaliogiannis%26aufirst%3DPanagiotis%26date%3D2018%26volume%3D12%26issue%3D10%26spage%3D1175%26epage%3D1184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaohong  Li</span>, <span class="hlFld-ContribAuthor ">Chen  Li</span>, <span class="hlFld-ContribAuthor ">Yiting  Tang</span>, <span class="hlFld-ContribAuthor ">Yanhong  Huang</span>, <span class="hlFld-ContribAuthor ">Qingmei  Cheng</span>, <span class="hlFld-ContribAuthor ">Xiaoting  Huang</span>, <span class="hlFld-ContribAuthor ">Feiyan  Zhao</span>, <span class="hlFld-ContribAuthor ">Caixia  Hao</span>, <span class="hlFld-ContribAuthor ">Dandan  Feng</span>, <span class="hlFld-ContribAuthor ">Jianping  Xu</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Han</span>, <span class="hlFld-ContribAuthor ">Siyuan  Tang</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Shaojie  Yue</span>, <span class="hlFld-ContribAuthor ">Ziqiang  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">NMDA receptor activation inhibits the antifibrotic effect of BM-MSCs on bleomycin-induced pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Lung Cellular and Molecular Physiology</span><span> <strong>2018,</strong> <em>315 </em>
                                    (3)
                                     , L404-L421. <a href="https://doi.org/10.1152/ajplung.00002.2018" title="DOI URL">https://doi.org/10.1152/ajplung.00002.2018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajplung.00002.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajplung.00002.2018%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Lung%2520Cellular%2520and%2520Molecular%2520Physiology%26atitle%3DNMDA%252Breceptor%252Bactivation%252Binhibits%252Bthe%252Bantifibrotic%252Beffect%252Bof%252BBM-MSCs%252Bon%252Bbleomycin-induced%252Bpulmonary%252Bfibrosis%26aulast%3DLi%26aufirst%3DXiaohong%26date%3D2018%26volume%3D315%26issue%3D3%26spage%3DL404%26epage%3DL421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunge  Guan</span>, <span class="hlFld-ContribAuthor ">Simiao  Qiao</span>, <span class="hlFld-ContribAuthor ">Qi  Lv</span>, <span class="hlFld-ContribAuthor ">Na  Cao</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Yue  Dai</span>, <span class="hlFld-ContribAuthor ">Zhifeng  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-γ and subsequent expression of HGF in colons. </span><span class="cited-content_cbyCitation_journal-name">Toxicology and Applied Pharmacology</span><span> <strong>2018,</strong> <em>343 </em>, 1-15. <a href="https://doi.org/10.1016/j.taap.2018.02.001" title="DOI URL">https://doi.org/10.1016/j.taap.2018.02.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.taap.2018.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.taap.2018.02.001%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicology%2520and%2520Applied%2520Pharmacology%26atitle%3DOrally%252Badministered%252Bberberine%252Bameliorates%252Bbleomycin-induced%252Bpulmonary%252Bfibrosis%252Bin%252Bmice%252Bthrough%252Bpromoting%252Bactivation%252Bof%252BPPAR-%2525CE%2525B3%252Band%252Bsubsequent%252Bexpression%252Bof%252BHGF%252Bin%252Bcolons%26aulast%3DGuan%26aufirst%3DChunge%26date%3D2018%26volume%3D343%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanni  Wang</span>, <span class="hlFld-ContribAuthor ">Guojin  Huang</span>, <span class="hlFld-ContribAuthor ">Zhixia  Wang</span>, <span class="hlFld-ContribAuthor ">Huiping  Qin</span>, <span class="hlFld-ContribAuthor ">Biwen  Mo</span>, <span class="hlFld-ContribAuthor ">Changming  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Elongation factor-2 kinase acts downstream of p38 MAPK to regulate proliferation, apoptosis and autophagy in human lung fibroblasts. </span><span class="cited-content_cbyCitation_journal-name">Experimental Cell Research</span><span> <strong>2018,</strong> <em>363 </em>
                                    (2)
                                     , 291-298. <a href="https://doi.org/10.1016/j.yexcr.2018.01.019" title="DOI URL">https://doi.org/10.1016/j.yexcr.2018.01.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.yexcr.2018.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.yexcr.2018.01.019%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Cell%2520Research%26atitle%3DElongation%252Bfactor-2%252Bkinase%252Bacts%252Bdownstream%252Bof%252Bp38%252BMAPK%252Bto%252Bregulate%252Bproliferation%25252C%252Bapoptosis%252Band%252Bautophagy%252Bin%252Bhuman%252Blung%252Bfibroblasts%26aulast%3DWang%26aufirst%3DYanni%26date%3D2018%26volume%3D363%26issue%3D2%26spage%3D291%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mitsuo  Yamauchi</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Barker</span>, <span class="hlFld-ContribAuthor ">Don L.  Gibbons</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Kurie</span>. </span><span class="cited-content_cbyCitation_article-title">The fibrotic tumor stroma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Investigation</span><span> <strong>2018,</strong> <em>128 </em>
                                    (1)
                                     , 16-25. <a href="https://doi.org/10.1172/JCI93554" title="DOI URL">https://doi.org/10.1172/JCI93554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/JCI93554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2FJCI93554%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Investigation%26atitle%3DThe%252Bfibrotic%252Btumor%252Bstroma%26aulast%3DYamauchi%26aufirst%3DMitsuo%26date%3D2018%26volume%3D128%26issue%3D1%26spage%3D16%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dino  Oglic</span>, <span class="hlFld-ContribAuthor ">Steven A.  Oatley</span>, <span class="hlFld-ContribAuthor ">Simon J. F.  Macdonald</span>, <span class="hlFld-ContribAuthor ">Thomas  Mcinally</span>, <span class="hlFld-ContribAuthor ">Roman  Garnett</span>, <span class="hlFld-ContribAuthor ">Jonathan D.  Hirst</span>, <span class="hlFld-ContribAuthor ">Thomas  Gärtner</span>. </span><span class="cited-content_cbyCitation_article-title">Active Search for Computer-aided Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2018,</strong> <em>37 </em>
                                    (1-2)
                                     , 1700130. <a href="https://doi.org/10.1002/minf.201700130" title="DOI URL">https://doi.org/10.1002/minf.201700130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.201700130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.201700130%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DActive%252BSearch%252Bfor%252BComputer-aided%252BDrug%252BDesign%26aulast%3DOglic%26aufirst%3DDino%26date%3D2018%26date%3D2018%26volume%3D37%26issue%3D1-2%26spage%3D1700130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Chen</span>, <span class="hlFld-ContribAuthor ">Zhangzhe  Peng</span>, <span class="hlFld-ContribAuthor ">Miaomiao  Lu</span>, <span class="hlFld-ContribAuthor ">Xuan  Xiong</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Qianbin  Li</span>, <span class="hlFld-ContribAuthor ">Zeneng  Cheng</span>, <span class="hlFld-ContribAuthor ">Dejian  Jiang</span>, <span class="hlFld-ContribAuthor ">Lijian  Tao</span>, <span class="hlFld-ContribAuthor ">Gaoyun  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (2)
                                     , 222-229. <a href="https://doi.org/10.1016/j.bmcl.2017.07.001" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.07.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B1-%2525284-%252528%2525283-%2525284-methylpiperazin-1-yl%252529propyl%252529amino%252529benzyl%252529-5-%252528trifluoromethyl%252529pyridin-2%2525281H%252529-one%25252C%252Ban%252Borally%252Bactive%252Bmulti-target%252Bagent%252Bfor%252Bthe%252Btreatment%252Bof%252Bdiabetic%252Bnephropathy%26aulast%3DChen%26aufirst%3DJun%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D222%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eoin P.  Brennan</span>, <span class="hlFld-ContribAuthor ">Antonino  Cacace</span>, <span class="hlFld-ContribAuthor ">Catherine  Godson</span>. </span><span class="cited-content_cbyCitation_article-title">Specialized pro-resolving mediators in renal fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Molecular Aspects of Medicine</span><span> <strong>2017,</strong> <em>58 </em>, 102-113. <a href="https://doi.org/10.1016/j.mam.2017.05.001" title="DOI URL">https://doi.org/10.1016/j.mam.2017.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mam.2017.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mam.2017.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Aspects%2520of%2520Medicine%26atitle%3DSpecialized%252Bpro-resolving%252Bmediators%252Bin%252Brenal%252Bfibrosis%26aulast%3DBrennan%26aufirst%3DEoin%2BP.%26date%3D2017%26volume%3D58%26spage%3D102%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaohong  Li</span>, <span class="hlFld-ContribAuthor ">Shaojie  Yue</span>, <span class="hlFld-ContribAuthor ">Ziqiang  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Mesenchymal stem cells in idiopathic pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (60)
                                     , 102600-102616. <a href="https://doi.org/10.18632/oncotarget.18126" title="DOI URL">https://doi.org/10.18632/oncotarget.18126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.18126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.18126%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DMesenchymal%252Bstem%252Bcells%252Bin%252Bidiopathic%252Bpulmonary%252Bfibrosis%26aulast%3DLi%26aufirst%3DXiaohong%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D60%26spage%3D102600%26epage%3D102616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danylo  Kaminskyy</span>, <span class="hlFld-ContribAuthor ">Anna  Kryshchyshyn</span>, <span class="hlFld-ContribAuthor ">Roman  Lesyk</span>. </span><span class="cited-content_cbyCitation_article-title">5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 542-594. <a href="https://doi.org/10.1016/j.ejmech.2017.09.031" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.031%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D5-Ene-4-thiazolidinones%252B%2525E2%252580%252593%252BAn%252Befficient%252Btool%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DKaminskyy%26aufirst%3DDanylo%26date%3D2017%26volume%3D140%26spage%3D542%26epage%3D594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emily  Stenke</span>, <span class="hlFld-ContribAuthor ">Billy  Bourke</span>, <span class="hlFld-ContribAuthor ">Ulla  Knaus</span>. </span><span class="cited-content_cbyCitation_article-title">Crohn’s Strictures—Moving Away from the Knife. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pediatrics</span><span> <strong>2017,</strong> <em>5 </em><a href="https://doi.org/10.3389/fped.2017.00141" title="DOI URL">https://doi.org/10.3389/fped.2017.00141</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fped.2017.00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffped.2017.00141%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pediatrics%26atitle%3DCrohn%2525E2%252580%252599s%252BStrictures%2525E2%252580%252594Moving%252BAway%252Bfrom%252Bthe%252BKnife%26aulast%3DStenke%26aufirst%3DEmily%26date%3D2017%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniele  Magnini</span>, <span class="hlFld-ContribAuthor ">Giuliano  Montemurro</span>, <span class="hlFld-ContribAuthor ">Bruno  Iovene</span>, <span class="hlFld-ContribAuthor ">Linda  Tagliaboschi</span>, <span class="hlFld-ContribAuthor ">Rafael Emanuele  Gerardi</span>, <span class="hlFld-ContribAuthor ">Erminia  Lo Greco</span>, <span class="hlFld-ContribAuthor ">Teresa  Bruni</span>, <span class="hlFld-ContribAuthor ">Alessio  Fabbrizzi</span>, <span class="hlFld-ContribAuthor ">Francesco  Lombardi</span>, <span class="hlFld-ContribAuthor ">Luca  Richeldi</span>. </span><span class="cited-content_cbyCitation_article-title">Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. </span><span class="cited-content_cbyCitation_journal-name">Respiration</span><span> <strong>2017,</strong> <em>93 </em>
                                    (6)
                                     , 379-395. <a href="https://doi.org/10.1159/000475780" title="DOI URL">https://doi.org/10.1159/000475780</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1159/000475780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1159%2F000475780%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiration%26atitle%3DIdiopathic%252BPulmonary%252BFibrosis%25253A%252BMolecular%252BEndotypes%252Bof%252BFibrosis%252BStratifying%252BExisting%252Band%252BEmerging%252BTherapies%26aulast%3DMagnini%26aufirst%3DDaniele%26date%3D2017%26date%3D2017%26volume%3D93%26issue%3D6%26spage%3D379%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pathogenesis and therapeutic targets of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pyrazolo-pyrido-diazepine, -pyrazine, and -oxazinedione derivatives as novel dual Nox4/Nox1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Novel pirfenidone analogues for the treatment of pulmonary fibrosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pirfenidone derivatives as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pyridin-2(1<i>H</i>)-one derivatives as regulators of translation initiation factor 3A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1<i>H</i>) pyridones as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. 5-Substituted-2(1<i>H</i>)-pyridone derivatives as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. N1-substituted phenylhydroquinolinone derivatives with antifibrosis activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. 1,5-Disubstituted pyridone derivatives as antifibrotic and anti-lung-cancer agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. 5-Ene amino/iminothiazolidinones as antifibrotic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Lysophosphatidic acid receptor 1 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. 5-Amino-4-cyanopyrazole derivatives as potent and highly selective LPA<sub>1</sub>R antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Protein kinase inhibitors with antifibrotic effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <b>40</b>, an orally active antifibrotic JNK inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. <b>42</b> as a JNK inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. 4-Oxoquinoline-3-carboxamides derivatives as potent antifibrosis agents for pulmonary fibrosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Patented compounds (<b>47</b>–<b>55</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Patented compounds (<b>56</b>–<b>65</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Patented compounds (<b>66</b>–<b>75</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Patented compounds (<b>76</b>–<b>83</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/medium/jm-2016-00935d_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Patented compounds (<b>84</b>–<b>87</b>) for the treatment of IPF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b00935/20170120/images/large/jm-2016-00935d_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00935&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32771" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32771" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 181 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordier, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancochea, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johkoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudden, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griss, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzko, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schünemann, H. J.</span><span> </span><span class="NLM_article-title">An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1164/rccm.2009-040GL</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.2009-040GL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21471066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=788-824&author=G.+Raghuauthor=H.+R.+Collardauthor=J.+J.+Eganauthor=F.+J.+Martinezauthor=J.+Behrauthor=K.+K.+Brownauthor=T.+V.+Colbyauthor=J.-F.+Cordierauthor=K.+R.+Flahertyauthor=J.+A.+Laskyauthor=D.+A.+Lynchauthor=J.+H.+Ryuauthor=J.+J.+Swigrisauthor=A.+U.+Wellsauthor=J.+Ancocheaauthor=D.+Bourosauthor=C.+Carvalhoauthor=U.+Costabelauthor=M.+Ebinaauthor=D.+M.+Hansellauthor=T.+Johkohauthor=D.+S.+Kimauthor=T.+E.+Kingauthor=Y.+Kondohauthor=J.+Myersauthor=N.+L.+M%C3%BCllerauthor=A.+G.+Nicholsonauthor=L.+Richeldiauthor=M.+Selmanauthor=R.+F.+Duddenauthor=B.+S.+Grissauthor=S.+L.+Protzkoauthor=H.+J.+Sch%C3%BCnemann&title=An+official+ATS%2FERS%2FJRS%2FALAT+statement%3A+idiopathic+pulmonary+fibrosis%3A+evidence-based+guidelines+for+diagnosis+and+management&doi=10.1164%2Frccm.2009-040GL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span></div><div class="casAuthors">Raghu Ganesh; Collard Harold R; Egan Jim J; Martinez Fernando J; Behr Juergen; Brown Kevin K; Colby Thomas V; Cordier Jean-Francois; Flaherty Kevin R; Lasky Joseph A; Lynch David A; Ryu Jay H; Swigris Jeffrey J; Wells Athol U; Ancochea Julio; Bouros Demosthenes; Carvalho Carlos; Costabel Ulrich; Ebina Masahito; Hansell David M; Johkoh Takeshi; Kim Dong Soon; King Talmadge E Jr; Kondoh Yasuhiro; Myers Jeffrey; Muller Nestor L; Nicholson Andrew G; Richeldi Luca; Selman Moises; Dudden Rosalind F; Griss Barbara S; Protzko Shandra L; Schunemann Holger J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association.  It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course.  For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format.  For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak).  Recommendations were based on majority vote.  It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd3NNagTHJTiXXDYhVZBdlfW6udTcc2eZi2omdDM-UkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D&md5=f47abe4551c8684d3af81f66598e9b2c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1164%2Frccm.2009-040GL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.2009-040GL%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DColby%26aufirst%3DT.%2BV.%26aulast%3DCordier%26aufirst%3DJ.-F.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DLynch%26aufirst%3DD.%2BA.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DAncochea%26aufirst%3DJ.%26aulast%3DBouros%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DC.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DEbina%26aufirst%3DM.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DJohkoh%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DN.%2BL.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DDudden%26aufirst%3DR.%2BF.%26aulast%3DGriss%26aufirst%3DB.%2BS.%26aulast%3DProtzko%26aufirst%3DS.%2BL.%26aulast%3DSch%25C3%25BCnemann%26aufirst%3DH.%2BJ.%26atitle%3DAn%2520official%2520ATS%252FERS%252FJRS%252FALAT%2520statement%253A%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520evidence-based%2520guidelines%2520for%2520diagnosis%2520and%2520management%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D788%26epage%3D824%26doi%3D10.1164%2Frccm.2009-040GL" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Spagnolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sverzellati, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzouvelekis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vancheri, C.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: an update</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.3109/07853890.2014.982165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3109%2F07853890.2014.982165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25613170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1ant70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=15-27&author=P.+Spagnoloauthor=N.+Sverzellatiauthor=G.+Rossiauthor=A.+Cavazzaauthor=A.+Tzouvelekisauthor=B.+Crestaniauthor=C.+Vancheri&title=Idiopathic+pulmonary+fibrosis%3A+an+update&doi=10.3109%2F07853890.2014.982165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: An update</span></div><div class="casAuthors">Spagnolo, Paolo; Sverzellati, Nicola; Rossi, Giulio; Cavazza, Alberto; Tzouvelekis, Argyris; Crestani, Bruno; Vancheri, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic interstitial pneumonia.  The disease, which occurs primarily in middle-aged and older adults, is thought to arise following an aberrant reparative response to alveolar epithelial cell injury characterized by secretion of excessive amts. of extracellular matrix components, resulting in scarring of the lung, architectural distortion, and irreversible loss of function.  A complex interplay between environmental and host factors is thought to contribute to the development of the disease, although the cause of IPF remains elusive and its pathogenesis incompletely understood.  Over the last decade, disease definition and diagnostic criteria have evolved significantly, and this has facilitated the design of a no. of high-quality clin. trials evaluating novel therapeutic agents for IPF.  This massive effort of the medical and industry community has led to the identification of two compds. (pirfenidone and nintedanib) able to reduce functional decline and disease progression.  These promising results notwithstanding, IPF remains a major cause of morbidity and mortality and a largely unmet medical need.  A real cure for this devastating disease has yet to emerge and will likely consist of a combination of drugs targeting the plethora of pathways potentially involved in disease pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKq0R58Wx0w7Vg90H21EOLACvtfcHk0ljQ4zrFfVfQ-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1ant70%253D&md5=04f982abb607ec3d577b084f668c7f5b</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.3109%2F07853890.2014.982165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07853890.2014.982165%26sid%3Dliteratum%253Aachs%26aulast%3DSpagnolo%26aufirst%3DP.%26aulast%3DSverzellati%26aufirst%3DN.%26aulast%3DRossi%26aufirst%3DG.%26aulast%3DCavazza%26aufirst%3DA.%26aulast%3DTzouvelekis%26aufirst%3DA.%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DVancheri%26aufirst%3DC.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520an%2520update%26jtitle%3DAnn.%2520Med.%26date%3D2015%26volume%3D47%26spage%3D15%26epage%3D27%26doi%3D10.3109%2F07853890.2014.982165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. P.,  3rd</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.2165/00003495-200464040-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2165%2F00003495-200464040-00005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=405-430&author=M.+Selmanauthor=V.+J.+Thannickalauthor=A.+Pardoauthor=D.+A.+Zismanauthor=F.+J.+Martinezauthor=J.+P.+Lynch&title=Idiopathic+pulmonary+fibrosis%3A+pathogenesis+and+therapeutic+approaches&doi=10.2165%2F00003495-200464040-00005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464040-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464040-00005%26sid%3Dliteratum%253Aachs%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DZisman%26aufirst%3DD.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520pathogenesis%2520and%2520therapeutic%2520approaches%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D405%26epage%3D430%26doi%3D10.2165%2F00003495-200464040-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ziobro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentsch, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbins, E.</span><span> </span><span class="NLM_article-title">Ceramide mediates lung fibrosis in cystic fibrosis</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">709</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bbrc.2013.03.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2013&pages=705-709&author=R.+Ziobroauthor=B.+Henryauthor=M.+J.+Edwardsauthor=A.+B.+Lentschauthor=E.+Gulbins&title=Ceramide+mediates+lung+fibrosis+in+cystic+fibrosis&doi=10.1016%2Fj.bbrc.2013.03.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DZiobro%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DB.%26aulast%3DEdwards%26aufirst%3DM.%2BJ.%26aulast%3DLentsch%26aufirst%3DA.%2BB.%26aulast%3DGulbins%26aufirst%3DE.%26atitle%3DCeramide%2520mediates%2520lung%2520fibrosis%2520in%2520cystic%2520fibrosis%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D434%26spage%3D705%26epage%3D709%26doi%3D10.1016%2Fj.bbrc.2013.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Wilson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Pulmonary fibrosis: pathogenesis, etiology and regulation</span> <span class="citation_source-journal">Mucosal Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/mi.2008.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fmi.2008.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19129758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=103-121&author=M.+S.+Wilsonauthor=T.+A.+Wynn&title=Pulmonary+fibrosis%3A+pathogenesis%2C+etiology+and+regulation&doi=10.1038%2Fmi.2008.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary fibrosis: pathogenesis, etiology and regulation</span></div><div class="casAuthors">Wilson, M. S.; Wynn, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mucosal Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-121</span>CODEN:
                <span class="NLM_cas:coden">MIUMAK</span>;
        ISSN:<span class="NLM_cas:issn">1933-0219</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences.  The etiol. of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chems., radiation and environmental particles.  However, the cause of one of the most common pulmonary fibrotic conditions, idiopathic pulmonary fibrosis (IPF), is still unclear.  This review examines common mechanisms of pulmonary wound-healing responses following lung injury, and highlights the pathogenesis of some of the most widespread pulmonary fibrotic diseases.  A 3 phase model of wound repair is reviewed that includes; (1) injury; (2) inflammation; and (3) repair.  In most pulmonary fibrotic conditions dysregulation at one or more of these phases was reported.  Chronic inflammation can lead to an imbalance in the prodn. of chemokines, cytokines, growth factors, and disrupt cellular recruitment.  These changes coupled with excessive pro-fibrotic IL-13 and/or TGFβ1 prodn. can turn a well-controlled healing response into a pathogenic fibrotic response.  Endogenous regulatory mechanisms are discussed including novel areas of therapeutic intervention.  Restoring homeostasis to these dysregulated healing responses, or simply neutralizing the key pro-fibrotic mediators may prevent or slow the progression of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPykZAQ68KP7Vg90H21EOLACvtfcHk0lgj-EUo6PiNGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D&md5=1e7d72291a39f09cfe113b5028188f28</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1038%2Fmi.2008.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmi.2008.85%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DM.%2BS.%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DPulmonary%2520fibrosis%253A%2520pathogenesis%252C%2520etiology%2520and%2520regulation%26jtitle%3DMucosal%2520Immunol.%26date%3D2009%26volume%3D2%26spage%3D103%26epage%3D121%26doi%3D10.1038%2Fmi.2008.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2013.11.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=220-223&author=Z.+Maauthor=Y.+Panauthor=W.+Huangauthor=Y.+Yangauthor=Z.+Wangauthor=Q.+Liauthor=Y.+Zhaoauthor=X.+Zhangauthor=Z.+Shen&title=Synthesis+and+biological+evaluation+of+the+pirfenidone+derivatives+as+antifibrotic+agents&doi=10.1016%2Fj.bmcl.2013.11.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%2520pirfenidone%2520derivatives%2520as%2520antifibrotic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D220%26epage%3D223%26doi%3D10.1016%2Fj.bmcl.2013.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomic, R.</span><span> </span><span class="NLM_article-title">Natural history of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1016/j.rmed.2015.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.rmed.2015.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25727856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2MrpvVehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2015&pages=661-670&author=H.+J.+Kimauthor=D.+Perlmanauthor=R.+Tomic&title=Natural+history+of+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.rmed.2015.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Natural history of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Kim Hyun Joo; Perlman David; Tomic Rade</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">661-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a parenchymal lung disease characterized by progressive interstitial fibrosis.  IPF has a poor prognosis, with a median survival time of 2-3 years from diagnosis, but varying from a few months to a decade.  The natural history of IPF is highly variable and the course of disease in an individual patient is difficult to predict.  Some patients with IPF experience rapid decline, others progress much more slowly, and some patients show periods of relative stability interspersed with acute deteriorations in respiratory function.  Many clinical, radiographic, serologic, and histopathologic variables have been shown to predict mortality in IPF.  However, the accuracy of these predictors varies due to the retrospective nature of some of the studies and variations in study design.  The ability to identify clinical characteristics that predict disease progression and survival would be useful for counseling patients, treatment decision-making, and prompt consideration for lung transplantation.  A number of indices for predicting mortality in patients with IPF are available, but they require further validation.  As high-resolution computed tomography scans become more widely available and patients with IPF are diagnosed earlier, survival times following diagnosis will improve.  Early referral to interstitial lung disease specialty centers is important for accurate diagnosis and may be associated with improved outcomes.  The goal of this review is to examine the natural history of IPF, discuss predictors of mortality, and highlight the importance of prompt diagnosis and referral for patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmk1qjjc9BVbHHuJhbyicZfW6udTcc2ealbTeARP-I37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrpvVehtg%253D%253D&md5=260adda76e9ac35c945dc04f6e981fd3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2015.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2015.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DPerlman%26aufirst%3DD.%26aulast%3DTomic%26aufirst%3DR.%26atitle%3DNatural%2520history%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Med.%26date%3D2015%26volume%3D109%26spage%3D661%26epage%3D670%26doi%3D10.1016%2Fj.rmed.2015.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Chakraborty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambi, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dastidar, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span> </span><span class="NLM_article-title">Emerging therapeutic interventions for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span><span class="refDoi"> DOI: 10.1517/13543784.2014.913569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F13543784.2014.913569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24766571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=893-910&author=S.+Chakrabortyauthor=P.+Chopraauthor=S.+V.+Ambiauthor=S.+G.+Dastidarauthor=A.+Ray&title=Emerging+therapeutic+interventions+for+idiopathic+pulmonary+fibrosis&doi=10.1517%2F13543784.2014.913569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapeutic interventions for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Chakraborty, Sushmita; Chopra, Puneet; Ambi, Senthil V.; Dastidar, Sunanda G.; Ray, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">893-910</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Idiopathic pulmonary fibrosis (IPF) is a devastating and relentlessly progressive lung disorder.  Previously, it was thought to be a chronic inflammatory disease; however, it is now considered to be an epithelial-fibroblastic disease.  In accordance with this paradigm change, efforts toward the development of novel therapeutic targets for IPF have acquired a new direction.  Currently available therapies are largely ineffective in reversing the lung damage, and lung transplantation is the only effective treatment for end-stage disease.  Limitations in advancement of IPF therapeutics are due to a poor understanding of its pathogenesis, unavailability of reliable animal models and slow disease progression.  Recent research on IPF has resulted in the identification of a plethora of novel targets that are in various stages of development and offers hope that in the near future that there will be better therapeutic options available for the treatment of IPF.  Areas covered: This review discusses existing therapies and highlights some of the recent, novel therapeutics being explored in the current clin. landscape for the treatment of this chronic, disabling disorder.  The review also discusses the pathogenic rationale behind current therapies.  Expert opinion: Targeting one fibrotic signaling pathway at a time may not have any significant effect on the control of IPF.  It is therefore recommended that future IPF management focuses on targeting multiple pro-fibrotic pathways assocd. with its complex pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxNRbowI1OJrVg90H21EOLACvtfcHk0lj70Bjr_zen2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WitLk%253D&md5=13687207ba9129eeac40f47c0e341e7f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.913569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.913569%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DChopra%26aufirst%3DP.%26aulast%3DAmbi%26aufirst%3DS.%2BV.%26aulast%3DDastidar%26aufirst%3DS.%2BG.%26aulast%3DRay%26aufirst%3DA.%26atitle%3DEmerging%2520therapeutic%2520interventions%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D893%26epage%3D910%26doi%3D10.1517%2F13543784.2014.913569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weycker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelsberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oster, G.</span><span> </span><span class="NLM_article-title">Incidence and prevalence of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1164/rccm.200602-163OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200602-163OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16809633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD28rmtFGisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2006&pages=810-816&author=G.+Raghuauthor=D.+Weyckerauthor=J.+Edelsbergauthor=W.+Z.+Bradfordauthor=G.+Oster&title=Incidence+and+prevalence+of+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.200602-163OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prevalence of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Raghu Ganesh; Weycker Derek; Edelsberg John; Bradford Williamson Z; Oster Gerry</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">810-6</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  Idiopathic pulmonary fibrosis is a chronic interstitial lung disease of unknown etiology; its epidemiology in the United States has not been well characterized.  OBJECTIVE:  To estimate the annual incidence and prevalence of idiopathic pulmonary fibrosis in the United States.  METHODS:  Retrospective cohort design utilizing a large health care claims database spanning the period January 1996 through December 2000.  MEASUREMENTS AND MAIN RESULTS:  Persons with idiopathic pulmonary fibrosis were identified based on diagnosis and procedure codes.  Using broad case-finding criteria, prevalence was estimated to range from 4.0 per 100,000 persons aged 18 to 34 yr to 227.2 per 100,000 among those 75 yr or older; annual incidence was estimated to range from 1.2 to 76.4 per 100,000.  Using narrow case-finding criteria, prevalence ranged from 0.8 to 64.7 per 100,000 persons; comparable figures for incidence were 0.4 to 27.1 per 100,000 persons.  Extrapolating these rates to the overall United States' population, prevalence was estimated to be 42.7 per 100,000 (incidence, 16.3 per 100,000) using broad criteria; with narrow criteria, prevalence was estimated to be 14.0 per 100,000 (incidence, 6.8 per 100,000).  CONCLUSIONS:  Our results suggest that idiopathic pulmonary fibrosis is probably more common in the United States than previously reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSTT_ssflIzuxsqfvU0ziafW6udTcc2eaB70l6Oi2Z67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rmtFGisw%253D%253D&md5=d99a682e24bdca385029acb81b80c594</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1164%2Frccm.200602-163OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200602-163OC%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DWeycker%26aufirst%3DD.%26aulast%3DEdelsberg%26aufirst%3DJ.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DOster%26aufirst%3DG.%26atitle%3DIncidence%2520and%2520prevalence%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D174%26spage%3D810%26epage%3D816%26doi%3D10.1164%2Frccm.200602-163OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Nalysnyk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid-Ruzafa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esser, D.</span><span> </span><span class="NLM_article-title">Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature</span> <span class="citation_source-journal">Eur. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1183/09059180.00002512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09059180.00002512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23204124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3s7osVSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=355-361&author=L.+Nalysnykauthor=J.+Cid-Ruzafaauthor=P.+Rotellaauthor=D.+Esser&title=Incidence+and+prevalence+of+idiopathic+pulmonary+fibrosis%3A+review+of+the+literature&doi=10.1183%2F09059180.00002512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature</span></div><div class="casAuthors">Nalysnyk Luba; Cid-Ruzafa Javier; Rotella Philip; Esser Dirk</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">126</span>),
    <span class="NLM_cas:pages">355-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown aetiology.  It is a rare disease, and its incidence and prevalence are not clear.  Therefore, we sought to review the published evidence on the global epidemiology of IPF.  A comprehensive review of English language literature was performed by searching Medline and EMBASE for studies on IPF epidemiology published between January 1990 and August 2011.  Studies providing quantitative data on IPF incidence and/or prevalence were identified and key data collected. 15 studies reporting on the incidence and/or prevalence of IPF were identified and summarised.  IPF prevalence estimates in the USA varied between 14 and 27.9 cases per 100,000 population using narrow case definitions, and 42.7 and 63 per 100,000 population using broad case definitions.  In Europe, IPF prevalence ranged from 1.25 to 23.4 cases per 100,000 population.  The annual incidence of IPF in the USA was estimated at 6.8-8.8 per 100,000 population using narrow case definitions and 16.3-17.4 per 100,000 population using broad case definitions.  In Europe, the annual incidence ranged between 0.22 and 7.4 per 100,000 population.  IPF prevalence and incidence increase with age, are higher among males and appear to be on the increase in recent years.  IPF is an orphan disease that affects a potentially increasing number of people in Europe and the USA.  The observed variability in IPF incidence and prevalence may be explained by the differences in diagnostic criteria used, case definition, study population and study design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEz6Y0MyQh7GPgL4LrC-0VfW6udTcc2eaB70l6Oi2Z67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7osVSmsw%253D%253D&md5=38b5db109bdda71b170d96860afdd6cc</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1183%2F09059180.00002512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09059180.00002512%26sid%3Dliteratum%253Aachs%26aulast%3DNalysnyk%26aufirst%3DL.%26aulast%3DCid-Ruzafa%26aufirst%3DJ.%26aulast%3DRotella%26aufirst%3DP.%26aulast%3DEsser%26aufirst%3DD.%26atitle%3DIncidence%2520and%2520prevalence%2520of%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520review%2520of%2520the%2520literature%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2012%26volume%3D21%26spage%3D355%26epage%3D361%26doi%3D10.1183%2F09059180.00002512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Olson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lezotte, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span> </span><span class="NLM_article-title">Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1164/rccm.200701-044OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200701-044OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17478620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2svitFCgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2007&pages=277-284&author=A.+L.+Olsonauthor=J.+J.+Swigrisauthor=D.+C.+Lezotteauthor=J.+M.+Norrisauthor=C.+G.+Wilsonauthor=K.+K.+Brown&title=Mortality+from+pulmonary+fibrosis+increased+in+the+United+States+from+1992+to+2003&doi=10.1164%2Frccm.200701-044OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003</span></div><div class="casAuthors">Olson Amy L; Swigris Jeffrey J; Lezotte Dennis C; Norris Jill M; Wilson Carla G; Brown Kevin K</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-84</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  From the late 1970s to the early 1990s, studies found that mortality rates for pulmonary fibrosis were increasing.  Recent data for mortality from pulmonary fibrosis are unavailable.  OBJECTIVES:  We sought to determine mortality rates for pulmonary fibrosis in the United States from 1992 through 2003.  METHODS:  Using data from the National Center for Health Statistics, we calculated age-adjusted mortality rates from the deaths of persons with pulmonary fibrosis and stratified the data to determine differences in mortality rates by age, sex, race/ethnicity, and geography of the decedent.  We developed a multivariable model to predict future mortality rates, and we determined the underlying cause of death in patients with pulmonary fibrosis.  MEASUREMENTS AND MAIN RESULTS:  From 1992 to 2003, there were 28,176,224 deaths in the United States and 175,088 decedents with pulmonary fibrosis.  The average age- and sex-adjusted mortality rate was 50.8 per 1,000,000 people.  The age-adjusted mortality rate increased 28.4% in men (from 40.2 deaths per 1,000,000 in 1992 to 61.9 deaths per 1,000,000 in 2003) and 41.3% in women (from 39.0 deaths per 1,000,000 in 1992 to 55.1 deaths per 1,000,000 in 2003).  While increases were significant in both men and women (p < 0.0001), the rate of increase was higher in women (p < 0.0001).  The most common cause of death in patients with pulmonary fibrosis was the disease itself.  CONCLUSIONS:  From 1992 to 2003, mortality rates for pulmonary fibrosis significantly increased.  Further investigation is needed to determine the etiology of these trends, which are predicted to continue to increase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgwRyAmhODdCXXDYhVZBdlfW6udTcc2eYpWQIrQx8aHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svitFCgsQ%253D%253D&md5=cf9d57b242028eb940ed2b424eb57d31</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1164%2Frccm.200701-044OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200701-044OC%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DA.%2BL.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DLezotte%26aufirst%3DD.%2BC.%26aulast%3DNorris%26aufirst%3DJ.%2BM.%26aulast%3DWilson%26aufirst%3DC.%2BG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26atitle%3DMortality%2520from%2520pulmonary%2520fibrosis%2520increased%2520in%2520the%2520United%2520States%2520from%25201992%2520to%25202003%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D176%26spage%3D277%26epage%3D284%26doi%3D10.1164%2Frccm.200701-044OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hutchinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever, T.</span><span> </span><span class="NLM_article-title">Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">806</span><span class="refDoi"> DOI: 10.1183/09031936.00185114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00185114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25976683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2MfktV2itw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=795-806&author=J.+Hutchinsonauthor=A.+Fogartyauthor=R.+Hubbardauthor=T.+McKeever&title=Global+incidence+and+mortality+of+idiopathic+pulmonary+fibrosis%3A+a+systematic+review&doi=10.1183%2F09031936.00185114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review</span></div><div class="casAuthors">Hutchinson John; Fogarty Andrew; Hubbard Richard; McKeever Tricia</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">795-806</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally.  This study aims to systematically assess all available studies to investigate the global burden of disease.Medline and Embase databases were searched systematically for all population-based studies of incidence or mortality of idiopathic pulmonary fibrosis.  Clinical case series and prevalence studies were excluded.  The search was supplemented using the Google search engine, hand-searching of references and conference abstracts.  Data were extracted independently by two authors using a pre-specified proforma, with assessment of methodological quality.34 studies were identified, providing data from 21 countries from 1968-2012. 28 studies reported incidence data and eight reported mortality data.  In studies from the year 2000 onwards, we estimated a conservative incidence range of 3-9 cases per 100 000 per year for Europe and North America.  Incidence was lower in East Asia and South America.  The majority of studies showed an increase in incidence over time.The incidence of idiopathic pulmonary fibrosis is increasing worldwide and rates are coming together across countries.  Current data suggest incidence is similar to that of conditions such as stomach, liver, testicular and cervical cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXhjIAwp-wmoFEOhA_Im3cfW6udTcc2eYpWQIrQx8aHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfktV2itw%253D%253D&md5=df2df5567392e37bf340ef3ee81d0b83</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1183%2F09031936.00185114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00185114%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DJ.%26aulast%3DFogarty%26aufirst%3DA.%26aulast%3DHubbard%26aufirst%3DR.%26aulast%3DMcKeever%26aufirst%3DT.%26atitle%3DGlobal%2520incidence%2520and%2520mortality%2520of%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520systematic%2520review%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D795%26epage%3D806%26doi%3D10.1183%2F09031936.00185114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gribbin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Jeune, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tata, L. J.</span><span> </span><span class="NLM_article-title">Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">980</span><span class="NLM_x">–</span> <span class="NLM_lpage">985</span><span class="refDoi"> DOI: 10.1136/thx.2006.062836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthx.2006.062836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16844727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD28njs1enuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2006&pages=980-985&author=J.+Gribbinauthor=R.+B.+Hubbardauthor=I.+Le+Jeuneauthor=C.+J.+P.+Smithauthor=J.+Westauthor=L.+J.+Tata&title=Incidence+and+mortality+of+idiopathic+pulmonary+fibrosis+and+sarcoidosis+in+the+UK&doi=10.1136%2Fthx.2006.062836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK</span></div><div class="casAuthors">Gribbin J; Hubbard R B; Le Jeune I; Smith C J P; West J; Tata L J</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">980-5</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in patients attending chest clinics, but little is known about the epidemiology of these diseases.  We used data from a general practice database to provide information on the current incidence of IPF and sarcoidosis in the UK.  METHODS:  Data were extracted for all patients with a diagnosis of IPF or sarcoidosis between 1991 and 2003.  The whole population of the database was used to calculate disease incidence stratified by age, sex, region, and time period.  Poisson regression was used to compare the incidence between populations and Cox regression was used to compare survival between populations.  RESULTS:  920 cases of IPF (mean age 71 years, 62% male) and 1019 cases of sarcoidosis (mean age 47 years, 47% male) were identified.  The overall incidence rate per 100 000 person-years was 4.6 for IPF and 5.0 for sarcoidosis.  The incidence of IPF increased progressively between 1991 and 2003 (p<0.00001), and was highest in Northern England and Scotland (p<0.0001).  The survival of patients with IPF was stable over time.  In contrast, the incidence of sarcoidosis was highest in London, West Midlands and Northern Ireland and remained stable over time.  CONCLUSIONS:  The incidence of IPF has more than doubled between 1990 and 2003; this is not due to the ageing of the UK population or an increased ascertainment of milder cases.  The incidence of sarcoidosis has not changed during this time period.  Our findings suggest that more than 4000 new cases of IPF and 3000 new cases of sarcoidosis are currently diagnosed each year in the UK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLGAqzGm7Sha91pGlMMoT5fW6udTcc2eZJ_t4gu6Oq1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28njs1enuw%253D%253D&md5=945d0b9613174e307c98d5c32b01e567</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.062836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.062836%26sid%3Dliteratum%253Aachs%26aulast%3DGribbin%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DR.%2BB.%26aulast%3DLe%2BJeune%26aufirst%3DI.%26aulast%3DSmith%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DTata%26aufirst%3DL.%2BJ.%26atitle%3DIncidence%2520and%2520mortality%2520of%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520sarcoidosis%2520in%2520the%2520UK%26jtitle%3DThorax%26date%3D2006%26volume%3D61%26spage%3D980%26epage%3D985%26doi%3D10.1136%2Fthx.2006.062836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Navaratnam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. B.</span><span> </span><span class="NLM_article-title">The rising incidence of idiopathic pulmonary fibrosis in the UK</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1136/thx.2010.148031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthx.2010.148031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21525528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3MrksVajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2011&pages=462-467&author=V.+Navaratnamauthor=K.+M.+Flemingauthor=J.+Westauthor=C.+J.+Smithauthor=R.+G.+Jenkinsauthor=A.+Fogartyauthor=R.+B.+Hubbard&title=The+rising+incidence+of+idiopathic+pulmonary+fibrosis+in+the+UK&doi=10.1136%2Fthx.2010.148031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The rising incidence of idiopathic pulmonary fibrosis in the U.K</span></div><div class="casAuthors">Navaratnam V; Fleming K M; West J; Smith C J P; Jenkins R G; Fogarty A; Hubbard R B</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">462-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Previous studies have shown that the incidence of idiopathic pulmonary fibrosis (IPF) is rising in the U.K. and U.S.A.  Death registrations and primary care data were used to determine the current trends in IPF incidence in the U.K.  Because routine clinical data sets were used, the term IPF clinical syndrome (IPF-CS) is used to describe individuals in this study.  METHODS:  Age- and stratum-specific death registration rates between 1968 and 2008 were calculated and these were applied to the 2008 population to generate annual standardised expected number of deaths.  Annual mortality rate ratios were calculated using Poisson regression.  Computerised primary care records were used to determine incidence rates of IPF-CS between 2000 and 2008 stratified by age, sex and geographical region, and survival rates between calendar periods were compared.  RESULTS:  Annual death certificate recording of IPF-CS rose sixfold across the study period from 0.92 per 100,000 in the 1968-1972 calendar periods to 5.10 per 100,000 in the 2006-2008 calendar period, and were higher in men and the older age groups.  The incidence of IPF-CS in primary care increased by 35% from 2000 to 2008, with an overall incidence rate of 7.44 per 100,000 person-years (95% CI 7.12 to 7.77).  Incidence was higher in men, the older population and in Northwest England.  CONCLUSIONS:  The incidence of IPF-CS in primary care and registered deaths from this cause in the U.K. continues to rise in the 21st century.  The current findings suggest that there are >5000 new cases diagnosed each year in the U.K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlwd8eUEX3NLt7lRqEFUJVfW6udTcc2eZJ_t4gu6Oq1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrksVajsQ%253D%253D&md5=9c28a75a8117323c90169470fe65630f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fthx.2010.148031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2010.148031%26sid%3Dliteratum%253Aachs%26aulast%3DNavaratnam%26aufirst%3DV.%26aulast%3DFleming%26aufirst%3DK.%2BM.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DC.%2BJ.%26aulast%3DJenkins%26aufirst%3DR.%2BG.%26aulast%3DFogarty%26aufirst%3DA.%26aulast%3DHubbard%26aufirst%3DR.%2BB.%26atitle%3DThe%2520rising%2520incidence%2520of%2520idiopathic%2520pulmonary%2520fibrosis%2520in%2520the%2520UK%26jtitle%3DThorax%26date%3D2011%26volume%3D66%26spage%3D462%26epage%3D467%26doi%3D10.1136%2Fthx.2010.148031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Macneal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. A.</span><span> </span><span class="NLM_article-title">The genetic and environmental causes of pulmonary fibrosis</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1513/pats.201112-055AW</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1513%2Fpats.201112-055AW" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22802285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKju7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=120-125&author=K.+Macnealauthor=D.+A.+Schwartz&title=The+genetic+and+environmental+causes+of+pulmonary+fibrosis&doi=10.1513%2Fpats.201112-055AW"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The genetic and environmental causes of pulmonary fibrosis</span></div><div class="casAuthors">MacNeal, Ken; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">120-125</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Although substantial progress has been made in understanding the clin., radiol., and pathol. manifestations of fibrosing interstitial lung diseases (ILD), it remains difficult for the clinician to predict the clin. course or the response to therapy for the subtypes of ILD, even from individual to individual with the same diagnosis.  This article reviews the genetic and environmental causes of pulmonary fibrosis, specifically focusing on genetic and epigenetic variants of MUC5B and several types of ILD, to discuss why only some individuals with the MUC5B promoter polymorphism develop pulmonary fibrosis.  Once we discover how these genetic and epigenetic risks lead to the development of ILD, we and others can apply these discoveries to: (1) identify individuals at risk of developing ILD, (2) diagnose the condition at an earlier stage, (3) Identify novel mechanisms that cause ILD, and (4) eventually develop personalized therapeutic strategies for intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdXK3H2s_FtLVg90H21EOLACvtfcHk0liTsllFrgXHyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKju7zP&md5=cbe10a294dacd985aae7ade5f18cb8af</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1513%2Fpats.201112-055AW&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.201112-055AW%26sid%3Dliteratum%253Aachs%26aulast%3DMacneal%26aufirst%3DK.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26atitle%3DThe%2520genetic%2520and%2520environmental%2520causes%2520of%2520pulmonary%2520fibrosis%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2012%26volume%3D9%26spage%3D120%26epage%3D125%26doi%3D10.1513%2Fpats.201112-055AW" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Yang, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. A.</span><span> </span><span class="NLM_article-title">Epigenetics of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Transl. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1016/j.trsl.2014.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.trsl.2014.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24746870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1eht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2015&pages=48-60&author=I.+V.+Yangauthor=D.+A.+Schwartz&title=Epigenetics+of+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.trsl.2014.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Yang, Ivana V.; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-60</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a complex lung disease of unknown etiol.  Development of IPF is influenced by both genetic and environmental factors.  Recent work by our and other groups has identified strong genetic predisposition factors for the development of pulmonary fibrosis, and cigarette smoke remains the most strongly assocd. environmental exposure risk factor.  Gene expression profiling studies of IPF lung have taught us quite a bit about the biol. of this fatal disease, and those of peripheral blood have provided important biomarkers.  However, epigenetic marks may be the missing link that connects the environmental exposure in genetically predisposed individuals to transcriptional changes assocd. with disease development.  Moreover, epigenetic marks represent a promising therapeutic target for IPF.  In this review, the disease is introduced, genetic and gene expression studies in IPF are summarized, exposures relevant to IPF and known epigenetic changes assocd. with cigarette smoke exposure are discussed, and epigenetic studies conducted so far in IPF are summarized.  Limitations, challenges, and future opportunities in this field are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrucclb9qMiKbVg90H21EOLACvtfcHk0liTsllFrgXHyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1eht74%253D&md5=f239cc89ca03fb73326c6a285711750d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2014.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2014.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DI.%2BV.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26atitle%3DEpigenetics%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DTransl.%2520Res.%26date%3D2015%26volume%3D165%26spage%3D48%26epage%3D60%26doi%3D10.1016%2Fj.trsl.2014.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wolters, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. D.</span><span> </span><span class="NLM_article-title">Pathogenesis of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1146/annurev-pathol-012513-104706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1146%2Fannurev-pathol-012513-104706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24050627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1emsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=157-179&author=P.+J.+Woltersauthor=H.+R.+Collardauthor=K.+D.+Jones&title=Pathogenesis+of+idiopathic+pulmonary+fibrosis&doi=10.1146%2Fannurev-pathol-012513-104706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Wolters, Paul J.; Collard, Harold R.; Jones, Kirk D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157-179</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease assocd. with aging that is characterized by the histopathol. pattern of usual interstitial pneumonia.  Although an understanding of the pathogenesis of IPF is incomplete, recent advances delineating specific clin. and pathol. features of IPF have led to better definition of the mol. pathways that are pathol. activated in the disease.  In this review we highlight several of these advances, with a focus on genetic predisposition to IPF and how genetic changes, which occur primarily in epithelial cells, lead to activation of profibrotic pathways in epithelial cells.  We then discuss the pathol. changes within IPF fibroblasts and the extracellular matrix, and we conclude with a summary of how these profibrotic pathways may be interrelated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8HgCa8pK4XrVg90H21EOLACvtfcHk0ljuUzztz7rW1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1emsbg%253D&md5=8ab726d67353aa8659d842ade0af9d1c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pathol-012513-104706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pathol-012513-104706%26sid%3Dliteratum%253Aachs%26aulast%3DWolters%26aufirst%3DP.%2BJ.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DJones%26aufirst%3DK.%2BD.%26atitle%3DPathogenesis%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2014%26volume%3D9%26spage%3D157%26epage%3D179%26doi%3D10.1146%2Fannurev-pathol-012513-104706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span>National Institutes of Health. <a href="https://www.nhlbi.nih.gov/" class="extLink">https://www.nhlbi.nih.gov/</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Institutes+of+Health.+https%3A%2F%2Fwww.nhlbi.nih.gov%2F+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Rafii, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. L.</span><span> </span><span class="NLM_article-title">A review of current and novel therapies for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">J. Thorac. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.3978/j.issn.2072-1439.2012.12.07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3978%2Fj.issn.2072-1439.2012.12.07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23372951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3szks1ymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=48-73&author=R.+Rafiiauthor=M.+M.+Juarezauthor=T.+E.+Albertsonauthor=A.+L.+Chan&title=A+review+of+current+and+novel+therapies+for+idiopathic+pulmonary+fibrosis&doi=10.3978%2Fj.issn.2072-1439.2012.12.07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A review of current and novel therapies for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Rafii Rokhsara; Juarez Maya M; Albertson Timothy E; Chan Andrew L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-73</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that is associated with a median survival of 2-3 years from initial diagnosis.  To date, there is no treatment approved for IPF in the United States, and only one pharmacological agent has been approved outside of the United States.  Nevertheless, research over the past 10 years has provided us with a wealth of information on its histopathology, diagnostic work-up, and a greater understanding of its pathophysiology.  Specifically, IPF is no longer thought to be a predominantly pro-inflammatory disorder.  Rather, the fibrosis in IPF is increasingly understood to be the result of a fibroproliferative and aberrant wound healing cascade.  The development of therapeutic targets has shifted in accord with this paradigm change.  This review highlights the current understanding of IPF, and the recent as well as novel therapeutics being explored in clinical trials for the treatment of this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQf4PiIM4UfkEwlCcfExbvbfW6udTcc2eb_uy6bMYY8KLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szks1ymtg%253D%253D&md5=595c026cb5e8897fb2a750f6a32f7c02</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2072-1439.2012.12.07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2072-1439.2012.12.07%26sid%3Dliteratum%253Aachs%26aulast%3DRafii%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DM.%2BM.%26aulast%3DAlbertson%26aufirst%3DT.%2BE.%26aulast%3DChan%26aufirst%3DA.%2BL.%26atitle%3DA%2520review%2520of%2520current%2520and%2520novel%2520therapies%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2013%26volume%3D5%26spage%3D48%26epage%3D73%26doi%3D10.3978%2Fj.issn.2072-1439.2012.12.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochwerg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuello Garcia, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brozek, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johkoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzko, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rind, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogsteden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schünemann, H. J.</span><span> </span><span class="NLM_article-title">An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3</span><span class="NLM_x">–</span> <span class="NLM_lpage">e19</span><span class="refDoi"> DOI: 10.1164/rccm.201506-1063ST</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201506-1063ST" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=e3-e19&author=G.+Raghuauthor=B.+Rochwergauthor=Y.+Zhangauthor=C.+A.+Cuello+Garciaauthor=A.+Azumaauthor=J.+Behrauthor=J.+L.+Brozekauthor=H.+R.+Collardauthor=W.+Cunninghamauthor=S.+Hommaauthor=T.+Johkohauthor=F.+J.+Martinezauthor=J.+Myersauthor=S.+L.+Protzkoauthor=L.+Richeldiauthor=D.+Rindauthor=M.+Selmanauthor=A.+Theodoreauthor=A.+U.+Wellsauthor=H.+Hoogstedenauthor=H.+J.+Sch%C3%BCnemann&title=An+official+ATS%2FERS%2FJRS%2FALAT+clinical+practice+guideline%3A+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.201506-1063ST"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1164%2Frccm.201506-1063ST&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201506-1063ST%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DRochwerg%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCuello%2BGarcia%26aufirst%3DC.%2BA.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBrozek%26aufirst%3DJ.%2BL.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DCunningham%26aufirst%3DW.%26aulast%3DHomma%26aufirst%3DS.%26aulast%3DJohkoh%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DProtzko%26aufirst%3DS.%2BL.%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DRind%26aufirst%3DD.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTheodore%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DHoogsteden%26aufirst%3DH.%26aulast%3DSch%25C3%25BCnemann%26aufirst%3DH.%2BJ.%26atitle%3DAn%2520official%2520ATS%252FERS%252FJRS%252FALAT%2520clinical%2520practice%2520guideline%253A%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D192%26spage%3De3%26epage%3De19%26doi%3D10.1164%2Frccm.201506-1063ST" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">136</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.7326/0003-4819-134-2-200101160-00015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.7326%2F0003-4819-134-2-200101160-00015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=11177318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD3M7ktVSgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2001&pages=136-151&author=M.+Selmanauthor=T.+E.+Kingauthor=A.+Pardo&title=Idiopathic+pulmonary+fibrosis%3A+prevailing+and+evolving+hypotheses+about+its+pathogenesis+and+implications+for+therapy&doi=10.7326%2F0003-4819-134-2-200101160-00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy</span></div><div class="casAuthors">Selman M; King T E; Pardo A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-51</span>
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and usually fatal lung disease characterized by fibroblast proliferation and extracellular matrix remodeling, which result in irreversible distortion of the lung's architecture.  Although the pathogenetic mechanisms remain to be determined, the prevailing hypothesis holds that fibrosis is preceded and provoked by a chronic inflammatory process that injures the lung and modulates lung fibrogenesis, leading to the end-stage fibrotic scar.  However, there is little evidence that inflammation is prominent in early disease, and it is unclear whether inflammation is relevant to the development of the fibrotic process.  Evidence suggests that inflammation does not play a pivotal role.  Inflammation is not a prominent histopathologic finding, and epithelial injury in the absence of ongoing inflammation is sufficient to stimulate the development of fibrosis.  In addition, the inflammatory response to a lung fibrogenic insult is not necessarily related to the fibrotic response.  Clinical measurements of inflammation fail to correlate with stage or outcome, and potent anti-inflammatory therapy does not improve outcome.  This review presents a growing body of evidence suggesting that idiopathic pulmonary fibrosis involves abnormal wound healing in response to multiple, microscopic sites of ongoing alveolar epithelial injury and activation associated with the formation of patchy fibroblast-myofibroblast foci, which evolve to fibrosis.  Progress in understanding the fibrogenic mechanisms in the lung is likely to yield more effective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSToVCX1QgwKeb6AVA-44PTfW6udTcc2eaPVD5A0qZVq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7ktVSgtA%253D%253D&md5=c47919b4b378653b30209ac0273a4642</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-134-2-200101160-00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-134-2-200101160-00015%26sid%3Dliteratum%253Aachs%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DPardo%26aufirst%3DA.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520prevailing%2520and%2520evolving%2520hypotheses%2520about%2520its%2520pathogenesis%2520and%2520implications%2520for%2520therapy%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2001%26volume%3D134%26spage%3D136%26epage%3D151%26doi%3D10.7326%2F0003-4819-134-2-200101160-00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">King, T. E.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">1949</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span><span class="refDoi"> DOI: 10.1016/S0140-6736(11)60052-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0140-6736%2811%2960052-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21719092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FksVeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=1949-1961&author=T.+E.+Kingauthor=A.+Pardoauthor=M.+Selman&title=Idiopathic+pulmonary+fibrosis&doi=10.1016%2FS0140-6736%2811%2960052-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis</span></div><div class="casAuthors">King Talmadge E Jr; Pardo Annie; Selman Moises</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9807</span>),
    <span class="NLM_cas:pages">1949-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a devastating, age-related lung disease of unknown cause that has few treatment options.  This disease was once thought to be a chronic inflammatory process, but current evidence indicates that the fibrotic response is driven by abnormally activated alveolar epithelial cells (AECs).  These cells produce mediators that induce the formation of fibroblast and myofibroblast foci through the proliferation of resident mesenchymal cells, attraction of circulating fibrocytes, and stimulation of the epithelial to mesenchymal transition.  The fibroblast and myofibroblast foci secrete excessive amounts of extracellular matrix, mainly collagens, resulting in scarring and destruction of the lung architecture.  The mechanisms that link idiopathic pulmonary fibrosis with ageing and aberrant epithelial activation are unknown; evidence suggests that the abnormal recapitulation of developmental pathways and epigenetic changes have a role.  In this Seminar, we review recent data on the clinical course, therapeutic options, and underlying mechanisms thought to be involved in the pathogenesis of idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9GcvvCbsuQA20zIbnCCI3fW6udTcc2eaPVD5A0qZVq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FksVeisg%253D%253D&md5=a3cae8b12a792e2d079ad6293c4023eb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960052-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960052-4%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DSelman%26aufirst%3DM.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D1949%26epage%3D1961%26doi%3D10.1016%2FS0140-6736%2811%2960052-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ahluwalia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span> </span><span class="NLM_article-title">New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">190</span><span class="NLM_x">, </span> <span class="NLM_fpage">867</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1164/rccm.201403-0509PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201403-0509PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25090037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyiur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2014&pages=867-878&author=N.+Ahluwaliaauthor=B.+S.+Sheaauthor=A.+M.+Tager&title=New+therapeutic+targets+in+idiopathic+pulmonary+fibrosis.+Aiming+to+rein+in+runaway+wound-healing+responses&doi=10.1164%2Frccm.201403-0509PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">New therapeutic targets in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Ahluwalia, Neil; Shea, Barry S.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">867-878</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival as short as 3 years from the time ofdiagnosis and no pharmacol. therapies yet approved by the U.S.  Food and Drug Administration.  To address the great unmet need for effective IPF therapy, a no. of new drugs have recently been, or are now being, evaluated in clin. trials.  The rationales for most of these therapeutic candidates are based on the current paradigm of IPF pathogenesis, in which recurrent injury to the alveolar epithelium is believed to drive aberrant wound healing responses, resulting in fibrosis rather than repair.  Here we discuss drugs in recently completed or currently ongoing phase II and Ill IPF clin. trials in the context of their putative mechanisms of action and the aberrant repair processes they are believed to target: innate immune activation and polarization, fibroblast accumulation and myofibroblast differentiation, or adracellular matrix deposition and stiffening.  Placed in this context, the pos. results of recently completed trials of pirfenidone and nintedanib, and results that will come from ongoing trials of other agents, should provide valuable insights into the still-enigmatic pathogenesis of this disease, in addn. to providing benefits to patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzLozevTD5CbVg90H21EOLACvtfcHk0lh1yqTflFl7aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyiur%252FK&md5=5a7939da26f2c40f9b01b3699bff0c2b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1164%2Frccm.201403-0509PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201403-0509PP%26sid%3Dliteratum%253Aachs%26aulast%3DAhluwalia%26aufirst%3DN.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DNew%2520therapeutic%2520targets%2520in%2520idiopathic%2520pulmonary%2520fibrosis.%2520Aiming%2520to%2520rein%2520in%2520runaway%2520wound-healing%2520responses%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2014%26volume%3D190%26spage%3D867%26epage%3D878%26doi%3D10.1164%2Frccm.201403-0509PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Chambers, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, P. F.</span><span> </span><span class="NLM_article-title">Mechanisms of alveolar epithelial injury, repair, and fibrosis</span> <span class="citation_source-journal">Ann. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">S16</span><span class="NLM_x">–</span> <span class="NLM_lpage">S20</span><span class="refDoi"> DOI: 10.1513/AnnalsATS.201410-448MG</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1513%2FAnnalsATS.201410-448MG" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=S16-S20&author=R.+C.+Chambersauthor=P.+F.+Mercer&title=Mechanisms+of+alveolar+epithelial+injury%2C+repair%2C+and+fibrosis&doi=10.1513%2FAnnalsATS.201410-448MG"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201410-448MG&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201410-448MG%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DR.%2BC.%26aulast%3DMercer%26aufirst%3DP.%2BF.%26atitle%3DMechanisms%2520of%2520alveolar%2520epithelial%2520injury%252C%2520repair%252C%2520and%2520fibrosis%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2015%26volume%3D12%26spage%3DS16%26epage%3DS20%26doi%3D10.1513%2FAnnalsATS.201410-448MG" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Fulton, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryerson, C. J.</span><span> </span><span class="NLM_article-title">Managing comorbidities in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Int. J. Gen. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">318</span><span class="refDoi"> DOI: 10.2147/IJGM.S74880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2147%2FIJGM.S74880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26451121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28zgsValtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=309-318&author=B.+G.+Fultonauthor=C.+J.+Ryerson&title=Managing+comorbidities+in+idiopathic+pulmonary+fibrosis&doi=10.2147%2FIJGM.S74880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Managing comorbidities in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Fulton Blair G; Ryerson Christopher J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of general medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">309-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pulmonary and extra-pulmonary diseases.  IPF can be associated with additional comorbidities through other mechanisms as either a cause or a consequence of these diseases.  We review the literature regarding the management of common pulmonary and extra-pulmonary comorbidities, including chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, venous thromboembolism, sleep-disordered breathing, gastroesophageal reflux disease, coronary artery disease, depression and anxiety, and deconditioning.  Recent studies have provided some guidance on the management of these diseases in IPF; however, most treatment recommendations are extrapolated from studies of non-IPF patients.  Additional studies are required to more accurately determine the clinical features of these comorbidities in patients with IPF and to evaluate conventional treatments and management strategies that are beneficial in non-IPF populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnrNHbQN3_Si-bLEOO4dYpfW6udTcc2eb6K3CHIvxn9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zgsValtA%253D%253D&md5=ee1ab3cc8be65592fc29a5e9745f7827</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2147%2FIJGM.S74880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJGM.S74880%26sid%3Dliteratum%253Aachs%26aulast%3DFulton%26aufirst%3DB.%2BG.%26aulast%3DRyerson%26aufirst%3DC.%2BJ.%26atitle%3DManaging%2520comorbidities%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DInt.%2520J.%2520Gen.%2520Med.%26date%3D2015%26volume%3D8%26spage%3D309%26epage%3D318%26doi%3D10.2147%2FIJGM.S74880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlers-Tenenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruhwyler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltmanns, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heussel, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herth, F. J. F.</span><span> </span><span class="NLM_article-title">Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0151425</span><span class="refDoi"> DOI: 10.1371/journal.pone.0151425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1371%2Fjournal.pone.0151425" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0151425&author=M.+Kreuterauthor=S.+Ehlers-Tenenbaumauthor=K.+Palmowskiauthor=J.+Bruhwylerauthor=U.+Oltmannsauthor=T.+Muleyauthor=C.+P.+Heusselauthor=A.+Warthauthor=M.+Kolbauthor=F.+J.+F.+Herth&title=Impact+of+comorbidities+on+mortality+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1371%2Fjournal.pone.0151425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0151425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0151425%26sid%3Dliteratum%253Aachs%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DEhlers-Tenenbaum%26aufirst%3DS.%26aulast%3DPalmowski%26aufirst%3DK.%26aulast%3DBruhwyler%26aufirst%3DJ.%26aulast%3DOltmanns%26aufirst%3DU.%26aulast%3DMuley%26aufirst%3DT.%26aulast%3DHeussel%26aufirst%3DC.%2BP.%26aulast%3DWarth%26aufirst%3DA.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DHerth%26aufirst%3DF.%2BJ.%2BF.%26atitle%3DImpact%2520of%2520comorbidities%2520on%2520mortality%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0151425%26doi%3D10.1371%2Fjournal.pone.0151425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lee, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span> </span><span class="NLM_article-title">Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">J. Neurogastroenterol. Motil.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span><span class="refDoi"> DOI: 10.5056/jnm15192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.5056%2Fjnm15192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26932897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28jmsVGquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=444-451&author=C.+M.+Leeauthor=D.+H.+Leeauthor=B.+K.+Ahnauthor=J.+J.+Hwangauthor=H.+Yoonauthor=C.+M.+Shinauthor=Y.+S.+Parkauthor=N.+Kim&title=Protective+effect+of+proton+pump+inhibitor+for+survival+in+patients+with+gastroesophageal+reflux+disease+and+idiopathic+pulmonary+fibrosis&doi=10.5056%2Fjnm15192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Protective Effect of Proton Pump Inhibitor for Survival in Patients with Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Lee Chang Min; Lee Dong Ho; Ahn Byung Kyu; Hwang Jae Jin; Yoon Hyuk; Shin Cheol Min; Park Young Soo; Kim Nayoung; Lee Dong Ho; Shin Cheol Min; Park Young Soo; Kim Nayoung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurogastroenterology and motility</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-51</span>
        ISSN:<span class="NLM_cas:issn">2093-0879</span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  The prevalence of gastroesophageal reflux disease (GERD) is high in patients with idiopathic pulmonary fibrosis (IPF).  GERD may cause chronic microaspiration that leads to repeated subclinical lung injury, which leads to pulmonary fibrosis.  Although some studies have suggested that proton pump inhibitors (PPI) were associated with a good prognosis in IPF, their effects remain unclear.  METHODS:  We retrospectively reviewed 786 consecutive adult patients with IPF at Seoul National University Bundang Hospital between April 2003 and March 2015.  RESULTS:  Mean duration of follow-up was 2.6 ± 2.8 years.  Of the 786 patients with IPF, 107 (13.6%) were given diagnoses of GERD, and 103 (13.1%) died due to IPF-related pneumonia or respiratory failure.  The prevalence of GERD and the cumulative incidence of de novo GERD increased depending on the period of follow-up in patients with IPF.  Patients administered PPI for more than four months had a lower IPF-related mortality rate than patients on PPI less than 4 months (Log-rank P -value = 0.024 in Kaplan-Meier curve).  In a univariate and multivariate Cox regression hazard model, younger age (hazard ratio [HR], 1.06; 95% CI, 1.03-1.10; P = 0.001), higher initial forced vital capacity (HR, 0.98; 95% CI, 0.96-0.99; P = 0.004), and longer duration of PPI use (HR, 0.97; 95% CI, 0.95-1.00; P = 0.022), but not a diagnosis of GERD, were significantly associated with lower IPF-related mortality.  CONCLUSIONS:  In Korean patients with IPF, the prevalence of GERD was lower than in other countries.  PPI use for at least 4 months may have a protective effect against IPF-related mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBc9R17lEcF9y3lHz94U-GfW6udTcc2eaI2uzzD9LPR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmsVGquw%253D%253D&md5=09e359c5e39e90ef7b607e4729ecae25</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.5056%2Fjnm15192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5056%252Fjnm15192%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DAhn%26aufirst%3DB.%2BK.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DC.%2BM.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DN.%26atitle%3DProtective%2520effect%2520of%2520proton%2520pump%2520inhibitor%2520for%2520survival%2520in%2520patients%2520with%2520gastroesophageal%2520reflux%2520disease%2520and%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Neurogastroenterol.%2520Motil.%26date%3D2016%26volume%3D22%26spage%3D444%26epage%3D451%26doi%3D10.5056%2Fjnm15192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Luppi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span> </span><span class="NLM_article-title">The big clinical trials in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Opin. Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1097/MCP.0b013e3283567ff9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1097%2FMCP.0b013e3283567ff9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22759771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=428-432&author=F.+Luppiauthor=P.+Spagnoloauthor=S.+Cerriauthor=L.+Richeldi&title=The+big+clinical+trials+in+idiopathic+pulmonary+fibrosis&doi=10.1097%2FMCP.0b013e3283567ff9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The big clinical trials in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Luppi, Fabrizio; Spagnolo, Paolo; Cerri, Stefania; Richeldi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">428-432</span>CODEN:
                <span class="NLM_cas:coden">COPMFY</span>;
        ISSN:<span class="NLM_cas:issn">1070-5287</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Since the late 1990 s, when a more uniform definition of idiopathic pulmonary fibrosis (IPF) was proposed, more than 3000 patients have been enrolled in clin. studies exploring novel therapies.  Some of the most relevant trials have been published only recently.  Recent findings: This review describes and comments on the randomized clin. trials in IPF published within the past 18 mo, with emphasis on the studies evaluating pirfenidone, which at present is the only drug approved for IPF (at least in Europe and Japan), and bosentan.  This latter represents the largest single trial performed in IPF so far.  Summary: Despite multiple clin. trials, there is no strong, definitive evidence in favor of any agent to treat IPF.  On the other hand, the placebo arms of these large trials have provided us with important crit. information on the natural history of this disease.  Clin. heterogeneity represents a crit. issue to be taken into account in designing future clin. trials.  The limited effectiveness of current treatment regimes has fuelled the search for a variety of new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1lqOC8P3lZrVg90H21EOLACvtfcHk0lgooWPh9YOxjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7M&md5=c0153c0bfb93c6898a16976ce2868028</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e3283567ff9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e3283567ff9%26sid%3Dliteratum%253Aachs%26aulast%3DLuppi%26aufirst%3DF.%26aulast%3DSpagnolo%26aufirst%3DP.%26aulast%3DCerri%26aufirst%3DS.%26aulast%3DRicheldi%26aufirst%3DL.%26atitle%3DThe%2520big%2520clinical%2520trials%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D428%26epage%3D432%26doi%3D10.1097%2FMCP.0b013e3283567ff9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Demedts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekhuijzen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNee, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomeer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallaert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbeken, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verschakelen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, C. D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capron, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petruzzelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vuyst, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Bosch, J. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Becerra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvasce, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lankhorst, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sardina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, M.</span><span> </span><span class="NLM_article-title">IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">2229</span><span class="NLM_x">–</span> <span class="NLM_lpage">2242</span><span class="refDoi"> DOI: 10.1056/NEJMoa042976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa042976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16306520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GrsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2229-2242&author=M.+Demedtsauthor=J.+Behrauthor=R.+Buhlauthor=U.+Costabelauthor=R.+Dekhuijzenauthor=H.+K.+Jansenauthor=W.+MacNeeauthor=M.+Thomeerauthor=B.+Wallaertauthor=F.+Laurentauthor=A.+G.+Nicholsonauthor=E.+K.+Verbekenauthor=J.+Verschakelenauthor=C.+D.+R.+Flowerauthor=F.+Capronauthor=S.+Petruzzelliauthor=P.+De+Vuystauthor=J.+M.+M.+van+den+Boschauthor=E.+Rodriguez-Becerraauthor=G.+Corvasceauthor=I.+Lankhorstauthor=M.+Sardinaauthor=M.+Montanari&title=IFIGENIA+Study+Group.+High-dose+acetylcysteine+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa042976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High dose acetylcysteine in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Demedts, Maurits; Behr, Juergen; Buhl, Roland; Costabel, Ulrich; Dekhuijzen, Richard; Jansen, Henk M.; MacNee, William; Thomeer, Michiel; Wallaert, Benoit; Laurent, Francois; Nicholson, Andrew G.; Verbeken, Eric K.; Verschakelen, Johny; Flower, Christopher D. R.; Capron, Frederique; Petruzzelli, Stefano; De Vuyst, Paul; van den Bosch, Jules M. M.; Rodriguez-Becerra, Eulogio; Corvasce, Giuseppina; Lankhorst, Ida; Sardina, Marco; Montanari, Mauro; Demedts, M.; Behr, J.; Buhl, R.; Costabel, U.; Dekhuijzen, P. N. R.; Jansen, H. M.; MacNee, W.; Wallaert, B.; Thomeer, M.; Flower, C. D. R.; Verschakelen, J.; Nicholson, A. G.; Verbeken, E. K.; Capron, F.; Behr, J.; van den Bosch, J. M. M.; De Vuyst, P.; Rodriguez-Becerra, E.; Petruzzelli, S.; Wallaert, B.; Corvasce, G.; Peviani, A.; Lankhorst, I.; Makin, E.; Licciardello, L.; Bellinvia, S.; Di Padova, C.; Sardina, M.; Kormoss, N.; Boulanger, P.; Esteras, A.; Sirtori, F.; Moroni, G.; Ardia, A.; Montanari, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2229-2242</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis.  METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to std. therapy with prednisone plus azathioprine.  The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DLCO).  RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo).  Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resoln. computed tomog. and histol. findings reviewed by expert committees, and did not withdraw consent before the start of treatment.  Fifty-seven of the 80 patients taking acetylcysteine (71 %) and 51 of the 75 patients taking placebo (68 %) completed one year of treatment.  Acetylcysteine slowed the deterioration of vital capacity and DLCO: at 12 mo, the abs. differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 L (95 % confidence interval, 0.03 to 0.32), ora relative difference of 9 %, for vital capacity (P = 0.02), and 0.75 mmol per min per kilopascal (95 % confidence interval, 0.27 to 1.23), or 24 %, for DLCO (P = 0.003).  Mortality during the study was 9 % among patients taking acetylcysteine and 11 % among those taking placebo (P = 0.69).  There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P = 0.03).  CONCLUSIONS Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DLCO in patients with idiopathic pulmonary fibrosis better than does std. therapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPUO4Xw_rvcLVg90H21EOLACvtfcHk0lgooWPh9YOxjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GrsbjP&md5=8f342bf2b15b6be1dc6eda6ce123ea0e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa042976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa042976%26sid%3Dliteratum%253Aachs%26aulast%3DDemedts%26aufirst%3DM.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DDekhuijzen%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DH.%2BK.%26aulast%3DMacNee%26aufirst%3DW.%26aulast%3DThomeer%26aufirst%3DM.%26aulast%3DWallaert%26aufirst%3DB.%26aulast%3DLaurent%26aufirst%3DF.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DVerbeken%26aufirst%3DE.%2BK.%26aulast%3DVerschakelen%26aufirst%3DJ.%26aulast%3DFlower%26aufirst%3DC.%2BD.%2BR.%26aulast%3DCapron%26aufirst%3DF.%26aulast%3DPetruzzelli%26aufirst%3DS.%26aulast%3DDe%2BVuyst%26aufirst%3DP.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DJ.%2BM.%2BM.%26aulast%3DRodriguez-Becerra%26aufirst%3DE.%26aulast%3DCorvasce%26aufirst%3DG.%26aulast%3DLankhorst%26aufirst%3DI.%26aulast%3DSardina%26aufirst%3DM.%26aulast%3DMontanari%26aufirst%3DM.%26atitle%3DIFIGENIA%2520Study%2520Group.%2520High-dose%2520acetylcysteine%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2229%26epage%3D2242%26doi%3D10.1056%2FNEJMoa042976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">The Idiopathic Pulmonary Fibrosis Clinical Research Network</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anstrom, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J. A.</span><span> </span><span class="NLM_article-title">Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">1968</span><span class="NLM_x">–</span> <span class="NLM_lpage">1977</span><span class="refDoi"> DOI: 10.1056/NEJMoa1113354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1113354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22607134" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1968-1977&author=The+Idiopathic+Pulmonary+Fibrosis+Clinical+Research+Networkauthor=G.+Raghuauthor=K.+J.+Anstromauthor=T.+E.+Kingauthor=J.+A.+Laskyauthor=F.+J.+A.+Martinez&title=Prednisone%2C+azathioprine%2C+and+N-acetylcysteine+for+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1113354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113354%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%2BA.%26atitle%3DPrednisone%252C%2520azathioprine%252C%2520and%2520N-acetylcysteine%2520for%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1968%26epage%3D1977%26doi%3D10.1056%2FNEJMoa1113354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">The Idiopathic Pulmonary Fibrosis Clinical Research Network</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Andrade, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anstrom, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span> </span><span class="NLM_article-title">Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2093</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1056/NEJMoa1401739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1401739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24836309" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2093-2101&author=The+Idiopathic+Pulmonary+Fibrosis+Clinical+Research+Networkauthor=F.+J.+Martinezauthor=J.+A.+de+Andradeauthor=K.+J.+Anstromauthor=T.+E.+Kingauthor=G.+Raghu&title=Randomized+trial+of+acetylcysteine+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1401739"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401739%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BAndrade%26aufirst%3DJ.%2BA.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DRaghu%26aufirst%3DG.%26atitle%3DRandomized%2520trial%2520of%2520acetylcysteine%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2093%26epage%3D2101%26doi%3D10.1056%2FNEJMoa1401739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendstrup, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Günther, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olschewski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sköld, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuyts, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koschel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallaert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albera, C.</span><span> </span><span class="NLM_article-title">Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, Phase 2 trial</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span><span class="refDoi"> DOI: 10.1016/S2213-2600(16)30044-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS2213-2600%2816%2930044-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=27161257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVChsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=445-453&author=J.+Behrauthor=E.+Bendstrupauthor=B.+Crestaniauthor=A.+G%C3%BCntherauthor=H.+Olschewskiauthor=C.+M.+Sk%C3%B6ldauthor=A.+Wellsauthor=W.+Wuytsauthor=D.+Koschelauthor=M.+Kreuterauthor=B.+Wallaertauthor=C.+Y.+Linauthor=J.+Beckauthor=C.+Albera&title=Safety+and+tolerability+of+acetylcysteine+and+pirfenidone+combination+therapy+in+idiopathic+pulmonary+fibrosis%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+Phase+2+trial&doi=10.1016%2FS2213-2600%2816%2930044-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial</span></div><div class="casAuthors">Behr, Juergen; Bendstrup, Elisabeth; Crestani, Bruno; Guenther, Andreas; Olschewski, Horst; Skoeld, C. Magnus; Wells, Athol; Wuyts, Wim; Koschel, Dirk; Kreuter, Michael; Wallaert, Benoit; Lin, Chin-Yu; Beck, Juergen; Albera, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">445-453</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Oral acetylcysteine (also known as N-acetylcysteine) is used with pirfenidone to treat idiopathic pulmonary fibrosis (IPF) in Europe.  However, no randomised studies have investigated the safety and tolerability of this combination.  The PANORAMA study assessed the safety and tolerability of acetylcysteine combined with pirfenidone in patients with IPF.  Exploratory efficacy endpoints were also assessed.  We did a double-blind randomised trial at 48 sites in eight countries.  Patients with IPF aged 40-80 years and established on pirfenidone (at least 1602 mg/day for 8 wk or longer) were randomly assigned in a 1:1 ratio by interactive voice response system to receive concomitant oral acetylcysteine (600 mg, three times daily) or placebo for 24 wk.  A stratified blocked randomisation scheme was used with a block size of 4.  Randomisation was stratified by dose of pirfenidone (2403 mg/day [the max. dose] or <2403 mg/day).  Patients, physicians, study staff and the sponsor were masked to treatment group allocation.  The primary endpoint was assessment of adverse events, which were collected at each visit and for 28 days after the last dose of study drug.  Exploratory efficacy measurements included forced vital capacity (FVC), carbon monoxide diffusing capacity, and 6 min walk distance.  Analyses were done in the modified intention-to-treat population, which included all patients who were randomised and received at least one dose of study medication.  This study is registered with the European Clin. Trials Database (EudraCT no. 2012-000564-14) and has been completed.123 patients participated in the study between June 28, 2013, and Feb 24, 2015. 61 were assigned to the acetylcysteine group (60 received study medication and included in anal.) and 62 were assigned to the placebo group (all included in anal.).  The occurrence of at least one adverse event (46 [77%] patients receiving acetylcysteine vs 50 [81%] receiving placebo), adverse events related to study treatment (17 [28%] vs 16 [26%]), and the no. of patients experiencing severe adverse events (three [5%] vs two [3%]), life-threatening adverse events (one [2%] vs one [2%]), or death (one [2%] vs three [5%]) was similar between treatment groups.  One case of diarrhoea in the acetylcysteine group was considered severe and related to study treatment.  Nine serious adverse events were reported by seven patients: dyspnoea, headache, hypertension, intervertebral disk protrusion, and malignant lung neoplasm in the acetylcysteine group, and aortic aneurysm, contusion, forearm fracture, and worsening IPF in the placebo group.  The most common adverse events were cough, nasopharyngitis, and diarrhoea.  Photosensitivity occurred more frequently with acetylcysteine (eight [13%] patients) than placebo (one [2%] patient; difference 11·7%; 95% CI 2·6-20·9; p=0·016]), and was not attributable to differences in location, season, or concomitant medication.  Four (7%) patients receiving acetylcysteine and three (5%) receiving placebo discontinued study treatment due to adverse events.  In the exploratory anal., change in FVC indicated that clin. benefit from addn. of acetylcysteine to pirfenidone is unlikely, with the possibility of a harmful effect in patients with IPF (adjusted rate of decline 125·6 mL/6 mo for acetylcysteine vs 34·3 mL/6 mo for placebo; difference -91·3 mL; 95% CI -174·4 to -8·3; p=0·031).  Findings from the PANORAMA study suggest that addn. of acetylcysteine to pirfenidone does not substantially alter the tolerability profile of pirfenidone, and is unlikely to be beneficial in IPF.  InterMune International AG (Roche).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfqE-KT1ZYU7Vg90H21EOLACvtfcHk0lhw3cvEiU7yEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVChsLc%253D&md5=7d910d8c1411570b986868d4bf7d1dce</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930044-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930044-3%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBendstrup%26aufirst%3DE.%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DG%25C3%25BCnther%26aufirst%3DA.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DSk%25C3%25B6ld%26aufirst%3DC.%2BM.%26aulast%3DWells%26aufirst%3DA.%26aulast%3DWuyts%26aufirst%3DW.%26aulast%3DKoschel%26aufirst%3DD.%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DWallaert%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DAlbera%26aufirst%3DC.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520acetylcysteine%2520and%2520pirfenidone%2520combination%2520therapy%2520in%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520Phase%25202%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D445%26epage%3D453%26doi%3D10.1016%2FS2213-2600%2816%2930044-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Comer, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerthoffer, W. T.</span><span> </span><span class="NLM_article-title">Epigenetic targets for novel therapies of lung diseases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.pharmthera.2014.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25448041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=91-110&author=B.+S.+Comerauthor=M.+Baauthor=C.+A.+Singerauthor=W.+T.+Gerthoffer&title=Epigenetic+targets+for+novel+therapies+of+lung+diseases&doi=10.1016%2Fj.pharmthera.2014.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic targets for novel therapies of lung diseases</span></div><div class="casAuthors">Comer, Brian S.; Ba, Mariam; Singer, Cherie A.; Gerthoffer, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-110</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  In spite of substantial advances in defining the immunobiol. and function of structural cells in lung diseases there is still insufficient knowledge to develop fundamentally new classes of drugs to treat many lung diseases.  For example, there is a compelling need for new therapeutic approaches to address severe persistent asthma that is insensitive to inhaled corticosteroids.  Although the prevalence of steroid-resistant asthma is 5-10%, severe asthmatics require a disproportionate level of health care spending and constitute a majority of fatal asthma episodes.  None of the established drug therapies including long-acting beta agonists or inhaled corticosteroids reverse established airway remodeling.  Obstructive airways remodeling in patients with chronic obstructive pulmonary disease (COPD), restrictive remodeling in idiopathic pulmonary fibrosis (IPF) and occlusive vascular remodeling in pulmonary hypertension are similarly unresponsive to current drug therapy.  Therefore, drugs are needed to achieve long-acting suppression and reversal of pathol. airway and vascular remodeling.  Novel drug classes are emerging from advances in epigenetics.  Novel mechanisms are emerging by which cells adapt to environmental cues, which include changes in DNA methylation, histone modifications and regulation of transcription and translation by noncoding RNAs.  In this review we will summarize current epigenetic approaches being applied to preclin. drug development addressing important therapeutic challenges in lung diseases.  These challenges are being addressed by advances in lung delivery of oligonucleotides and small mols. that modify the histone code, DNA methylation patterns and miRNA function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorspcOaxa6BrVg90H21EOLACvtfcHk0ljaOH9Tb6AidQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrtLvL&md5=cde9d2ce965b31bc6700235f7fcf48d1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DComer%26aufirst%3DB.%2BS.%26aulast%3DBa%26aufirst%3DM.%26aulast%3DSinger%26aufirst%3DC.%2BA.%26aulast%3DGerthoffer%26aufirst%3DW.%2BT.%26atitle%3DEpigenetic%2520targets%2520for%2520novel%2520therapies%2520of%2520lung%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D147%26spage%3D91%26epage%3D110%26doi%3D10.1016%2Fj.pharmthera.2014.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deguzman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apparsundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C.M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denton, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span> </span><span class="NLM_article-title">Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and <i>in vivo</i> models of lung fibrosis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1016/j.ajpath.2013.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ajpath.2013.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23759512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2013&pages=470-479&author=X.+Tangauthor=R.+Pengauthor=J.+E.+Phillipsauthor=J.+Deguzmanauthor=Y.+Renauthor=S.+Apparsundaramauthor=Q.+Luoauthor=C.+M.+Bauerauthor=M.+E.+Fuentesauthor=J.+A.+DeMartinoauthor=G.+Tyagiauthor=R.+Garridoauthor=C.M.+Hogaboamauthor=C.+P.+Dentonauthor=A.+M.+Holmesauthor=C.+Kitsonauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Assessment+of+Brd4+inhibition+in+idiopathic+pulmonary+fibrosis+lung+fibroblasts+and+in+vivo+models+of+lung+fibrosis&doi=10.1016%2Fj.ajpath.2013.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis</span></div><div class="casAuthors">Tang, Xiaoyan; Peng, Ruoqi; Phillips, Jonathan E.; Deguzman, Jeremy; Ren, Yonglin; Apparsundaram, Subramanium; Luo, Qi; Bauer, Carla M.; Fuentes, Maria E.; DeMartino, Julie A.; Tyagi, Gaurav; Garrido, Rosario; Hogaboam, Cory M.; Denton, Christopher P.; Holmes, Alan M.; Kitson, Christopher; Stevenson, Christopher S.; Budd, David C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">470-479</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of high unmet medical need.  Although bromodomain (Brd) and extra terminal domain isoforms have recently been implicated in mediating inflammatory and oncol. indications, their roles in lung fibrosis have not been comprehensively assessed.  We investigated the role of Brd on the profibrotic responses of lung fibroblasts (LFs) in patients with rapidly progressing IPF and a mouse bleomycin model of lung fibrosis.  The enhanced migration, proliferation, and IL-6 release obsd. in LFs from patients with rapidly progressing IPF are attenuated by pharmacol. inhibition of Brd4.  These changes are accompanied by enhanced histone H4 lysine5 acetylation and assocn. of Brd4 with genes involved in the profibrotic responses in IPF LFs as demonstrated using chromatin immunopptn. and quant. PCR.  Oral administration of 200 mg/kg per day Brd4 inhibitor JQ1 in a therapeutic dosing regimen substantially attenuated lung fibrosis induced by bleomycin in C57BL/6 mice.  In conclusion, this study shows that the Brd4 inhibitor JQ1, administered in a therapeutic dosage, is capable of inhibiting the profibrotic effects of IPF LFs and attenuates bleomycin-induced lung fibrosis in mice.  These results suggest that Brd4 inhibitors may represent a novel therapy for the treatment of rapidly progressing IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeyA6Tfi6PObVg90H21EOLACvtfcHk0ljaOH9Tb6AidQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I&md5=8a7b094630ce44df6cd1b2b9de6cc6ec</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2013.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2013.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DDeguzman%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DApparsundaram%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DBauer%26aufirst%3DC.%2BM.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DTyagi%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DR.%26aulast%3DHogaboam%26aufirst%3DC.M.%26aulast%3DDenton%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BM.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DAssessment%2520of%2520Brd4%2520inhibition%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520lung%2520fibroblasts%2520and%2520in%2520vivo%2520models%2520of%2520lung%2520fibrosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2013%26volume%3D183%26spage%3D470%26epage%3D479%26doi%3D10.1016%2Fj.ajpath.2013.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Tang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apparsundaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deguzman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span> </span><span class="NLM_article-title">BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in belomycin-induced pulmonary fibrosis</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span><span class="refDoi"> DOI: 10.1124/mol.112.081661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1124%2Fmol.112.081661" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=283-293&author=X.+Tangauthor=R.+Pengauthor=Y.+Renauthor=S.+Apparsundaramauthor=J.+Deguzmanauthor=C.+M.+Bauerauthor=A.+F.+Hoffmanauthor=S.+Hamiltonauthor=Z.+Liangauthor=H.+Zengauthor=M.+E.+Fuentesauthor=J.+A.+DeMartinoauthor=C.+Kitsonauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=BET+bromodomain+proteins+mediate+downstream+signaling+events+following+growth+factor+stimulation+in+human+lung+fibroblasts+and+are+involved+in+belomycin-induced+pulmonary+fibrosis&doi=10.1124%2Fmol.112.081661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.081661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.081661%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DApparsundaram%26aufirst%3DS.%26aulast%3DDeguzman%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DC.%2BM.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DHamilton%26aufirst%3DS.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DBET%2520bromodomain%2520proteins%2520mediate%2520downstream%2520signaling%2520events%2520following%2520growth%2520factor%2520stimulation%2520in%2520human%2520lung%2520fibroblasts%2520and%2520are%2520involved%2520in%2520belomycin-induced%2520pulmonary%2520fibrosis%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D283%26epage%3D293%26doi%3D10.1124%2Fmol.112.081661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sanders, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagood, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambalavanan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1448</span><span class="NLM_x">–</span> <span class="NLM_lpage">1458</span><span class="refDoi"> DOI: 10.1183/09031936.00095113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00095113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24603818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1448-1458&author=Y.+Y.+Sandersauthor=J.+S.+Hagoodauthor=H.+Liuauthor=W.+Zhangauthor=N.+Ambalavananauthor=V.+J.+Thannickal&title=Histone+deacetylase+inhibition+promotes+fibroblast+apoptosis+and+ameliorates+pulmonary+fibrosis+in+mice&doi=10.1183%2F09031936.00095113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice</span></div><div class="casAuthors">Sanders, Yan Y.; Hagood, James S.; Liu, Hui; Zhang, Wei; Ambalavanan, Namasivayam; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1448-1458</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a fatal disease, and therapeutic agents have shown only modest efficacy.  Epigenetic alterations contribute to the pathogenesis of IPF.  The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), has been approved for clin. use in cancer; however, its potential efficacy in modulating fibroblast survival and lung fibrosis has not been extensively investigated.  We investigated the effects of SAHA on apoptosis of primary IPF myofibroblasts and on injury-induced lung fibrosis in a murine model.  SAHA-induced apoptosis of IPF myofibroblasts, an effect that was mediated, at least in part, by upregulation of the pro-apoptotic gene Bak and downregulation of the anti-apoptotic gene Bcl-xL.  Alterations in the expression of these apoptosis-related genes were assocd. with histone modifications and changes in DNA methylation.  In addn. to the expected higher levels of histone acetylation in treated cells, we also detected changes in other histone modifications, such as histone methylation.  In a murine model of bleomycin-induced pulmonary fibrosis, SAHA-treated mice displayed decreased lung fibrosis and improved lung function compared to the bleomycin only group.  These results suggest that histone deacetylase inhibitors may offer a new therapeutic strategy in IPF by modulating myofibroblast susceptibility to apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruyks7TCWdMbVg90H21EOLACvtfcHk0lhbMhZCqLiJBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73J&md5=86f2617a181392acfc8040c9449d8102</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1183%2F09031936.00095113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00095113%26sid%3Dliteratum%253Aachs%26aulast%3DSanders%26aufirst%3DY.%2BY.%26aulast%3DHagood%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DAmbalavanan%26aufirst%3DN.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DHistone%2520deacetylase%2520inhibition%2520promotes%2520fibroblast%2520apoptosis%2520and%2520ameliorates%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1448%26epage%3D1458%26doi%3D10.1183%2F09031936.00095113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Cronkhite, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, C. K.</span><span> </span><span class="NLM_article-title">Telomere shortening in familial and sporadic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">737</span><span class="refDoi"> DOI: 10.1164/rccm.200804-550OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200804-550OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18635888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GqsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2008&pages=729-737&author=J.+T.+Cronkhiteauthor=C.+Xingauthor=G.+Raghuauthor=K.+M.+Chinauthor=F.+Torresauthor=R.+L.+Rosenblattauthor=C.+K.+Garcia&title=Telomere+shortening+in+familial+and+sporadic+pulmonary+fibrosis&doi=10.1164%2Frccm.200804-550OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Telomere shortening in familial and sporadic pulmonary fibrosis</span></div><div class="casAuthors">Cronkhite, Jennifer T.; Xing, Chao; Raghu, Ganesh; Chin, Kelly M.; Torres, Fernando; Rosenblatt, Randall L.; Garcia, Christine Kim</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">729-737</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Heterozygous mutations in the coding regions of the telomerase genes, TERT and TERC, have been found in familial and sporadic cases of idiopathic interstitial pneumonia.  All affected patients with mutations have short telomeres.  To test whether telomere shortening is a frequent mechanism underlying pulmonary fibrosis, we have characterized telomere lengths in subjects with familial or sporadic disease who do not have coding mutations in TERT or TERC.  Using a modified Southern blot assay, the telomerase restriction fragment length method, and a quant. polymerase chain reaction assay we have measured telomere lengths of genomic DNA isolated from circulating leukocytes from normal control subjects and subjects with pulmonary fibrosis.  All affected patients with telomerase mutations, including case subjects heterozygous for newly reported mutations in TERT, have short telomere lengths.  A significantly higher proportion of probands with familial pulmonary fibrosis (24%) and sporadic case subjects (23%) in which no coding mutation in TERT or TERC was found had telomere lengths less than the 10th percentile when compared with control subjects (P = 2.6 × 10-8).  Pulmonary fibrosis affectation status was significantly assocd. with telomerase restriction fragment lengths, even after controlling for age, sex, and ethnicity (P = 6.1 × 10-11).  Overall, 25% of sporadic cases and 37% of familial cases of pulmonary fibrosis had telomere lengths less than the 10th percentile.  A significant fraction of individuals with pulmonary fibrosis have short telomere lengths that cannot be explained by coding mutations in telomerase.  Telomere shortening of circulating leukocytes may be a marker for an increased predisposition toward the development of this age-assocd. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5OLrx3eOI7Vg90H21EOLACvtfcHk0lhteGz_qDg5uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GqsLzI&md5=49b8d3a32dea7e1368dcd8e403e02cb3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1164%2Frccm.200804-550OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200804-550OC%26sid%3Dliteratum%253Aachs%26aulast%3DCronkhite%26aufirst%3DJ.%2BT.%26aulast%3DXing%26aufirst%3DC.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DChin%26aufirst%3DK.%2BM.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DRosenblatt%26aufirst%3DR.%2BL.%26aulast%3DGarcia%26aufirst%3DC.%2BK.%26atitle%3DTelomere%2520shortening%2520in%2520familial%2520and%2520sporadic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D178%26spage%3D729%26epage%3D737%26doi%3D10.1164%2Frccm.200804-550OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Seibold, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyd, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingerlin, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudmundsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groshong, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garantziotis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickey, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kervitsky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbert, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slifer, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auerbach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennessy, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. A.</span><span> </span><span class="NLM_article-title">A common <i>MUC5B</i> promoter polymorphism and pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1503</span><span class="NLM_x">–</span> <span class="NLM_lpage">1512</span><span class="refDoi"> DOI: 10.1056/NEJMoa1013660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1013660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21506741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlCjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1503-1512&author=M.+A.+Seiboldauthor=A.+L.+Wiseauthor=M.+C.+Speerauthor=M.+P.+Steeleauthor=K.+K.+Brownauthor=J.+E.+Loydauthor=T.+E.+Fingerlinauthor=W.+Zhangauthor=G.+Gudmundssonauthor=S.+D.+Groshongauthor=C.+M.+Evansauthor=S.+Garantziotisauthor=K.+B.+Adlerauthor=B.+F.+Dickeyauthor=R.+M.+du+Boisauthor=I.+V.+Yangauthor=A.+Herronauthor=D.+Kervitskyauthor=J.+L.+Talbertauthor=C.+Markinauthor=J.+Parkauthor=A.+L.+Crewsauthor=S.+H.+Sliferauthor=S.+Auerbachauthor=M.+G.+Royauthor=J.+Linauthor=C.+E.+Hennessyauthor=M.+I.+Schwarzauthor=D.+A.+Schwartz&title=A+common+MUC5B+promoter+polymorphism+and+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1013660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A common MUC5B promoter polymorphism and pulmonary fibrosis</span></div><div class="casAuthors">Seibold, Max A.; Wise, Anastasia L.; Speer, Marcy C.; Steele, Mark P.; Brown, Kevin K.; Loyd, James E.; Fingerlin, Tasha E.; Zhang, Weiming; Gudmundsson, Gunnar; Groshong, Steve D.; Evans, Christopher M.; Garantziotis, Stavros; Adler, Kenneth B.; Dickey, Burton F.; Du Bois, Roland M.; Yang, Ivana V.; Herron, Aretha; Kervitsky, Dolly; Talbert, Janet L.; Markin, Cheryl; Park, Joungjoa; Crews, Anne L.; Slifer, Susan H.; Auerbach, Scott; Roy, Michelle G.; Lin, Jia; Hennessy, Corinne E.; Schwarz, Marvin I.; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1503-1512</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The mutations that have been implicated in pulmonary fibrosis account for only a small proportion of the population risk.  METHODS Using a genomewide linkage scan, we detected linkage between idiopathic interstitial pneumonia and a 3.4-Mb region of chromosome 11p15 in 82 families.  We then evaluated genetic variation in this region in gel-forming mucin genes expressed in the lung among 83 subjects with familial interstitial pneumonia, 492 subjects with idiopathic pulmonary fibrosis, and 322 controls.  MUC5B expression was assessed in lung tissue.  RESULTS Linkage and fine mapping were used to identify a region of interest on the p-terminus of chromosome 11 that included gel-forming mucin genes.  The minor-allele of the single-nucleotide polymorphism (SNP) rs35705950, located 3 kb upstream of the MUCSB transcription start site, was present at a frequency of 34% among subjects with familial interstitial pneumonia, 38% among subjects with idiopathic pulmonary fibrosis, and 9% among controls (allelic assocn. with familial interstitial pneumonia, P = 1.2 x 10-15; allelic assocn. with idiopathic pulmonary fibrosis, P = 2.5 x 10-37).  The odds ratios for disease among subjects who were heterozygous and those who were homozygous for the minor allele of this SNP were 6.8 (95% confidence interval [CI], 3.9 to 12.0) and 20.8 (95% CI, 3.8 to 113.7), resp., for familial interstitial pneumonia and 9.0 (95% CI, 6.2 to 13.1) and 21.8 (95% CI, 5.1 to 93.5), resp., for idiopathic pulmonary fibrosis.  MUC5B expression in the lung was 14.1 times as high in subjects who had idiopathic pulmonary fibrosis as in those who did not (P < 0.001).  The variant allele of rs35705950 was assocd. with up-regulation in MUCSB expression in the lung in unaffected subjects (expression was 37.4 times as high as in unaffected subjects homozygous for the wild-type allele, P < 0.001).  MUC5B protein was expressed in lesions of idiopathic pulmonary fibrosis.  CONCLUSIONS A common polymorphism in the promoter of MUCSB is assocd. with familial interstitial pneumonia and idiopathic pulmonary fibrosis.  Our findings suggest that dys-regulated MUCSB expression in the lung may be involved in the pathogenesis of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqgU61mlv8D7Vg90H21EOLACvtfcHk0lhteGz_qDg5uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlCjt74%253D&md5=035e9ac9ba09c6f8a1764228a112ef20</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1013660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1013660%26sid%3Dliteratum%253Aachs%26aulast%3DSeibold%26aufirst%3DM.%2BA.%26aulast%3DWise%26aufirst%3DA.%2BL.%26aulast%3DSpeer%26aufirst%3DM.%2BC.%26aulast%3DSteele%26aufirst%3DM.%2BP.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DFingerlin%26aufirst%3DT.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGudmundsson%26aufirst%3DG.%26aulast%3DGroshong%26aufirst%3DS.%2BD.%26aulast%3DEvans%26aufirst%3DC.%2BM.%26aulast%3DGarantziotis%26aufirst%3DS.%26aulast%3DAdler%26aufirst%3DK.%2BB.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DI.%2BV.%26aulast%3DHerron%26aufirst%3DA.%26aulast%3DKervitsky%26aufirst%3DD.%26aulast%3DTalbert%26aufirst%3DJ.%2BL.%26aulast%3DMarkin%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DA.%2BL.%26aulast%3DSlifer%26aufirst%3DS.%2BH.%26aulast%3DAuerbach%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DM.%2BG.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHennessy%26aufirst%3DC.%2BE.%26aulast%3DSchwarz%26aufirst%3DM.%2BI.%26aulast%3DSchwartz%26aufirst%3DD.%2BA.%26atitle%3DA%2520common%2520MUC5B%2520promoter%2520polymorphism%2520and%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1503%26epage%3D1512%26doi%3D10.1056%2FNEJMoa1013660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Hunninghake, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatabu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latourelle, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zazueta, O. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurugol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San José Estépar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyd, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingerlin, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosas, I. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washko, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D.</span><span> </span><span class="NLM_article-title">A. <i>MUC5B</i> promoter polymorphism and interstitial lung abnormalities</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2192</span><span class="NLM_x">–</span> <span class="NLM_lpage">2200</span><span class="refDoi"> DOI: 10.1056/NEJMoa1216076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1216076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23692170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2192-2200&author=G.+M.+Hunninghakeauthor=H.+Hatabuauthor=Y.+Okajimaauthor=W.+Gaoauthor=J.+Dupuisauthor=J.+C.+Latourelleauthor=M.+Nishinoauthor=T.+Arakiauthor=O.+E.+Zazuetaauthor=S.+Kurugolauthor=J.+C.+Rossauthor=R.+San+Jos%C3%A9+Est%C3%A9parauthor=E.+Murphyauthor=M.+P.+Steeleauthor=J.+E.+Loydauthor=M.+I.+Schwarzauthor=T.+E.+Fingerlinauthor=I.+O.+Rosasauthor=G.+R.+Washkoauthor=G.+T.+O%E2%80%99Connorauthor=D.+Schwartz&title=A.+MUC5B+promoter+polymorphism+and+interstitial+lung+abnormalities&doi=10.1056%2FNEJMoa1216076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">MUC5B promoter polymorphism and interstitial lung abnormalities</span></div><div class="casAuthors">Hunninghake, Gary M.; Hatabu, Hiroto; Okajima, Yuka; Gao, Wei; Dupuis, Josee; Latourelle, Jeanne C.; Nishino, Mizuki; Araki, Tetsuro; Zazueta, Oscar E.; Kurugol, Sila; Ross, James C.; Estepar, Raul San Jose; Murphy, Elissa; Steele, Mark P.; Loyd, James E.; Schwarz, Marvin I.; Fingerlin, Tasha E.; Rosas, Ivan O.; Washko, George R.; O'Connor, George T.; Schwartz, David A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2192-2200</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: A common promoter polymorphism (rs35705950) in MUC5B, the gene encoding mucin 5B, is assocd. with idiopathic pulmonary fibrosis.  It is not known whether this polymorphism is assocd. with interstitial lung disease in the general population.  Methods: We performed a blinded assessment of interstitial lung abnormalities detected in 2633 participants in the Framingham Heart Study by means of volumetric chest computed tomog. (CT).  We evaluated the relationship between the abnormalities and the genotype at the rs35705950 locus.  Results: Of the 2633 chest CT scans that were evaluated, interstitial lung abnormalities were present in 177 (7%).  Participants with such abnormalities were more likely to have shortness of breath and chronic cough and reduced measures of total lung and diffusion capacity, as compared with participants without such abnormalities.  After adjustment for covariates, for each copy of the minor rs35705950 allele, the odds of interstitial lung abnormalities were 2.8 times greater (95% confidence interval [CI], 2.0 to 3.9; P<0.001), and the odds of definite CT evidence of pulmonary fibrosis were 6.3 times greater (95% CI, 3.1 to 12.7; P<0.001).  Although the evidence of an assocn. between the MUC5B genotype and interstitial lung abnormalities was greater among participants who were older than 50 years of age, a history of cigarette smoking did not appear to influence the assocn.  Conclusions: The MUC5B promoter polymorphism was found to be assocd. with interstitial lung disease in the general population.  Although this assocn. was more apparent in older persons, it did not appear to be influenced by cigarette smoking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6MPYpJhlNvbVg90H21EOLACvtfcHk0lhv9BtVvtHbaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1Oqu7c%253D&md5=3893c4b4eebefee6aa436588f00f2d53</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1216076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1216076%26sid%3Dliteratum%253Aachs%26aulast%3DHunninghake%26aufirst%3DG.%2BM.%26aulast%3DHatabu%26aufirst%3DH.%26aulast%3DOkajima%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DLatourelle%26aufirst%3DJ.%2BC.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DZazueta%26aufirst%3DO.%2BE.%26aulast%3DKurugol%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BJos%25C3%25A9%2BEst%25C3%25A9par%26aufirst%3DR.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DSteele%26aufirst%3DM.%2BP.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DSchwarz%26aufirst%3DM.%2BI.%26aulast%3DFingerlin%26aufirst%3DT.%2BE.%26aulast%3DRosas%26aufirst%3DI.%2BO.%26aulast%3DWashko%26aufirst%3DG.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DG.%2BT.%26aulast%3DSchwartz%26aufirst%3DD.%26atitle%3DA.%2520MUC5B%2520promoter%2520polymorphism%2520and%2520interstitial%2520lung%2520abnormalities%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2192%26epage%3D2200%26doi%3D10.1056%2FNEJMoa1216076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Guo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPietro, L. A.</span><span> </span><span class="NLM_article-title">Factors affecting would healing</span> <span class="citation_source-journal">J. Dent. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1177/0022034509359125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1177%2F0022034509359125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20139336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2010&pages=219-229&author=S.+Guoauthor=L.+A.+DiPietro&title=Factors+affecting+would+healing&doi=10.1177%2F0022034509359125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Factors affecting wound healing</span></div><div class="casAuthors">Guo, S.; Di Pietro, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dental Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-229</span>CODEN:
                <span class="NLM_cas:coden">JDREAF</span>;
        ISSN:<span class="NLM_cas:issn">0022-0345</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Wound healing, as a normal biol. process in the human body, is achieved through four precisely and highly programmed phases: hemostasis, inflammation, proliferation, and remodeling.  For a wound to heal successfully, all four phases must occur in the proper sequence and time frame.  Many factors can interfere with one or more phases of this process, thus causing improper or impaired wound healing.  This article reviews the recent literature on the most significant factors that affect cutaneous wound healing and the potential cellular and/or mol. mechanisms involved.  The factors discussed include oxygenation, infection, age and sex hormones, stress, diabetes, obesity, medications, alcoholism, smoking, and nutrition.  A better understanding of the influence of these factors on repair may lead to therapeutics that improve wound healing and resolve impaired wounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXmA0AOrfXT7Vg90H21EOLACvtfcHk0ljZx_0zo0saOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOnsLc%253D&md5=a42f3a6d9a5a275ced98dd32f6f7870f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1177%2F0022034509359125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0022034509359125%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DDiPietro%26aufirst%3DL.%2BA.%26atitle%3DFactors%2520affecting%2520would%2520healing%26jtitle%3DJ.%2520Dent.%2520Res.%26date%3D2010%26volume%3D89%26spage%3D219%26epage%3D229%26doi%3D10.1177%2F0022034509359125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Crooks, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S. P.</span><span> </span><span class="NLM_article-title">Coagulation and anticoagulation in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span><span class="refDoi"> DOI: 10.1183/16000617.00008414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F16000617.00008414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26324800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC287nvVyisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=392-399&author=M.+G.+Crooksauthor=S.+P.+Hart&title=Coagulation+and+anticoagulation+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F16000617.00008414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Coagulation and anticoagulation in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Crooks Michael G; Hart Simon P</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">137</span>),
    <span class="NLM_cas:pages">392-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers.  Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.  Coagulation and fibrinolytic systems play central roles in wound healing and repair, processes hypothesised to be abnormal within the IPF lung.  Animal models of pulmonary fibrosis have demonstrated an imbalance between thrombosis and fibrinolysis within the alveolar compartment, a finding that is also observed in IPF patients.  A systemic prothrombotic state also occurs in IPF and is associated with increased mortality, but trials of anticoagulation in IPF have provided conflicting results.  Differences in methodology, intervention and study populations may contribute to the inconsistent trial outcomes.  The new oral anticoagulants have properties that may prove advantageous in targeting both thrombotic risk and progression of lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9BMw_xouW2nO4gDb7JggCfW6udTcc2ebObf8NWFHX-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nvVyisw%253D%253D&md5=a1a305119d546bdd570344669869ef8d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1183%2F16000617.00008414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.00008414%26sid%3Dliteratum%253Aachs%26aulast%3DCrooks%26aufirst%3DM.%2BG.%26aulast%3DHart%26aufirst%3DS.%2BP.%26atitle%3DCoagulation%2520and%2520anticoagulation%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2015%26volume%3D24%26spage%3D392%26epage%3D399%26doi%3D10.1183%2F16000617.00008414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Navaratnam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumaran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pointon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, R. B.</span><span> </span><span class="NLM_article-title">Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1136/thoraxjnl-2013-203740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthoraxjnl-2013-203740" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=207-215&author=V.+Navaratnamauthor=A.+W.+Fogartyauthor=T.+McKeeverauthor=N.+Thompsonauthor=G.+Jenkinsauthor=S.+R.+Johnsonauthor=G.+Dolanauthor=M.+Kumaranauthor=K.+Pointonauthor=R.+B.+Hubbard&title=Presence+of+a+prothrombotic+state+in+people+with+idiopathic+pulmonary+fibrosis%3A+a+population-based+case-control+study&doi=10.1136%2Fthoraxjnl-2013-203740"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2013-203740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2013-203740%26sid%3Dliteratum%253Aachs%26aulast%3DNavaratnam%26aufirst%3DV.%26aulast%3DFogarty%26aufirst%3DA.%2BW.%26aulast%3DMcKeever%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DN.%26aulast%3DJenkins%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DDolan%26aufirst%3DG.%26aulast%3DKumaran%26aufirst%3DM.%26aulast%3DPointon%26aufirst%3DK.%26aulast%3DHubbard%26aufirst%3DR.%2BB.%26atitle%3DPresence%2520of%2520a%2520prothrombotic%2520state%2520in%2520people%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520population-based%2520case-control%2520study%26jtitle%3DThorax%26date%3D2014%26volume%3D69%26spage%3D207%26epage%3D215%26doi%3D10.1136%2Fthoraxjnl-2013-203740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Noth, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anstrom, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Andrade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olman, M. A.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis clinical network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1164/rccm.201202-0314OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201202-0314OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22561965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Sht7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2012&pages=88-95&author=I.+Nothauthor=K.+J.+Anstromauthor=S.+B.+Calvertauthor=J.+de+Andradeauthor=K.+R.+Flahertyauthor=C.+Glazerauthor=R.+J.+Kanerauthor=M.+A.+Olman&title=Idiopathic+pulmonary+fibrosis+clinical+network+%28IPFnet%29.+A+placebo-controlled+randomized+trial+of+warfarin+in+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.201202-0314OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Noth, Imre; Anstrom, Kevin J.; Calvert, Sara Bristol; de Andrade, Joao; Flaherty, Kevin R.; Glazer, Craig; Kaner, Robert J.; Olman, Mitchell A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis.  Objectives: In a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC.  Methods: This was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients with IPF.  Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 wk.  International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy.  Measurements and Main Results: The primary outcome measure was the composite outcome of time to death, hospitalization (nonbleeding, nonelective), or a 10% or greater abs. decline in FVC.  Due to a low probability of benefit and an increase in mortality obsd. in the subjects randomized to warfarin (14 warfarin vs. 3 placebo deaths; P = 0.005) an independent Data and Safety Monitoring Board recommended stopping the study after 145 of the planned 256 subjects were enrolled (72 warfarin, 73 placebo).  The mean follow-up was 28 wk.  Conclusions: This study did not show a benefit for warfarin in the treatment of patients with progressive IPF.  Treatment with warfarin was assocd. with an increased risk of mortality in an IPF population who lacked other indications for anticoagulation.  Clin. trial registered with www.clinicaltrials.gov (NCT00957242).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotkK3yFmGEFbVg90H21EOLACvtfcHk0liD1ivUEjchjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Sht7nI&md5=904caeacc1f8a5350cf7f13f59101d55</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1164%2Frccm.201202-0314OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201202-0314OC%26sid%3Dliteratum%253Aachs%26aulast%3DNoth%26aufirst%3DI.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DCalvert%26aufirst%3DS.%2BB.%26aulast%3Dde%2BAndrade%26aufirst%3DJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DGlazer%26aufirst%3DC.%26aulast%3DKaner%26aufirst%3DR.%2BJ.%26aulast%3DOlman%26aufirst%3DM.%2BA.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%2520clinical%2520network%2520%2528IPFnet%2529.%2520A%2520placebo-controlled%2520randomized%2520trial%2520of%2520warfarin%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D186%26spage%3D88%26epage%3D95%26doi%3D10.1164%2Frccm.201202-0314OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijsenbeek, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasakova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weycker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchgaessler, K.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, T. M.</span><span> </span><span class="NLM_article-title">Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1776</span><span class="NLM_x">–</span> <span class="NLM_lpage">1784</span><span class="refDoi"> DOI: 10.1183/13993003.02087-2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.02087-2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=27103382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28bit1Khtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2016&pages=1776-1784&author=M.+Kreuterauthor=M.+S.+Wijsenbeekauthor=M.+Vasakovaauthor=P.+Spagnoloauthor=M.+Kolbauthor=U.+Costabelauthor=D.+Weyckerauthor=K.-U.+Kirchgaesslerauthor=T.+M.+Maher&title=Unfavourable+effects+of+medically+indicated+oral+anticoagulants+on+survival+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F13993003.02087-2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Kreuter Michael; Wijsenbeek Marlies S; Vasakova Martina; Spagnolo Paolo; Kolb Martin; Costabel Ulrich; Weycker Derek; Kirchgaessler Klaus-Uwe; Maher Toby M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1776-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Procoagulant and antifibrinolytic activity has been associated with idiopathic pulmonary fibrosis (IPF); however, investigation of anticoagulant therapy in IPF has suggested deleterious effects.  This post hoc analysis evaluated the effect of medically indicated anticoagulation on mortality and other clinical outcomes in IPF.Patients randomised to placebo (n=624) from three controlled trials in IPF were analysed by oral anticoagulant use.  End-points included all-cause and IPF-related mortality, disease progression, hospitalisation, and adverse events, over 1 year.At baseline, 32 (5.1%) patients randomised to placebo were prescribed anticoagulants for non-IPF indications, 29 (90.6%) of whom received warfarin.  Unadjusted analyses demonstrated significantly higher all-cause and IPF-related mortality at 1 year in baseline anticoagulant users versus nonusers (15.6% versus 6.3%, p=0.039 and 15.6% versus 3.9%, p=0.002, respectively).  In multivariate analyses, baseline use of anticoagulants was an independent predictor of IPF-related mortality (hazard ratio 4.7, p=0.034), but not other end-points.  Rates of bleeding and cardiac events did not differ significantly between groups.  In an exploratory analysis, anticoagulant use at any time during the study was an independent predictor of all end-points.This post hoc analysis suggests that anticoagulants used for non-IPF indications may have unfavourable effects in IPF patients.  Future studies are needed to explore this relationship further.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-HQ8dhmJilT0O18WR3iAofW6udTcc2eZRfJ2_4qcH67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bit1Khtg%253D%253D&md5=c8f3bc8a4e1fec3272aedcc46c5ce14d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1183%2F13993003.02087-2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02087-2015%26sid%3Dliteratum%253Aachs%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DWijsenbeek%26aufirst%3DM.%2BS.%26aulast%3DVasakova%26aufirst%3DM.%26aulast%3DSpagnolo%26aufirst%3DP.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DWeycker%26aufirst%3DD.%26aulast%3DKirchgaessler%26aufirst%3DK.-U.%26aulast%3DMaher%26aufirst%3DT.%2BM.%26atitle%3DUnfavourable%2520effects%2520of%2520medically%2520indicated%2520oral%2520anticoagulants%2520on%2520survival%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2016%26volume%3D47%26spage%3D1776%26epage%3D1784%26doi%3D10.1183%2F13993003.02087-2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Bogatkevich, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwicka-bradley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. M.</span><span> </span><span class="NLM_article-title">Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3455</span><span class="NLM_x">–</span> <span class="NLM_lpage">3464</span><span class="refDoi"> DOI: 10.1002/art.24935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fart.24935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19877031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFentLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=3455-3464&author=G.+S.+Bogatkevichauthor=A.+Ludwicka-bradleyauthor=R.+M.+Silver&title=Dabigatran%2C+a+direct+thrombin+inhibitor%2C+demonstrates+antifibrotic+effects+on+lung+fibroblasts&doi=10.1002%2Fart.24935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts</span></div><div class="casAuthors">Bogatkevich, Galina S.; Ludwicka-Bradley, Anna; Silver, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3455-3464</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. Myofibroblasts are the principal mesenchymal cells responsible for tissue remodeling, collagen deposition, and the restrictive nature of lung parenchyma assocd. with pulmonary fibrosis.  We previously reported that thrombin activates protease-activated receptor 1 (PAR-1) and induces a myofibroblast phenotype in normal lung fibroblasts resembling the phenotype of scleroderma lung myofibroblasts.  We undertook this study to investigate whether a selective direct thrombin inhibitor, dabigatran, interferes with signal transduction in human lung fibroblasts induced by thrombin and mediated via PAR-1.  Methods. Lung fibroblast proliferation was analyzed using the Quick Cell Proliferation Assay.  Expression and organization of α-smooth muscle actin (α-SMA) was studied by immunofluorescence staining and immunoblotting.  Contractile activity of lung fibroblasts was measured by a collagen gel contraction assay.  Connective tissue growth factor (CTGF) and type I collagen expression was analyzed on Western blots.  Results. Dabigatran, at concns. of 50-1,000 ng/mL, inhibited thrombin-induced cell proliferation, α-SMA expression and organization, and the prodn. of collagen and CTGF in normal lung fibroblasts.  Moreover, when treated with dabigatran (1 μg/mL), scleroderma lung myofibroblasts produced 6-fold less α-SMA, 3-fold less CTGF, and 2-fold less type I collagen compared with untreated cells.  Conclusion. Dabigatran restrains important profibrotic events in lung fibroblasts and warrants study as a potential antifibrotic drug for the treatment of fibrosing lung diseases such as scleroderma lung disease and idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ8f5odQC10LVg90H21EOLACvtfcHk0lheuKInhTBtGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFentLzE&md5=e97b12aac12c7e25c28c2ab0f1dfb961</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fart.24935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24935%26sid%3Dliteratum%253Aachs%26aulast%3DBogatkevich%26aufirst%3DG.%2BS.%26aulast%3DLudwicka-bradley%26aufirst%3DA.%26aulast%3DSilver%26aufirst%3DR.%2BM.%26atitle%3DDabigatran%252C%2520a%2520direct%2520thrombin%2520inhibitor%252C%2520demonstrates%2520antifibrotic%2520effects%2520on%2520lung%2520fibroblasts%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D3455%26epage%3D3464%26doi%3D10.1002%2Fart.24935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Bogatkevich, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwicka-bradley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nietert, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Ryn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, R. M.</span><span> </span><span class="NLM_article-title">Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1416</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span><span class="refDoi"> DOI: 10.1002/art.30255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fart.30255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21312187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=1416-1425&author=G.+S.+Bogatkevichauthor=A.+Ludwicka-bradleyauthor=P.+J.+Nietertauthor=T.+Akterauthor=J.+van+Rynauthor=R.+M.+Silver&title=Antiinflammatory+and+antifibrotic+effects+of+the+oral+direct+thrombin+inhibitor+dabigatran+etexilate+in+a+murine+model+of+interstitial+lung+disease&doi=10.1002%2Fart.30255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease</span></div><div class="casAuthors">Bogatkevich, Galina S.; Ludwicka-Bradley, Anna; Nietert, Paul J.; Akter, Tanjina; van Ryn, Joanne; Silver, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1416-1425</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Activation of the coagulation cascade leading to generation of thrombin has been documented extensively in various forms of lung injury, including that assocd. with systemic sclerosis.  We previously demonstrated that the direct thrombin inhibitor dabigatran inhibits thrombin-induced profibrotic signaling in lung fibroblasts.  This study was undertaken to test whether dabigatran etexilate attenuates lung injury in a murine model of interstitial lung disease.  Lung injury was induced in female C57BL/6 mice by a single intratracheal instillation of bleomycin.  Dabigatran etexilate was given as supplemented chow beginning on day 1 of bleomycin instillation (early treatment, study of antiinflammatory effect) or on day 8 following bleomycin instillation (late treatment, study of antifibrotic effect).  Mice were killed 2 wk or 3 wk after bleomycin instillation, and lung tissue, bronchoalveolar lavage (BAL) fluid, and plasma were investigated.  Both early treatment and late treatment with dabigatran etexilate attenuated the development of bleomycin-induced pulmonary fibrosis.  Dabigatran etexilate significantly reduced thrombin activity and levels of transforming growth factor β1 in BAL fluid, while simultaneously reducing the no. of inflammatory cells and protein concns.  Histol. evident lung inflammation and fibrosis were significantly decreased in dabigatran etexilate-treated mice.  Addnl., dabigatran etexilate reduced collagen, connective tissue growth factor, and α-smooth muscle actin expression in mice with bleomycin-induced lung fibrosis, whereas it had no effect on basal levels of these proteins.  Inhibition of thrombin using the oral direct thrombin inhibitor dabigatran etexilate has marked antiinflammatory and antifibrotic effects in a bleomycin model of pulmonary fibrosis.  Our data provide preclin. information about the feasibility and efficacy of dabigatran etexilate as a new therapeutic approach for the treatment of interstitial lung disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6d_EuqwQ5grVg90H21EOLACvtfcHk0lheuKInhTBtGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGht74%253D&md5=40fbb918854846010a3045f597458d49</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fart.30255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.30255%26sid%3Dliteratum%253Aachs%26aulast%3DBogatkevich%26aufirst%3DG.%2BS.%26aulast%3DLudwicka-bradley%26aufirst%3DA.%26aulast%3DNietert%26aufirst%3DP.%2BJ.%26aulast%3DAkter%26aufirst%3DT.%26aulast%3Dvan%2BRyn%26aufirst%3DJ.%26aulast%3DSilver%26aufirst%3DR.%2BM.%26atitle%3DAntiinflammatory%2520and%2520antifibrotic%2520effects%2520of%2520the%2520oral%2520direct%2520thrombin%2520inhibitor%2520dabigatran%2520etexilate%2520in%2520a%2520murine%2520model%2520of%2520interstitial%2520lung%2520disease%26jtitle%3DArthritis%2520Rheum.%26date%3D2011%26volume%3D63%26spage%3D1416%26epage%3D1425%26doi%3D10.1002%2Fart.30255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Scotton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupiczojc, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Königshoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffatt, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derian, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickelberg, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">2550</span><span class="NLM_x">–</span> <span class="NLM_lpage">2563</span><span class="refDoi"> DOI: 10.1172/JCI33288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1172%2FJCI33288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=2550-2563&author=C.+J.+Scottonauthor=M.+A.+Krupiczojcauthor=M.+K%C3%B6nigshoffauthor=P.+F.+Mercerauthor=Y.+C.+Leeauthor=N.+Kaminskiauthor=J.+Morserauthor=J.+M.+Postauthor=T.+M.+Maherauthor=A.+G.+Nicholsonauthor=J.+D.+Moffattauthor=G.+J.+Laurentauthor=C.+K.+Derianauthor=O.+Eickelbergauthor=R.+C.+Chambers&title=Increased+local+expression+of+coagulation+factor+X+contributes+to+the+fibrotic+response+in+human+and+murine+lung+injury&doi=10.1172%2FJCI33288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1172%2FJCI33288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI33288%26sid%3Dliteratum%253Aachs%26aulast%3DScotton%26aufirst%3DC.%2BJ.%26aulast%3DKrupiczojc%26aufirst%3DM.%2BA.%26aulast%3DK%25C3%25B6nigshoff%26aufirst%3DM.%26aulast%3DMercer%26aufirst%3DP.%2BF.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DMaher%26aufirst%3DT.%2BM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DMoffatt%26aufirst%3DJ.%2BD.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DDerian%26aufirst%3DC.%2BK.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DIncreased%2520local%2520expression%2520of%2520coagulation%2520factor%2520X%2520contributes%2520to%2520the%2520fibrotic%2520response%2520in%2520human%2520and%2520murine%2520lung%2520injury%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D2550%26epage%3D2563%26doi%3D10.1172%2FJCI33288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spong, S.</span><span> </span><span class="NLM_article-title">CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">S24</span><span class="refDoi"> DOI: 10.1186/1755-1536-5-S1-S24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2F1755-1536-5-S1-S24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=S24&author=K.+E.+Lipsonauthor=C.+Wongauthor=Y.+Tengauthor=S.+Spong&title=CTGF+is+a+central+mediator+of+tissue+remodeling+and+fibrosis+and+its+inhibition+can+reverse+the+process+of+fibrosis&doi=10.1186%2F1755-1536-5-S1-S24"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-5-S1-S24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-5-S1-S24%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DTeng%26aufirst%3DY.%26aulast%3DSpong%26aufirst%3DS.%26atitle%3DCTGF%2520is%2520a%2520central%2520mediator%2520of%2520tissue%2520remodeling%2520and%2520fibrosis%2520and%2520its%2520inhibition%2520can%2520reverse%2520the%2520process%2520of%2520fibrosis%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2012%26volume%3D5%26spage%3DS24%26doi%3D10.1186%2F1755-1536-5-S1-S24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Kono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukamachi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, P.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maekawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chida, K.</span><span> </span><span class="NLM_article-title">Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)</span> <span class="citation_source-journal">Clin. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">412</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2215</span><span class="refDoi"> DOI: 10.1016/j.cca.2011.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.cca.2011.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21864521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2011&pages=2211-2215&author=M.+Konoauthor=Y.+Nakamuraauthor=T.+Sudaauthor=M.+Katoauthor=Y.+Kaidaauthor=D.+Hashimotoauthor=N.+Inuiauthor=E.+Hamadaauthor=O.+Miyazakiauthor=S.+Kurashitaauthor=I.+Fukamachiauthor=K.+Endoauthor=P.-S.+Ngauthor=K.+Takeharaauthor=H.+Nakamuraauthor=M.+Maekawaauthor=K.+Chida&title=Plasma+CCN2+%28connective+tissue+growth+factor%3B+CTGF%29+is+a+potential+biomarker+in+idiopathic+pulmonary+fibrosis+%28IPF%29&doi=10.1016%2Fj.cca.2011.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)</span></div><div class="casAuthors">Kono, Masato; Nakamura, Yutaro; Suda, Takafumi; Kato, Masato; Kaida, Yusuke; Hashimoto, Dai; Inui, Naoki; Hamada, Etsuko; Miyazaki, Osamu; Kurashita, Syunsuke; Fukamachi, Isamu; Endo, Koki; Ng, Poh-Sing; Takehara, Kazuhiko; Nakamura, Hirotoshi; Maekawa, Masato; Chida, Kingo</div><div class="citationInfo"><span class="NLM_cas:title">Clinica Chimica Acta</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">412</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">2211-2215</span>CODEN:
                <span class="NLM_cas:coden">CCATAR</span>;
        ISSN:<span class="NLM_cas:issn">0009-8981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal pulmonary fibrotic disease and useful biomarkers are required to diagnose and predict disease activity.  CCN2 (connective tissue growth factor; CTGF) has been reported as one of the key profibrotic factors assocd. with transforming growth factor-β (TGF-β), and its assay has potential as a non-invasive measure in various fibrotic diseases.  Recently, we developed a new subtraction method for detn. of plasma CCN2 levels.  We examd. the utility of plasma CCN2 levels as a surrogate marker in IPF.  Plasma CCN2 levels were calcd. in 33 patients with IPF, 14 patients with non-IPF idiopathic interstitial pneumonias (IIPs) and 101 healthy volunteers by sandwich ELISA using specific monoclonal antibodies for two distinct epitopes of human CCN2.  We evaluated the utility of plasma CCN2 levels by comparison with clin. parameters.  Plasma CCN2 levels were significantly higher in patients with IPF than in those with non-IPF IIPs and healthy volunteers.  Importantly, plasma CCN2 levels showed significantly neg. correlation with 6-mo change of forced vital capacity (FVC) in patients with IPF.  Plasma CCN2 is a potential biomarker for IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9kmyL2fV0ObVg90H21EOLACvtfcHk0lgvB-T7H8Gmsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktLvJ&md5=d7512848b4254b3a14cc1d0672600011</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cca.2011.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cca.2011.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DSuda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKaida%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DD.%26aulast%3DInui%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DE.%26aulast%3DMiyazaki%26aufirst%3DO.%26aulast%3DKurashita%26aufirst%3DS.%26aulast%3DFukamachi%26aufirst%3DI.%26aulast%3DEndo%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DP.-S.%26aulast%3DTakehara%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DMaekawa%26aufirst%3DM.%26aulast%3DChida%26aufirst%3DK.%26atitle%3DPlasma%2520CCN2%2520%2528connective%2520tissue%2520growth%2520factor%253B%2520CTGF%2529%2520is%2520a%2520potential%2520biomarker%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528IPF%2529%26jtitle%3DClin.%2520Chim.%2520Acta%26date%3D2011%26volume%3D412%26spage%3D2211%26epage%3D2215%26doi%3D10.1016%2Fj.cca.2011.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Type 2 cytokines: mechanisms and therapeutic strategies</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1038/nri3831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnri3831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25882242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=271-282&author=T.+A.+Wynn&title=Type+2+cytokines%3A+mechanisms+and+therapeutic+strategies&doi=10.1038%2Fnri3831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 cytokines: mechanisms and therapeutic strategies</span></div><div class="casAuthors">Wynn, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">271-282</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Type 2 immune responses are defined by the cytokines interleukin-4 (IL-4), IL-5, IL-9 and IL-13, which can either be host protective or have pathogenic activity.  Type 2 immunity promotes antihelminth immunity, suppresses type 1-driven autoimmune disease, neutralizes toxins, maintains metabolic homeostasis, and regulates wound repair and tissue regeneration pathways following infection or injury.  Nevertheless, when type 2 responses are dysregulated, they can become important drivers of disease.  Type 2 immunity induces a complex inflammatory response characterized by eosinophils, mast cells, basophils, type 2 innate lymphoid cells, IL-4-and/or IL-13-conditioned macrophages and T helper 2 (TH2) cells, which are crucial to the pathogenesis of many allergic and fibrotic disorders.  As chronic type 2 immune responses promote disease, the mechanisms that regulate their maintenance are thought to function as crucial disease modifiers.  This Review discusses the many endogenous neg. regulatory mechanisms that antagonize type 2 immunity and highlights how therapies that target some of these pathways are being developed to treat type 2-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU2G_VQvzQ2LVg90H21EOLACvtfcHk0li0PalpPDoDsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wru7zP&md5=d9e3a4a8e7d9752eff45f2746f2024f5</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnri3831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3831%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DType%25202%2520cytokines%253A%2520mechanisms%2520and%2520therapeutic%2520strategies%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2015%26volume%3D15%26spage%3D271%26epage%3D282%26doi%3D10.1038%2Fnri3831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Murray, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oak, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleeman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzog, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogaboam, C. M.</span><span> </span><span class="NLM_article-title">Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">994</span><span class="refDoi"> DOI: 10.1165/rcmb.2013-0342OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2013-0342OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24325475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=985-994&author=L.+A.+Murrayauthor=H.+Zhangauthor=S.+R.+Oakauthor=A.+L.+Coelhoauthor=A.+Herathauthor=K.+R.+Flahertyauthor=J.+Leeauthor=M.+Bellauthor=D.+A.+Knightauthor=F.+J.+Martinezauthor=M.+A.+Sleemanauthor=E.+L.+Herzogauthor=C.+M.+Hogaboam&title=Targeting+interleukin-13+with+tralokinumab+attenuates+lung+fibrosis+and+epithelial+damage+in+a+humanized+SCID+idiopathic+pulmonary+fibrosis+model&doi=10.1165%2Frcmb.2013-0342OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model</span></div><div class="casAuthors">Murray, Lynne A.; Zhang, Huilan; Oak, Sameer R.; Coelho, Ana Lucia; Herath, Athula; Flaherty, Kevin R.; Lee, Joyce; Bell, Matt; Knight, Darryl A.; Martinez, Fernando J.; Sleeman, Matthew A.; Herzog, Erica L.; Hogaboam, Cory M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">985-994, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The aberrant fibrotic and repair responses in the lung are major hallmarks of idiopathic pulmonary fibrosis (IPF).  Numerous antifibrotic strategies have been used in the clinic with limited success, raising the possibility that an effective therapeutic strategy in this disease must inhibit fibrosis and promote appropriate lung repair mechanisms.  IL-13 represents an attractive target in IPF, but its disease assocn. and mechanism of action remains unknown.  In the present study, an overexpression of IL-13 and IL-13 pathway markers was assocd. with IPF, particularly a rapidly progressive form of this disease.  Targeting IL-13 in a humanized exptl. model of pulmonary fibrosis using tralokinumab (CAT354) was found to therapeutically block aberrant lung remodeling in this model.  However, targeting IL-13 was also found to promote lung repair and to restore epithelial integrity.  Thus, targeting IL-13 inhibits fibrotic processes and enhances repair processes in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ5PV-S-_ZNbVg90H21EOLACvtfcHk0li0PalpPDoDsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLvL&md5=2b557ab3778dccc984e59ba622e1eb77</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0342OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0342OC%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DL.%2BA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DOak%26aufirst%3DS.%2BR.%26aulast%3DCoelho%26aufirst%3DA.%2BL.%26aulast%3DHerath%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DBell%26aufirst%3DM.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DSleeman%26aufirst%3DM.%2BA.%26aulast%3DHerzog%26aufirst%3DE.%2BL.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26atitle%3DTargeting%2520interleukin-13%2520with%2520tralokinumab%2520attenuates%2520lung%2520fibrosis%2520and%2520epithelial%2520damage%2520in%2520a%2520humanized%2520SCID%2520idiopathic%2520pulmonary%2520fibrosis%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D50%26spage%3D985%26epage%3D994%26doi%3D10.1165%2Frcmb.2013-0342OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span>ClinicalTrials.gov. A study of lebrikizumab in patients with idiopathic pulmonary fibrosis. <a href="https://clinicaltrials.gov/ct2/show/NCT01872689" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01872689</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+study+of+lebrikizumab+in+patients+with+idiopathic+pulmonary+fibrosis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01872689+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Wilson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Pulmonary fibrosis: pathogenesis, etiology and regulation</span> <span class="citation_source-journal">Mucosal Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/mi.2008.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fmi.2008.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19129758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=103-121&author=M.+S.+Wilsonauthor=T.+A.+Wynn&title=Pulmonary+fibrosis%3A+pathogenesis%2C+etiology+and+regulation&doi=10.1038%2Fmi.2008.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary fibrosis: pathogenesis, etiology and regulation</span></div><div class="casAuthors">Wilson, M. S.; Wynn, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mucosal Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-121</span>CODEN:
                <span class="NLM_cas:coden">MIUMAK</span>;
        ISSN:<span class="NLM_cas:issn">1933-0219</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung function, often with fatal consequences.  The etiol. of pulmonary fibrotic diseases is varied, with an array of triggers including allergens, chems., radiation and environmental particles.  However, the cause of one of the most common pulmonary fibrotic conditions, idiopathic pulmonary fibrosis (IPF), is still unclear.  This review examines common mechanisms of pulmonary wound-healing responses following lung injury, and highlights the pathogenesis of some of the most widespread pulmonary fibrotic diseases.  A 3 phase model of wound repair is reviewed that includes; (1) injury; (2) inflammation; and (3) repair.  In most pulmonary fibrotic conditions dysregulation at one or more of these phases was reported.  Chronic inflammation can lead to an imbalance in the prodn. of chemokines, cytokines, growth factors, and disrupt cellular recruitment.  These changes coupled with excessive pro-fibrotic IL-13 and/or TGFβ1 prodn. can turn a well-controlled healing response into a pathogenic fibrotic response.  Endogenous regulatory mechanisms are discussed including novel areas of therapeutic intervention.  Restoring homeostasis to these dysregulated healing responses, or simply neutralizing the key pro-fibrotic mediators may prevent or slow the progression of pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPykZAQ68KP7Vg90H21EOLACvtfcHk0ljy9owe2GLxfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCgur8%253D&md5=1e7d72291a39f09cfe113b5028188f28</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fmi.2008.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmi.2008.85%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DM.%2BS.%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DPulmonary%2520fibrosis%253A%2520pathogenesis%252C%2520etiology%2520and%2520regulation%26jtitle%3DMucosal%2520Immunol.%26date%3D2009%26volume%3D2%26spage%3D103%26epage%3D121%26doi%3D10.1038%2Fmi.2008.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Staitieh, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzoni, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veeraraghavan, S.</span><span> </span><span class="NLM_article-title">Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.3109/07853890.2014.991751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3109%2F07853890.2014.991751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25613169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=100-105&author=B.+S.+Staitiehauthor=E.+A.+Renzoniauthor=S.+Veeraraghavan&title=Pharmacologic+therapies+for+idiopathic+pulmonary+fibrosis%2C+past+and+future&doi=10.3109%2F07853890.2014.991751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future</span></div><div class="casAuthors">Staitieh, Bashar S.; Renzoni, Elisabetta A.; Veeraraghavan, Srihari</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-105</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a severe, progressive fibrotic disease of the lung of unknown etiol. that affects approx. 150,000 patients in the United States.  It carries a median survival of two to three years, but clin. course can vary markedly from patient to patient.  There has been no established treatment for IPF, but recent advances in coordinated clin. trials through groups such as IPFnet and academia-industry partnerships have allowed this relatively rare disease to be studied in much greater depth.  Historically, the default therapy for IPF was a combination of prednisone, N-acetylcysteine, and azathioprine, but recent trials have shown that this regimen actually increases mortality.  An enormous body of work in recent years, spanning the bench to the bedside, has radically altered our understanding of the mol. mechanisms underlying IPF.  Newer modalities, particularly those involving monoclonal antibodies targeted at specific pathways known to contribute to the fibrotic process, have generated a great deal of excitement in the field, and recent clin. trials on therapies such as pirfenidone and nintedanib herald a new era in targeted IPF therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHl-kNPBMJOLVg90H21EOLACvtfcHk0ljy9owe2GLxfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gsb8%253D&md5=d9e113052b26d7160b3f315d20e6ef1a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3109%2F07853890.2014.991751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07853890.2014.991751%26sid%3Dliteratum%253Aachs%26aulast%3DStaitieh%26aufirst%3DB.%2BS.%26aulast%3DRenzoni%26aufirst%3DE.%2BA.%26aulast%3DVeeraraghavan%26aufirst%3DS.%26atitle%3DPharmacologic%2520therapies%2520for%2520idiopathic%2520pulmonary%2520fibrosis%252C%2520past%2520and%2520future%26jtitle%3DAnn.%2520Med.%26date%3D2015%26volume%3D47%26spage%3D100%26epage%3D105%26doi%3D10.3109%2F07853890.2014.991751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Horan, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukashev, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinreb, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahm, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allaire, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinaldi, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feghali-Bostwick, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matteson, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafyatis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violette, S. M.</span><span> </span><span class="NLM_article-title">Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1164/rccm.200706-805OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200706-805OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17916809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12mt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2008&pages=56-65&author=G.+S.+Horanauthor=S.+Woodauthor=V.+Onaauthor=D.+J.+Liauthor=M.+E.+Lukashevauthor=P.+H.+Weinrebauthor=K.+J.+Simonauthor=K.+Hahmauthor=N.+E.+Allaireauthor=N.+J.+Rinaldiauthor=J.+Goyalauthor=C.+A.+Feghali-Bostwickauthor=E.+L.+Mattesonauthor=C.+O%E2%80%99Haraauthor=R.+Lafyatisauthor=G.+S.+Davisauthor=X.+Huangauthor=D.+Sheppardauthor=S.+M.+Violette&title=Partial+inhibition+of+integrin+%CE%B1v%CE%B26+prevents+pulmonary+fibrosis+without+exacerbating+inflammation&doi=10.1164%2Frccm.200706-805OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation</span></div><div class="casAuthors">Horan, Gerald S.; Wood, Susan; Ona, Victor; Li, Dan Jun; Lukashev, Matvey E.; Weinreb, Paul H.; Simon, Kenneth J.; Hahm, Kyungmin; Allaire, Norman E.; Rinaldi, Nicola J.; Goyal, Jaya; Feghali-Bostwick, Carol A.; Matteson, Eric L.; O'Hara, Carl; Lafyatis, Robert; Davis, Gerald S.; Huang, Xiaozhu; Sheppard, Dean; Violette, Shelia M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-65</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Transforming growth factor (TGF)-β has a central role in driving many of the pathol. processes that characterize pulmonary fibrosis.  Inhibition of the integrin αvβ6, a key activator of TCF-β in lung, is an attractive therapeutic strategy, as it may be possible to inhibit TGF-β at sites of αvβ6 up-regulation without affecting other homeostatic roles of TGF-β.  Objectives: To analyze the expression of αvβ6 in human pulmonary fibrosis, and to functionally test the efficacy of therapeutic inhibition of αvβ6-mediated TGF-β activation in murine bleomycin-induced pulmonary fibrosis.  Methods: Lung biopsies from patients with a diagnosis of systemic sclerosis or idiopathic pulmonary fibrosis were stained for αvβ6 expression.  A range of concns. of a monoclonal antibody that blocks αvβ6-mediated TGF-β activation was evaluated in murine bleomycin-induced lung fibrosis.  Measurements and Main Results: αvβ6 is overexpressed in human lung fibrosis within pneumocytes lining the alveolar ducts and alveoli.  In the bleomycin model, αvβ6 antibody was effective in blocking pulmonary fibrosis.  At high doses, there was increased expression of markers of inflammation and macrophage activation, consistent with the effects of TGF-β inhibition in the lung.  Low doses of antibody attenuated collagen expression without increasing alveolar inflammatory cell populations or macrophage activation markers.  Conclusions: Partial inhibition of TGF-β using αvβ6 integrin antibodies is effective in blocking murine pulmonary fibrosis without exacerbating inflammation.  In addn., the elevated expression of αvβ6, an activator of the fibrogenic cytokine, TGF-β, in human pulmonary fibrosis suggests that αvβ6 monoclonal antibodies could represent a promising new therapeutic strategy for treating pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQeX6SpcmK-7Vg90H21EOLACvtfcHk0ljNq7oF_h6w6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12mt70%253D&md5=54ef649e15766e07b4716672c4634d08</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1164%2Frccm.200706-805OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200706-805OC%26sid%3Dliteratum%253Aachs%26aulast%3DHoran%26aufirst%3DG.%2BS.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DOna%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DD.%2BJ.%26aulast%3DLukashev%26aufirst%3DM.%2BE.%26aulast%3DWeinreb%26aufirst%3DP.%2BH.%26aulast%3DSimon%26aufirst%3DK.%2BJ.%26aulast%3DHahm%26aufirst%3DK.%26aulast%3DAllaire%26aufirst%3DN.%2BE.%26aulast%3DRinaldi%26aufirst%3DN.%2BJ.%26aulast%3DGoyal%26aufirst%3DJ.%26aulast%3DFeghali-Bostwick%26aufirst%3DC.%2BA.%26aulast%3DMatteson%26aufirst%3DE.%2BL.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DC.%26aulast%3DLafyatis%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DG.%2BS.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DViolette%26aufirst%3DS.%2BM.%26atitle%3DPartial%2520inhibition%2520of%2520integrin%2520%25CE%25B1v%25CE%25B26%2520prevents%2520pulmonary%2520fibrosis%2520without%2520exacerbating%2520inflammation%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D177%26spage%3D56%26epage%3D65%26doi%3D10.1164%2Frccm.200706-805OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Porte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, G.</span><span> </span><span class="NLM_article-title">Assessment of the effect of potential antifibrotic compounds on total and αvβ6 integrin-mediated TGF-β activation</span> <span class="citation_source-journal">Pharmacol. Res. Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e00030</span><span class="refDoi"> DOI: 10.1002/prp2.30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fprp2.30" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=e00030&author=J.+Porteauthor=G.+Jenkins&title=Assessment+of+the+effect+of+potential+antifibrotic+compounds+on+total+and+%CE%B1v%CE%B26+integrin-mediated+TGF-%CE%B2+activation&doi=10.1002%2Fprp2.30"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fprp2.30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.30%26sid%3Dliteratum%253Aachs%26aulast%3DPorte%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DG.%26atitle%3DAssessment%2520of%2520the%2520effect%2520of%2520potential%2520antifibrotic%2520compounds%2520on%2520total%2520and%2520%25CE%25B1v%25CE%25B26%2520integrin-mediated%2520TGF-%25CE%25B2%2520activation%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2014%26volume%3D2%26spage%3De00030%26doi%3D10.1002%2Fprp2.30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span>ClinicalTrials.gov. STX-100 in patients with idiopathic pulmonary fibrosis (IPF). <a href="http://clinicaltrials.gov/ct2/show/NCT01371305" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01371305</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+STX-100+in+patients+with+idiopathic+pulmonary+fibrosis+%28IPF%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01371305+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholand, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Andrade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mageto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wencel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neff, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, S.</span><span> </span><span class="NLM_article-title">FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1481</span><span class="NLM_x">–</span> <span class="NLM_lpage">1491</span><span class="refDoi"> DOI: 10.1183/13993003.01030-2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.01030-2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26965296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28jptVyqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2016&pages=1481-1491&author=G.+Raghuauthor=M.+B.+Scholandauthor=J.+de+Andradeauthor=L.+Lancasterauthor=Y.+Magetoauthor=J.+Goldinauthor=K.+K.+Brownauthor=K.+R.+Flahertyauthor=M.+Wencelauthor=J.+Wangerauthor=T.+Neffauthor=F.+Valoneauthor=J.+Staufferauthor=S.+Porter&title=FG-3019+anti-connective+tissue+growth+factor+monoclonal+antibody%3A+results+of+an+open-label+clinical+trial+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F13993003.01030-2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Raghu Ganesh; Scholand Mary Beth; de Andrade Joao; Lancaster Lisa; Mageto Yolanda; Goldin Jonathan; Brown Kevin K; Flaherty Kevin R; Wencel Mark; Wanger Jack; Neff Thomas; Valone Frank; Stauffer John; Porter Seth</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1481-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FG-3019 is a fully human monoclonal antibody that interferes with the action of connective tissue growth factor, a central mediator in the pathogenesis of fibrosis.This open-label phase 2 trial evaluated the safety and efficacy of two doses of FG-3019 administered by intravenous infusion every 3 weeks for 45 weeks in patients with idiopathic pulmonary fibrosis (IPF).  Subjects had a diagnosis of IPF within the prior 5 years defined by either usual interstitial pneumonia (UIP) pattern on a recent high-resolution computed tomography (HRCT) scan, or a possible UIP pattern on HRCT scan and a recent surgical lung biopsy showing UIP pattern.  Pulmonary function tests were performed every 12 weeks, and changes in the extent of pulmonary fibrosis were measured by quantitative HRCT scans performed at baseline and every 24 weeks.FG-3019 was safe and well-tolerated in IPF patients participating in the study.  Changes in fibrosis were correlated with changes in pulmonary function.Further investigation of FG-3019 in IPF with a placebo-controlled clinical trial is warranted and is underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiPI6xnbyBKcK3uFsUIZtkfW6udTcc2ea02GSaFPGVULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jptVyqsw%253D%253D&md5=08922be8777c18f497dc4640cd5846da</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1183%2F13993003.01030-2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01030-2015%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DScholand%26aufirst%3DM.%2BB.%26aulast%3Dde%2BAndrade%26aufirst%3DJ.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DMageto%26aufirst%3DY.%26aulast%3DGoldin%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DWencel%26aufirst%3DM.%26aulast%3DWanger%26aufirst%3DJ.%26aulast%3DNeff%26aufirst%3DT.%26aulast%3DValone%26aufirst%3DF.%26aulast%3DStauffer%26aufirst%3DJ.%26aulast%3DPorter%26aufirst%3DS.%26atitle%3DFG-3019%2520anti-connective%2520tissue%2520growth%2520factor%2520monoclonal%2520antibody%253A%2520results%2520of%2520an%2520open-label%2520clinical%2520trial%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2016%26volume%3D47%26spage%3D1481%26epage%3D1491%26doi%3D10.1183%2F13993003.01030-2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">José, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Proteinase-activated receptors in fibroproliferative lung disease</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">190</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1136/thoraxjnl-2013-204367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthoraxjnl-2013-204367" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=190-192&author=R.+J.+Jos%C3%A9author=A.+E.+Williamsauthor=R.+C.+Chambers&title=Proteinase-activated+receptors+in+fibroproliferative+lung+disease&doi=10.1136%2Fthoraxjnl-2013-204367"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2013-204367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2013-204367%26sid%3Dliteratum%253Aachs%26aulast%3DJos%25C3%25A9%26aufirst%3DR.%2BJ.%26aulast%3DWilliams%26aufirst%3DA.%2BE.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DProteinase-activated%2520receptors%2520in%2520fibroproliferative%2520lung%2520disease%26jtitle%3DThorax%26date%3D2014%26volume%3D69%26spage%3D190%26epage%3D192%26doi%3D10.1136%2Fthoraxjnl-2013-204367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Howell, D. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johns, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scotton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">1353</span><span class="NLM_x">–</span> <span class="NLM_lpage">1365</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)62354-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0002-9440%2810%2962354-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15855637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFGmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2005&pages=1353-1365&author=D.+C.+J.+Howellauthor=R.+H.+Johnsauthor=J.+A.+Laskyauthor=B.+Shanauthor=C.+J.+Scottonauthor=G.+J.+Laurentauthor=R.+C.+Chambers&title=Absence+of+proteinase-activated+receptor-1+signaling+affords+protection+from+bleomycin-induced+lung+inflammation+and+fibrosis&doi=10.1016%2FS0002-9440%2810%2962354-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis</span></div><div class="casAuthors">Howell, David C. J.; Johns, Robin H.; Lasky, Joseph A.; Shan, Bin; Scotton, Chris J.; Laurent, Geoffrey J.; Chambers, Rachel C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1353-1365</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Activation of the coagulation cascade is commonly obsd. in the lungs of patients with both acute and chronic inflammatory and fibrotic lung disorders, as well as in animal models of these disorders.  The aim of this study was to examine the contribution of the major thrombin receptor, proteinase-activated receptor-1 (PAR-1), during the acute inflammatory and chronic fibrotic phases of lung injury induced by intratracheal instillation of bleomycin in mice.  Inflammatory cell recruitment and increases in bronchoalveolar lavage fluid (BALF) protein were attenuated by 56 ± 10% (P < 0.05) and 53 ± 12% (P < 0.05), resp., in PAR-1-deficient (PAR-1-/-) mice compared with wild-type (WT) mice.  PAR-1-/- mice were also protected from bleomycin-induced pulmonary fibrosis with total lung collagen accumulation reduced by 59 ± 5% (P < 0.05).  The protection afforded by PAR-1 deficiency was accompanied by significant redns. in pulmonary levels of the potent PAR-1-inducible proinflammatory and profibrotic mediators, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor-β-1 (TGF-β1), and connective tissue growth factor/fibroblast-inducible secreted protein-12 (CTGF/FISP12).  In addn., PAR-1 was highly expressed in inflammatory and fibroproliferative lesions in lung sections obtained from patients with fibrotic lung disease.  These data show for the first time that PAR-1 signaling plays a key role in exptl. induced lung injury, and they further identify PAR-1 as one of the crit. receptors involved in orchestrating the interplay between coagulation, inflammation, and remodeling in response to tissue injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRfQvRih-qwrVg90H21EOLACvtfcHk0lgZ1Y9VzpE2EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFGmtLo%253D&md5=869016992c6de14641ccaec373da99de</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2962354-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252962354-1%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DD.%2BC.%2BJ.%26aulast%3DJohns%26aufirst%3DR.%2BH.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DScotton%26aufirst%3DC.%2BJ.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DAbsence%2520of%2520proteinase-activated%2520receptor-1%2520signaling%2520affords%2520protection%2520from%2520bleomycin-induced%2520lung%2520inflammation%2520and%2520fibrosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D166%26spage%3D1353%26epage%3D1365%26doi%3D10.1016%2FS0002-9440%2810%2962354-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Liu, R.-M.</span><span> </span><span class="NLM_article-title">Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis</span> <span class="citation_source-journal">Antioxid. Redox Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span><span class="refDoi"> DOI: 10.1089/ars.2007.1903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1089%2Fars.2007.1903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17979497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Siug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=303-319&author=R.-M.+Liu&title=Oxidative+stress%2C+plasminogen+activator+inhibitor+1%2C+and+lung+fibrosis&doi=10.1089%2Fars.2007.1903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Stress, Plasminogen Activator Inhibitor 1, and Lung Fibrosis</span></div><div class="casAuthors">Liu, Rui-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-320</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Fibrosis is characterized by excessive accumulation of extracellular matrix (ECM) in basement membranes and interstitial tissues, resulting from increased synthesis or decreased degrdn. of ECM or both.  The plasminogen activator/plasmin system plays an important role in ECM degrdn., whereas the plasminogen activator inhibitor 1 (PAI-1) is a physiol. inhibitor of plasminogen activators.  PAI-1 expression is increased in the lung fibrotic diseases and in exptl. fibrosis models.  The deletion of the PAI-1 gene reduces, whereas the overexpression of PAI-1 enhances, the susceptibility of animals to lung fibrosis induced by different stimuli, indicating an important role of PAI-1 in the development of lung fibrosis.  Many growth factors, including transforming growth factor beta (TGF-β) and tumor necrosis factor alpha (TNF-α), as well as other chems./agents, induce PAI-1 expression in cultured cells and in vivo.  Reactive oxygen and nitrogen species (ROS/RNS) have been shown to mediate the induction of PAI-1 by many of these stimuli.  This review summarizes some recent findings that help us to understand the role of PAI-1 in the development of lung fibrosis and ROS/RNS in the regulation of PAI-1 expression during fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo040YfNXbqg7Vg90H21EOLACvtfcHk0lgZ1Y9VzpE2EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Siug%253D%253D&md5=2630491829edc69e7689d894e5dd610c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1089%2Fars.2007.1903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2007.1903%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.-M.%26atitle%3DOxidative%2520stress%252C%2520plasminogen%2520activator%2520inhibitor%25201%252C%2520and%2520lung%2520fibrosis%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2008%26volume%3D10%26spage%3D303%26epage%3D319%26doi%3D10.1089%2Fars.2007.1903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Osterholzer, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lama, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subbotina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdock, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morey, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olszewski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sisson, T. H.</span><span> </span><span class="NLM_article-title">PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">170</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1002/path.3992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fpath.3992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22262246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWqtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2012&pages=170-180&author=J.+J.+Osterholzerauthor=P.+J.+Christensenauthor=V.+Lamaauthor=J.+C.+Horowitzauthor=N.+Hattoriauthor=N.+Subbotinaauthor=A.+Cunninghamauthor=Y.+Linauthor=B.+J.+Murdockauthor=R.+E.+Moreyauthor=M.+A.+Olszewskiauthor=D.+A.+Lawrenceauthor=R.+H.+Simonauthor=T.+H.+Sisson&title=PAI-1+promotes+the+accumulation+of+exudate+macrophages+and+worsens+pulmonary+fibrosis+following+type+II+alveolar+epithelial+cell+injury&doi=10.1002%2Fpath.3992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury</span></div><div class="casAuthors">Osterholzer, John J.; Christensen, Paul J.; Lama, Vibha; Horowitz, Jeffrey C.; Hattori, Noboru; Subbotina, Natalya; Cunningham, Andrew; Lin, Yujing; Murdock, Benjamin J.; Morey, Roger E.; Olszewski, Michal A.; Lawrence, Daniel A.; Simon, Richard H.; Sisson, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-180</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Fibrotic disorders of the lung are assocd. with perturbations in the plasminogen activation system.  Specifically, plasminogen activator inhibitor-1 (PAI-1) expression is increased relative to the plasminogen activators.  A direct role for this imbalance in modulating the severity of lung scarring following injury has been substantiated in the bleomycin model of pulmonary fibrosis.  However, it remains unclear whether derangements in the plasminogen activation system contribute more generally to the pathogenesis of lung fibrosis beyond bleomycin injury.  To answer this question, we employed an alternative model of lung scarring, in which type II alveolar epithelial cells (AECs) are specifically injured by administering diphtheria toxin (DT) to mice genetically engineered to express the human DT receptor (DTR) off the surfactant protein C promoter.  This targeted AEC injury results in the diffuse accumulation of interstitial collagen.  In the present study, we found that this targeted type II cell insult also increases PAI-1 expression in the alveolar compartment.  We identified AECs and lung macrophages to be sources of PAI-1 prodn.  To det. whether this elevated PAI-1 concn. was directly related to the severity of fibrosis, DTR+ mice were crossed into a PAI-1-deficient background (DTR+: PAI-1-/-).  DT administration to DTR+: PAI-1-/- animals caused significantly less fibrosis than was measured in DTR+ mice with intact PAI-1 prodn.  PAI-1 deficiency also abrogated the accumulation of CD11b+ exudate macrophages that were found to express PAI-1 and type-1 collagen.  These observations substantiate the crit. function of PAI-1 in pulmonary fibrosis pathogenesis and provide new insight into a potential mechanism by which this pro-fibrotic mol. influences collagen accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdORCT8myTPLVg90H21EOLACvtfcHk0lgZ1Y9VzpE2EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWqtr3N&md5=fdec8c935840db1f9f6edec85b64dde2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fpath.3992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3992%26sid%3Dliteratum%253Aachs%26aulast%3DOsterholzer%26aufirst%3DJ.%2BJ.%26aulast%3DChristensen%26aufirst%3DP.%2BJ.%26aulast%3DLama%26aufirst%3DV.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DHattori%26aufirst%3DN.%26aulast%3DSubbotina%26aufirst%3DN.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DMurdock%26aufirst%3DB.%2BJ.%26aulast%3DMorey%26aufirst%3DR.%2BE.%26aulast%3DOlszewski%26aufirst%3DM.%2BA.%26aulast%3DLawrence%26aufirst%3DD.%2BA.%26aulast%3DSimon%26aufirst%3DR.%2BH.%26aulast%3DSisson%26aufirst%3DT.%2BH.%26atitle%3DPAI-1%2520promotes%2520the%2520accumulation%2520of%2520exudate%2520macrophages%2520and%2520worsens%2520pulmonary%2520fibrosis%2520following%2520type%2520II%2520alveolar%2520epithelial%2520cell%2520injury%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D228%26spage%3D170%26epage%3D180%26doi%3D10.1002%2Fpath.3992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Omori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senoo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujitaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, N.</span><span> </span><span class="NLM_article-title">Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0148969</span><span class="refDoi"> DOI: 10.1371/journal.pone.0148969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1371%2Fjournal.pone.0148969" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0148969&author=K.+Omoriauthor=N.+Hattoriauthor=T.+Senooauthor=Y.+Takayamaauthor=T.+Masudaauthor=T.+Nakashimaauthor=H.+Iwamotoauthor=K.+Fujitakaauthor=H.+Hamadaauthor=N.+Kohno&title=Inhibition+of+plasminogen+activator+inhibitor-1+attenuates+transforming+growth+factor-%CE%B2-dependent+epithelial+mesenchymal+transition+and+differentiation+of+fibroblasts+to+myofibroblasts&doi=10.1371%2Fjournal.pone.0148969"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0148969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0148969%26sid%3Dliteratum%253Aachs%26aulast%3DOmori%26aufirst%3DK.%26aulast%3DHattori%26aufirst%3DN.%26aulast%3DSenoo%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DY.%26aulast%3DMasuda%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DFujitaka%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DH.%26aulast%3DKohno%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520plasminogen%2520activator%2520inhibitor-1%2520attenuates%2520transforming%2520growth%2520factor-%25CE%25B2-dependent%2520epithelial%2520mesenchymal%2520transition%2520and%2520differentiation%2520of%2520fibroblasts%2520to%2520myofibroblasts%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0148969%26doi%3D10.1371%2Fjournal.pone.0148969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Tager, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCamera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campanella, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polosukhin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karimi-Shah, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA<sub>1</sub> links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1038/nm1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18066075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=45-54&author=A.+M.+Tagerauthor=P.+LaCameraauthor=B.+S.+Sheaauthor=G.+S.+Campanellaauthor=M.+Selmanauthor=Z.+Zhaoauthor=V.+Polosukhinauthor=J.+Wainauthor=B.+A.+Karimi-Shahauthor=N.+D.+Kimauthor=W.+K.+Hartauthor=A.+Pardoauthor=T.+S.+Blackwellauthor=Y.+Xuauthor=J.+Chunauthor=A.+D.+Luster&title=The+lysophosphatidic+acid+receptor+LPA1+links+pulmonary+fibrosis+to+lung+injury+by+mediating+fibroblast+recruitment+and+vascular+leak&doi=10.1038%2Fnm1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span></div><div class="casAuthors">Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Selman, Moises; Zhao, Zhenwen; Polosukhin, Vasiliy; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Pardo, Annie; Blackwell, Timothy S.; Xu, Yan; Chun, Jerold; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathol. responses have yet to be fully identified.  We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model.  The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury.  In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid.  LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pk5JY4qBbLVg90H21EOLACvtfcHk0lhbVVEP2OfvnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D&md5=1a7e86264154df8960699d18a7ef2407</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnm1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1685%26sid%3Dliteratum%253Aachs%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DLaCamera%26aufirst%3DP.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DCampanella%26aufirst%3DG.%2BS.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolosukhin%26aufirst%3DV.%26aulast%3DWain%26aufirst%3DJ.%26aulast%3DKarimi-Shah%26aufirst%3DB.%2BA.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DHart%26aufirst%3DW.%2BK.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DBlackwell%26aufirst%3DT.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520links%2520pulmonary%2520fibrosis%2520to%2520lung%2520injury%2520by%2520mediating%2520fibroblast%2520recruitment%2520and%2520vascular%2520leak%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnm1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Funke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA<sub>1</sub> promotes epithelial cell apoptosis after lung injury</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1165/rcmb.2010-0155OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2010-0155OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22021336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1ertbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=355-364&author=M.+Funkeauthor=Z.+Zhaoauthor=Y.+Xuauthor=J.+Chunauthor=A.+M.+Tager&title=The+lysophosphatidic+acid+receptor+LPA1+promotes+epithelial+cell+apoptosis+after+lung+injury&doi=10.1165%2Frcmb.2010-0155OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury</span></div><div class="casAuthors">Funke, Manuela; Zhao, Zhenwen; Xu, Yan; Chun, Jerold; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Increased epithelial cell apoptosis in response to lung injury has been implicated in the development of idiopathic pulmonary fibrosis (IPF), but the mol. pathways promoting epithelial cell apoptosis in this disease have yet to be fully identified.  Lysophosphatidic acid (LPA), which we have previously demonstrated to mediate bleomycin lung injury-induced fibroblast recruitment and vascular leak in mice and fibroblast recruitment in patients with IPF, is an important regulator of survival and apoptosis in many cell types.  We now show that LPA signaling through its receptor LPA1 promotes epithelial cell apoptosis induced by bleomycin injury.  The no. of apoptotic cells present in the alveolar and bronchial epithelia of LPA1-deficient mice was significantly reduced compared with wild-type mice at Day 3 after bleomycin challenge, as was lung caspase-3 activity.  Consistent with these in vivo results, we found that LPA signaling through LPA1 induced apoptosis in normal human bronchial epithelial cells in culture.  LPA-LPA1 signaling appeared to specifically mediate anoikis, the apoptosis of anchorage-dependent cells induced by their detachment.  Similarly, LPA neg. regulated attachment of R3/1 rat alveolar epithelial cell line cells.  In contrast, LPA signaling through LPA1 promoted the resistance of lung fibroblasts to apoptosis, which has also been implicated in IPF.  The ability of LPA-LPA1 signaling to promote epithelial cell apoptosis and fibroblast resistance to apoptosis may therefore contribute to the capacity of this signaling pathway to regulate the development of pulmonary fibrosis after lung injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_okuklehf2bVg90H21EOLACvtfcHk0lj8SJQ9tlF5nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1ertbw%253D&md5=ae97ec6b86cb2006ed7c3ce6b7d35c0b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2010-0155OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2010-0155OC%26sid%3Dliteratum%253Aachs%26aulast%3DFunke%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520promotes%2520epithelial%2520cell%2520apoptosis%2520after%2520lung%2520injury%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2012%26volume%3D46%26spage%3D355%26epage%3D364%26doi%3D10.1165%2Frcmb.2010-0155OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stebbins, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodanovich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span> </span><span class="NLM_article-title">A novel, orally active LPA<sub>1</sub> receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1699</span><span class="NLM_x">–</span> <span class="NLM_lpage">1713</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00828.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1111%2Fj.1476-5381.2010.00828.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20649573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1699-1713&author=J.+S.+Swaneyauthor=C.+Chapmanauthor=L.+D.+Correaauthor=K.+J.+Stebbinsauthor=R.+A.+Bundeyauthor=P.+C.+Prodanovichauthor=P.+Faganauthor=C.+S.+Bacceiauthor=A.+M.+Santiniauthor=J.+H.+Hutchinsonauthor=T.+J.+Seidersauthor=T.+A.+Parrauthor=P.+Prasitauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=A+novel%2C+orally+active+LPA1+receptor+antagonist+inhibits+lung+fibrosis+in+the+mouse+bleomycin+model&doi=10.1111%2Fj.1476-5381.2010.00828.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span></div><div class="casAuthors">Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Bundey, R. A.; Prodanovich, P. C.; Fagan, P.; Baccei, C. S.; Santini, A. M.; Hutchinson, J. H.; Seiders, T. J.; Parr, T. A.; Prasit, P.; Evans, J. F.; Lorrain, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699-1713</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to assess the potential of an antagonist selective for the lysophosphatidic acid receptor, LPA1, in treating lung fibrosis.  We evaluated the in vitro and in vivo pharmacol. properties of the high affinity, selective, oral LPA1-antagonist (4'-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (AM966).  The potency and selectivity of AM966 for LPA1 receptors was detd. in vitro by calcium flux and cell chemotaxis assays using recombinant and native cell cultures.  The in vivo efficacy of AM966 to reduce tissue injury, vascular leakage, inflammation and fibrosis was assessed at several time points in the mouse bleomycin model.  AM966 was a potent antagonist of LPA1 receptors, with selectivity for this receptor over the other LPA receptors.  In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC50 = 17 nM) from Chinese hamster ovary cells stably expressing human LPA1 receptors and inhibited LPA-induced chemotaxis (IC50 = 181 nM) of human IMR-90 lung fibroblasts expressing LPA1 receptors.  AM966 demonstrated a good pharmacokinetic profile following oral dosing in mice.  In the mouse, AM966 reduced lung injury, vascular leakage, inflammation and fibrosis at multiple time points following intratracheal bleomycin instillation.  AM966 also decreased lactate dehydrogenase activity and tissue inhibitor of metalloproteinase-1, transforming growth factor β1, hyaluronan and matrix metalloproteinase-7, in bronchoalveolar lavage fluid.  These findings demonstrate that AM966 is a potent, selective, orally bioavailable LPA1 receptor antagonist that may be beneficial in treating lung injury and fibrosis, as well as other diseases that are characterized by pathol. inflammation, edema and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0rImMbkAWbVg90H21EOLACvtfcHk0lj8SJQ9tlF5nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ&md5=73f26734408141d8b0350d7488b54a6c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00828.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00828.x%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBundey%26aufirst%3DR.%2BA.%26aulast%3DProdanovich%26aufirst%3DP.%2BC.%26aulast%3DFagan%26aufirst%3DP.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DSeiders%26aufirst%3DT.%2BJ.%26aulast%3DParr%26aufirst%3DT.%2BA.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DA%2520novel%252C%2520orally%2520active%2520LPA1%2520receptor%2520antagonist%2520inhibits%2520lung%2520fibrosis%2520in%2520the%2520mouse%2520bleomycin%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1699%26epage%3D1713%26doi%3D10.1111%2Fj.1476-5381.2010.00828.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">González-Gil, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vázquez-Villa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega-Gutiérrez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Rodríguez, M. L.</span><span> </span><span class="NLM_article-title">The status of the lysophosphatidic acid receptor type 1 (LPA<sub>1</sub>R)</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1039/C4MD00333K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1039%2FC4MD00333K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=13-23&author=I.+Gonz%C3%A1lez-Gilauthor=D.+Zianauthor=H.+V%C3%A1zquez-Villaauthor=S.+Ortega-Guti%C3%A9rrezauthor=M.+L.+L%C3%B3pez-Rodr%C3%ADguez&title=The+status+of+the+lysophosphatidic+acid+receptor+type+1+%28LPA1R%29&doi=10.1039%2FC4MD00333K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2FC4MD00333K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00333K%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Gil%26aufirst%3DI.%26aulast%3DZian%26aufirst%3DD.%26aulast%3DV%25C3%25A1zquez-Villa%26aufirst%3DH.%26aulast%3DOrtega-Guti%25C3%25A9rrez%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez-Rodr%25C3%25ADguez%26aufirst%3DM.%2BL.%26atitle%3DThe%2520status%2520of%2520the%2520lysophosphatidic%2520acid%2520receptor%2520type%25201%2520%2528LPA1R%2529%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D13%26epage%3D23%26doi%3D10.1039%2FC4MD00333K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span>ClinicalTrials.gov. Safety and efficacy of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis. <a href="https://clinicaltrials.gov/ct2/show/NCT01766817" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01766817</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+Safety+and+efficacy+of+a+lysophosphatidic+acid+receptor+antagonist+in+idiopathic+pulmonary+fibrosis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01766817+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">U.S. Food and Drug Administration</span><span class="NLM_x">. Novel drug approvalsfor 2014. </span><a href="http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm429247.htm" class="extLink">http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm429247.htm</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+and+Drug+Administration.+Novel+drug+approvalsfor+2014.+http%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdevelopmentapprovalprocess%2Fdruginnovation%2Fucm429247.htm+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span>Data were generated using Micromedex. <a href="http://www.micromedexsolutions.com/micromedex2/librarian" class="extLink">http://www.micromedexsolutions.com/micromedex2/librarian</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Data+were+generated+using+Micromedex.+http%3A%2F%2Fwww.micromedexsolutions.com%2Fmicromedex2%2Flibrarian+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Pirfenidone: a review of its use in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.1007/s40265-015-0350-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs40265-015-0350-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25604027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVagtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=219-230&author=E.+S.+Kimauthor=G.+M.+Keating&title=Pirfenidone%3A+a+review+of+its+use+in+idiopathic+pulmonary+fibrosis&doi=10.1007%2Fs40265-015-0350-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Kim, Esther S.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-230</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Pirfenidone (Esbriet) is an orally administered, synthetic, pyridone compd. that is approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU, and for the treatment of IPF in the USA.  This article summarizes pharmacol., efficacy and tolerability data relevant to the use of pirfenidone in these indications.  In the randomized, double-blind, placebo-controlled, multinational CAPACITY trials in patients with mild to moderate IPF, a significant redn. in the rate of decline in forced vital capacity (FVC) was seen with pirfenidone vs. placebo in study 004 but not in study 006.  Pirfenidone also reduced the rate of decline in FVC to a significantly greater extent than placebo in the randomized, double-blind, multinational ASCEND trial in this patient population.  In addn., pirfenidone showed a significant treatment effect on the 6-min walking test distance and progression-free survival in the ASCEND trial and in a pooled anal. of the CAPACITY trials.  Pirfenidone had a manageable tolerability profile in all three studies.  Gastrointestinal and skin-related events (e.g. nausea, rash, photosensitivity reaction), which were the most commonly occurring treatment-emergent adverse events, were generally mild to moderate in severity.  In addn., a prespecified mortality anal. across all three studies demonstrated a significant redn. in IPF-related and all-cause mortality with pirfenidone.  In conclusion, oral pirfenidone is a valuable agent for use in patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTFreSdm1Nx7Vg90H21EOLACvtfcHk0lgboNakKWAqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVagtb4%253D&md5=e025359ae98f4366a18062a4e7d58e96</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0350-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0350-9%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DPirfenidone%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D219%26epage%3D230%26doi%3D10.1007%2Fs40265-015-0350-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Xaubet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Mollar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancochea, J.</span><span> </span><span class="NLM_article-title">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span><span class="refDoi"> DOI: 10.1517/14656566.2014.867328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F14656566.2014.867328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24308635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=275-281&author=A.+Xaubetauthor=A.+Serrano-Mollarauthor=J.+Ancochea&title=Pirfenidone+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1517%2F14656566.2014.867328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Xaubet, Antoni; Serrano-Mollar, Anna; Ancochea, Julio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-281</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal fibrosing interstitial pneumonia.  The median survival from the onset of the symptoms is 2.8 - 4.2 years and the 5-yr survival rate is 20%.  Its poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies.  During the past decade there has been a huge rise in clin. trials with anti-fibrotic drugs, although only (Esbriet) has shown a beneficial effect.  Areas covered: This article reviews the medical literature on the effectiveness and safety of pirfenidone in IPF, by means of a PubMed search from 1995 to present, completed with some data on file from the manufacturer.  Expert opinion: Pirfenidone is the only anti-fibrotic drug approved for the treatment of IPF.  Pirfenidone provides a meaningful clin. effect on redns. in the decrease in forced vital capacity (FVC), six-minute walk test (6MWT) distance and mortality, and it improves the progression-free survival in IPF patients with mild-to-moderate disease.  Pirfenidone is well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity.  Pirfenidone has a favorable benefit-risk profile and represents a suitable treatment option for patients with mild-to-moderate IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Ejf0R_dDv7Vg90H21EOLACvtfcHk0liH9vbA1ifxEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptFartg%253D%253D&md5=52c09f1582966cfb0897289c36f983d5</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1517%2F14656566.2014.867328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2014.867328%26sid%3Dliteratum%253Aachs%26aulast%3DXaubet%26aufirst%3DA.%26aulast%3DSerrano-Mollar%26aufirst%3DA.%26aulast%3DAncochea%26aufirst%3DJ.%26atitle%3DPirfenidone%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2014%26volume%3D15%26spage%3D275%26epage%3D281%26doi%3D10.1517%2F14656566.2014.867328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Poletti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravaglia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassetti, S.</span><span> </span><span class="NLM_article-title">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Expert Rev. Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1586/17476348.2014.915750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1586%2F17476348.2014.915750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25113033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=539-545&author=V.+Polettiauthor=C.+Ravagliaauthor=S.+Tomassetti&title=Pirfenidone+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1586%2F17476348.2014.915750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone for the treatment of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Poletti, Venerino; Ravaglia, Claudia; Tomassetti, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">539-545</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Pirfenidone is an orally administered drug with anti-fibrotic, anti-inflammatory and anti-oxidant properties.  The efficacy of pirfenidone is supported by a no. of Phase III trials as well as a Cochrane meta-anal. and tolerability data are also provided by clin. trials and a long-term extension phase of these studies.  These trials led to the approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan in 2008 and in Europe in 2011 and it is now indicated for treatment of patients with mild-to-moderate IPF.  The primary endpoint of these studies has usually been the change in percentage predicted forced vital capacity from baseline; there has been no improvement in respiratory symptoms and/or quality of life measurements and/or decrease in mortality.  Clin. and basic research studies are needed to expand our knowledge, understanding the final role of pirfenidone in the treatment of IPF and also identifing genetic factors that influence the effectiveness of this treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8jIYgIAB-m7Vg90H21EOLACvtfcHk0liH9vbA1ifxEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7rE&md5=60e8cab50dc8d5203f9a1d2599c55dcf</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1586%2F17476348.2014.915750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17476348.2014.915750%26sid%3Dliteratum%253Aachs%26aulast%3DPoletti%26aufirst%3DV.%26aulast%3DRavaglia%26aufirst%3DC.%26aulast%3DTomassetti%26aufirst%3DS.%26atitle%3DPirfenidone%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2014%26volume%3D8%26spage%3D539%26epage%3D545%26doi%3D10.1586%2F17476348.2014.915750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Hisatomi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukae, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishimatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakugawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamichi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubota, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, S.</span><span> </span><span class="NLM_article-title">Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells</span> <span class="citation_source-journal">BMC Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="refDoi"> DOI: 10.1186/1471-2466-12-24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2F1471-2466-12-24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22694981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=24&author=K.+Hisatomiauthor=H.+Mukaeauthor=N.+Sakamotoauthor=Y.+Ishimatsuauthor=T.+Kakugawaauthor=S.+Haraauthor=H.+Fujitaauthor=S.+Nakamichiauthor=H.+Okuauthor=Y.+Urataauthor=H.+Kubotaauthor=K.+Nagataauthor=S.+Kohno&title=Pirfenidone+inhibits+TGF-%CE%B21-induced+over-expression+of+collagen+type+I+and+heat+shock+protein+47+in+A549+cells&doi=10.1186%2F1471-2466-12-24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells</span></div><div class="casAuthors">Hisatomi, Keiko; Mukae, Hiroshi; Sakamoto, Noriho; Ishimatsu, Yuji; Kakugawa, Tomoyuki; Hara, Shintaro; Fujita, Hanako; Nakamichi, Seiko; Oku, Hisashi; Urata, Yoshishige; Kubota, Hiroshi; Nagata, Kazuhiro; Kohno, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24</span>CODEN:
                <span class="NLM_cas:coden">BPMMBB</span>;
        ISSN:<span class="NLM_cas:issn">1471-2466</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Pirfenidone is a novel anti-fibrotic and anti-inflammatory agent that inhibits the progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis (IPF).  We previously showed that pirfenidone inhibits the over-expression of collagen type I and of heat shock protein (HSP) 47, a collagen-specific mol. chaperone, in human lung fibroblasts stimulated with transforming growth factor (TGF)-β1 in vitro.  The increased nos. of HSP47-pos. type II pneumocytes as well as fibroblasts were also diminished by pirfenidone in an animal model of pulmonary fibrosis induced by bleomycin.  The present study evaluates the effects of pirfenidone on collagen type I and HSP47 expression in the human alveolar epithelial cell line, A549 cells in vitro.  Methods: The expression of collagen type I, HSP47 and E-cadherin mRNAs in A549 cells stimulated with TGF-β1 was evaluated by Northern blotting or real-time PCR.  The expression of collagen type I, HSP47 and fibronectin proteins was assessed by immunocytochem. staining.  Results: TGF-β1 stimulated collagen type I and HSP47 mRNA and protein expression in A549 cells, and pirfenidone significantly inhibited this process.  Pirfenidone also inhibited over-expression of the fibroblast phenotypic marker fibronectin in A549 cells induced by TGF-β1.  Conclusion: We concluded that the anti-fibrotic effects of pirfenidone might be mediated not only through the direct inhibition of collagen type I expression but also through the inhibition of HSP47 expression in alveolar epithelial cells, which results in reduced collagen synthesis in lung fibrosis.  Furthermore, pirfenidone might partially inhibit the epithelial-mesenchymal transition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCyJFZ5P_kJLVg90H21EOLACvtfcHk0liv2wFuvYFQFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCgu7fN&md5=fd4d8fc33321044a60fb4d2f809b88ad</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1186%2F1471-2466-12-24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2466-12-24%26sid%3Dliteratum%253Aachs%26aulast%3DHisatomi%26aufirst%3DK.%26aulast%3DMukae%26aufirst%3DH.%26aulast%3DSakamoto%26aufirst%3DN.%26aulast%3DIshimatsu%26aufirst%3DY.%26aulast%3DKakugawa%26aufirst%3DT.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DNakamichi%26aufirst%3DS.%26aulast%3DOku%26aufirst%3DH.%26aulast%3DUrata%26aufirst%3DY.%26aulast%3DKubota%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DS.%26atitle%3DPirfenidone%2520inhibits%2520TGF-%25CE%25B21-induced%2520over-expression%2520of%2520collagen%2520type%2520I%2520and%2520heat%2520shock%2520protein%252047%2520in%2520A549%2520cells%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2012%26volume%3D12%26spage%3D24%26doi%3D10.1186%2F1471-2466-12-24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Akhurst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, A.</span><span> </span><span class="NLM_article-title">Targeting the TGFβ signaling pathway in disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1038/nrd3810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd3810" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=790-811&author=R.+J.+Akhurstauthor=A.+Hata&title=Targeting+the+TGF%CE%B2+signaling+pathway+in+disease&doi=10.1038%2Fnrd3810"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrd3810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3810%26sid%3Dliteratum%253Aachs%26aulast%3DAkhurst%26aufirst%3DR.%2BJ.%26aulast%3DHata%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520TGF%25CE%25B2%2520signaling%2520pathway%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D790%26epage%3D811%26doi%3D10.1038%2Fnrd3810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Nakazato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span> </span><span class="NLM_article-title">A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">185</span><span class="refDoi"> DOI: 10.1016/S0014-2999(02)01758-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0014-2999%2802%2901758-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12098600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFGqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2002&pages=177-185&author=H.+Nakazatoauthor=H.+Okuauthor=S.+Yamaneauthor=Y.+Tsurutaauthor=R.+Suzuki&title=A+novel+anti-fibrotic+agent+pirfenidone+suppresses+tumor+necrosis+factor-%CE%B1+at+the+translational+level&doi=10.1016%2FS0014-2999%2802%2901758-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level</span></div><div class="casAuthors">Nakazato, Hitoshi; Oku, Hisashi; Yamane, Shoji; Tsuruta, Yuji; Suzuki, Ryuji</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">177-185</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A new exptl. drug pirfenidone (5-methyl-1-phenyl-2-1H-pyridine-2-one) has been reported to have beneficial effects for the treatment of certain fibrotic diseases.  Here, we studied the anti-inflammatory activities of pirfenidone by investigating the mechanism of its inhibitory effect on cytokine prodn.  In RAW264.7 cells, a murine macrophage-like cell line, pirfenidone suppressed the proinflammatory cytokine tumor necrosis factor-α (TNF-α) by a translational mechanism, which was independent of activation of the mitogen-activated protein kinase (MAPK) 2, p38 MAP kinase, and c-Jun N-terminal kinase (JNK).  In the murine endotoxin shock model, pirfenidone potently inhibited the prodn. of the proinflammatory cytokines, TNF-α, interferon-γ, and interleukin-6, but enhanced the prodn. of the anti-inflammatory cytokine, interleukin-10.  The in vivo model also showed that pirfenidone suppressed the cytokine prodn. by a translational mechanism, though interleukin-10 transcription was activated by pirfenidone.  These findings show that pirfenidone inhibits the prodn. of the proinflammatory cytokine selectively at the translational level.  Therefore, cytokine inhibitory activities play an important role in the anti-inflammatory activities of pirfenidone.  Coupled with the fact that this inhibitory effect is selective, translational, and not for total protein synthesis, this drug may have a clin. effect on inflammation and fibrosis with very low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeMS2f7xnkhLVg90H21EOLACvtfcHk0liv2wFuvYFQFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFGqsro%253D&md5=763cf51977561bd6158283e9cdd26704</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901758-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901758-2%26sid%3Dliteratum%253Aachs%26aulast%3DNakazato%26aufirst%3DH.%26aulast%3DOku%26aufirst%3DH.%26aulast%3DYamane%26aufirst%3DS.%26aulast%3DTsuruta%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26atitle%3DA%2520novel%2520anti-fibrotic%2520agent%2520pirfenidone%2520suppresses%2520tumor%2520necrosis%2520factor-%25CE%25B1%2520at%2520the%2520translational%2520level%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D446%26spage%3D177%26epage%3D185%26doi%3D10.1016%2FS0014-2999%2802%2901758-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Oku, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span> </span><span class="NLM_article-title">Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">446</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span><span class="refDoi"> DOI: 10.1016/S0014-2999(02)01757-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0014-2999%2802%2901757-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12098599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFGqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=446&publication_year=2002&pages=167-176&author=H.+Okuauthor=H.+Nakazatoauthor=T.+Horikawaauthor=Y.+Tsurutaauthor=R.+Suzuki&title=Pirfenidone+suppresses+tumor+necrosis+factor-%CE%B1%2C+enhances+interleukin-10+and+protects+mice+from+endotoxic+shock&doi=10.1016%2FS0014-2999%2802%2901757-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock</span></div><div class="casAuthors">Oku, Hisashi; Nakazato, Hitoshi; Horikawa, Tatsuya; Tsuruta, Yuji; Suzuki, Ryuji</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">446</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A new exptl. drug, pirfenidone (5-methyl-1-phenyl-1H-pyridine-one; S-7701), has been reported to have beneficial effects for the treatment of certain fibrotic diseases.  We investigated the anti-inflammatory properties in murine endotoxic shock to det. the pharmacol. characteristics.  The present study describes the prophylactic effect, cytokine regulatory profiles and therapeutic effect of pirfenidone in murine endotoxic shock, which was induced in mice using an i.p. injection of lipopolysaccharide and d-galactosamine.  First, we examd. the prophylactic effect and cytokine regulatory profiles.  A single oral administration of pirfenidone prior to lipopolysaccharide/d-galactosamine challenge inhibited the prodn. of circulating tumor necrosis factor-α (TNF-α), interleukin-12 and interferon-γ, markedly enhanced that of interleukin-10, and offered protection from subsequent lethal symptoms in a dose-dependent manner.  Second, we examd. the therapeutic effect.  A single oral administration of pirfenidone 1, 2, 3, 4 and 5 h post lipopolysaccharide/d-galactosamine challenge provided protection against lethal shock in a time-dependent manner.  At the histopathol. level, apoptotic pos. cells were suppressed in the liver.  The transforming growth factor (TGF)-β1 level was markedly elevated in the liver of lipopolysaccharide/d-galactosamine-challenged mice, suppressed in pirfenidone-treated mice.  These findings may offer an alternative for both protective and therapeutical treatment of several human acute or chronic inflammatory diseases by pirfenidone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1KVDArelcFbVg90H21EOLACvtfcHk0lhgLqXxOIDbAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFGqsr0%253D&md5=7cf35223ba991350fa09f9f59c4e7282</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901757-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901757-0%26sid%3Dliteratum%253Aachs%26aulast%3DOku%26aufirst%3DH.%26aulast%3DNakazato%26aufirst%3DH.%26aulast%3DHorikawa%26aufirst%3DT.%26aulast%3DTsuruta%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26atitle%3DPirfenidone%2520suppresses%2520tumor%2520necrosis%2520factor-%25CE%25B1%252C%2520enhances%2520interleukin-10%2520and%2520protects%2520mice%2520from%2520endotoxic%2520shock%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D446%26spage%3D167%26epage%3D176%26doi%3D10.1016%2FS0014-2999%2802%2901757-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Misra, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabideau, C.</span><span> </span><span class="NLM_article-title">Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1023/A:1007023532508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1023%2FA%3A1007023532508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2000&pages=119-126&author=H.+P.+Misraauthor=C.+Rabideau&title=Pirfenidone+inhibits+NADPH-dependent+microsomal+lipid+peroxidation+and+scavenges+hydroxyl+radicals&doi=10.1023%2FA%3A1007023532508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1023%2FA%3A1007023532508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1007023532508%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DH.%2BP.%26aulast%3DRabideau%26aufirst%3DC.%26atitle%3DPirfenidone%2520inhibits%2520NADPH-dependent%2520microsomal%2520lipid%2520peroxidation%2520and%2520scavenges%2520hydroxyl%2520radicals%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2000%26volume%3D204%26spage%3D119%26epage%3D126%26doi%3D10.1023%2FA%3A1007023532508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">The Pirfenidone Clinical Study Group in Japan.</span><span> </span><span class="NLM_article-title">Pirfenidone in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">821</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span><span class="refDoi"> DOI: 10.1183/09031936.00005209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00005209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19996196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVWjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=821-829&author=H.+Taniguchiauthor=M.+Ebinaauthor=Y.+Kondohauthor=T.+Oguraauthor=A.+Azumaauthor=M.+Sugaauthor=Y.+Taguchiauthor=H.+Takahashiauthor=K.+Nakataauthor=A.+Satoauthor=M.+Takeuchiauthor=G.+Raghuauthor=S.+Kudohauthor=T.+Nukiwaauthor=The+Pirfenidone+Clinical+Study+Group+in+Japan.&title=Pirfenidone+in+idiopathic+pulmonary+fibrosis&doi=10.1183%2F09031936.00005209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Taniguchi, H.; Ebina, M.; Kondoh, Y.; Ogura, T.; Azuma, A.; Suga, M.; Taguchi, Y.; Takahashi, H.; Nakata, K.; Sato, A.; Takeuchi, M.; Raghu, G.; Kudoh, S.; Nukiwa, T.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">821-829</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy.  A multicenter, double-blind, placebo-controlled, randomized phase III clin. trial was conducted in Japanese patients with well-defined IPF to det. the efficacy and safety of pirfenidone, a novel antifibrotic oral agent, over 52 wk.  Of 275 patients randomized (high-dose, 1800 mg/day-1; low-dose, 1200 mg/day-1; or placebo groups in the ratio 2:1:2), 267 patients were evaluated for the efficacy of pirfenidone.  Prior to unblinding, the primary end-point was revised; the change in vital capacity (VC) was assessed at week 52.  Secondary end-points included the progression-free survival (PFS) time.  Significant differences were obsd. in VC decline (primary end-point) between the placebo group (-0.16 L) and the high-dose group (-0.09 L) (p = 0.0416); differences between the two groups (p = 0.0280) were also obsd. in the PFS (the secondary end-point).  Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients.  Pirfenidone was relatively well tolerated in patients with IPF.  Treatment with pirfenidone may decrease the rate of decline in VC and may increase the PFS time over 52 wk.  Addnl. studies are needed to confirm these findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEG3o2Gv6tFrVg90H21EOLACvtfcHk0lgN-kPjWVq5WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVWjtrc%253D&md5=5a6a211535e0fc5f2bc494b903c93292</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1183%2F09031936.00005209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00005209%26sid%3Dliteratum%253Aachs%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DEbina%26aufirst%3DM.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DSuga%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DNakata%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DA.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26aulast%3D%26atitle%3DPirfenidone%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D821%26epage%3D829%26doi%3D10.1183%2F09031936.00005209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glassberg, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardatzke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szwarcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valeyre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span> </span><span class="NLM_article-title">CAPACITY Study group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1760</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Bois&title=CAPACITY+Study+group.+Pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis+%28CAPACITY%29%3A+two+randomized+trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DCAPACITY%2520Study%2520group.%2520Pirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528CAPACITY%2529%253A%2520two%2520randomized%2520trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Bernardini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspole, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glassberg, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardatzke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span> </span><span class="NLM_article-title">ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2092</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1402582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24836312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2083-2092&author=T.+E.+Kingauthor=W.+Z.+Bradfordauthor=S.+Castro-Bernardiniauthor=E.+A.+Faganauthor=I.+Glaspoleauthor=M.+K.+Glassbergauthor=E.+Gorinaauthor=P.+M.+Hopkinsauthor=D.+Kardatzkeauthor=L.+Lancasterauthor=D.+J.+Ledererauthor=S.+D.+Nathanauthor=C.+A.+Pereiraauthor=S.+A.+Sahnauthor=R.+Sussmanauthor=J.+J.+Swigrisauthor=P.+W.+Noble&title=ASCEND+Study+Group.+A+phase+3+trial+of+pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1402582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">King, Talmadge E.; Bradford, Williamson Z.; Castro-Bernardini, Socorro; Fagan, Elizabeth A.; Glaspole, Ian; Glassberg, Marilyn K.; Gorina, Eduard; Hopkins, Peter M.; Kardatzke, David; Lancaster, Lisa; Lederer, David J.; Nathan, Steven D.; Pereira, Carlos A.; Sahn, Steven A.; Sussman, Robert; Swigris, Jeffrey J.; Noble, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2083-2092, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved.  We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients.  Methods: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 wk.  The primary end point was the change in FVC or death at week 52.  Secondary end points were the 6-min walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis.  Results: In the pirfenidone group, as compared with the placebo group, there was a relative redn. of 47.9% in the proportion of patients who had an abs. decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P < 0.001).  Pirfenidone reduced the decline in the 6-min walk distance (P = 0.04) and improved progression-free survival (P < 0.001).  There was no significant between-group difference in dyspnea scores (P = 0.16) or in rates of death from any cause (P = 0.10) or from idiopathic pulmonary fibrosis (P = 0.23).  However, in a prespecified pooled anal. incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P = 0.01) and from idiopathic pulmonary fibrosis (P = 0.006).  Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation.  Conclusions: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.  Treatment was assocd. with an acceptable sideeffect profile and fewer deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBkQ8hqTWxxLVg90H21EOLACvtfcHk0ljT189uchHoNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ&md5=17bfe4782c11521d3b7890ae387bbaf6</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402582%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCastro-Bernardini%26aufirst%3DS.%26aulast%3DFagan%26aufirst%3DE.%2BA.%26aulast%3DGlaspole%26aufirst%3DI.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DGorina%26aufirst%3DE.%26aulast%3DHopkins%26aufirst%3DP.%2BM.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DNathan%26aufirst%3DS.%2BD.%26aulast%3DPereira%26aufirst%3DC.%2BA.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSussman%26aufirst%3DR.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26atitle%3DASCEND%2520Study%2520Group.%2520A%2520phase%25203%2520trial%2520of%2520pirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2083%26epage%3D2092%26doi%3D10.1056%2FNEJMoa1402582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">–</span> <span class="NLM_lpage">4480</span><span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF1120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Dimitroulis, I. A.</span><span> </span><span class="NLM_article-title">Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Care.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1450</span><span class="NLM_x">–</span> <span class="NLM_lpage">1455</span><span class="refDoi"> DOI: 10.4187/respcare.03023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4187%2Frespcare.03023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24782550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2cnosV2htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1450-1455&author=I.+A.+Dimitroulis&title=Nintedanib%3A+a+novel+therapeutic+approach+for+idiopathic+pulmonary+fibrosis&doi=10.4187%2Frespcare.03023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Dimitroulis Ioannis A</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory care</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1450-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and few therapeutic options.  Growth factors that act as mediators in the development of this disease might be important therapeutic targets.  Nintedanib is a triple-tyrosine kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, and it is currently evaluated in clinical trials as a potential IPF therapy.  Treatment with nintedanib may slow decline in lung function, decrease the frequency of exacerbations, and improve quality of life in subjects with IPF.  This observation, together with extensive safety and pharmacokinetic data from studies of nintedanib in malignancy, led the way for the clinical development of this drug in IPF.  Observations from clinical trials, together with the preclinical data, suggest that nintedanib may become an important therapeutic option for individuals with IPF.  High-dose nintedanib improved the quality of life, slowed the progression of lung fibrosis and the decline of lung function, and reduced the rate of exacerbations in individuals with mild and moderate IPF.  This is a short review based on the available data (September 2013) on nintedanib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-hhlDQr-lqP_I8Jvzw4xCfW6udTcc2eak5yxO6pulrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnosV2htA%253D%253D&md5=dbcd4d2ca9e17ba7a3ea6948ac2fd5d0</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.4187%2Frespcare.03023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4187%252Frespcare.03023%26sid%3Dliteratum%253Aachs%26aulast%3DDimitroulis%26aufirst%3DI.%2BA.%26atitle%3DNintedanib%253A%2520a%2520novel%2520therapeutic%2520approach%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Care.%26date%3D2014%26volume%3D59%26spage%3D1450%26epage%3D1455%26doi%3D10.4187%2Frespcare.03023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollin, S.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span> </span><span class="NLM_article-title">Nintedanib: from discovery to the clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span><span class="refDoi"> DOI: 10.1021/jm501562a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501562a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1053-1063&author=G.+J.+Rothauthor=R.+Binderauthor=F.+Colbatzkyauthor=C.+Dallingerauthor=R.+Schlenker-Hercegauthor=F.+Hilbergauthor=S.-L.+Wollinauthor=R.+Kaiser&title=Nintedanib%3A+from+discovery+to+the+clinic&doi=10.1021%2Fjm501562a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Nintedanib: From Discovery to the Clinic</span></div><div class="casAuthors">Roth, Gerald J.; Binder, Rudolf; Colbatzky, Florian; Dallinger, Claudia; Schlenker-Herceg, Rozsa; Hilberg, Frank; Wollin, Stefan-Lutz; Kaiser, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1053-1063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nintedanib (BIBF1120) is a potent, oral, small-mol. tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis.  Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the VEGFR family, the fibroblast growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family, as well as Src and Flt-3 kinases.  The compd. was identified during a lead optimization program for small-mol. inhibitors of angiogenesis and has since undergone extensive clin. investigation for the treatment of various solid tumors, and in patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF).  Recent clin. evidence from phase III studies has shown that nintedanib has significant efficacy in the treatment of NSCLC, ovarian cancer, and IPF.  This review article provides a comprehensive summary of the preclin. and clin. research and development of nintedanib from the initial drug discovery process to the latest available clin. trial data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogcUBGOgC1bbVg90H21EOLACvtfcHk0lgB9ehu9fFh0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegurnO&md5=dd1bc3c81b83b21cfb9b0d3da7f7b55d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm501562a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501562a%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DBinder%26aufirst%3DR.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DDallinger%26aufirst%3DC.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DWollin%26aufirst%3DS.-L.%26aulast%3DKaiser%26aufirst%3DR.%26atitle%3DNintedanib%253A%2520from%2520discovery%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1053%26epage%3D1063%26doi%3D10.1021%2Fjm501562a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span>Data were generated using Micromedex. <a href="http://www.micromedexsolutions.com/micromedex2/librarian" class="extLink">http://www.micromedexsolutions.com/micromedex2/librarian</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Data+were+generated+using+Micromedex.+http%3A%2F%2Fwww.micromedexsolutions.com%2Fmicromedex2%2Flibrarian+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Noskovičová, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petřek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickelberg, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinzelmann, K.</span><span> </span><span class="NLM_article-title">Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1165/rcmb.2014-0294TR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2014-0294TR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25303647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1ansLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2015&pages=263-284&author=N.+Noskovi%C4%8Dov%C3%A1author=M.+Pet%C5%99ekauthor=O.+Eickelbergauthor=K.+Heinzelmann&title=Platelet-derived+growth+factor+signaling+in+the+lung.+From+lung+development+and+disease+to+clinical+studies&doi=10.1165%2Frcmb.2014-0294TR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet-derived growth factor signaling in the lung from lung development and disease to clinical studies</span></div><div class="casAuthors">Noskovicova, Nina; Petrek, Martin; Eickelberg, Oliver; Heinzelmann, Katharina</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">263-284</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) represent one of the most intensively studied families of growth factors in the last four decades.  PDGF signaling plays an essential role in cell proliferation, differentiation, migration, and survival.  In vivo studies have documented an important role of PDGF signaling in the normal development of several organs, such as the kidney, eye, or lung.  PDGF signaling is essential for the formation of intact mesenchymal cells during embryogenesis.  Recently, this knowledge has been extended to a role of PDGF signaling in diseases in general, such as cancer and atherosclerosis, and more importantly in lung diseases, including pulmonary arterial hypertension, lung cancer, and lung fibrosis.  In this review, we provide an up-to-date overview of PDGF signaling, including tissue- and cell-type-specific expression patterns and effects.  We highlight current therapeutic approaches modifying PDGF signaling in lung diseases and summarize clin. trials in which PDGF signaling has been inhibited.  In conclusion, although PDGF inhibition has been used in multiple clin. trials, we suggest that more elaborate and specific approaches for spatiotemporal control of PDGF signaling are required for developing personalized approaches involving PDGF signaling in lung disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6hnrAtTuUrVg90H21EOLACvtfcHk0lgB9ehu9fFh0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1ansLs%253D&md5=d050eff86a550d5455faf649069e7133</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2014-0294TR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2014-0294TR%26sid%3Dliteratum%253Aachs%26aulast%3DNoskovi%25C4%258Dov%25C3%25A1%26aufirst%3DN.%26aulast%3DPet%25C5%2599ek%26aufirst%3DM.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DHeinzelmann%26aufirst%3DK.%26atitle%3DPlatelet-derived%2520growth%2520factor%2520signaling%2520in%2520the%2520lung.%2520From%2520lung%2520development%2520and%2520disease%2520to%2520clinical%2520studies%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2015%26volume%3D52%26spage%3D263%26epage%3D284%26doi%3D10.1165%2Frcmb.2014-0294TR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Andrae, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betsholtz, C.</span><span> </span><span class="NLM_article-title">Role of platelet-derived growth factors in physiology and medicine</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">–</span> <span class="NLM_lpage">1312</span><span class="refDoi"> DOI: 10.1101/gad.1653708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1101%2Fgad.1653708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18483217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVWmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1276-1312&author=J.+Andraeauthor=R.+Galliniauthor=C.+Betsholtz&title=Role+of+platelet-derived+growth+factors+in+physiology+and+medicine&doi=10.1101%2Fgad.1653708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Role of platelet-derived growth factors in physiology and medicine</span></div><div class="casAuthors">Andrae, Johanna; Gallini, Radiosa; Betsholtz, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1276-1312</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have served as prototypes for growth factor and receptor tyrosine kinase function for more than 25 years.  Studies of PDGFs and PDGFRs in animal development have revealed roles for PDGFR-α signaling in gastrulation and in the development of the cranial and cardiac neural crest, gonads, lung, intestine, skin, CNS, and skeleton.  Similarly, roles for PDGFR-β signaling have been established in blood vessel formation and early hematopoiesis.  PDGF signaling is implicated in a range of diseases.  Autocrine activation of PDGF signaling pathways is involved in certain gliomas, sarcomas, and leukemias.  Paracrine PDGF signaling is commonly obsd. in epithelial cancers, where it triggers stromal recruitment and may be involved in epithelial-mesenchymal transition, thereby affecting tumor growth, angiogenesis, invasion, and metastasis.  PDGFs drive pathol. mesenchymal responses in vascular disorders such as atherosclerosis, restenosis, pulmonary hypertension, and retinal diseases, as well as in fibrotic diseases, including pulmonary fibrosis, liver cirrhosis, scleroderma, glomerulosclerosis, and cardiac fibrosis.  The authors review basic aspects of the PDGF ligands and receptors, their developmental and pathol. functions, principles of their pharmacol. inhibition, and results using PDGF pathway-inhibitory or stimulatory drugs in preclin. and clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEyOanAaNQd7Vg90H21EOLACvtfcHk0ligd2zhI6PjXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVWmsbs%253D&md5=f043191bea91ed97baf40963fe01fa1f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1101%2Fgad.1653708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1653708%26sid%3Dliteratum%253Aachs%26aulast%3DAndrae%26aufirst%3DJ.%26aulast%3DGallini%26aufirst%3DR.%26aulast%3DBetsholtz%26aufirst%3DC.%26atitle%3DRole%2520of%2520platelet-derived%2520growth%2520factors%2520in%2520physiology%2520and%2520medicine%26jtitle%3DGenes%2520Dev.%26date%3D2008%26volume%3D22%26spage%3D1276%26epage%3D1312%26doi%3D10.1101%2Fgad.1653708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aono, Y.</span><span> </span><span class="NLM_article-title">Targeting platelet-derived growth factors as a therapeutic approach in pulmonary fibrosis</span> <span class="citation_source-journal">J. Med. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.2152/jmi.60.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2152%2Fjmi.60.175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=175-183&author=Y.+Nishiokaauthor=M.+Azumaauthor=M.+Kishiauthor=Y.+Aono&title=Targeting+platelet-derived+growth+factors+as+a+therapeutic+approach+in+pulmonary+fibrosis&doi=10.2152%2Fjmi.60.175"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2152%2Fjmi.60.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2152%252Fjmi.60.175%26sid%3Dliteratum%253Aachs%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DKishi%26aufirst%3DM.%26aulast%3DAono%26aufirst%3DY.%26atitle%3DTargeting%2520platelet-derived%2520growth%2520factors%2520as%2520a%2520therapeutic%2520approach%2520in%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Invest.%26date%3D2013%26volume%3D60%26spage%3D175%26epage%3D183%26doi%3D10.2152%2Fjmi.60.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Abdollahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ping, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plathow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domhan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gröne, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, P. E.</span><span> </span><span class="NLM_article-title">Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">201</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1084/jem.20041393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1084%2Fjem.20041393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=925-935&author=A.+Abdollahiauthor=M.+Liauthor=G.+Pingauthor=C.+Plathowauthor=S.+Domhanauthor=F.+Kiesslingauthor=L.+B.+Leeauthor=G.+McMahonauthor=H.-J.+Gr%C3%B6neauthor=K.+E.+Lipsonauthor=P.+E.+Huber&title=Inhibition+of+platelet-derived+growth+factor+signaling+attenuates+pulmonary+fibrosis&doi=10.1084%2Fjem.20041393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041393%26sid%3Dliteratum%253Aachs%26aulast%3DAbdollahi%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DPing%26aufirst%3DG.%26aulast%3DPlathow%26aufirst%3DC.%26aulast%3DDomhan%26aufirst%3DS.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DGr%25C3%25B6ne%26aufirst%3DH.-J.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DHuber%26aufirst%3DP.%2BE.%26atitle%3DInhibition%2520of%2520platelet-derived%2520growth%2520factor%2520signaling%2520attenuates%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D925%26epage%3D935%26doi%3D10.1084%2Fjem.20041393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Bonner, J. C.</span><span> </span><span class="NLM_article-title">Regulation of PDGF and its receptors in fibrotic diseases</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2004.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.cytogfr.2004.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15207816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVKhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=255-273&author=J.+C.+Bonner&title=Regulation+of+PDGF+and+its+receptors+in+fibrotic+diseases&doi=10.1016%2Fj.cytogfr.2004.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of PDGF and its receptors in fibrotic diseases</span></div><div class="casAuthors">Bonner, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-273</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  Platelet-derived growth factor (PDGF) isoforms play a major role in stimulating the replication, survival, and migration of myofibroblasts during the pathogenesis of fibrotic diseases.  During fibrogenesis, PDGF is secreted by a variety of cell types as a response to injury, and many pro-inflammatory cytokines mediate their mitogenic effects via the autocrine release of PDGF.  PDGF action is detd. by the relative expression of PDGF α-receptors (PDGFRα) and β-receptors (PDGFRβ) on the surface of myofibroblasts.  These receptors are induced during fibrogenesis, thereby amplifying biol. responses to PDGF isoforms.  PDGF action is also modulated by extracellular binding proteins and matrix mols.  This review summarizes the literature on the role of PDGF and its receptors in the development of fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbPFb3UPOMdrVg90H21EOLACvtfcHk0lhS6xbNwWXVuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVKhtL8%253D&md5=bae162438898b6cf16c769f825d2bd9c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2004.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2004.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DBonner%26aufirst%3DJ.%2BC.%26atitle%3DRegulation%2520of%2520PDGF%2520and%2520its%2520receptors%2520in%2520fibrotic%2520diseases%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2004%26volume%3D15%26spage%3D255%26epage%3D273%26doi%3D10.1016%2Fj.cytogfr.2004.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Dosanjh, A.</span><span> </span><span class="NLM_article-title">The fibroblast growth factor pathway and its role in the pathogenesis of lung disease</span> <span class="citation_source-journal">J. Interferon Cytokine Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1089/jir.2011.0079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1089%2Fjir.2011.0079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22280103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFKlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=111-114&author=A.+Dosanjh&title=The+fibroblast+growth+factor+pathway+and+its+role+in+the+pathogenesis+of+lung+disease&doi=10.1089%2Fjir.2011.0079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The Fibroblast Growth Factor Pathway and Its Role in the Pathogenesis of Lung Disease</span></div><div class="casAuthors">Dosanjh, Amrita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Interferon & Cytokine Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">111-114</span>CODEN:
                <span class="NLM_cas:coden">JICRFJ</span>;
        ISSN:<span class="NLM_cas:issn">1079-9907</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  The fibroblast growth factor (FGF) signaling pathway is integral to the pathogenesis of many airway diseases and in the growth and development of the normal lung.  The FGF pathway has a role in key regulatory pathways of fibrosis, and provides a no. of potential therapeutic targets for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0X7WljOq6HrVg90H21EOLACvtfcHk0lhS6xbNwWXVuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFKlu7s%253D&md5=b046be487ed5dd60f2585b582ce2ba8f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1089%2Fjir.2011.0079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjir.2011.0079%26sid%3Dliteratum%253Aachs%26aulast%3DDosanjh%26aufirst%3DA.%26atitle%3DThe%2520fibroblast%2520growth%2520factor%2520pathway%2520and%2520its%2520role%2520in%2520the%2520pathogenesis%2520of%2520lung%2520disease%26jtitle%3DJ.%2520Interferon%2520Cytokine%2520Res.%26date%3D2012%26volume%3D32%26spage%3D111%26epage%3D114%26doi%3D10.1089%2Fjir.2011.0079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Yan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ping, Z.</span><span> </span><span class="NLM_article-title">Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Autoimmun. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1020</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span><span class="refDoi"> DOI: 10.1016/j.autrev.2014.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.autrev.2014.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25182202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1020-1025&author=Z.+Yanauthor=Z.+Kuiauthor=Z.+Ping&title=Reviews+and+prospectives+of+signaling+pathway+analysis+in+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.autrev.2014.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Yan, Zheng; Zhang, kui; Ping, Zhu</div><div class="citationInfo"><span class="NLM_cas:title">Autoimmunity Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1020-1025</span>CODEN:
                <span class="NLM_cas:coden">ARUEBU</span>;
        ISSN:<span class="NLM_cas:issn">1568-9972</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing disease with disappointing survival rate, and uneffective therapeutic progress has been made in the last few years, forcing the urgent need to improve research to this disease.  The commonly accepted pathogenic hypothesis of IPF is the trigger from continuous alveolar epithelium microinjuries and in the following series events, many signaling pathways were reported to lead to abnormal tissue repair and lung structure derangement in IPF, such as TGF-β, wnt, VEGF and PI3K-Akt signaling pathways.  Traditional research of IPF related signaling pathway always focus on the independent function of pathway and disease signals, but the crosstalks and interactions among them were rarely valued.  In this review, we summarize the signaling pathways which were reported to play important roles in the pathol. changes of IPF and the synergistic effect among those pathways.  Next we discuss the application of genomics research and bioinformatics tools on IPF related pathway anal., and give a systems biol. perspective by integrating multi-level disease related data.  The novel prospective of pathway anal. could tease out the complex pathway interaction profiles of IPF, and is powerful to detect IPF related biomarkers for early diagnose and potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSHUGveibP8LVg90H21EOLACvtfcHk0li4Zg379gVaGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtr7I&md5=ca1f4c1ca4cd3d9848e049baea2b0cac</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.autrev.2014.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.autrev.2014.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DKui%26aufirst%3DZ.%26aulast%3DPing%26aufirst%3DZ.%26atitle%3DReviews%2520and%2520prospectives%2520of%2520signaling%2520pathway%2520analysis%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAutoimmun.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D1020%26epage%3D1025%26doi%3D10.1016%2Fj.autrev.2014.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Ou, X.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, F.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.intimp.2008.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.intimp.2008.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18976720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Wrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=70-79&author=X.-M.+Ouauthor=W.-C.+Liauthor=D.-S.+Liuauthor=Y.-P.+Liauthor=F.-Q.+Wenauthor=Y.-L.+Fengauthor=S.-F.+Zhangauthor=X.-Y.+Huangauthor=T.+Wangauthor=K.+Wangauthor=X.+Wangauthor=L.+Chen&title=VEGFR-2+antagonist+SU5416+attenuates+bleomycin-induced+pulmonary+fibrosis+in+mice&doi=10.1016%2Fj.intimp.2008.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Ou, Xue-Mei; Li, Wan-Cheng; Liu, Dai-Shun; Li, Yan-Ping; Wen, Fu-Qiang; Feng, Yu-Lin; Zhang, Shang-Fu; Huang, Xiang-Yang; Wang, Tao; Wang, Ke; Wang, Xun; Chen, Lei</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Abnormal angiogenesis is a central hallmark for the development and progression of idiopathic pulmonary fibrosis.  It has been shown that vascular endothelial growth factor (VEGF) is one of the crit. angiogenic factors in angiogenesis.  The aim of the present study was to assess whether disruption of VEGF pathway would attenuate bleomycin-induced pulmonary fibrosis.  Methods: Bleomycin-induced pulmonary fibrosis mice were treated i.p. with VEGF receptor tyrosine kinase inhibitor SU5416 at different phases after bleomycin infusion.  We measured angiogenesis and inflammatory response in both bleomycin-treated and control mice, and correlated these levels with pulmonary fibrosis.  Results: The increased expressions of VEGF/VEGFR (Flk-1) were correlated to a larger no. of microvessels and a higher score of pulmonary fibrosis.  Early administration of SU5416 inhibited pulmonary collagen deposition, histopathol. fibroplasias and the activation of TGF-β1/Smad3 signaling pathway in bleomycin-stimulated lung.  These were also paralleled by a redn. of VEGF/VEGFR-2 (Flk-1) expression and microvessel nos. in lung.  Furthermore, SU5416 inhibited inflammatory cell nos. and LDH activity in BALF and IL-13 expression in lung tissue at early inflammatory phase of bleomycin-induced pulmonary fibrosis.  These results suggest that the VEGFR-2 inhibitor, SU5416, attenuates histopathol. fibroplasias and collagen deposition by regulating angiogenesis and inflammation in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG6t_l12OTo7Vg90H21EOLACvtfcHk0li4Zg379gVaGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Wrug%253D%253D&md5=03dbeb3ca2eb7eed6501617614b465ea</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2008.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2008.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DX.-M.%26aulast%3DLi%26aufirst%3DW.-C.%26aulast%3DLiu%26aufirst%3DD.-S.%26aulast%3DLi%26aufirst%3DY.-P.%26aulast%3DWen%26aufirst%3DF.-Q.%26aulast%3DFeng%26aufirst%3DY.-L.%26aulast%3DZhang%26aufirst%3DS.-F.%26aulast%3DHuang%26aufirst%3DX.-Y.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DVEGFR-2%2520antagonist%2520SU5416%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2009%26volume%3D9%26spage%3D70%26epage%3D79%26doi%3D10.1016%2Fj.intimp.2008.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Chaudhary, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller-Quernheim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zissel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. E.</span><span> </span><span class="NLM_article-title">Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">976</span><span class="NLM_x">–</span> <span class="NLM_lpage">985</span><span class="refDoi"> DOI: 10.1183/09031936.00152106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.00152106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17301095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFOhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=976-985&author=N.+I.+Chaudharyauthor=G.+J.+Rothauthor=F.+Hilbergauthor=J.+M%C3%BCller-Quernheimauthor=A.+Prasseauthor=G.+Zisselauthor=A.+Schnappauthor=J.+E.+Park&title=Inhibition+of+PDGF%2C+VEGF+and+FGF+signalling+attenuates+fibrosis&doi=10.1183%2F09031936.00152106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis</span></div><div class="casAuthors">Chaudhary, N. I.; Roth, G. J.; Hilberg, F.; Mueller-Quernheim, J.; Prasse, A.; Zissel, G.; Schnapp, A.; Park, J. E.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">976-985</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">BIBF 1000 is a small mol. inhibitor targeting the receptor kinases of platelet-derived growth factor (PDGF), basic fibroblast growth factor and vascular endothelial growth factor, which have known roles in the pathogenesis of pulmonary fibrosis.  The anti-fibrotic potential of BIBF 1000 was detd. in a rat model of bleomycin-induced lung fibrosis and in an ex vivo fibroblast differentiation assay.  Rats exposed to a single intra-tracheal injection of bleomycin were treated with BIBF 1000 starting 10 days after bleomycin administration.  To gauge for anti-fibrotic activity, collagen deposition and pro-fibrotic growth factor gene expression was analyzed in isolated lungs.  Furthermore, the activity of BIBF 1000 was compared with imatinib mesylate (combined PDGF receptor, c-kit and c-abl kinase inhibitor) and SB-431542 (transforming growth factor (TGF)-β receptor I kinase inhibitor) in an ex vivo TGF-β-driven fibroblast to myofibroblast differentiation assay, performed in primary human bronchial fibroblasts.  Treatment of rats with BIBF 1000 resulted in the attenuation of fibrosis as assessed by the redn. of collagen deposition and the inhibition of pro-fibrotic gene expression.  In the cellular assay both SB-431542 and BIBF 1000 showed dose-dependent inhibition of TGF-β-induced differentiation, whereas imatinib mesylate was inactive.  BIBF 1000, or related small mols. with a similar kinase inhibition profile, may represent a novel therapeutic approach for the treatment of idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKuwMAPritBrVg90H21EOLACvtfcHk0lj8mGhZ_z_iKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFOhurw%253D&md5=fdaef254b5e6a2d950ffb47cdf2d3bbb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1183%2F09031936.00152106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00152106%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DN.%2BI.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Quernheim%26aufirst%3DJ.%26aulast%3DPrasse%26aufirst%3DA.%26aulast%3DZissel%26aufirst%3DG.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26atitle%3DInhibition%2520of%2520PDGF%252C%2520VEGF%2520and%2520FGF%2520signalling%2520attenuates%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2007%26volume%3D29%26spage%3D976%26epage%3D985%26doi%3D10.1183%2F09031936.00152106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Hostettler, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papakonstantinou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakiulakis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lardinois, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, M.</span><span> </span><span class="NLM_article-title">Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="refDoi"> DOI: 10.1186/s12931-014-0157-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2Fs12931-014-0157-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25496490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFOjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=157&author=K.+E.+Hostettlerauthor=J.+Zhongauthor=E.+Papakonstantinouauthor=G.+Karakiulakisauthor=M.+Tammauthor=P.+Seidelauthor=Q.+Sunauthor=J.+Mandalauthor=D.+Lardinoisauthor=C.+Lambersauthor=M.+Roth&title=Anti-fibrotic+effects+of+nintedanib+in+lung+fibroblasts+derived+from+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1186%2Fs12931-014-0157-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Hostettler, Katrin E.; Zhong, Jun; Papakonstantinou, Eleni; Karakiulakis, George; Tamm, Michael; Seidel, Petra; Sun, Qingzhu; Mandal, Jyotshna; Lardinois, Didier; Lambers, Christopher; Roth, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157/1-157/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis.  The kinase inhibitor nintedanib specific for vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) significantly reduced the rate of decline of forced vital capacity vs. placebo.  Aim: To det. the in vitro effect of nintedanib on primary human lung fibroblasts.  Methods: Fibroblasts were isolated from lungs of IPF patients and from non-fibrotic controls.  We assessed the effect of VEGF, PDGF-BB and basic FGF (bFGF) ± nintedanib on: (i) expression/activation of VEGFR, PDGFR, and FGFR, (ii) cell proliferation, secretion of (iii) matrix metalloproteinases (MMP), (iv) tissue inhibitor of metalloproteinase (TIMP), and (v) collagen.  Results: IPF fibroblasts expressed higher levels of PDGFR and FGFR than controls.  PDGF-BB, bFGF, and VEGF caused a pro-proliferative effect which was prevented by nintedanib.  Nintedanib enhanced the expression of pro-MMP-2, and inhibited the expression of TIMP-2.  Transforming growth factor-beta-induced secretion of collagens was inhibited by nintedanib.  Conclusion: Our data demonstrate a significant anti-fibrotic effect of nintedanib in IPF fibroblasts.  This effect consists of the drug's anti-proliferative capacity, and on its effect on the extracellular matrix, the degrdn. of which seems to be enhanced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRsCwj6A3mwrVg90H21EOLACvtfcHk0lj8mGhZ_z_iKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFOjt78%253D&md5=9e01a92fcdfcf165a4d99c62c6c9a46b</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fs12931-014-0157-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-014-0157-3%26sid%3Dliteratum%253Aachs%26aulast%3DHostettler%26aufirst%3DK.%2BE.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DPapakonstantinou%26aufirst%3DE.%26aulast%3DKarakiulakis%26aufirst%3DG.%26aulast%3DTamm%26aufirst%3DM.%26aulast%3DSeidel%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DMandal%26aufirst%3DJ.%26aulast%3DLardinois%26aufirst%3DD.%26aulast%3DLambers%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DM.%26atitle%3DAnti-fibrotic%2520effects%2520of%2520nintedanib%2520in%2520lung%2520fibroblasts%2520derived%2520from%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Res.%26date%3D2014%26volume%3D15%26spage%3D157%26doi%3D10.1186%2Fs12931-014-0157-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Inomata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span> </span><span class="NLM_article-title">Ninedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Core Evidence</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.2147/CE.S82905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2147%2FCE.S82905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=89-98&author=M.+Inomataauthor=Y.+Nishiokaauthor=A.+Azuma&title=Ninedanib%3A+evidence+for+its+therapeutic+potential+in+idiopathic+pulmonary+fibrosis&doi=10.2147%2FCE.S82905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.2147%2FCE.S82905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCE.S82905%26sid%3Dliteratum%253Aachs%26aulast%3DInomata%26aufirst%3DM.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DAzuma%26aufirst%3DA.%26atitle%3DNinedanib%253A%2520evidence%2520for%2520its%2520therapeutic%2520potential%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DCore%2520Evidence%26date%3D2015%26volume%3D10%26spage%3D89%26epage%3D98%26doi%3D10.2147%2FCE.S82905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Bonella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollin, L.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6407</span><span class="NLM_x">–</span> <span class="NLM_lpage">6419</span><span class="refDoi"> DOI: 10.2147/DDDT.S76648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2147%2FDDDT.S76648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26715838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6407-6419&author=F.+Bonellaauthor=S.+Stowasserauthor=L.+Wollin&title=Idiopathic+pulmonary+fibrosis%3A+current+treatment+options+and+critical+appraisal+of+nintedanib&doi=10.2147%2FDDDT.S76648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: Current treatment options and critical appraisal of nintedanib</span></div><div class="casAuthors">Bonella, Francesco; Stowasser, Susanne; Wollin, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6407-6419</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is characterized by a poor prognosis, with an estd. 5-yr survival of approx. 20%.  Progressive and irreversible lung functional impairment leads to chronic respiratory insufficiency with a severely impaired quality of life.  In the last 2 decades, novel treatments for IPF have been developed as a consequence of an increasing understanding of disease pathogenesis and pathobiol.  In IPF, injured dysfunctional alveolar epithelial cells promote fibroblast recruitment and proliferation, resulting in scarring of the lung tissue.  Recently, pirfenidone and nintedanib have been approved for the treatment of IPF, having shown efficacy to slow functional decline and disease progression.  This article focuses on the pharmacol. characteristics and clin. evidence supporting the use of nintedanib, a potent small-mol. tyrosine kinase inhibitor, as therapy for IPF.  After introducing the mechanism of action and pharmacokinetics, an overview of the safety and efficacy results from the most recent clin. trials of nintedanib in IPF is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfjUsaFPn0erVg90H21EOLACvtfcHk0lhcQp_z1a1AxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D&md5=ad6fa39dba483ae329daf63d5e38cc5a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S76648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S76648%26sid%3Dliteratum%253Aachs%26aulast%3DBonella%26aufirst%3DF.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DWollin%26aufirst%3DL.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520treatment%2520options%2520and%2520critical%2520appraisal%2520of%2520nintedanib%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6407%26epage%3D6419%26doi%3D10.2147%2FDDDT.S76648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juhel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüglich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span> </span><span class="NLM_article-title">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span><span class="refDoi"> DOI: 10.1056/NEJMoa1103690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1103690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21992121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1079-1087&author=L.+Richeldiauthor=U.+Costabelauthor=M.+Selmanauthor=D.+S.+Kimauthor=D.+M.+Hansellauthor=A.+G.+Nicholsonauthor=K.+K.+Brownauthor=K.+R.+Flahertyauthor=P.+W.+Nobleauthor=G.+Raghuauthor=M.+Brunauthor=A.+Guptaauthor=N.+Juhelauthor=M.+Kl%C3%BCglichauthor=R.+M.+du+Bois&title=Efficacy+of+a+tyrosine+kinase+inhibitor+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1103690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; Costabel, Ulrich; Selman, Moises; Kim, Dong Soon; Hansell, David M.; Nicholson, Andrew G.; Brown, Kevin K.; Flaherty, Kevin R.; Noble, Paul W.; Raghu, Ganesh; Brun, Michele; Gupta, Abhya; Juhel, Nolwenn; Kluglich, Matthias; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1079-1087</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate.  Because the signaling pathways activated by several tyrosine kinase receptors were shown to be involved in lung fibrosis, it was suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis.  In a 12-mo, phase 2 trial, we assessed the efficacy and safety of 4 different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity.  A total of 432 patients underwent randomization to receive one of 4 doses of B1BF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo.  In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 L per yr, as compared with 0.19 L per yr in the placebo group, a 68.4% redn. in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure).  This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007).  Gastrointestinal symptoms (which led to more discontinuations in the. group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group.  In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was assocd. with a trend toward a redn. in the decline in lung function, with fewer acute exacerbations and preserved quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4JXOIjFKCRbVg90H21EOLACvtfcHk0lhcQp_z1a1AxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN&md5=6c076ac8d837944b4638ee7c444bb775</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103690%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DJuhel%26aufirst%3DN.%26aulast%3DKl%25C3%25BCglich%26aufirst%3DM.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DEfficacy%2520of%2520a%2520tyrosine%2520kinase%2520inhibitor%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1079%26epage%3D1087%26doi%3D10.1056%2FNEJMoa1103690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Maulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">INPULSIS trial investigators</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2082</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1056%2FNEJMoa1402584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24836310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2071-2082&author=L.+Richeldiauthor=R.+M.+du+Boisauthor=G.+Raghuauthor=A.+Azumaauthor=K.+K.+Brownauthor=U.+Costabelauthor=V.+Cottinauthor=K.+R.+Flahertyauthor=D.+M.+Hansellauthor=Y.+Inoueauthor=D.+S.+Kimauthor=M.+Kolbauthor=A.+G.+Nicholsonauthor=P.+W.+Nobleauthor=M.+Selmanauthor=H.+Taniguchiauthor=M.+Brunauthor=F.+Le+Maulfauthor=M.+Girardauthor=S.+Stowasserauthor=R.+Schlenker-Hercegauthor=B.+Disseauthor=H.+R.+Collard&title=INPULSIS+trial+investigators&doi=10.1056%2FNEJMoa1402584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; du Bois, Roland M.; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, David M.; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moises; Taniguchi, Hiroyuki; Brun, Michele; Le Maulf, Florence; Girard, Mannaig; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Disse, Bernd; Collard, Harold R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2071-2082, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases.  A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.  Methods: We conducted two replicate 52-wk, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St.  George's Respiratory Questionnaire, both assessed over a 52-wk period.  Results: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo.  The adjusted annual rate of change in FVC was -114.7 mL with nintedanib vs. -239.9 mL with placebo (difference, 125.3 mL; 95% confidence interval [CI], 77.7 to 172.8; P < 0.001) in INPULSIS-1 and -113.6 mL with nintedanib vs. -207.3 mL with placebo (difference, 93.7 mL; 95% CI, 44.8 to 142.7; P < 0.001) in INPULSIS-2.  In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P = 0.67); in INPULSIS-2, there was a significant benefit with nintedanib vs. placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).  The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, resp., in INPULSIS-1 and 63.2% and 18.3% in the two groups, resp., in INPULSIS-2.  Conclusions: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently assocd. with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuOhVKeZaSrVg90H21EOLACvtfcHk0liyTzre3u2VUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK&md5=be977cd3b402c7c401f4a3dfaa0f484f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402584%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DLe%2BMaulf%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DINPULSIS%2520trial%2520investigators%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2071%26epage%3D2082%26doi%3D10.1056%2FNEJMoa1402584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelling, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaresma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, M.</span><span> </span><span class="NLM_article-title">Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">OA4495</span><span class="refDoi"> DOI: 10.1183/13993003.congress-2015.OA4495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.congress-2015.OA4495" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=OA4495&author=B.+Crestaniauthor=T.+Oguraauthor=K.+Pellingauthor=C.+Coeckauthor=M.+Quaresmaauthor=M.+Kreuterauthor=M.+Kaye&title=Interim+analysis+of+nintedanib+in+an+open-label+extension+of+the+INPULSIS%C2%AE+trials+%28INPULSIS%C2%AE-ON%29&doi=10.1183%2F13993003.congress-2015.OA4495"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.OA4495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.OA4495%26sid%3Dliteratum%253Aachs%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DPelling%26aufirst%3DK.%26aulast%3DCoeck%26aufirst%3DC.%26aulast%3DQuaresma%26aufirst%3DM.%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DKaye%26aufirst%3DM.%26atitle%3DInterim%2520analysis%2520of%2520nintedanib%2520in%2520an%2520open-label%2520extension%2520of%2520the%2520INPULSIS%25C2%25AE%2520trials%2520%2528INPULSIS%25C2%25AE-ON%2529%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3DOA4495%26doi%3D10.1183%2F13993003.congress-2015.OA4495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Hecker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagirdar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luckhardt, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennathur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V.</span><span> </span><span class="NLM_article-title">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span><span class="refDoi"> DOI: 10.1038/nm.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19701206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1077-1081&author=L.+Heckerauthor=R.+Vittalauthor=T.+Jonesauthor=R.+Jagirdarauthor=T.+R.+Luckhardtauthor=J.+C.+Horowitzauthor=S.+Pennathurauthor=F.+J.+Martinezauthor=V.+Thannickal&title=NADPH+oxidase-4+mediates+myofibroblast+activation+and+fibrogenic+responses+to+lung+injury&doi=10.1038%2Fnm.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span></div><div class="casAuthors">Hecker, Louise; Vittal, Ragini; Jones, Tamara; Jagirdar, Rajesh; Luckhardt, Tracy R.; Horowitz, Jeffrey C.; Pennathur, Subramaniam; Martinez, Fernando J.; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1081</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Members of the NADPH oxidase (NOX) family of enzymes, which catalyze the redn. of O2 to reactive oxygen species, have increased in no. during eukaryotic evolution.  Seven isoforms of the NOX gene family have been identified in mammals; however, specific roles of NOX enzymes in mammalian physiol. and pathophysiol. have not been fully elucidated.  The best established physiol. role of NOX enzymes is in host defense against pathogen invasion in diverse species, including plants.  The prototypical member of this family, NOX-2 (gp91phox), is expressed in phagocytic cells and mediates microbicidal activities.  Here we report a role for the NOX4 isoform in tissue repair functions of myofibroblasts and fibrogenesis.  Transforming growth factor-β1 (TGF-β1) induces NOX-4 expression in lung mesenchymal cells via SMAD-3, a receptor-regulated protein that modulates gene transcription.  NOX-4-dependent generation of hydrogen peroxide (H2O2) is required for TGF-β1-induced myofibroblast differentiation, extracellular matrix (ECM) prodn. and contractility.  NOX-4 is upregulated in lungs of mice subjected to noninfectious injury and in cases of human idiopathic pulmonary fibrosis (IPF).  Genetic or pharmacol. targeting of NOX-4 abrogates fibrogenesis in two murine models of lung injury.  These studies support a function for NOX4 in tissue fibrogenesis and provide proof of concept for therapeutic targeting of NOX-4 in recalcitrant fibrotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmporyhulB_bVg90H21EOLACvtfcHk0ljJXmVbUA7BmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM&md5=7b7eaee1597ce9e91807879f5d0f7f1d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnm.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2005%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DL.%26aulast%3DVittal%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DJagirdar%26aufirst%3DR.%26aulast%3DLuckhardt%26aufirst%3DT.%2BR.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DPennathur%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DThannickal%26aufirst%3DV.%26atitle%3DNADPH%2520oxidase-4%2520mediates%2520myofibroblast%2520activation%2520and%2520fibrogenic%2520responses%2520to%2520lung%2520injury%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D1077%26epage%3D1081%26doi%3D10.1038%2Fnm.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Laleu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaggini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orchard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioraso-Cartier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagnon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houngninou-Molango, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duboux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szyndralewiez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, P.</span><span> </span><span class="NLM_article-title">First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7715</span><span class="NLM_x">–</span> <span class="NLM_lpage">7730</span><span class="refDoi"> DOI: 10.1021/jm100773e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100773e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7715-7730&author=B.+Laleuauthor=F.+Gagginiauthor=M.+Orchardauthor=L.+Fioraso-Cartierauthor=L.+Cagnonauthor=S.+Houngninou-Molangoauthor=A.+Gradiaauthor=G.+Dubouxauthor=C.+Merlotauthor=F.+Heitzauthor=C.+Szyndralewiezauthor=P.+Page&title=First+in+class%2C+potent%2C+and+orally+bioavailable+NADPH+oxidase+isoform+4+%28Nox4%29+inhibitors+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1021%2Fjm100773e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98aR"><div class="casContent"><span class="casTitleNuber">98a</span><div class="casTitle"><span class="NLM_cas:atitle">First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Laleu, Benoit; Gaggini, Francesca; Orchard, Mike; Fioraso-Cartier, Laetitia; Cagnon, Laurene; Houngninou-Molango, Sophie; Gradia, Angelo; Duboux, Guillaume; Merlot, Cedric; Heitz, Freddy; Szyndralewiez, Cedric; Page, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7715-7730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and optimization of first-in-class series of inhibitors I (R1 = H, MeCO, 4-FC6H4CH2, etc.; R2 = Ph, 2-ClC6H4, 2-benzothiazolyl, etc.; R3 = Me, 2-FC6H4, 1-pyrrolidinylmethyl, PhCH2NMeCH2, etc.; R4 = MeOCH2CH2, 3-pyridylmethyl, 4-morpholinyl, etc.) of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease, is described.  Initially, several moderately potent pyrazolopyridine dione derivs. were found during a high-throughput screening campaign.  SAR investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) prodn., showing high potency on Nox4 and Nox1.  The compds. have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms.  The specificity of these compds. was confirmed in an extensive in vitro pharmacol. profile, as well as in a counterscreening assay for potential ROS scavenging.  Concomitant benefits are good oral bioavailability and high plasma concns. in vivo, allowing further clin. trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSPjijoh4dLVg90H21EOLACvtfcHk0ljJXmVbUA7BmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI&md5=39f3be6bed0d02fce6693e626788f125</span></div><a href="/servlet/linkout?suffix=cit98a&amp;dbid=16384&amp;doi=10.1021%2Fjm100773e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100773e%26sid%3Dliteratum%253Aachs%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DGaggini%26aufirst%3DF.%26aulast%3DOrchard%26aufirst%3DM.%26aulast%3DFioraso-Cartier%26aufirst%3DL.%26aulast%3DCagnon%26aufirst%3DL.%26aulast%3DHoungninou-Molango%26aufirst%3DS.%26aulast%3DGradia%26aufirst%3DA.%26aulast%3DDuboux%26aufirst%3DG.%26aulast%3DMerlot%26aufirst%3DC.%26aulast%3DHeitz%26aufirst%3DF.%26aulast%3DSzyndralewiez%26aufirst%3DC.%26aulast%3DPage%26aufirst%3DP.%26atitle%3DFirst%2520in%2520class%252C%2520potent%252C%2520and%2520orally%2520bioavailable%2520NADPH%2520oxidase%2520isoform%25204%2520%2528Nox4%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7715%26epage%3D7730%26doi%3D10.1021%2Fjm100773e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit98b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gaggini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laleu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orchard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioraso-Cartier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagnon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houngninou-Molango, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duboux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szyndralewiez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, P.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6989</span><span class="NLM_x">–</span> <span class="NLM_lpage">6999</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmc.2011.10.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=6989-6999&author=F.+Gagginiauthor=B.+Laleuauthor=M.+Orchardauthor=L.+Fioraso-Cartierauthor=L.+Cagnonauthor=S.+Houngninou-Molangoauthor=A.+Gradiaauthor=G.+Dubouxauthor=C.+Merlotauthor=F.+Heitzauthor=C.+Szyndralewiezauthor=P.+Page&title=Design%2C+synthesis+and+biological+activity+of+original+pyrazolo-pyrido-diazepine%2C+-pyrazine+and+-oxazine+dione+derivatives+as+novel+dual+Nox4%2FNox1+inhibitors&doi=10.1016%2Fj.bmc.2011.10.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DGaggini%26aufirst%3DF.%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DOrchard%26aufirst%3DM.%26aulast%3DFioraso-Cartier%26aufirst%3DL.%26aulast%3DCagnon%26aufirst%3DL.%26aulast%3DHoungninou-Molango%26aufirst%3DS.%26aulast%3DGradia%26aufirst%3DA.%26aulast%3DDuboux%26aufirst%3DG.%26aulast%3DMerlot%26aufirst%3DC.%26aulast%3DHeitz%26aufirst%3DF.%26aulast%3DSzyndralewiez%26aufirst%3DC.%26aulast%3DPage%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520activity%2520of%2520original%2520pyrazolo-pyrido-diazepine%252C%2520-pyrazine%2520and%2520-oxazine%2520dione%2520derivatives%2520as%2520novel%2520dual%2520Nox4%252FNox1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D6989%26epage%3D6999%26doi%3D10.1016%2Fj.bmc.2011.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Kehrer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span> </span><span class="NLM_article-title">Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1016/S0378-4274(96)03845-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0378-4274%2896%2903845-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=9067480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADyaK2sXhtFSgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1997&pages=125-132&author=J.+P.+Kehrerauthor=S.+B.+Margolin&title=Pirfenidone+diminishes+cyclophosphamide-induced+lung+fibrosis+in+mice&doi=10.1016%2FS0378-4274%2896%2903845-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice</span></div><div class="casAuthors">Kehrer, James P.; Margolin, Solomon B.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The deposition of excess or abnormal collagen characteristic of pulmonary fibrosis can disrupt gas exchange resulting in severe respiratory impairment.  There currently are no effective pharmacol. agents available that inhibit the fibrotic process.  Pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) is an investigational drug that, when administered at 0.5% (wt./wt.) of the diet, decreases both histol. and biochem. evidence of lung fibrosis in hamsters treated intratracheally with bleomycin.  The effectiveness of pirfenidone against lung fibrosis initiated by a systemically administered agent was investigated in mice treated i.p. with 200 mg/kg cyclophosphamide (CP).  Control and treated animals were fed a diet contg. 0.277% (wt./wt.) pirfenidone beginning 1 day after CP.  Despite anorexia in the CP-treated mice the first day after treatment, they ingested a greater av. pirfenidone dose over 20 days than saline-treated control mice (717 vs. 564 mg/kg per day, resp.).  Total lung hydroxyproline content, an index of fibrosis, was significantly lower 21 days after treatment with CP plus pirfenidone as compared to mice treated with CP alone.  Although microscopic lung fibrosis scores were not significantly decreased by pirfenidone in CP-treated mice, the overall incidence of fibrosis was significantly decreased.  Histol., mice treated with CP showed fibrosis while mice treated with CP plus pirfenidone exhibited fewer abnormalities.  The rate of hydroxyproline synthesis by lung tissue 9 days after treatment with CP was significantly elevated.  This rate was not affected by pirfenidone treatment.  Overall, these data support an antifibrotic effect of pirfenidone against CP-induced lung fibrosis in mice.  The mechanism of its effect is not known, but appears to be unrelated to an inhibition of collagen synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeSnHwnNvRIrVg90H21EOLACvtfcHk0ljw1eYcao99gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtFSgur4%253D&md5=016c5be3f31afffcf7dd2e2dbd4c2224</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2FS0378-4274%2896%2903845-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-4274%252896%252903845-3%26sid%3Dliteratum%253Aachs%26aulast%3DKehrer%26aufirst%3DJ.%2BP.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26atitle%3DPirfenidone%2520diminishes%2520cyclophosphamide-induced%2520lung%2520fibrosis%2520in%2520mice%26jtitle%3DToxicol.%2520Lett.%26date%3D1997%26volume%3D90%26spage%3D125%26epage%3D132%26doi%3D10.1016%2FS0378-4274%2896%2903845-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Yehualaeshet, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begleiter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy-Ullrich, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalil, N.</span><span> </span><span class="NLM_article-title">A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1165/ajrcmb.23.2.4089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Fajrcmb.23.2.4089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10919987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1Ogurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=204-212&author=T.+Yehualaeshetauthor=R.+O%E2%80%99Connorauthor=A.+Begleiterauthor=J.+E.+Murphy-Ullrichauthor=R.+Silversteinauthor=N.+Khalil&title=A+CD36+synthetic+peptide+inhibits+bleomycin-induced+pulmonary+inflammation+and+connective+tissue+synthesis+in+the+rat&doi=10.1165%2Fajrcmb.23.2.4089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat</span></div><div class="casAuthors">Yehualaeshet, Teshome; O'Connor, Robert; Begleiter, Asher; Murphy-Ullrich, Joanne E.; Silverstein, Roy; Khalil, Nasreen</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">204-212</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Transforming growth factor (TGF)-β1 is an important regulator of inflammation and fibrosis.  TGF-β1 is usually secreted as a biol. latent protein called latent TGF-β1 (L-TGF-β1).  L-TGF-β1 has no biol. effect unless L-TGF-β1 is converted to its active form.  Using a well-recognized model of lung injury induced by the antineoplastic antibiotic bleomycin (Blm), the authors demonstrated that 7 d after intratracheal Blm administration, total lung TGF-β was maximally increased.  This induction was due to TGF-β1 prodn. by alveolar macrophages that, when explanted, generated increased quantities of L-TGF-β1 complexed with the glycoprotein thrombospondin (TSP)-1.  The TSP-1/L-TGF-β1 complex was assocd. with CD36, a receptor for TSP-1.  The assocn. of TSP-1/L-TGF-β1 to CD36 was crit. for plasmin-mediated release of mature TGF-β1.  In this paper the authors show that, compared with administration of Blm by itself, when a synthetic peptide of CD36 between amino acids 93 and 110 is given concomitantly with Blm to rats, alveolar macrophages generate markedly less active TGF-β1, the rats gain wt. more rapidly, and there is less inflammation, collagen I and III, and fibronectin synthesis.  These findings demonstrate a novel in vivo mechanism of activation of L-TGF-β1 in lung injury and the importance of alveolar macrophage-derived active TGF-β1 in the pathogenesis of pulmonary inflammation and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSLhDKfWOyKbVg90H21EOLACvtfcHk0lgvAilVCSOVrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1Ogurw%253D&md5=acce0ceab84802df9a5d5b62a94e570c</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1165%2Fajrcmb.23.2.4089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Fajrcmb.23.2.4089%26sid%3Dliteratum%253Aachs%26aulast%3DYehualaeshet%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DBegleiter%26aufirst%3DA.%26aulast%3DMurphy-Ullrich%26aufirst%3DJ.%2BE.%26aulast%3DSilverstein%26aufirst%3DR.%26aulast%3DKhalil%26aufirst%3DN.%26atitle%3DA%2520CD36%2520synthetic%2520peptide%2520inhibits%2520bleomycin-induced%2520pulmonary%2520inflammation%2520and%2520connective%2520tissue%2520synthesis%2520in%2520the%2520rat%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2000%26volume%3D23%26spage%3D204%26epage%3D212%26doi%3D10.1165%2Fajrcmb.23.2.4089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Iyer, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurujeyalakshmi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S. N.</span><span> </span><span class="NLM_article-title">Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">291</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10490926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlaktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=367-373&author=S.+N.+Iyerauthor=G.+Gurujeyalakshmiauthor=S.+N.+Giri&title=Effects+of+pirfenidone+on+transforming+growth+factor-beta+gene+expression+at+the+transcriptional+level+in+bleomycin+hamster+model+of+lung+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis</span></div><div class="casAuthors">Iyer, S. N.; Gurujeyalakshmi, G.; Giri, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">367-373</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was undertaken to investigate whether treatment with the antifibrotic drug pirfenidone (PD) down-regulates the bleomycin (BL)-induced overexpression of transforming growth factor (TGF)-β gene in the lungs.  Hamsters were intratracheally instilled with SA or BL (6.5 U/kg/4 mL) under anesthesia.  They were fed a diet contg. 0.5% PD or the same control diet (CD) without the drug 2 days before and throughout the study.  After the animals were sacrificed, their lungs were appropriately processed.  The BL treatment elevated the total influx of inflammatory cells, including macrophages, by severalfold at different days in bronchoalveolar lavage fluid (BALF) from hamsters in BL + CD groups, relative to the corresponding SA + CD control groups.  Treatment with PD significantly (P ≤.05) suppressed the influx of inflammatory cells and macrophages at day 7 in the BL + PD groups, relative to the corresponding BL + CD groups.  In addn., the levels of TGF-β in BALF from hamsters in BL + CD groups were elevated by 2.6- to 4.5-fold at different days, relative to the corresponding SA + CD groups.  Treatment with PD significantly (P ≤.05) reduced the TGF-β protein in BALF from BL + PD groups at 14 and 21 days, when compared with the corresponding BL + CD groups.  The intratracheal instillation of BL significantly (P ≤.05) elevated the TGF-β mRNA at 7, 14, and 21 days in BL + CD groups, relative to the corresponding SA + CD groups, and treatment with PD significantly (P ≤.05) suppressed the TGF-β gene expression in BL + PD groups at these times, when compared with the corresponding BL + CD groups.  Nuclear runoff studies revealed that PD suppressed the BL-induced increase in TGF-β gene transcription by 33%.  It was concluded that one of the mechanisms for antifibrotic effect of PD is its ability to suppress the BL-induced overexpression of TGF-β gene at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4drE2AFRazLVg90H21EOLACvtfcHk0lgvAilVCSOVrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlaktrw%253D&md5=bf01d4da527b591684e703edff65dde3</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%2BN.%26aulast%3DGurujeyalakshmi%26aufirst%3DG.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26atitle%3DEffects%2520of%2520pirfenidone%2520on%2520transforming%2520growth%2520factor-beta%2520gene%2520expression%2520at%2520the%2520transcriptional%2520level%2520in%2520bleomycin%2520hamster%2520model%2520of%2520lung%2520fibrosis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D367%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Iyer, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiedt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S. N.</span><span> </span><span class="NLM_article-title">Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters</span> <span class="citation_source-journal">J. Lab. Clin. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">785</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=1995&pages=779-785&author=S.+N.+Iyerauthor=J.+S.+Wildauthor=M.+J.+Schiedtauthor=D.+M.+Hydeauthor=S.+B.+Margolinauthor=S.+N.+Giri&title=Dietary+intake+of+pirfenidone+ameliorates+bleomycin-induced+lung+fibrosis+in+hamsters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%2BN.%26aulast%3DWild%26aufirst%3DJ.%2BS.%26aulast%3DSchiedt%26aufirst%3DM.%2BJ.%26aulast%3DHyde%26aufirst%3DD.%2BM.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26atitle%3DDietary%2520intake%2520of%2520pirfenidone%2520ameliorates%2520bleomycin-induced%2520lung%2520fibrosis%2520in%2520hamsters%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1995%26volume%3D125%26spage%3D779%26epage%3D785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Shetlar, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetlar, C. L.</span><span> </span><span class="NLM_article-title">Effect of antifibrosis drug on the survival of keloid transplants in athymic mice</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">A967</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=A967&author=M.+R.+Shetlarauthor=C.+L.+Shetlar&title=Effect+of+antifibrosis+drug+on+the+survival+of+keloid+transplants+in+athymic+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShetlar%26aufirst%3DM.%2BR.%26aulast%3DShetlar%26aufirst%3DC.%2BL.%26atitle%3DEffect%2520of%2520antifibrosis%2520drug%2520on%2520the%2520survival%2520of%2520keloid%2520transplants%2520in%2520athymic%2520mice%26jtitle%3DFASEB%2520J.%26date%3D1995%26volume%3D9%26spage%3DA967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Ammar, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail, M. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sehrawi, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noaman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayomi, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawer, T. Z.</span><span> </span><span class="NLM_article-title">Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span><span class="refDoi"> DOI: 10.1002/ardp.200600017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fardp.200600017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2006&pages=429-436&author=Y.+A.+Ammarauthor=M.+M.+F.+Ismailauthor=H.+M.+El-Sehrawiauthor=E.+Noamanauthor=A.+H.+Bayomiauthor=T.+Z.+Shawer&title=Novel+pirfenidone+analogues%3A+synthesis+of+pyridin-2-ones+for+the+treatment+of+pulmonary+fibrosis&doi=10.1002%2Fardp.200600017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis</span></div><div class="casAuthors">Ammar, Yousry A.; Ismail, Magda M. F.; El-Sehrawi, Hend M.; Noaman, Eman; Bayomi, Ashraf H.; Shawer, Taghreed Z.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">429-436</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of polysubstituted 1-aryl-2-oxo-1,2-dihydropyridine-3-carbonitriles and pyrazolo[3,4-b]pyridine-5-carbonitriles and pyrido[2,3-d]pyrimidine-6-carbonitriles have been synthesized and tested for their antifibrotic activity.  Among the tested compds., two compds. exhibited higher antifibrotic activity than the std. pirfenidone PD.  However, bicyclic pyridone displayed a high mortality rate.  Detailed syntheses, spectroscopic and biol. data are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRbqTVxHLNw7Vg90H21EOLACvtfcHk0lhpeUxGkPOPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWgs74%253D&md5=838f7948a2b0a2c6ebaf59a6a89dc793</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fardp.200600017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200600017%26sid%3Dliteratum%253Aachs%26aulast%3DAmmar%26aufirst%3DY.%2BA.%26aulast%3DIsmail%26aufirst%3DM.%2BM.%2BF.%26aulast%3DEl-Sehrawi%26aufirst%3DH.%2BM.%26aulast%3DNoaman%26aufirst%3DE.%26aulast%3DBayomi%26aufirst%3DA.%2BH.%26aulast%3DShawer%26aufirst%3DT.%2BZ.%26atitle%3DNovel%2520pirfenidone%2520analogues%253A%2520synthesis%2520of%2520pyridin-2-ones%2520for%2520the%2520treatment%2520of%2520pulmonary%2520fibrosis%26jtitle%3DArch.%2520Pharm.%26date%3D2006%26volume%3D339%26spage%3D429%26epage%3D436%26doi%3D10.1002%2Fardp.200600017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Giri, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lango, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckpitt, A. R.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration</span> <span class="citation_source-journal">Biopharm. Drug Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1002/bdd.311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fbdd.311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12116052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvV2nsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=203-211&author=S.+N.+Giriauthor=Q.+Wangauthor=Y.+Xieauthor=J.+Langoauthor=D.+Morinauthor=S.+B.+Margolinauthor=A.+R.+Buckpitt&title=Pharmacokinetics+and+metabolism+of+a+novel+antifibrotic+drug+pirfenidone%2C+in+mice+following+intravenous+administration&doi=10.1002%2Fbdd.311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration</span></div><div class="casAuthors">Giri, Shri N.; Wang, Qingjian; Xie, Yan; Lango, Jozsef; Morin, Dexter; Margolin, Solomon B.; Buckpitt, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The present study describes the pharmacokinetics and metab. of pirfenidone (PD), a compd. which has been shown to have significant antifibrotic effects in rodent models of pulmonary and cardiac fibrosis.  Despite the fact that this compd. is currently in phase II clin. trials, little data are available on the metab. and disposition of this agent in rodents or humans.  Radioactive PD [benzene ring 14C(U)] was administered i.v. to mice at 40 mg PD/kg body wt., and animals were killed at varying times for detn. of parent compd. and metabolites in various tissues.  The disappearance of parent compd. from the plasma followed apparent 2-compartment elimination kinetics with a terminal elimination half-life of 8.6 min.  Cl (0.10 mL/min/g) and Vd(ss) (0.67 mL/g) indicated that PD was rapidly distributed in body water.  This is consistent with the finding that peak tissue radioactivity occurred within 5 min following the i.v. administration of [14C]-PD and that well-perfused tissues, kidney > liver > lung have much higher levels of parent compd. and metabolites than did fat.  Two peaks isolated from plasma samples by HPLC yielded mass spectra that were consistent with initial oxidn. to the alc. followed by further metab. to the carboxylic acid.  The radioactivity recovered in the 24 h urine samples averaged 97% of the administered dose and none of that was assocd. with the parent compd.  The short plasma half-life of parent compd. in mice supports the need for addnl. studies in humans where the compd. has been shown to have clin. benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ifBkB7uIJbVg90H21EOLACvtfcHk0lhpeUxGkPOPeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvV2nsr0%253D&md5=4dcedca61461a161f06068c3eaa90e69</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1002%2Fbdd.311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.311%26sid%3Dliteratum%253Aachs%26aulast%3DGiri%26aufirst%3DS.%2BN.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DLango%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DD.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DBuckpitt%26aufirst%3DA.%2BR.%26atitle%3DPharmacokinetics%2520and%2520metabolism%2520of%2520a%2520novel%2520antifibrotic%2520drug%2520pirfenidone%252C%2520in%2520mice%2520following%2520intravenous%2520administration%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2002%26volume%3D23%26spage%3D203%26epage%3D211%26doi%3D10.1002%2Fbdd.311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G. Y.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2302</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2012.01.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2300-2302&author=J.+Chenauthor=M.+M.+Luauthor=B.+Liuauthor=Z.+Chenauthor=Q.+B.+Liauthor=L.+J.+Taoauthor=G.+Y.+Hu&title=Synthesis+and+structure%E2%80%93activity+relationship+of+5-substituent-2%281H%29-pyridone+derivatives+as+anti-fibrosis+agents&doi=10.1016%2Fj.bmcl.2012.01.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%2BB.%26aulast%3DTao%26aufirst%3DL.%2BJ.%26aulast%3DHu%26aufirst%3DG.%2BY.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%25205-substituent-2%25281H%2529-pyridone%2520derivatives%2520as%2520anti-fibrosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2300%26epage%3D2302%26doi%3D10.1016%2Fj.bmcl.2012.01.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span> </span><span class="NLM_article-title">Design, synthesis and anti-fibrosis activity study of N<sub>1</sub>-substituted phenylhydroquinolinone derivatives</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1373</span><span class="NLM_x">–</span> <span class="NLM_lpage">1387</span><span class="refDoi"> DOI: 10.3390/molecules17021373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3390%2Fmolecules17021373" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1373-1387&author=L.+Wuauthor=B.+Liuauthor=Q.+Liauthor=J.+Chenauthor=L.+Taoauthor=G.+Hu&title=Design%2C+synthesis+and+anti-fibrosis+activity+study+of+N1-substituted+phenylhydroquinolinone+derivatives&doi=10.3390%2Fmolecules17021373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3390%2Fmolecules17021373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules17021373%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520anti-fibrosis%2520activity%2520study%2520of%2520N1-substituted%2520phenylhydroquinolinone%2520derivatives%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D1373%26epage%3D1387%26doi%3D10.3390%2Fmolecules17021373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Lou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span> </span><span class="NLM_article-title">Design, synthesis and antifibrotic activities of carbohydrate- modified 1-(substituted aryl)-5-trifluoromethyl-2(1<i>H</i>) pyridones</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">884</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span><span class="refDoi"> DOI: 10.3390/molecules17010884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3390%2Fmolecules17010884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=884-896&author=Q.+Louauthor=X.+Mengauthor=Z.+Laoauthor=L.+Xuanauthor=J.+Baiauthor=Q.+Houauthor=G.+Huauthor=R.+Luoauthor=L.+Taoauthor=Z.+Li&title=Design%2C+synthesis+and+antifibrotic+activities+of+carbohydrate-+modified+1-%28substituted+aryl%29-5-trifluoromethyl-2%281H%29+pyridones&doi=10.3390%2Fmolecules17010884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.3390%2Fmolecules17010884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules17010884%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DQ.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DLao%26aufirst%3DZ.%26aulast%3DXuan%26aufirst%3DL.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520antifibrotic%2520activities%2520of%2520carbohydrate-%2520modified%25201-%2528substituted%2520aryl%2529-5-trifluoromethyl-2%25281H%2529%2520pyridones%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D884%26epage%3D896%26doi%3D10.3390%2Fmolecules17010884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Kossen, K.; Seiwert, S. D.; Serebryany, V.; Ruhrmund, D.; Beigelman, L.; Raveglia, L. F.; Vallese, S.; Bianchi, I.; Hu, T.</span><span> </span><span class="NLM_article-title">Compounds and methods for treating inflammatory and fibrotic disorders</span>. U.S. Patent 20090318455 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Kossen&author=S.+D.+Seiwert&author=V.+Serebryany&author=D.+Ruhrmund&author=L.+Beigelman&author=L.+F.+Raveglia&author=S.+Vallese&author=I.+Bianchi&author=T.+Hu&title=Compounds+and+methods+for+treating+inflammatory+and+fibrotic+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKossen%26aufirst%3DK.%26atitle%3DCompounds%2520and%2520methods%2520for%2520treating%2520inflammatory%2520and%2520fibrotic%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2013.11.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=220-223&author=Z.+Maauthor=Y.+Panauthor=W.+Huangauthor=Y.+Yangauthor=Z.+Wangauthor=Q.+Liauthor=Y.+Zhaoauthor=X.+Zhangauthor=Z.+Shen&title=Synthesis+and+biological+evaluation+of+the+pirfenidone+derivatives+as+antifibrotic+agents&doi=10.1016%2Fj.bmcl.2013.11.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520the%2520pirfenidone%2520derivatives%2520as%2520antifibrotic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D220%26epage%3D223%26doi%3D10.1016%2Fj.bmcl.2013.11.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Ueki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amuro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashino, K.</span><span> </span><span class="NLM_article-title">Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">1137</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1137&publication_year=1992&pages=189-196&author=N.+Uekiauthor=M.+Nakazatoauthor=T.+Ohkawaauthor=T.+Ikedaauthor=Y.+Amuroauthor=T.+Hadaauthor=K.+Higashino&title=Excessive+production+of+transforming+growth-factor+beta+1+can+play+an+important+role+in+the+development+of+tumorigenesis+by+its+action+for+angiogenesis%3A+validity+of+neutralizing+antibodies+to+block+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUeki%26aufirst%3DN.%26aulast%3DNakazato%26aufirst%3DM.%26aulast%3DOhkawa%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DAmuro%26aufirst%3DY.%26aulast%3DHada%26aufirst%3DT.%26aulast%3DHigashino%26aufirst%3DK.%26atitle%3DExcessive%2520production%2520of%2520transforming%2520growth-factor%2520beta%25201%2520can%2520play%2520an%2520important%2520role%2520in%2520the%2520development%2520of%2520tumorigenesis%2520by%2520its%2520action%2520for%2520angiogenesis%253A%2520validity%2520of%2520neutralizing%2520antibodies%2520to%2520block%2520tumor%2520growth%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1992%26volume%3D1137%26spage%3D189%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K. S.</span><span> </span><span class="NLM_article-title">Lung cancer in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1216</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1183/09031936.01.99055301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.01.99055301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=11491167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD3MvksFWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2001&pages=1216-1219&author=J.+Parkauthor=D.+S.+Kimauthor=T.+S.+Shimauthor=C.+M.+Limauthor=Y.+Kohauthor=S.+D.+Leeauthor=W.+S.+Kimauthor=W.+D.+Kimauthor=J.+S.+Leeauthor=K.+S.+Song&title=Lung+cancer+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1183%2F09031936.01.99055301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Lung cancer in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Park J; Kim D S; Shim T S; Lim C M; Koh Y; Lee S D; Kim W S; Kim W D; Lee J S; Song K S</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1216-9</span>
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) was reported to be associated with increased risk of lung cancer as a result of the occurrence of atypical or dysplastic epithelial changes in fibrosis which progressed to invasive malignancy.  In that situation, the cancer will develop in the area of major fibrosis.  To investigate the direct relationship between fibrosis and cancer development, the real concordance rate of the two lesions in the chest computed tomography (CT) was analysed and compared to the histological types of lung cancer.  The subjects included 63 patients with combined lung cancer and IPF (IPF-CA), 218 patients with lone IPF, and 2,660 patients with primary lung cancer.  All patients were diagnosed at Asan Medical Center during the same period.  The age, percentage of smokers, and the male sex were significantly higher in IPF-CA compared with lone IPF.  The odds ratio of smoking was 2.71 compared to nonsmoking IPF controls.  In IPF-CA, 56% of the cancer was located in the periphery of the lung and 52% in the upper lobe.  The majority of the cancers (64%) were found in the nonfibrotic area at chest CT.  The most frequent cell type was squamous cell carcinoma (35%), and there was no significant difference in the cancer cell type between IPF-CA and total lung cancer population.  These findings suggest that in combined lung cancer and idiopathic pulmonary fibrosis patients, the features of the lung cancer are similar to the total lung cancer population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcWbvkNiVQre_Q9URG6Dx8fW6udTcc2eaU2u0E2E9FBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvksFWltA%253D%253D&md5=d188ff9c1ae1adeac619ebf862a3f3cf</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1183%2F09031936.01.99055301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.01.99055301%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DShim%26aufirst%3DT.%2BS.%26aulast%3DLim%26aufirst%3DC.%2BM.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DSong%26aufirst%3DK.%2BS.%26atitle%3DLung%2520cancer%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2001%26volume%3D17%26spage%3D1216%26epage%3D1219%26doi%3D10.1183%2F09031936.01.99055301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Aubry, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazelaar, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washington Stephens, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschamps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pankratz, V. S.</span><span> </span><span class="NLM_article-title">Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Mayo Clin. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.4065/77.8.763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4065%2F77.8.763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12173712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD38vhvFCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2002&pages=763-770&author=M.+C.+Aubryauthor=J.+L.+Myersauthor=W.+W.+Douglasauthor=H.+D.+Tazelaarauthor=T.+L.+Washington+Stephensauthor=T.+E.+Hartmanauthor=C.+Deschampsauthor=V.+S.+Pankratz&title=Primary+pulmonary+carcinoma+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.4065%2F77.8.763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Aubry Marie-Christine; Myers Jeffrey L; Douglas William W; Tazelaar Henry D; Washington Stephens Tanya L; Hartman Thomas E; Deschamps Claude; Pankratz V Shane</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">763-70</span>
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    </div><div class="casAbstract">OBJECTIVE:  To identify distinguishing characteristics between patients with idiopathic pulmonary fibrosis (IPF) and primary lung carcinoma and patients with either IPF or carcinoma alone.  PATIENTS AND METHODS:  The study group consisted of 24 patients with histologically proven usual interstitial pneumonia and lung carcinoma identified through a search of the Rochester Mayo Clinic database for 1990 to 1998.  Medical records, radiographs, and histological slides were reviewed.  Several variables including survival were compared in 2 control groups, IPF only and carcinoma only, by using various statistical methods.  RESULTS:  Our study group included 21 men and 3 women (mean age, 72.3 years).  Twenty-two were past or current smokers.  Approximately half of the lung carcinomas were incidental findings.  Of the 14 patients with preoperative computed tomographic scans, 12 had peripheral tumors situated in areas of fibrosis.  Squamous cell carcinoma was the most common histological type, accounting for 16 cases.  Almost all patients underwent surgical treatment; nearly 40% developed postoperative complications, and 3 died within 30 days of surgery.  The ratio of men to women in patients with IPF and carcinoma was 7:1 compared with 1:1 in patients with IPF only (P=.003).  Patients with IPF and carcinoma were also older, with a mean age of 72.3 years compared with 64.4 years (P=.001), and were more often smokers (P=.002).  Carcinomas involved the lower lobes in 42% of patients with IPF and carcinoma compared with 29% of patients with carcinoma only (P=.004) and were mainly composed of squamous cell carcinoma (P=.004).  Mean survival in patients with IPF and lung carcinoma was 2.3 years after the diagnosis of IPF and 1.6 years after that of carcinoma.  This finding did not differ significantly from survival of patients with either IPF or carcinoma alone.  However, statistical power was limited.  CONCLUSION:  Carcinoma in patients with IPF arises in older male smokers and usually presents as peripheral squamous cell carcinoma.  The prognosis is poor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7PQKpEBgkRMzK395ZObgVfW6udTcc2eYeZE86OGSZvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vhvFCqsg%253D%253D&md5=cbe0368942849a52db53f3a5998fa6c4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.4065%2F77.8.763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4065%252F77.8.763%26sid%3Dliteratum%253Aachs%26aulast%3DAubry%26aufirst%3DM.%2BC.%26aulast%3DMyers%26aufirst%3DJ.%2BL.%26aulast%3DDouglas%26aufirst%3DW.%2BW.%26aulast%3DTazelaar%26aufirst%3DH.%2BD.%26aulast%3DWashington%2BStephens%26aufirst%3DT.%2BL.%26aulast%3DHartman%26aufirst%3DT.%2BE.%26aulast%3DDeschamps%26aufirst%3DC.%26aulast%3DPankratz%26aufirst%3DV.%2BS.%26atitle%3DPrimary%2520pulmonary%2520carcinoma%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2002%26volume%3D77%26spage%3D763%26epage%3D770%26doi%3D10.4065%2F77.8.763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span> </span><span class="NLM_article-title">Synthesis, pharmacophores, and mechanism study of pyridin-2(1<i>H</i>)-one derivatives as regulators of translation initiation factor 3A</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">654</span><span class="NLM_x">–</span> <span class="NLM_lpage">666</span><span class="refDoi"> DOI: 10.1002/ardp.201300138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fardp.201300138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1yks7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=654-666&author=W.+Zhuauthor=J.+Shenauthor=Q.+Liauthor=Q.+Peiauthor=J.+Chenauthor=Z.+Chenauthor=Z.+Liuauthor=G.+Hu&title=Synthesis%2C+pharmacophores%2C+and+mechanism+study+of+pyridin-2%281H%29-one+derivatives+as+regulators+of+translation+initiation+factor+3A&doi=10.1002%2Fardp.201300138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, pharmacophores, and mechanism study of pyridin-2(1H)-one derivatives as regulators of translation initiation factor 3a</span></div><div class="casAuthors">Zhu, Weixing; Shen, Jie; Li, Qianbin; Pei, Qi; Chen, Jun; Chen, Zhuo; Liu, Zhaoqian; Hu, Gaoyun</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">654-666</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Twenty-seven 1,5-disubstituted-pyridin-2(1H)-one derivs. were synthesized and evaluated for their anticancer and antifibrosis activity by A549 and NIH3T3 cell viability assays, resp.  To study the selectivity between the cancer and fibrosis cell lines, pharmacophore models (F1-F4) were built in advance for compds. with pyridin-2(1H)-one scaffold, which revealed the relationship between the occupation of the arom. sub-site F4 and potent anti-cancer activity.  The relationship between structure and anti-cancer activity for all target compds. is also reported herein: 1-Phenyl-5-((m-tolylamino)methyl)pyridine-2(1H)-one (22) displayed both potency and selectivity (IC50 = 0.13 mM) toward the A549 cell line through the inhibition of translation initiation, esp. by eIF3a suppression, and can be treated as a lead for the design of novel eIF3a regulators and anti-lung cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHSDWP5U8VebVg90H21EOLACvtfcHk0liuDXmcA1D8wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1yks7%252FP&md5=b644c20f431f198399fa919bdeb427c6</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fardp.201300138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201300138%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DPei%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520pharmacophores%252C%2520and%2520mechanism%2520study%2520of%2520pyridin-2%25281H%2529-one%2520derivatives%2520as%2520regulators%2520of%2520translation%2520initiation%2520factor%25203A%26jtitle%3DArch.%2520Pharm.%26date%3D2013%26volume%3D346%26spage%3D654%26epage%3D666%26doi%3D10.1002%2Fardp.201300138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Lasky, J.</span><span> </span><span class="NLM_article-title">Pirfenidone</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15057662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntF2ksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=166-172&author=J.+Lasky&title=Pirfenidone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone(InterMune/Shionogi/Marnac)</span></div><div class="casAuthors">Lasky, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-172</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_3VFnr6wLWrVg90H21EOLACvtfcHk0liuDXmcA1D8wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntF2ksr0%253D&md5=79bbb53c4305e82fab25a0a249b47f96</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLasky%26aufirst%3DJ.%26atitle%3DPirfenidone%26jtitle%3DIDrugs%26date%3D2004%26volume%3D7%26spage%3D166%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Tao, L. J.; Hu, G. Y.; Tan, G. S.</span><span> </span><span class="NLM_article-title">Antifibrosis pyridinone medicine and its preparing process</span>. CN 1386737A,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=L.+J.+Tao&author=G.+Y.+Hu&author=G.+S.+Tan&title=Antifibrosis+pyridinone+medicine+and+its+preparing+process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%2BJ.%26atitle%3DAntifibrosis%2520pyridinone%2520medicine%2520and%2520its%2520preparing%2520process%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Tao, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G. Y.</span><span> </span><span class="NLM_article-title">Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H)-pyridone on renal fibroblast in rats</span> <span class="citation_source-journal">Zhong Nan Da Xue Xue Bao Yi Xue Ban</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16145895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2MvnslWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=139-141&author=L.+J.+Taoauthor=J.+Zhangauthor=G.+Y.+Hu&title=Effects+of+1-%283-fluorophenyl%29-5-methyl-2-%281H%29-pyridone+on+renal+fibroblast+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H)-pyridone on renal fibroblast in rats</span></div><div class="casAuthors">Tao Li-Jian; Zhang Jun; Hu Gao-Yun</div><div class="citationInfo"><span class="NLM_cas:title">Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-41</span>
        ISSN:<span class="NLM_cas:issn">1672-7347</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore the curative effects of 1-(3-fluorophenyl)-5-methyl-2- (1H)-pyridone (FMP) on renal fibrosis in rats.  METHODS:  The effects of FMP on the cell proliferation and Fn secretion were measured by methyl thiazolyl tetrazolium and enzyme-linked immunoabsorbent assay, respectively.  RESULTS:  FMP obviously inhibited the proliferation and Fn secretion in rat renal fibroblast 48 hours after the treatment.  FMP (1 000 microg/ml) obviously inhibited the proliferation of rat renal fibroblast 24 hours after the treatment.  CONCLUSION:  1-(3-Fluorophenyl) -5-methyl-2-(1H)-pyridone can obviously inhibit the proliferation of rat renal fibroblast, which may be effective for renal interstitial fibrosis prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkJliHwPw3BpPlX7E30qdzfW6udTcc2ebaSYSFUAIgUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvnslWnsQ%253D%253D&md5=72a018ad9bbb35f8f5ff8bb2816bf602</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DG.%2BY.%26atitle%3DEffects%2520of%25201-%25283-fluorophenyl%2529-5-methyl-2-%25281H%2529-pyridone%2520on%2520renal%2520fibroblast%2520in%2520rats%26jtitle%3DZhong%2520Nan%2520Da%2520Xue%2520Xue%2520Bao%2520Yi%2520Xue%2520Ban%26date%3D2004%26volume%3D29%26spage%3D139%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Mirkovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenning, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strachan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, L.</span><span> </span><span class="NLM_article-title">Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0704539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fsj.bjp.0704539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=11861324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1Cntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=961-968&author=S.+Mirkovicauthor=A.+M.+Seymourauthor=A.+Fenningauthor=A.+Strachanauthor=S.+B.+Margolinauthor=S.+M.+Taylorauthor=L.+Brown&title=Attenuation+of+cardiac+fibrosis+by+pirfenidone+and+amiloride+in+DOCA-salt+hypertensive+rats&doi=10.1038%2Fsj.bjp.0704539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats</span></div><div class="casAuthors">Mirkovic, Stevo; Seymour, Anne-Marie L.; Fenning, Andrew; Strachan, Anna; Margolin, Solomon B.; Taylor, Stephen M.; Brown, Lindsay</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">961-968</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This study has administered pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) or amiloride to attenuate the remodelling and assocd. functional changes, esp. an increased cardiac stiffness, in DOCA-salt hypertensive rats.  In control rats, the elimination half-life of pirfenidone following a single i.v. dose of 200 mg kg-1 was 37 min while oral bioavailability at this dose was 25.7%.  Plasma pirfenidone concns. in control rats averaged 1.9±0.1 μg ml-1 over 24 h after 14 days' administration as a 0.4% mixt. in food.  Pirfenidone (approx. 250-300 mg kg-1 day-1 as 0.4% in food) and amiloride (1 mg kg-1 day-1 s.c.) were administered for 2 wk starting 2 wk post-surgery.  Pirfenidone but not amiloride attenuated ventricular hypertrophy (2.69±0.09, UNX 2.01±0.05. DOCA-salt 3.11±0.09 mg kg-1 body wt.) without lowering systolic blood pressure.  Collagen deposition was significantly increased in the interstitium after 2 wk and further increased with scarring of the left ventricle after 4 wk; pirfenidone and amiloride reversed the increases and prevented further increases.  This accumulation of collagen was accompanied by an increase in diastolic stiffness const.; both amiloride and pirfenidone reversed this increase.  Noradrenaline potency (pos. chronotropy) was decreased in right atria (neg. log EC50: control 6.92±0.06; DOCA-salt 6.64±0.08); pirfenidone but not amiloride reversed this change.  Noradrenaline was a more potent vasoconstrictor in thoracic aortic rings (neg. log EC50: control 6.91±0.10; DOCA-salt 7.90±0.07); pirfenidone treatment did not change noradrenaline potency.  Thus, pirfenidone and amiloride reverse and prevent cardiac remodelling and the increased cardiac stiffness without reversing the increased vascular responses to noradrenaline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaFFgkYGNrArVg90H21EOLACvtfcHk0lhmErMDK8Daow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1Cntbo%253D&md5=e3966b0ae08814933f0784cc40987502</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704539%26sid%3Dliteratum%253Aachs%26aulast%3DMirkovic%26aufirst%3DS.%26aulast%3DSeymour%26aufirst%3DA.%2BM.%26aulast%3DFenning%26aufirst%3DA.%26aulast%3DStrachan%26aufirst%3DA.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DTaylor%26aufirst%3DS.%2BM.%26aulast%3DBrown%26aufirst%3DL.%26atitle%3DAttenuation%2520of%2520cardiac%2520fibrosis%2520by%2520pirfenidone%2520and%2520amiloride%2520in%2520DOCA-salt%2520hypertensive%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D961%26epage%3D968%26doi%3D10.1038%2Fsj.bjp.0704539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Iyer, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S. N.</span><span> </span><span class="NLM_article-title">Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model</span> <span class="citation_source-journal">Exp. Lung Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.3109/01902149809046058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.3109%2F01902149809046058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=9457473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADyaK1cXit1Kis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1998&pages=119-132&author=S.+N.+Iyerauthor=S.+B.+Margolinauthor=D.+M.+Hydeauthor=S.+N.+Giri&title=Lung+fibrosis+is+ameliorated+by+pirfenidone+fed+in+diet+after+the+second+dose+in+a+three-dose+bleomycin-hamster+model&doi=10.3109%2F01902149809046058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model</span></div><div class="casAuthors">Iyer, Swarnalatha N.; Margolin, S. B.; Hyde, D. M.; Giri, S. N.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Lung Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-132</span>CODEN:
                <span class="NLM_cas:coden">EXLRDA</span>;
        ISSN:<span class="NLM_cas:issn">0190-2148</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis</span>)
        </div><div class="casAbstract">Interstitial lung fibrosis (ILF) is a life-threatening disease which has no known drug for prevention and cure.  In the present study, we evaluated the antifibrotic potential of pirfenidone (PD) (5-methyl-1-phenyl-2-(1H)-pyridone) in a three-dose bleomycin (BL)-hamster model of lung fibrosis.  Hamsters were intratracheally (IT) instilled with three consecutive doses of bleomycin sulfate (2.5 U/kg/5mL, 2.0 U/kg/5mL, 1.5 U/kg/3.75mL) or an equiv. vol. of saline at weekly intervals.  Hamsters were fed a diet after the second dose of BL contg. 0.5% PD and hamsters in the control groups were fed the same diet without the drug.  The four groups were saline-instilled fed control diet (SCD); saline-instilled fed the same diet contg. PD (SPD); BL-instilled fed control diet (BCD); and BL-instilled fed the diet contg. PD (BPD).  Hamsters were sacrificed at 28 days after IT instillation of last dose of saline or BL and their lungs processed for various assays.  Lung hydroxyproline, an index of fibrosis, in SCD, SPD, BCD and BPD were 830, 804, 1609, 1235 μg/lung, resp.  Lung prolyl hydroxylase activities in the SPD, BCD and BPD groups were 103%, 313%, 157% of the control SCD group (5.99 × 104 dpm/lung/30 min) resp.  Malondialdehyde equiv. levels and superoxide dismutase activity in the corresponding groups were 99, 79, 240 and 145 nmoles/lung and 412, 433, 538 and 410 units/lung resp.  Lung myeloperoxidase activities in the corresponding groups were 56%, 179%, and 116% of the control group (0.44 units/lung).  It is concluded that PD is a novel antifibrotic drug that has therapeutic potential in arresting the progression of an ongoing fibrotic process in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYluNu74sAH7Vg90H21EOLACvtfcHk0ljBwZG-eTMOig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1Kis78%253D&md5=af6f0f9cc056c47a3360bb73259c098e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3109%2F01902149809046058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F01902149809046058%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%2BN.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DHyde%26aufirst%3DD.%2BM.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26atitle%3DLung%2520fibrosis%2520is%2520ameliorated%2520by%2520pirfenidone%2520fed%2520in%2520diet%2520after%2520the%2520second%2520dose%2520in%2520a%2520three-dose%2520bleomycin-hamster%2520model%26jtitle%3DExp.%2520Lung%2520Res.%26date%3D1998%26volume%3D24%26spage%3D119%26epage%3D132%26doi%3D10.3109%2F01902149809046058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G. Y.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationship of 5-substituent-2(1<i>H</i>)-pyridone derivatives as anti-fibrosis agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2300</span><span class="NLM_x">–</span> <span class="NLM_lpage">2302</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2012.01.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2300-2302&author=J.+Chenauthor=M.+M.+Luauthor=B.+Liuauthor=Z.+Chenauthor=Q.+B.+Liauthor=L.+J.+Taoauthor=G.+Y.+Hu&title=Synthesis+and+structure%E2%80%93activity+relationship+of+5-substituent-2%281H%29-pyridone+derivatives+as+anti-fibrosis+agents&doi=10.1016%2Fj.bmcl.2012.01.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%2BB.%26aulast%3DTao%26aufirst%3DL.%2BJ.%26aulast%3DHu%26aufirst%3DG.%2BY.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%25205-substituent-2%25281H%2529-pyridone%2520derivatives%2520as%2520anti-fibrosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2300%26epage%3D2302%26doi%3D10.1016%2Fj.bmcl.2012.01.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span> </span><span class="NLM_article-title">Synthesis, preliminary biological evaluation and 3D-QSAR study of novel 1,5-disubstituted-2(1<i>H</i>)-pyridone derivatives as potential anti-lung cancer agents</span> <span class="citation_source-journal">Arabian J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1016/j.arabjc.2015.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.arabjc.2015.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWht7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=721-735&author=Q.+Xuauthor=X.+Jiangauthor=W.+Zhuauthor=C.+Chenauthor=G.+Huauthor=Q.+Li&title=Synthesis%2C+preliminary+biological+evaluation+and+3D-QSAR+study+of+novel+1%2C5-disubstituted-2%281H%29-pyridone+derivatives+as+potential+anti-lung+cancer+agents&doi=10.1016%2Fj.arabjc.2015.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, preliminary biological evaluation and 3D-QSAR study of novel 1,5-disubstituted-2(1H)-pyridone derivatives as potential anti-lung cancer agents</span></div><div class="casAuthors">Xu, Qifei; Jiang, Xiaoding; Zhu, Weixing; Chen, Chuo; Hu, Gaoyun; Li, Qianbin</div><div class="citationInfo"><span class="NLM_cas:title">Arabian Journal of Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-735</span>CODEN:
                <span class="NLM_cas:coden">AJCRDR</span>;
        ISSN:<span class="NLM_cas:issn">1878-5352</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Twenty-eight novel 1,5-disubstituted-2(1H)-pyridone derivs. I (R1 = 2-F, 4-Me, 2-MeO, etc.; R2 = H, 2-F, 4-F, 4-OMe), II were designed and synthesized for discovering more potent anti-lung cancer agents combined with anti-fibrotic profiles.  The in vitro antiproliferative activities of the derivs. against A549 and NIH3T3 cell lines were tested by MTT assays.  The majority of the tested analogs exhibited equiv. or an improved anti-lung cancer activity.  Prominently, compd. II (R1 = 4-F; R2 = 4-OMe) displayed the best potency and selectivity toward A549 with an IC50 value of 20 μM, nearly comparable to the pos. control cisplatin (IC50 = 10 μM) and even superior to the lead compd. III (IC50 = 130 μM).  Simultaneously, compd. II (R1 = 4-F; R2 = 4-OMe) showed significant inhibitory activity against NIH3T3 (IC50 = 55 μM), which may contribute to hindering the proliferation of lung cancer cells fundamentally.  The 3D-QSAR models established on the activity data provided new insights into the design of novel 2(1H)-pyridone derivs. and lay a theor. foundation for further studies of promising anti-lung cancer activity with the maintenance of anti-fibrotic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDnfEPmL404rVg90H21EOLACvtfcHk0ljBwZG-eTMOig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWht7%252FJ&md5=73e83d3f303ead0e8638de3f071d4f7b</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.arabjc.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.arabjc.2015.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DSynthesis%252C%2520preliminary%2520biological%2520evaluation%2520and%25203D-QSAR%2520study%2520of%2520novel%25201%252C5-disubstituted-2%25281H%2529-pyridone%2520derivatives%2520as%2520potential%2520anti-lung%2520cancer%2520agents%26jtitle%3DArabian%2520J.%2520Chem.%26date%3D2016%26volume%3D9%26spage%3D721%26epage%3D735%26doi%3D10.1016%2Fj.arabjc.2015.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Semen, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminskyy, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirota, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maij, N. G. A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelisyeyeva, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span> </span><span class="NLM_article-title">Redox modulation by amaranth oil in human lung fibroblasts</span> <span class="citation_source-journal">Nat. Prod. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1000122</span><span class="refDoi"> DOI: 10.4172/2329-6836.1000122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4172%2F2329-6836.1000122" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=1000122&author=K.+O.+Semenauthor=G.+J.+den+Hartogauthor=D.+V.+Kaminskyyauthor=T.+V.+Sirotaauthor=N.+G.+A.+A.+Maijauthor=O.+P.+Yelisyeyevaauthor=A.+Bast&title=Redox+modulation+by+amaranth+oil+in+human+lung+fibroblasts&doi=10.4172%2F2329-6836.1000122"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.4172%2F2329-6836.1000122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2329-6836.1000122%26sid%3Dliteratum%253Aachs%26aulast%3DSemen%26aufirst%3DK.%2BO.%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DKaminskyy%26aufirst%3DD.%2BV.%26aulast%3DSirota%26aufirst%3DT.%2BV.%26aulast%3DMaij%26aufirst%3DN.%2BG.%2BA.%2BA.%26aulast%3DYelisyeyeva%26aufirst%3DO.%2BP.%26aulast%3DBast%26aufirst%3DA.%26atitle%3DRedox%2520modulation%2520by%2520amaranth%2520oil%2520in%2520human%2520lung%2520fibroblasts%26jtitle%3DNat.%2520Prod.%2520Chem.%2520Res.%26date%3D2013%26volume%3D2%26spage%3D1000122%26doi%3D10.4172%2F2329-6836.1000122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Tilburg, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koek, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span> </span><span class="NLM_article-title">Superoxide anion radicals activate hepatic stellate cells after entry through chloride channels: a new target in liver fibrosis</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">724</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2013.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ejphar.2013.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24378345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=724&publication_year=2014&pages=140-144&author=G.+J.+den+Hartogauthor=S.+Qiauthor=J.+H.+van+Tilburgauthor=G.+H.+Koekauthor=A.+Bast&title=Superoxide+anion+radicals+activate+hepatic+stellate+cells+after+entry+through+chloride+channels%3A+a+new+target+in+liver+fibrosis&doi=10.1016%2Fj.ejphar.2013.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123aR"><div class="casContent"><span class="casTitleNuber">123a</span><div class="casTitle"><span class="NLM_cas:atitle">Superoxide anion radicals activate hepatic stellate cells after entry through chloride channels: A new target in liver fibrosis</span></div><div class="casAuthors">den Hartog, Gertjan J. M.; Qi, Shufan; van Tilburg, Jonathan H. O.; Koek, Ger H.; Bast, Aalt</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">724</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">140-144</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It is generally accepted that reactive oxygen species (ROS) play an important role in the pathogenesis of liver fibrosis.  ROS, however, constitute a group of species with varying properties making it likely that their contribution to the pathol. mechanism varies.  LX-2 hepatic stellate cells (HSCs) were exposed to superoxide anion radicals (O2-) generated by xanthine and xanthine oxidase.  To rule out that the activation of HSCs is due to hydrogen peroxide derived from O2-, control incubations with copper, zinc-superoxide dismutase and tempol were studied as well.  Influx of O2- activated HSCs, evidenced by the expression of α-smooth muscle actin and the secretion of transforming growth factor β1 and collagen.  We further found that blockade of chloride channels with 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), 5-nitro-2-(3-phenylpropyl-amino) benzoic acid (NPPB) or indanyloxyacetic acid (IAA-94) prevented the increase of intracellular O2- levels as well as the activation of HSCs.  These findings suggest that O2- is involved in the development of liver fibrosis and that entry of O2-, through chloride channels, in stellate cells is crit. for their activation.  This study provides new insight into the mechanism by which ROS induce liver fibrosis.  Furthermore, our data suggest that chloride channels constitute a potential target for new anti-fibrotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritMGazRQYlLVg90H21EOLACvtfcHk0li-uPz9D5FILA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGmtbg%253D&md5=5dbd1070a25c30903aa41393ff6623e8</span></div><a href="/servlet/linkout?suffix=cit123a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.12.033%26sid%3Dliteratum%253Aachs%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DQi%26aufirst%3DS.%26aulast%3Dvan%2BTilburg%26aufirst%3DJ.%2BH.%26aulast%3DKoek%26aufirst%3DG.%2BH.%26aulast%3DBast%26aufirst%3DA.%26atitle%3DSuperoxide%2520anion%2520radicals%2520activate%2520hepatic%2520stellate%2520cells%2520after%2520entry%2520through%2520chloride%2520channels%253A%2520a%2520new%2520target%2520in%2520liver%2520fibrosis%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D724%26spage%3D140%26epage%3D144%26doi%3D10.1016%2Fj.ejphar.2013.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit123b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span> </span><span class="NLM_article-title">Superoxide radicals increase transforming growth factor-beta1 and collagen release from human lung fibroblasts via cellular influx through chloride channels</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1016/j.taap.2009.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.taap.2009.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19268487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Grtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2009&pages=111-118&author=S.+Qiauthor=G.+J.+den+Hartogauthor=A.+Bast&title=Superoxide+radicals+increase+transforming+growth+factor-beta1+and+collagen+release+from+human+lung+fibroblasts+via+cellular+influx+through+chloride+channels&doi=10.1016%2Fj.taap.2009.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123bR"><div class="casContent"><span class="casTitleNuber">123b</span><div class="casTitle"><span class="NLM_cas:atitle">Superoxide radicals increase transforming growth factor-β1 and collagen release from human lung fibroblasts via cellular influx through chloride channels</span></div><div class="casAuthors">Qi, Shufan; den Hartog, Gertjan J. M.; Bast, Aalt</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Reactive oxygen species (ROS) have been implicated in the pathogenesis of fibrosis.  However, it remains unclear which ROS is the major cause.  We hypothesize that superoxide elicits specific toxicity to human lung fibroblasts and plays an important role in the development of pulmonary fibrosis.  In this study, superoxide generated from xanthine and xanthine oxidase activated lung fibroblasts by increasing the release of TGF-β1 and collagen.  This was assocd. with increased levels of intracellular superoxide.  SOD and tempol, by scavenging resp. extracellular and intracellular superoxide, prevented the activation of fibroblasts induced by exposure to exogenous superoxide, whereas catalase did not.  Moreover, hydrogen peroxide did not activate fibroblasts.  Apparently, superoxide rather than hydrogen peroxide is involved in the regulation of TGF-β1 and collagen release in lung fibroblasts.  The chloride channel blocker, DIDS, inhibited the increase of intracellular superoxide levels induced by exogenous superoxide and consequently prevented the activation of fibroblasts.  This suggests that the cellular influx of superoxide through chloride channels is essential for superoxide-induced activation of fibroblasts.  ERK1/2 and p38 MAPKs are involved in the intracellular pathway leading to superoxide-induced fibroblasts activation.  Superoxide possesses until now undiscovered specific pro-fibrotic properties in human lung fibroblasts.  This takes place via the cellular influx of superoxide through chloride channels rather than via the formation of hydrogen peroxide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHtiBrV1pMLVg90H21EOLACvtfcHk0ljQwv-ed0vkew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Grtbk%253D&md5=d4d32ee5e40169e385f2397fa19078c5</span></div><a href="/servlet/linkout?suffix=cit123b&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2009.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2009.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DS.%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DBast%26aufirst%3DA.%26atitle%3DSuperoxide%2520radicals%2520increase%2520transforming%2520growth%2520factor-beta1%2520and%2520collagen%2520release%2520from%2520human%2520lung%2520fibroblasts%2520via%2520cellular%2520influx%2520through%2520chloride%2520channels%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2009%26volume%3D237%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.taap.2009.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kaminskyy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subtel’na, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimenkovsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gzella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesyk, R.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2(5<i>H</i>)-one derivatives</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">530</span><span class="refDoi"> DOI: 10.2174/1573406411666150211112049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F1573406411666150211112049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25669320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OmsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=517-530&author=D.+Kaminskyyauthor=I.+Subtel%E2%80%99naauthor=B.+Zimenkovskyauthor=O.+Karpenkoauthor=A.+Gzellaauthor=R.+Lesyk&title=Synthesis+and+evaluation+of+anticancer+activity+of+5-ylidene-4-aminothiazol-2%285H%29-one+derivatives&doi=10.2174%2F1573406411666150211112049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124aR"><div class="casContent"><span class="casTitleNuber">124a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Anticancer Activity of 5-Ylidene-4- Aminothiazol-2(5H)-one Derivatives</span></div><div class="casAuthors">Kaminskyy, Danylo; Subtel'na, Ivanna; Zimenkovsky, Borys; Karpenko, Olexandr; Gzella, Andrzej; Lesyk, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">517-530</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The synthesis and antitumor activity screening of 4-aminothiazol-2(5H)-one derivs. were performed.  The absence of possible 4-amino-imino tautomerism of thiazolidinones-2 has been confirmed based on the study of the mol. structures.  The existence of the alone amino-form was confirmed.  An anticancer activity screening was performed within the Developmental Therapeutics Program (National Cancer Institute/NIH, USA).  Tested compds. possess low to moderate anticancer activity (av. values - 60 cancer cell lines assay) with significant selective action on certain cancer cell lines (CCRF-CEM and RPMI-8226/leukemia, U251/CNS cancer, RFX 393/renal cancer, OVCAR/ovarian cancer etc.).  The advantage of 5-ylidene-4-R-amino derivs. in comparison with compds. with free amino group was shown.  Some structure-activity findings, the comparison of target compds. with isomeric 5-ylidene-2-imino(amino)thiazol-4(5H)-ones, as well as COMPARE anal. were described.  Among the tested compds. (Z)-5-(furan-2-ylmethylidene)-4-(4-chlorophenylamino)thiazol-2(5H)-one (IIIk) and (Z)-5-(4-diethylaminophenylmethylidene)-4-(4-hydroxy-5-isopropyl-2-methylphenylamino)thiazol-2(5H)-one (IIIp) possessed the highest levels of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolfT0YO0xtcrVg90H21EOLACvtfcHk0ljQwv-ed0vkew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OmsLvJ&md5=413ccbe723aa8cb74cb3e5aa9f385e37</span></div><a href="/servlet/linkout?suffix=cit124a&amp;dbid=16384&amp;doi=10.2174%2F1573406411666150211112049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406411666150211112049%26sid%3Dliteratum%253Aachs%26aulast%3DKaminskyy%26aufirst%3DD.%26aulast%3DSubtel%25E2%2580%2599na%26aufirst%3DI.%26aulast%3DZimenkovsky%26aufirst%3DB.%26aulast%3DKarpenko%26aufirst%3DO.%26aulast%3DGzella%26aufirst%3DA.%26aulast%3DLesyk%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520anticancer%2520activity%2520of%25205-ylidene-4-aminothiazol-2%25285H%2529-one%2520derivatives%26jtitle%3DMed.%2520Chem.%26date%3D2015%26volume%3D11%26spage%3D517%26epage%3D530%26doi%3D10.2174%2F1573406411666150211112049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit124b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124bR"><div class="casContent"><span class="casTitleNuber">124b</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0liz9awfhlEHDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit124b&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit124c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mendgen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steuer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C. D.</span><span> </span><span class="NLM_article-title">Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">743</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1021/jm201243p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201243p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=743-753&author=T.+Mendgenauthor=C.+Steuerauthor=C.+D.+Klein&title=Privileged+scaffolds+or+promiscuous+binders%3A+a+comparative+study+on+rhodanines+and+related+heterocycles+in+medicinal+chemistry&doi=10.1021%2Fjm201243p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124cR"><div class="casContent"><span class="casTitleNuber">124c</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry</span></div><div class="casAuthors">Mendgen, Thomas; Steuer, Christian; Klein, Christian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">743-753</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rhodanines and related five-membered heterocycles with multiple heteroatoms have recently gained a reputation of being unselective compds. that appear as "frequent hitters" in screening campaigns and therefore have little value in drug discovery.  However, this judgment appears to be based mostly on anecdotal evidence.  Having identified various rhodanines and related compds. in screening campaigns, we decided to perform a systematic study on their promiscuity.  An amt. of 163 rhodanines, hydantoins, thiohydantoins, and thiazolidinediones were synthesized and tested against several targets.  The compds. were also characterized with respect to aggregation and electrophilic reactivity, and the binding modes of rhodanines and related compds. in published x-ray cocrystal structures were analyzed.  The results indicate that the exocyclic, double bonded sulfur atom in rhodanines and thiohydantoins, in addn. to other structural features, offers a particularly high d. of interaction sites for polar interactions and hydrogen bonds.  This causes a promiscuous behavior at concns. in the "screening range" but should not be regarded as a general knockout criterion that excludes such screening hits from further development.  It is suggested that special criteria for target affinity and selectivity are applied to these classes of compds. and that their exceptional and potentially valuable biomol. binding properties are consequently exploited in a useful way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzna8Pcz1iLVg90H21EOLACvtfcHk0liz9awfhlEHDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN&md5=6a94d097f44bdbaaec9a56fd6b371521</span></div><a href="/servlet/linkout?suffix=cit124c&amp;dbid=16384&amp;doi=10.1021%2Fjm201243p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201243p%26sid%3Dliteratum%253Aachs%26aulast%3DMendgen%26aufirst%3DT.%26aulast%3DSteuer%26aufirst%3DC.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26atitle%3DPrivileged%2520scaffolds%2520or%2520promiscuous%2520binders%253A%2520a%2520comparative%2520study%2520on%2520rhodanines%2520and%2520related%2520heterocycles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D743%26epage%3D753%26doi%3D10.1021%2Fjm201243p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit124d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span> </span><span class="NLM_article-title">A decade of fragment-based drug design: strategic advances and lessons learned</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1038/nrd2220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd2220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17290284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit12rtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=211-219&author=P.+J.+Hajdukauthor=J.+Greer&title=A+decade+of+fragment-based+drug+design%3A+strategic+advances+and+lessons+learned&doi=10.1038%2Fnrd2220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124dR"><div class="casContent"><span class="casTitleNuber">124d</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of fragment-based drug design: strategic advances and lessons learned</span></div><div class="casAuthors">Hajduk, Philip J.; Greer, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the early 1990s, several technol. and scientific advances - such as combinatorial chem., high-throughput screening and the sequencing of the human genome - have been heralded as remedies to the problems facing the pharmaceutical industry.  The use of these technologies in some form is now well established at most pharmaceutical companies; however, the return on investment in terms of marketed products has not met expectations.  Fragment-based drug design is another tool for drug discovery that has emerged in the past decade.  Here, we describe the development and evolution of fragment-based drug design, analyze the role that this approach can have in combination with other discovery technologies and highlight the impact that fragment-based methods have made in progressing new medicines into the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB8K3AESqTbVg90H21EOLACvtfcHk0ljepuOKll0IUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit12rtr4%253D&md5=bae574da3671475d8488615c3bfa9849</span></div><a href="/servlet/linkout?suffix=cit124d&amp;dbid=16384&amp;doi=10.1038%2Fnrd2220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2220%26sid%3Dliteratum%253Aachs%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%26atitle%3DA%2520decade%2520of%2520fragment-based%2520drug%2520design%253A%2520strategic%2520advances%2520and%2520lessons%2520learned%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D211%26epage%3D219%26doi%3D10.1038%2Fnrd2220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit124e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Forman, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ursini, F.</span><span> </span><span class="NLM_article-title">How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo</span> <span class="citation_source-journal">Free Radical Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2013.05.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.freeradbiomed.2013.05.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23747930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCgtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=24-35&author=H.+J.+Formanauthor=K.+J.+Daviesauthor=F.+Ursini&title=How+do+nutritional+antioxidants+really+work%3A+nucleophilic+tone+and+para-hormesis+versus+free+radical+scavenging+in+vivo&doi=10.1016%2Fj.freeradbiomed.2013.05.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124eR"><div class="casContent"><span class="casTitleNuber">124e</span><div class="casTitle"><span class="NLM_cas:atitle">How do nutritional antioxidants really work: Nucleophilic tone and para-hormesis versus free radical scavenging in vivo</span></div><div class="casAuthors">Forman, Henry J.; Davies, Kelvin J. A.; Ursini, Fulvio</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-35</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  We present arguments for an evolution in our understanding of how antioxidants in fruits and vegetables exert their health-protective effects.  There is much epidemiol. evidence for disease prevention by dietary antioxidants and chem. evidence that such compds. react in one-electron reactions with free radicals in vitro.  Nonetheless, kinetic constraints indicate that in vivo scavenging of radicals is ineffective in antioxidant defense.  Instead, enzymic removal of nonradical electrophiles, such as hydroperoxides, in two-electron redox reactions is the major antioxidant mechanism.  Furthermore, we propose that a major mechanism of action for nutritional antioxidants is the paradoxical oxidative activation of the Nrf2 (NF-E2-related factor 2) signaling pathway, which maintains protective oxidoreductases and their nucleophilic substrates.  This maintenance of "nucleophilic tone," by a mechanism that can be called "para-hormesis," provides a means for regulating physiol. nontoxic concns. of the nonradical oxidant electrophiles that boost antioxidant enzymes, and damage removal and repair systems (for proteins, lipids, and DNA), at the optimal levels consistent with good health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvuNaIhdw4WrVg90H21EOLACvtfcHk0ljcUr9f7yTMww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCgtrfN&md5=3731cb7e45d0f9d6744b6c4a26ab7792</span></div><a href="/servlet/linkout?suffix=cit124e&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2013.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2013.05.045%26sid%3Dliteratum%253Aachs%26aulast%3DForman%26aufirst%3DH.%2BJ.%26aulast%3DDavies%26aufirst%3DK.%2BJ.%26aulast%3DUrsini%26aufirst%3DF.%26atitle%3DHow%2520do%2520nutritional%2520antioxidants%2520really%2520work%253A%2520nucleophilic%2520tone%2520and%2520para-hormesis%2520versus%2520free%2520radical%2520scavenging%2520in%2520vivo%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2014%26volume%3D66%26spage%3D24%26epage%3D35%26doi%3D10.1016%2Fj.freeradbiomed.2013.05.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Kaminskyy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojtyra, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelyukh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gzella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesyk, R.</span><span> </span><span class="NLM_article-title">Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ejmech.2016.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26896707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislyqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2016&pages=180-195&author=D.+Kaminskyyauthor=G.+J.+den+Hartogauthor=M.+Wojtyraauthor=M.+Lelyukhauthor=A.+Gzellaauthor=A.+Bastauthor=R.+Lesyk&title=Antifibrotic+and+anticancer+action+of+5-ene+amino%2Fiminothiazolidinones&doi=10.1016%2Fj.ejmech.2016.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones</span></div><div class="casAuthors">Kaminskyy, Danylo; den Hartog, Gertjan J. M.; Wojtyra, Magdalena; Lelyukh, Maryan; Gzella, Andrzej; Bast, Aalt; Lesyk, Roman</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180-195</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Here we describe the synthesis and the antifibrotic and anticancer activity detn. of amino(imino)thiazolidinone derivs.  An efficient one-pot three-component reaction which involved [2 + 3]-cyclocondensation and Knoevenagel condensation was used for the synthesis of 5-ene-2-amino(imino)-4-thiazolidinones.  Following amino-imino tautomerism, the compd. structures were confirmed by X-ray anal.  Comparison of SRB assays on fibroblasts and cancer cells revealed that compds. which significantly reduced the viability of fibroblasts did not possess an anticancer effect.  A series of thiazolidinone derivs. as interesting candidates for further testing has been identified.  Among the tested compds. 2-{3-furan-2-ylmethyl-2-[(2-methyl-3-phenylallylidene)hydrazono]-thiazolidin-4-one-5-yl}-N-(3-trifluoromethylphenyl)-acetamide, N-(2-methoxyphenyl)-2-[5-(4-oxothiazolidin-2-ylideneamino)-[1,3,4]thiadiazol-2-ylsulfanyl]-acetamide, 3-[3-allyl-4-oxo-2-(thiazol-2-ylimino)thiazolidin-5-ylidene]-1,3-dihydroindol-2-one, and 5(Z)-(thiophen-2-ylmethylene)-4-(4-chlorophenylamino)thiazol-2(5H)-one possessed high antifibrotic activity levels, had a similar effect as Pirfenidone, and did not scavenge superoxide radicals.  Their antifibrotic potential was confirmed using the xCelligence system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn9EH9so_baLVg90H21EOLACvtfcHk0lh6Z6QotNV0og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislyqsbo%253D&md5=ec9388a3e08c29a5ae23375b7aca275c</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DKaminskyy%26aufirst%3DD.%26aulast%3Dden%2BHartog%26aufirst%3DG.%2BJ.%26aulast%3DWojtyra%26aufirst%3DM.%26aulast%3DLelyukh%26aufirst%3DM.%26aulast%3DGzella%26aufirst%3DA.%26aulast%3DBast%26aufirst%3DA.%26aulast%3DLesyk%26aufirst%3DR.%26atitle%3DAntifibrotic%2520and%2520anticancer%2520action%2520of%25205-ene%2520amino%252Fiminothiazolidinones%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D112%26spage%3D180%26epage%3D195%26doi%3D10.1016%2Fj.ejmech.2016.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parrill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span> </span><span class="NLM_article-title">Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1625</span><span class="refDoi"> DOI: 10.1517/13543776.2010.533658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F13543776.2010.533658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21047298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1619-1625&author=A.+L.+Parrillauthor=D.+L.+Baker&title=Autotaxin+inhibitors%3A+a+perspective+on+initial+medicinal+chemistry+efforts&doi=10.1517%2F13543776.2010.533658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126aR"><div class="casContent"><span class="casTitleNuber">126a</span><div class="casTitle"><span class="NLM_cas:atitle">Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts</span></div><div class="casAuthors">Parrill, Abby L.; Baker, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1619-1625</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The lysophospholipase D enzyme, autotaxin (ATX), has been linked to numerous human diseases including cancer, neurophatic pain, obesity and Alzheimer's disease.  Although the ATX protein was initially purified and characterized in 1992, a link to bioactive lipid metab. was not made until 2002.  In the past decade, metal chelators, lysophospholipid product analogs, and more recently, small non-lipid inhibitors of the enzyme were successfully identified.  The majority of these inhibitors have been characterized using recombinant purified ATX in vitro, with very few examples studied in more complex systems.  Translation of ATX inhibitors from the hands of medicinal chemists to clin. use will require substantially expanded characterization of ATX inhibitors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWuFyKHNmQC7Vg90H21EOLACvtfcHk0lh6Z6QotNV0og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7fN&md5=5aed6b92b1ccd459bfe0546e282c2d9d</span></div><a href="/servlet/linkout?suffix=cit126a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.533658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.533658%26sid%3Dliteratum%253Aachs%26aulast%3DParrill%26aufirst%3DA.%2BL.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26atitle%3DAutotaxin%2520inhibitors%253A%2520a%2520perspective%2520on%2520initial%2520medicinal%2520chemistry%2520efforts%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D1619%26epage%3D1625%26doi%3D10.1517%2F13543776.2010.533658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span> </span><span class="NLM_article-title">Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance</span> <span class="citation_source-journal">Prostaglandins Other Lipid Mediators</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1016/j.prostaglandins.2009.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.prostaglandins.2009.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20331961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslSiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2010&pages=130-138&author=M.+E.+Linauthor=D.+R.+Herrauthor=J.+Chun&title=Lysophosphatidic+acid+%28LPA%29+receptors%3A+signaling+properties+and+disease+relevance&doi=10.1016%2Fj.prostaglandins.2009.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126bR"><div class="casContent"><span class="casTitleNuber">126b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance</span></div><div class="casAuthors">Lin, Mu-En; Herr, Deron R.; Chun, Jerold</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins & Other Lipid Mediators</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">POLMFL</span>;
        ISSN:<span class="NLM_cas:issn">1098-8823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Lysophosphatidic acid (LPA), a water-sol. phospholipid, has gained significant attention in recent years since the discovery that it acts as a potent signaling mol. with wide-ranging effects on many different target tissues.  There are currently five identified G protein-coupled receptors for LPA and more are undergoing validation.  The complexity of the expression pattern and signaling properties of LPA receptors results in multiple influences on developmental, physiol., and pathol. processes.  This review provides a summary of LPA receptor signaling and current views on the potential involvement of this pathway in human diseases that include cardiovascular, cancer, neuropathic pain, neuropsychiatric disorders, reproductive disorders, and fibrosis.  The involvement of LPA signaling in these processes implicates multiple, potential drug targets including LPA receptor subtypes and LPA metabolizing enzymes.  Modulation of LPA signaling may thus provide therapeutic inroads for the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqIqNSV9ngb7Vg90H21EOLACvtfcHk0lh6Z6QotNV0og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslSiu7k%253D&md5=097555859468db9673c1ccf9ea8c2a60</span></div><a href="/servlet/linkout?suffix=cit126b&amp;dbid=16384&amp;doi=10.1016%2Fj.prostaglandins.2009.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prostaglandins.2009.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DM.%2BE.%26aulast%3DHerr%26aufirst%3DD.%2BR.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DLysophosphatidic%2520acid%2520%2528LPA%2529%2520receptors%253A%2520signaling%2520properties%2520and%2520disease%2520relevance%26jtitle%3DProstaglandins%2520Other%2520Lipid%2520Mediators%26date%3D2010%26volume%3D91%26spage%3D130%26epage%3D138%26doi%3D10.1016%2Fj.prostaglandins.2009.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Tager, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCamera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campanella, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polosukhin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karimi-Shah, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1038/nm1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18066075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=45-54&author=A.+M.+Tagerauthor=P.+LaCameraauthor=B.+S.+Sheaauthor=G.+S.+Campanellaauthor=M.+Selmanauthor=Z.+Zhaoauthor=V.+Polosukhinauthor=J.+Wainauthor=B.+A.+Karimi-Shahauthor=N.+D.+Kimauthor=W.+K.+Hartauthor=A.+Pardoauthor=T.+S.+Blackwellauthor=Y.+Xuauthor=J.+Chunauthor=A.+D.+Luster&title=The+lysophosphatidic+acid+receptor+LPA1+links+pulmonary+fibrosis+to+lung+injury+by+mediating+fibroblast+recruitment+and+vascular+leak&doi=10.1038%2Fnm1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span></div><div class="casAuthors">Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Selman, Moises; Zhao, Zhenwen; Polosukhin, Vasiliy; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Pardo, Annie; Blackwell, Timothy S.; Xu, Yan; Chun, Jerold; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathol. responses have yet to be fully identified.  We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model.  The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury.  In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid.  LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pk5JY4qBbLVg90H21EOLACvtfcHk0li7_xx9JltEhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D&md5=1a7e86264154df8960699d18a7ef2407</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fnm1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1685%26sid%3Dliteratum%253Aachs%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DLaCamera%26aufirst%3DP.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DCampanella%26aufirst%3DG.%2BS.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolosukhin%26aufirst%3DV.%26aulast%3DWain%26aufirst%3DJ.%26aulast%3DKarimi-Shah%26aufirst%3DB.%2BA.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DHart%26aufirst%3DW.%2BK.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DBlackwell%26aufirst%3DT.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520links%2520pulmonary%2520fibrosis%2520to%2520lung%2520injury%2520by%2520mediating%2520fibroblast%2520recruitment%2520and%2520vascular%2520leak%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnm1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ohta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damirin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malchinkhuu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishitoba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nochi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okajima, F.</span><span> </span><span class="NLM_article-title">Ki16425, a subtypeselective antagonist for EDG-family lysophosphatidic acid receptors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">994</span><span class="NLM_x">–</span> <span class="NLM_lpage">1005</span><span class="refDoi"> DOI: 10.1124/mol.64.4.994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1124%2Fmol.64.4.994" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=994-1005&author=H.+Ohtaauthor=K.+Satoauthor=N.+Murataauthor=A.+Damirinauthor=E.+Malchinkhuuauthor=J.+Konauthor=T.+Kimuraauthor=M.+Toboauthor=Y.+Yamazakiauthor=T.+Watanabeauthor=M.+Yagiauthor=M.+Satoauthor=R.+Suzukiauthor=H.+Murookaauthor=T.+Sakaiauthor=T.+Nishitobaauthor=D.+S.+Imauthor=H.+Nochiauthor=K.+Tamotoauthor=H.+Tomuraauthor=F.+Okajima&title=Ki16425%2C+a+subtypeselective+antagonist+for+EDG-family+lysophosphatidic+acid+receptors&doi=10.1124%2Fmol.64.4.994"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1124%2Fmol.64.4.994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.64.4.994%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DN.%26aulast%3DDamirin%26aufirst%3DA.%26aulast%3DMalchinkhuu%26aufirst%3DE.%26aulast%3DKon%26aufirst%3DJ.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DTobo%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DYagi%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DNishitoba%26aufirst%3DT.%26aulast%3DIm%26aufirst%3DD.%2BS.%26aulast%3DNochi%26aufirst%3DH.%26aulast%3DTamoto%26aufirst%3DK.%26aulast%3DTomura%26aufirst%3DH.%26aulast%3DOkajima%26aufirst%3DF.%26atitle%3DKi16425%252C%2520a%2520subtypeselective%2520antagonist%2520for%2520EDG-family%2520lysophosphatidic%2520acid%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D64%26spage%3D994%26epage%3D1005%26doi%3D10.1124%2Fmol.64.4.994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stebbins, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundey, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodanovich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span> </span><span class="NLM_article-title">A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1699</span><span class="NLM_x">–</span> <span class="NLM_lpage">1713</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00828.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1111%2Fj.1476-5381.2010.00828.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20649573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1699-1713&author=J.+S.+Swaneyauthor=C.+Chapmanauthor=L.+D.+Correaauthor=K.+J.+Stebbinsauthor=R.+A.+Bundeyauthor=P.+C.+Prodanovichauthor=P.+Faganauthor=C.+S.+Bacceiauthor=A.+M.+Santiniauthor=J.+H.+Hutchinsonauthor=T.+J.+Seidersauthor=T.+A.+Parrauthor=P.+Prasitauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=A+novel%2C+orally+active+LPA%281%29+receptor+antagonist+inhibits+lung+fibrosis+in+the+mouse+bleomycin+model&doi=10.1111%2Fj.1476-5381.2010.00828.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128bR"><div class="casContent"><span class="casTitleNuber">128b</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model</span></div><div class="casAuthors">Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Bundey, R. A.; Prodanovich, P. C.; Fagan, P.; Baccei, C. S.; Santini, A. M.; Hutchinson, J. H.; Seiders, T. J.; Parr, T. A.; Prasit, P.; Evans, J. F.; Lorrain, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699-1713</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to assess the potential of an antagonist selective for the lysophosphatidic acid receptor, LPA1, in treating lung fibrosis.  We evaluated the in vitro and in vivo pharmacol. properties of the high affinity, selective, oral LPA1-antagonist (4'-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (AM966).  The potency and selectivity of AM966 for LPA1 receptors was detd. in vitro by calcium flux and cell chemotaxis assays using recombinant and native cell cultures.  The in vivo efficacy of AM966 to reduce tissue injury, vascular leakage, inflammation and fibrosis was assessed at several time points in the mouse bleomycin model.  AM966 was a potent antagonist of LPA1 receptors, with selectivity for this receptor over the other LPA receptors.  In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC50 = 17 nM) from Chinese hamster ovary cells stably expressing human LPA1 receptors and inhibited LPA-induced chemotaxis (IC50 = 181 nM) of human IMR-90 lung fibroblasts expressing LPA1 receptors.  AM966 demonstrated a good pharmacokinetic profile following oral dosing in mice.  In the mouse, AM966 reduced lung injury, vascular leakage, inflammation and fibrosis at multiple time points following intratracheal bleomycin instillation.  AM966 also decreased lactate dehydrogenase activity and tissue inhibitor of metalloproteinase-1, transforming growth factor β1, hyaluronan and matrix metalloproteinase-7, in bronchoalveolar lavage fluid.  These findings demonstrate that AM966 is a potent, selective, orally bioavailable LPA1 receptor antagonist that may be beneficial in treating lung injury and fibrosis, as well as other diseases that are characterized by pathol. inflammation, edema and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0rImMbkAWbVg90H21EOLACvtfcHk0lhsSgpEKFaoLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlejsbzJ&md5=73f26734408141d8b0350d7488b54a6c</span></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00828.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00828.x%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBundey%26aufirst%3DR.%2BA.%26aulast%3DProdanovich%26aufirst%3DP.%2BC.%26aulast%3DFagan%26aufirst%3DP.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DSeiders%26aufirst%3DT.%2BJ.%26aulast%3DParr%26aufirst%3DT.%2BA.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DA%2520novel%252C%2520orally%2520active%2520LPA%25281%2529%2520receptor%2520antagonist%2520inhibits%2520lung%2520fibrosis%2520in%2520the%2520mouse%2520bleomycin%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1699%26epage%3D1713%26doi%3D10.1111%2Fj.1476-5381.2010.00828.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit128c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stebbins, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadhead, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darlington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccei, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roppe, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1124/jpet.110.175901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1124%2Fjpet.110.175901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21159750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVKqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=693-700&author=J.+S.+Swaneyauthor=C.+Chapmanauthor=L.+D.+Correaauthor=K.+J.+Stebbinsauthor=A.+R.+Broadheadauthor=G.+Bainauthor=A.+M.+Santiniauthor=J.+Darlingtonauthor=C.+D.+Kingauthor=C.+S.+Bacceiauthor=C.+Leeauthor=T.+A.+Parrauthor=J.+R.+Roppeauthor=T.+J.+Seidersauthor=J.+Ziffauthor=P.+Prasitauthor=J.+H.+Hutchinsonauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=Pharmacokinetic+and+pharmacodynamic+characterization+of+an+oral+lysophosphatidic+acid+type+1+receptor-selective+antagonist&doi=10.1124%2Fjpet.110.175901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128cR"><div class="casContent"><span class="casTitleNuber">128c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist</span></div><div class="casAuthors">Swaney, J. S.; Chapman, C.; Correa, L. D.; Stebbins, K. J.; Broadhead, A. R.; Bain, G.; Santini, A. M.; Darlington, J.; King, C. D.; Baccei, C. S.; Lee, C.; Parr, T. A.; Roppe, J. R.; Seiders, T. J.; Ziff, J.; Prasit, P.; Hutchinson, J. H.; Evans, J. F.; Lorrain, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-700</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lysophosphatidic acid (LPA) is a bioactive phospholipid that signals through a family of at least six G protein-coupled receptors designated LPA1-6.  LPA type 1 receptor (LPA1) exhibits wide-spread tissue distribution and regulates a variety of physiol. and pathol. cellular functions.  Here, we evaluated the in vitro pharmacol., pharmacokinetic, and pharmacodynamic properties of the LPA1-selective antagonist AM095 (sodium, {4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetate) and assessed the effects of AM095 in rodent models of lung and kidney fibrosis and dermal wound healing.  In vitro, AM095 was a potent LPA1 receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 μM, resp., and exhibited no LPA1 agonism.  In functional assays, AM095 inhibited LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 (IC50 = 778 nM) and human A2058 melanoma cells (IC50 = 233 nM).  In vivo, we demonstrated that AM095: (1) had high oral bioavailability and a moderate half-life and was well tolerated at the doses tested in rats and dogs after oral and i.v. dosing, (2) dose-dependently reduced LPA-stimulated histamine release, (3) attenuated bleomycin-induced increases in collagen, protein, and inflammatory cell infiltration in bronchalveolar lavage fluid, and (4) decreased kidney fibrosis in a mouse unilateral ureteral obstruction model.  Despite its antifibrotic activity, AM095 had no effect on normal wound healing after incisional and excisional wounding in rats.  These data demonstrate that AM095 is an LPA1 receptor antagonist with good oral exposure and antifibrotic activity in rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYo8MBYXos7Vg90H21EOLACvtfcHk0lhsSgpEKFaoLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVKqtr4%253D&md5=72388f534912ad0e440a6fff949d7710</span></div><a href="/servlet/linkout?suffix=cit128c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.175901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.175901%26sid%3Dliteratum%253Aachs%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DCorrea%26aufirst%3DL.%2BD.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBroadhead%26aufirst%3DA.%2BR.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DParr%26aufirst%3DT.%2BA.%26aulast%3DRoppe%26aufirst%3DJ.%2BR.%26aulast%3DSeiders%26aufirst%3DT.%2BJ.%26aulast%3DZiff%26aufirst%3DJ.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520characterization%2520of%2520an%2520oral%2520lysophosphatidic%2520acid%2520type%25201%2520receptor-selective%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D693%26epage%3D700%26doi%3D10.1124%2Fjpet.110.175901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit128d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Castelino, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaney, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorrain, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luster, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span> </span><span class="NLM_article-title">Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1002/art.30262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fart.30262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21305523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltlGhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=1405-1415&author=F.+V.+Castelinoauthor=J.+Seidersauthor=G.+Bainauthor=S.+F.+Brooksauthor=C.+D.+Kingauthor=J.+S.+Swaneyauthor=D.+S.+Lorrainauthor=J.+Chunauthor=A.+D.+Lusterauthor=A.+M.+Tager&title=Amelioration+of+dermal+fibrosis+by+genetic+deletion+or+pharmacologic+antagonism+of+lysophosphatidic+acid+receptor+1+in+a+mouse+model+of+scleroderma&doi=10.1002%2Fart.30262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128dR"><div class="casContent"><span class="casTitleNuber">128d</span><div class="casTitle"><span class="NLM_cas:atitle">Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma</span></div><div class="casAuthors">Castelino, Flavia V.; Seiders, Jon; Bain, Gretchen; Brooks, Sarah F.; King, Christopher D.; Swaney, James S.; Lorrain, Daniel S.; Chun, Jerold; Luster, Andrew D.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1405-1415</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Scleroderma (systemic sclerosis [SSc]), is characterized by progressive multiorgan fibrosis.  We recently implicated lysophosphatidic acid (LPA) in the pathogenesis of pulmonary fibrosis.  The purpose of the present study was to investigate the roles of LPA and two of its receptors, LPA1 and LPA2, in dermal fibrosis in a mouse model of SSc.  Methods : Wild type (WT), and LPA1-knockout (KO) and LPA2-KO mice were injected s.c. with bleomycin or phosphate buffered saline (PBS) once daily for 28 days.  Dermal thickness, collagen content, and nos. of cells pos. for α-smooth muscle actin (α-SMA) or phospho-Smad2 were detd. in bleomycin-injected and PBS-injected skin.  In sep. expts., a novel selective LPA1 antagonist AM095 or vehicle alone was administered by oral gavage to C57BL/6 mice that were challenged with 28 daily injections of bleomycin or PBS.  AM095 or vehicle treatments were initiated concurrently with, or 7 or 14 days after, the initiation of bleomycin and PBS injections and continued to the end of the expts.  Dermal thickness and collagen content were detd. in injected skin.  Results : The LPA1-KO mice were markedly resistant to bleomycin-induced increases in dermal thickness and collagen content, whereas the LPA2-KO mice were as susceptible as the WT mice.  Bleomycin-induced increases in dermal α-SMA+ and phospho-Smad2+ cells were abrogated in LPA1-KO mice.  Pharmacol. antagonism of LPA1 with AM095 significantly attenuated bleomycin-induced dermal fibrosis when administered according to either a preventive regimen or two therapeutic regimens.  Conclusion : These results suggest that LPA/LPA1 pathway inhibition has the potential to be an effective new therapeutic strategy for SSc, and that LPA1 is an attractive pharmacol. target in dermal fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR6SISG5m67LVg90H21EOLACvtfcHk0ljyFke20Id8Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltlGhtrY%253D&md5=a13b1f9f7826b3075728ed13e533102c</span></div><a href="/servlet/linkout?suffix=cit128d&amp;dbid=16384&amp;doi=10.1002%2Fart.30262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.30262%26sid%3Dliteratum%253Aachs%26aulast%3DCastelino%26aufirst%3DF.%2BV.%26aulast%3DSeiders%26aufirst%3DJ.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DBrooks%26aufirst%3DS.%2BF.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DSwaney%26aufirst%3DJ.%2BS.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26aulast%3DTager%26aufirst%3DA.%2BM.%26atitle%3DAmelioration%2520of%2520dermal%2520fibrosis%2520by%2520genetic%2520deletion%2520or%2520pharmacologic%2520antagonism%2520of%2520lysophosphatidic%2520acid%2520receptor%25201%2520in%2520a%2520mouse%2520model%2520of%2520scleroderma%26jtitle%3DArthritis%2520Rheum.%26date%3D2011%26volume%3D63%26spage%3D1405%26epage%3D1415%26doi%3D10.1002%2Fart.30262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidduri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span> </span><span class="NLM_article-title">Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7920</span><span class="NLM_x">–</span> <span class="NLM_lpage">7939</span><span class="refDoi"> DOI: 10.1021/jm301022v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301022v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7920-7939&author=Y.+Qianauthor=M.+Hamiltonauthor=A.+Sidduriauthor=S.+Gabrielauthor=Y.+Renauthor=R.+Pengauthor=R.+Kondruauthor=A.+Narayananauthor=T.+Truittauthor=R.+Hamidauthor=Y.+Chenauthor=L.+Zhangauthor=A.+J.+Fretlandauthor=R.+A.+Sanchezauthor=K.+C.+Changauthor=M.+Lucasauthor=R.+C.+Schoenfeldauthor=D.+Laineauthor=M.+E.+Fuentesauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Discovery+of+highly+selective+and+orally+active+lysophosphatidic+acid+receptor-1+antagonists+with+potent+activity+on+human+lung+fibroblasts&doi=10.1021%2Fjm301022v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm301022v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301022v%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DHamid%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFretland%26aufirst%3DA.%2BJ.%26aulast%3DSanchez%26aufirst%3DR.%2BA.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DLaine%26aufirst%3DD.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DDiscovery%2520of%2520highly%2520selective%2520and%2520orally%2520active%2520lysophosphatidic%2520acid%2520receptor-1%2520antagonists%2520with%2520potent%2520activity%2520on%2520human%2520lung%2520fibroblasts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7920%26epage%3D7939%26doi%3D10.1021%2Fjm301022v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rancoule, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradere, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bascands, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schanstra, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier-Blache, J. S.</span><span> </span><span class="NLM_article-title">Lysophosphatidic acid-1-receptor targeting agents for fibrosis</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1517/13543784.2011.566864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F13543784.2011.566864" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=657-667&author=C.+Rancouleauthor=J.+P.+Pradereauthor=J.+Gonzalezauthor=J.+Kleinauthor=P.+Valetauthor=J.+L.+Bascandsauthor=J.+P.+Schanstraauthor=J.+S.+Saulnier-Blache&title=Lysophosphatidic+acid-1-receptor+targeting+agents+for+fibrosis&doi=10.1517%2F13543784.2011.566864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.566864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.566864%26sid%3Dliteratum%253Aachs%26aulast%3DRancoule%26aufirst%3DC.%26aulast%3DPradere%26aufirst%3DJ.%2BP.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DKlein%26aufirst%3DJ.%26aulast%3DValet%26aufirst%3DP.%26aulast%3DBascands%26aufirst%3DJ.%2BL.%26aulast%3DSchanstra%26aufirst%3DJ.%2BP.%26aulast%3DSaulnier-Blache%26aufirst%3DJ.%2BS.%26atitle%3DLysophosphatidic%2520acid-1-receptor%2520targeting%2520agents%2520for%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D657%26epage%3D667%26doi%3D10.1517%2F13543784.2011.566864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit130b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Budd, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span> </span><span class="NLM_article-title">Development of lysophosphatidic acid pathway modulators as therapies for fibrosis</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1935</span><span class="NLM_x">–</span> <span class="NLM_lpage">1952</span><span class="refDoi"> DOI: 10.4155/fmc.13.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4155%2Ffmc.13.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24175745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislynsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1935-1952&author=D.+C.+Buddauthor=Y.+Qian&title=Development+of+lysophosphatidic+acid+pathway+modulators+as+therapies+for+fibrosis&doi=10.4155%2Ffmc.13.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130bR"><div class="casContent"><span class="casTitleNuber">130b</span><div class="casTitle"><span class="NLM_cas:atitle">Development of lysophosphatidic acid pathway modulators as therapies for fibrosis</span></div><div class="casAuthors">Budd, David C.; Qian, Yimin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1935-1952</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Lysophosphatidic acid (LPA) is a class of bioactive phospholipid that displays a wide range of cellular effects via LPA receptors, of which six have been identified (LPAR1-6).  In serum and plasma, LPA prodn. occurs mainly by the hydrolysis of lysophosphatidylcholine by the phospholipase D activity of autotaxin (ATX).  The involvement of the LPA pathway in driving chronic wound-healing conditions, such as idiopathic pulmonary fibrosis, has suggested targets in this pathway could provide potential therapeutic approaches.  Mice with LPAR1 knockout or tissue-specific ATX deletion have demonstrated reduced lung fibrosis following bleomycin challenge.  Therefore, strategies aimed at antagonizing LPA receptors or inhibiting ATX have gained considerable attention.  This Review will summarize the current status of identifying small-mol. modulators of the LPA pathway.  The therapeutic utility of LPA modulators for the treatment of fibrotic diseases will soon be revealed as clin. trials are already in progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Jpew1zYC8rVg90H21EOLACvtfcHk0lgBO6WKNzc53w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislynsg%253D%253D&md5=ee2db60359f2a0217de52a3bf115dd22</span></div><a href="/servlet/linkout?suffix=cit130b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.154%26sid%3Dliteratum%253Aachs%26aulast%3DBudd%26aufirst%3DD.%2BC.%26aulast%3DQian%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520lysophosphatidic%2520acid%2520pathway%2520modulators%2520as%2520therapies%2520for%2520fibrosis%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D1935%26epage%3D1952%26doi%3D10.4155%2Ffmc.13.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Sidduri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budd, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span> </span><span class="NLM_article-title">Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4450</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2014.08.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4450-4454&author=A.+Sidduriauthor=D.+C.+Buddauthor=M.+E.+Fuentesauthor=T.+Lambrosauthor=Y.+Renauthor=V.+Roongtaauthor=R.+C.+Schoenfeldauthor=P.+Gillespieauthor=C.+S.+Stevensonauthor=T.+Truittauthor=Y.+Qian&title=Discovery+of+novel+non-carboxylic+acid+5-amino-4-cyanopyrazole+derivatives+as+potent+and+highly+selective+LPA1R+antagonists&doi=10.1016%2Fj.bmcl.2014.08.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DLambros%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DRoongta%26aufirst%3DV.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DGillespie%26aufirst%3DP.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DQian%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520non-carboxylic%2520acid%25205-amino-4-cyanopyrazole%2520derivatives%2520as%2520potent%2520and%2520highly%2520selective%2520LPA1R%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4450%26epage%3D4454%26doi%3D10.1016%2Fj.bmcl.2014.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Garneau-Tsodikova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2632</span><span class="NLM_x">–</span> <span class="NLM_lpage">2640</span><span class="refDoi"> DOI: 10.2174/092986708785908969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F092986708785908969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=18855683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2632-2640&author=S.+Garneau-Tsodikovaauthor=V.+J.+Thannickal&title=Protein+kinase+inhibitors+in+the+treatment+of+pulmonary+fibrosis&doi=10.2174%2F092986708785908969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span></div><div class="casAuthors">Garneau-Tsodikova, Sylvie; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2632-2640</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis of the lung and other organ systems is an increasing cause of morbidity and mortality worldwide.  Effective anti-fibrotic agents for such disorders are currently lacking.  Injury to epithelium-lined tissues in mammals is typically assocd. with a mesenchymal response, including the activation of myofibroblasts.  Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease that results from effacement of the normal alveolar architecture of the lung.  Loss of lung capacity for gas-exchange and increased work of breathing eventually leads to respiratory failure and death.  In cutaneous wound models, apoptosis of myofibroblasts are essential to scar-less wound healing.  Recent studies indicate that acquisition of an apoptosis-resistant myofibroblast phenotype in the injured lung is assocd. with non-resolving and persistent fibrosis.  The acquired resistance to apoptosis in myofibroblasts is mediated, at least in part, by the sustained activation of two crit. pro-survival protein kinases, focal adhesion kinase (FAK) and protein kinase B (PKB/AKT).  Therapeutic interventions that modulate the activity of these protein kinases with resultant alterations in the phenotype of myofibroblasts may prove to be effective anti-fibrotic therapeutic strategies.  We discuss the potential roles for protein kinase inhibitors as novel drugs for fibrotic disorders.  Progress in pre-clin. and clin. development of small mol. inhibitors targeting pro-survival protein kinases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriAW2A7_uv37Vg90H21EOLACvtfcHk0lgBO6WKNzc53w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN&md5=030118de5dbd67f6ba3cedb95b872d52</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2174%2F092986708785908969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785908969%26sid%3Dliteratum%253Aachs%26aulast%3DGarneau-Tsodikova%26aufirst%3DS.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2632%26epage%3D2640%26doi%3D10.2174%2F092986708785908969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Daniels, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkes, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottom, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limper, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leof, E. B.</span><span> </span><span class="NLM_article-title">Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1308</span><span class="NLM_x">–</span> <span class="NLM_lpage">1316</span><span class="refDoi"> DOI: 10.1172/JCI200419603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1172%2FJCI200419603" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=1308-1316&author=C.+E.+Danielsauthor=M.+C.+Wilkesauthor=M.+Edensauthor=T.+J.+Kottomauthor=S.+J.+Murphyauthor=A.+H.+Limperauthor=E.+B.+Leof&title=Imatinib+mesylate+inhibits+the+profibrogenic+activity+of+TGF-beta+and+prevents+bleomycin-mediated+lung+fibrosis&doi=10.1172%2FJCI200419603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133a&amp;dbid=16384&amp;doi=10.1172%2FJCI200419603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200419603%26sid%3Dliteratum%253Aachs%26aulast%3DDaniels%26aufirst%3DC.%2BE.%26aulast%3DWilkes%26aufirst%3DM.%2BC.%26aulast%3DEdens%26aufirst%3DM.%26aulast%3DKottom%26aufirst%3DT.%2BJ.%26aulast%3DMurphy%26aufirst%3DS.%2BJ.%26aulast%3DLimper%26aufirst%3DA.%2BH.%26aulast%3DLeof%26aufirst%3DE.%2BB.%26atitle%3DImatinib%2520mesylate%2520inhibits%2520the%2520profibrogenic%2520activity%2520of%2520TGF-beta%2520and%2520prevents%2520bleomycin-mediated%2520lung%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D1308%26epage%3D1316%26doi%3D10.1172%2FJCI200419603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit133b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aono, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishioka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, S.</span><span> </span><span class="NLM_article-title">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">1279</span><span class="NLM_x">–</span> <span class="NLM_lpage">1285</span><span class="refDoi"> DOI: 10.1164/rccm.200404-531OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200404-531OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15735062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2005&pages=1279-1285&author=Y.+Aonoauthor=Y.+Nishiokaauthor=M.+Inayamaauthor=M.+Ugaiauthor=J.+Kishiauthor=H.+Ueharaauthor=K.+Izumiauthor=S.+Sone&title=Imatinib+as+a+novel+antifibrotic+agent+in+bleomycin-induced+pulmonary+fibrosis+in+mice&doi=10.1164%2Frccm.200404-531OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133bR"><div class="casContent"><span class="casTitleNuber">133b</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Aono Yoshinori; Nishioka Yasuhiko; Inayama Mami; Ugai Momoyo; Kishi Jun; Uehara Hisanori; Izumi Keisuke; Sone Saburo</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1279-85</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Imatinib mesylate is a potent and specific tyrosine kinase inhibitor against c-ABL, BCR-ABL, and c-KIT, and has been demonstrated to be highly active in chronic myeloid leukemia and gastrointestinal stromal tumors.  We examined the antifibrotic effects of imatinib using a bleomycin-induced lung fibrosis model in mice because imatinib also inhibits tyrosine kinase of platelet-derived growth factor receptors (PDGFRs).  Imatinib inhibited the growth of primary murine lung fibroblasts and the autophosphorylation of PDGFR-beta induced by PDGF.  Administration of imatinib significantly prevented bleomycin-induced pulmonary fibrosis in mice, partly by reducing the number of mesenchymal cells incorporating bromodeoxyuridine.  Analysis of bronchoalveolar lavage cells demonstrated that imatinib did not suppress early inflammation on Days 7 and 14 caused by bleomycin.  These results suggest that imatinib has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that imatinib might be useful for the treatment of pulmonary fibrosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6Hl7Y7MSGmVZoq0fPSOTvfW6udTcc2ea-UOr2DB_QP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D&md5=998232993f5ca1d46769358d0ac73cb1</span></div><a href="/servlet/linkout?suffix=cit133b&amp;dbid=16384&amp;doi=10.1164%2Frccm.200404-531OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200404-531OC%26sid%3Dliteratum%253Aachs%26aulast%3DAono%26aufirst%3DY.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DInayama%26aufirst%3DM.%26aulast%3DUgai%26aufirst%3DM.%26aulast%3DKishi%26aufirst%3DJ.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DIzumi%26aufirst%3DK.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DImatinib%2520as%2520a%2520novel%2520antifibrotic%2520agent%2520in%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D171%26spage%3D1279%26epage%3D1285%26doi%3D10.1164%2Frccm.200404-531OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit133c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chaudhary, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. E.</span><span> </span><span class="NLM_article-title">Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">776</span><span class="refDoi"> DOI: 10.1164/rccm.200505-717OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.200505-717OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16415276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Cgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2006&pages=769-776&author=N.+I.+Chaudharyauthor=A.+Schnappauthor=J.+E.+Park&title=Pharmacologic+differentiation+of+inflammation+and+fibrosis+in+the+rat+bleomycin+model&doi=10.1164%2Frccm.200505-717OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133cR"><div class="casContent"><span class="casTitleNuber">133c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model</span></div><div class="casAuthors">Chaudhary, Nveed I.; Schnapp, Andreas; Park, John E.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-776</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The model most often used to study the pathogenesis of pulmonary fibroses is the bleomycin (BLM)-induced lung fibrosis model.  Several treatments have been efficacious in this model, but not in the clinic.  To describe the time course of inflammation and fibrosis in the BLM model and to study the effect of timing of antiinflammatory and antifibrotic treatments on efficacy.  Rats were given single intratracheal injections of BLM on Day 0.  At specified time points, 10 rats were killed and their lungs studied for proinflammatory cytokines and for profibrotic growth factor mRNA.  After a single intratracheal injection of BLM on Day 0, rats were treated from Day 1 or 10 daily with oral prednisolone (10 mg/kg) or oral imatinib mesylate (50 mg/kg) for 21 d.  After BLM administration, the expression of inflammatory cytokines was elevated and returned to background levels at later time points.  Profibrotic gene expression peaked between Days 9 and 14 and remained elevated till the end of the expt., suggesting a "switch" between inflammation and fibrosis in this interval.  Antiinflammatory treatment (oral prednisolone) was beneficial when commenced at Day 1, but had no effect if administered from Day 10 onward.  However, imatinib mesylate was effective independently of the dosing regime.  The response of the BLM model to antifibrotic or antiinflammatory interventions is critically dependent on timing after the initial injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCR_9p19ggt7Vg90H21EOLACvtfcHk0ljsHgSycka4Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Cgsbc%253D&md5=02b62c6b17e03e86b6515d966da516f6</span></div><a href="/servlet/linkout?suffix=cit133c&amp;dbid=16384&amp;doi=10.1164%2Frccm.200505-717OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200505-717OC%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhary%26aufirst%3DN.%2BI.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26atitle%3DPharmacologic%2520differentiation%2520of%2520inflammation%2520and%2520fibrosis%2520in%2520the%2520rat%2520bleomycin%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D173%26spage%3D769%26epage%3D776%26doi%3D10.1164%2Frccm.200505-717OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Easton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">mTOR and cancer therapy</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6436</span><span class="NLM_x">–</span> <span class="NLM_lpage">6446</span><span class="refDoi"> DOI: 10.1038/sj.onc.1209886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fsj.onc.1209886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17041628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6436-6446&author=J.+B.+Eastonauthor=P.+J.+Houghton&title=mTOR+and+cancer+therapy&doi=10.1038%2Fsj.onc.1209886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134aR"><div class="casContent"><span class="casTitleNuber">134a</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR and cancer therapy</span></div><div class="casAuthors">Easton, J. B.; Houghton, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">6436-6446</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of the targets of the mTOR kinase, are overexpressed or mutated in cancer.  Rapamycin, the naturally occurring inhibitor of mTOR, along with a no. of recently developed rapamycin analogs (rapalogs) consisting of synthetically derived compds. contg. minor chem. modifications to the parent structure, inhibit the growth of cell lines derived from multiple tumor types in vitro, and tumor models in vivo.  Results from clin. trials indicate that the rapalogs may be useful for the treatment of subsets of certain types of cancer.  The sporadic responses from the initial clin. trials, based on the hypothesis of general translation inhibition of cancer cells are now beginning to be understood owing to a more complete understanding of the dynamics of mTOR regulation and the function of mTOR in the tumor microenvironment.  This review will summarize the preclin. and clin. data and recent discoveries of the function of mTOR in cancer and growth regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDA4eeQiQCbVg90H21EOLACvtfcHk0li6P3w7jRPF_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrN&md5=7a676e4128d249409e320924b26356eb</span></div><a href="/servlet/linkout?suffix=cit134a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209886%26sid%3Dliteratum%253Aachs%26aulast%3DEaston%26aufirst%3DJ.%2BB.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DmTOR%2520and%2520cancer%2520therapy%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6436%26epage%3D6446%26doi%3D10.1038%2Fsj.onc.1209886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mota, A.</span><span> </span><span class="NLM_article-title">Sirolimus: a new option in transplantation</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span><span class="refDoi"> DOI: 10.1517/14656566.6.3.479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1517%2F14656566.6.3.479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15794738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVyrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=479-487&author=A.+Mota&title=Sirolimus%3A+a+new+option+in+transplantation&doi=10.1517%2F14656566.6.3.479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134bR"><div class="casContent"><span class="casTitleNuber">134b</span><div class="casTitle"><span class="NLM_cas:atitle">Sirolimus: A new option in transplantation</span></div><div class="casAuthors">Mota, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">This review of immunosuppression in renal transplantation has allowed us to highlight the deleterious effect of calcineurin inhibitor nephrotoxicity and to emphasize the importance of sirolimus.  Now, a whole new set of possibilities has opened up in immunosuppression: sirolimus-based immunosuppression without calcineurin inhibitors; sirolimus in combination with calcineurin inhibitors in reduced doses; early calcineurin inhibitor withdrawal from a regimen that combines sirolimus, calcineurin inhibitors and steroids; and calcineurin inhibitor conversion to sirolimus when the first signs of graft nephrotoxicity appear.  These new strategies in immunosuppression in renal transplantation are assocd. with good results in graft and patient survival in year 1, and with better renal function.  Therefore, we can hope for better long-term results in transplantation, with a significant increase in the graft half-life and in the patient survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKyY1zznLvrVg90H21EOLACvtfcHk0li6P3w7jRPF_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVyrtrg%253D&md5=e57687bee134605a1852492bd2d97339</span></div><a href="/servlet/linkout?suffix=cit134b&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.3.479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.3.479%26sid%3Dliteratum%253Aachs%26aulast%3DMota%26aufirst%3DA.%26atitle%3DSirolimus%253A%2520a%2520new%2520option%2520in%2520transplantation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D479%26epage%3D487%26doi%3D10.1517%2F14656566.6.3.479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Simler, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsack, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasleton, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span> </span><span class="NLM_article-title">The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1183/09031936.02.00281602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F09031936.02.00281602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=12108867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVWktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1124-1127&author=N.+R.+Simlerauthor=D.+C.+Howellauthor=R.+P.+Marshallauthor=N.+R.+Goldsackauthor=P.+S.+Hasletonauthor=G.+J.+Laurentauthor=R.+C.+Chambersauthor=J.+J.+Egan&title=The+rapamycin+analogue+SDZ+RAD+attenuates+bleomycin-induced+pulmonary+fibrosis+in+rats&doi=10.1183%2F09031936.02.00281602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134cR"><div class="casContent"><span class="casTitleNuber">134c</span><div class="casTitle"><span class="NLM_cas:atitle">The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats</span></div><div class="casAuthors">Simler, N. R.; Howell, D. C. J.; Marshall, R. P.; Goldsack, N. R.; Hasleton, P. S.; Laurent, G. J.; Chambers, R. C.; Egan, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1124-1127</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix proteins within the pulmonary interstitium.  The new macrolide immunosuppressant SDZ RAD, a rapamycin analog, inhibits growth-factor dependent proliferation of mesenchymal cells and might therefore be of therapeutic interest for the treatment of fibrotic lung disease.  In this study the effect of SDZ RAD on lung-collagen accumulation in the bleomycin model of pulmonary fibrosis in rats was investigated.  SDZ RAD (2.5 mg·kg-1.day-1) or drug vehicle were administered orally by daily gavage.  Successful dosing was confirmed by measuring splenic wt.  Total lung-collagen content was measured by high-performance liq. chromatog. quantitation of hydroxyproline.  In animals given bleomycin and drug vehicle, total lung collagen was increased by 182±11% (mean±SEM) compared with saline controls at 14 days (p<0.001).  The increase in lung-collagen accumulation was reduced by 75±12% (p<0.01) in animals given SDZ RAD and was accompanied by a concomitant 56±6%, (p<0.001) redn. in lung wt.  SDZ RAD is currently in clin. trials for the prevention of solid organ graft rejection, another condition characterized by excessive extracellular matrix prodn.  The authors propose that SDZ RAD warrants evaluation as a novel therapeutic agent for fibrotic lung disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp116TYl5H2vrVg90H21EOLACvtfcHk0li6P3w7jRPF_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVWktbc%253D&md5=847a4c29fbbeac6d0a8d02a0ef684543</span></div><a href="/servlet/linkout?suffix=cit134c&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00281602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00281602%26sid%3Dliteratum%253Aachs%26aulast%3DSimler%26aufirst%3DN.%2BR.%26aulast%3DHowell%26aufirst%3DD.%2BC.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DGoldsack%26aufirst%3DN.%2BR.%26aulast%3DHasleton%26aufirst%3DP.%2BS.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520rapamycin%2520analogue%2520SDZ%2520RAD%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520rats%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D19%26spage%3D1124%26epage%3D1127%26doi%3D10.1183%2F09031936.02.00281602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Laping, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huet, S.</span><span> </span><span class="NLM_article-title">TGF-β receptor kinase inhibitors for treatment of fibrosis</span> <span class="citation_source-journal">Smad Signal Transduction</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span><span class="refDoi"> DOI: 10.1007/1-4020-4709-6_22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2F1-4020-4709-6_22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=443-459&author=N.+J.+Lapingauthor=S.+Huet&title=TGF-%CE%B2+receptor+kinase+inhibitors+for+treatment+of+fibrosis&doi=10.1007%2F1-4020-4709-6_22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1007%2F1-4020-4709-6_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F1-4020-4709-6_22%26sid%3Dliteratum%253Aachs%26aulast%3DLaping%26aufirst%3DN.%2BJ.%26aulast%3DHuet%26aufirst%3DS.%26atitle%3DTGF-%25CE%25B2%2520receptor%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520fibrosis%26jtitle%3DSmad%2520Signal%2520Transduction%26date%3D2006%26volume%3D5%26spage%3D443%26epage%3D459%26doi%3D10.1007%2F1-4020-4709-6_22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hanke, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weringer, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connelly, P. A.</span><span> </span><span class="NLM_article-title">Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span><span class="refDoi"> DOI: 10.1074/jbc.271.2.695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1074%2Fjbc.271.2.695" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=695-701&author=J.+H.+Hankeauthor=J.+P.+Gardnerauthor=R.+L.+Dowauthor=P.+S.+Changelianauthor=W.+H.+Brissetteauthor=E.+J.+Weringerauthor=B.+A.+Pollokauthor=P.+A.+Connelly&title=Discovery+of+a+novel%2C+potent%2C+and+Src+family-selective+tyrosine+kinase+inhibitor.+Study+of+Lck-+and+FynT-dependent+T+cell+activation&doi=10.1074%2Fjbc.271.2.695"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.2.695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.2.695%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DJ.%2BH.%26aulast%3DGardner%26aufirst%3DJ.%2BP.%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DWeringer%26aufirst%3DE.%2BJ.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26aulast%3DConnelly%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%252C%2520potent%252C%2520and%2520Src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor.%2520Study%2520of%2520Lck-%2520and%2520FynT-dependent%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D695%26epage%3D701%26doi%3D10.1074%2Fjbc.271.2.695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit136b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vittal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horowitz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toews, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standiford, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thannickal, V. J.</span><span> </span><span class="NLM_article-title">Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">375</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)62260-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2FS0002-9440%2810%2962260-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=15681821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2005&pages=367-375&author=R.+Vittalauthor=J.+C.+Horowitzauthor=B.+B.+Mooreauthor=H.+Zhangauthor=F.+J.+Martinezauthor=G.+B.+Toewsauthor=T.+J.+Standifordauthor=V.+J.+Thannickal&title=Modulation+of+prosurvival+signaling+in+fibroblasts+by+a+protein+kinase+inhibitor+protects+against+fibrotic+tissue+injury&doi=10.1016%2FS0002-9440%2810%2962260-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136bR"><div class="casContent"><span class="casTitleNuber">136b</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury</span></div><div class="casAuthors">Vittal, Ragini; Horowitz, Jeffrey C.; Moore, Bethany B.; Zhang, Hengmin; Martinez, Fernando J.; Toews, Galen B.; Standiford, Theodore J.; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">367-375</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Progressive fibrotic diseases involving diverse organ systems are assocd. with the persistence of fibroblasts/myofibroblasts in injured tissues.  Activation of focal adhesion kinase (FAK) and protein kinase B (PKB/Akt) by transforming growth factor-β1 mediate stable induction of myofibroblast differentiation and survival.  In this report, we demonstrate that transforming growth factor-β1-induced activation of both PKB/Akt and FAK are dose dependently inhibited by the protein kinase inhibitor, AG1879, in cultured human lung fibroblasts.  In a murine model of intratracheal bleomycin-induced lung fibrosis, regions of active fibrogenesis demonstrate elevated expression of PKB/Akt and FAK phosphorylation in vivo, effects that are attenuated in mice receiving daily i.p. injections of AG1879 (bleomycin-AG1879) vs. a chem. inactive analog (bleomycin-control).  PKB/Akt and FAK phosphorylation are elevated in fibroblasts isolated from lungs of bleomycin-injured mice, effects that are inhibited in bleomycin-AG1879 mice.  Accumulation of α-smooth muscle actin-expressing myofibroblasts is markedly reduced in lungs of bleomycin-AG1879 mice.  The nos. of recruited inflammatory cells were not significantly different between these groups.  Bleomycin-AG1879 mice are protected from lung fibrosis as evidenced by histopathol., trichrome staining, and biochem. anal. for collagen.  Thus, targeting of prosurvival signaling pathways in fibroblasts/myofibroblasts may provide a novel and effective strategy for anti-fibrotic therapy of treatment-unresponsive fibrotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLhlwNwRkt7Vg90H21EOLACvtfcHk0lhGjNyCL3rQuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGntbc%253D&md5=443cc2237e453023d72f83d58785fa20</span></div><a href="/servlet/linkout?suffix=cit136b&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2962260-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252962260-2%26sid%3Dliteratum%253Aachs%26aulast%3DVittal%26aufirst%3DR.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DMoore%26aufirst%3DB.%2BB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DToews%26aufirst%3DG.%2BB.%26aulast%3DStandiford%26aufirst%3DT.%2BJ.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DModulation%2520of%2520prosurvival%2520signaling%2520in%2520fibroblasts%2520by%2520a%2520protein%2520kinase%2520inhibitor%2520protects%2520against%2520fibrotic%2520tissue%2520injury%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D166%26spage%3D367%26epage%3D375%26doi%3D10.1016%2FS0002-9440%2810%2962260-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Son, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheen, Y. Y.</span><span> </span><span class="NLM_article-title">EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1704</span><span class="NLM_x">–</span> <span class="NLM_lpage">1716</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1158%2F1535-7163.MCT-13-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=24817629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1704-1716&author=J.+Y.+Sonauthor=S.+Y.+Parkauthor=S.+J.+Kimauthor=S.+J.+Leeauthor=S.+A.+Parkauthor=M.+J.+Kimauthor=S.+W.+Kimauthor=D.+K.+Kimauthor=J.+S.+Namauthor=Y.+Y.+Sheen&title=EW-7197%2C+a+novel+ALK-5+kinase+inhibitor%2C+potently+inhibits+breast+to+lung+metastasis&doi=10.1158%2F1535-7163.MCT-13-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis</span></div><div class="casAuthors">Son, Ji Yeon; Park, So-Yeon; Kim, Sol-Ji; Lee, Seon Joo; Park, Sang-A.; Kim, Min-Jin; Kim, Seung Won; Kim, Dae-Kee; Nam, Jeong-Seok; Sheen, Yhun Yhong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1704-1716</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Advanced tumors produce an excessive amt. of transforming growth factor β (TGFβ), which promotes tumor progression at late stages of malignancy.  The purpose of this study was to develop anti-TGFβ therapeutics for cancer.  We synthesized a novel small-mol. TGFβ receptor I kinase (activin receptor-like kinase 5) inhibitor termed N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]methyl]-2-fluoroaniline (EW-7197), and we investigated its potential antimetastatic efficacy in mouse mammary tumor virus (MMTV)/c-Neu mice and 4T1 orthotopic-grafted mice.  EW-7197 inhibited Smad/TGFβ signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice and 4T1 orthotopic-grafted mice.  EW-7197 also inhibited the epithelial-to-mesenchymal transition (EMT) in both TGFβ-treated breast cancer cells and 4T1 orthotopic-grafted mice.  Furthermore, EW-7197 enhanced cytotoxic T lymphocyte activity in 4T1 orthotopic-grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor-bearing mice.  In summary, EW-7197 showed potent in vivo antimetastatic activity, indicating its potential for use as an anticancer therapy.  Mol Cancer Ther; 13(7); 1704-16. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAUbXlCEkKMrVg90H21EOLACvtfcHk0liDcI6iptyGpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfP&md5=4507cbbaf0f2c41bb0ae751a0368fce9</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0903%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DJ.%2BY.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DNam%26aufirst%3DJ.%2BS.%26aulast%3DSheen%26aufirst%3DY.%2BY.%26atitle%3DEW-7197%252C%2520a%2520novel%2520ALK-5%2520kinase%2520inhibitor%252C%2520potently%2520inhibits%2520breast%2520to%2520lung%2520metastasis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1704%26epage%3D1716%26doi%3D10.1158%2F1535-7163.MCT-13-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Siddiqui, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P. A.</span><span> </span><span class="NLM_article-title">Small molecule JNK (c-Jun N-terminal kinase) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3005</span><span class="NLM_x">–</span> <span class="NLM_lpage">3012</span><span class="refDoi"> DOI: 10.1021/jm9003279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9003279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3005-3012&author=M.+A.+Siddiquiauthor=P.+A.+Reddy&title=Small+molecule+JNK+%28c-Jun+N-terminal+kinase%29+inhibitors&doi=10.1021%2Fjm9003279"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm9003279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9003279%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26aulast%3DReddy%26aufirst%3DP.%2BA.%26atitle%3DSmall%2520molecule%2520JNK%2520%2528c-Jun%2520N-terminal%2520kinase%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3005%26epage%3D3012%26doi%3D10.1021%2Fjm9003279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Plantevin Krenitsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadolny, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayala, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clareen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgraf, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Sidocky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapienza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahmanyar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delker, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giegel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celeridad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowitzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khatsenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirley, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benish, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodine, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blease, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cathers, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span> </span><span class="NLM_article-title">Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.12.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2011.12.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22244937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1433-1438&author=V.+Plantevin+Krenitskyauthor=L.+Nadolnyauthor=M.+Delgadoauthor=L.+Ayalaauthor=S.+S.+Clareenauthor=R.+Hilgrafauthor=R.+Albersauthor=S.+Hegdeauthor=N.+D%E2%80%99Sidockyauthor=J.+Sapienzaauthor=J.+Wrightauthor=M.+McCarrickauthor=S.+Bahmanyarauthor=P.+Chamberlainauthor=S.+L.+Delkerauthor=J.+Muirauthor=D.+Giegelauthor=L.+Xuauthor=M.+Celeridadauthor=J.+Lachowitzerauthor=B.+Bennettauthor=M.+Moghaddamauthor=O.+Khatsenkoauthor=J.+Katzauthor=R.+Fanauthor=A.+Baiauthor=Y.+Tangauthor=M.+A.+Shirleyauthor=B.+Benishauthor=T.+Bodineauthor=K.+Bleaseauthor=H.+Raymonauthor=B.+E.+Cathersauthor=Y.+Satoh&title=Discovery+of+CC-930%2C+an+orally+active+anti-fibrotic+JNK+inhibitor&doi=10.1016%2Fj.bmcl.2011.12.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor</span></div><div class="casAuthors">Plantevin Krenitsky, Veronique; Nadolny, Lisa; Delgado, Mercedes; Ayala, Leticia; Clareen, Steven S.; Hilgraf, Robert; Albers, Ronald; Hegde, Sayee; D'Sidocky, Neil; Sapienza, John; Wright, Jonathan; McCarrick, Meg; Bahmanyar, Sogole; Chamberlain, Philip; Delker, Silvia L.; Muir, Jeff; Giegel, David; Xu, Li; Celeridad, Maria; Lachowitzer, Jeff; Bennett, Brydon; Moghaddam, Mehran; Khatsenko, Oleg; Katz, Jason; Fan, Rachel; Bai, April; Tang, Yang; Shirley, Michael A.; Benish, Brent; Bodine, Tracey; Blease, Kate; Raymon, Heather; Cathers, Brian E.; Satoh, Yoshitaka</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1433-1438</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors.  Improving the physico-chem. properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors.  Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 1 (CC-930, I) as a development candidate, which is currently in Phase II clin. trial for IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKdVqRxZzsLVg90H21EOLACvtfcHk0liDcI6iptyGpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCls7c%253D&md5=fc99284fc784d1649286c95888a94e5e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.12.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.12.027%26sid%3Dliteratum%253Aachs%26aulast%3DPlantevin%2BKrenitsky%26aufirst%3DV.%26aulast%3DNadolny%26aufirst%3DL.%26aulast%3DDelgado%26aufirst%3DM.%26aulast%3DAyala%26aufirst%3DL.%26aulast%3DClareen%26aufirst%3DS.%2BS.%26aulast%3DHilgraf%26aufirst%3DR.%26aulast%3DAlbers%26aufirst%3DR.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Sidocky%26aufirst%3DN.%26aulast%3DSapienza%26aufirst%3DJ.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DMcCarrick%26aufirst%3DM.%26aulast%3DBahmanyar%26aufirst%3DS.%26aulast%3DChamberlain%26aufirst%3DP.%26aulast%3DDelker%26aufirst%3DS.%2BL.%26aulast%3DMuir%26aufirst%3DJ.%26aulast%3DGiegel%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCeleridad%26aufirst%3DM.%26aulast%3DLachowitzer%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DB.%26aulast%3DMoghaddam%26aufirst%3DM.%26aulast%3DKhatsenko%26aufirst%3DO.%26aulast%3DKatz%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DR.%26aulast%3DBai%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShirley%26aufirst%3DM.%2BA.%26aulast%3DBenish%26aufirst%3DB.%26aulast%3DBodine%26aufirst%3DT.%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DRaymon%26aufirst%3DH.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DSatoh%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520CC-930%252C%2520an%2520orally%2520active%2520anti-fibrotic%2520JNK%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1433%26epage%3D1438%26doi%3D10.1016%2Fj.bmcl.2011.12.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Cook, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romashkan, S.</span><span> </span><span class="NLM_article-title">Why do we need a trial on the effects of testosterone therapy in older men?</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1038/clpt.2010.217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fclpt.2010.217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21170069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=29-31&author=N.+L.+Cookauthor=S.+Romashkan&title=Why+do+we+need+a+trial+on+the+effects+of+testosterone+therapy+in+older+men%3F&doi=10.1038%2Fclpt.2010.217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Why Do We Need a Trial on the Effects of Testosterone Therapy in Older Men?</span></div><div class="casAuthors">Cook, N. L.; Romashkan, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-31</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Decreases in levels of sex hormones occur with aging.  Observational studies have found assocns. of low testosterone concns. in older men with adverse symptoms; however, these assocns. do not prove causality.  Therefore, the question arises whether to treat older men whose serum testosterone is low.  In 2009, the Testosterone Trial (T Trial) was funded to examine the efficacy of therapy in 800 elderly men with low testosterone levels; potentially assocd. symptoms; and abnormalities in phys., sexual, or cognitive function or vitality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXHB8555yibVg90H21EOLACvtfcHk0liSFwehtEylXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zO&md5=38da4d2f09437a48e96387bc0a727818</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.217%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DN.%2BL.%26aulast%3DRomashkan%26aufirst%3DS.%26atitle%3DWhy%2520do%2520we%2520need%2520a%2520trial%2520on%2520the%2520effects%2520of%2520testosterone%2520therapy%2520in%2520older%2520men%253F%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D29%26epage%3D31%26doi%3D10.1038%2Fclpt.2010.217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span>ClinicalTrials.gov. A study to characterize the safety, PK and biological activity of CC-930 in idiopathic pulmonary fibrosis (IPF). <a href="http://clinicaltrials.gov/ct2/show/NCT01203943" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01203943</a> (accessed May 20,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+study+to+characterize+the+safety%2C+PK+and+biological+activity+of+CC-930+in+idiopathic+pulmonary+fibrosis+%28IPF%29.+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01203943+%28accessed+May+20%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Deleuze-Masquefa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moarbess, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">David, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gayraud-Paniagua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bressolle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinguet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, P. A.</span><span> </span><span class="NLM_article-title">New imidazo[1,2-<i>a</i>]quinoxaline derivatives: Synthesis and <i>in vitro</i> activity against human melanoma</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3406</span><span class="NLM_x">–</span> <span class="NLM_lpage">3411</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2009.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.ejmech.2009.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=3406-3411&author=C.+Deleuze-Masquefaauthor=G.+Moarbessauthor=S.+Khierauthor=N.+Davidauthor=S.+Gayraud-Paniaguaauthor=F.+Bressolleauthor=F.+Pinguetauthor=P.+A.+Bonnet&title=New+imidazo%5B1%2C2-a%5Dquinoxaline+derivatives%3A+Synthesis+and+in+vitro+activity+against+human+melanoma&doi=10.1016%2Fj.ejmech.2009.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DDeleuze-Masquefa%26aufirst%3DC.%26aulast%3DMoarbess%26aufirst%3DG.%26aulast%3DKhier%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DN.%26aulast%3DGayraud-Paniagua%26aufirst%3DS.%26aulast%3DBressolle%26aufirst%3DF.%26aulast%3DPinguet%26aufirst%3DF.%26aulast%3DBonnet%26aufirst%3DP.%2BA.%26atitle%3DNew%2520imidazo%255B1%252C2-a%255Dquinoxaline%2520derivatives%253A%2520Synthesis%2520and%2520in%2520vitro%2520activity%2520against%2520human%2520melanoma%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D3406%26epage%3D3411%26doi%3D10.1016%2Fj.ejmech.2009.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cociorva, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liyanage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cajica, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreder, K. R.</span><span> </span><span class="NLM_article-title">Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5217</span><span class="NLM_x">–</span> <span class="NLM_lpage">5222</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2013.06.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5217-5222&author=B.+Liauthor=O.+M.+Cociorvaauthor=T.+Nomanbhoyauthor=H.+Weissigauthor=Q.+Liauthor=K.+Nakamuraauthor=M.+Liyanageauthor=M.+C.+Zhangauthor=A.+Y.+Shihauthor=A.+Abanauthor=Y.+Huauthor=J.+Cajicaauthor=L.+Phamauthor=J.+W.+Kozarichauthor=K.+R.+Shreder&title=Hit-to-lead+optimization+and+kinase+selectivity+of+imidazo%5B1%2C2-a%5Dquinoxalin-4-amine+derived+JNK1+inhibitors&doi=10.1016%2Fj.bmcl.2013.06.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.087%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCociorva%26aufirst%3DO.%2BM.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DLiyanage%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DM.%2BC.%26aulast%3DShih%26aufirst%3DA.%2BY.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCajica%26aufirst%3DJ.%26aulast%3DPham%26aufirst%3DL.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26atitle%3DHit-to-lead%2520optimization%2520and%2520kinase%2520selectivity%2520of%2520imidazo%255B1%252C2-a%255Dquinoxalin-4-amine%2520derived%2520JNK1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5217%26epage%3D5222%26doi%3D10.1016%2Fj.bmcl.2013.06.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wynn, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, T. R.</span><span> </span><span class="NLM_article-title">Mechanisms of fibrosis: therapeutic translation for fibrotic disease</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1040</span><span class="refDoi"> DOI: 10.1038/nm.2807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnm.2807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22772564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1028-1040&author=T.+A.+Wynnauthor=T.+R.+Ramalingam&title=Mechanisms+of+fibrosis%3A+therapeutic+translation+for+fibrotic+disease&doi=10.1038%2Fnm.2807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144aR"><div class="casContent"><span class="casTitleNuber">144a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fibrosis: therapeutic translation for fibrotic disease</span></div><div class="casAuthors">Wynn, Thomas A.; Ramalingam, Thirumalai R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1028-1040</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis is a pathol. feature of most chronic inflammatory diseases.  Fibrosis, or scarring, is defined by the accumulation of excess extracellular matrix components.  If highly progressive, the fibrotic process eventually leads to organ malfunction and death.  Fibrosis affects nearly every tissue in the body.  Here we discuss how key components of the innate and adaptive immune response contribute to the pathogenesis of fibrosis.  We also describe how cell-intrinsic changes in important structural cells can perpetuate the fibrotic response by regulating the differentiation, recruitment, proliferation and activation of extracellular matrix-producing myofibroblasts.  Finally, we highlight some of the key mechanisms and pathways of fibrosis that are being targeted as potential therapies for a variety of important human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnrbAxW_Afa7Vg90H21EOLACvtfcHk0ljiXe6WEuQcBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGgtLc%253D&md5=1ddde8289d7c57ae16e4d14348ef3b7f</span></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=10.1038%2Fnm.2807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2807%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26aulast%3DRamalingam%26aufirst%3DT.%2BR.%26atitle%3DMechanisms%2520of%2520fibrosis%253A%2520therapeutic%2520translation%2520for%2520fibrotic%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D1028%26epage%3D1040%26doi%3D10.1038%2Fnm.2807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartram, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speer, C. P.</span><span> </span><span class="NLM_article-title">The role of transforming growth factor beta in lung development and disease</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">754</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span><span class="refDoi"> DOI: 10.1378/chest.125.2.754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1378%2Fchest.125.2.754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=14769761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Fmsl2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2004&pages=754-765&author=U.+Bartramauthor=C.+P.+Speer&title=The+role+of+transforming+growth+factor+beta+in+lung+development+and+disease&doi=10.1378%2Fchest.125.2.754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144bR"><div class="casContent"><span class="casTitleNuber">144b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of transforming growth factor beta in lung development and disease</span></div><div class="casAuthors">Bartram Ulrike; Speer Christian P</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">754-65</span>
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">Transforming growth factor (TGF) beta plays an important role in normal pulmonary morphogenesis and function and in the pathogenesis of lung disease.  The effect of TGFbeta is regulated via a selective pathway of TGFbeta synthesis and signaling that involves activation of latent TGFbeta, specific TGFbeta receptors, and intracellular signaling via Smad molecules.  All three isoforms of TGFbeta are expressed at high levels during normal lung development, being particularly important for branching morphogenesis and epithelial cell differentiation with maturation of surfactant synthesis.  Small amounts of TGFbeta are still present in the adult lung, and TGFbeta is involved in normal tissue repair following lung injury.  However, in a variety of forms of pulmonary pathology, the expression of TGFbeta is increased.  These include chronic lung disease of prematurity as well as several forms of acute and chronic adult lung disease.  While TGFbeta1 appears to be the predominant isoform involved, elevated levels of all three isoforms have been demonstrated.  The increase in TGFbeta precedes abnormalities in lung function and detectable lung pathology, but correlates with the severity of the disease.  TGFbeta plays a key role in mediating fibrotic tissue remodeling by increasing the production and decreasing the degradation of connective tissue via several mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRidiEnxLJRVU2yPDyEFiigfW6udTcc2ebXZlJE3A_knrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Fmsl2ksw%253D%253D&md5=a1e1522ae1ab55078fa7f2ca085ba5a4</span></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=10.1378%2Fchest.125.2.754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.125.2.754%26sid%3Dliteratum%253Aachs%26aulast%3DBartram%26aufirst%3DU.%26aulast%3DSpeer%26aufirst%3DC.%2BP.%26atitle%3DThe%2520role%2520of%2520transforming%2520growth%2520factor%2520beta%2520in%2520lung%2520development%2520and%2520disease%26jtitle%3DChest%26date%3D2004%26volume%3D125%26spage%3D754%26epage%3D765%26doi%3D10.1378%2Fchest.125.2.754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Strieter, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehrad, B.</span><span> </span><span class="NLM_article-title">New mechanisms of pulmonary fibrosis</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">1364</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span><span class="refDoi"> DOI: 10.1378/chest.09-0510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1378%2Fchest.09-0510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19892675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjkt1agtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=1364-1370&author=R.+M.+Strieterauthor=B.+Mehrad&title=New+mechanisms+of+pulmonary+fibrosis&doi=10.1378%2Fchest.09-0510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144cR"><div class="casContent"><span class="casTitleNuber">144c</span><div class="casTitle"><span class="NLM_cas:atitle">New mechanisms of pulmonary fibrosis</span></div><div class="casAuthors">Strieter Robert M; Mehrad Borna</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1364-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The understanding of the pathogenesis of pulmonary fibrosis continues to evolve.  The initial hypothetical model suggested chronic inflammation as the cause of pulmonary fibrosis, whereas a subsequent hypothesis posited epithelial injury and impaired wound repair as the etiology of fibrosis without preceding inflammation.  Over the past decade, several concepts have led to refinement of these hypotheses.  These include the following: (1) the importance of the integrity of the alveolar-capillary barrier basement membrane (BM) to conserving the architecture of the injured lung; (2) conversely, that the failure of reepithelialization and reendothelialization of this BM results in pathologic fibrosis; (3) transforming growth factor-beta is necessary but not sufficient to the pathologic fibrosis of the lungs; (4) the role of persistent antigens in the pathogenesis of usual interstitial pneumonia; and (5) the contribution of epithelial-to-mesenchymal transformation and bone marrow-derived progenitor cells in the pathogenesis of lung fibrosis.  In this review, we will discuss these evolving conceptual mechanisms for the pathogenesis of pulmonary fibrosis relevant to idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr0URydcEFMukdrW1FkXG-fW6udTcc2ebXZlJE3A_knrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjkt1agtA%253D%253D&md5=91f35d9b6466b7393deca1a9cd02a7ce</span></div><a href="/servlet/linkout?suffix=cit144c&amp;dbid=16384&amp;doi=10.1378%2Fchest.09-0510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.09-0510%26sid%3Dliteratum%253Aachs%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26aulast%3DMehrad%26aufirst%3DB.%26atitle%3DNew%2520mechanisms%2520of%2520pulmonary%2520fibrosis%26jtitle%3DChest%26date%3D2009%26volume%3D136%26spage%3D1364%26epage%3D1370%26doi%3D10.1378%2Fchest.09-0510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Arribillaga, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basagoiti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riezu-Boj, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrás-Cuesta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasarte, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarobe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornet, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feijoó, E.</span><span> </span><span class="NLM_article-title">Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis</span> <span class="citation_source-journal">Cytokine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1016/j.cyto.2010.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.cyto.2010.11.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2011&pages=327-333&author=L.+Arribillagaauthor=J.+Dotorauthor=M.+Basagoitiauthor=J.+I.+Riezu-Bojauthor=F.+Borr%C3%A1s-Cuestaauthor=J.+J.+Lasarteauthor=P.+Sarobeauthor=M.+E.+Cornetauthor=E.+Feijo%C3%B3&title=Therapeutic+effect+of+a+peptide+inhibitor+of+TGF-%CE%B2+on+pulmonary+fibrosis&doi=10.1016%2Fj.cyto.2010.11.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144d&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2010.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2010.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DArribillaga%26aufirst%3DL.%26aulast%3DDotor%26aufirst%3DJ.%26aulast%3DBasagoiti%26aufirst%3DM.%26aulast%3DRiezu-Boj%26aufirst%3DJ.%2BI.%26aulast%3DBorr%25C3%25A1s-Cuesta%26aufirst%3DF.%26aulast%3DLasarte%26aufirst%3DJ.%2BJ.%26aulast%3DSarobe%26aufirst%3DP.%26aulast%3DCornet%26aufirst%3DM.%2BE.%26aulast%3DFeijo%25C3%25B3%26aufirst%3DE.%26atitle%3DTherapeutic%2520effect%2520of%2520a%2520peptide%2520inhibitor%2520of%2520TGF-%25CE%25B2%2520on%2520pulmonary%2520fibrosis%26jtitle%3DCytokine%26date%3D2011%26volume%3D53%26spage%3D327%26epage%3D333%26doi%3D10.1016%2Fj.cyto.2010.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Khasnis, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, L. H.</span><span> </span><span class="NLM_article-title">Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span><span class="refDoi"> DOI: 10.1016/j.semarthrit.2009.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.semarthrit.2009.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19914686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Wht7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=147-163&author=A.+A.+Khasnisauthor=L.+H.+Calabrese&title=Tumor+necrosis+factor+inhibitors+and+lung+disease%3A+a+paradox+of+efficacy+and+risk&doi=10.1016%2Fj.semarthrit.2009.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144eR"><div class="casContent"><span class="casTitleNuber">144e</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Necrosis Factor Inhibitors and Lung Disease: A Paradox of Efficacy and Risk</span></div><div class="casAuthors">Khasnis, Atul A.; Calabrese, Leonard H.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Arthritis and Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-163</span>CODEN:
                <span class="NLM_cas:coden">SAHRBF</span>;
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Objective: Tumor necrosis factor inhibitors (TNFi) are being increasingly used for a wide range of indications.  There are increasing reports of pulmonary toxicity related to the use of TNFi.  In this review, we have attempted to synthesize the available literature regarding noninfectious complications related to TNFi use.  Methods: We reviewed case reports, case series, and clin. trials accessed from the PubMed database (www.pubmed.gov), European League Against Rheumatism web archive (http://www.abstrs.2view.com/eular/index.php), and the British Society of Rheumatol. Biologics Register Newsletter website (http://www.rheumatol.org.uk/publications) using 23 search terms.  Results: There are increasing data available about use of TNFi in treatment of systemic inflammatory rheumatol. disorders and their attempted use for various pulmonary indications.  Currently reported noninfectious pulmonary complications related to TNFi use include most commonly granulomatous disease and pulmonary fibrosis/interstitial lung disease and rarely alveolar hemorrhage and antisynthetase syndrome.  De novo granulomatous disease seems to be mostly reversible, whereas pulmonary fibrosis carries the worst prognosis esp. in the setting of prior lung fibrosis.  Conclusions: Serious and potentially fatal pulmonary toxicity has been reported during the use of TNFi, specifically from pulmonary fibrosis.  Increased awareness during trial design and increased postmarketing surveillance is needed to provide more information about the epidemiol. of these complications.  Early recognition of these complications may help avert therapeutic misadventures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-bdekO323bVg90H21EOLACvtfcHk0lhqKxM5ZfPuLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Wht7rF&md5=a5568339efdc982a6cb5dbfc054c9376</span></div><a href="/servlet/linkout?suffix=cit144e&amp;dbid=16384&amp;doi=10.1016%2Fj.semarthrit.2009.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semarthrit.2009.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKhasnis%26aufirst%3DA.%2BA.%26aulast%3DCalabrese%26aufirst%3DL.%2BH.%26atitle%3DTumor%2520necrosis%2520factor%2520inhibitors%2520and%2520lung%2520disease%253A%2520a%2520paradox%2520of%2520efficacy%2520and%2520risk%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D2010%26volume%3D40%26spage%3D147%26epage%3D163%26doi%3D10.1016%2Fj.semarthrit.2009.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 4-oxoquinoline-3-carboxamides derivatives as potent anti-fibrosis agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">5666</span><span class="NLM_x">–</span> <span class="NLM_lpage">5670</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.bmcl.2014.10.071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5666-5670&author=J.+Zhuauthor=L.+Heauthor=L.+Maauthor=Z.+Weiauthor=J.+Heauthor=Z.+Yangauthor=Y.+Puauthor=D.+Caoauthor=Y.+Wuauthor=M.+Xiangauthor=A.+Pengauthor=Y.+Weiauthor=L.+Chen&title=Synthesis+and+biological+evaluation+of+4-oxoquinoline-3-carboxamides+derivatives+as+potent+anti-fibrosis+agents&doi=10.1016%2Fj.bmcl.2014.10.071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPu%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DA.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25204-oxoquinoline-3-carboxamides%2520derivatives%2520as%2520potent%2520anti-fibrosis%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5666%26epage%3D5670%26doi%3D10.1016%2Fj.bmcl.2014.10.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Schwiebert, E.; Streiff, J.; Dixon, J.; Gao, H.; Ritchie, J. P.; Seales, E. C.; Mai, D.</span><span> </span><span class="NLM_article-title">Coumarin derivatives and methods of use in treating hyperproliferative diseases</span>. U.S. Patent 20160038475 A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Schwiebert&author=J.+Streiff&author=J.+Dixon&author=H.+Gao&author=J.+P.+Ritchie&author=E.+C.+Seales&author=D.+Mai&title=Coumarin+derivatives+and+methods+of+use+in+treating+hyperproliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchwiebert%26aufirst%3DE.%26atitle%3DCoumarin%2520derivatives%2520and%2520methods%2520of%2520use%2520in%2520treating%2520hyperproliferative%2520diseases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gilbert, F.; Robert, G. J.; Jonathan, L.; Maurice, L. R.; Fletcher, S. R.</span><span> </span><span class="NLM_article-title">Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)</span>. U.S. Patent 20160039807 A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Gilbert&author=G.+J.+Robert&author=L.+Jonathan&author=L.+R.+Maurice&author=S.+R.+Fletcher&title=Novel+dihydropyrimidinoisoquinolinones+and+pharmaceutical+compositions+thereof+for+the+treatment+of+inflammatory+disorders+%28gpr84+antagonists%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DF.%26atitle%3DNovel%2520dihydropyrimidinoisoquinolinones%2520and%2520pharmaceutical%2520compositions%2520thereof%2520for%2520the%2520treatment%2520of%2520inflammatory%2520disorders%2520%2528gpr84%2520antagonists%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit147b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gilbert, F.; Robert, G. J.; Jonathan, L.; Maurice, L. R.; Fletcher, S. R.</span><span> </span><span class="NLM_article-title">Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders</span>. U.S. Patent 20140121204 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=F.+Gilbert&author=G.+J.+Robert&author=L.+Jonathan&author=L.+R.+Maurice&author=S.+R.+Fletcher&title=Novel+dihydropyrimidinoisoquinolinones+and+pharmaceutical+compositions+thereof+for+the+treatment+of+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DF.%26atitle%3DNovel%2520dihydropyrimidinoisoquinolinones%2520and%2520pharmaceutical%2520compositions%2520thereof%2520for%2520the%2520treatment%2520of%2520inflammatory%2520disorders%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Stadlwieser, J.; Schmidt, B.; Bernsmann, H.; Dunkern, T.; Benediktus, E.; Pahl, A.; Hussong, R.; Nimz, O.; Mueller, M.; Viertelhaus, M.</span><span> </span><span class="NLM_article-title">Methylpyrrolopyrimidinecarboxamides</span>. U.S. Patent 20150073001,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Stadlwieser&author=B.+Schmidt&author=H.+Bernsmann&author=T.+Dunkern&author=E.+Benediktus&author=A.+Pahl&author=R.+Hussong&author=O.+Nimz&author=M.+Mueller&author=M.+Viertelhaus&title=Methylpyrrolopyrimidinecarboxamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStadlwieser%26aufirst%3DJ.%26atitle%3DMethylpyrrolopyrimidinecarboxamides%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hood, J.; Kumar, S. K. C.; Wallace, D. M.</span><span> </span><span class="NLM_article-title">1H-Pyrazolo[3,4-b]pyridines and therapeutic uses thereof</span>. U.S. Patent 20150150862,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Hood&author=S.+K.+C.+Kumar&author=D.+M.+Wallace&title=1H-Pyrazolo%5B3%2C4-b%5Dpyridines+and+therapeutic+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHood%26aufirst%3DJ.%26atitle%3D1H-Pyrazolo%255B3%252C4-b%255Dpyridines%2520and%2520therapeutic%2520uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit149b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hood, J.; Kumar, S. K. C.; Wallace, D. M.</span><span> </span><span class="NLM_article-title">1H-Pyrazolo[3,4-b]pyridines and therapeutic uses thereof</span>. U.S. Patent 20130296302,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Hood&author=S.+K.+C.+Kumar&author=D.+M.+Wallace&title=1H-Pyrazolo%5B3%2C4-b%5Dpyridines+and+therapeutic+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHood%26aufirst%3DJ.%26atitle%3D1H-Pyrazolo%255B3%252C4-b%255Dpyridines%2520and%2520therapeutic%2520uses%2520thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Notte, G.</span><span> </span><span class="NLM_article-title">Apoptosis signal-regulating kinase inhibitors</span>. U.S. Patent 20140179663 A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+Notte&title=Apoptosis+signal-regulating+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNotte%26aufirst%3DG.%26atitle%3DApoptosis%2520signal-regulating%2520kinase%2520inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Allegretti, M.; Cesta, M. C.; Bertini, R.; Mosca, M.; Colotta, F.</span><span> </span><span class="NLM_article-title">2-Phenylpropionic acid derivatives and pharmaceutical compositions containing them</span>. U.S. Patent 20120004264 A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Allegretti&author=M.+C.+Cesta&author=R.+Bertini&author=M.+Mosca&author=F.+Colotta&title=2-Phenylpropionic+acid+derivatives+and+pharmaceutical+compositions+containing+them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DM.%26atitle%3D2-Phenylpropionic%2520acid%2520derivatives%2520and%2520pharmaceutical%2520compositions%2520containing%2520them%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Moriconi, A.; Allegretti, M.; Cesta, M. C.; Bertini, R.; Bizzarri, C.; Colotta, F.</span><span> </span><span class="NLM_article-title">2-Aryl-acetic acids, their derivatives and pharmaceutical compositions containing them</span>. U.S. Patent 20110195967 A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Moriconi&author=M.+Allegretti&author=M.+C.+Cesta&author=R.+Bertini&author=C.+Bizzarri&author=F.+Colotta&title=2-Aryl-acetic+acids%2C+their+derivatives+and+pharmaceutical+compositions+containing+them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoriconi%26aufirst%3DA.%26atitle%3D2-Aryl-acetic%2520acids%252C%2520their%2520derivatives%2520and%2520pharmaceutical%2520compositions%2520containing%2520them%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Holsinger, L.</span><span> </span><span class="NLM_article-title">Inhibitors of cathepsinb</span>. U.S. Patent 20090203629 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=L.+Holsinger&title=Inhibitors+of+cathepsinb"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHolsinger%26aufirst%3DL.%26atitle%3DInhibitors%2520of%2520cathepsinb%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Kossen, K.; Seiwert, S. D.; Serebryany, V.; Ruhrmund, D.; Beigelman, L.; Raveglia, L. F.; Vallese, S.; Bianchi, I.; Hu, T.</span><span> </span><span class="NLM_article-title">Compounds and methods for treating inflammatory and fibrotic disorders</span>. U.S. Patent 20090318455 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Kossen&author=S.+D.+Seiwert&author=V.+Serebryany&author=D.+Ruhrmund&author=L.+Beigelman&author=L.+F.+Raveglia&author=S.+Vallese&author=I.+Bianchi&author=T.+Hu&title=Compounds+and+methods+for+treating+inflammatory+and+fibrotic+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKossen%26aufirst%3DK.%26atitle%3DCompounds%2520and%2520methods%2520for%2520treating%2520inflammatory%2520and%2520fibrotic%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Gant, T. G.; Sarshar, S.</span><span> </span><span class="NLM_article-title">Substituted n-aryl pyridinones</span>. U.S. Patent 20080319026 A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+G.+Gant&author=S.+Sarshar&title=Substituted+n-aryl+pyridinones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DSubstituted%2520n-aryl%2520pyridinones%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Hart, B.; Axon, J. R.; Chakravarty, S.; Murphy, A.; Mcenroe, G.</span><span> </span><span class="NLM_article-title">Heterocyclic inhibitors of TGF-β</span>. WO 2006105063 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+Hart&author=J.+R.+Axon&author=S.+Chakravarty&author=A.+Murphy&author=G.+Mcenroe&title=Heterocyclic+inhibitors+of+TGF-%CE%B2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DB.%26atitle%3DHeterocyclic%2520inhibitors%2520of%2520TGF-%25CE%25B2%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Levin, J.; Li, Z.; Diamantidis, G.; Lovering, F.; Wang, W.; Condon, J.; Lin, Y.- I.; Skotnicki, J.; Park, K.</span><span> </span><span class="NLM_article-title">Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase</span>. U.S. Patent 20060211730 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+Levin&author=Z.+Li&author=G.+Diamantidis&author=F.+Lovering&author=W.+Wang&author=J.+Condon&author=Y.-+I.+Lin&author=J.+Skotnicki&author=K.+Park&title=Beta-sulfonamide+hydroxamic+acid+inhibitors+of+tace%2Fmatrix+metalloproteinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DJ.%26atitle%3DBeta-sulfonamide%2520hydroxamic%2520acid%2520inhibitors%2520of%2520tace%252Fmatrix%2520metalloproteinase%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nanthakumar, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatley, R. J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauldie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span><span class="refDoi"> DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26338155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&author=C.+B.+Nanthakumarauthor=R.+J.+D.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+F.+Macdonald&title=Dissecting+fibrosis%3A+therapeutic+insights+from+the+small-molecule+toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158aR"><div class="casContent"><span class="casTitleNuber">158a</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span></div><div class="casAuthors">Nanthakumar, Carmel B.; Hatley, Richard J. D.; Lemma, Seble; Gauldie, Jack; Marshall, Richard P.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-720</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estd. to contribute to ∼45% of deaths in the developed world, and so new therapeutics to modulate fibrosis are urgently needed.  Major advances in our understanding of the mechanisms underlying pathol. fibrosis are supporting the search for such therapeutics, and the recent approval of two anti-fibrotic drugs for idiopathic pulmonary fibrosis has demonstrated the tractability of this area for drug discovery.  This Review examines the pharmacol. and structural information for small mols. being evaluated for lung, liver, kidney and skin fibrosis.  In particular, we discuss the insights gained from the use of these pharmacol. tools, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk6pfSk3gsCrVg90H21EOLACvtfcHk0lhznmhxx8eRFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ&md5=b05a37db6ede2acc0f5c65826aa344f3</span></div><a href="/servlet/linkout?suffix=cit158a&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%2BD.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DDissecting%2520fibrosis%253A%2520therapeutic%2520insights%2520from%2520the%2520small-molecule%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit158b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span><span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158bR"><div class="casContent"><span class="casTitleNuber">158b</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lhznmhxx8eRFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit158b&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159a"><span><span class="NLM_label">(a) </span><span> </span><span class="NLM_article-title">Regulatory watch: First drug for idiopathic pulmonary fibrosis approved in Japan</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">966</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span>, DOI: <span class="refDoi"> DOI: 10.1038/nrd2767</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1038%2Fnrd2767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Regulatory+watch%3A+First+drug+for+idiopathic+pulmonary+fibrosis+approved+in+Japan.+Nat.+Rev.+Drug+Discovery+2008%2C+7%2C+966%E2%80%93967%2C+DOI%3A+10.1038%2Fnrd2767."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2767%26sid%3Dliteratum%253Aachs%26atitle%3DRegulatory%2520watch%253A%2520First%2520drug%2520for%2520idiopathic%2520pulmonary%2520fibrosis%2520approved%2520in%2520Japan%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D966%26epage%3D967%26doi%3D10.1038%2Fnrd2767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit159b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Macías-Barragán, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandoval-Rodríguez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro-Partida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armendáriz-Borunda, J.</span><span> </span><span class="NLM_article-title">The multifaceted role of pirfenidone and its novel targets</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="refDoi"> DOI: 10.1186/1755-1536-3-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1186%2F1755-1536-3-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=20809935" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=16&author=J.+Mac%C3%ADas-Barrag%C3%A1nauthor=A.+Sandoval-Rodr%C3%ADguezauthor=J.+Navarro-Partidaauthor=J.+Armend%C3%A1riz-Borunda&title=The+multifaceted+role+of+pirfenidone+and+its+novel+targets&doi=10.1186%2F1755-1536-3-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159b&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-3-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-3-16%26sid%3Dliteratum%253Aachs%26aulast%3DMac%25C3%25ADas-Barrag%25C3%25A1n%26aufirst%3DJ.%26aulast%3DSandoval-Rodr%25C3%25ADguez%26aufirst%3DA.%26aulast%3DNavarro-Partida%26aufirst%3DJ.%26aulast%3DArmend%25C3%25A1riz-Borunda%26aufirst%3DJ.%26atitle%3DThe%2520multifaceted%2520role%2520of%2520pirfenidone%2520and%2520its%2520novel%2520targets%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2010%26volume%3D3%26spage%3D16%26doi%3D10.1186%2F1755-1536-3-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit159c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Han, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwangbo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span> </span><span class="NLM_article-title">A phase II study of nintedanib in patients with relapsed small cell lung cancer</span> <span class="citation_source-journal">Lung Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2016.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.lungcan.2016.04.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=108-112&author=Y.+J.+Hanauthor=H.+Y.+Kimauthor=K.+Y.+Limauthor=B.+Hwangboauthor=J.+S.+Lee&title=A+phase+II+study+of+nintedanib+in+patients+with+relapsed+small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2016.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159c&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DLim%26aufirst%3DK.%2BY.%26aulast%3DHwangbo%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520nintedanib%2520in%2520patients%2520with%2520relapsed%2520small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer.%26date%3D2016%26volume%3D96%26spage%3D108%26epage%3D112%26doi%3D10.1016%2Fj.lungcan.2016.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Korfei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skwarna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henneke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klymenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von der Beck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahavadi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellusci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crestani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullamsetti, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krämer, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guenther, A.</span><span> </span><span class="NLM_article-title">Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1032</span><span class="refDoi"> DOI: 10.1136/thoraxjnl-2014-206411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1136%2Fthoraxjnl-2014-206411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26359372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC283htFemsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=1022-1032&author=M.+Korfeiauthor=S.+Skwarnaauthor=I.+Hennekeauthor=B.+MacKenzieauthor=O.+Klymenkoauthor=S.+Saitoauthor=C.+Ruppertauthor=D.+von+der+Beckauthor=P.+Mahavadiauthor=W.+Klepetkoauthor=S.+Bellusciauthor=B.+Crestaniauthor=S.+S.+Pullamsettiauthor=L.+Finkauthor=W.+Seegerauthor=O.+H.+Kr%C3%A4merauthor=A.+Guenther&title=Aberrant+expression+and+activity+of+histone+deacetylases+in+sporadic+idiopathic+pulmonary+fibrosis&doi=10.1136%2Fthoraxjnl-2014-206411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Korfei Martina; Skwarna Sylwia; Henneke Ingrid; MacKenzie BreAnne; Klymenko Oleksiy; von der Beck Daniel; Mahavadi Poornima; Saito Shigeki; Ruppert Clemens; Bellusci Saverio; Seeger Werner; Klepetko Walter; Crestani Bruno; Pullamsetti Soni Savai; Fink Ludger; Kramer Oliver Holger; Guenther Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1022-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Activation and differentiation of fibroblasts into contractile protein-expressing myofibroblasts and their acquired apoptosis-resistant phenotype are critical factors towards the development of idiopathic pulmonary fibrosis (IPF), a fatal disease characterised by distorted pulmonary structure and excessive extracellular matrix (ECM) deposition.  The molecular mechanisms underlying these processes in IPF remain incompletely understood.  We investigated the possible implication of aberrant overexpression and activity of histone deacetylases (HDACs) in IPF.  METHODS:  We analysed lung tissues from patients with sporadic IPF (n=26) and non-diseased control lungs (n=16) for expression of class I and II HDACs.  Primary IPF fibroblasts were treated with HDAC inhibitors (HDACi) LBH589 or valproic acid (VPA).  RESULTS:  Compared to control lungs, protein levels of class I (HDAC1, HDAC2, HDAC3, HDAC8) and class II HDACs (HDAC4, HDAC 5, HDAC 7, HDAC 9) were significantly elevated in IPF lungs.  Using immunohistochemistry, strong induction of nearly all HDAC enzymes was observed in myofibroblasts of fibroblast foci and in abnormal bronchiolar basal cells at sites of aberrant re-epithelialisation in IPF lungs, but not in controls.  Treatment of primary IPF fibroblasts with the pan-HDACi LBH589 resulted in significantly reduced expression of genes associated with ECM synthesis, proliferation and cell survival, as well as in suppression of HDAC7, and was paralleled by induction of endoplasmic reticulum stress and apoptosis.  The profibrotic and apoptosis-resistant phenotype of IPF fibroblasts was also partly attenuated by the class I HDACi VPA.  CONCLUSIONS:  Aberrant overexpression of HDACs in basal cells of IPF lungs may contribute to the bronchiolisation process in this disease.  Similarly, generation and apoptosis resistance of IPF fibroblasts are mediated by enhanced activity of HDAC enzymes.  Therefore, pan-HDAC inhibition by LBH589 may present a novel therapeutic option for patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAcwMJAE2LJNhSDZx9hyjKfW6udTcc2ebEZdE6zn0t8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htFemsQ%253D%253D&md5=621f4bd5c66ff41ed4c4cbf894644a4a</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2014-206411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2014-206411%26sid%3Dliteratum%253Aachs%26aulast%3DKorfei%26aufirst%3DM.%26aulast%3DSkwarna%26aufirst%3DS.%26aulast%3DHenneke%26aufirst%3DI.%26aulast%3DMacKenzie%26aufirst%3DB.%26aulast%3DKlymenko%26aufirst%3DO.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DRuppert%26aufirst%3DC.%26aulast%3Dvon%2Bder%2BBeck%26aufirst%3DD.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DBellusci%26aufirst%3DS.%26aulast%3DCrestani%26aufirst%3DB.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DFink%26aufirst%3DL.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%2BH.%26aulast%3DGuenther%26aufirst%3DA.%26atitle%3DAberrant%2520expression%2520and%2520activity%2520of%2520histone%2520deacetylases%2520in%2520sporadic%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DThorax%26date%3D2015%26volume%3D70%26spage%3D1022%26epage%3D1032%26doi%3D10.1136%2Fthoraxjnl-2014-206411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, E.</span><span> </span><span class="NLM_article-title">The medicinal chemistry of hybrid-based drugs targeting multiple sites of action</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2714</span><span class="NLM_x">–</span> <span class="NLM_lpage">2715</span><span class="refDoi"> DOI: 10.2174/156802611798184382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F156802611798184382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22039874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2714-2715&author=J.+Marco-Contellesauthor=E.+Soriano&title=The+medicinal+chemistry+of+hybrid-based+drugs+targeting+multiple+sites+of+action&doi=10.2174%2F156802611798184382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161aR"><div class="casContent"><span class="casTitleNuber">161a</span><div class="casTitle"><span class="NLM_cas:atitle">The medicinal chemistry of hybrid-based drugs targeting multiple sites of action</span></div><div class="casAuthors">Marco-Contelles, Jose; Soriano, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2714-2715</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz2NIERHgjDrVg90H21EOLACvtfcHk0lhtMZj8YEkD6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtLc%253D&md5=3764c335948f5ab792c5d9b764e8892c</span></div><a href="/servlet/linkout?suffix=cit161a&amp;dbid=16384&amp;doi=10.2174%2F156802611798184382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184382%26sid%3Dliteratum%253Aachs%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSoriano%26aufirst%3DE.%26atitle%3DThe%2520medicinal%2520chemistry%2520of%2520hybrid-based%2520drugs%2520targeting%2520multiple%2520sites%2520of%2520action%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2714%26epage%3D2715%26doi%3D10.2174%2F156802611798184382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit161b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Viegas-Junior, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danuello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Silva Bolzani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barreiro, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraga, C. A.</span><span> </span><span class="NLM_article-title">Molecular hybridization: a useful tool in the design of new drug prototypes</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1829</span><span class="NLM_x">–</span> <span class="NLM_lpage">1852</span><span class="refDoi"> DOI: 10.2174/092986707781058805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F092986707781058805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=17627520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFanuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1829-1852&author=C.+Viegas-Juniorauthor=A.+Danuelloauthor=V.+da+Silva+Bolzaniauthor=E.+J.+Barreiroauthor=C.+A.+Fraga&title=Molecular+hybridization%3A+a+useful+tool+in+the+design+of+new+drug+prototypes&doi=10.2174%2F092986707781058805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161bR"><div class="casContent"><span class="casTitleNuber">161b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular hybridization: a useful tool in the design of new drug prototypes</span></div><div class="casAuthors">Viegas-Junior, Claudio; Danuello, Amanda; da Silva Bolzani, Vanderlan; Barreiro, Eliezer J.; Fraga, Carlos Alberto Manssour</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1829-1852</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mol. hybridization is a new concept in drug design and development based on the combination of pharmacophoric moieties of different bioactive substances to produce a new hybrid compd. with improved affinity and efficacy, when compared to the parent drugs.  Addnl., this strategy can result in compds. presenting modified selectivity profile, different and/or dual modes of action and reduced undesired side effects.  So, in this paper, we described several examples of different strategies for drug design, discovery and pharmacomodulation focused on new innovative hybrid compds. presenting analgesic, anti-inflammatory, platelet anti-aggregating, anti-infectious, anticancer, cardio- and neuroactive properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvbzA71FPqLVg90H21EOLACvtfcHk0lhzPL9gfoGIUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFanuro%253D&md5=7d3a16e3deeacb735bc0357fc6a99c37</span></div><a href="/servlet/linkout?suffix=cit161b&amp;dbid=16384&amp;doi=10.2174%2F092986707781058805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707781058805%26sid%3Dliteratum%253Aachs%26aulast%3DViegas-Junior%26aufirst%3DC.%26aulast%3DDanuello%26aufirst%3DA.%26aulast%3Dda%2BSilva%2BBolzani%26aufirst%3DV.%26aulast%3DBarreiro%26aufirst%3DE.%2BJ.%26aulast%3DFraga%26aufirst%3DC.%2BA.%26atitle%3DMolecular%2520hybridization%253A%2520a%2520useful%2520tool%2520in%2520the%2520design%2520of%2520new%2520drug%2520prototypes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D1829%26epage%3D1852%26doi%3D10.2174%2F092986707781058805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit161c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Biot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chibale, K.</span><span> </span><span class="NLM_article-title">Novel approaches to antimalarial drug discovery</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.2174/187152606784112155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.2174%2F187152606784112155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16789878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFersL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=173-204&author=C.+Biotauthor=K.+Chibale&title=Novel+approaches+to+antimalarial+drug+discovery&doi=10.2174%2F187152606784112155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161cR"><div class="casContent"><span class="casTitleNuber">161c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches to antimalarial drug discovery</span></div><div class="casAuthors">Biot, Christophe; Chibale, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-204</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Major advances in the understanding of malaria parasite biol. have been made.  Coupled with the completion of the malaria genome, this has presented exciting opportunities for target-based antimalarial drug discovery.  However, the unraveling of more validated biol. targets will not necessarily translate into the identification of new chem. entities that are effective against drug-resistant parasites in the long term.  As history has already shown, development of antiplasmodial agents aimed at a single parasite target or specialized process has failed to stem the tide of drug resistance.  This review highlights recent starting points and(or) approaches to antimalarial drug discovery with particular emphasis on innovative efforts, which are not necessarily based on the identification of new drug targets and attendant inhibitor design.  Approaches covered include utilization of validated chem. scaffolds, bioprecursor and carrier prodrugs, double drug development and(or) multi-therapeutic strategies, use of metallocenic scaffolds, the medicinal chem. of antimalarial natural products, and in silico drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKDqBssJ35LVg90H21EOLACvtfcHk0lhzPL9gfoGIUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFersL0%253D&md5=f0e513e08db67f0f0186d279142cf99a</span></div><a href="/servlet/linkout?suffix=cit161c&amp;dbid=16384&amp;doi=10.2174%2F187152606784112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606784112155%26sid%3Dliteratum%253Aachs%26aulast%3DBiot%26aufirst%3DC.%26aulast%3DChibale%26aufirst%3DK.%26atitle%3DNovel%2520approaches%2520to%2520antimalarial%2520drug%2520discovery%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D173%26epage%3D204%26doi%3D10.2174%2F187152606784112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit161d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tietze, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekhar, S.</span><span> </span><span class="NLM_article-title">Natural product hybrids as new leads for drug discovery</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3996</span><span class="NLM_x">–</span> <span class="NLM_lpage">4028</span><span class="refDoi"> DOI: 10.1002/anie.200200553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1002%2Fanie.200200553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslSlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=3996-4028&author=L.+F.+Tietzeauthor=H.+P.+Bellauthor=S.+Chandrasekhar&title=Natural+product+hybrids+as+new+leads+for+drug+discovery&doi=10.1002%2Fanie.200200553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161dR"><div class="casContent"><span class="casTitleNuber">161d</span><div class="casTitle"><span class="NLM_cas:atitle">Natural product hybrids as new leads for drug discovery</span></div><div class="casAuthors">Tietze, Lutz F.; Bell, Hubertus P.; Chandrasekhar, Srivari</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3996-4028</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Natural products play an important role in the development of drugs, esp. for the treatment of infections and cancer, as well as immunosuppressive compds.  However, the no. of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepd.  This new approach seems to be very promising in the development of leads for both medicinal and agrochem. applications, as the biol. activity of several new hybrids exceeds that of the parent compds.  The advantage of this concept over a combinatorial chem. approach is the high diversity and the inherent biol. activity of the hybrids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGTkEzD4p1YbVg90H21EOLACvtfcHk0lg6AJvpWHnxTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslSlsrk%253D&md5=b0582d7a40ce53ce5b957b287b74d750</span></div><a href="/servlet/linkout?suffix=cit161d&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200553%26sid%3Dliteratum%253Aachs%26aulast%3DTietze%26aufirst%3DL.%2BF.%26aulast%3DBell%26aufirst%3DH.%2BP.%26aulast%3DChandrasekhar%26aufirst%3DS.%26atitle%3DNatural%2520product%2520hybrids%2520as%2520new%2520leads%2520for%2520drug%2520discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D3996%26epage%3D4028%26doi%3D10.1002%2Fanie.200200553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">Molecular biomarkers in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Physiol. Lung Cell Mol. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">L681</span><span class="NLM_x">–</span> <span class="NLM_lpage">L691</span><span class="refDoi"> DOI: 10.1152/ajplung.00014.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1152%2Fajplung.00014.2014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2014&pages=L681-L691&author=B.+Leyauthor=K.+K.+Brownauthor=H.+R.+Collard&title=Molecular+biomarkers+in+idiopathic+pulmonary+fibrosis&doi=10.1152%2Fajplung.00014.2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00014.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00014.2014%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DB.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DMolecular%2520biomarkers%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2014%26volume%3D307%26spage%3DL681%26epage%3DL691%26doi%3D10.1152%2Fajplung.00014.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit162b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Small molecular inhibitors targeting activator protein 1 (AP-1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6930</span><span class="NLM_x">–</span> <span class="NLM_lpage">6948</span><span class="refDoi"> DOI: 10.1021/jm5004733</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004733" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6930-6948&author=N.+Yeauthor=Y.+Dingauthor=C.+Wildauthor=Q.+Shenauthor=J.+Zhou&title=Small+molecular+inhibitors+targeting+activator+protein+1+%28AP-1%29&doi=10.1021%2Fjm5004733"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=10.1021%2Fjm5004733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004733%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DWild%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DSmall%2520molecular%2520inhibitors%2520targeting%2520activator%2520protein%25201%2520%2528AP-1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6930%26epage%3D6948%26doi%3D10.1021%2Fjm5004733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit162c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jarman, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khambata, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cope, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellenie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarai, G.</span><span> </span><span class="NLM_article-title">An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">158</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1165/rcmb.2013-0174OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1165%2Frcmb.2013-0174OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23977848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtV2mtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=158-169&author=E.+R.+Jarmanauthor=V.+S.+Khambataauthor=C.+Copeauthor=P.+Jonesauthor=J.+Rogerauthor=L.+Y.+Yeauthor=N.+Dugganauthor=D.+Headauthor=A.+Pearceauthor=N.+J.+Pressauthor=B.+Bellenieauthor=B.+Sohalauthor=G.+Jarai&title=An+inhibitor+of+NADPH+oxidase-4+attenuates+established+pulmonary+fibrosis+in+a+rodent+disease+model&doi=10.1165%2Frcmb.2013-0174OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162cR"><div class="casContent"><span class="casTitleNuber">162c</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model</span></div><div class="casAuthors">Jarman, Elizabeth R.; Khambata, Valerie S.; Cope, Claire; Jones, Peter; Roger, Jan; Ye, Li Yun; Duggan, Nicholas; Head, Denise; Pearce, Andrew; Press, Neil J.; Bellenie, Ben; Sohal, Bindi; Jarai, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-169, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a chronic progressive disease of increasing prevalence for which there is no effective therapy.  Increased oxidative stress assocd. with an oxidant-antioxidant imbalance is thought to contribute to disease progression.  NADPH oxidases (Nox) are a primary source of reactive oxygen species within the lung and cardiovascular system.  We demonstrate that the Nox4 isoform is up-regulated in the lungs of patients with IPF and in a rodent model of bleomycin-induced pulmonary fibrosis and vascular remodeling.  Nox4 is constitutively active, and therefore increased expression levels are likely to contribute to disease pathol.  Using a small mol. Nox4/Nox1 inhibitor, we demonstrate that targeting Nox4 results in attenuation of an established fibrotic response, with redns. in gene transcripts for the extracellular matrix components collagen 1α1, collagen 3α1, and fibronectin and in principle pathway components assocd. with pulmonary fibrosis and hypoxia-mediated vascular remodeling: transforming growth factor (TGF)-β1, plasminogen activator inhibitor-1, hypoxia-inducible factor, and Nox4.  TGF-β1 is a principle fibrotic mediator responsible for inducing up-regulation of profibrotic pathways assocd. with disease pathol.  Using normal human lung-derived primary fibroblasts, we demonstrate that inhibition of Nox4 activity using a small mol. antagonist attenuates TGF-β1-mediated up-regulation in expression of profibrotic genes and inhibits the differentiation of fibroblast to myofibroblasts, that is assocd. with up-regulation in smooth muscle actin and acquisition of a contractile phenotype.  These studies support the view that targeting Nox4 may provide a therapeutic approach for attenuating pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWfXYamqYDi7Vg90H21EOLACvtfcHk0ljnq6lME8Zbgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtV2mtr4%253D&md5=da9e2288b3be2c59a9991f8e69f83902</span></div><a href="/servlet/linkout?suffix=cit162c&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2013-0174OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2013-0174OC%26sid%3Dliteratum%253Aachs%26aulast%3DJarman%26aufirst%3DE.%2BR.%26aulast%3DKhambata%26aufirst%3DV.%2BS.%26aulast%3DCope%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DRoger%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DL.%2BY.%26aulast%3DDuggan%26aufirst%3DN.%26aulast%3DHead%26aufirst%3DD.%26aulast%3DPearce%26aufirst%3DA.%26aulast%3DPress%26aufirst%3DN.%2BJ.%26aulast%3DBellenie%26aufirst%3DB.%26aulast%3DSohal%26aufirst%3DB.%26aulast%3DJarai%26aufirst%3DG.%26atitle%3DAn%2520inhibitor%2520of%2520NADPH%2520oxidase-4%2520attenuates%2520established%2520pulmonary%2520fibrosis%2520in%2520a%2520rodent%2520disease%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D50%26spage%3D158%26epage%3D169%26doi%3D10.1165%2Frcmb.2013-0174OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit162d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Vij, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noth, I.</span><span> </span><span class="NLM_article-title">Peripheral blood biomarkers in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Transl. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.trsl.2012.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.trsl.2012.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=22424426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVGntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2012&pages=218-227&author=R.+Vijauthor=I.+Noth&title=Peripheral+blood+biomarkers+in+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.trsl.2012.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162dR"><div class="casContent"><span class="casTitleNuber">162d</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral blood biomarkers in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Vij, Rekha; Noth, Imre</div><div class="citationInfo"><span class="NLM_cas:title">Translational Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">218-227</span>CODEN:
                <span class="NLM_cas:coden">TRRECL</span>;
        ISSN:<span class="NLM_cas:issn">1878-1810</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">In this article, we review the evidence for peripheral blood biomarkers in idiopathic pulmonary fibrosis (IPF), a life-threatening fibrotic lung disease of unknown etiol.  We focus on selected biomarkers present in peripheral blood, as they are easy to obtain, can be measured longitudinally, and have the greatest likelihood of achieving clin. utility.  This article concs. on biomarkers with mechanistic plausibility that may be directly involved in the development of IPF, including KL-6, surfactant proteins A and D, matrix metalloproteases (MMP) 1 and 7, CCL18, VEGF, YKL-40, osteopontin, circulating fibrocytes, and T cells.  After reviewing the evidence base for each, we designate the biomarkers that may have utility as: (1) diagnostic biomarkers to distinguish IPF from other interstitial lung diseases, (2) prognostic biomarkers that are correlated with disease progression or mortality, or (3) biomarkers that can be used as tools for serial monitoring of disease severity.  Although there are no validated biomarkers that are currently available, the need for surrogates of diagnosis, prognosis, and monitoring of disease course with emerging therapies is great.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEIy7th6E_17Vg90H21EOLACvtfcHk0ljnq6lME8Zbgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVGntLs%253D&md5=4636c31e0d430ca5596a87af5c6f6123</span></div><a href="/servlet/linkout?suffix=cit162d&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2012.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2012.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DVij%26aufirst%3DR.%26aulast%3DNoth%26aufirst%3DI.%26atitle%3DPeripheral%2520blood%2520biomarkers%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DTransl.%2520Res.%26date%3D2012%26volume%3D159%26spage%3D218%26epage%3D227%26doi%3D10.1016%2Fj.trsl.2012.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Orens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estenne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcasoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshavjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotloff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vachiery, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanville, A. R.</span><span> </span><span class="NLM_article-title">International guidelines for the selection of lung transplant candidates: 2006 updates-a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation</span> <span class="citation_source-journal">J. Heart. Lung. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1016/j.healun.2006.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.healun.2006.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=16818116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD28zpvFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=J.+B.+Orensauthor=M.+Estenneauthor=S.+Arcasoyauthor=J.+V.+Conteauthor=P.+Corrisauthor=J.+J.+Eganauthor=T.+Eganauthor=S.+Keshavjeeauthor=C.+Knoopauthor=R.+Kotloffauthor=F.+J.+Martinezauthor=S.+Nathanauthor=S.+Palmerauthor=A.+Pattersonauthor=L.+Singerauthor=G.+Snellauthor=S.+Studerauthor=J.+L.+Vachieryauthor=A.+R.+Glanville&title=International+guidelines+for+the+selection+of+lung+transplant+candidates%3A+2006+updates-a+consensus+report+from+the+pulmonary+scientific+council+of+the+international+society+for+heart+and+lung+transplantation&doi=10.1016%2Fj.healun.2006.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation</span></div><div class="casAuthors">Orens Jonathan B; Estenne Marc; Arcasoy Selim; Conte John V; Corris Paul; Egan Jim J; Egan Thomas; Keshavjee Shaf; Knoop Christiane; Kotloff Robert; Martinez Fernando J; Nathan Steven; Palmer Scott; Patterson Alec; Singer Lianne; Snell Gregory; Studer Sean; Vachiery J L; Glanville Allan R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">745-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlo1JPaJWqwJVVjGoY74BafW6udTcc2ealCZnkgB1F8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zpvFOrsg%253D%253D&md5=8aaba362d6b0fcec46366a6b06b6212c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2006.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2006.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DOrens%26aufirst%3DJ.%2BB.%26aulast%3DEstenne%26aufirst%3DM.%26aulast%3DArcasoy%26aufirst%3DS.%26aulast%3DConte%26aufirst%3DJ.%2BV.%26aulast%3DCorris%26aufirst%3DP.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26aulast%3DEgan%26aufirst%3DT.%26aulast%3DKeshavjee%26aufirst%3DS.%26aulast%3DKnoop%26aufirst%3DC.%26aulast%3DKotloff%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNathan%26aufirst%3DS.%26aulast%3DPalmer%26aufirst%3DS.%26aulast%3DPatterson%26aufirst%3DA.%26aulast%3DSinger%26aufirst%3DL.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DStuder%26aufirst%3DS.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGlanville%26aufirst%3DA.%2BR.%26atitle%3DInternational%2520guidelines%2520for%2520the%2520selection%2520of%2520lung%2520transplant%2520candidates%253A%25202006%2520updates-a%2520consensus%2520report%2520from%2520the%2520pulmonary%2520scientific%2520council%2520of%2520the%2520international%2520society%2520for%2520heart%2520and%2520lung%2520transplantation%26jtitle%3DJ.%2520Heart.%2520Lung.%2520Transplant.%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755%26doi%3D10.1016%2Fj.healun.2006.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Weill, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dark, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshavjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verleden, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamora, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanville, A. R.</span><span> </span><span class="NLM_article-title">A consensus document for the selection of lung transplant candidates: 2014-an updates from the pulmonary transplantation council of the international society for heart and lung transplantation</span> <span class="citation_source-journal">J. Heart. Lung. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.healun.2014.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.healun.2014.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25085497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2cbotFehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=1-15&author=D.+Weillauthor=C.+Bendenauthor=P.+A.+Corrisauthor=J.+H.+Darkauthor=R.+D.+Davisauthor=S.+Keshavjeeauthor=D.+J.+Ledererauthor=M.+J.+Mulliganauthor=G.+A.+Pattersonauthor=L.+G.+Singerauthor=G.+I.+Snellauthor=G.+M.+Verledenauthor=M.+R.+Zamoraauthor=A.+R.+Glanville&title=A+consensus+document+for+the+selection+of+lung+transplant+candidates%3A+2014-an+updates+from+the+pulmonary+transplantation+council+of+the+international+society+for+heart+and+lung+transplantation&doi=10.1016%2Fj.healun.2014.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation</span></div><div class="casAuthors">Weill David; Benden Christian; Corris Paul A; Dark John H; Davis R Duane; Keshavjee Shaf; Singer Lianne G; Lederer David J; Mulligan Michael J; Patterson G Alexander; Snell Greg I; Verleden Geert M; Zamora Martin R; Glanville Allan R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The appropriate selection of lung transplant recipients is an important determinant of outcomes.  This consensus document is an update of the recipient selection guidelines published in 2006.  The Pulmonary Council of the International Society for Heart and Lung Transplantation (ISHLT) organized a Writing Committee of international experts to provide consensus opinion regarding the appropriate timing of referral and listing of candidates for lung transplantation.  A comprehensive search of the medical literature was conducted with the assistance of a medical librarian.  Writing Committee members were assigned specific topics to research and discuss.  The Chairs of the Writing Committee were responsible for evaluating the completeness of the literature search, providing editorial support for the manuscript, and organizing group discussions regarding its content.  The consensus document makes specific recommendations regarding the timing of referral and of listing for lung transplantation.  These recommendations include discussions not present in previous ISHLT guidelines, including lung allocation scores, bridging to transplant with mechanical circulatory and ventilator support, and expanded indications for lung transplantation.  In the absence of high-grade evidence to support decision making, these consensus guidelines remain part of a continuum of expert opinion based on available studies and personal experience.  Some positions are immutable.  Although transplant is rightly a treatment of last resort for end-stage lung disease, early referral allows proper evaluation and thorough patient education.  Subsequent waiting list activation implies a tacit agreement that transplant offers a significant individual survival advantage.  It is both the challenge and the responsibility of the transplant community globally to ensure organ allocation maximizes the potential benefits of a scarce resource, thereby achieving that advantage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPdE4kgM2ochOk4JA3soTqfW6udTcc2eZvVD8B9fGP47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbotFehuw%253D%253D&md5=cccd0b6dc28554515625ebbbb0e99878</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2014.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2014.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DWeill%26aufirst%3DD.%26aulast%3DBenden%26aufirst%3DC.%26aulast%3DCorris%26aufirst%3DP.%2BA.%26aulast%3DDark%26aufirst%3DJ.%2BH.%26aulast%3DDavis%26aufirst%3DR.%2BD.%26aulast%3DKeshavjee%26aufirst%3DS.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DMulligan%26aufirst%3DM.%2BJ.%26aulast%3DPatterson%26aufirst%3DG.%2BA.%26aulast%3DSinger%26aufirst%3DL.%2BG.%26aulast%3DSnell%26aufirst%3DG.%2BI.%26aulast%3DVerleden%26aufirst%3DG.%2BM.%26aulast%3DZamora%26aufirst%3DM.%2BR.%26aulast%3DGlanville%26aufirst%3DA.%2BR.%26atitle%3DA%2520consensus%2520document%2520for%2520the%2520selection%2520of%2520lung%2520transplant%2520candidates%253A%25202014-an%2520updates%2520from%2520the%2520pulmonary%2520transplantation%2520council%2520of%2520the%2520international%2520society%2520for%2520heart%2520and%2520lung%2520transplantation%26jtitle%3DJ.%2520Heart.%2520Lung.%2520Transplant.%26date%3D2015%26volume%3D34%26spage%3D1%26epage%3D15%26doi%3D10.1016%2Fj.healun.2014.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Thabut, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauriat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jebrak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesèche, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mal, H.</span><span> </span><span class="NLM_article-title">Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.7326/0003-4819-151-11-200912010-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.7326%2F0003-4819-151-11-200912010-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=19949142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjpt1Cnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2009&pages=767-774&author=G.+Thabutauthor=J.+D.+Christieauthor=P.+Ravaudauthor=Y.+Castierauthor=G.+Dauriatauthor=G.+Jebrakauthor=M.+Fournierauthor=G.+Les%C3%A8cheauthor=R.+Porcherauthor=H.+Mal&title=Survival+after+bilateral+versus+single-lung+transplantation+for+idiopathic+pulmonary+fibrosis&doi=10.7326%2F0003-4819-151-11-200912010-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Thabut Gabriel; Christie Jason D; Ravaud Philippe; Castier Yves; Dauriat Gaelle; Jebrak Gilles; Fournier Michel; Leseche Guy; Porcher Raphael; Mal Herve</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">767-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Patients with end-stage idiopathic pulmonary fibrosis (IPF) are increasingly having bilateral rather than single-lung transplantation.  OBJECTIVE:  To compare survival after single and bilateral lung transplantation in patients with IPF.  DESIGN:  Analysis of data from the United Network of Organ Sharing registry.  SETTING:  Transplantation centers in the United States.  PATIENTS:  3327 patients with IPF who had single (2146 patients [64.5%]) or bilateral (1181 patients [35.5%]) lung transplantation between 1987 and 2009.  MEASUREMENTS:  Survival times and causes of death after lung transplantation.  Selection bias was accounted for by multivariate risk adjustment, propensity score risk adjustment, and propensity-based matching.  RESULTS:  Median survival time was longer after bilateral lung transplantation than single-lung transplantation (5.2 years [CI, 4.3 to 6.7 years] vs. 3.8 years [CI, 3.6 to 4.1 years]; P < 0.001).  However, survival times for the 2 procedures did not differ after adjustment for baseline differences, with adjusted hazard ratios (HRs) for mortality with bilateral transplantation ranging from 0.89 (95% CI, 0.79 to 1.02) to 0.96 (CI, 0.77 to 1.20) in different analyses.  Bilateral lung transplantation seemed to result in harm within the first year (HR, 1.18 [CI, 0.98 to 1.42]) but survival benefit thereafter (HR, 0.72 [CI, 0.59 to 0.87]).  Primary graft failure was a more common cause of death among patients who had bilateral rather than single-lung transplantation (3.7% vs. 1.9%; P = 0.002).  Cancer was a more common cause of death among patients who had single rather than bilateral lung transplantation (unadjusted HR for death among single vs. bilateral transplant recipients, 3.60 [CI, 2.16 to 6.05]; P <0.001).  LIMITATION:  Causes of death were ascertained without an adjudication committee and must be interpreted cautiously.  CONCLUSION:  Survival did not differ between patients who had single and bilateral lung transplantation.  Single-lung transplantation confers short-term survival benefit but long-term harm, whereas bilateral transplantation confers short-term harm but long-term survival benefit.  PRIMARY FUNDING SOURCE:  None.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSijjivBBaVk5dYoSR9eyvsfW6udTcc2ea4ZkngVocXn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjpt1Cnuw%253D%253D&md5=b89c199bbd9edb3f44e73b76fd75af64</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-151-11-200912010-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-151-11-200912010-00004%26sid%3Dliteratum%253Aachs%26aulast%3DThabut%26aufirst%3DG.%26aulast%3DChristie%26aufirst%3DJ.%2BD.%26aulast%3DRavaud%26aufirst%3DP.%26aulast%3DCastier%26aufirst%3DY.%26aulast%3DDauriat%26aufirst%3DG.%26aulast%3DJebrak%26aufirst%3DG.%26aulast%3DFournier%26aufirst%3DM.%26aulast%3DLes%25C3%25A8che%26aufirst%3DG.%26aulast%3DPorcher%26aufirst%3DR.%26aulast%3DMal%26aufirst%3DH.%26atitle%3DSurvival%2520after%2520bilateral%2520versus%2520single-lung%2520transplantation%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2009%26volume%3D151%26spage%3D767%26epage%3D774%26doi%3D10.7326%2F0003-4819-151-11-200912010-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanam, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozzay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seethamraju, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shariati, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, M. J.</span><span> </span><span class="NLM_article-title">Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation</span> <span class="citation_source-journal">J. Heart. Lung. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span><span class="refDoi"> DOI: 10.1016/j.healun.2015.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1016%2Fj.healun.2015.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26856664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28nosleqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=657-660&author=D.+Chauhanauthor=A.+B.+Karanamauthor=A.+Merloauthor=T.+Bozzayauthor=M.+J.+Zuckerauthor=H.+Seethamrajuauthor=N.+Shariatiauthor=M.+J.+Russo&title=Post-transplant+survival+in+idiopathic+pulmonary+fibrosis+patients+concurrently+listed+for+single+and+double+lung+transplantation&doi=10.1016%2Fj.healun.2015.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation</span></div><div class="casAuthors">Chauhan Dhaval; Karanam Ashwin B; Merlo Aurelie; Tom Bozzay P A; Zucker Mark J; Seethamraju Harish; Shariati Nazly; Russo Mark J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung transplantation is a widely accepted treatment for patients with end-stage lung disease related to idiopathic pulmonary fibrosis (IPF).  However, there are conflicting data on whether double lung transplant (DLT) or single lung transplant (SLT) is the superior therapy in these patients.  The purpose of this study was to determine whether actuarial post-transplant graft survival among IPF patients concurrently listed for DLT and SLT is greater for recipients undergoing the former or the latter.  METHODS:  The United Network for Organ Sharing provided de-identified patient-level data.  Analysis included lung transplant candidates with IPF listed between January 1, 2001 and December 31, 2009 (n = 3,411).  The study population included 1,001 (29.3%) lung transplant recipients concurrently listed for DLT and SLT, all ≥18 years of age.  The primary outcome measure was actuarial post-transplant graft survival, expressed in years.  RESULTS:  Among the study population, 433 (43.26%) recipients underwent SLT and 568 (56.74%) recipients underwent DLT.  The analysis included 2,722.5 years at risk, with median graft survival of 5.31 years.  On univariate (p = 0.317) and multivariate (p = 0.415) regression analyses, there was no difference in graft survival between DLT and SLT.  CONCLUSIONS:  Among IPF recipients concurrently listed for DLT and SLT, there is no statistical difference in actuarial graft survival between recipients undergoing DLT vs SLT.  This analysis suggests that increased use of SLT for IPF patients may increase the availability of organs to other candidates, and thus increase the net benefit of these organs, without measurably compromising outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ74ukb0R4Fylm8bhe6roZYfW6udTcc2ea4ZkngVocXn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nosleqsA%253D%253D&md5=04b20065ddae1833e55d29ed7e043df8</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2015.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2015.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DKaranam%26aufirst%3DA.%2BB.%26aulast%3DMerlo%26aufirst%3DA.%26aulast%3DBozzay%26aufirst%3DT.%26aulast%3DZucker%26aufirst%3DM.%2BJ.%26aulast%3DSeethamraju%26aufirst%3DH.%26aulast%3DShariati%26aufirst%3DN.%26aulast%3DRusso%26aufirst%3DM.%2BJ.%26atitle%3DPost-transplant%2520survival%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520patients%2520concurrently%2520listed%2520for%2520single%2520and%2520double%2520lung%2520transplantation%26jtitle%3DJ.%2520Heart.%2520Lung.%2520Transplant.%26date%3D2016%26volume%3D35%26spage%3D657%26epage%3D660%26doi%3D10.1016%2Fj.healun.2015.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Bennett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargagli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Refini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieroni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiribelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paladini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voltolini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottoli, P.</span><span> </span><span class="NLM_article-title">Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">681</span><span class="refDoi"> DOI: 10.1007/s00408-015-9767-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs00408-015-9767-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2015&pages=677-681&author=D.+Bennettauthor=A.+Fossiauthor=E.+Bargagliauthor=R.+M.+Refiniauthor=M.+Pieroniauthor=L.+Luzziauthor=C.+Ghiribelliauthor=P.+Paladiniauthor=L.+Voltoliniauthor=P.+Rottoli&title=Mortality+on+the+waiting+list+for+lung+transplantation+in+patients+with+idiopathic+pulmonary+fibrosis%3A+a+single-centre+experience&doi=10.1007%2Fs00408-015-9767-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1007%2Fs00408-015-9767-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-015-9767-x%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DD.%26aulast%3DFossi%26aufirst%3DA.%26aulast%3DBargagli%26aufirst%3DE.%26aulast%3DRefini%26aufirst%3DR.%2BM.%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DLuzzi%26aufirst%3DL.%26aulast%3DGhiribelli%26aufirst%3DC.%26aulast%3DPaladini%26aufirst%3DP.%26aulast%3DVoltolini%26aufirst%3DL.%26aulast%3DRottoli%26aufirst%3DP.%26atitle%3DMortality%2520on%2520the%2520waiting%2520list%2520for%2520lung%2520transplantation%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520single-centre%2520experience%26jtitle%3DLung%26date%3D2015%26volume%3D193%26spage%3D677%26epage%3D681%26doi%3D10.1007%2Fs00408-015-9767-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">He, W.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.-N.</span><span> </span><span class="NLM_article-title">Outcomes of Chinese patients with end-stage pulmonary disease while awaiting lung transplantation: a single-center study</span> <span class="citation_source-journal">Chin. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.4103/0366-6999.172547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4103%2F0366-6999.172547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26712425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC28bhs1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2016&pages=3-7&author=W.-X.+Heauthor=Y.-L.+Yangauthor=Y.+Xiaauthor=N.+Songauthor=M.+Liuauthor=P.+Zhangauthor=J.+Fanauthor=G.-N.+Jiang&title=Outcomes+of+Chinese+patients+with+end-stage+pulmonary+disease+while+awaiting+lung+transplantation%3A+a+single-center+study&doi=10.4103%2F0366-6999.172547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Outcomes of Chinese Patients with End-stage Pulmonary Disease while Awaiting Lung Transplantation: A Single-center Study</span></div><div class="casAuthors">He Wen-Xin; Yang Yu-Ling; Xia Yan; Song Nan; Liu Ming; Zhang Peng; Fan Jiang; Jiang Ge-Ning</div><div class="citationInfo"><span class="NLM_cas:title">Chinese medical journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-7</span>
        ISSN:<span class="NLM_cas:issn">0366-6999</span>.
    </div><div class="casAbstract">BACKGROUND:  The factors affecting the outcome of patients referred for lung transplantation (LTx) still have not been investigated extensively.  The aim of this study was to characterize the patient outcomes and identify the prognostic factors for death while awaiting the LTx.  METHODS:  From January 2003 to November 2013, the clinical data of 103 patients with end-stage lung disease that had been referred for LTx to Department of Thoracic Surgery, Shanghai Pulmonary Hospital were analyzed retrospectively.  The relationship between predictors and survival was evaluated using the Kaplan-Meier method and the Cox proportional hazards model.  RESULTS:  Twenty-five patients (24.3%) died while awaiting the LTx.  Fifty patients (48.5%) underwent LTx, and 28 patients (27.2%) were still on the waitlist.  Compared to the candidates with chronic obstructive pulmonary disease (COPD), patients with idiopathic pulmonary fibrosis (IPF) had a higher mortality while awaiting the LTx (40.0% vs. 12.3%, P = 0.003).  Patients requiring mechanical ventilation (MV) had a higher mortality while waiting than others (50.0% vs. 20.2%, P = 0.038).  Two variables, using MV and IPF but not COPD as primary disease, emerged as significant independent risk factors for death on the waitlist (hazard ratio [HR] = 56.048, 95% confidence interval [CI]: 3.935-798.263, P = 0.003 and HR = 14.859, 95% CI: 2.695-81.932, P = 0.002, respectively).  CONCLUSION:  The type of end-stage lung disease, pulmonary hypertension, and MV may be distinctive prognostic factors for death while awaiting the LTx.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyUx63XGow6ZSWdIdmEou5fW6udTcc2eaJxZ6eHxHlmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhs1Wguw%253D%253D&md5=8c373484c0e1881d1adab3e062a7ed49</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.4103%2F0366-6999.172547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0366-6999.172547%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.-X.%26aulast%3DYang%26aufirst%3DY.-L.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DG.-N.%26atitle%3DOutcomes%2520of%2520Chinese%2520patients%2520with%2520end-stage%2520pulmonary%2520disease%2520while%2520awaiting%2520lung%2520transplantation%253A%2520a%2520single-center%2520study%26jtitle%3DChin.%2520Med.%2520J.%26date%3D2016%26volume%3D129%26spage%3D3%26epage%3D7%26doi%3D10.4103%2F0366-6999.172547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Kenn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloeckl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span> </span><span class="NLM_article-title">Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis-a review</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1159/000354112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1159%2F000354112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=89-99&author=K.+Kennauthor=R.+Gloecklauthor=J.+Behr&title=Pulmonary+rehabilitation+in+patients+with+idiopathic+pulmonary+fibrosis-a+review&doi=10.1159%2F000354112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1159%2F000354112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000354112%26sid%3Dliteratum%253Aachs%26aulast%3DKenn%26aufirst%3DK.%26aulast%3DGloeckl%26aufirst%3DR.%26aulast%3DBehr%26aufirst%3DJ.%26atitle%3DPulmonary%2520rehabilitation%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis-a%2520review%26jtitle%3DRespiration%26date%3D2013%26volume%3D86%26spage%3D89%26epage%3D99%26doi%3D10.1159%2F000354112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Nishiyama, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arizono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span> </span><span class="NLM_article-title">Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respirology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span><span class="refDoi"> DOI: 10.1111/j.1440-1843.2007.01205.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1111%2Fj.1440-1843.2007.01205.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=394-399&author=O.+Nishiyamaauthor=Y.+Kondohauthor=T.+Kimuraauthor=K.+Katoauthor=K.+Kataokaauthor=T.+Ogawaauthor=F.+Watanabeauthor=S.+Arizonoauthor=K.+Nishimuraauthor=H.+Taniguchi&title=Effects+of+pulmonary+rehabilitation+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1111%2Fj.1440-1843.2007.01205.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2007.01205.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2007.01205.x%26sid%3Dliteratum%253Aachs%26aulast%3DNishiyama%26aufirst%3DO.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DK.%26aulast%3DKataoka%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DF.%26aulast%3DArizono%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DK.%26aulast%3DTaniguchi%26aufirst%3DH.%26atitle%3DEffects%2520of%2520pulmonary%2520rehabilitation%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespirology%26date%3D2008%26volume%3D13%26spage%3D394%26epage%3D399%26doi%3D10.1111%2Fj.1440-1843.2007.01205.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Vainshelboim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soreck, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruchter, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. R.</span><span> </span><span class="NLM_article-title">Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1007/s00408-015-9703-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs00408-015-9703-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2015&pages=345-354&author=B.+Vainshelboimauthor=J.+Oliveiraauthor=B.+D.+Foxauthor=Y.+Soreckauthor=O.+Fruchterauthor=M.+R.+Kramer&title=Long-term+effects+of+a+12-week+exercise+training+program+on+clinical+outcomes+in+idiopathic+pulmonary+fibrosis&doi=10.1007%2Fs00408-015-9703-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1007%2Fs00408-015-9703-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-015-9703-0%26sid%3Dliteratum%253Aachs%26aulast%3DVainshelboim%26aufirst%3DB.%26aulast%3DOliveira%26aufirst%3DJ.%26aulast%3DFox%26aufirst%3DB.%2BD.%26aulast%3DSoreck%26aufirst%3DY.%26aulast%3DFruchter%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DM.%2BR.%26atitle%3DLong-term%2520effects%2520of%2520a%252012-week%2520exercise%2520training%2520program%2520on%2520clinical%2520outcomes%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DLung%26date%3D2015%26volume%3D193%26spage%3D345%26epage%3D354%26doi%3D10.1007%2Fs00408-015-9703-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairclough, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Make, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozora, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wamboldt, F. S.</span><span> </span><span class="NLM_article-title">Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respir. Care.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">789</span><span class="refDoi"> DOI: 10.4187/respcare.00939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4187%2Frespcare.00939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21333082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3MnhtFWisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2011&pages=783-789&author=J.+J.+Swigrisauthor=D.+L.+Faircloughauthor=M.+Morrisonauthor=B.+Makeauthor=E.+Kozoraauthor=K.+K.+Brownauthor=F.+S.+Wamboldt&title=Benefits+of+pulmonary+rehabilitation+in+idiopathic+pulmonary+fibrosis&doi=10.4187%2Frespcare.00939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Swigris Jeffrey J; Fairclough Diane L; Morrison Marianne; Make Barry; Kozora Elizabeth; Brown Kevin K; Wamboldt Frederick S</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory care</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">783-9</span>
        ISSN:<span class="NLM_cas:issn">0020-1324</span>.
    </div><div class="casAbstract">BACKGROUND:  Information on the benefits of pulmonary rehabilitation (PR) in patients with idiopathic pulmonary fibrosis (IPF) is growing, but PR's effects on certain important outcomes is lacking.  METHODS:  We conducted a pilot study of PR in IPF and analyzed changes in functional capacity, fatigue, anxiety, depression, sleep, and health status from baseline to after completion of a standard, 6-week PR program.  RESULTS:  Six-min walk distance improved a mean ± standard error 202 ± 135 feet (P = .01) from baseline.  Fatigue Severity Scale score also improved significantly, declining an average 1.5 ± 0.5 points from baseline.  There were trends toward improvement in anxiety, depression, and health status.  CONCLUSIONS:  PR improves functional capacity and fatigue in patients with IPF. (Clinical Trials.gov registration NCT00692796.)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ20JQt49kmKUewzGPswiWOfW6udTcc2eYbv8rLvDp3NLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnhtFWisA%253D%253D&md5=1681c09003b057942d2967dba0252aef</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.4187%2Frespcare.00939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4187%252Frespcare.00939%26sid%3Dliteratum%253Aachs%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DFairclough%26aufirst%3DD.%2BL.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DMake%26aufirst%3DB.%26aulast%3DKozora%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DWamboldt%26aufirst%3DF.%2BS.%26atitle%3DBenefits%2520of%2520pulmonary%2520rehabilitation%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespir.%2520Care.%26date%3D2011%26volume%3D56%26spage%3D783%26epage%3D789%26doi%3D10.4187%2Frespcare.00939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Gaunaurd, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Marín, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalin, L.P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenas, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. M.</span><span> </span><span class="NLM_article-title">Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program</span> <span class="citation_source-journal">Respir. Care.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.4187/respcare.03180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.4187%2Frespcare.03180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25185149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsFyqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1872-1879&author=I.+A.+Gaunaurdauthor=O.+W.+G%C3%B3mez-Mar%C3%ADnauthor=C.+F.+Ramosauthor=C.+M.+Solauthor=M.+I.+Cohenauthor=L.P.+Cahalinauthor=D.+D.+Cardenasauthor=R.+M.+Jackson&title=Physical+activity+and+quality+of+life+improvements+of+patients+with+idiopathic+pulmonary+fibrosis+completing+a+pulmonary+rehabilitation+program&doi=10.4187%2Frespcare.03180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program</span></div><div class="casAuthors">Gaunaurd Ignacio A; Ramos Carol F; Sol Constanza M; Jackson Robert M; Gomez-Marin Orlando W; Cohen Meryl I; Cahalin Lawrence P; Cardenas Diana D</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory care</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1872-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Pulmonary rehabilitation is effective for patients with COPD, but its benefit is less clearly established in idiopathic pulmonary fibrosis (IPF), especially in regard to levels of physical activity and health-related quality of life.  The objectives were to determine whether pulmonary rehabilitation increased physical activity as assessed by the International Physical Activity Questionnaire (IPAQ), and improved quality of life and symptoms as assessed by the St George respiratory questionnaire for IPF (SGRQ-I) and the Borg dyspnea index (BDI).  METHODS:  Subjects who met current criteria for IPF were randomized to a 3-month pulmonary rehabilitation program (n = 11) or to a control group (n = 10).  The rehabilitation group participated in twice-weekly, 90-min exercise sessions (24 total sessions).  The control group maintained its preceding, normal physical activity.  All subjects underwent 6-min walk tests to assess the postexertion BDI.  The SGRQ-I and a 5-point self-assessment of health were completed at baseline, after 3 months of intervention or observation, and after 3-month follow-up.  All subjects completed the IPAQ weekly.  RESULTS:  Subjects in the rehabilitation group maintained significantly higher levels of physical activity throughout the 3-month rehabilitation program (rehabilitation: 51,364 ± 57,713 [mean ± SD] metabolic equivalent of task-minutes; control: 20,832 ± 37,155, P = .027 by 2-tailed Mann-Whitney test).  SGRQ-I symptom domain scores improved considerably by -9 ± 22 in the rehabilitation group, whereas in the control group they worsened (16 ± 12 rehabilitation compared with control, P = .013 by 2-tailed Mann-Whitney test).  During the 3-month follow-up, self-reported physical activity levels in the rehabilitation group were 14,428 ± 8,884 metabolic equivalent of task-minutes and in the control group 16,923 ± 32,620 (P = .17 by 2-tailed Mann-Whitney test), demonstrating substantial reversal of activity in the rehabilitation group.  BDI scores after 6-min walk tests did not change significantly.  CONCLUSIONS:  A 3-month rehabilitation program significantly improved symptoms (SGRQ-I) and physical activity levels (IPAQ) in subjects with IPF while they participated actively in the program. (ClinicalTrials.gov registration NCT01118221.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLF3vyupOcNa__Jf7-eMvJfW6udTcc2eYbv8rLvDp3NLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsFyqsg%253D%253D&md5=962e922c199aeca7aa4d90dd6d4791ae</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.4187%2Frespcare.03180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4187%252Frespcare.03180%26sid%3Dliteratum%253Aachs%26aulast%3DGaunaurd%26aufirst%3DI.%2BA.%26aulast%3DG%25C3%25B3mez-Mar%25C3%25ADn%26aufirst%3DO.%2BW.%26aulast%3DRamos%26aufirst%3DC.%2BF.%26aulast%3DSol%26aufirst%3DC.%2BM.%26aulast%3DCohen%26aufirst%3DM.%2BI.%26aulast%3DCahalin%26aufirst%3DL.P.%26aulast%3DCardenas%26aufirst%3DD.%2BD.%26aulast%3DJackson%26aufirst%3DR.%2BM.%26atitle%3DPhysical%2520activity%2520and%2520quality%2520of%2520life%2520improvements%2520of%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520completing%2520a%2520pulmonary%2520rehabilitation%2520program%26jtitle%3DRespir.%2520Care.%26date%3D2014%26volume%3D59%26spage%3D1872%26epage%3D1879%26doi%3D10.4187%2Frespcare.03180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Vainshelboim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yehoshua, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruchter, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. R.</span><span> </span><span class="NLM_article-title">Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span><span class="refDoi"> DOI: 10.1159/000367899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1159%2F000367899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=378-388&author=B.+Vainshelboimauthor=J.+Oliveiraauthor=L.+Yehoshuaauthor=I.+Weissauthor=B.+D.+Foxauthor=O.+Fruchterauthor=M.+R.+Kramer&title=Exercise+training-based+pulmonary+rehabilitation+program+is+clinically+beneficial+for+idiopathic+pulmonary+fibrosis&doi=10.1159%2F000367899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1159%2F000367899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000367899%26sid%3Dliteratum%253Aachs%26aulast%3DVainshelboim%26aufirst%3DB.%26aulast%3DOliveira%26aufirst%3DJ.%26aulast%3DYehoshua%26aufirst%3DL.%26aulast%3DWeiss%26aufirst%3DI.%26aulast%3DFox%26aufirst%3DB.%2BD.%26aulast%3DFruchter%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DM.%2BR.%26atitle%3DExercise%2520training-based%2520pulmonary%2520rehabilitation%2520program%2520is%2520clinically%2520beneficial%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DRespiration%26date%3D2014%26volume%3D88%26spage%3D378%26epage%3D388%26doi%3D10.1159%2F000367899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Jackson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Marín, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sol, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaunaurd, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalin, L.P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenas, D. D.</span><span> </span><span class="NLM_article-title">Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span><span class="refDoi"> DOI: 10.1007/s00408-014-9566-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs00408-014-9566-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=367-376&author=R.+M.+Jacksonauthor=O.+W.+G%C3%B3mez-Mar%C3%ADnauthor=C.+F.+Ramosauthor=C.+M.+Solauthor=M.+I.+Cohenauthor=I.+A.+Gaunaurdauthor=L.P.+Cahalinauthor=D.+D.+Cardenas&title=Exercise+limitation+in+IPF+patients%3A+a+randomized+trial+of+pulmonary+rehabilitation&doi=10.1007%2Fs00408-014-9566-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1007%2Fs00408-014-9566-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-014-9566-9%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DR.%2BM.%26aulast%3DG%25C3%25B3mez-Mar%25C3%25ADn%26aufirst%3DO.%2BW.%26aulast%3DRamos%26aufirst%3DC.%2BF.%26aulast%3DSol%26aufirst%3DC.%2BM.%26aulast%3DCohen%26aufirst%3DM.%2BI.%26aulast%3DGaunaurd%26aufirst%3DI.%2BA.%26aulast%3DCahalin%26aufirst%3DL.P.%26aulast%3DCardenas%26aufirst%3DD.%2BD.%26atitle%3DExercise%2520limitation%2520in%2520IPF%2520patients%253A%2520a%2520randomized%2520trial%2520of%2520pulmonary%2520rehabilitation%26jtitle%3DLung%26date%3D2014%26volume%3D192%26spage%3D367%26epage%3D376%26doi%3D10.1007%2Fs00408-014-9566-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elicker, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydell, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolters, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">1390</span><span class="NLM_x">–</span> <span class="NLM_lpage">1394</span><span class="refDoi"> DOI: 10.1164/rccm.201101-0138OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1164%2Frccm.201101-0138OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=21700909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Flsl2msQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2011&pages=1390-1394&author=J.+S.+Leeauthor=J.+H.+Ryuauthor=B.+M.+Elickerauthor=C.+P.+Lydellauthor=K.+D.+Jonesauthor=P.+J.+Woltersauthor=T.+E.+Kingauthor=H.+R.+Collard&title=Gastroesophageal+reflux+therapy+is+associated+with+longer+survival+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1164%2Frccm.201101-0138OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Lee Joyce S; Ryu Jay H; Elicker Brett M; Lydell Carmen P; Jones Kirk D; Wolters Paul J; King Talmadge E Jr; Collard Harold R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1390-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Gastroesophageal reflux (GER) is highly prevalent in patients with idiopathic pulmonary fibrosis (IPF).  Chronic microaspiration secondary to GER may play a role in the pathogenesis and natural history of IPF.  OBJECTIVES:  To investigate the relationship between GER-related variables and survival time in patients with IPF.  METHODS:  Regression analysis was used to investigate the relationship between GER-related variables and survival time in a retrospectively identified cohort of patients with well-characterized IPF from two academic medical centers.  MEASUREMENTS AND MAIN RESULTS:  Two hundred four patients were identified for inclusion.  GER-related variables were common in this cohort: reported symptoms of GER (34%), a history of GER disease (45%), reported use of GER medications (47%), and Nissen fundoplication (5%).  These GER-related variables were significantly associated with longer survival time on unadjusted analysis.  After adjustment, the use of GER medications was an independent predictor of longer survival time.  In addition, the use of gastroesophageal reflux medications was associated with a lower radiologic fibrosis score.  These findings were present regardless of center.  CONCLUSIONS:  The reported use of GER medications is associated with decreased radiologic fibrosis and is an independent predictor of longer survival time in patients with IPF.  These findings further support the hypothesis that GER and chronic microaspiration may play important roles in the pathobiology of IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdrLw-Ift0GacY7HFp97qMfW6udTcc2ebIW1_BOXd1N7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Flsl2msQ%253D%253D&md5=75fcba1dfad357fc957aefccb1e8f647</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1164%2Frccm.201101-0138OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201101-0138OC%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DElicker%26aufirst%3DB.%2BM.%26aulast%3DLydell%26aufirst%3DC.%2BP.%26aulast%3DJones%26aufirst%3DK.%2BD.%26aulast%3DWolters%26aufirst%3DP.%2BJ.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DGastroesophageal%2520reflux%2520therapy%2520is%2520associated%2520with%2520longer%2520survival%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D184%26spage%3D1390%26epage%3D1394%26doi%3D10.1164%2Frccm.201101-0138OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatto, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span> </span><span class="NLM_article-title">Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1113</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1183/13993003.02316-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F13993003.02316-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26424523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVChsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=1113-1130&author=G.+Raghuauthor=V.+C.+Amattoauthor=J.+Behrauthor=S.+Stowasser&title=Comorbidities+in+idiopathic+pulmonary+fibrosis+patients%3A+a+systematic+literature+review&doi=10.1183%2F13993003.02316-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review</span></div><div class="casAuthors">Raghu, Ganesh; Amatto, Valeria C.; Behr, Jurgen; Stowasser, Susanne</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1113-1130</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is assocd. with a fatal prognosis and manifests in patients over 60 years old who may have comorbidities.  The prevalence and impact of comorbidities on the clin. course of IPF is unclear.  This systematic literature review examd. the prevalence of comorbidities and mortality assocd. with comorbidities in IPF patients.  Relevant observational studies published in English from Jan. 1990 to Jan. 2015 identified via MEDLINE and EMBASE were included; bibliogs. of articles were also searched.  Among the 126 studies included, prevalence of pulmonary hypertension (PH) was 3-86%, 6-91% for obstructive sleep apnoea, 3-48% for lung cancer and 6-67% for chronic obstructive pulmonary disease (COPD).  Nonrespiratory comorbidities included ischemic heart disease (IHD) (3-68%) and gastro-oesophageal reflux (GER) (0-94%).  Mortality was highest among patients with IPF and lung cancer.  Most studies assessed relatively small samples of patients with IPF.  PH, COPD, lung cancer, GER and IHD are significant comorbidities; differences in IPF severity, case definitions and patient characteristics limited the comparability of findings.  The identification and prompt treatment of comorbidities may have a clin. significant impact on overall outcome that is meaningful for patients with IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJU8q6LwCJLVg90H21EOLACvtfcHk0ljd67QlbUcOHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVChsr4%253D&md5=694f040b69595ffe1b260309d6b521eb</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1183%2F13993003.02316-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02316-2014%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAmatto%26aufirst%3DV.%2BC.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DStowasser%26aufirst%3DS.%26atitle%3DComorbidities%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520patients%253A%2520a%2520systematic%2520literature%2520review%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D1113%26epage%3D1130%26doi%3D10.1183%2F13993003.02316-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">King, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S. D.</span><span> </span><span class="NLM_article-title">Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases</span> <span class="citation_source-journal">Curr. Opin. Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1097/MCP.0b013e328363f460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1097%2FMCP.0b013e328363f460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23912191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3sfms1Chsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=466-473&author=C.+Kingauthor=S.+D.+Nathan&title=Identification+and+treatment+of+comorbidities+in+idiopathic+pulmonary+fibrosis+and+other+fibrotic+lung+diseases&doi=10.1097%2FMCP.0b013e328363f460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases</span></div><div class="casAuthors">King Christopher; Nathan Steven D</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pulmonary medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The interstitial lung diseases (ILDs) frequently result in considerable disability and reduced survival in affected patients.  Unfortunately, they are often poorly responsive to available therapies.  Comorbidities, both pulmonary and nonpulmonary, frequently accompany ILDs and contribute to adverse outcomes.  RECENT FINDINGS:  Multiple comorbidities, including gastroesophageal reflux disease, venous thromboembolism, coronary artery disease, sleep-disordered breathing, depression, emphysema, pulmonary hypertension, and lung cancer contribute to the morbidity and mortality of fibrotic lung disease.  SUMMARY:  The identification and treatment of comorbidities may improve morbidity and potentially impact mortality in patients with ILD.  A high index of suspicion and an awareness of the spectrum of comorbidities are important in optimizing outcomes in this group of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxX3oP0Et5cBdUSIfHIn4FfW6udTcc2eZGYfaZmhPfq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfms1Chsg%253D%253D&md5=40242bafcd55ba2d5495092bfee08a20</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e328363f460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e328363f460%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DC.%26aulast%3DNathan%26aufirst%3DS.%2BD.%26atitle%3DIdentification%2520and%2520treatment%2520of%2520comorbidities%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520other%2520fibrotic%2520lung%2520diseases%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D466%26epage%3D473%26doi%3D10.1097%2FMCP.0b013e328363f460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Schiza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermigkis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margaritopoulos, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniil, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poletti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzoni, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torre, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouloukaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sourvinos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoniou, K. M.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night</span> <span class="citation_source-journal">Eur. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1183/16000617.00009114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1183%2F16000617.00009114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=26028644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2MblslSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=327-339&author=S.+Schizaauthor=C.+Mermigkisauthor=G.+A.+Margaritopoulosauthor=Z.+Daniilauthor=S.+Harariauthor=V.+Polettiauthor=E.+A.+Renzoniauthor=O.+Torreauthor=D.+Viscaauthor=I.+Bouloukakiauthor=G.+Sourvinosauthor=K.+M.+Antoniou&title=Idiopathic+pulmonary+fibrosis+and+sleep+disorders%3A+no+longer+strangers+in+the+night&doi=10.1183%2F16000617.00009114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night</span></div><div class="casAuthors">Schiza Sophia; Mermigkis Charalampos; Margaritopoulos George A; Daniil Zoi; Harari Sergio; Torre Olga; Poletti Venerino; Renzoni Elizabetta A; Visca Dina; Bouloukaki Isolde; Sourvinos George; Antoniou Katerina M</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">136</span>),
    <span class="NLM_cas:pages">327-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prevalence of obstructive sleep apnoea (OSA) is continuously increasing in patients with idiopathic pulmonary fibrosis (IPF) and, for the first time, the recent IPF guidelines recognise OSA as an important associated comorbidity that can affect patient's survival.  Thus, it becomes conceivable that clinicians should refer patients with newly diagnosed IPF to sleep centres for the diagnosis and treatment of OSA as well as for addressing issues regarding the reduced compliance of patients with continuous positive airway pressure therapy.  The discovery of biomarkers common to both disorders may help early diagnosis, institution of the most appropriate treatment and follow-up of patients.  Better understanding of epigenetic changes may provide useful information about pathogenesis and, possibly, development of new drugs for a dismal disease like IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQImIQDUdvi8g20zIbnCCI3fW6udTcc2eZGYfaZmhPfq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblslSitg%253D%253D&md5=0c76f651ce845b7fbe08b35acd6a1314</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1183%2F16000617.00009114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.00009114%26sid%3Dliteratum%253Aachs%26aulast%3DSchiza%26aufirst%3DS.%26aulast%3DMermigkis%26aufirst%3DC.%26aulast%3DMargaritopoulos%26aufirst%3DG.%2BA.%26aulast%3DDaniil%26aufirst%3DZ.%26aulast%3DHarari%26aufirst%3DS.%26aulast%3DPoletti%26aufirst%3DV.%26aulast%3DRenzoni%26aufirst%3DE.%2BA.%26aulast%3DTorre%26aufirst%3DO.%26aulast%3DVisca%26aufirst%3DD.%26aulast%3DBouloukaki%26aufirst%3DI.%26aulast%3DSourvinos%26aufirst%3DG.%26aulast%3DAntoniou%26aufirst%3DK.%2BM.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%2520and%2520sleep%2520disorders%253A%2520no%2520longer%2520strangers%2520in%2520the%2520night%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2015%26volume%3D24%26spage%3D327%26epage%3D339%26doi%3D10.1183%2F16000617.00009114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Pihtili, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingol, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuhadaroglu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issever, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulbaran, Z.</span><span> </span><span class="NLM_article-title">Obstructive sleep apnea is common in patients with interstitial lung disease</span> <span class="citation_source-journal">Sleep. Breath.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1288</span><span class="refDoi"> DOI: 10.1007/s11325-013-0834-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs11325-013-0834-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=23563999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC3srivFOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1281-1288&author=A.+Pihtiliauthor=Z.+Bingolauthor=E.+Kiyanauthor=C.+Cuhadarogluauthor=H.+Isseverauthor=Z.+Gulbaran&title=Obstructive+sleep+apnea+is+common+in+patients+with+interstitial+lung+disease&doi=10.1007%2Fs11325-013-0834-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Obstructive sleep apnea is common in patients with interstitial lung disease</span></div><div class="casAuthors">Pihtili Aylin; Bingol Zuleyha; Kiyan Esen; Cuhadaroglu Caglar; Issever Halim; Gulbaran Ziya</div><div class="citationInfo"><span class="NLM_cas:title">Sleep & breathing = Schlaf & Atmung</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1281-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The incidence of obstructive sleep apnea (OSA) in interstitial lung disease (ILD) has been reported at different frequencies in several studies.  The aims of our study were to evaluate the frequency of OSA in ILD and to analyze the relationship between polysomnography (PSG) findings and pulmonary function, disease severity, parenchymal involvement, and Epworth Sleepiness Scale (ESS) scores.  METHODS:  ILD patients with parenchymal involvement were evaluated.  The disease severity was assessed using an index consisting of body mass index (BMI), carbon monoxide diffusion capacity, the Modified Medical Research Council dyspnea scale, and the 6-min walking distance.  All of the patients had lung function, chest X-ray, PSG, ESS scoring, and an upper airway examination.  Patients with a BMI ≥ 30 or significant upper airway pathologies were excluded.  RESULTS:  Of 62 patients, 50 patients comprised the study group (14 male, 36 female; mean age 54 ± 12.35 years, mean BMI 25.9 ± 3.44 kg/m(2)) with diagnoses of idiopathic pulmonary fibrosis (IPF; n = 17), stage II-III sarcoidosis (n = 15), or scleroderma (n = 18).  The frequency of OSA was 68 %.  The mean apnea-hypopnea index (AHI) was 11.4 ± 12.5.  OSA was more common in IPF patients (p = 0.009).  The frequency of rapid eye movement-related sleep apnea was 52.9 %.  The frequency of OSA was higher in patients with a disease severity index ≥3 (p = 0.04).  The oxygen desaturation index and the AHI were higher in patients with diffuse radiological involvement (p = 0.007 and p = 0.043, respectively).  CONCLUSIONS:  OSA is common in ILD.  PSG or at minimum nocturnal oximetry should be performed, particularly in patients with functionally and radiologically severe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQl8YUkrTWr9ts4TFFB11gfW6udTcc2eYIkbfGHUfVALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srivFOgsg%253D%253D&md5=b24f98f5a342674eefa653e195e88052</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1007%2Fs11325-013-0834-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11325-013-0834-3%26sid%3Dliteratum%253Aachs%26aulast%3DPihtili%26aufirst%3DA.%26aulast%3DBingol%26aufirst%3DZ.%26aulast%3DKiyan%26aufirst%3DE.%26aulast%3DCuhadaroglu%26aufirst%3DC.%26aulast%3DIssever%26aufirst%3DH.%26aulast%3DGulbaran%26aufirst%3DZ.%26atitle%3DObstructive%2520sleep%2520apnea%2520is%2520common%2520in%2520patients%2520with%2520interstitial%2520lung%2520disease%26jtitle%3DSleep.%2520Breath.%26date%3D2013%26volume%3D17%26spage%3D1281%26epage%3D1288%26doi%3D10.1007%2Fs11325-013-0834-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Mermigkis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouloukaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoniou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadogiannis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannarakis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varouchakis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siafakas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiza, E. S.</span><span> </span><span class="NLM_article-title">Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Sleep. Breath.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1007/s11325-014-1033-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=10.1007%2Fs11325-014-1033-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=25028171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;key=1%3ACAS%3A280%3ADC%252BC2cbis1ehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=385-391&author=C.+Mermigkisauthor=I.+Bouloukakiauthor=K.+Antoniouauthor=G.+Papadogiannisauthor=I.+Giannarakisauthor=G.+Varouchakisauthor=N.+Siafakasauthor=E.+S.+Schiza&title=Obstructive+sleep+apnea+should+be+treated+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1007%2Fs11325-014-1033-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Mermigkis Charalampos; Bouloukaki Izolde; Antoniou Katerina; Papadogiannis Georgios; Giannarakis Ioannis; Varouchakis Georgios; Siafakas Nikolaos; Schiza Sophia E</div><div class="citationInfo"><span class="NLM_cas:title">Sleep & breathing = Schlaf & Atmung</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">385-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVES:  The most recent idiopathic pulmonary fibrosis (IPF) guidelines include obstructive sleep apnea (OSA) among the IPF-associated comorbidities.  Furthermore, they recognize the paucity of studies related to continuous positive airway pressure(CPAP) treatment in this patient group and call for intensive research in this field.  Our aim was to assess the effect of CPAP treatment on sleep and overall life quality parameters, morbidity, and mortality in IPF patients with OSA.  METHODS:  Ninety-two treatment-naive, newly diagnosed, consecutive IPF patients underwent overnight-attended polysomnography (PSG).  In those patients with an apnea-hypopnea index (AHI) of ≥15, therapy with CPAP was initiated.  Patients were divided into poor and good CPAP compliance groups.  All subjects completed multiple quality-of-life and sleep instruments before CPAP initiation and at 1 year after the start of CPAP treatment.  RESULTS:  The good CPAP compliance group (37 patients) showed statistically significant improvement in all quality-of-life and sleep instruments after 1 year's CPAP treatment.  The poor CPAP compliance group (18 patients) showed significant changes of smaller strength only in a minority of the used instruments.  During the 24-month follow-up period after CPAP initiation, three patients from the CPAP poor compliance group died, whereas all patients from the good CPAP compliance group remained alive.  CONCLUSION:  Early OSA recognition and treatment is crucial in a fatal disease such as IPF.  Effective CPAP treatment in IPF patients with OSA results in a significant improvement in daily living activities and quality of sleep and life.  Good CPAP compliance appears to improve mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC-JJtYEFupLHHuJhbyicZfW6udTcc2eYIkbfGHUfVALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbis1ehtg%253D%253D&md5=935828b75d0920f1c8dbaff21b2b5374</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1007%2Fs11325-014-1033-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11325-014-1033-6%26sid%3Dliteratum%253Aachs%26aulast%3DMermigkis%26aufirst%3DC.%26aulast%3DBouloukaki%26aufirst%3DI.%26aulast%3DAntoniou%26aufirst%3DK.%26aulast%3DPapadogiannis%26aufirst%3DG.%26aulast%3DGiannarakis%26aufirst%3DI.%26aulast%3DVarouchakis%26aufirst%3DG.%26aulast%3DSiafakas%26aufirst%3DN.%26aulast%3DSchiza%26aufirst%3DE.%2BS.%26atitle%3DObstructive%2520sleep%2520apnea%2520should%2520be%2520treated%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DSleep.%2520Breath.%26date%3D2015%26volume%3D19%26spage%3D385%26epage%3D391%26doi%3D10.1007%2Fs11325-014-1033-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HP2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HP2','PDB','3HP2'); return false;">PDB: 3HP2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QSC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QSC','PDB','1QSC'); return false;">PDB: 1QSC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FAA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FAA','PDB','3FAA'); return false;">PDB: 3FAA</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00935%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00935" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994346c810248d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
